Clustering O 0 0.0007670529885217547
of O 0 7.677358371438459e-05
missense O 0 0.00016752090596128255
mutations O 0 8.400058504776098e-06
in O 0 1.8331679711991455e-06
the O 0 9.934364243235905e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.0387734619143885e-05
in O 0 1.4971561768106767e-06
a O 0 3.5295231555210194e-06
sporadic B-Disease 0 9.81211123871617e-05
T I-Disease 1 0.9999988079071045
- I-Disease 1 0.9999779462814331
cell I-Disease 1 0.9157788157463074
leukaemia I-Disease 1 0.9998416900634766
. O 0 9.545322245685384e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.12872552871704102
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3784010661765933e-06
is O 0 5.348289278117591e-07
a O 0 7.118245548554114e-07
recessive B-Disease 0 3.896851922036149e-06
multi I-Disease 1 0.7513840794563293
- I-Disease 1 1.0
system I-Disease 1 0.999975323677063
disorder I-Disease 1 0.9999996423721313
caused O 0 4.864617039856967e-06
by O 0 2.403010626039759e-07
mutations O 0 2.749867746842938e-07
in O 0 2.8184155098642805e-07
the O 0 9.60993702392443e-07
ATM O 0 3.647714402177371e-05
gene O 0 1.1464285307738464e-06
at O 0 3.318977405797341e-06
11q22 O 0 3.8151792978169397e-05
- O 0 3.184054367011413e-05
q23 O 0 6.792818749090657e-05
( O 0 2.7639864583761664e-06
ref O 0 9.318786032963544e-05
. O 0 2.0848738131462596e-06
3 O 0 1.3275677702040412e-05
) O 0 1.2624234841496218e-05
. O 0 3.5707220376934856e-05

The O 0 5.8102352340938523e-05
risk O 0 6.247872079256922e-05
of O 0 3.613927765400149e-05
cancer B-Disease 1 0.9999982118606567
, O 0 6.509789272968192e-06
especially O 0 3.1957467854226707e-06
lymphoid B-Disease 1 0.9943460822105408
neoplasias I-Disease 1 0.9999788999557495
, O 0 5.964266620139824e-06
is O 0 1.410042159477598e-06
substantially O 0 1.210712866850372e-06
elevated O 0 5.212814357946627e-05
in O 0 6.861315000605828e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.214868800365366e-06
and O 0 2.658056530435715e-07
has O 0 4.828827968594851e-07
long O 0 8.349258564521733e-07
been O 0 6.611494427488651e-07
associated O 0 9.150350024356158e-07
with O 0 2.6134034669667017e-06
chromosomal O 1 0.9999998807907104
instability O 1 1.0
. O 0 0.0004518752102740109

By O 0 4.424257349455729e-05
analysing O 0 0.0006149625987745821
tumour B-Disease 1 1.0
DNA O 0 2.5598861611797474e-05
from O 0 3.951207418140257e-06
patients O 0 1.8622296238390845e-06
with O 0 5.044955742050661e-07
sporadic B-Disease 0 0.00019572340534068644
T I-Disease 1 0.9999992847442627
- I-Disease 1 0.9982988238334656
cell I-Disease 0 0.13202492892742157
prolymphocytic I-Disease 1 0.9999827146530151
leukaemia I-Disease 1 0.9999994039535522
( O 0 7.76054002926685e-06
T B-Disease 1 0.5017902255058289
- I-Disease 0 0.0030743482057005167
PLL I-Disease 1 0.9906613230705261
) O 0 1.0390301667939639e-06
, O 0 5.094440211905749e-07
a O 0 1.0079429557663389e-06
rare O 0 3.695079158205772e-06
clonal B-Disease 0 8.12069556559436e-05
malignancy I-Disease 1 0.8393687009811401
with O 0 5.310961341820075e-07
similarities O 0 8.559996445001161e-07
to O 0 6.754269747943908e-07
a O 0 2.5137171633105027e-06
mature B-Disease 0 9.472898454987444e-06
T I-Disease 0 0.03806370496749878
- I-Disease 0 0.0037261417601257563
cell I-Disease 0 4.5493645302485675e-05
leukaemia I-Disease 0 0.30564916133880615
seen O 0 1.631738541618688e-06
in O 0 6.510799721581861e-07
A B-Disease 1 0.9980217218399048
- I-Disease 1 0.999821126461029
T I-Disease 1 0.9999997615814209
, O 0 9.470941222389229e-07
we O 0 2.237177056940709e-07
demonstrate O 0 3.831424919553683e-07
a O 0 3.5319942526257364e-07
high O 0 1.3527591136153205e-06
frequency O 0 7.083573336785776e-07
of O 0 9.49404693528777e-07
ATM O 0 7.000182085903361e-05
mutations O 0 2.427000481475261e-06
in O 0 4.463421191758243e-06
T B-Disease 1 0.9996820688247681
- I-Disease 1 0.9940645098686218
PLL I-Disease 1 0.9998435974121094
. O 0 0.00033033592626452446

In O 0 3.3407304727006704e-05
marked O 0 2.5975134121836163e-05
contrast O 0 7.688349796808325e-06
to O 0 1.433973352504836e-06
the O 0 2.160740677936701e-06
ATM O 0 0.00015010181232355535
mutation O 0 2.971410140162334e-06
pattern O 0 1.6507714235558524e-06
in O 0 6.339666356325324e-07
A B-Disease 1 0.9999874830245972
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
, O 0 9.793309345695889e-07
the O 0 3.639398755694856e-07
most O 0 1.901913435631286e-07
frequent O 0 4.1793370542109187e-07
nucleotide O 0 4.638349935248698e-07
changes O 0 1.5755513516069186e-07
in O 0 2.476497229508823e-07
this O 0 7.094890293046774e-07
leukaemia B-Disease 0 0.00012212242290843278
were O 0 4.235198503010906e-06
missense O 0 0.00014211494999472052
mutations O 0 3.5381413908908144e-05
. O 0 5.0214734073961154e-05

These O 0 1.5814412108738907e-05
clustered O 0 2.77967301371973e-05
in O 0 1.8503033061278984e-06
the O 0 1.5502581618420663e-06
region O 0 1.2659128287850763e-06
corresponding O 0 5.766334538748197e-07
to O 0 4.529805437414325e-07
the O 0 1.5105773627510644e-06
kinase O 0 6.247564670047723e-06
domain O 0 1.5483565221074969e-06
, O 0 5.1046816906819e-07
which O 0 2.0631377140034601e-07
is O 0 3.0667774808534887e-07
highly O 0 6.33474712685711e-07
conserved O 0 1.6182714261958608e-06
in O 0 3.1133882316680683e-07
ATM O 0 2.3814065571059473e-05
- O 0 5.798335678264266e-06
related O 0 8.878454309524386e-07
proteins O 0 2.3404599858167785e-07
in O 0 3.280778173575527e-07
mouse O 0 8.85841109266039e-06
, O 0 1.4272156931838254e-06
yeast O 0 5.367488029150991e-06
and O 0 3.3502956284792162e-06
Drosophila O 0 7.711727812420577e-05
. O 0 6.163161742733791e-05

The O 0 4.972861643182114e-05
resulting O 0 1.1587346307351254e-05
amino O 0 3.803911113209324e-06
- O 0 6.511037554446375e-06
acid O 0 3.0072678782744333e-06
substitutions O 0 3.156383627356263e-06
are O 0 2.1076607481518295e-07
predicted O 0 1.7558078297952306e-06
to O 0 3.883319266151375e-07
interfere O 0 1.5218995486065978e-06
with O 0 9.035589982886449e-07
ATP O 1 0.9977676868438721
binding O 0 4.105154403077904e-06
or O 0 3.856981038552476e-06
substrate O 0 1.8452972653904e-05
recognition O 0 3.140155240544118e-05
. O 0 9.011731162900105e-05

Two O 0 1.875495036074426e-05
of O 0 2.8779535568901338e-05
seventeen O 0 0.00011170249490533024
mutated O 0 9.22420367714949e-05
T B-Disease 1 0.8790038228034973
- I-Disease 0 0.035734135657548904
PLL I-Disease 1 0.9573572278022766
samples O 0 2.3924287688714685e-06
had O 0 1.2958589650224894e-06
a O 0 7.510898285545409e-07
previously O 0 1.6471325352540589e-06
reported O 0 2.853155137927388e-06
A B-Disease 1 0.9891975522041321
- I-Disease 1 0.9999767541885376
T I-Disease 1 0.9999996423721313
allele O 0 0.0001367324875900522
. O 0 0.00010555137851042673

In O 0 2.0457233404158615e-05
contrast O 0 7.884937076596543e-06
, O 0 2.1869573174626566e-06
no O 0 9.427964187125326e-07
mutations O 0 7.875887604313903e-07
were O 0 2.79075408116114e-07
detected O 0 7.835582209736458e-07
in O 0 2.243728260964417e-07
the O 0 7.28454836007586e-07
p53 O 0 4.012812951259548e-06
gene O 0 7.139436775105423e-07
, O 0 3.8417061887230375e-07
suggesting O 0 6.400915708582033e-07
that O 0 2.1183996068430133e-07
this O 0 1.0587211818346987e-06
tumour B-Disease 1 1.0
suppressor O 1 0.9999997615814209
is O 0 3.348736527186702e-06
not O 0 2.6981260248248873e-07
frequently O 0 8.528234616278496e-07
altered O 0 1.5100415566848824e-06
in O 0 8.939661597651138e-07
this O 0 3.4358472476014867e-06
leukaemia B-Disease 0 0.037225764244794846
. O 0 8.289547258755192e-05

Occasional O 0 0.000526958319824189
missense O 0 0.00028625549748539925
mutations O 0 8.86320231074933e-06
in O 0 1.4307522633316694e-06
ATM O 0 0.0013635007198899984
were O 0 1.0628629070197348e-06
also O 0 4.846239107791916e-07
found O 0 3.9813093621887674e-07
in O 0 6.268048196034215e-07
tumour B-Disease 1 1.0
DNA O 0 2.4220385057560634e-06
from O 0 4.0097620512824506e-07
patients O 0 3.12482228537192e-07
with O 0 1.738917632110315e-07
B B-Disease 0 0.03144517540931702
- I-Disease 0 0.0017194057581946254
cell I-Disease 0 7.552274473709986e-05
non I-Disease 0 0.0019057737663388252
- I-Disease 1 0.9999995231628418
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 1 0.9999046325683594
( O 0 2.8404060685716104e-06
B B-Disease 0 7.35094872652553e-05
- I-Disease 0 5.332817636372056e-06
NHL I-Disease 0 7.112431921996176e-05
) O 0 5.904746558371698e-07
and O 0 3.095564977684262e-07
a O 0 1.4717721796841943e-06
B B-Disease 0 6.395903619704768e-05
- I-Disease 0 0.0001575738424435258
NHL I-Disease 1 0.9976625442504883
cell O 0 0.00014959200052544475
line O 0 8.991816139314324e-05
. O 0 8.012566104298458e-05

The O 0 2.489409780537244e-05
evidence O 0 4.991288733435795e-06
of O 0 2.463487817294663e-06
a O 0 1.1296391448922805e-06
significant O 0 8.344586035491375e-07
proportion O 0 5.300689736031927e-07
of O 0 7.821009262443113e-07
loss O 0 3.8151683838805184e-05
- O 0 5.188464911043411e-06
of O 0 1.4230555507310783e-06
- O 0 7.1667423071630765e-06
function O 0 2.523906630358397e-07
mutations O 0 1.4102772638580063e-07
and O 0 6.384077977372726e-08
a O 0 2.0894248109470936e-07
complete O 0 2.622368526772334e-07
absence O 0 7.375872996817634e-07
of O 0 5.677423473571253e-07
the O 0 3.799455612352176e-07
normal O 0 2.563789394116611e-07
copy O 0 6.152121727609483e-07
of O 0 5.35684932856384e-07
ATM O 0 1.0656901395122986e-05
in O 0 2.73118331506339e-07
the O 0 4.4682960265163274e-07
majority O 0 2.6116094886674546e-07
of O 0 1.3998952681504306e-06
mutated O 0 2.028898052230943e-05
tumours B-Disease 1 0.9999996423721313
establishes O 0 1.2787364539690316e-05
somatic O 0 9.517775652057026e-06
inactivation O 0 4.840090332436375e-05
of O 0 6.671456276308163e-07
this O 0 9.802170808370647e-08
gene O 0 9.985858895333877e-08
in O 0 8.683413454946276e-08
the O 0 4.549746961401979e-07
pathogenesis O 0 0.10977017879486084
of O 0 7.882614227128215e-06
sporadic B-Disease 0 0.0055582658387720585
T I-Disease 1 0.9999985694885254
- I-Disease 1 0.9876748323440552
PLL I-Disease 1 0.9985322952270508
and O 0 1.8299506336916238e-06
suggests O 0 1.6232361303991638e-06
that O 0 3.692761083584628e-07
ATM O 0 2.8313559596426785e-05
acts O 0 1.7928284705703845e-06
as O 0 4.142705165577354e-06
a O 0 6.0978021792834625e-05
tumour B-Disease 1 1.0
suppressor O 1 0.9999998807907104
. O 0 0.0002134768001269549

As O 0 2.6376048481324688e-05
constitutional O 0 1.8225367966806516e-05
DNA O 0 8.7717726273695e-06
was O 0 5.236764081928413e-06
not O 0 1.9625224467745284e-07
available O 0 2.541374328757229e-07
, O 0 3.4199294418613135e-07
a O 0 1.361843374070304e-06
putative O 0 3.566488885553554e-05
hereditary O 1 0.997900128364563
predisposition O 1 0.9999486207962036
to O 0 0.00013476151798386127
T B-Disease 1 1.0
- I-Disease 1 0.9998582601547241
PLL I-Disease 1 0.9997246861457825
will O 0 2.3720770059298957e-06
require O 0 1.2497670240918524e-06
further O 0 1.7678598851489369e-06
investigation O 0 9.179444532492198e-06
. O 0 5.273328952171141e-06
. O 0 1.8626844394020736e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.0001361092581646517
kinase O 0 4.83298790641129e-05
is O 0 1.2958960269315867e-06
involved O 0 3.2631203339406056e-07
in O 0 1.4344763599183352e-07
the O 0 2.1543260686485155e-07
modulation O 0 1.7748773188941414e-06
of O 0 1.6212944728977163e-06
the O 0 2.88810360871139e-06
Ca2 O 0 7.233652286231518e-05
+ O 0 9.469295764574781e-05
homeostasis O 0 0.0001472444855608046
in O 0 9.848269655776676e-06
skeletal O 1 0.9999934434890747
muscle O 1 0.9227248430252075
cells O 0 7.01912576914765e-05
. O 0 6.72734240652062e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999306201934814
DM B-Disease 1 1.0
) O 0 3.0959163268562406e-05
, O 0 2.537344698794186e-06
the O 0 1.1736063925127382e-06
most O 0 2.26560291594069e-06
prevalent O 1 0.9278769493103027
muscular B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 1.3357844181882683e-05
adults O 0 2.0664629118982702e-06
, O 0 3.4098468404408777e-07
is O 0 2.147511821704029e-07
caused O 0 3.127290995053045e-07
by O 0 1.3710524626731058e-07
( O 0 1.0457582675371668e-06
CTG O 0 0.48263871669769287
) O 0 8.621360620963969e-07
n O 0 7.785616276123619e-07
- O 0 2.08212190955237e-06
repeat O 0 1.3099768239044352e-06
expansion O 0 1.2504513051680988e-06
in O 0 1.3627511918912205e-07
a O 0 3.7272678810040816e-07
gene O 0 3.1768354347150307e-07
encoding O 0 5.908937623644306e-07
a O 0 1.4626589290855918e-06
protein O 0 2.6407519726490136e-06
kinase O 0 1.0255567758576944e-05
( O 0 2.9389493647613563e-06
DM B-Disease 1 1.0
protein O 0 5.158719432074577e-06
kinase O 0 8.476377843180671e-06
; O 0 6.670107381978596e-07
DMPK O 0 0.05049722641706467
) O 0 8.868079248713912e-07
and O 0 3.097425462783576e-07
involves O 0 6.357454935823625e-07
changes O 0 1.9563633202324127e-07
in O 0 6.357296911119192e-07
cytoarchitecture O 0 0.00012611065176315606
and O 0 4.8369165597250685e-06
ion O 0 0.0007469010888598859
homeostasis O 0 0.005447773728519678
. O 0 0.00015433364023920149

To O 0 2.1418110918602906e-05
obtain O 0 6.811037565057632e-06
clues O 0 1.4623083188780583e-05
to O 0 1.2646917184611084e-06
the O 0 8.706048220119555e-07
normal O 0 6.738590059285343e-07
biological O 0 1.0812883601829526e-06
role O 0 9.064312394002627e-07
of O 0 2.8900983579660533e-06
DMPK O 1 0.9999966621398926
in O 0 1.9904159671568777e-06
cellular O 0 8.577618245908525e-06
ion O 0 0.00010579029185464606
homeostasis O 0 0.00012673521996475756
, O 0 8.213303317461396e-07
we O 0 2.9602642825921066e-07
have O 0 1.0346720102916152e-07
compared O 0 4.2256186816302943e-07
the O 0 4.269512885457516e-07
resting O 0 7.472798188246088e-06
[ O 0 1.606842374712869e-06
Ca2 O 0 1.931524820975028e-06
+ O 0 1.4147457250146545e-06
] O 0 1.049901243277418e-06
i O 0 4.869003760177293e-07
, O 0 1.1267928101688085e-07
the O 0 1.3052513736511173e-07
amplitude O 0 6.427108587558905e-07
and O 0 2.2059150239783776e-07
shape O 0 1.532420583316707e-06
of O 0 1.3538767689169617e-06
depolarization O 0 6.765610578440828e-06
- O 0 2.4926050173235126e-05
induced O 0 1.082495873561129e-05
Ca2 O 0 8.634462574264035e-06
+ O 0 5.061044703325024e-06
transients O 0 4.904290562990354e-06
, O 0 5.238564995124761e-07
and O 0 1.699971079460738e-07
the O 0 3.1108831421988725e-07
content O 0 4.4511304508887406e-07
of O 0 1.25717599530617e-06
ATP O 1 0.9999974966049194
- O 0 0.013330183923244476
driven O 0 1.2084371519449633e-05
ion O 0 1.8659235138329677e-05
pumps O 0 1.4852566891931929e-05
in O 0 1.941366008395562e-06
cultured O 0 1.3015541298955213e-05
skeletal O 0 0.20493696630001068
muscle O 0 1.689403688942548e-05
cells O 0 4.877583137385955e-07
of O 0 1.0897274478338659e-06
wild O 0 5.468718427437125e-06
- O 0 8.512897693435661e-06
type O 0 2.980978024424985e-06
and O 0 8.001990181583096e-07
DMPK O 1 0.9997418522834778
[ O 0 1.2656335456995293e-05
- O 0 4.466338941711001e-05
/ O 0 0.0001429524418199435
- O 0 0.00024009145272430032
] O 0 5.9511276049306616e-05
knockout O 0 0.006624002940952778
mice O 0 0.00015633793373126537
. O 0 7.825656211934984e-05

In O 0 4.594607889885083e-05
vitro O 0 5.582569428952411e-05
- O 0 7.967757119331509e-05
differentiated O 0 7.594537601107731e-05
DMPK O 1 0.9998946189880371
[ O 0 2.5640643798396923e-05
- O 0 8.082160638878122e-05
/ O 0 0.00022678634559269994
- O 0 0.00011709149839589372
] O 0 1.5252866433002055e-05
myotubes O 0 5.296197923598811e-05
exhibit O 0 5.001867066312116e-06
a O 0 1.174325234387652e-06
higher O 0 1.7814263628679328e-06
resting O 0 1.2159674042777624e-05
[ O 0 5.091946604807163e-06
Ca2 O 0 8.120658094412647e-06
+ O 0 3.944716354453703e-06
] O 0 1.4989792589403805e-06
i O 0 9.966713605535915e-07
than O 0 1.5362118688244664e-07
do O 0 2.537736349950137e-07
wild O 0 1.2612204045581166e-06
- O 0 2.6488355615583714e-06
type O 0 1.9509207049850374e-06
myotubes O 0 2.512597529857885e-05
because O 0 2.447131635108235e-07
of O 0 3.8081907405285165e-07
an O 0 3.3570717050679377e-07
altered O 0 6.792394060539664e-07
open O 0 1.166498577731545e-06
probability O 0 5.70328722915292e-07
of O 0 9.148691901827988e-07
voltage O 0 9.237748599844053e-06
- O 0 8.164305654645432e-06
dependent O 0 1.265176592823991e-06
l O 0 2.0841164314333582e-06
- O 0 5.135447281645611e-06
type O 0 4.991945843357826e-06
Ca2 O 0 1.194545257021673e-05
+ O 0 6.447431587730534e-06
and O 0 2.9143966457922943e-06
Na O 0 0.03694118931889534
+ O 0 8.58205821714364e-05
channels O 0 6.028966527082957e-05
. O 0 6.269513687584549e-05

The O 0 0.00013795160339213908
mutant O 0 0.0004296828992664814
myotubes O 0 0.006123373284935951
exhibit O 0 4.121785968891345e-05
smaller O 0 9.493606739852112e-06
and O 0 2.362256964261178e-06
slower O 0 5.63974163014791e-06
Ca2 O 0 1.2237640476087108e-05
+ O 0 3.2483578706887783e-06
responses O 0 3.2383067605223914e-07
upon O 0 4.4291959966358263e-07
triggering O 0 1.7463843278164859e-06
by O 0 3.272840842782898e-07
acetylcholine O 0 1.5117307157197502e-05
or O 0 1.8654807263374096e-06
high O 0 1.66896716109477e-05
external O 0 1.4383697816811036e-05
K O 0 0.00018905381148215383
+ O 0 0.00017953722272068262
. O 0 7.289894710993394e-05

In O 0 1.223190065502422e-05
addition O 0 5.0882185860245954e-06
, O 0 1.68868405125977e-06
we O 0 3.583268721740751e-07
observed O 0 2.5855959506770887e-07
that O 0 1.2048876385506446e-07
these O 0 1.5641164452517842e-07
Ca2 O 0 6.47091928840382e-06
+ O 0 6.295423190749716e-06
transients O 0 6.847587883385131e-06
partially O 0 2.5121187263721367e-06
result O 0 2.766183229141461e-07
from O 0 1.696039220178136e-07
an O 0 2.531193388222164e-07
influx O 0 8.259922879005899e-07
of O 0 1.0982198546116706e-06
extracellular O 0 4.1248067645938136e-06
Ca2 O 0 7.2735360845399555e-06
+ O 0 2.191870407841634e-06
through O 0 2.723456020703452e-07
the O 0 4.838881864088762e-07
l O 0 3.018738198079518e-06
- O 0 7.812414878571872e-06
type O 0 7.166127488744678e-06
Ca2 O 0 2.7859650799655356e-05
+ O 0 2.4373302949243225e-05
channel O 0 3.0445706215687096e-05
. O 0 2.4099783331621438e-05

Neither O 0 8.638209692435339e-05
the O 0 1.1189642464159988e-05
content O 0 7.148776148824254e-06
nor O 0 3.257947582824272e-06
the O 0 1.2873867945017992e-06
activity O 0 1.3171347745810635e-06
of O 0 2.964707391583943e-06
Na O 1 0.9727263450622559
+ O 0 2.2173871911945753e-05
/ O 0 3.1518018658971414e-05
K O 0 1.587241786182858e-05
+ O 0 1.1857389836222865e-05
ATPase O 0 3.3440352126490325e-05
and O 0 2.7233932087256107e-06
sarcoplasmic O 0 0.00023243293981067836
reticulum O 0 7.40773684810847e-05
Ca2 O 0 6.946783105377108e-05
+ O 0 4.269295823178254e-05
- O 0 5.004163540434092e-05
ATPase O 0 8.206225174944848e-05
are O 0 9.349226388621901e-07
affected O 0 1.9866988623107318e-06
by O 0 2.6229115519527113e-06
DMPK O 1 0.9999910593032837
absence O 0 0.00026642833836376667
. O 0 0.00017067819135263562

In O 0 3.406104588066228e-05
conclusion O 0 1.0434020623506512e-05
, O 0 3.4141785363317467e-06
our O 0 1.1671272659441456e-06
data O 0 6.739471132277686e-07
suggest O 0 9.355202337246737e-07
that O 0 3.474341951914539e-07
DMPK O 1 0.9926965236663818
is O 0 6.445437179536384e-07
involved O 0 3.290099925834511e-07
in O 0 1.418017205878641e-07
modulating O 0 2.5481404009042308e-06
the O 0 4.1273077044934325e-07
initial O 0 7.752054216325632e-07
events O 0 4.647591254069994e-07
of O 0 8.803709192761744e-07
excitation O 0 6.454771209973842e-06
- O 0 9.020172728924081e-05
contraction O 0 1.4333841136249248e-05
coupling O 0 7.395288321276894e-06
in O 0 3.945562639273703e-06
skeletal O 1 0.9976162910461426
muscle O 0 0.001369920326396823
. O 0 1.7376625692122616e-05
. O 0 4.676372554968111e-05

Constitutional O 0 0.0030322337988764048
RB1 O 1 0.9999998807907104
- O 0 0.0487375408411026
gene O 0 3.1174218747764826e-05
mutations O 0 5.8860746321443e-06
in O 0 1.7247153891730704e-06
patients O 0 2.2736894607078284e-06
with O 0 1.8467741256245063e-06
isolated O 0 7.027229003142565e-05
unilateral B-Disease 0 0.00026956110377795994
retinoblastoma I-Disease 1 0.9999942779541016
. O 0 0.0003486202040221542

In O 0 3.490721792331897e-05
most O 0 6.785169716749806e-06
patients O 0 2.3479499304812634e-06
with O 0 6.26270036718779e-07
isolated O 0 1.2069916010659654e-05
unilateral B-Disease 0 3.88300686609e-05
retinoblastoma I-Disease 1 1.0
, O 0 0.0016609557205811143
tumor B-Disease 1 0.9999951124191284
development O 0 8.798866701908992e-07
is O 0 3.51151044242215e-07
initiated O 0 9.962056992662838e-07
by O 0 2.297379211313455e-07
somatic O 0 3.242471166231553e-06
inactivation O 0 2.2025920770829543e-05
of O 0 1.9272724784968887e-06
both O 0 4.339486565640982e-07
alleles O 0 9.91613319456519e-07
of O 0 5.561436410062015e-06
the O 0 2.4641087293275632e-05
RB1 O 1 0.999998927116394
gene O 0 8.304936636704952e-05
. O 0 7.042094512144104e-05

However O 0 2.904746179410722e-05
, O 0 4.1467919800197706e-06
some O 0 1.5285235122064478e-06
of O 0 2.1379107693064725e-06
these O 0 5.825767175338115e-07
patients O 0 1.629942062209011e-06
can O 0 5.458362579702225e-07
transmit O 0 1.5850468116695993e-05
retinoblastoma B-Disease 1 0.9897666573524475
predisposition O 0 0.10432521998882294
to O 0 7.231352356029674e-06
their O 0 3.6971766803617356e-06
offspring O 0 3.826004103757441e-05
. O 0 3.8433521694969386e-05

To O 0 9.624256563256495e-06
determine O 0 1.728540496515052e-06
the O 0 1.2102510709155467e-06
frequency O 0 1.4059602335692034e-06
and O 0 6.184499170558411e-07
nature O 0 1.3698189604838262e-06
of O 0 2.236158479718142e-06
constitutional O 0 1.997929393837694e-05
RB1 O 1 1.0
- O 0 0.007201236207038164
gene O 0 3.765622523133061e-06
mutations O 0 9.281540656047582e-07
in O 0 2.512269361432118e-07
patients O 0 3.214080948055198e-07
with O 0 1.926587458456197e-07
isolated O 0 4.571791123453295e-06
unilateral B-Disease 0 7.916954018583056e-06
retinoblastoma I-Disease 1 0.9678270220756531
, O 0 1.0434231398903648e-06
we O 0 2.630195581332373e-07
analyzed O 0 4.6860844804541557e-07
DNA O 0 5.870865606993902e-07
from O 0 4.79652555895882e-07
peripheral O 1 0.9817835688591003
blood O 0 4.219463789922884e-06
and O 0 1.801786083888146e-06
from O 0 1.292403794650454e-05
tumor B-Disease 1 1.0
tissue O 0 0.00047366463695652783
. O 0 5.991151920170523e-05

The O 0 3.222114537493326e-05
analysis O 0 8.988956324174069e-06
of O 0 1.1033428563678171e-05
tumors B-Disease 1 0.9999926090240479
from O 0 2.15900627154042e-06
54 O 0 8.464099664706737e-06
( O 0 7.963241159814061e-07
71 O 0 2.834501401594025e-06
% O 0 2.713836977363826e-07
) O 0 2.9610802698698535e-07
of O 0 7.816013862793625e-07
76 O 0 9.141329428530298e-06
informative O 0 1.0458816177560948e-05
patients O 0 1.1952913610002724e-06
showed O 0 6.294009153862135e-07
loss O 0 2.578472049208358e-06
of O 0 2.1291857592586894e-06
constitutional O 0 1.068338860932272e-05
heterozygosity O 1 0.9999971389770508
( O 0 7.5259042205289e-05
LOH O 1 1.0
) O 0 1.1698200978571549e-05
at O 0 5.660600436385721e-05
intragenic O 0 0.0007421289919875562
loci O 0 0.00022874123533256352
. O 0 9.255095210392028e-05

Three O 0 3.6271176213631406e-05
of O 0 2.8048152671544813e-05
13 O 0 5.4557734983973205e-05
uninformative O 1 0.9827331304550171
patients O 0 2.6481677195988595e-05
had O 0 1.681290268606972e-05
constitutional O 0 6.40404032310471e-05
deletions O 0 0.0005767480470240116
. O 0 0.00019691897614393383

For O 0 4.103243554709479e-05
39 O 0 5.6694061640882865e-05
randomly O 0 1.232452177646337e-05
selected O 0 2.2702341084368527e-05
tumors B-Disease 1 1.0
, O 0 1.158215309260413e-05
SSCP O 1 0.9999997615814209
, O 0 8.490082109346986e-06
hetero O 0 5.375488399295136e-05
- O 0 1.181969309982378e-05
duplex O 0 1.0622047739161644e-05
analysis O 0 3.7101321481713967e-07
, O 0 2.416816187178483e-07
sequencing O 0 9.138585141954536e-07
, O 0 2.578616999926453e-07
and O 0 2.792748148294777e-07
Southern O 0 2.185806351917563e-06
blot O 0 1.8546508727013133e-05
analysis O 0 6.752891295036534e-07
were O 0 4.908286541649431e-07
used O 0 5.754902190346911e-07
to O 0 1.0290877980878577e-06
identify O 0 9.504006811766885e-06
mutations O 0 2.279156251461245e-05
. O 0 4.135506969760172e-05

Mutations O 0 5.322906145011075e-05
were O 0 4.287362116883742e-06
detected O 0 2.3788868475094205e-06
in O 0 2.6070156877722184e-07
21 O 0 1.4827991208221647e-06
( O 0 3.3689059364405693e-07
91 O 0 2.0810082332900492e-06
% O 0 2.2207771621651773e-07
) O 0 3.5281263421893527e-07
of O 0 2.0384511572046904e-06
23 O 0 0.00010341858433093876
tumors B-Disease 1 1.0
with O 0 0.0002812475722748786
LOH O 1 1.0
. O 0 0.0018411434721201658

In O 0 1.6660505934851244e-05
6 O 0 1.4200570149114355e-05
( O 0 1.0842333040272933e-06
38 O 0 2.9423147225315915e-06
% O 0 3.163074495660112e-07
) O 0 2.6904896799351263e-07
of O 0 8.133431492751697e-07
16 O 0 3.31427545461338e-05
tumors B-Disease 1 1.0
without O 0 2.4890180156944552e-06
LOH O 1 1.0
, O 0 1.0811152151291026e-06
one O 0 2.1017997653416387e-07
mutation O 0 1.875221897762458e-07
was O 0 7.834042321519519e-07
detected O 0 5.314010991241958e-07
, O 0 1.1514970310599892e-07
and O 0 8.097475756585482e-08
in O 0 9.881537010869579e-08
9 O 0 5.50580239178089e-07
( O 0 1.8227937914616632e-07
56 O 0 4.440907730440813e-07
% O 0 9.821408752941352e-08
) O 0 1.3124511610840273e-07
of O 0 3.5721663493859523e-07
the O 0 2.105944076902233e-06
tumors B-Disease 1 1.0
without O 0 3.557164973244653e-06
LOH O 1 1.0
, O 0 3.6919511785526993e-06
both O 0 8.936166295825387e-07
mutations O 0 2.201698180215317e-06
were O 0 2.3584661903441884e-06
found O 0 8.20544119051192e-06
. O 0 2.30896348512033e-05

Thus O 0 4.369343150756322e-05
, O 0 3.6365991036291234e-06
a O 0 1.5815323877177434e-06
total O 0 1.1217913424843573e-06
of O 0 7.164044859564456e-07
45 O 0 1.6002389884306467e-06
mutations O 0 4.76759367984414e-07
were O 0 3.823548127002141e-07
identified O 0 7.265843464665522e-07
in O 0 1.2847118568970473e-06
tumors B-Disease 1 0.9999998807907104
of O 0 0.0001816342701204121
36 O 0 0.0008494892390444875
patients O 0 3.447253038757481e-05
. O 0 3.3063832233892754e-05

Thirty O 0 0.000147978775203228
- O 0 3.275945346103981e-05
nine O 0 5.13331269758055e-06
of O 0 2.37586255025235e-06
the O 0 1.2821158179576742e-06
mutations O 0 8.51028858050995e-07
- O 0 2.355620381422341e-06
including O 0 5.612253630715713e-07
34 O 0 1.7536474388180068e-06
small O 0 6.431517363125749e-07
mutations O 0 3.451373800089641e-07
, O 0 2.0599762251549691e-07
2 O 0 7.703046662754787e-07
large O 0 6.626625008721021e-07
structural O 0 3.84863687941106e-06
alterations O 0 7.052848104649456e-06
, O 0 1.001230771180417e-06
and O 0 5.717233761970419e-07
hypermethylation O 0 0.04355594143271446
in O 0 1.2812137129003531e-06
3 O 0 0.0561542734503746
tumors O 1 1.0
- O 0 1.630897168070078e-05
were O 0 4.0289964431394765e-07
not O 0 1.2054299247665767e-07
detected O 0 3.781143504966167e-07
in O 0 1.9965212061379134e-07
the O 0 7.471961112059944e-07
corresponding O 0 3.9236306292878e-06
peripheral O 1 0.9495771527290344
blood O 0 7.634997746208683e-05
DNA O 0 5.501718624145724e-05
. O 0 4.299571082810871e-05

In O 0 1.7339116311632097e-05
6 O 0 1.824493483582046e-05
( O 0 1.6692428062015097e-06
17 O 0 2.3520242393715307e-06
% O 0 3.409775217733113e-07
) O 0 1.7378465599904303e-07
of O 0 3.4629229617166857e-07
the O 0 3.8089319787104614e-07
36 O 0 1.7332399693259504e-06
patients O 0 2.8126262918704015e-07
, O 0 1.4847148577246116e-07
a O 0 2.580152056452789e-07
mutation O 0 4.6850300350342877e-07
was O 0 1.0380902040196816e-06
detected O 0 2.6454753765392525e-07
in O 0 7.360105769294023e-08
constitutional O 0 2.4835546241774864e-07
DNA O 0 2.733786743647215e-07
, O 0 1.1220080864404736e-07
and O 0 6.158025911418008e-08
1 O 0 3.6876545550512674e-07
of O 0 2.240349772364425e-07
these O 0 4.1635512815219045e-08
mutations O 0 1.2097785884179757e-07
is O 0 1.3396009990174207e-07
known O 0 3.0591036193072796e-07
to O 0 1.8245783905967983e-07
be O 0 1.9560684449970722e-07
associated O 0 4.832513127439597e-07
with O 0 1.2546464631668641e-06
reduced O 0 2.0837585907429457e-05
expressivity O 0 0.0007004229701124132
. O 0 7.338957220781595e-05

The O 0 4.3643423850880936e-05
presence O 0 1.029391114570899e-05
of O 0 3.237527380406391e-06
a O 0 2.3002849047770724e-06
constitutional O 0 4.654240456147818e-06
mutation O 0 1.4950417153158924e-06
was O 0 2.2438468931795796e-06
not O 0 8.115102190231482e-08
associated O 0 9.291011338063981e-08
with O 0 8.421536534797269e-08
an O 0 3.1021465929370606e-07
early O 0 8.655416650071857e-07
age O 0 2.3712855181656778e-06
at O 0 1.1756422281905543e-05
treatment O 0 2.4918324925238267e-05
. O 0 2.8161899535916746e-05

In O 0 2.664941166585777e-05
1 O 0 5.515597513294779e-05
patient O 0 1.577801776875276e-05
, O 0 4.529405032371869e-06
somatic O 0 5.787964619230479e-05
mosaicism O 1 0.9997515082359314
was O 0 2.1705180188291706e-05
demonstrated O 0 1.2869546708316193e-06
by O 0 1.3460348213811812e-07
molecular O 0 4.6991343083391257e-07
analysis O 0 2.318670198064865e-07
of O 0 4.067747454428172e-07
DNA O 0 6.438212380999175e-07
and O 0 3.3818528777374013e-07
RNA O 0 1.2558180060295854e-05
from O 0 7.367826583504211e-06
peripheral O 1 0.999991774559021
blood O 0 0.0002218366862507537
. O 0 6.369817128870636e-05

In O 0 3.9733884477755055e-05
2 O 0 4.615815487341024e-05
patients O 0 3.8028592825867236e-06
without O 0 5.268429958960041e-07
a O 0 9.600611292626127e-07
detectable O 0 1.6578504073549993e-05
mutation O 0 1.120079900829296e-06
in O 0 6.079321792640258e-07
peripheral O 1 0.9996945858001709
blood O 0 1.0071385986520909e-05
, O 0 1.6611770661256742e-06
mosaicism O 1 0.501514196395874
was O 0 5.561844773183111e-06
suggested O 0 8.336321570823202e-07
because O 0 2.0973926950773603e-07
1 O 0 6.789660460526648e-07
of O 0 5.703727765649091e-07
the O 0 9.290635603065311e-07
patients O 0 1.7190632206620649e-06
showed O 0 0.00013011603732593358
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 1.7331936987829977e-06
the O 0 1.160307533609739e-06
other O 0 3.692384211717581e-07
later O 0 1.8245519868287374e-06
developed O 0 4.676727257901803e-06
bilateral B-Disease 0 4.331788659328595e-05
retinoblastoma I-Disease 1 0.9999535083770752
. O 0 0.00020699026936199516

In O 0 1.9219429304939695e-05
conclusion O 0 8.654295925225597e-06
, O 0 2.3717650492471876e-06
our O 0 6.484680739049509e-07
results O 0 3.85249251166897e-07
emphasize O 0 1.1439374247856904e-06
that O 0 1.335142201241979e-07
the O 0 4.3116131109854905e-07
manifestation O 0 8.209378393075895e-06
and O 0 6.348427064040152e-07
transmissibility O 0 0.001084117335267365
of O 0 3.6805961372010643e-06
retinoblastoma B-Disease 0 0.00011600073048612103
depend O 0 3.1832891522753926e-07
on O 0 3.9246717165042355e-07
the O 0 2.8578071464835375e-07
nature O 0 4.298696296700655e-07
of O 0 2.0302161374274874e-07
the O 0 1.3762347350620985e-07
first O 0 1.6241158107277442e-07
mutation O 0 1.5046322232592502e-07
, O 0 6.632581772691992e-08
its O 0 2.767161433325782e-08
time O 0 4.0158269598578045e-08
in O 0 4.224699878818683e-08
development O 0 7.709427762847554e-08
, O 0 9.991383365104411e-08
and O 0 7.914425026456229e-08
the O 0 8.106623994308393e-08
number O 0 8.375801030524599e-08
and O 0 9.684054447234303e-08
types O 0 2.1674243555480643e-07
of O 0 8.473165280520334e-07
cells O 0 3.2633005275783944e-07
that O 0 9.834754877147134e-08
are O 0 9.361470176827424e-08
affected O 0 7.057867605908541e-07
. O 0 2.934085159722599e-06
. O 0 1.6830292224767618e-05

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.987048327922821
the I-Disease 0 0.02431102655827999
fifth I-Disease 1 0.5985868573188782
component I-Disease 0 0.001292371191084385
of I-Disease 0 2.0387513359310105e-05
complement I-Disease 0 2.0381738067953847e-05
in O 0 8.56504721014062e-06
man O 0 0.0001310810330323875
. O 0 9.655693429522216e-05

I O 1 0.5593487024307251
. O 0 0.0018826480954885483

Clinical O 0 0.12968756258487701
, O 0 3.599907722673379e-05
immunochemical O 1 0.9898315072059631
, O 0 1.184903612738708e-05
and O 0 4.250899110047612e-06
family O 0 1.66454519785475e-05
studies O 0 1.3297533769218717e-05
. O 0 3.516538708936423e-05

The O 0 3.1905834475765005e-05
first O 0 1.1157503649883438e-05
recognized O 0 9.660892828833312e-06
human O 0 2.5409044610569254e-06
kindred O 0 0.056333012878894806
with O 0 6.5059725784522016e-06
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999998807907104
the I-Disease 1 0.9833388328552246
fifth I-Disease 1 0.9706051349639893
component I-Disease 0 0.002280773129314184
of I-Disease 0 3.924262728105532e-06
complement I-Disease 0 1.015070483845193e-05
( O 0 9.508285984338727e-06
C5 O 1 1.0
) O 0 5.838882316311356e-06
is O 0 6.133250735729234e-06
described O 0 1.2980634892301168e-05
. O 0 2.7415031581767835e-05

The O 0 9.200572094414383e-05
proband O 0 0.001043393393047154
, O 0 6.5528552113391925e-06
a O 0 3.223835165044875e-06
20 O 0 3.5788948480330873e-06
- O 0 5.467456048791064e-06
year O 0 1.9773726762650767e-06
- O 0 1.4203196769813076e-05
old O 0 3.3218882890651e-05
black O 0 1.0221490811090916e-05
female O 0 2.8851359274995048e-06
with O 0 1.0853510502784047e-05
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9951203465461731
age O 0 0.0004847686504945159
11 O 0 5.206884907238418e-06
, O 0 1.2116830703234882e-06
lacked O 0 1.0522114280320238e-05
serum O 0 4.8300942580681294e-05
hemolytic O 1 0.9999957084655762
complement O 0 3.4268625313416123e-05
activity O 0 5.085977136332076e-06
, O 0 2.204580823672586e-06
even O 0 3.233491270293598e-06
during O 0 1.214664735016413e-05
remission O 0 0.00016402648179791868
. O 0 6.749614840373397e-05

C5 O 1 1.0
was O 0 0.000630469061434269
undetectable O 0 0.0004370860115159303
in O 0 2.6852142127609113e-06
her O 0 2.6316006369597744e-06
serum O 0 3.564771986930282e-06
by O 0 3.510291719521774e-07
both O 0 1.2175885331089376e-06
immunodiffusion O 0 0.18216505646705627
and O 0 3.275804556324147e-05
hemolytic O 1 0.9999978542327881
assays O 0 0.00024792569456622005
. O 0 0.00013391875836532563

Other O 0 1.4248331353883259e-05
complement O 0 2.4534818294341676e-05
components O 0 7.166284376580734e-06
were O 0 7.340505590036628e-07
normal O 0 6.387500093296694e-07
during O 0 6.396790581675305e-07
remission O 0 1.2526268619694747e-05
of O 0 1.1597915545280557e-05
lupus O 1 1.0
, O 0 3.486810328467982e-06
but O 0 8.511562441526621e-07
C1 O 1 0.9999716281890869
, O 0 4.0808286030369345e-06
C4 O 1 1.0
, O 0 5.634280114463763e-06
C2 O 1 0.9996362924575806
, O 0 1.744253722790745e-06
and O 0 1.4922469517841819e-06
C3 O 1 1.0
levels O 0 1.4752101378689986e-05
fell O 0 0.0012681704247370362
during O 0 3.037870737898629e-05
exacerbations O 0 0.09596537053585052
. O 0 0.00010297085100319237

A O 0 0.0003417513216845691
younger O 0 4.56588932138402e-05
half O 0 6.606473561987514e-06
- O 0 6.0605903854593635e-05
sister O 0 1.1915029972442426e-05
, O 0 1.1528005643413053e-06
who O 0 1.174268049908278e-06
had O 0 1.3713063253817381e-06
no O 0 2.2584024463867536e-06
underlying O 1 0.9986340403556824
disease O 1 0.9869935512542725
, O 0 1.2150944712630007e-06
was O 0 5.584007340075914e-06
also O 0 4.096970087630325e-07
found O 0 2.4211138338614546e-07
to O 0 4.631507408703328e-07
lack O 0 7.5817370088770986e-06
immunochemically O 1 0.9858028888702393
detectable O 1 0.9494521021842957
C5 O 1 1.0
. O 0 0.00021175143774598837

By O 0 7.217651727842167e-05
hemolytic O 1 0.966516375541687
assay O 0 4.069092756253667e-05
, O 0 7.281726084329421e-06
she O 0 2.910763441832387e-06
exhibited O 0 2.708314013943891e-06
1 O 0 2.138606078005978e-06
- O 0 2.1168677903915523e-06
2 O 0 1.848296278694761e-06
% O 0 2.6180504164585727e-07
of O 0 3.3596336379559943e-07
the O 0 6.301396524577285e-07
normal O 0 1.4328277302411152e-06
serum O 0 1.638054891373031e-05
C5 O 1 0.9999972581863403
level O 0 4.5308179323910736e-06
and O 0 4.6716763790755067e-07
normal O 0 3.554543184236536e-07
concentrations O 0 7.703604865128e-07
of O 0 7.102893277988187e-07
other O 0 3.403040693683579e-07
complement O 0 9.357599992654286e-06
components O 0 2.2978616470936686e-05
. O 0 3.7798665289301425e-05

C5 O 1 0.9999995231628418
levels O 0 4.327824353822507e-05
of O 0 5.880699063709471e-06
other O 0 7.477456733795407e-07
family O 0 9.095130053538014e-07
members O 0 1.9210575885608705e-07
were O 0 3.3635450336078065e-07
either O 0 2.4961204303508566e-07
normal O 0 2.5755400656635175e-07
or O 0 1.6567614125051477e-07
approximately O 0 2.54143714073507e-07
half O 0 4.77880973903666e-07
- O 0 2.4551709429943003e-06
normal O 0 4.950096013089933e-07
, O 0 3.196912530256668e-07
consistent O 0 4.347107847024745e-07
with O 0 3.5340295312380476e-07
autosomal O 0 4.4318426262179855e-06
codominant O 0 8.909690222935751e-05
inheritance O 0 4.640465704142116e-06
of O 0 2.245143832624308e-06
the O 0 3.1064232643984724e-06
gene O 0 5.716607574868249e-06
determining O 0 0.0011887068394571543
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00025518471375107765

Normal O 0 0.000604762404691428
hemolytic O 1 0.9999350309371948
titers O 0 0.007144547533243895
were O 0 8.051324584812392e-06
restored O 0 1.8265842300024815e-05
to O 0 2.61091713582573e-06
both O 0 1.5814599692021147e-06
homozygous O 0 0.00012962095206603408
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 7.792533142492175e-05
C5D B-Disease 1 1.0
) O 0 6.0437628235376906e-06
sera O 0 0.00010694281809264794
by O 0 4.2515537757026323e-07
addition O 0 9.915045211528195e-07
of O 0 3.2396767437603557e-06
highly O 0 1.6290736311930232e-05
purified O 0 7.933062443044037e-05
human O 0 3.9106256735976785e-05
C5 O 1 0.9999998807907104
. O 0 0.00016381140449084342

In O 0 4.422502388479188e-05
specific O 0 2.067771856673062e-05
C5 O 1 0.9999996423721313
titrations O 0 0.0003057809663005173
, O 0 2.2044609977456275e-06
however O 0 5.686580948349729e-07
, O 0 4.402807292080979e-07
it O 0 2.1017014262270095e-07
was O 0 1.6286943491650163e-06
noted O 0 3.4931599657284096e-07
that O 0 7.6135513893405e-08
when O 0 1.4359683575548843e-07
limited O 0 1.7342077285320556e-07
amounts O 0 5.467094297273434e-07
of O 0 1.0817906286320067e-06
C5 O 1 0.9999953508377075
were O 0 7.343642778323556e-07
assayed O 0 2.565068598414655e-06
in O 0 1.707308285858744e-07
the O 0 2.1346946255107468e-07
presence O 0 3.69593550431091e-07
of O 0 6.356084440994891e-07
low O 0 2.1600092168228002e-06
dilutions O 0 1.964703551493585e-05
of O 0 1.9267799871158786e-06
either O 0 3.3190597150678514e-06
C5D B-Disease 1 1.0
serum O 0 1.7835407561506145e-05
, O 0 1.2234047517267754e-06
curving O 0 7.040388481982518e-06
rather O 0 3.760537765629124e-07
than O 0 2.2381971120921662e-07
linear O 0 6.166318939904158e-07
dose O 0 2.158993993361946e-06
- O 0 2.2356359750119736e-06
response O 0 4.302276863654697e-07
plots O 0 9.410179018232157e-07
were O 0 2.8503762905529584e-07
consistently O 0 7.726185344836267e-07
obtained O 0 4.966002506989753e-07
, O 0 6.947412316549162e-07
suggesting O 0 1.7189535128636635e-06
some O 0 9.74215936366818e-07
inhibitory O 0 2.768065496638883e-05
effect O 0 2.1049434508313425e-05
. O 0 3.777683014050126e-05

Further O 0 2.6622083169058897e-05
studies O 0 5.172862984181847e-06
suggested O 0 2.9702541723963805e-06
that O 0 4.504294679463783e-07
low O 0 4.026198894280242e-06
dilutions O 0 6.277194188442081e-05
of O 0 1.806148065952584e-05
C5D B-Disease 1 1.0
serum O 0 1.4859891962260008e-05
contain O 0 1.056048972714052e-06
a O 0 7.287953280865622e-07
factor O 0 1.3954764881418669e-06
( O 0 2.751483521024056e-07
or O 0 1.6879678810255427e-07
factors O 0 2.120999056387518e-07
) O 0 2.7173589955964417e-07
interfering O 0 7.616862376380595e-07
at O 0 9.177267088489316e-07
some O 0 1.764777834978304e-07
step O 0 9.058409773388121e-07
in O 0 3.0593605515605304e-07
the O 0 1.2175653409940423e-06
hemolytic O 0 0.0002572947705630213
assay O 0 3.0919466098566772e-06
of O 0 1.8913167878054082e-05
C5 O 1 1.0
, O 0 1.4599818314309232e-06
rather O 0 3.0783135684941954e-07
than O 0 2.8819906106036797e-07
a O 0 2.085647565763793e-06
true O 0 1.1339737284288276e-05
C5 O 1 0.9999985694885254
inhibitor O 0 0.0002727502433117479
or O 0 2.760578536253888e-05
inactivator O 0 0.0012034366372972727
. O 0 0.00010052249854197726

Of O 0 0.00010811840184032917
clinical O 0 0.00020427130220923573
interest O 0 3.9253259274119046e-06
are O 0 2.560021812314517e-07
( O 0 3.466471696356166e-07
a O 0 3.5929528507949726e-07
) O 0 2.0629960317819496e-07
the O 0 1.9624512503924052e-07
documentation O 0 1.120130150411569e-06
of O 0 5.186486305319704e-06
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 1 0.9999977350234985
vasculitis B-Disease 1 1.0
, O 0 0.11556794494390488
and O 0 0.003408326767385006
arthritis B-Disease 1 1.0
in O 0 2.3521317871200154e-06
an O 0 1.406147816851444e-06
individual O 0 7.651233318028972e-07
lacking O 0 4.774989793077111e-05
C5 O 1 1.0
( O 0 1.5745254131616093e-06
and O 0 3.0666222983199987e-07
its O 0 2.452336502756225e-07
biologic O 0 5.00450096296845e-06
functions O 0 2.3295396545108815e-07
) O 0 2.6420289600537217e-07
, O 0 1.764811514703979e-07
and O 0 1.1660609544605904e-07
( O 0 2.726054617596674e-07
b O 0 9.188949547933589e-07
) O 0 2.850892997230403e-07
a O 0 5.377132197281753e-07
remarkable O 0 2.3449915715900715e-06
propensity O 0 9.681035407993477e-06
to O 0 1.545777536193782e-06
bacterial B-Disease 1 0.9999990463256836
infections I-Disease 1 0.9942995309829712
in O 0 4.993708557776699e-07
the O 0 1.7911809209181229e-06
proband O 0 0.3075850307941437
, O 0 8.215363322960911e-07
even O 0 2.8189529643896094e-07
during O 0 2.39321309436491e-07
periods O 0 3.743647880583012e-07
of O 0 4.09633713616131e-07
low O 0 2.03696072276216e-06
- O 0 4.0731301851337776e-06
dose O 0 3.516427341310191e-06
or O 0 5.262289164420508e-07
alternate O 0 1.4559010423909058e-06
- O 0 1.0780752745631617e-05
day O 0 1.1136818102386314e-05
corticosteroid O 0 0.002337460871785879
therapy O 0 7.717340486124158e-05
. O 0 4.144034028286114e-05

Other O 0 1.6653406419209205e-05
observations O 0 1.1055473805754445e-05
indicate O 0 2.2217270725377603e-06
that O 0 4.983085659659992e-07
the O 0 2.315279516551527e-06
C5D B-Disease 1 1.0
state O 0 1.6206190593948122e-06
is O 0 6.812166475356207e-07
compatible O 0 1.492706701355928e-06
with O 0 2.2936598043088452e-07
normal O 0 1.1695171906467294e-06
coagulation O 0 3.120723704341799e-05
function O 0 4.74858552479418e-07
and O 0 2.766069826520834e-07
the O 0 5.821701165587001e-07
capacity O 0 9.828695510805119e-07
to O 0 8.769629857852124e-07
mount O 0 5.49277538084425e-05
a O 0 1.6018977476051077e-05
neutrophilic O 1 0.9993502497673035
leukocytosis O 1 0.9972164630889893
during O 0 9.037582640303299e-05
pyogenic B-Disease 1 0.9999969005584717
infection I-Disease 0 0.0005167062627151608
. O 0 1.7592788935871795e-05
. O 0 3.367582758073695e-05

Susceptibility O 1 0.6563877463340759
to O 0 0.0008254305575974286
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.006688483525067568
twins O 0 1.6710344425518997e-05
: O 0 1.0591190857667243e-06
the O 0 6.831202199464315e-07
role O 0 1.2655048067244934e-06
of O 0 1.112246764023439e-06
genes O 0 6.89646356022422e-07
, O 0 2.982578962473781e-06
HLA O 1 0.9999998807907104
, O 0 6.598068011953728e-06
and O 0 3.164982899761526e-06
the O 0 1.0631168152031023e-05
environment O 0 1.9096800315310247e-05
. O 0 4.857133899349719e-05

OBJECTIVE O 0 0.0004224369768053293
To O 0 7.3137894105457235e-06
determine O 0 1.7229433524335036e-06
the O 0 1.2263344615348615e-06
relative O 0 1.0539763479755493e-06
effects O 0 1.5629281051587895e-06
of O 0 1.227273969561793e-06
genetic O 0 1.0701902510845684e-06
and O 0 4.414689271925454e-07
environmental O 0 5.329944997356506e-06
factors O 0 7.470008540622075e-07
in O 0 3.8767734622524586e-07
susceptibility O 0 1.7490776372142136e-05
to O 0 1.8725013433140703e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.999854564666748
AS B-Disease 1 1.0
) O 0 3.790464688790962e-05
. O 0 6.809266051277518e-05

METHODS O 0 0.00019101175712421536
Twins O 0 2.1879874111618847e-05
with O 0 1.0595858839224093e-06
AS B-Disease 0 0.02010299079120159
were O 0 7.229996299429331e-07
identified O 0 3.204739584816707e-07
from O 0 2.2635288132732967e-07
the O 0 6.100124778640748e-07
Royal O 0 0.00026406432152725756
National O 0 0.06568746268749237
Hospital O 1 0.9999734163284302
for O 0 0.0002514903899282217
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 0.034596726298332214
. O 0 0.00014075015496928245

Clinical O 0 0.001165998401120305
and O 0 1.4500573342957068e-05
radiographic O 0 0.00028960368945263326
examinations O 0 1.7747010133462027e-05
were O 0 1.2998295915167546e-06
performed O 0 1.296384311899601e-06
to O 0 5.380435936785943e-07
establish O 0 1.3916211401010514e-06
diagnoses O 0 0.002750462619587779
, O 0 2.9870880098314956e-06
and O 0 6.929705705260858e-06
disease O 1 0.995165228843689
severity O 0 0.015749450773000717
was O 0 2.3572729332954623e-05
assessed O 0 3.4012766718660714e-06
using O 0 4.108771065602923e-07
a O 0 6.963219334465975e-07
combination O 0 7.91676370681671e-07
of O 0 1.543129201309057e-06
validated O 0 8.91114632395329e-06
scoring O 0 1.7641244994592853e-05
systems O 0 8.038763189688325e-05
. O 0 3.8397545722546056e-05

HLA O 1 0.991292417049408
typing O 0 0.0003270397719461471
for O 0 2.3673226678511128e-05
HLA O 1 0.9999984502792358
- O 1 0.9952310919761658
B27 O 1 0.970817506313324
, O 0 1.0324811228201725e-05
HLA O 1 0.9971064925193787
- O 0 0.04083644226193428
B60 O 0 0.036879491060972214
, O 0 2.6684626845963066e-06
and O 0 1.5351646425187937e-06
HLA O 1 0.9999890327453613
- O 1 0.9996196031570435
DR1 O 1 1.0
was O 0 5.338991468306631e-05
performed O 0 1.880197828540986e-06
by O 0 4.055298461480561e-07
polymerase O 0 3.07707387037226e-06
chain O 0 2.283346248077578e-06
reaction O 0 4.2308124648116063e-07
with O 0 8.589093880573273e-08
sequence O 0 3.9695638065495586e-07
- O 0 9.238929692401143e-07
specific O 0 2.8668262075370876e-07
primers O 0 2.9216400889708893e-06
, O 0 5.26316227933421e-07
and O 0 4.362012475667143e-07
zygosity O 0 3.765166547964327e-05
was O 0 1.2002090443274938e-05
assessed O 0 1.2691460142377764e-05
using O 0 7.43533564673271e-06
microsatellite O 0 0.0002611434902064502
markers O 0 0.00017908087465912104
. O 0 8.410118607571349e-05

Genetic O 0 5.167063864064403e-05
and O 0 2.9663929126400035e-06
environmental O 0 5.741926997870905e-06
variance O 0 2.70542795988149e-06
components O 0 1.7610213944863062e-06
were O 0 3.3111419384113105e-07
assessed O 0 1.2912524880448473e-06
with O 0 1.9396991035591782e-07
the O 0 4.696795485870098e-07
program O 0 9.465803714192589e-07
Mx O 0 0.0602857805788517
, O 0 3.8726349771422974e-07
using O 0 1.5041344170185766e-07
data O 0 1.0403255856772375e-07
from O 0 1.0793498717021066e-07
this O 0 4.2422378498940816e-08
and O 0 8.601652012885097e-08
previous O 0 3.208592715964187e-07
studies O 0 4.342575152804784e-07
of O 0 8.940863267525856e-07
twins O 0 2.9807590635755332e-06
with O 0 1.8731498130364344e-06
AS B-Disease 1 0.9993141889572144
. O 0 9.390954073751345e-05

RESULTS O 0 5.949453407083638e-05
Six O 0 1.0147105058422312e-05
of O 0 7.97264146967791e-06
8 O 0 2.8383419703459367e-05
monozygotic O 0 0.00022685251315124333
( O 0 1.8777051081997342e-05
MZ O 1 1.0
) O 0 6.896714239701396e-06
twin O 0 2.1076031771372072e-05
pairs O 0 1.3402276408669422e-06
were O 0 8.651463758724276e-07
disease O 0 1.290671934839338e-05
concordant O 0 3.404691960895434e-05
, O 0 8.489164429192897e-07
compared O 0 4.818656975658087e-07
with O 0 1.3386764408096496e-07
4 O 0 1.3020541018704535e-06
of O 0 7.795474630256649e-07
15 O 0 1.638315552554559e-06
B27 O 0 2.254002720292192e-05
- O 0 6.273637609410798e-06
positive O 0 1.434456066817802e-06
dizygotic O 0 3.671977901831269e-05
( O 0 3.250471309002023e-06
DZ O 1 0.9999818801879883
) O 0 1.4352633570524631e-06
twin O 0 2.4335454327228945e-06
pairs O 0 2.012920958804898e-07
( O 0 1.3956162092654267e-07
27 O 0 5.693809157492069e-07
% O 0 1.4526207792187051e-07
) O 0 1.4392092850812332e-07
and O 0 1.0117646098706246e-07
4 O 0 1.551413220113318e-06
of O 0 1.4028421446710126e-06
32 O 0 2.1102276150486432e-05
DZ O 1 0.9999969005584717
twin O 0 2.361451151955407e-05
pairs O 0 1.3911023870605277e-06
overall O 0 2.4141586436599027e-06
( O 0 6.431572501242044e-07
12 O 0 1.0819258022820577e-06
. O 0 3.418788310227683e-07
5 O 0 3.321472604511655e-06
% O 0 2.5167298645101255e-06
) O 0 4.882012945017777e-06
. O 0 2.2581896701012738e-05

Nonsignificant O 0 0.046205755323171616
increases O 0 1.4722910236741882e-05
in O 0 1.9338176571181975e-06
similarity O 0 2.769585535133956e-06
with O 0 4.669890074637806e-07
regard O 0 1.5296361652872292e-06
to O 0 6.474984388660232e-07
age O 0 1.141476423072163e-05
at O 0 0.0013613090850412846
disease O 0 0.08030778914690018
onset O 0 9.607676474843174e-06
and O 0 2.7507331878950936e-07
all O 0 1.9708818399521988e-07
of O 0 1.0027443977378425e-06
the O 0 5.386070370150264e-06
disease O 0 0.008914888836443424
severity O 0 8.438001714239363e-06
scores O 0 1.611074026186543e-06
assessed O 0 1.5814931657587294e-06
were O 0 3.258890615143173e-07
noted O 0 8.746593493924593e-07
in O 0 9.305151138505607e-07
disease O 0 0.000161652424139902
- O 0 0.038081493228673935
concordant O 1 0.9260926246643066
MZ O 1 0.9999998807907104
twins O 0 2.548153861425817e-05
compared O 0 1.0086188012792263e-05
with O 0 8.020579116418958e-06
concordant O 0 0.2235511839389801
DZ O 1 1.0
twins O 0 0.0004953328752890229
. O 0 0.0001524159306427464

HLA O 1 0.9999995231628418
- O 1 0.9388083815574646
B27 O 0 0.26485657691955566
and O 0 1.0725467291194946e-05
B60 O 0 0.0001076517510227859
were O 0 9.838279311225051e-07
associated O 0 4.6155722088769835e-07
with O 0 2.29309122801169e-07
the O 0 3.6541973713610787e-06
disease O 0 0.023000355809926987
in O 0 6.471916549344314e-07
probands O 1 0.9953036308288574
, O 0 1.1875877135025803e-06
and O 0 4.1874679368447687e-07
the O 0 4.937083417644317e-07
rate O 0 6.90808178660518e-07
of O 0 2.1488549464265816e-06
disease O 0 3.655703039839864e-05
concordance O 0 1.3737102563027292e-05
was O 0 5.447371677291812e-06
significantly O 0 1.0335127171856584e-06
increased O 0 1.337756657449063e-06
among O 0 2.926871957242838e-06
DZ O 1 0.9999994039535522
twin O 0 1.1769615412049461e-05
pairs O 0 4.0936620848697203e-07
in O 0 1.8524347922266315e-07
which O 0 1.601109147486568e-07
the O 0 5.626540655612189e-07
co O 0 5.099484042148106e-06
- O 0 4.0039092709776014e-05
twin O 0 1.5229552445816807e-05
was O 0 3.2881407605600543e-06
positive O 0 4.3633068003146036e-07
for O 0 6.921488306943502e-07
both O 0 1.4575223303836538e-06
B27 O 0 0.00020510914328042418
and O 0 3.477387872408144e-05
DR1 O 1 0.9991372227668762
. O 0 0.00024341266544070095

Additive O 0 0.00018193814321421087
genetic O 0 1.8051941879093647e-05
effects O 0 5.92197375226533e-06
were O 0 9.660852811066434e-07
estimated O 0 6.89481339577469e-07
to O 0 2.3554468953079777e-07
contribute O 0 6.785699042666238e-07
97 O 0 6.0142679103591945e-06
% O 0 6.311241804723977e-07
of O 0 1.3256409374662326e-06
the O 0 2.032241809502011e-06
population O 0 2.257429059682181e-06
variance O 0 2.492474413884338e-05
. O 0 2.9364669899223372e-05

CONCLUSION O 0 0.000250289827818051
Susceptibility O 0 0.0001693572849035263
to O 0 4.839006578549743e-06
AS B-Disease 1 0.9849661588668823
is O 0 1.8631479861141997e-06
largely O 0 9.96297899291676e-07
genetically O 0 5.750518994318554e-07
determined O 0 3.5436579537417856e-07
, O 0 1.6825421766952786e-07
and O 0 9.205616890994861e-08
the O 0 2.814987851706974e-07
environmental O 0 2.0765694443980465e-06
trigger O 0 1.1520147609189735e-06
for O 0 4.2190387716800615e-07
the O 0 4.281837846065173e-06
disease O 0 0.18725676834583282
is O 0 3.969991212215973e-06
probably O 0 1.3705696801480372e-05
ubiquitous O 0 0.00018060790898744017
. O 0 5.219842933001928e-05

HLA O 1 0.9999877214431763
- O 0 0.0027494963724166155
B27 O 0 0.0003266618005000055
accounts O 0 3.366238615853945e-06
for O 0 6.275638497754699e-07
a O 0 1.2844594721173053e-06
minority O 0 7.594449016323779e-07
of O 0 1.0631355280565913e-06
the O 0 9.189256502395438e-07
overall O 0 5.2166569730616175e-06
genetic O 0 6.019794000167167e-06
susceptibility O 0 2.1320394807844423e-05
to O 0 7.311313765967498e-06
AS B-Disease 1 0.9999986886978149
. O 0 0.0001069470017682761

Cell O 0 0.0005764288362115622
cycle O 0 7.201042171800509e-05
- O 0 3.96311043004971e-05
dependent O 0 9.103069714910816e-06
colocalization O 0 5.8228040870744735e-05
of O 0 1.3465240954246838e-05
BARD1 O 1 0.9999943971633911
and O 0 6.553705134137999e-06
BRCA1 O 0 2.4267355911433697e-05
proteins O 0 6.821450142524554e-07
in O 0 8.236780786319287e-07
discrete O 0 6.787422080378747e-06
nuclear O 0 2.3844562747399323e-05
domains O 0 3.437883788137697e-05
. O 0 6.326822767732665e-05

Germ O 1 0.9918107986450195
- O 0 0.00013645102444570512
line O 0 1.4655865015811287e-05
mutations O 0 2.158849838451715e-06
of O 0 1.7372713045915589e-06
the O 0 3.365660631970968e-06
BRCA1 O 0 0.0005100405542179942
gene O 0 3.093746045124135e-06
predispose O 0 1.391121531924e-05
women O 0 2.1889218260184862e-07
to O 0 1.8160822889967676e-07
early O 0 1.0282303719577612e-06
- O 1 0.8806765675544739
onset O 1 0.999976634979248
breast B-Disease 1 1.0
and I-Disease 1 0.9997938275337219
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 8.936473818721424e-07
compromising O 0 9.742691872816067e-06
the O 0 1.941417849593563e-06
genes O 0 1.3504943581210682e-06
presumptive O 0 2.5710374757181853e-05
function O 0 1.124153982345888e-06
as O 0 2.3416885142069077e-06
a O 0 1.88727026397828e-05
tumor B-Disease 1 0.9999988079071045
suppressor O 1 0.999995231628418
. O 0 0.00014400795043911785

Although O 0 3.774449214688502e-05
the O 0 1.2669438547163736e-05
biochemical O 0 2.1449242922244594e-05
properties O 0 8.8782180682756e-06
of O 0 8.5529818534269e-06
BRCA1 O 0 0.00012773201160598546
polypeptides O 0 3.4969302760146093e-06
are O 0 1.2353582690138865e-07
not O 0 8.6218555850337e-08
understood O 0 8.53900189667911e-07
, O 0 2.58213844972488e-07
their O 0 1.1587577120053538e-07
expression O 0 4.2700341396084696e-07
pattern O 0 8.888688398656086e-07
and O 0 4.92946185204346e-07
subcellular O 0 8.976980097941123e-06
localization O 0 6.425456376746297e-06
suggest O 0 1.1209551757929148e-06
a O 0 1.131987914959609e-06
role O 0 2.7846524517372018e-06
in O 0 1.4861401496091275e-06
cell O 0 1.3894536095904186e-05
- O 0 3.3484746381873265e-05
cycle O 0 1.6033176507335156e-05
regulation O 0 2.732787652348634e-05
. O 0 3.256921627325937e-05

When O 0 0.00011439913214417174
resting O 0 0.0029556548688560724
cells O 0 4.856824943999527e-06
are O 0 3.7676596775781945e-07
induced O 0 1.2255837873453856e-06
to O 0 5.204703370509378e-07
proliferate O 0 3.6802032354898984e-06
, O 0 6.357636266329791e-07
the O 0 5.481900871018297e-07
steady O 0 2.822831447701901e-06
- O 0 1.4831160797257326e-06
state O 0 1.9209349488846783e-07
levels O 0 3.149294798276969e-07
of O 0 5.096057975606527e-07
BRCA1 O 0 1.1744102721422678e-06
increase O 0 1.2124340287300583e-07
in O 0 2.2692630352594279e-07
late O 0 9.819514161790721e-07
G1 O 0 6.70720255584456e-05
and O 0 4.4466926851782773e-07
reach O 0 6.391857141352375e-07
a O 0 7.633572636223107e-07
maximum O 0 1.9030942439712817e-06
during O 0 3.246010692237178e-06
S O 0 0.00015570982941426337
phase O 0 5.5643966334173456e-05
. O 0 4.096252814633772e-05

Moreover O 0 9.819243132369593e-05
, O 0 1.1546487257874105e-05
in O 0 2.516101176297525e-06
S O 0 0.00032054170151241124
phase O 0 1.5249682292051148e-05
cells O 0 3.0400419746001717e-06
, O 0 2.0099355424463283e-06
BRCA1 O 0 1.4440681297855917e-05
polypeptides O 0 4.589290711010108e-06
are O 0 6.759656230315159e-07
hyperphosphorylated O 0 4.181297117611393e-05
and O 0 1.552851927044685e-06
accumulate O 0 4.337391146691516e-06
into O 0 1.9797651020780904e-06
discrete O 0 7.236616056616185e-06
subnuclear O 0 0.00011782389628933743
foci O 0 0.00011497743980726227
termed O 0 4.128993532503955e-05
" O 0 2.3416587282554246e-05
BRCA1 O 0 0.00020850144210271537
nuclear O 0 0.00012185045488877222
dots O 0 0.0003169136180076748
. O 0 0.00013718029367737472

" O 0 0.0004252952930983156
BRCA1 O 0 0.04440892115235329
associates O 0 0.0010752722155302763
in O 0 4.480056759348372e-06
vivo O 0 1.773489566403441e-05
with O 0 1.5342923234129557e-06
a O 0 7.802960681146942e-06
structurally O 0 3.5788769309874624e-05
related O 0 1.0069043128169142e-05
protein O 0 3.361044218763709e-05
termed O 0 0.00025358080165460706
BARD1 O 1 0.9999979734420776
. O 0 0.00023146164312493056

Here O 0 1.6181193132069893e-05
we O 0 2.3634017907170346e-06
show O 0 1.214155076922907e-06
that O 0 1.6827587501211383e-07
the O 0 8.753870019972965e-07
steady O 0 3.437466375544318e-06
- O 0 1.6517005860805511e-06
state O 0 3.5724798408409697e-07
levels O 0 3.810167186202307e-07
of O 0 8.053806368479854e-07
BARD1 O 1 0.9999580383300781
, O 0 7.100130119397363e-07
unlike O 0 4.3976794472655456e-07
those O 0 1.3172260082683351e-07
of O 0 6.902873224134964e-07
BRCA1 O 0 3.5271521483082324e-05
, O 0 7.692629537814355e-07
remain O 0 1.0143621693714522e-06
relatively O 0 6.269554546634026e-07
constant O 0 1.7816388435676345e-06
during O 0 3.2123664368555183e-06
cell O 0 2.579279498604592e-05
cycle O 0 5.63296525797341e-05
progression O 0 0.00017749362450558692
. O 0 4.839993562200107e-05

However O 0 7.092046143952757e-05
, O 0 1.8213831936009228e-05
immunostaining O 0 0.0004412642738316208
revealed O 0 2.5008646844071336e-05
that O 0 3.4814740956790047e-06
BARD1 O 1 0.9998574256896973
resides O 0 5.126713585923426e-05
within O 0 2.8694978482235456e-06
BRCA1 O 0 2.834571205312386e-05
nuclear O 0 6.705455689370865e-06
dots O 0 4.835353138332721e-06
during O 0 1.2714760941889836e-06
S O 0 1.3412181942840107e-05
phase O 0 1.7462243704358116e-06
of O 0 6.752041485924565e-07
the O 0 7.272567472682567e-07
cell O 0 1.4998214510342223e-06
cycle O 0 1.0741216556198196e-06
, O 0 3.063269673475588e-07
but O 0 1.7795743190163194e-07
not O 0 1.6899458898933517e-07
during O 0 1.2085268963346607e-06
the O 0 6.693316663586302e-06
G1 O 0 0.07044210284948349
phase O 0 0.00019358309509698302
. O 0 7.85249940236099e-05

Nevertheless O 0 0.00032931845635175705
, O 0 4.642770727514289e-05
BARD1 O 1 0.949161946773529
polypeptides O 0 3.690788435051218e-05
are O 0 9.730506462801713e-07
found O 0 7.152562488954572e-07
exclusively O 0 5.892235890314623e-07
in O 0 1.6702017546776915e-07
the O 0 3.143011895190284e-07
nuclear O 0 1.1821549605883774e-06
fractions O 0 8.996226483759528e-07
of O 0 2.923720501257776e-07
both O 0 3.8735251450816577e-07
G1 O 1 0.6675238013267517
- O 0 3.137563180644065e-05
and O 0 1.7600475530343829e-06
S O 0 0.0008168572094291449
- O 0 8.411867020186037e-05
phase O 0 5.2227856940589845e-05
cells O 0 1.5899035133770667e-05
. O 0 2.5181483579217456e-05

Therefore O 0 5.6158987717935815e-05
, O 0 9.149161996901967e-06
progression O 0 1.7907124856719747e-05
to O 0 2.236062528027105e-06
S O 0 7.876025483710691e-05
phase O 0 4.4278335735725705e-06
is O 0 7.433906716869387e-07
accompanied O 0 1.4538031791744288e-06
by O 0 2.021763236825791e-07
the O 0 5.180838229534857e-07
aggregation O 0 2.5443694084970048e-06
of O 0 3.197008936695056e-06
nuclear O 0 1.477729165344499e-05
BARD1 O 0 0.005699556320905685
polypeptides O 0 1.3999371731188148e-05
into O 0 5.878176125406753e-06
BRCA1 O 0 0.00014670228119939566
nuclear O 0 7.388293306576088e-05
dots O 0 0.00034898496232926846
. O 0 0.00013402607874013484

This O 0 3.619066410465166e-05
cell O 0 5.167693961993791e-05
cycle O 0 1.8033910237136297e-05
- O 0 1.7420030417270027e-05
dependent O 0 2.392538362983032e-06
colocalization O 0 3.693630060297437e-05
of O 0 6.056941856513731e-06
BARD1 O 1 0.9999902248382568
and O 0 4.336402071203338e-06
BRCA1 O 0 1.868895924417302e-05
indicates O 0 1.4991765056038275e-06
a O 0 8.308851420224528e-07
role O 0 1.1933016139664687e-06
for O 0 9.088930141842866e-07
BARD1 O 1 0.9999023675918579
in O 0 4.522848485066788e-06
BRCA1 O 0 0.0011908068554475904
- O 0 0.02895239368081093
mediated O 0 0.0010017710737884045
tumor B-Disease 1 0.9999998807907104
suppression O 1 0.9999772310256958
. O 0 0.00024862639838829637

Ethnic O 0 0.0001287268241867423
differences O 0 2.756661706371233e-05
in O 0 5.244150997896213e-06
the O 0 9.567182132741436e-06
HFE O 1 0.8368807435035706
codon O 0 9.677778143668547e-05
282 O 0 8.41164292069152e-05
( O 0 1.6670519471517764e-05
Cys O 1 1.0
/ O 1 0.9962983727455139
Tyr O 1 0.9994832277297974
) O 0 3.5573586501413956e-05
polymorphism O 0 7.55835571908392e-05
. O 0 8.457111107418314e-05

Recent O 0 3.2860072678886354e-05
studies O 0 5.222201707510976e-06
have O 0 3.6364949096423516e-07
shown O 0 1.051127583195921e-06
that O 0 1.8185170347351232e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 1.0
HH B-Disease 1 1.0
) O 0 4.1543538827681914e-05
is O 0 1.3103790479362942e-06
likely O 0 2.871148865324358e-07
to O 0 1.7459998957747302e-07
be O 0 2.687361302378122e-07
caused O 0 5.349451726033294e-07
by O 0 1.7627694148814044e-07
homozygosity O 0 2.102865073538851e-05
for O 0 9.668898428571993e-07
a O 0 2.5277345230279025e-06
Cys282Tyr O 0 7.04323683748953e-05
mutation O 0 1.44255011491623e-06
in O 0 5.677184731212037e-07
the O 0 2.666753061930649e-06
HFE O 0 0.10251523554325104
gene O 0 1.2465205145417713e-05
located O 0 3.947246295865625e-05
4 O 0 6.831112841609865e-05
. O 0 6.587438110727817e-05

5 O 0 0.0007212557829916477
Mb O 0 0.04437245428562164
telomeric O 0 0.0032696332782506943
to O 0 8.405357220908627e-05
HLA O 1 0.9999997615814209
- O 1 0.9998363256454468
A O 1 0.863143265247345
. O 0 0.0003117223677691072

Population O 0 1.2536713256849907e-05
studies O 0 2.8617009775189217e-06
of O 0 1.2507233577707666e-06
this O 0 4.669284408009844e-07
polymorphism O 0 9.368737323711684e-07
are O 0 1.2434631457836076e-07
facilitated O 0 8.007975225154951e-07
by O 0 1.8319080652418052e-07
the O 0 5.006259016226977e-07
fact O 0 3.097788692230097e-07
that O 0 1.5029141309241822e-07
the O 0 9.04621174413478e-07
Cys282Tyr O 0 0.00015962932957336307
mutation O 0 3.386172011232702e-06
creates O 0 5.596461505774641e-06
a O 0 6.6155021158920135e-06
Rsal O 0 0.00047536398051306605
restriction O 0 2.7135132768307813e-05
site O 0 7.091619772836566e-05
. O 0 6.787969323340803e-05

We O 0 4.3151270801899955e-05
have O 0 4.171877208136721e-06
studied O 0 1.3255220437713433e-05
the O 0 5.60853641218273e-06
codon O 0 4.20440046582371e-05
282 O 0 3.344360811752267e-05
( O 0 1.6578187569393776e-05
Cys O 1 1.0
/ O 1 0.9588662981987
Tyr O 1 0.7117184400558472
) O 0 4.728741714643547e-06
polymorphism O 0 2.191985231547733e-06
in O 0 6.875108624626591e-07
different O 0 4.456193494206673e-07
ethnic O 0 3.3982612421823433e-06
groups O 0 3.858688160107704e-06
. O 0 2.4298802600242198e-05

In O 0 1.405955117661506e-05
agreement O 0 3.871685748890741e-06
with O 0 1.145049623119121e-06
previous O 0 2.392962642261409e-06
observations O 0 5.816612429043744e-06
the O 0 4.293044639780419e-06
Tyr O 0 0.05147673189640045
allele O 0 3.4624647469172487e-06
appeared O 0 2.4420405679848045e-06
to O 0 3.4731493769868393e-07
be O 0 2.595133992144838e-07
rare O 0 6.171954964884208e-07
or O 0 4.910918391942687e-07
absent O 0 9.292745062339236e-07
in O 0 4.2103209807464737e-07
Asiatic O 0 3.430360447964631e-05
( O 0 5.269299663268612e-07
Indian O 0 1.2972078593520564e-06
, O 0 1.0068159781440045e-06
Chinese O 0 4.614586941897869e-06
) O 0 4.8867545956454705e-06
populations O 0 1.465133664169116e-05
. O 0 3.518303492455743e-05

The O 0 3.0578503356082365e-05
highest O 0 2.0029676306876354e-05
allele O 0 3.2409436698799254e-06
frequency O 0 1.4275642570282798e-06
( O 0 6.951030968593841e-07
7 O 0 1.178188540507108e-06
. O 0 1.4841840823009989e-07
5 O 0 6.938665819689049e-07
% O 0 2.669236494057259e-07
) O 0 3.546166453816113e-07
was O 0 4.1575626710255165e-06
found O 0 1.488455040998815e-06
in O 0 2.078578518194263e-06
Swedes O 0 9.634997695684433e-05
. O 0 6.129933899501339e-05

Saamis O 0 0.0023859061766415834
( O 0 9.805591616895981e-06
2 O 0 9.685024451755453e-06
% O 0 1.234922933690541e-06
) O 0 4.0199580553235137e-07
and O 0 3.293973804829875e-07
Mordvinians O 0 6.759211828466505e-05
( O 0 7.006390205788193e-07
1 O 0 1.2206683095428161e-06
. O 0 1.9565088393846963e-07
8 O 0 7.319185897358693e-07
% O 0 2.246396064720102e-07
) O 0 2.512801415832655e-07
had O 0 4.4442930402510683e-07
significantly O 0 3.6590617469300923e-07
lower O 0 5.504552973434329e-07
frequencies O 0 6.035597266418335e-07
of O 0 2.245069026685087e-06
the O 0 9.383971701026894e-06
Tyr O 0 0.0024303507525473833
allele O 0 7.418312452500686e-05
. O 0 7.167172589106485e-05

Comparisons O 0 9.110796236200258e-05
with O 0 7.270006335602375e-06
allele O 0 8.362059816136025e-06
frequencies O 0 1.9502547274896642e-06
based O 0 1.1809784155047964e-06
on O 0 1.9829908524116036e-06
prevalence O 0 5.949247224634746e-06
estimates O 0 1.934998181241099e-06
of O 0 4.378423000162002e-06
HH B-Disease 1 1.0
showed O 0 4.5159263208915945e-06
some O 0 6.504059797407535e-07
disagreements O 0 1.6624022691758e-06
with O 0 2.795863736082538e-07
the O 0 9.86686245596502e-07
RFLP O 0 1.63166259881109e-05
data O 0 7.656889806639811e-07
, O 0 8.63954142005241e-07
particularly O 0 1.4728265114172245e-06
in O 0 3.321637223052676e-06
Finns O 0 0.0002450482570566237
. O 0 6.845563621027395e-05

The O 0 0.00013907159154769033
newly O 0 0.00014201915473677218
described O 0 4.548939614323899e-05
HFE O 1 0.9966523051261902
marker O 0 0.00019722543947864324
provides O 0 3.5264210964669473e-06
a O 0 1.1092943168478087e-06
new O 0 4.0416153979094815e-07
approach O 0 4.786975296156015e-07
to O 0 1.0907572800533671e-07
the O 0 1.863027563331343e-07
screening O 0 6.928925131433061e-07
of O 0 1.4026416010892717e-06
HH B-Disease 1 1.0
as O 0 1.6649122471790179e-06
well O 0 3.6583813312063285e-07
as O 0 2.433999668483011e-07
studies O 0 2.567745980286418e-07
of O 0 3.8596198237428325e-07
the O 0 3.2494747870259744e-07
relationship O 0 2.5400754566362593e-07
between O 0 2.8319055900283274e-07
the O 0 2.5594706585252425e-06
HFE O 1 0.9999974966049194
Tyr O 1 0.9959856867790222
allele O 0 8.414955118496437e-06
and O 0 1.9406718365644338e-06
different O 0 1.857206711974868e-06
disorders O 1 0.9999827146530151
including O 1 0.9688448905944824
cancer B-Disease 1 1.0

Autosomal B-Disease 1 0.9999884366989136
dominant I-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999997615814209
associated O 0 1.435152535123052e-05
with O 0 2.760430106718559e-06
a O 0 7.823851774446666e-06
missense O 0 3.083743649767712e-05
mutation O 0 4.339004590292461e-06
encoding O 0 9.504097761237063e-06
Gly23 O 1 0.5165373682975769
- O 0 0.0020016103517264128
- O 0 0.0010456772288307548
> O 0 0.00011598446144489571
Val O 0 0.035794444382190704
in O 0 2.5320887289126404e-05
neurophysin O 1 0.9459938406944275
II O 1 0.9999998807907104
. O 0 0.0004323436878621578

Autosomal B-Disease 1 0.9999748468399048
dominant I-Disease 1 0.9999988079071045
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.11684777587652206
ADNDI B-Disease 1 1.0
) O 0 8.238569535023998e-06
is O 0 1.7457481362725957e-06
an O 0 1.3795918675896246e-05
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.11460235714912415
by O 0 2.761222731351154e-06
progressive O 1 0.9999998807907104
degeneration O 1 1.0
of O 1 0.9999978542327881
the O 1 0.735525369644165
magnocellular O 1 0.9999992847442627
neurons O 0 1.0180701792705804e-05
of O 0 1.0694856428017374e-05
the O 0 1.1987699508608785e-05
hypothalamus O 0 0.0004687005130108446
leading O 0 4.6222106902860105e-05
to O 0 1.1177952501384425e-06
decreased O 0 3.188392156516784e-06
ability O 0 4.168804821347294e-07
to O 0 2.3137620530633285e-07
produce O 0 5.25621999258874e-07
the O 0 1.0774612064778921e-06
hormone O 0 5.220747880230192e-06
arginine O 0 1.6955271348706447e-05
vasopressin O 0 7.607454608660191e-05
( O 0 1.4609701793233398e-05
AVP O 1 0.9999957084655762
) O 0 5.470204268931411e-05
. O 0 7.501228537876159e-05

Affected O 0 4.404803257784806e-05
individuals O 0 1.6736357792979106e-06
are O 0 4.5489835542866786e-07
not O 0 3.787964999446558e-07
symptomatic O 0 0.00036944448947906494
at O 0 1.1514883226482198e-05
birth O 0 1.505669956713973e-06
, O 0 6.263919090088166e-07
but O 0 3.6243042700334627e-07
usually O 0 4.878987738266005e-07
develop O 0 3.660726861198782e-06
diabetes B-Disease 1 0.9999349117279053
insipidus I-Disease 1 0.9943181872367859
at O 0 9.106299330596812e-06
1 O 0 8.758197509450838e-06
- O 0 1.3614092495117802e-05
6 O 0 2.6094929125974886e-05
yr O 0 0.0008124126470647752
of O 0 2.0529743778752163e-05
age O 0 4.45997211500071e-05
. O 0 6.0345002566464245e-05

The O 0 4.17963856307324e-05
genetic O 0 1.7065223801182583e-05
locus O 0 6.720718374708667e-05
of O 0 8.689975402376149e-06
the O 0 8.568477824155707e-06
disease O 0 0.04934303089976311
is O 0 1.3313903082234901e-06
the O 0 2.3552252059744205e-06
AVP O 1 1.0
- O 1 0.9124600887298584
neurophysin O 1 0.9999731779098511
II O 1 1.0
( O 0 4.773080490849679e-06
NPII O 1 0.9999849796295166
) O 0 1.018368038785411e-06
gene O 0 4.827087423109333e-07
, O 0 3.812958766502561e-07
and O 0 3.195071656136861e-07
mutations O 0 8.11094480468455e-07
that O 0 2.7174783667760494e-07
cause O 0 6.52262860967312e-06
ADNDI B-Disease 1 1.0
have O 0 2.618557459754811e-07
been O 0 3.229615685995668e-07
found O 0 1.0015309470645661e-07
in O 0 9.058974370645956e-08
both O 0 6.261517881966938e-08
the O 0 1.8451565608756937e-07
signal O 0 7.24822257325286e-07
peptide O 0 8.915226885619632e-07
of O 0 1.2130243476349278e-06
the O 0 2.5620274755056016e-06
prepro O 0 0.06414168328046799
- O 0 0.14190040528774261
AVP O 1 0.9999998807907104
- O 0 0.05420277640223503
NPII O 1 0.9999685287475586
precursor O 0 2.816528285620734e-05
and O 0 3.0127134778012987e-06
within O 0 6.809504611737793e-06
NPII O 1 0.9998075366020203
itself O 0 4.492970765568316e-05
. O 0 3.996287705376744e-05

An O 0 4.2308900447096676e-05
affected O 0 1.474255168432137e-05
girl O 0 1.944063842529431e-05
who O 0 1.6075258599812514e-06
presented O 0 1.1658835319394711e-06
at O 0 9.991551905841334e-07
9 O 0 1.1061558780056657e-06
months O 0 2.620815848786151e-07
of O 0 2.877387714761426e-07
age O 0 4.1524333482811926e-07
and O 0 1.2254103864961507e-07
her O 0 4.337028940426535e-07
similarly O 0 3.914713602171105e-07
affected O 0 2.205757425599586e-07
younger O 0 5.672163183589873e-07
brother O 0 1.238438699147082e-06
and O 0 1.826747819677621e-07
father O 0 5.017984108235396e-07
were O 0 1.0182014875681489e-07
all O 0 6.408196639995367e-08
found O 0 6.414861530856797e-08
to O 0 5.830124294448069e-08
have O 0 6.65968400426209e-08
a O 0 4.581304722250934e-07
novel O 0 3.7149650324863615e-06
missense O 0 6.953179308766266e-06
mutation O 0 1.0927725497822394e-06
( O 0 8.47113710733538e-07
G1758 O 0 3.8392492569983006e-05
- O 0 1.8778519006446004e-05
- O 0 1.926029108290095e-05
> O 0 8.430232810496818e-06
T O 0 7.241518233058741e-06
) O 0 2.833702126281423e-07
encoding O 0 4.015712704585894e-07
the O 0 4.3406706140558526e-07
amino O 0 3.265398902385641e-07
acid O 0 8.318151571984345e-07
substitution O 0 3.3920448458957253e-06
Gly23 O 0 0.0005555839743465185
- O 0 0.00022266355517785996
- O 0 0.0006822593277320266
> O 0 0.00026967807207256556
Val O 0 0.2517506182193756
within O 0 4.921166328131221e-05
NPII O 1 0.99947589635849
. O 0 0.00020967067393939942

The O 0 0.00011651376553345472
mutation O 0 3.626370380516164e-05
was O 0 1.899459857668262e-05
confirmed O 0 4.81748520542169e-06
by O 0 2.345354005228728e-06
restriction O 0 1.6083346054074354e-05
endonuclease O 0 0.00030854978831484914
analysis O 0 3.8722169847460464e-05
. O 0 5.282558413455263e-05

A O 0 0.001116126892156899
T1 O 1 0.9723578691482544
- O 0 0.00028065615333616734
weighted O 0 7.130591257009655e-05
magnetic O 0 1.657047323533334e-05
resonance O 0 8.496692316839471e-06
imaging O 0 1.3168460100132506e-05
of O 0 3.4329846130276565e-06
the O 0 6.865477644169005e-06
fathers O 0 2.5810408260440454e-05
pituitary O 1 0.9999992847442627
gland O 1 0.9999911785125732
demonstrates O 0 2.0239162040525116e-05
an O 0 9.174482329399325e-06
attenuated O 0 0.0026395933236926794
posterior O 0 0.1731630563735962
pituitary O 1 1.0
bright O 1 0.992975115776062
spot O 0 0.007959245704114437
. O 0 0.00015545019414275885

This O 0 1.913791311380919e-05
mutation O 0 1.2711893759842496e-05
may O 0 1.2143542562625953e-06
be O 0 2.781677324037446e-07
valuable O 0 8.391294272769301e-07
for O 0 2.1726995669268945e-07
developing O 0 2.1121236670751387e-07
models O 0 5.554332460633304e-07
of O 0 2.5325387014163425e-06
dominantly B-Disease 1 0.9999985694885254
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 5.545696240005782e-06
as O 0 4.400486091071798e-07
the O 0 2.745695724115649e-07
early O 0 2.901629159168806e-07
age O 0 5.058088277110073e-07
of O 0 9.529987323730893e-07
onset O 0 0.02743649296462536
of O 0 0.0067295231856405735
symptoms O 0 0.04969591274857521
suggests O 0 6.7864493757952e-07
that O 0 6.624274817568221e-08
this O 0 8.780393301321965e-08
mutation O 0 3.228858247439348e-07
may O 0 1.5946358189466991e-07
be O 0 1.605832835593901e-07
particularly O 0 4.611286783529067e-07
deleterious O 0 4.68174312118208e-06
to O 0 1.3052891745246598e-06
the O 0 7.511954208894167e-06
magnocellular O 1 0.5478386282920837
neuron O 0 0.00015964030171744525
. O 0 2.0452063836273737e-05
. O 0 5.5037970014382154e-05

Frequent O 0 0.0003380464331712574
inactivation O 0 0.0016054277075454593
of O 0 0.00037400712608359754
PTEN O 1 1.0
/ O 1 0.9999760389328003
MMAC1 O 1 1.0
in O 0 8.085121226031333e-05
primary O 1 0.9999985694885254
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00034531456185504794

Sporadic B-Disease 1 0.9999996423721313
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 0.04159731790423393
the O 0 5.870535005669808e-06
most O 0 8.430309321738605e-07
common O 0 1.234218871104531e-06
male B-Disease 0 5.187505394133041e-06
cancer I-Disease 0 0.09594296663999557
in O 0 1.3280269683946244e-07
the O 0 3.835157258436084e-07
Western O 0 9.74899080574687e-07
world O 0 3.7524841900449246e-07
, O 0 1.903208897147124e-07
yet O 0 6.873011670904816e-08
many O 0 2.8262039819537677e-08
of O 0 1.1918011466605094e-07
the O 0 1.641816140818264e-07
major O 0 8.95145092272287e-07
genetic O 0 6.336438787002407e-07
events O 0 3.5645197726807965e-07
involved O 0 4.300808313928428e-07
in O 0 1.6877281439064973e-07
the O 0 2.912366596774518e-07
progression O 0 3.0150124530337052e-06
of O 0 5.787711643279181e-07
this O 0 2.836568171460385e-07
often O 0 1.1465805300758802e-06
fatal O 1 0.9992318153381348
cancer B-Disease 1 0.9981389045715332
remain O 0 2.1263367671053857e-06
to O 0 9.913853773468873e-07
be O 0 4.774400622409303e-06
elucidated O 0 0.0001733985700411722
. O 0 8.358709601452574e-05

Numerous O 0 0.00029648919007740915
cytogenetic O 0 0.21420376002788544
and O 0 3.4347143810009584e-05
allelotype O 1 0.9815607070922852
studies O 0 1.5319632439059205e-05
have O 0 1.2859610478699324e-06
reported O 0 1.918356929309084e-06
frequent O 0 5.524476364371367e-06
loss O 0 4.486882244236767e-05
of O 0 3.971577825723216e-05
heterozygosity O 1 0.9992280006408691
on O 0 1.5823161447769962e-05
chromosomal O 0 0.0008361205109395087
arm O 0 0.00022764161985833198
10q O 0 0.00586614478379488
in O 0 1.0615768587740604e-05
sporadic B-Disease 1 0.9988652467727661
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00026787532260641456

Deletion O 0 0.0002504597941879183
mapping O 0 4.091279333806597e-05
studies O 0 5.416978183347965e-06
have O 0 7.790221161485533e-07
unambiguously O 0 1.1419108886912e-05
identified O 0 1.4247597164285253e-06
a O 0 1.5829415360713028e-06
region O 0 2.0572604171320563e-06
of O 0 2.569347998360172e-06
chromosome O 0 3.613650733313989e-06
10q23 O 0 1.647198587306775e-05
to O 0 5.366927098293672e-07
be O 0 3.07115897157928e-07
the O 0 7.008689522081113e-07
minimal O 0 4.677307515521534e-06
area O 0 1.3012140698265284e-05
of O 0 1.6735095414333045e-05
loss O 0 0.0025499211624264717
. O 0 0.00012205069651827216

A O 0 0.00016562070231884718
new O 0 3.3358119253534824e-05
tumor B-Disease 1 0.9580433964729309
suppressor O 1 0.9989309906959534
gene O 0 1.5450492355739698e-05
, O 0 1.137364779424388e-05
PTEN O 1 1.0
/ O 1 0.9995995163917542
MMAC1 O 1 1.0
, O 0 9.402820069226436e-06
was O 0 2.260938890685793e-05
isolated O 0 2.5908138923114166e-06
recently O 0 1.0707987030400545e-06
at O 0 1.1611432455538306e-06
this O 0 2.2501009766529023e-07
region O 0 6.814921675868391e-07
of O 0 8.760634955251589e-07
chromosome O 0 2.316083282494219e-06
10q23 O 0 2.189849692513235e-05
and O 0 4.879257744505594e-07
found O 0 1.853102702398246e-07
to O 0 8.789777439233148e-08
be O 0 6.975695043820451e-08
inactivated O 0 1.7908223526319489e-06
by O 0 1.4803278247654816e-07
mutation O 0 4.763385561545874e-07
in O 0 4.199954162231734e-07
three O 0 9.80186177912401e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.6710084676742554
lines O 0 5.982633592793718e-05
. O 0 7.006967643974349e-05

We O 0 4.053267912240699e-05
screened O 0 0.0001297405397053808
80 O 0 0.0023110019974410534
prostate B-Disease 1 1.0
tumors I-Disease 1 1.0
by O 0 1.9895428522431757e-06
microsatellite O 0 4.367514338809997e-05
analysis O 0 1.3428082183963852e-06
and O 0 6.948790769456537e-07
found O 0 8.295422730952851e-07
chromosome O 0 1.480394416830677e-06
10q23 O 0 1.2108041119063273e-05
to O 0 3.715939271842217e-07
be O 0 3.781316593176598e-07
deleted O 0 3.1080412554729264e-06
in O 0 9.703169325803174e-07
23 O 0 9.251589290215634e-06
cases O 0 6.990184829192003e-06
. O 0 2.8659929739660583e-05

We O 0 2.4201604901463725e-05
then O 0 6.946988378331298e-06
proceeded O 0 2.972867150674574e-06
with O 0 3.434913082855928e-07
sequence O 0 4.4448398739405093e-07
analysis O 0 2.3780539493145625e-07
of O 0 6.324569881144271e-07
the O 0 2.078800662275171e-06
entire O 0 4.848868047702126e-05
PTEN O 1 1.0
/ O 1 0.9010536074638367
MMAC1 O 1 0.9999996423721313
coding O 0 7.861325866542757e-05
region O 0 2.3386555767501704e-06
and O 0 5.938313165643194e-07
tested O 0 4.300816556224163e-07
for O 0 2.1902206981394556e-07
homozygous O 0 9.535606295685284e-07
deletion O 0 6.929361688889912e-07
with O 0 1.819497441601925e-07
new O 0 7.36256936306745e-07
intragenic O 0 0.0093025341629982
markers O 0 4.901793545286637e-06
in O 0 3.4511927538005693e-07
these O 0 1.0815817574894027e-07
23 O 0 8.720989512767119e-07
cases O 0 3.048587302600936e-07
with O 0 6.390449698301381e-07
10q23 O 0 0.11627785116434097
loss O 0 0.0012121362378820777
of O 0 0.001208954956382513
heterozygosity O 1 0.9998494386672974
. O 0 0.00021481153089553118

The O 0 2.3416228941641748e-05
identification O 0 5.83688915867242e-06
of O 0 3.486388095552684e-06
the O 0 1.7660518096818123e-06
second O 0 3.819374796876218e-06
mutational O 0 9.753294580150396e-05
event O 0 2.455857156746788e-06
in O 0 3.3829141443675326e-07
10 O 0 6.9667459001721e-07
( O 0 5.058623742115742e-07
43 O 0 2.1925206965534016e-06
% O 0 6.940372827557439e-07
) O 0 3.971498244936811e-06
tumors B-Disease 1 0.9999984502792358
establishes O 0 0.00026622851146385074
PTEN O 1 1.0
/ O 1 0.9351597428321838
MMAC1 O 1 0.9999934434890747
as O 0 1.907200385176111e-06
a O 0 1.5284506389434682e-06
main O 0 5.272906491882168e-06
inactivation O 0 4.628783426596783e-05
target O 0 2.805451686072047e-06
of O 0 1.91657227333053e-06
10q O 0 0.00017503832350485027
loss O 0 1.9446904843789525e-05
in O 0 3.920997187378816e-06
sporadic B-Disease 1 0.9999332427978516
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.281755900592543e-05
. O 0 6.036549530108459e-05

Risk O 0 0.0005056200898252428
reversals O 0 0.00013252155622467399
in O 0 8.166407496901229e-06
predictive O 0 5.623652759823017e-05
testing O 0 2.4108172510750592e-05
for O 0 7.866440864745528e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0002641310857143253

The O 0 3.0303392122732475e-05
first O 0 7.032510893623112e-06
predictive O 0 1.427160077582812e-05
testing O 0 3.824470240942901e-06
for O 0 1.203719057230046e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 4.630439889297122e-06
HD B-Disease 1 0.9999550580978394
) O 0 8.848969628161285e-07
was O 0 1.2338799706412829e-06
based O 0 1.5903090400115616e-07
on O 0 1.9040585641505459e-07
analysis O 0 1.778376628180922e-07
of O 0 5.928676500843721e-07
linked O 0 2.2234057723835576e-06
polymorphic O 0 3.866859060508432e-06
DNA O 0 1.2115514209654066e-06
markers O 0 1.7467006045990274e-06
to O 0 2.7403567059991474e-07
estimate O 0 6.718383929182892e-07
the O 0 3.619893220729864e-07
likelihood O 0 1.2789919310307596e-06
of O 0 1.1584046433199546e-06
inheriting O 0 7.857051969040185e-06
the O 0 2.0463103282963857e-06
mutation O 0 3.263336566305952e-06
for O 0 3.2720718081691302e-06
HD B-Disease 1 0.9952027797698975
. O 0 9.340100950794294e-05

Limits O 0 8.196870476240292e-05
to O 0 5.070165116194403e-06
accuracy O 0 6.333838427963201e-06
included O 0 1.9048699186896556e-06
recombination O 0 8.672099056639127e-07
between O 0 2.669618197614909e-07
the O 0 3.190382642515033e-07
DNA O 0 6.457483436861366e-07
markers O 0 1.0319339480702183e-06
and O 0 1.8235223819829116e-07
the O 0 2.769855029782775e-07
mutation O 0 3.223971987154073e-07
, O 0 2.62496342884333e-07
pedigree O 0 3.2468897188664414e-06
structure O 0 1.1300292044325033e-06
, O 0 3.1350609219771286e-07
and O 0 1.1186916282213133e-07
whether O 0 8.941231754988621e-08
DNA O 0 1.844315562493648e-07
samples O 0 1.0243081760563655e-07
were O 0 8.273121920865378e-08
available O 0 1.4041295059996628e-07
from O 0 5.074056161902263e-07
family O 0 2.6366501515440177e-06
members O 0 3.5470022794470424e-06
. O 0 2.7286805561743677e-05

With O 0 1.065464584826259e-05
direct O 0 3.123796432191739e-06
tests O 0 5.393350761551119e-07
for O 0 2.536028489430464e-07
the O 0 8.150452117661189e-07
HD B-Disease 1 0.9991353154182434
mutation O 0 1.3434255379252136e-06
, O 0 4.3553825435083127e-07
we O 0 9.098021536146916e-08
have O 0 3.785176616588615e-08
assessed O 0 2.838586965481227e-07
the O 0 2.2251784059790225e-07
accuracy O 0 4.967233735442278e-07
of O 0 3.908293706444965e-07
results O 0 8.192129286044292e-08
obtained O 0 7.069374419188534e-08
by O 0 5.0358607950329315e-08
linkage O 0 1.4145136901788646e-06
approaches O 0 9.492399044574995e-07
when O 0 2.930665914391284e-07
requested O 0 2.9691932468267623e-07
to O 0 1.4274579029915913e-07
do O 0 1.9884986102169933e-07
so O 0 1.4031283512849768e-07
by O 0 1.535489815296387e-07
the O 0 7.105535360096837e-07
test O 0 1.897190145427885e-06
individuals O 0 2.033174268945004e-06
. O 0 1.9232522390666418e-05

For O 0 1.5020794307929464e-05
six O 0 2.7930595933867153e-06
such O 0 6.14199109350011e-07
individuals O 0 2.937061935881502e-07
, O 0 6.058248800400179e-07
there O 0 4.5507971435654326e-07
was O 0 3.617740276240511e-06
significant O 0 1.5745961263746722e-06
disparity O 0 1.3422367374005262e-05
between O 0 1.555346329951135e-06
the O 0 5.730269549530931e-06
tests O 0 5.314144800649956e-06
. O 0 2.2076539607951418e-05

Three O 0 2.3944736312841997e-05
went O 0 1.4963488865760155e-05
from O 0 2.056958010143717e-06
a O 0 2.337939804419875e-06
decreased O 0 3.283831574663054e-06
risk O 0 6.134433760962565e-07
to O 0 1.466913772674161e-07
an O 0 2.146631317145875e-07
increased O 0 3.368276395576686e-07
risk O 0 8.579856967116939e-07
, O 0 1.3145216826160322e-07
while O 0 1.071052508905268e-07
in O 0 8.863820966098501e-08
another O 0 2.7087381226920115e-07
three O 0 1.8946214197512745e-07
the O 0 1.0635959597493638e-06
risk O 0 8.612726560386363e-06
was O 0 4.27924569521565e-05
decreased O 0 4.977572461939417e-05
. O 0 4.149305823375471e-05

Knowledge O 0 0.00010061762441182509
of O 0 1.3162433788238559e-05
the O 0 3.1959236821421655e-06
potential O 0 2.343576397834113e-06
reasons O 0 7.473158234461152e-07
for O 0 1.2188962728032493e-07
these O 0 3.5254011265806184e-08
changes O 0 5.122057089579357e-08
in O 0 5.235668254499615e-08
results O 0 7.550125502575611e-08
and O 0 9.183257532185962e-08
impact O 0 5.511665790436382e-07
of O 0 5.175085675546143e-07
these O 0 6.999231771942505e-08
risk O 0 4.798200166078459e-07
reversals O 0 1.3549179129768163e-06
on O 0 6.960344194339996e-07
both O 0 2.2952528411224193e-07
patients O 0 2.0018806878852047e-07
and O 0 1.078321005820726e-07
the O 0 3.87728732675896e-07
counseling O 0 7.488861797355639e-07
team O 0 2.5211497245436476e-07
can O 0 6.643963956776133e-08
assist O 0 2.700149366319238e-07
in O 0 1.0529199556685853e-07
the O 0 1.0235289238380574e-07
development O 0 9.405031420328669e-08
of O 0 2.230392226465483e-07
strategies O 0 2.4441462187496654e-07
for O 0 7.341038354979901e-08
the O 0 2.6944746878143633e-07
prevention O 0 2.6634538698999677e-06
and O 0 1.5371908546057966e-07
, O 0 1.9800830841631978e-07
where O 0 1.7797678708575404e-07
necessary O 0 1.0282269613526296e-07
, O 0 1.0579243081565437e-07
management O 0 5.206326250117854e-07
of O 0 4.816061505152902e-07
a O 0 1.3050002962700091e-06
risk O 0 1.6734060181988752e-06
reversal O 0 1.2369514479360078e-06
in O 0 2.0182146442948579e-07
any O 0 4.140198939239781e-07
predictive O 0 2.5134079351119e-06
testing O 0 2.218511099272291e-06
program O 0 4.938194706483046e-06
. O 0 6.032459168636706e-06
. O 0 2.2296986571745947e-05

A O 0 0.00028482056222856045
novel O 0 0.0001222911523655057
common O 0 1.048057310981676e-05
missense O 0 6.910785305080935e-05
mutation O 0 8.286794582090806e-06
G301C O 0 3.5196055250708014e-05
in O 0 7.010895046732912e-07
the O 0 1.3443200259644073e-06
N O 0 9.918886462401133e-06
- O 0 2.1685356841771863e-05
acetylgalactosamine O 0 0.00026599582633934915
- O 0 3.1268697057385e-05
6 O 0 2.909659087890759e-05
- O 0 5.080919072497636e-05
sulfate O 0 7.233030919451267e-05
sulfatase O 0 0.0009397966205142438
gene O 0 3.574101720005274e-05
in O 0 3.18321654049214e-05
mucopolysaccharidosis B-Disease 1 0.9990334510803223
IVA I-Disease 1 1.0
. O 0 0.0014281097101047635

Mucopolysaccharidosis B-Disease 1 0.9999990463256836
IVA I-Disease 1 1.0
( O 1 0.9013530611991882
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 6.371893687173724e-05
is O 0 7.328493666136637e-06
an O 0 8.000685738807078e-06
autosomal B-Disease 1 0.9905248284339905
recessive I-Disease 1 0.9999995231628418
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.02603919990360737
by O 0 9.325165706286498e-07
a O 0 2.182931530114729e-05
genetic B-Disease 1 0.9993395209312439
defect I-Disease 1 0.9999257326126099
in O 0 2.41363136410655e-06
N O 0 4.418965181685053e-05
- O 0 4.629476461559534e-05
acetylgalactosamine O 0 0.0015854132361710072
- O 0 2.5099390768446028e-05
6 O 0 1.7150190615211613e-05
- O 0 5.531842907657847e-05
sulfate O 0 8.25212337076664e-05
sulfatase O 1 0.9155322313308716
( O 0 2.4429476980003528e-05
GALNS O 1 0.9999793767929077
) O 0 3.946937795262784e-05
. O 0 8.14161539892666e-05

In O 0 1.5731440726085566e-05
previous O 0 6.588447376998374e-06
studies O 0 2.2264912331593223e-06
, O 0 8.974992056209885e-07
we O 0 1.937478799618475e-07
have O 0 9.166021186501894e-08
found O 0 1.5331529823470191e-07
two O 0 6.35129779880117e-08
common O 0 2.553920523951092e-07
mutations O 0 4.6965894284767273e-07
in O 0 5.469555617310107e-07
Caucasians O 0 3.827795808319934e-05
and O 0 1.745323743307381e-06
Japanese O 0 3.419493805267848e-05
, O 0 5.926561698288424e-06
respectively O 0 1.6348742065019906e-05
. O 0 3.5038654459640384e-05

To O 0 4.4452383008319885e-05
characterize O 0 7.309651118703187e-05
the O 0 8.623904250271153e-06
mutational O 0 0.00011210755474166945
spectrum O 0 7.845079380786046e-06
in O 0 4.789847025676863e-07
various O 0 2.493983686235879e-07
ethnic O 0 3.8228660059758113e-07
groups O 0 1.550735646560497e-07
, O 0 2.086398325218397e-07
mutations O 0 1.7168501642572664e-07
in O 0 1.7354815895487263e-07
the O 0 8.113552212307695e-07
GALNS O 1 0.9996902942657471
gene O 0 6.859312406959361e-07
in O 0 3.272875233051309e-07
Colombian O 0 0.0004041845095343888
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.0010796448914334178
were O 0 8.089979246506118e-07
investigated O 0 4.847070613323012e-06
, O 0 4.43776229985815e-07
and O 0 2.3240676227942458e-07
genetic O 0 5.560618205890933e-07
backgrounds O 0 2.9026503511886403e-07
were O 0 1.9491747593747277e-07
extensively O 0 5.996176923872554e-07
analyzed O 0 3.0671108675051073e-07
to O 0 1.7815816022448416e-07
identify O 0 2.0196704042518832e-07
racial O 0 7.686923595429107e-07
origin O 0 2.1410455985915178e-07
, O 0 1.55352580577528e-07
based O 0 1.8636778520431108e-07
on O 0 4.561333639685472e-07
mitochondrial O 0 1.643617565605382e-06
DNA O 0 1.8844056057787384e-06
( O 0 1.6929540151977562e-06
mtDNA O 0 3.62244918505894e-06
) O 0 3.994774942839285e-06
lineages O 0 2.433748886687681e-05
. O 0 5.028244049753994e-05

Three O 0 5.19222448929213e-05
novel O 0 8.840629016049206e-05
missense O 0 5.528451583813876e-05
mutations O 0 5.624573532259092e-06
never O 0 2.9760581128357444e-06
identified O 0 6.373419978444872e-07
previously O 0 6.06194817009964e-07
in O 0 2.0557803281917586e-07
other O 0 1.3796132236620906e-07
populations O 0 1.3936330844899203e-07
and O 0 1.177464667989625e-07
found O 0 1.9684117091856024e-07
in O 0 1.5275283260507422e-07
16 O 0 5.518766101886285e-07
out O 0 2.74294279734022e-07
of O 0 4.108034374894487e-07
19 O 0 2.972152515212656e-06
Colombian O 0 1.8318978618481196e-05
MPS B-Disease 0 0.12482663244009018
IVA I-Disease 1 1.0
unrelated O 0 5.0870563427452e-05
alleles O 0 4.7102885218919255e-06
account O 0 2.2751514734409284e-06
for O 0 4.751869710162282e-06
84 O 0 0.00014425560948438942
. O 0 5.469964162330143e-05

2 O 0 5.797195990453474e-05
% O 0 6.805012162658386e-06
of O 0 4.484827059059171e-06
the O 0 3.889648723998107e-06
alleles O 0 2.6291572794434614e-06
in O 0 2.402791324129794e-06
this O 0 4.1263851926487405e-06
study O 0 2.592581404314842e-05
. O 0 5.393202809500508e-05

The O 0 0.00017963018035516143
G301C O 0 0.0010078806662932038
and O 0 2.6961790354107507e-05
S162F O 0 0.0003823472943622619
mutations O 0 2.0422616216819733e-05
account O 0 5.1026895562245045e-06
for O 0 8.30755743663758e-06
68 O 0 0.00025233032647520304
. O 0 0.00011303997598588467

4 O 0 0.00020287376537453383
% O 0 2.8423348339856602e-05
and O 0 1.1497557352413423e-05
10 O 0 6.120267062215135e-05
. O 0 0.0001066977420123294

5 O 0 3.240529622416943e-05
% O 0 4.635397544916486e-06
of O 0 2.4494902390870266e-06
mutations O 0 1.4283036762208212e-06
, O 0 9.014769375426113e-07
respectively O 0 1.0086351949212258e-06
, O 0 6.876551310597279e-07
whereas O 0 5.771665883003152e-07
the O 0 7.75449336742895e-07
remaining O 0 6.364859018503921e-06
F69V O 1 0.9999665021896362
is O 0 1.5897039702394977e-06
limited O 0 5.911552989346092e-07
to O 0 5.054018856753828e-07
a O 0 2.70998316409532e-06
single O 0 8.169351531250868e-06
allele O 0 3.7948448152747005e-05
. O 0 4.1275168769061565e-05

The O 0 5.785498797195032e-05
skewed O 0 8.194738620659336e-05
prevalence O 0 4.922870721202344e-05
of O 0 1.1941534467041492e-05
G301C O 0 0.002133474452421069
in O 0 1.5910660522422404e-06
only O 0 7.409325917251408e-07
Colombian O 0 1.4774389455851633e-05
patients O 0 1.0669901939763804e-06
and O 0 6.334892077575205e-07
haplotype O 0 5.449106993182795e-06
analysis O 0 3.028947332950338e-07
by O 0 1.9679632146107906e-07
restriction O 0 9.773901865628432e-07
fragment O 0 1.4740941196578206e-06
length O 0 3.9722604583403154e-07
polymorphisms O 0 6.139414949757338e-07
in O 0 2.8995683010180073e-07
the O 0 1.121081254495948e-06
GALNS O 1 0.898769736289978
gene O 0 1.6903276218727115e-06
suggest O 0 6.363787292684719e-07
that O 0 3.257616754126502e-07
G301C O 0 3.0462751965387724e-05
originated O 0 2.4888329335226445e-06
from O 0 1.4686245322081959e-06
a O 0 3.7675911244150484e-06
common O 0 6.834552550571971e-06
ancestor O 0 7.405801443383098e-05
. O 0 6.344755092868581e-05

Investigation O 0 6.943676999071613e-05
of O 0 7.881561941758264e-06
the O 0 2.466548494339804e-06
genetic O 0 1.8318468164579826e-06
background O 0 9.883682423605933e-07
by O 0 1.9640314974367357e-07
means O 0 4.459671174572577e-07
of O 0 7.637141266059189e-07
mtDNA O 0 1.2263320741112693e-06
lineages O 0 8.444744707958307e-07
indicate O 0 2.3802775217518501e-07
that O 0 9.020404689863426e-08
all O 0 1.2644586888654885e-07
our O 0 2.8407833951860084e-07
patients O 0 4.1911434323083085e-07
are O 0 9.535772704793999e-08
probably O 0 1.375672013637086e-06
of O 0 3.8789803511463106e-06
native O 0 1.4476780052063987e-05
American O 0 4.095729309483431e-05
descent O 0 0.000225917887291871

Low O 0 0.00012977689038962126
frequency O 0 2.23989445657935e-05
of O 0 1.2565009456011467e-05
BRCA1 O 0 7.851968257455155e-05
germline O 0 2.7040327040595002e-05
mutations O 0 2.1193200154812075e-06
in O 0 7.208543593151262e-07
45 O 0 6.379771548381541e-06
German O 1 0.9999984502792358
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.5326926333946176e-05
. O 0 5.6008266255958006e-05

In O 0 1.897308902698569e-05
this O 0 2.303173459949903e-06
study O 0 1.6855851754371542e-06
we O 0 4.793800485458632e-07
investigated O 0 2.9392183478194056e-06
45 O 0 5.332110958988778e-06
German O 1 0.999302864074707
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.7144065484208113e-07
for O 0 5.05987827637e-07
germline O 0 9.048394531419035e-06
mutations O 0 8.906100674721529e-07
in O 0 1.1292310091448599e-06
the O 0 6.866459898446919e-06
BRCA1 O 0 0.00019402452744543552
gene O 0 3.139257023576647e-05
. O 0 4.889721822110005e-05

We O 0 2.464479985064827e-05
identified O 0 1.1197221283509862e-05
four O 0 3.778994596359553e-06
germline O 0 3.1019331800052896e-05
mutations O 0 1.1149802503496176e-06
in O 0 4.828339683626837e-07
three O 0 2.6756233637570404e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9964990615844727
families O 0 1.159282732032807e-07
and O 0 1.1704305080684207e-07
in O 0 2.3200017551516794e-07
one O 0 3.3442174753872678e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.2533357676147716e-06
. O 0 1.1660564069870816e-07
among O 0 1.4273652482188481e-07
these O 0 3.501370571257212e-08
were O 0 1.5789326823778538e-07
one O 0 3.360140112818044e-07
frameshift O 0 8.294217877846677e-06
mutation O 0 6.897121238580439e-07
, O 0 3.957513570185256e-07
one O 0 5.5390239594999e-07
nonsense O 0 4.755088411911856e-06
mutation O 0 5.336132744560018e-07
, O 0 3.471920706488163e-07
one O 0 4.834845981349645e-07
novel O 0 2.7290820980852004e-06
splice O 0 9.662459888204467e-06
site O 0 3.7907941532466793e-06
mutation O 0 1.0229332474409603e-06
, O 0 4.5310409291232645e-07
and O 0 4.0636140852257085e-07
one O 0 2.071814378723502e-06
missense O 0 0.00010935372847598046
mutation O 0 4.2879422835540026e-05
. O 0 3.996806117356755e-05

The O 0 7.554146577604115e-05
missense O 0 0.00014603958697989583
mutation O 0 1.4561464013240766e-05
was O 0 2.155554284399841e-05
also O 0 1.7921635162565508e-06
found O 0 1.610376557437121e-06
in O 0 1.942592007253552e-06
2 O 0 5.159864667803049e-05
. O 0 4.3013595131924376e-05

8 O 0 3.0040433557587676e-05
% O 0 2.811156264215242e-06
of O 0 1.771137135619938e-06
the O 0 1.1252661806793185e-06
general O 0 1.5852619981160387e-06
population O 0 3.4791995062732894e-07
, O 0 3.0849730592308333e-07
suggesting O 0 5.584234941125032e-07
that O 0 7.023088954838386e-08
it O 0 2.1490708945748338e-07
is O 0 5.795322408630454e-07
not O 0 7.929155003694177e-07
disease O 0 1.9727393009816296e-05
associated O 0 7.257793640746968e-06
. O 0 3.75173294742126e-05

The O 0 5.350928768166341e-05
average O 0 1.5706600606790744e-05
age O 0 9.680537004896905e-06
of O 0 3.916790956282057e-05
disease O 1 0.9996277093887329
onset O 0 0.007310500834137201
in O 0 6.909907028784801e-07
those O 0 3.9149114172687405e-07
families O 0 4.521673702129192e-07
harbouring O 0 0.01461279857903719
causative O 0 0.0016744743334129453
mutations O 0 8.050387805269565e-06
was O 0 3.863843812723644e-05
between O 0 7.74972704675747e-06
32 O 0 8.631367381894961e-05
. O 0 7.206153532024473e-05

3 O 0 0.00046922152978368104
and O 0 8.292780694318935e-05
37 O 0 0.00036166069912724197
. O 0 0.0002074016083497554

4 O 0 6.327510345727205e-05
years O 0 9.637244147597812e-06
, O 0 2.3145773866417585e-06
whereas O 0 1.8943860595754813e-06
the O 0 9.915574992191978e-07
family O 0 2.848910753527889e-06
harbouring O 0 0.0003014055546373129
the O 0 2.602574340926367e-06
missense O 0 2.832422796927858e-05
mutation O 0 1.6253908370345016e-06
had O 0 8.002204481272202e-07
an O 0 2.9362220743678336e-07
average O 0 6.548873443534831e-07
age O 0 8.383271961065475e-07
of O 0 1.0983036418110714e-06
onset O 0 1.548753607494291e-05
of O 0 1.570164386066608e-05
51 O 0 0.000182770992978476
. O 0 5.717150270356797e-05

2 O 0 0.0009972407715395093
years O 0 0.0004277504631318152
. O 0 0.00037704582791775465

These O 0 1.123849597206572e-05
findings O 0 4.216989964334061e-06
show O 0 3.538643341016723e-06
that O 0 1.2275420431251405e-06
BRCA1 O 0 3.255533738411032e-05
is O 0 1.9250112472946057e-06
implicated O 0 6.628681603615405e-06
in O 0 4.494464462823089e-07
a O 0 1.1752797490771627e-06
small O 0 8.462473033432616e-07
fraction O 0 2.9613897822855506e-06
of O 0 3.925174678443e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.545215807003842e-07
suggesting O 0 3.601405751396669e-07
the O 0 2.225174284831155e-07
involvement O 0 5.109986318529991e-07
of O 0 8.647017466500984e-07
another O 0 2.378462795604719e-06
susceptibility O 0 1.3100632713758387e-05
gene O 0 6.2681892813998275e-06
( O 0 9.374311048304662e-06
s O 0 0.0001195144432131201
) O 0 7.602768891956657e-05

Paternal O 0 0.004076533019542694
transmission O 1 0.7693608999252319
of O 1 0.9999966621398926
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999953508377075

We O 0 2.823666000040248e-05
report O 0 6.365884928527521e-06
a O 0 4.050469669891754e-06
rare O 0 3.4790577956300694e-06
case O 0 2.882803528336808e-06
of O 0 1.5147395970416255e-05
paternally O 1 0.997700035572052
transmitted O 1 0.9984130859375
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 1.0
DM B-Disease 1 1.0
) O 0 0.001833982183597982
. O 0 8.232473919633776e-05

The O 0 0.0001036986504914239
proband O 0 0.0014511710032820702
is O 0 5.252589744486613e-06
a O 0 2.103370889017242e-06
23 O 0 3.905304311047075e-06
year O 0 1.7094733948397334e-06
old O 0 5.7800883951131254e-05
, O 0 1.842933488660492e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.020476780831813812
who O 1 0.8715665936470032
suffers O 1 1.0
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9994232654571533

He O 0 0.0001234591763932258
presented O 0 6.343919812934473e-05
with O 0 2.4284185201395303e-05
respiratory O 1 0.9999997615814209
and O 0 3.274845585110597e-05
feeding O 0 0.012591966427862644
difficulties O 0 0.0002922778658103198
at O 0 0.0003420748107600957
birth O 0 4.577922300086357e-05
. O 0 9.25710701267235e-05

His O 0 0.0004016852763015777
two O 0 6.799351831432432e-05
sibs O 1 0.9995712637901306
suffer O 0 0.00025702331913635135
from O 0 4.2112384107895195e-05
childhood O 1 0.998401939868927
onset O 1 0.9999998807907104
DM B-Disease 1 1.0
. O 0 0.39392682909965515

Their O 0 8.769547093834262e-06
late O 0 1.4024746633367613e-05
father O 0 1.3333076822164003e-05
had O 0 1.7376921732648043e-06
the O 0 6.295348384810495e-07
adult O 0 9.820928426051978e-07
type O 0 2.4848866360116517e-06
of O 0 4.6474840928567573e-05
DM B-Disease 1 1.0
, O 0 7.339445801335387e-06
with O 0 4.907491302219569e-07
onset O 0 1.6248892279691063e-05
around O 0 3.2170660233532544e-06
30 O 0 7.531882147304714e-06
years O 0 1.0448756256664637e-05
. O 0 2.8383798053255305e-05

Only O 0 1.3303520972840488e-05
six O 0 2.66360643763619e-06
other O 0 3.4383870683996065e-07
cases O 0 3.5076212157036935e-07
of O 0 1.2343825801508501e-06
paternal O 0 0.00010642856068443507
transmission O 1 0.744554340839386
of O 1 1.0
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.29101961851119995
been O 0 1.8998203813680448e-05
reported O 0 1.3262504580779932e-05
recently O 0 4.4317312131170183e-05
. O 0 5.4389427532441914e-05

We O 0 1.554108166601509e-05
review O 0 1.3240236512501724e-05
the O 0 3.2107034257933265e-06
sex O 0 2.1965136056678602e-06
related O 0 1.3067389090792858e-06
effects O 0 2.757641141215572e-06
on O 0 3.669422994789784e-06
transmission O 0 2.623786531330552e-05
of O 1 0.821707010269165
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9919496774673462

Decreased O 0 0.000678539217915386
fertility O 0 9.500626038061455e-05
of O 0 6.264006060519023e-06
males O 0 1.0461512829351705e-06
with O 0 3.798151340106415e-07
adult O 0 1.0537719390413258e-05
onset O 1 0.9998883008956909
DM B-Disease 1 1.0
and O 0 4.295014514354989e-05
contraction O 0 6.952383500902215e-06
of O 0 1.1596215472309268e-06
the O 0 7.729848334747658e-07
repeat O 0 1.8974471913679736e-06
upon O 0 4.5726096686848905e-07
male O 0 9.807964715946582e-07
transmission O 0 9.173775765702885e-07
contribute O 0 3.984476961704786e-07
to O 0 2.2057950843645813e-07
the O 0 4.892313540949544e-07
almost O 0 7.507360919589701e-07
absent O 0 1.3852667279934394e-06
occurrence O 0 2.3781974505254766e-06
of O 0 1.96751216208213e-06
paternal O 0 1.300946041737916e-05
transmission O 0 3.239494617446326e-05
of O 1 0.9757012128829956
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9847474694252014

Also O 0 4.400567559059709e-05
the O 0 7.142056801967556e-06
fathers O 0 4.874178557656705e-06
of O 0 3.97679696106934e-06
the O 0 3.535738869686611e-06
reported O 0 1.2714622243947815e-05
congenitally O 0 0.0018565852660685778
affected O 0 1.2465923191484762e-06
children O 0 4.946613216816331e-07
showed O 0 7.156000947361463e-07
, O 0 2.4692522515579185e-07
on O 0 3.4364791190455435e-07
average O 0 8.990214723780809e-07
, O 0 5.623053880299267e-07
shorter O 0 4.478988103073789e-06
CTG O 0 0.02364947274327278
repeat O 0 5.81364520257921e-06
lengths O 0 1.0689992450352293e-05
and O 0 5.95978747242043e-07
hence O 0 9.878896207737853e-07
less O 0 9.1901415544271e-07
severe O 0 0.00028058019233867526
clinical O 1 0.9825623035430908
symptoms O 0 0.00474706944078207
than O 0 4.777971867042652e-07
the O 0 8.709984626875666e-07
mothers O 0 5.228133659329615e-07
of O 0 1.0409602282379637e-06
children O 0 1.985539711313322e-06
with O 0 2.7358850275049917e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9989427924156189

We O 0 2.8338819902273826e-05
conclude O 0 9.465133189223707e-06
that O 0 1.3283946600495256e-06
paternal O 0 7.425485364365159e-06
transmission O 0 3.720983659150079e-05
of O 1 0.999992847442627
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 1 0.9985039234161377
rare O 0 9.962997864931822e-06
and O 0 7.369207537522016e-07
preferentially O 0 1.5509339164054836e-06
occurs O 0 2.1452396481436153e-07
with O 0 1.9539841389359935e-07
onset O 0 6.986499556660419e-06
of O 0 4.4186366721987724e-05
DM B-Disease 1 1.0
past O 0 9.549580681778025e-06
30 O 0 1.7942550130101154e-06
years O 0 5.031300815971917e-07
in O 0 2.848783822173573e-07
the O 0 1.2379887266433798e-06
father O 0 6.998696335358545e-06
. O 0 4.923288088320987e-06
. O 0 2.6807296308106743e-05

The O 0 0.00032129010651260614
RB1 O 1 0.9996904134750366
gene O 0 3.533070412231609e-05
mutation O 0 1.1080933290941175e-05
in O 0 1.8625439679453848e-06
a O 0 7.354796707659261e-06
child O 0 1.3090977518004365e-05
with O 0 1.569815503899008e-05
ectopic B-Disease 1 0.9999674558639526
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.0004582884139381349

The O 0 0.00036034605000168085
RB1 O 1 0.9998306035995483
gene O 0 2.7646148737403564e-05
mutation O 0 8.052645171119366e-06
was O 0 1.3079646123514976e-05
investigated O 0 8.279305802716408e-06
in O 0 6.941968422324862e-07
a O 0 2.8822373678849544e-06
child O 0 3.89907881981344e-06
with O 0 2.7288763249089243e-06
ectopic B-Disease 1 0.9681887626647949
intracranial I-Disease 1 0.9999998807907104
retinoblastoma I-Disease 0 0.004469661507755518
using O 0 8.954780810199736e-07
DNA O 0 4.659956118757691e-07
obtained O 0 2.6850707968151255e-07
from O 0 1.4911472590029007e-07
both O 0 2.5322438546027115e-07
the O 0 1.679186766523344e-06
pineal B-Disease 1 0.9999805688858032
and I-Disease 0 1.7745283912518062e-05
retinal I-Disease 1 1.0
tumours I-Disease 1 1.0
of O 1 0.9998447895050049
the O 0 0.3759719133377075
patient O 0 0.0009775497019290924
. O 0 5.060782496002503e-05

A O 0 0.0003109091194346547
nonsense O 0 0.0002700969926081598
mutation O 0 1.1912143236258999e-05
in O 0 2.373504912611679e-06
exon O 0 2.400340417807456e-05
17 O 0 4.703385457105469e-06
( O 0 9.157578233498498e-07
codon O 0 4.952823928761063e-06
556 O 0 5.4873480621608905e-06
) O 0 5.615636951006309e-07
of O 0 9.643446219342877e-07
the O 0 2.407947931715171e-06
RB1 O 1 0.9999916553497314
gene O 0 1.2958416846231557e-06
was O 0 2.7087016860605218e-06
found O 0 2.514407526632567e-07
to O 0 1.5197529990018666e-07
be O 0 1.0411851292246865e-07
present O 0 2.136122247975436e-07
homozygously O 0 1.3593232324637938e-05
in O 0 3.0443075615949056e-07
both O 0 2.4022131128731417e-07
the O 0 1.6937099189817673e-06
retinal B-Disease 1 0.9986787438392639
and I-Disease 0 7.604416623507859e-06
the I-Disease 0 0.00041931637679226696
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.0005562037113122642

The O 0 2.1725309125031345e-05
same O 0 1.825265599109116e-06
mutation O 0 1.6866175656105042e-06
was O 0 3.0068263185967226e-06
present O 0 6.900680773469503e-07
heterozygously O 0 2.3635780962649733e-05
in O 0 2.66923393610341e-07
the O 0 2.8839647825407155e-07
DNA O 0 2.0902858466342877e-07
from O 0 8.905728776653632e-08
the O 0 1.9531083239598956e-07
constitutional O 0 5.220052798904362e-07
cells O 0 1.6086103471479873e-07
of O 0 4.6638191975034715e-07
the O 0 9.654783070800477e-07
patient O 0 1.0140090580534888e-06
, O 0 4.53340533113078e-07
proving O 0 1.6653949614919838e-06
it O 0 1.0215025270099432e-07
to O 0 2.197472213083529e-07
be O 0 3.910597570211394e-07
of O 0 3.026452077392605e-06
germline O 0 5.0834391004173085e-05
origin O 0 8.850845006236341e-06
. O 0 2.8108986953157e-05

The O 0 3.866763290716335e-05
initial O 0 1.4318989087769296e-05
mutation O 0 5.07692493556533e-06
was O 0 6.184384801599663e-06
shown O 0 4.2762363250403723e-07
to O 0 3.086197182256001e-07
have O 0 1.6894929899535782e-07
occurred O 0 6.58509691220388e-07
in O 0 6.807594559177232e-07
the O 0 4.041648935526609e-06
paternally O 0 9.936038259183988e-05
derived O 0 3.375138476258144e-05
RB1 O 1 0.7022584676742554
allele O 0 0.00011306368105579168
. O 0 9.66224106377922e-05

The O 0 3.300510434200987e-05
mutation O 0 7.923373232188169e-06
is O 0 8.17803766040015e-07
in O 0 1.8885114627664734e-07
an O 0 3.3567192758710007e-07
area O 0 9.194989729621739e-07
of O 0 8.903620027922443e-07
the O 0 5.129849114382523e-07
gene O 0 2.8181358402434853e-07
that O 0 1.4198695907907677e-07
encodes O 0 7.250034173011954e-07
the O 0 3.388612981325423e-07
protein O 0 2.8452703304537863e-07
- O 0 6.282225513132289e-07
binding O 0 2.633596523082815e-07
region O 0 5.592233947027125e-07
known O 0 4.527222756678384e-07
as O 0 3.7285195730873966e-07
the O 0 1.4433427395488252e-06
pocket O 1 0.9999994039535522
region O 0 3.919423306797398e-06
and O 0 3.9553816577608814e-07
has O 0 2.990013001635816e-07
been O 0 2.14529080722059e-07
detected O 0 3.8892528664291603e-07
in O 0 6.784949135862917e-08
other O 0 6.956031484151026e-08
cases O 0 1.5906306316537666e-07
of O 0 4.447580522537464e-06
retinoblastoma B-Disease 1 0.9999954700469971
. O 0 1.7004855180857703e-05
. O 0 3.2969936000881717e-05

Low O 0 0.00011056697985623032
levels O 0 8.788729246589355e-06
of O 0 4.483924840315012e-06
beta O 0 2.3351889467448927e-05
hexosaminidase O 1 0.9336652755737305
A O 0 5.863032856723294e-05
in O 0 1.2727996363537386e-06
healthy O 0 1.255899860552745e-06
individuals O 0 1.0709850073453708e-07
with O 0 1.9428425446221809e-07
apparent O 0 0.04696639999747276
deficiency O 1 0.9999890327453613
of O 0 0.01161252986639738
this O 0 8.660786079417448e-06
enzyme O 0 2.641556602611672e-05
. O 0 4.12430235883221e-05

Appreciable O 0 0.0011776844039559364
beta O 0 0.0001941283408086747
hexosaminidase O 0 0.009069754742085934
A O 0 0.00012012512888759375
( O 0 3.973316779593006e-06
hex O 0 0.10063277184963226
A O 0 4.216630622977391e-05
) O 0 1.1410359093133593e-06
activity O 0 4.154548491897003e-07
has O 0 2.7004867320101766e-07
been O 0 2.7177503625352983e-07
detected O 0 6.729548545081343e-07
in O 0 4.3652875092448085e-07
cultured O 0 1.4233896763471421e-05
skin O 1 0.6141597032546997
fibroblasts O 0 8.694655844010413e-05
and O 0 0.0008669894305057824
melanoma B-Disease 1 1.0
tissue O 1 0.5984600186347961
from O 0 2.903632321249461e-06
healthy O 0 2.5505960365990177e-06
individuals O 0 9.60433155228202e-08
previously O 0 5.156979909770598e-07
reported O 0 3.497903549032344e-07
as O 0 4.092924257292907e-07
having O 0 1.7125507838500198e-06
deficiency B-Disease 1 0.678245484828949
of I-Disease 0 0.00024226376262959093
hex I-Disease 1 0.9999665021896362
A I-Disease 0 2.1107247448526323e-05
activity O 0 7.214334232230613e-07
indistinguishable O 0 7.479061991944036e-07
from O 0 1.1746920591804155e-07
that O 0 5.4338386235031066e-08
of O 0 2.7165819460606144e-07
patients O 0 4.026039164273243e-07
with O 0 1.4666146626041154e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 0.00017772700812201947
TSD B-Disease 1 0.9999995231628418
) O 0 6.0423197282943875e-05
. O 0 7.74431464378722e-05

Identification O 0 0.0001281069708056748
and O 0 1.3680702068086248e-05
quantitation O 0 0.00043915040441788733
of O 0 6.655391916865483e-05
hex O 1 0.9981605410575867
A O 0 0.001658500637859106
, O 0 8.574232197133824e-06
amounting O 0 2.3249387595569715e-05
to O 0 6.973944891797146e-06
3 O 0 9.14419288164936e-05
. O 0 6.581636262126267e-05

5 O 0 0.00029895748593844473
% O 0 9.925763879437e-05
- O 0 0.000293935852823779
6 O 0 0.0003242558450438082
. O 0 0.00014987470058258623

9 O 0 6.0249207308515906e-05
% O 0 3.560164941518451e-06
of O 0 1.6013503909562132e-06
total O 0 1.3837153574058902e-06
beta O 0 1.0719822967075743e-05
hexosaminidase O 0 0.006967208813875914
activity O 0 1.8022637959802523e-06
, O 0 5.363571631278319e-07
has O 0 3.328872821839468e-07
been O 0 2.5541351078572916e-07
obtained O 0 3.531310710513935e-07
by O 0 4.565594338146184e-07
cellulose O 0 2.8926548111485317e-05
acetate O 0 4.333267133915797e-05
gel O 0 8.435564086539671e-05
electrophoresis O 0 1.4842144992144313e-05
, O 0 2.7246144327364163e-06
DEAE O 0 0.008314975537359715
- O 0 2.0007340935990214e-05
cellulose O 0 3.4332930226810277e-05
ion O 0 3.3019274269463494e-05
- O 0 3.9704038499621674e-05
exchange O 0 5.9200428950134665e-06
chromatography O 0 0.00013162688992451876
, O 0 3.824711257038871e-06
radial O 0 0.00012427214824128896
immunodiffusion O 0 0.13346269726753235
, O 0 1.2288865036680363e-05
and O 0 2.3078453523339704e-05
radioimmunoassay O 0 0.04283830150961876
. O 0 0.00023451964079868048

Previous O 0 0.00015763755072839558
family O 0 1.4832157830824144e-05
studies O 0 2.449796284054173e-06
suggested O 0 1.3386220416577999e-06
that O 0 1.4994668617873685e-07
these O 0 1.456318727832695e-07
individuals O 0 1.0847240616840281e-07
may O 0 2.880913143599173e-07
be O 0 2.7037106065108674e-07
compound O 0 2.9430668746499578e-06
heterozygotes O 0 1.5469897789444076e-06
for O 0 1.9182000698947377e-07
the O 0 6.790709790038818e-07
common O 0 1.2197734804431093e-06
mutant O 0 2.4117003704304807e-05
TSD B-Disease 1 0.9953503608703613
gene O 0 7.779485144965292e-07
and O 0 2.957047797735868e-07
a O 0 1.158863142336486e-06
rare O 0 2.0257671167200897e-06
( O 0 2.380575324423262e-06
allelic O 0 5.277568561723456e-05
) O 0 6.402176040865015e-06
mutant O 0 5.567152038565837e-05
gene O 0 2.995378599734977e-05
. O 0 5.753960431320593e-05

Thus O 0 6.132858106866479e-05
, O 0 7.266318789334036e-06
the O 0 5.54377675143769e-06
postulated O 0 2.33378195844125e-05
rate O 0 1.9682927359099267e-06
mutant O 0 5.684451025445014e-06
gene O 0 6.460896315729769e-07
appears O 0 4.688561148213921e-07
to O 0 8.660753536560151e-08
code O 0 1.7851564848569978e-07
for O 0 1.2741425337026158e-07
the O 0 4.3797282955893024e-07
expression O 0 3.804814809882373e-07
of O 0 6.109923447183974e-07
low O 0 2.942606442957185e-06
amounts O 0 2.3720408535155e-06
of O 0 5.818487352371449e-06
hex O 0 0.006140946876257658
A O 0 0.0001266781910089776
. O 0 4.602843546308577e-05

Heterozygotes O 0 0.0005935315857641399
for O 0 1.5250438082148321e-05
the O 0 1.2634821359824855e-05
rare O 0 1.671190511842724e-05
mutant O 0 5.8799763792194426e-05
may O 0 5.557076860895904e-07
be O 0 2.61344297314281e-07
indistinguishable O 0 1.0119418902831967e-06
from O 0 3.3832367307695677e-07
heterozygotes O 0 4.899129635305144e-06
for O 0 7.62495858452894e-07
the O 0 2.068831236101687e-06
common O 0 7.6183096098247916e-06
TSD B-Disease 1 0.9999961853027344
mutant O 0 0.0010404671775177121
. O 0 5.7247558288509026e-05

However O 0 2.040186336671468e-05
, O 0 4.213323791191215e-06
direct O 0 3.706931465785601e-06
visualization O 0 1.899668131954968e-05
and O 0 1.9677859199873637e-06
quantitation O 0 0.00010041155474027619
of O 0 1.5824036381673068e-05
hex O 0 0.42600247263908386
A O 0 7.421903319482226e-06
by O 0 2.888949666157714e-07
the O 0 5.52125129615888e-07
methods O 0 5.325893539520621e-07
described O 0 1.3283516864248668e-06
may O 0 4.684592056491965e-07
prevent O 0 1.1810573141701752e-06
false O 0 2.0620902887458215e-06
- O 0 3.937935616704635e-06
positive O 0 1.0732502460086835e-06
prenatal O 0 2.8332960937405005e-06
diagnosis O 0 7.622873908985639e-06
of O 0 6.732001565978862e-06
TSD B-Disease 1 1.0
in O 0 2.063827650999883e-06
fetuses O 0 2.1833561731909867e-06
having O 0 5.415926693785877e-07
the O 0 5.420112074716599e-07
incomplete O 0 3.5660095818457194e-06
hex B-Disease 1 0.7141891121864319
A I-Disease 0 0.1605328470468521
deficiency I-Disease 1 0.9311906695365906
of O 0 4.78504898637766e-06
the O 0 2.841630475813872e-06
type O 0 5.413105100160465e-06
described O 0 7.344693244704104e-07
in O 0 3.9305001564571285e-07
the O 0 1.5138222124733147e-06
four O 0 2.6021350549854105e-06
healthy O 0 2.1683994418708608e-05
individuals O 0 1.5952222383930348e-05

The O 0 0.00036714895395562053
tumor B-Disease 1 0.999945878982544
suppressor O 1 0.9999083280563354
gene O 0 6.169158586999401e-05
Smad4 O 1 0.9999544620513916
/ O 1 0.8583672046661377
Dpc4 O 1 0.9729915857315063
is O 0 9.600317980584805e-07
required O 0 2.021204181801295e-07
for O 0 2.5851198870441294e-07
gastrulation O 0 1.3932444744568784e-05
and O 0 4.4692083633890434e-07
later O 0 6.28417296866246e-07
for O 0 5.060134071754874e-07
anterior O 0 1.2251911357452627e-05
development O 0 1.7553372799739009e-06
of O 0 6.8413742155826185e-06
the O 0 1.66226254805224e-05
mouse O 0 0.0005071724881418049
embryo O 0 9.969769598683342e-05
. O 0 4.196637019049376e-05

Mutations O 0 4.781013558385894e-05
in O 0 6.499733444798039e-06
the O 0 1.5253754099830985e-05
SMAD4 O 1 0.9999998807907104
/ O 1 0.9999954700469971
DPC4 O 1 1.0
tumor B-Disease 1 0.9999997615814209
suppressor O 1 0.9987339377403259
gene O 0 2.9972522952448344e-06
, O 0 1.1088427527283784e-06
a O 0 1.675250359767233e-06
key O 0 4.63416836282704e-06
signal O 0 3.68782707482751e-06
transducer O 0 1.3393955669016577e-05
in O 0 6.509284844469221e-07
most O 0 6.258019880078791e-07
TGFbeta O 0 0.39808717370033264
- O 0 0.0001454272132832557
related O 0 2.3705913463345496e-06
pathways O 0 1.6756418972363463e-06
, O 0 3.058193556171318e-07
are O 0 7.390378442551082e-08
involved O 0 1.732541363708151e-07
in O 0 1.5468555147890584e-07
50 O 0 8.604168328929518e-07
% O 0 1.1624229045992251e-06
of O 0 2.0676279746112414e-05
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999997615814209
. O 0 0.00016013912681955844

Homozygous O 0 0.0017185219330713153
Smad4 O 1 0.980168342590332
mutant O 0 0.031231539323925972
mice O 0 0.00017441707313992083
die O 0 3.714580088853836e-05
before O 0 6.2686494857189246e-06
day O 0 9.71983445197111e-06
7 O 0 4.88810364913661e-05
. O 0 3.5852164728567004e-05

5 O 0 0.0004170789325144142
of O 0 0.0003254364419262856
embryogenesis O 0 0.0016153175383806229
. O 0 0.0004109131987206638

Mutant O 0 0.0005068675382062793
embryos O 0 1.8165748770115897e-05
have O 0 8.244875857599254e-07
reduced O 0 1.426913627255999e-06
size O 0 2.2443689431383973e-06
, O 0 1.0756501751529868e-06
fail O 0 1.0054601489173365e-06
to O 0 6.812699666625122e-07
gastrulate O 0 0.0001144663619925268
or O 0 1.3451972336042672e-06
express O 0 1.0589010344119743e-06
a O 0 8.869483849593962e-07
mesodermal O 0 2.0586834580171853e-05
marker O 0 8.277643792098388e-05
, O 0 1.4976446891523665e-06
and O 0 8.939304052546504e-07
show O 0 5.811688424728345e-06
abnormal O 0 2.5022005502250977e-05
visceral O 0 0.0040109106339514256
endoderm O 0 0.4684169292449951
development O 0 8.065899601206183e-05
. O 0 0.0001052700390573591

Growth B-Disease 1 0.9998738765716553
retardation I-Disease 1 0.9999998807907104
of O 0 0.0005428284639492631
the O 0 0.0001580739044584334
Smad4 O 1 0.9999998807907104
- O 1 0.9827345013618469
deficient O 0 0.00024730406585149467
embryos O 0 1.0826153129528393e-06
results O 0 2.2490476681014115e-07
from O 0 2.7505444677444757e-07
reduced O 0 1.3611501117338776e-06
cell O 0 3.0412074920604937e-06
proliferation O 0 7.1037584348232485e-06
rather O 0 1.2757989225065103e-06
than O 0 1.4303483339972445e-06
increased O 0 7.076995643728878e-06
apoptosis O 0 0.00011053504567826167
. O 0 6.70976223773323e-05

Aggregation O 0 0.00029889168217778206
of O 0 0.00011292577255517244
mutant O 0 0.024338215589523315
Smad4 O 1 0.9999997615814209
ES O 1 0.9999992847442627
cells O 0 9.073602086573374e-06
with O 0 1.8269635120304883e-06
wild O 0 2.8206894057802856e-05
- O 0 0.00011292943236185238
type O 0 6.597692117793486e-05
tetraploid O 0 0.0001163574488600716
morulae O 0 0.0012808131286874413
rescues O 0 0.00018381858535576612
the O 0 4.254834493622184e-05
gastrulation B-Disease 0 0.007534878794103861
defect I-Disease 0 0.01966753974556923
. O 0 0.00018717728380579501

These O 0 1.5200402231130283e-05
results O 0 3.037770056835143e-06
indicate O 0 1.4306880302683567e-06
that O 0 4.6414476173595176e-07
Smad4 O 0 0.0006490501691587269
is O 0 4.814233420802339e-07
initially O 0 5.018319484406675e-07
required O 0 7.683971858796212e-08
for O 0 8.194614053991245e-08
the O 0 2.1041302034063847e-07
differentiation O 0 5.2586170795621e-07
of O 0 1.158999111794401e-06
the O 0 1.3956282600702252e-06
visceral O 0 0.0009048001375049353
endoderm O 0 0.000301728694466874
and O 0 5.953566528660303e-07
that O 0 2.1685760032141843e-07
the O 0 9.015224691211188e-07
gastrulation B-Disease 0 0.00014453730545938015
defect I-Disease 0 2.098463664879091e-05
in O 0 4.887039608547639e-07
the O 0 2.3201089334179414e-06
epiblast O 1 0.7145799398422241
is O 0 1.338822471552703e-06
secondary O 0 2.7592880087468075e-06
and O 0 8.475889217152144e-07
non O 0 1.1559245649550576e-05
- O 0 0.05601518601179123
cell O 0 0.00016592103929724544
autonomous O 0 9.637534094508737e-05
. O 0 4.511191218625754e-05

Rescued O 0 0.000525962735991925
embryos O 0 4.0270919271279126e-05
show O 0 2.7474052330944687e-05
severe O 0 0.00017552149074617773
anterior O 0 0.016746876761317253
truncations O 1 0.9999812841415405
, O 0 2.6603200240060687e-05
indicating O 0 6.108349225542042e-06
a O 0 1.8759924387268256e-06
second O 0 2.039161017819424e-06
important O 0 1.130354803535738e-06
role O 0 2.5729500521265436e-06
for O 0 2.0357215362309944e-06
Smad4 O 1 0.7756096124649048
in O 0 6.5699819060682785e-06
anterior O 0 0.0023681283928453922
patterning O 0 0.001336687128059566
during O 0 0.00010614820348564535
embryogenesis O 0 0.00044639557017944753
. O 0 0.00016161760140676051

Prevalence O 0 0.0010731329675763845
of O 0 0.00010194168862653896
p16 O 0 0.0005696736043319106
and O 0 2.11444785236381e-05
CDK4 O 1 0.9999750852584839
germline O 0 9.510089876130223e-05
mutations O 0 3.707613586811931e-06
in O 0 8.698330589140824e-07
48 O 0 3.5543878766475245e-05
melanoma B-Disease 1 1.0
- O 1 0.9999988079071045
prone O 1 0.9943555593490601
families O 0 1.6790617110018502e-06
in O 0 4.0329932744498365e-06
France O 0 9.528316877549514e-05
. O 0 7.495078898500651e-05

The O 0 0.00014938019739929587
French O 0 0.14979742467403412
Familial B-Disease 1 1.0
Melanoma I-Disease 1 1.0
Study O 0 0.0213991180062294
Group O 0 0.0001894121232908219
. O 0 8.88386566657573e-05

Germline O 0 0.0010578653309494257
mutations O 0 2.574364589236211e-05
in O 0 3.1778217817191035e-06
the O 0 4.41019665231579e-06
p16 O 0 6.949777889531106e-05
and O 0 4.673392595577752e-06
CDK4 O 1 0.9999997615814209
genes O 0 1.5721202544227708e-06
have O 0 1.6503214794738597e-07
been O 0 3.6401900160853984e-07
reported O 0 3.1207781603370677e-07
in O 0 1.7854527811778098e-07
a O 0 7.032806479401188e-07
subset O 0 2.417937366772094e-06
of O 0 8.446503670711536e-06
melanoma B-Disease 1 1.0
pedigrees O 0 1.2744218111038208e-05
, O 0 9.411372730028233e-07
but O 0 1.8189734873885754e-07
their O 0 1.1533796850926592e-07
prevalence O 0 3.4483277886465658e-06
is O 0 4.969801921106409e-07
not O 0 2.3990813247110054e-07
well O 0 1.6897151908779051e-06
known O 0 1.7817761545302346e-05
. O 0 4.072206138516776e-05

We O 0 2.246252006443683e-05
searched O 0 1.541305573482532e-05
for O 0 8.700205285094853e-07
such O 0 7.108612294359773e-07
germline O 0 1.2132152733101975e-05
mutations O 0 7.790087011017022e-07
in O 0 3.8523421608260833e-07
48 O 0 5.49704827790265e-06
French O 1 0.9930598735809326
melanoma B-Disease 1 1.0
- O 1 0.9997199177742004
prone O 0 0.0024685899261385202
families O 0 1.9289332442440354e-07
selected O 0 1.9197737799458992e-07
according O 0 4.678600262764121e-08
to O 0 6.061051749384205e-08
two O 0 4.0601118911354206e-08
major O 0 8.7698805373293e-07
criteria O 0 7.72513885749504e-07
families O 0 5.0350731584103414e-08
with O 0 4.783196416724422e-08
at O 0 7.26104985915299e-07
least O 0 7.338588403627e-08
three O 0 5.109733081098966e-08
affected O 0 6.876617675288799e-08
members O 0 4.2289485691071604e-08
( O 0 1.2010947614271572e-07
n O 0 3.0172310516718426e-07
= O 0 4.692917912052508e-07
20 O 0 3.3625090622990683e-07
) O 0 1.8556139025349694e-07
or O 0 1.205186208608211e-07
families O 0 2.658160092039452e-08
with O 0 1.9988906529988526e-08
two O 0 3.9351728986503076e-08
affected O 0 8.981279364661532e-08
members O 0 5.8933373736635986e-08
, O 0 1.0954860130141242e-07
one O 0 8.328821365921613e-08
of O 0 2.523899240713945e-07
them O 0 9.150823387926721e-08
affected O 0 1.0419758211810404e-07
before O 0 1.205741568810481e-07
the O 0 1.2798884085896134e-07
age O 0 2.504055203189637e-07
of O 0 2.3831508144667168e-07
50 O 0 4.6177120793799986e-07
( O 0 2.3589784348132525e-07
n O 0 6.132486305432394e-07
= O 0 4.2546807321741653e-07
28 O 0 6.460390977736097e-07
) O 0 2.368351204040664e-07
, O 0 2.327372357058266e-07
and O 0 1.375208853460208e-07
one O 0 5.501099735738535e-07
additional O 0 1.6309886632370763e-06
minor O 0 6.787347956560552e-05
criterion O 1 0.9985161423683167
. O 0 0.00010592555918265134

Sixteen O 0 0.0005968305631540716
different O 0 1.740412335493602e-05
p16 O 0 0.00020186961046420038
germline O 0 7.058095798129216e-05
mutations O 0 3.5508401197148487e-06
were O 0 5.718569582313648e-07
found O 0 3.57465438582949e-07
in O 0 1.8821950220626604e-07
21 O 0 1.2053833415848203e-06
families O 0 7.96878936171197e-08
, O 0 1.9543624318885122e-07
while O 0 2.2532661603236193e-07
one O 0 3.598487410272355e-07
germline O 0 4.396875738166273e-06
mutation O 0 8.528072044100554e-07
, O 0 5.833655905007618e-07
Arg24His O 0 0.01564900204539299
, O 0 1.1266309911661665e-06
was O 0 2.776938117676764e-06
detected O 0 1.1221681006645667e-06
in O 0 7.169286959651799e-07
the O 0 5.364939170249272e-06
CDK4 O 1 0.9914041757583618
gene O 0 4.822578193852678e-05
. O 0 6.848239718237892e-05

The O 0 2.9350250770221464e-05
frequency O 0 7.521014595113229e-06
of O 0 6.481023319793167e-06
p16 O 0 3.40916303684935e-05
gene O 0 1.4611672440878465e-06
mutation O 0 4.950152288074605e-07
in O 0 1.569670757817221e-07
our O 0 1.5151987042827386e-07
sample O 0 1.9681509400015784e-07
( O 0 1.2924830627980555e-07
44 O 0 5.962635327705357e-07
% O 0 1.092764634336163e-07
) O 0 1.539284113505346e-07
is O 0 2.3202053966997482e-07
among O 0 2.0764476005297183e-07
the O 0 2.473938138791709e-07
highest O 0 2.114486960635986e-06
rates O 0 2.686566915599542e-07
yet O 0 2.0144842949321173e-07
reported O 0 1.8718662886385573e-07
and O 0 8.328170508775656e-08
the O 0 3.0652216764792684e-07
CDK4 O 1 0.9374194145202637
mutation O 0 8.897865200196975e-07
is O 0 3.178678014137404e-07
the O 0 3.4928933700939524e-07
second O 0 1.3179401321394835e-06
mutation O 0 1.1928453886866919e-06
detected O 0 1.1213261359444004e-06
in O 0 4.121958170344442e-07
this O 0 5.988393354527943e-07
gene O 0 4.568313215713715e-06
worldwide O 0 1.4095369806454983e-05
. O 0 4.079840437043458e-05

In O 0 2.6973055355483666e-05
summary O 0 1.9834387785522267e-05
, O 0 3.226535682188114e-06
our O 0 1.0840617505891714e-06
results O 0 4.933497166348388e-07
show O 0 1.267795141757233e-06
frequent O 0 1.5341489643105888e-06
involvement O 0 1.9072949726250954e-06
of O 0 1.916065912155318e-06
the O 0 2.061146687992732e-06
p16 O 0 2.023124943661969e-05
gene O 0 7.185399795162084e-07
in O 0 7.060143047965539e-07
familial B-Disease 1 0.9750023484230042
melanoma I-Disease 1 1.0
and O 0 7.158765242820664e-07
confirm O 0 2.7732647822631407e-07
the O 0 2.4902570316953643e-07
role O 0 5.728099381485663e-07
of O 0 1.1346932069500326e-06
the O 0 1.5471299548153183e-06
CDK4 O 1 0.9994854927062988
gene O 0 1.4545327076120884e-06
as O 0 9.549820561005617e-07
a O 0 6.51299978926545e-06
melanoma B-Disease 1 1.0
- O 1 0.9612782597541809
predisposing O 0 0.1451595276594162
gene O 0 7.470190212188754e-06
. O 0 5.755781785410363e-06
. O 0 3.259261211496778e-05

Progression O 0 0.001082891714759171
of O 0 8.130226342473179e-05
somatic O 0 0.0005345277604646981
CTG O 1 0.9994012117385864
repeat O 0 3.084475974901579e-05
length O 0 3.6512224141915794e-06
heterogeneity O 0 1.935201908054296e-05
in O 0 1.0186711278947769e-06
the O 0 1.240270648850128e-06
blood O 0 9.319119271822274e-06
cells O 0 5.171620159671875e-06
of O 0 0.0006933932309038937
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.999308705329895
. O 0 0.00021560459572356194

The O 0 4.8833837354322895e-05
genetic O 0 1.3947387742518913e-05
basis O 0 5.413105100160465e-06
of O 0 0.0019886475056409836
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999980926513672
DM B-Disease 1 1.0
) O 0 4.099630132259335e-06
is O 0 5.938947538197681e-07
the O 0 3.103019139416574e-07
expansion O 0 1.6899375623324886e-06
of O 0 1.0065529068015167e-06
an O 0 1.8219437833977281e-06
unstable O 0 4.6805125748505816e-05
CTG O 1 0.9920423626899719
repeat O 0 1.0089401257573627e-05
in O 0 6.928528364369413e-07
the O 0 8.47227681788354e-07
34 O 0 4.930627710564295e-06
UTR O 0 0.0003578659088816494
of O 0 7.720028406765778e-06
the O 0 1.0987208042934071e-05
DM B-Disease 1 1.0
protein O 0 2.1656280296156183e-05
kinase O 0 2.500454502296634e-05
gene O 0 3.6230296700523468e-06
on O 0 5.030868123867549e-06
chromosome O 0 2.9682905733352527e-05
19 O 0 4.5011958718532696e-05
. O 0 4.3321768316673115e-05

One O 0 2.5409684894839302e-05
of O 0 9.463056812819559e-06
the O 0 3.367631961737061e-06
principal O 0 9.981104994949419e-06
features O 0 2.1851124074601103e-06
of O 0 4.38674805991468e-06
the O 0 1.391847399645485e-05
DM B-Disease 1 1.0
mutation O 0 5.1719653129111975e-06
is O 0 5.75613171349687e-07
an O 0 3.744619334611343e-07
extraordinarily O 0 2.1043761080363765e-06
high O 0 2.5446920517424587e-06
level O 0 1.6339216699634562e-06
of O 0 2.684993887669407e-06
somatic O 0 2.9848224585293792e-05
mosaicism O 1 0.7502292394638062
, O 0 4.935793640470365e-07
due O 0 3.1707395464763977e-07
to O 0 1.480776745665935e-07
an O 0 2.6606360847836186e-07
extremely O 0 4.5412852500703593e-07
high O 0 1.1105827297797077e-06
degree O 0 1.315427539338998e-06
of O 0 1.1732819302778807e-06
somatic O 0 1.1450472811702639e-05
instability O 0 5.497462552739307e-06
both O 0 2.898747197832563e-07
within O 0 3.7352174331317656e-07
and O 0 6.065295679036353e-07
between O 0 1.6437242038591648e-06
different O 0 2.375885060246219e-06
tissues O 0 2.8177752028568648e-05
. O 0 4.046725734951906e-05

This O 0 2.9477489078999497e-05
instability O 0 7.785009074723348e-05
appears O 0 7.173183803388383e-06
to O 0 9.731415957503486e-07
be O 0 2.510578269721009e-07
biased O 0 9.82509732239123e-07
towards O 0 4.935482706969196e-07
further O 0 3.4202034271402226e-07
expansion O 0 1.2489246046243352e-06
and O 0 2.1131795335804782e-07
continuous O 0 4.195982512555929e-07
throughout O 0 1.663185571487702e-07
the O 0 2.4526548259018455e-07
life O 0 1.4958703786760452e-07
of O 0 1.826557962658626e-07
an O 0 1.404058593834634e-07
individual O 0 6.69376234441188e-08
, O 0 9.575157378094445e-08
features O 0 2.1935903760095243e-07
that O 0 4.400120801051344e-08
could O 0 5.0368409887369125e-08
be O 0 3.993218200548654e-08
associated O 0 6.792277673639546e-08
with O 0 6.826657283909299e-08
the O 0 5.457790166474297e-07
progressive O 0 1.4412943528441247e-05
nature O 0 5.04916170029901e-06
of O 0 6.687203949695686e-06
the O 0 4.080789949512109e-05
disease O 0 0.3321744203567505
. O 0 5.282482743496075e-05

Although O 0 4.536774576990865e-05
increasing O 0 1.4124490007816348e-05
measured O 0 8.00054840510711e-06
allele O 0 6.210768333403394e-06
size O 0 3.5618359106592834e-06
between O 0 1.0515727808524389e-06
patients O 0 1.2989646620553685e-06
clearly O 0 4.940093276672997e-07
correlates O 0 1.0878408147618757e-06
with O 0 7.732783302571988e-08
an O 0 2.3304707497118216e-07
increased O 0 4.839939151679573e-07
severity O 0 4.453841029317118e-06
of O 0 4.3208556235185824e-06
symptoms O 0 9.876448530121706e-06
and O 0 1.2401211790802336e-07
an O 0 1.4187787655828288e-07
earlier O 0 2.7151367021360784e-07
age O 0 6.198628739184642e-07
of O 0 7.123929890440195e-07
onset O 0 1.0379277227912098e-05
, O 0 3.585525121252431e-07
this O 0 8.841194443220957e-08
correlation O 0 3.2294494189955003e-07
is O 0 9.94886235616832e-08
not O 0 3.588795038922399e-08
precise O 0 2.005245391956123e-07
and O 0 7.958505676697314e-08
measured O 0 2.657820914464537e-07
allele O 0 2.218106089912908e-07
length O 0 1.7829955822890042e-07
cannot O 0 1.0142609596641705e-07
be O 0 4.188945368355235e-08
used O 0 6.87134686927493e-08
as O 0 1.2499226897944027e-07
an O 0 2.512686307909462e-07
accurate O 0 1.3616706837638048e-06
predictor O 0 2.0202678570058197e-05
of O 0 3.30667808157159e-06
age O 0 4.770613941218471e-06
of O 0 1.5720986993983388e-05
onset O 0 0.0011519677937030792
. O 0 8.159638673532754e-05

In O 0 1.823458296712488e-05
order O 0 3.459157596807927e-06
to O 0 1.7329622323813965e-06
further O 0 1.4587599252990913e-06
characterize O 0 6.0639818002528045e-06
the O 0 2.3593952391820494e-06
dynamics O 0 9.24691357795382e-06
of O 0 3.903777542291209e-05
DM B-Disease 1 1.0
CTG O 1 1.0
repeat O 0 0.0007150841993279755
somatic O 0 0.00010508869308978319
instability O 0 3.844275852316059e-05
, O 0 1.0795306479849387e-06
we O 0 2.6118831897292694e-07
have O 0 1.2649519476326532e-07
studied O 0 6.25613381544099e-07
repeat O 0 5.808048513245012e-07
length O 0 2.7082575115855434e-07
changes O 0 1.006241276968467e-07
over O 0 2.595421051410085e-07
time O 0 3.777964536766376e-07
in O 0 8.310603334393818e-07
111 O 0 0.07375427335500717
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 8.27123221824877e-06
with O 0 4.840954375140427e-07
varying O 0 1.0151682090508984e-06
clinical O 0 2.157578092010226e-05
severity O 0 0.0007945819525048137
and O 0 2.9562822874140693e-06
CTG O 1 0.9996196031570435
repeat O 0 3.88085254598991e-06
size O 0 1.1397330581530696e-06
over O 0 4.312143744300556e-07
time O 0 2.3185951647519687e-07
intervals O 0 5.415369059846853e-07
of O 0 4.30065654200007e-07
1 O 0 2.4023970581765752e-06
- O 0 1.0263288459100295e-05
7 O 0 1.359139150736155e-05
years O 0 1.784056075848639e-05
. O 0 2.9691906092921272e-05

We O 0 2.4154636776074767e-05
have O 0 1.3953381312603597e-06
found O 0 6.906849989718467e-07
a O 0 5.899702841816179e-07
direct O 0 7.163613986449491e-07
progression O 0 4.099106263311114e-06
of O 0 1.0844205462490208e-06
the O 0 6.130147198746272e-07
size O 0 1.4606126796934404e-06
heterogeneity O 0 4.648119102057535e-06
over O 0 9.400177987117786e-07
time O 0 3.7800833752044127e-07
related O 0 4.261990795839665e-07
to O 0 2.798312266349967e-07
initial O 0 2.042878577412921e-06
CTG O 0 0.025494014844298363
repeat O 0 6.9164739215921145e-06
size O 0 1.9068020264967345e-06
and O 0 2.707012924929586e-07
the O 0 2.9846054871995875e-07
time O 0 2.208801248571035e-07
interval O 0 1.2190291727165459e-06
and O 0 4.230674903737963e-07
always O 0 1.644661779209855e-06
biased O 0 4.442735189513769e-06
towards O 0 2.892414386224118e-06
further O 0 5.654853794112569e-06
expansion O 0 5.595259426627308e-05
. O 0 6.349506293190643e-05

Attempts O 0 8.883729606168345e-05
to O 0 7.5560114964901e-06
mathematically O 0 1.4435862794925924e-05
model O 0 1.9300277926959097e-06
the O 0 1.3593365792985423e-06
dynamics O 0 5.482619599206373e-06
have O 0 2.4795124886622943e-07
proved O 0 1.9429626263445243e-06
only O 0 3.065534599500097e-07
partially O 0 1.9055931943512405e-06
successful O 0 7.079034958223929e-07
suggesting O 0 4.0417387481284095e-07
that O 0 4.9653010592010105e-08
individual O 0 3.986627916674479e-08
specific O 0 4.687496968358573e-08
genetic O 0 2.2673053479138616e-07
and O 0 1.1030465429939795e-07
/ O 0 6.369902257574722e-05
or O 0 5.937378659837123e-07
environmental O 0 1.91942945093615e-06
factors O 0 3.934002563710237e-07
also O 0 3.000341450842825e-07
play O 0 5.104531624056108e-07
a O 0 7.642197488166858e-07
role O 0 1.7865475001599407e-06
in O 0 3.526569116729661e-06
somatic O 0 0.00011192266538273543
mosaicism O 1 0.9702489972114563
. O 0 1.4850754268991295e-05
. O 0 4.427570820553228e-05

Aspartylglucosaminuria B-Disease 1 0.9999994039535522
among O 0 0.00042692210990935564
Palestinian O 0 0.0007424310315400362
Arabs O 0 0.0006680617807433009
. O 0 0.0003097396111115813

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.7246142029762268
AGU B-Disease 1 1.0
) O 0 1.706650982669089e-05
is O 0 3.1505044262303272e-06
a O 0 3.866025508614257e-06
rare O 0 6.560156907653436e-05
disorder B-Disease 1 0.9999995231628418
of I-Disease 1 0.9994544386863708
glycoprotein I-Disease 1 1.0
metabolism I-Disease 0 0.0038942715618759394
caused O 0 3.517859113344457e-06
by O 0 5.241823259893863e-07
the O 0 3.6471647035796195e-06
deficiency B-Disease 1 0.6928620934486389
of I-Disease 0 1.3905578271078411e-05
the I-Disease 0 1.3564792425313499e-05
lysosomal I-Disease 1 0.9991220831871033
enzyme I-Disease 0 2.0875038899248466e-05
aspartylglucosaminidase I-Disease 0 0.07047927379608154
( O 0 1.3697766007680912e-05
AGA O 1 0.9999620914459229
) O 0 4.4569278543349355e-05
. O 0 7.558643847005442e-05

AGU B-Disease 1 1.0
is O 0 0.0002202169125666842
inherited O 0 0.06369709223508835
as O 0 6.428324923035689e-06
an O 0 1.1282738341833465e-05
autosomal O 1 0.9698606729507446
recessive O 1 0.9941417574882507
trait O 1 0.9847965240478516
and O 0 2.4940793537098216e-06
occurs O 0 1.5800218022832269e-07
with O 0 1.1748287676027758e-07
a O 0 5.23565802268422e-07
high O 0 2.695348257475416e-06
frequency O 0 6.072577320992423e-07
in O 0 3.1335781613961444e-07
Finland O 0 2.5760043627087725e-06
because O 0 4.1311983522973605e-07
of O 0 1.2477484006012673e-06
a O 0 6.578257853107061e-06
founder O 0 0.00025233201449736953
effect O 0 3.0427623642026447e-05
. O 0 6.859626591904089e-05

While O 0 4.248744517099112e-05
very O 0 4.6685372581123374e-06
few O 0 3.876287792081712e-06
patients O 0 1.8876899048336782e-06
with O 0 2.5456292860326357e-06
AGU B-Disease 1 1.0
have O 0 1.1049116892536404e-06
been O 0 6.388030442394665e-07
reported O 0 2.872008906251722e-07
from O 0 2.4288519284709764e-07
non O 0 8.012406169655151e-07
- O 0 3.528688239384792e-06
Finnish O 0 0.00012430296919774264
origin O 0 3.8687957726324385e-07
, O 0 4.3018667383876164e-07
we O 0 5.439717369881691e-07
diagnosed O 0 0.047276124358177185
the O 0 2.2812782844994217e-06
disorder O 1 0.9802224040031433
in O 0 5.88516002153483e-07
8 O 0 7.176604867709102e-06
patients O 0 2.6025148258668196e-07
originating O 0 1.7247583627977292e-07
from O 0 1.1211781014708322e-07
3 O 0 8.434957408098853e-07
unrelated O 0 6.545089945575455e-07
families O 0 4.9870170215626786e-08
, O 0 9.346483409444772e-08
all O 0 1.2452112230221246e-07
Palestinian O 0 8.147661674229312e-07
Arabs O 0 9.154103395303537e-07
from O 0 3.3164701562782284e-07
the O 0 9.48394756505877e-07
region O 0 2.548206111896434e-06
of O 0 1.0939030289591756e-05
Jerusalem O 0 0.0005499835242517292
. O 0 9.434936509933323e-05

The O 0 8.75715195434168e-05
clinical O 0 0.006727793253958225
diagnosis O 1 0.8110734224319458
of O 1 0.9985108971595764
AGU B-Disease 1 1.0
is O 0 2.070851951430086e-05
often O 0 3.585504657621641e-07
difficult O 0 4.0657192812432186e-07
, O 0 2.6010704345935665e-07
in O 0 1.2054495357460837e-07
particular O 0 1.0842814646139232e-07
early O 0 1.3604177695469843e-07
in O 0 5.8539363578802295e-08
the O 0 1.6409880743140093e-07
course O 0 9.473696422901412e-07
of O 0 6.611891762986488e-07
the O 0 1.1613569768087473e-06
disease O 0 0.00750541128218174
, O 0 1.512399308012391e-07
and O 0 8.980867960417527e-08
most O 0 5.9212464265101517e-08
of O 0 3.033295001841907e-07
the O 0 6.45423938294698e-07
patients O 0 6.161280907690525e-07
are O 0 1.2148113626153645e-07
diagnosed O 0 2.0055136701557785e-05
after O 0 4.799344424100127e-07
the O 0 4.94597657052509e-07
age O 0 8.891257152754406e-07
of O 0 9.474374564888421e-07
5 O 0 6.29349642622401e-06
years O 0 7.95812411524821e-06
. O 0 2.023808156081941e-05

However O 0 4.101162267033942e-05
, O 0 5.440098448161734e-06
since O 0 1.4200959412846714e-06
these O 0 3.9368325133182225e-07
patients O 0 9.586786973159178e-07
excrete O 0 5.2844748097413685e-06
early O 0 7.551247449555376e-07
large O 0 8.958829766925192e-07
amounts O 0 6.945213044673437e-07
of O 0 1.2418330470609362e-06
aspartylglucosamine O 0 5.347918704501353e-05
in O 0 6.08483787800651e-07
urine O 0 1.4430950159294298e-06
, O 0 3.3554260880919173e-07
biochemical O 0 1.97125700651668e-06
screening O 0 1.615827159184846e-06
is O 0 7.835603810235625e-07
easy O 0 1.236293428519275e-06
by O 0 9.708400057206745e-07
urine O 0 2.510010926926043e-05
chromatography O 0 0.0004339250735938549
. O 0 1.699135100352578e-05
. O 0 5.242515908321366e-05

Detection O 0 0.00022651188191957772
of O 0 2.8296557502471842e-05
heterozygous O 0 1.82331568794325e-05
carriers O 0 3.8051373394409893e-06
of O 0 4.564463779388461e-06
the O 0 2.1431495042634197e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0004392839327920228
ATM O 1 0.559729278087616
) O 0 2.2390263438865077e-06
gene O 0 1.1039028322556987e-06
by O 0 6.608185003642575e-07
G2 O 1 0.9991238713264465
phase O 0 3.9154991100076586e-05
chromosomal O 0 0.00018348587036598474
radiosensitivity O 1 0.9860233068466187
of O 0 0.0702565461397171
peripheral O 1 1.0
blood O 1 0.9824331998825073
lymphocytes O 0 0.005140440072864294
. O 0 0.00012790094478987157

In O 0 0.00016030717233661562
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.6443007588386536
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.339662154961843e-06
patients O 0 9.171387773676543e-07
, O 0 2.783452544008469e-07
mutations O 0 1.5745284542845184e-07
in O 0 8.694617292803741e-08
a O 0 2.970065224872087e-07
single O 0 1.7738608448780724e-07
gene O 0 2.0773211417690618e-07
, O 0 3.1992124149837764e-07
ATM O 0 0.0010431857081130147
, O 0 4.442852343800041e-07
result O 0 3.711873262091103e-07
in O 0 2.3685228711656237e-07
an O 0 4.38543474956532e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.6110786873468896e-06
embraces O 0 5.503941338247387e-06
a O 0 4.909372819383861e-07
variety O 0 5.494231345437584e-07
of O 0 9.686693829280557e-07
clinical O 0 1.0118461432284676e-05
features O 0 2.499643869668944e-06
and O 0 6.498975722024625e-07
manifests O 0 1.7742156614986015e-06
extreme O 0 5.4860506679688115e-06
radiosensitivity O 0 0.018424395471811295
and O 0 1.2245334346516756e-06
a O 0 2.2414747036236804e-06
strong O 0 3.5357456908968743e-06
pre O 0 4.388544402900152e-05
- O 0 9.721379319671541e-05
disposition O 0 8.746178355067968e-05
to O 0 1.795373646018561e-05
malignancy B-Disease 1 0.9973741769790649
. O 0 0.0001024198136292398

Heterozygotes O 0 0.0005296925082802773
for O 0 6.585997198271798e-06
the O 0 4.863309186475817e-06
ATM O 0 0.0003892981621902436
gene O 0 2.230099426014931e-06
have O 0 3.850391863124969e-07
no O 0 5.720391413888137e-07
clinical O 0 3.2216378258453915e-06
expression O 0 5.48713103398768e-07
of O 0 2.9305476800800534e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 4.3140519778717135e-07
may O 0 3.1822449386709195e-07
be O 0 3.884600801029592e-07
cancer B-Disease 0 0.00029113711207173765
prone O 0 6.881005901959725e-06
with O 0 4.215451383515756e-07
a O 0 2.5406184249732178e-06
moderate O 0 4.7444978008570615e-06
increase O 0 7.68411666740576e-07
in O 0 7.149799898797937e-07
in O 0 2.4176031274691923e-06
vitro O 0 2.581183798611164e-05
radiosensitivity O 0 0.0008075698278844357
. O 0 7.167972216848284e-05

We O 0 2.7358904844732024e-05
performed O 0 1.6940985005930997e-05
a O 0 6.576037321792683e-06
blind O 0 2.2628631995758042e-05
chromosomal O 0 9.218843842973001e-06
analysis O 0 1.99013493329403e-06
on O 0 4.4907851588504855e-06
G2 O 1 0.9999932050704956
- O 0 4.60089067928493e-05
phase O 0 8.27784515422536e-06
lymphocytes O 0 2.5338479190395446e-06
from O 0 3.468416309715394e-07
7 O 0 2.144682412108523e-06
unrelated O 0 4.291395271138754e-06
A B-Disease 1 0.9999203681945801
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 1.2715537422991474e-06
, O 0 4.638730501937971e-07
13 O 0 1.2073529660483473e-06
obligate O 0 3.674507752293721e-06
A B-Disease 1 0.9999886751174927
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
heterozygotes O 0 2.294097976118792e-05
( O 0 9.356450618724921e-07
parents O 0 1.3194187431508908e-07
of O 0 2.427328524845507e-07
the O 0 4.545297258573555e-07
patients O 0 2.395055673787283e-07
) O 0 2.1166850672216242e-07
, O 0 1.6800376556602714e-07
and O 0 1.6341742536951642e-07
14 O 0 9.33153557980404e-07
normal O 0 3.929982597128401e-07
controls O 0 1.413717996001651e-06
following O 0 5.013406507714535e-07
X O 0 3.8079620026110206e-06
- O 0 2.4057583232206525e-06
irradiation O 0 1.960926283572917e-06
with O 0 2.391862210515683e-07
1 O 0 4.347217782196822e-06
Gy O 0 9.433012019144371e-05
in O 0 3.20075059789815e-07
order O 0 2.1021725160608185e-07
to O 0 1.7092925475026277e-07
evaluate O 0 5.59215436624072e-07
this O 0 1.9431891473686846e-07
cytogenetic O 0 7.914749403425958e-06
method O 0 4.852149118050875e-07
as O 0 3.2108059144775325e-07
a O 0 3.8127842572066584e-07
tool O 0 2.7111050258099567e-06
for O 0 4.921711251881788e-07
detection O 0 8.461847755825147e-06
of O 0 1.1726570846803952e-05
ATM O 1 0.8885344862937927
carriers O 0 4.7679644922027364e-05
. O 0 6.275722262216732e-05

Both O 0 7.57886009523645e-05
A B-Disease 1 0.9999980926513672
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 1 0.998325526714325
and O 0 1.0171530448133126e-05
heterozygotes O 0 6.869393109809607e-05
showed O 0 2.5859953893814236e-06
significantly O 0 7.676440532122797e-07
increased O 0 3.564761357210955e-07
levels O 0 4.410985923186672e-07
of O 0 1.278092099710193e-06
radiation O 0 0.11890994757413864
- O 0 0.0016358582070097327
induced O 0 3.8738417060812935e-05
chromatid O 0 0.012975185178220272
damage O 0 1.538512333354447e-05
relative O 0 1.2992557003599359e-06
to O 0 3.6348131970953546e-07
that O 0 2.9994546935085964e-07
of O 0 2.522044724173611e-06
normal O 0 5.492395303008379e-06
controls O 0 2.8957187168998644e-05
. O 0 3.457587445154786e-05

These O 0 9.99871099338634e-06
results O 0 2.9001098482694943e-06
show O 0 2.616058964122203e-06
that O 0 8.759198522056977e-07
the O 0 3.0453404633590253e-06
G2 O 1 0.9999972581863403
- O 0 0.00014735573495272547
phase O 0 1.57038593897596e-05
chromosomal O 0 1.539266850159038e-05
radiosensitivity O 0 3.681736416183412e-05
assay O 0 2.0610916635632748e-06
can O 0 1.4179860841068148e-07
be O 0 8.200070311659147e-08
used O 0 7.747946284553109e-08
for O 0 7.520775824332304e-08
the O 0 2.2845520675218722e-07
detection O 0 3.018119514308637e-06
of O 0 6.419123110390501e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.0014951461926102638
. O 0 0.00013061962090432644

In O 0 1.8362496120971628e-05
combination O 0 9.2021200543968e-06
with O 0 1.0726917025749572e-06
molecular O 0 8.342934961547144e-06
genetic O 0 1.4759649502593675e-06
analyses O 0 1.0188945225308998e-06
, O 0 5.267983169687795e-07
this O 0 1.1415045975127214e-07
test O 0 1.5950023168898042e-07
may O 0 6.975535882247641e-08
be O 0 4.324902036501044e-08
of O 0 1.0463532618132376e-07
value O 0 1.8317963679237437e-07
in O 0 1.0210857226411463e-07
studies O 0 1.8853820904496388e-07
of O 0 3.3973500990214234e-07
familial B-Disease 0 9.816257261263672e-06
and I-Disease 0 9.390053037350299e-07
sporadic I-Disease 0 1.8479035134078003e-05
cancers I-Disease 0 0.028084583580493927
aimed O 0 1.8833131889550714e-06
at O 0 1.3060922583463253e-06
determination O 0 5.632048782899801e-07
of O 0 5.341244673218171e-07
the O 0 3.794675649260171e-07
potential O 0 8.785483487372403e-07
involvement O 0 1.0921557986875996e-06
of O 0 1.4672134511783952e-06
ATM O 0 0.09152530878782272
mutations O 0 1.8987360590472235e-06
in O 0 1.8549180822446942e-06
tumor B-Disease 1 1.0
risk O 0 1.0507835213502403e-05
or O 0 1.4135724768493674e-06
development O 0 2.1790003756905207e-06
. O 0 5.343860266293632e-06
. O 0 2.3135791707318276e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
: O 0 1.0539106369833462e-05
identification O 0 2.6334837457397953e-06
and O 0 5.293768481351435e-07
detection O 0 5.242860879661748e-06
of O 0 5.40192468179157e-06
founder O 0 0.2771627604961395
- O 0 9.14135580387665e-06
effect O 0 6.655162678725901e-07
mutations O 0 1.4516582780288445e-07
in O 0 1.0171902431466151e-07
the O 0 5.819697435072158e-07
ATM O 0 9.453335223952308e-05
gene O 0 2.1436517272377387e-06
in O 0 1.5602414578097523e-06
ethnic O 0 6.385962478816509e-06
populations O 0 1.3374580703384709e-05
. O 0 3.722588007804006e-05

To O 0 2.2437236111727543e-05
facilitate O 0 1.1206985618628096e-05
the O 0 3.83093856726191e-06
evaluation O 0 4.288875061320141e-06
of O 0 5.829685051139677e-06
ATM O 1 0.9970158338546753
heterozygotes O 0 4.3381875002523884e-05
for O 0 1.2312902981648222e-06
susceptibility O 0 7.818854101060424e-06
to O 0 5.408127776718175e-07
other O 0 3.7098487837283756e-07
diseases O 1 0.5816999077796936
, O 0 3.3163468060593004e-07
such O 0 2.4497279582647025e-07
as O 0 0.00018456725229043514
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
, O 0 3.3119786735369416e-07
we O 0 6.674765273828598e-08
have O 0 3.5887129712364185e-08
attempted O 0 3.299853688076837e-07
to O 0 9.943190093508747e-08
define O 0 2.1218367862729792e-07
the O 0 2.2491333595553442e-07
most O 0 1.7710414113025763e-07
common O 0 1.6025894922222506e-07
mutations O 0 1.2774250990332803e-07
and O 0 9.154419444712403e-08
their O 0 6.314083123015735e-08
frequencies O 0 6.731364692313946e-07
in O 0 7.150100032049522e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0003371404600329697
A B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
T I-Disease 1 0.9999998807907104
) O 0 4.063167125423206e-06
homozygotes O 0 3.230360016459599e-05
from O 0 2.5249182726838626e-06
10 O 0 8.808867278276011e-06
ethnic O 0 2.0086337826796807e-05
populations O 0 1.8642622308107093e-05
. O 0 3.689690129249357e-05

Both O 0 2.63379915850237e-05
genomic O 0 3.771923002204858e-05
mutations O 0 5.891623004572466e-06
and O 0 1.1417369023547508e-06
their O 0 3.3715477343321254e-07
effects O 0 3.18726415571291e-06
on O 0 2.7773935471486766e-06
cDNA O 0 3.4400542062940076e-05
were O 0 5.293180038279388e-06
characterized O 0 3.6531317164190114e-05
. O 0 6.453556852648035e-05

Protein O 0 7.141778769437224e-05
- O 0 4.931718285661191e-05
truncation O 0 7.037712202873081e-05
testing O 0 3.7215288557490567e-06
of O 0 2.121257239195984e-06
the O 0 1.5209012644845643e-06
entire O 0 5.877772764506517e-06
ATM O 0 3.76836396753788e-05
cDNA O 0 2.1447054677992128e-05
detected O 0 3.8595826481468976e-06
92 O 0 9.279148798668757e-06
( O 0 1.3549514505939442e-06
66 O 0 6.251528247958049e-06
% O 0 7.405129736071103e-07
) O 0 1.1815124025815749e-06
truncating O 0 1.2682047781709116e-05
mutations O 0 1.3278715869091684e-06
in O 0 9.211709652845457e-07
140 O 0 1.801448524929583e-05
mutant O 0 5.477345621329732e-05
alleles O 0 3.0031067581148818e-05
screened O 0 0.00014541749260388315
. O 0 9.992764535127208e-05

The O 0 0.0001782622712198645
haplotyping O 1 0.8453946709632874
of O 0 8.402374805882573e-05
patients O 0 6.108069555921247e-06
with O 0 8.380889653381018e-07
identical O 0 1.521765966572275e-06
mutations O 0 1.2913707223560777e-06
indicates O 0 9.267610039387364e-07
that O 0 6.62013235341874e-08
almost O 0 1.0988615173346261e-07
all O 0 6.410531483425075e-08
of O 0 2.054306520449245e-07
these O 0 6.292082588288395e-08
represent O 0 1.423092044205987e-07
common O 0 2.657400273164967e-07
ancestry O 0 1.9000840723037982e-07
and O 0 1.4019258287589764e-07
that O 0 1.4951145033137436e-07
very O 0 3.0104536108410684e-07
few O 0 9.372633940074593e-07
spontaneously O 0 4.571799763652962e-06
recurring O 0 0.0003894046531058848
ATM O 1 0.7644743919372559
mutations O 0 2.2789996364735998e-05
exist O 0 1.0261604984407313e-05
. O 0 2.9610500860144384e-05

Assays O 0 0.00011445881682448089
requiring O 0 1.7289119568886235e-05
minimal O 0 1.7678567019174807e-05
amounts O 0 4.792410891241161e-06
of O 0 1.5606730130457436e-06
genomic O 0 3.329661467432743e-06
DNA O 0 8.401992204198905e-07
were O 0 1.4647513069121487e-07
designed O 0 3.4320248687436106e-07
to O 0 1.3096928341838066e-07
allow O 0 1.3614274507744994e-07
rapid O 0 8.13568874491466e-07
screening O 0 1.2701428886430222e-06
for O 0 5.673223313351627e-07
common O 0 1.902386429719627e-06
ethnic O 0 6.635759291384602e-06
mutations O 0 1.883152981463354e-05
. O 0 3.8434547604992986e-05

These O 0 2.8486247174441814e-05
rapid O 0 3.332848064019345e-05
assays O 0 1.1577714758459479e-05
detected O 0 4.8723477448220365e-06
mutations O 0 6.810471404605778e-07
in O 0 2.8536837248793745e-07
76 O 0 2.66638676293951e-06
% O 0 2.7326083795742306e-07
of O 0 4.673387365983217e-07
Costa O 0 4.046130015922245e-06
Rican O 0 1.7639831639826298e-05
patients O 0 3.368777470313944e-07
( O 0 1.4001059867041477e-07
3 O 0 4.609356949458743e-07
) O 0 1.519113936865324e-07
, O 0 1.560105999942607e-07
50 O 0 2.6253388796249055e-07
% O 0 1.1976221969689504e-07
of O 0 2.376260539449504e-07
Norwegian O 0 2.820858981067431e-06
patients O 0 2.7724925644179166e-07
( O 0 9.954177215831805e-08
1 O 0 2.622978740873805e-07
) O 0 6.743380254192743e-08
, O 0 4.8316103118395404e-08
25 O 0 1.1630489638037034e-07
% O 0 7.218408626386008e-08
of O 0 2.4803568976494716e-07
Polish O 0 0.00026431572041474283
patients O 0 4.5499464818021806e-07
( O 0 1.7955372300093586e-07
4 O 0 7.866624400776345e-07
) O 0 1.6582173145707202e-07
, O 0 1.0024157148791346e-07
and O 0 8.1562546938585e-08
14 O 0 3.14638270992873e-07
% O 0 8.508058613188041e-08
of O 0 2.2750204209387448e-07
Italian O 0 7.297281990759075e-05
patients O 0 3.14219676056382e-07
( O 0 1.2225051193581749e-07
1 O 0 9.200173280987656e-07
) O 0 1.7784189765279734e-07
, O 0 1.1403979982560486e-07
as O 0 1.1077397488179486e-07
well O 0 1.8818988678503956e-07
as O 0 2.373099050601013e-07
in O 0 3.009259330610803e-07
patients O 0 5.357651389203966e-07
of O 0 2.1337596081139054e-06
Amish O 0 3.408473639865406e-05
/ O 0 0.0013954591704532504
Mennonite O 0 5.04262134199962e-05
and O 0 3.0794517442700453e-06
Irish O 0 4.317592902225442e-05
English O 0 3.7979432818247005e-05
backgrounds O 0 4.375030766823329e-05
. O 0 6.116077565820888e-05

Additional O 0 4.974066177965142e-05
mutations O 0 7.5097336775797885e-06
were O 0 1.1418392205087002e-06
observed O 0 8.300210652123496e-07
in O 0 4.769503902934957e-07
Japanese O 0 3.0310159218061017e-06
, O 0 1.0595464345897199e-06
Utah O 0 1.5182814422587398e-05
Mormon O 0 5.264776063995669e-06
, O 0 7.694867463214905e-07
and O 0 9.406895173924568e-07
African O 0 4.3000636651413515e-06
American O 0 3.121030385955237e-05
patients O 0 2.8896663934574462e-05
. O 0 4.872350109508261e-05

These O 0 8.915838407119736e-06
assays O 0 6.105396096245386e-06
should O 0 8.234204642576515e-07
facilitate O 0 8.394575843340135e-07
screening O 0 1.1276694067419157e-06
for O 0 1.0512056860534358e-06
A B-Disease 1 0.999997615814209
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
heterozygotes O 0 2.734044028329663e-05
in O 0 8.741690180613659e-07
the O 0 1.1607556871240376e-06
populations O 0 6.721485874550126e-07
studied O 0 4.988804448657902e-06
. O 0 4.040954991069157e-06
. O 0 2.0738285456900485e-05

The O 0 0.00018825370352715254
von B-Disease 1 0.8197208046913147
Hippel I-Disease 1 0.9999954700469971
- I-Disease 1 0.999993085861206
Lindau I-Disease 1 1.0
tumor I-Disease 1 0.9999998807907104
suppressor O 1 0.999273955821991
gene O 0 2.9754933166259434e-06
is O 0 6.439772164412716e-07
required O 0 3.313002423510625e-07
for O 0 5.248566026239132e-07
cell O 0 4.189491392025957e-06
cycle O 0 3.4285872061445843e-06
exit O 0 8.05770014267182e-06
upon O 0 4.331781383370981e-06
serum O 0 2.987903826578986e-05
withdrawal O 0 3.747985465452075e-05
. O 0 7.145443669287488e-05

The O 0 8.115833043120801e-05
inactivation O 0 0.0002509026962798089
of O 0 1.5200865163933486e-05
the O 0 1.1785351489379536e-05
von B-Disease 1 0.8169060945510864
Hippel I-Disease 1 0.9999994039535522
- I-Disease 1 0.9998071789741516
Lindau I-Disease 1 0.9999991655349731
( I-Disease 0 6.610003038076684e-05
VHL I-Disease 1 1.0
) I-Disease 0 2.9920609449618496e-05
tumor I-Disease 1 0.9999997615814209
suppressor O 1 0.9999997615814209
gene O 0 4.400857142172754e-05
predisposes O 0 0.005857924930751324
affected O 0 7.991724828571023e-07
individuals O 0 1.5691799148953578e-07
to O 0 3.057735682432394e-07
the O 0 2.6878685730480356e-06
human O 1 0.8474140167236328
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.5500880863328348e-06
is O 0 6.244266614885419e-07
associated O 0 3.2860546639312815e-07
with O 0 5.969486096546461e-07
sporadic B-Disease 1 0.9921112060546875
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 1 0.9999961853027344
RCC B-Disease 1 1.0
) O 0 0.00013682860299013555
and O 0 2.4715176550671458e-05
brain B-Disease 1 0.6018156409263611
hemangioblastomas I-Disease 1 0.9865589141845703
. O 0 0.00011998270929325372

VHL O 1 0.9999278783798218
- O 0 0.0006854087114334106
negative O 0 4.939824066241272e-05
786 O 0 0.007884400896728039
- O 0 0.024926666170358658
0 O 0 0.0002141863078577444
RCC B-Disease 1 1.0
cells O 0 5.962862360320287e-06
are O 0 4.790683192368306e-07
tumorigenic O 0 0.00023352628340944648
in O 0 2.2150841232360108e-06
nude O 0 0.00014178386481944472
mice O 0 4.335790436016396e-06
which O 0 2.3964491902006557e-07
is O 0 6.268939500841952e-07
suppressed O 0 5.141975179867586e-06
by O 0 5.269370149107999e-07
the O 0 2.4181588287319755e-06
reintroduction O 0 8.201874879887328e-05
of O 0 4.8565318138571456e-05
VHL B-Disease 1 0.9999957084655762
. O 0 0.00018284925317857414

Remarkably O 0 0.0003919756563846022
, O 0 5.741965651395731e-06
this O 0 9.291149467571813e-07
occurs O 0 4.010381360330939e-07
without O 0 3.163436304021161e-07
affecting O 0 1.2357959349174052e-06
the O 0 9.345401963400946e-07
growth O 0 8.278755103674484e-07
rate O 0 3.7871052427362883e-07
and O 0 2.1523032955883536e-07
cell O 0 1.0769741720650927e-06
cycle O 0 8.149791028699838e-07
profile O 0 1.3066940027783858e-06
of O 0 8.086808520602062e-07
these O 0 1.9331746159423346e-07
cells O 0 6.547605835294235e-07
in O 0 1.5319412796088727e-06
culture O 0 1.587122278579045e-05
. O 0 3.1347157346317545e-05

The O 0 7.53697968320921e-05
786 O 0 0.000754285603761673
- O 0 9.477091953158379e-05
0 O 0 1.888602491817437e-05
cell O 0 7.107322744559497e-06
line O 0 5.385644271882484e-06
, O 0 1.1640759112196974e-06
like O 0 1.2698982345682452e-06
many O 0 1.1265493640166824e-06
cancer B-Disease 1 0.9984745383262634
cells O 0 8.387693810618657e-07
, O 0 4.1500737779642805e-07
fails O 0 7.762373570585623e-07
to O 0 5.876859177078586e-07
exit O 0 5.3775866035721265e-06
the O 0 3.3589910799491918e-06
cell O 0 6.382875199051341e-06
cycle O 0 6.767914328520419e-06
upon O 0 4.578283551381901e-06
serum O 0 3.865620601573028e-05
withdrawal O 0 3.8985872379271314e-05
. O 0 5.048308594268747e-05

Here O 0 3.8893966120667756e-05
, O 0 5.222390882408945e-06
it O 0 9.17925433441269e-07
is O 0 6.579535352102539e-07
shown O 0 1.8537107848715095e-07
that O 0 1.4880900778280193e-07
reintroduction O 0 5.192731805436779e-06
of O 0 1.078365812645643e-06
the O 0 8.254568797383399e-07
wild O 0 6.5006015574908815e-06
- O 0 4.613438795786351e-05
type O 0 2.784836215141695e-05
VHL B-Disease 1 0.9905357956886292
gene O 0 3.096860382356681e-06
restores O 0 7.231828021758702e-06
the O 0 9.947531225407147e-07
ability O 0 7.115611424524104e-07
of O 0 3.602158358262386e-06
VHL O 1 1.0
- O 1 0.9978713989257812
negative O 0 0.001252792659215629
RCC B-Disease 1 1.0
cancer I-Disease 1 0.9975212216377258
cells O 0 3.282152079009393e-07
to O 0 1.758237999638368e-07
exit O 0 1.911428398670978e-06
the O 0 9.94351921690395e-07
cell O 0 2.477480165907764e-06
cycle O 0 2.7036328447138658e-06
and O 0 1.599772076588124e-06
enter O 0 8.987070032162592e-06
G0 O 1 0.8796142935752869
/ O 0 0.00037248883745633066
quiescence O 0 0.0002770347346086055
in O 0 1.3544782632379793e-05
low O 0 6.634695455431938e-05
serum O 0 0.00014589220518246293
. O 0 6.252424645936117e-05

Both O 0 0.0001975250634131953
VHL O 1 0.9999889135360718
- O 0 0.0011413313914090395
positive O 0 1.739335675665643e-05
and O 0 9.537111509416718e-06
VHL O 1 0.9999978542327881
- O 0 0.33197706937789917
negative O 0 3.405088136787526e-05
RCC B-Disease 1 1.0
cells O 0 4.9453205974714365e-06
exit O 0 7.281698344741017e-06
the O 0 1.917489953484619e-06
cell O 0 6.2419903770205565e-06
cycle O 0 4.6810337153146975e-06
by O 0 1.0966437002934981e-06
contact O 0 5.751567641709698e-06
inhibition O 0 3.357987952767871e-05
. O 0 3.802252467721701e-05

The O 0 0.00013861113984603435
cyclin O 0 0.00038065743865445256
- O 0 9.182009671349078e-05
dependent O 0 1.1588273991947062e-05
kinase O 0 2.7402849809732288e-05
inhibitor O 0 2.224495074187871e-05
, O 0 2.3703855731582735e-06
p27 O 0 4.088470814167522e-05
, O 0 1.0040400866273558e-06
accumulates O 0 4.229995738569414e-06
upon O 0 6.417835720640142e-07
serum O 0 2.0790980670426507e-06
withdrawal O 0 7.557010235359485e-07
, O 0 2.5674299308775517e-07
only O 0 1.0268824723880243e-07
in O 0 1.1728998572380078e-07
the O 0 2.106418861558268e-07
presence O 0 5.875020860912628e-07
of O 0 3.631349045463139e-06
VHL B-Disease 1 0.999998927116394
, O 0 1.3966588312541717e-06
as O 0 4.934951221002848e-07
a O 0 4.103026753909944e-07
result O 0 2.1864119048586872e-07
of O 0 4.605683443514863e-07
the O 0 6.633624707319541e-07
stabilization O 0 8.23570280772401e-06
of O 0 5.190761385165388e-06
the O 0 6.988865152379731e-06
protein O 0 2.2142765374155715e-05
. O 0 3.102377013419755e-05

We O 0 2.1938296413281932e-05
propose O 0 1.378216256853193e-05
that O 0 6.764570912309864e-07
the O 0 1.246617330252775e-06
loss O 0 1.042302119458327e-05
of O 0 6.491235581052024e-06
wild O 0 0.00010462026693858206
- O 0 0.30924925208091736
type O 0 0.0029659406282007694
VHL B-Disease 1 0.9999479055404663
gene O 0 1.0528601706027985e-06
results O 0 2.7997430152026936e-07
in O 0 1.4650419188910746e-07
a O 0 3.3557270739947853e-07
specific O 0 2.811403305713611e-07
cellular O 0 7.646829544682987e-06
defect O 0 1.614461507415399e-05
in O 0 7.476530186067976e-07
serum O 0 5.680202775693033e-06
- O 0 1.102396345231682e-05
dependent O 0 6.463028512371238e-07
growth O 0 5.835052547809028e-07
control O 0 7.566529802716104e-07
, O 0 4.239924464854994e-07
which O 0 2.0027265179578535e-07
may O 0 6.722011676174589e-07
initiate O 0 9.039355973072816e-06
tumor B-Disease 1 0.9999040365219116
formation O 0 0.00012216992035973817
. O 0 7.105978147592396e-05

This O 0 2.0503797713899985e-05
is O 0 7.232531970657874e-06
corrected O 0 6.564807790709892e-06
by O 0 4.0252368194160226e-07
the O 0 1.1156439541082364e-06
reintroduction O 0 1.9390219677006826e-05
of O 0 5.340874395187711e-06
wild O 0 2.0699200831586495e-05
- O 0 0.004875184502452612
type O 0 0.0021679920610040426
VHL B-Disease 1 0.9999998807907104
, O 0 4.2870101424341556e-06
implicating O 0 0.34699952602386475
VHL B-Disease 1 0.9999994039535522
as O 0 3.7798849916725885e-06
the O 0 2.318144879609463e-06
first O 0 3.2325353913620347e-06
tumor B-Disease 1 0.9995498061180115
suppressor O 1 0.9350534677505493
involved O 0 1.1689841130646528e-06
in O 0 3.5651760299515445e-07
the O 0 4.776677542395191e-07
regulation O 0 6.850127647339832e-07
of O 0 1.2386169601086294e-06
cell O 0 3.192995791323483e-06
cycle O 0 1.98783413907222e-06
exit O 0 2.1565513179666596e-06
, O 0 2.2941388522212947e-07
which O 0 1.5552632248727605e-07
is O 0 2.1071403466521588e-07
consistent O 0 3.6268974668018927e-07
with O 0 1.398059197299517e-07
its O 0 4.558911541607813e-07
gatekeeper O 0 7.777188875479624e-05
function O 0 7.912890964689723e-07
in O 0 1.1180533192600706e-06
the O 0 1.084513951354893e-05
kidney O 1 0.9999996423721313
. O 0 1.4069249118620064e-05
. O 0 3.932540857931599e-05

Piebaldism B-Disease 1 1.0
with O 0 0.00028475894941948354
deafness B-Disease 1 1.0
: O 0 4.3215964979026467e-05
molecular O 0 2.475522705935873e-05
evidence O 0 3.5805605875793844e-06
for O 0 1.4578128002540325e-06
an O 0 5.157573014002992e-06
expanded O 0 0.0004495084285736084
syndrome O 1 0.9999986886978149
. O 0 0.00016790821973700076

In O 0 3.06893780361861e-05
a O 0 1.3684747500519734e-05
South O 0 9.184418559016194e-06
African O 0 4.127927695662947e-06
girl O 0 1.1889286724908743e-05
of O 0 4.675264790421352e-06
Xhosa O 1 0.975200891494751
stock O 0 8.431012247456238e-05
with O 0 2.5527326670271577e-06
severe O 1 0.9721250534057617
piebaldism B-Disease 1 1.0
and O 0 0.1816050112247467
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.0007816270808689296
identified O 0 2.6370876184955705e-06
a O 0 1.1559005770322983e-06
novel O 0 5.318053808878176e-06
missense O 0 4.166613052802859e-06
substitution O 0 1.4156607903714757e-06
at O 0 1.7986855027629645e-06
a O 0 8.315026889249566e-07
highly O 0 1.2055097613483667e-06
conserved O 0 2.527594688217505e-06
residue O 0 2.611823674669722e-06
in O 0 3.1336438155449287e-07
the O 0 5.598269012807577e-07
intracellular O 0 2.289047642989317e-06
kinase O 0 3.5303748973092297e-06
domain O 0 1.7995021153183188e-06
of O 0 2.0202533050905913e-06
the O 0 2.4584885522926925e-06
KIT O 0 0.014427484013140202
proto O 0 0.3724880516529083
- O 1 0.8511978983879089
oncogene O 1 0.9870303273200989
, O 0 2.95104764518328e-05
R796G O 0 0.0008378432830795646
. O 0 8.865990093909204e-05

Though O 0 0.00012676639016717672
auditory B-Disease 0 0.03065435029566288
anomalies I-Disease 0 0.21392789483070374
have O 0 1.8762893887469545e-06
been O 0 1.207721425089403e-06
observed O 0 6.463706654358248e-07
in O 0 3.077113035487855e-07
mice O 0 1.1244563893342274e-06
with O 0 3.064634199745342e-07
dominant O 0 0.00015374259965028614
white O 0 3.142045170534402e-05
spotting O 1 0.9891574382781982
( O 0 5.3848684729018714e-06
W O 0 0.0007540599326603115
) O 0 5.289438718136807e-07
due O 0 1.9615271185102756e-07
to O 0 2.3253977587955887e-07
KIT O 1 0.9763654470443726
mutations O 0 5.281653102429118e-06
, O 0 1.5012945368653163e-05
deafness B-Disease 1 1.0
is O 0 4.587461717164842e-06
not O 0 4.983019152859924e-07
typical O 0 2.894578074119636e-06
in O 0 1.043413249135483e-06
human O 0 5.619662260869518e-06
piebaldism B-Disease 0 0.20927852392196655
. O 0 7.436933810822666e-05

Thus O 0 5.668725134455599e-05
, O 0 4.84058500660467e-06
the O 0 3.140667786283302e-06
occurrence O 0 1.5830361007829197e-05
of O 0 0.0056592319160699844
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 0.00371475238353014
this O 0 2.4517385099898092e-06
patient O 0 3.163187557220226e-06
extends O 0 1.9383949165785452e-06
considerably O 0 6.079982881601609e-07
the O 0 4.2367355490569025e-07
phenotypic O 0 1.627458345865307e-06
range O 0 1.4019728951097932e-06
of O 0 1.6571912055951543e-06
piebaldism B-Disease 0 0.00010266633034916595
due O 0 1.0060548447654583e-06
to O 0 7.543480933236424e-07
KIT O 0 0.00024114520056173205
gene O 0 1.3836163361702347e-06
mutation O 0 4.04156907052311e-07
in O 0 1.3744771365509223e-07
humans O 0 2.886325489726005e-07
and O 0 3.4239695878568455e-07
tightens O 0 1.0514069799683057e-05
the O 0 9.155936595561798e-07
clinical O 0 2.8732492864946835e-06
similarity O 0 1.284174118154624e-06
between O 0 6.161521923786495e-07
piebaldism B-Disease 0 0.00035367265809327364
and O 0 4.374639672732883e-07
the O 0 3.428858121878875e-07
various O 0 3.014282867752627e-07
forms O 0 1.1937945600948296e-06
of O 1 0.7227053046226501
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 7.577103679068387e-05
. O 0 0.00012953901023138314

Cycloheximide O 0 0.009244549088180065
facilitates O 0 0.00015954425907693803
the O 0 1.2771276487910654e-05
identification O 0 6.426265372283524e-06
of O 0 5.258353667159099e-06
aberrant O 0 1.9705543309100904e-05
transcripts O 0 8.97168956726091e-06
resulting O 0 1.9277467799838632e-06
from O 0 1.0873999372051912e-06
a O 0 3.564812686818186e-06
novel O 0 6.187458438944304e-06
splice O 0 2.1615944206132554e-05
- O 0 7.550213467766298e-06
site O 0 5.684906227543252e-06
mutation O 0 1.2885966498288326e-06
in O 0 5.562792466662358e-07
COL17A1 O 1 0.9027279019355774
in O 0 1.4768689879929298e-06
a O 0 2.7008081815438345e-06
patient O 0 5.060846888227388e-06
with O 0 4.523693860392086e-06
generalized O 0 0.0074673122726380825
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
. O 0 0.0024506989866495132

Patients O 0 0.0004131614987272769
with O 0 3.304274287074804e-05
generalized O 1 0.8787901401519775
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
often O 0 3.233133611502126e-05
show O 0 1.2725187843898311e-05
decreased O 0 1.0686057976272423e-05
expression O 0 2.9869654554204317e-06
of O 0 4.316555987315951e-06
type O 0 0.40735316276550293
XVII O 1 1.0
collagen O 1 0.9999713897705078
, O 0 5.875161150470376e-06
a O 0 6.0311303968774155e-06
transmembrane O 0 2.4671324354130775e-05
hemidesmosomal O 0 8.091553172562271e-05
protein O 0 6.792848125769524e-06
encoded O 0 3.9225942600751296e-06
by O 0 5.480152140080463e-06
COL17A1 O 1 0.9967617392539978
. O 0 0.00020659988513216376

This O 0 3.472430762485601e-05
report O 0 6.745419796061469e-06
documents O 0 5.634333774651168e-06
a O 0 3.974264018324902e-06
novel O 0 1.2995150427741464e-05
splice O 0 6.275806663325056e-05
- O 0 3.8361897168215364e-05
site O 0 1.2700345905614085e-05
mutation O 0 2.232372025900986e-06
in O 0 1.123247329815058e-06
COL17A1 O 1 0.9442416429519653
in O 0 1.6993936924336595e-06
a O 0 3.096325826845714e-06
patient O 0 3.229032245144481e-06
with O 0 1.7594903738427092e-06
generalized O 0 0.025556614622473717
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 9.708885045256466e-06
and O 0 1.2501401442932547e-06
applies O 0 1.2100906587875215e-06
a O 0 5.911924745305441e-07
new O 0 3.1989378612706787e-07
methodology O 0 1.0419215641377377e-06
to O 0 3.5627493844003766e-07
define O 0 9.451001119487046e-07
and O 0 7.150052283577679e-07
characterize O 0 9.534837772662286e-06
the O 0 3.648427309599356e-06
resulting O 0 1.0090710020449478e-05
mRNA O 0 4.0377512050326914e-05
splice O 0 0.00023635993420612067
variants O 0 0.00015174322470556945
. O 0 9.793564822757617e-05

Mutational O 0 0.003042621770873666
analysis O 0 3.3938584238057956e-05
of O 0 3.802085484494455e-05
COL17A1 O 1 0.9999202489852905
identified O 0 1.2911964404338505e-05
a O 0 6.676129487459548e-06
maternally O 0 4.4607630115933716e-05
inherited O 0 7.116434426279739e-05
G O 0 7.558918150607497e-05
- O 0 1.628994505153969e-05
to O 0 2.857975232473109e-06
- O 0 0.013727025128901005
T O 0 0.09060455858707428
transversion O 0 0.0001160746396635659
at O 0 3.8068435515015153e-06
the O 0 1.052808897838986e-06
- O 0 2.440988055241178e-06
1 O 0 4.314333637012169e-06
position O 0 4.429189175425563e-06
of O 0 4.377420737000648e-06
exon O 0 9.878032869892195e-05
32 O 0 6.121438491391018e-05
. O 0 6.352322088787332e-05

This O 0 2.008158844546415e-05
acceptor O 0 2.5263023417210206e-05
splice O 0 9.481548477197066e-05
- O 0 3.2779451430542395e-05
site O 0 9.615486305847298e-06
mutation O 0 1.5213972801575437e-06
led O 0 1.072887016562163e-06
to O 0 2.429435710382677e-07
the O 0 5.54670975816407e-07
formation O 0 2.1916550849709893e-06
of O 0 3.1057065825734753e-06
aberrant O 0 8.040767170314211e-06
transcripts O 0 7.664629265491385e-06
present O 0 2.0267489162506536e-06
at O 0 9.787569069885649e-06
extremely O 0 7.853178431105334e-06
low O 0 3.271412060712464e-05
levels O 0 2.050240982498508e-05
. O 0 4.262770380591974e-05

Based O 0 4.422392521519214e-05
on O 0 1.1286245353403501e-05
our O 0 2.9298321351234335e-06
recent O 0 3.856208877550671e-06
finding O 0 4.002306468464667e-06
that O 0 1.4958660585762118e-06
cycloheximide O 0 0.00019626235007308424
stabilized O 0 7.5688716606237e-05
mutant O 0 6.290701276157051e-05
COL17A1 O 1 0.9897956252098083
transcripts O 0 1.4940903383831028e-05
in O 0 1.5560065094177844e-06
keratinocytes O 0 5.44686781722703e-06
homozygous O 0 2.29929355555214e-06
for O 0 4.6377971330002765e-07
a O 0 1.8675668798096012e-06
frameshift O 0 1.4581642972189002e-05
mutation O 0 8.590959623688832e-07
, O 0 3.0801578532191343e-07
the O 0 2.521419162349048e-07
effects O 0 5.749575393565465e-07
of O 0 5.613195526166237e-07
the O 0 9.459765806241194e-07
splice O 0 1.4523907339025754e-05
- O 0 5.076702109363396e-06
site O 0 2.919618282248848e-06
mutation O 0 3.6964502214686945e-07
on O 0 4.019896664431144e-07
splicing O 0 1.251594312634552e-06
of O 0 1.0326506298952154e-06
COL17A1 O 0 0.009999701753258705
transcripts O 0 8.11063546279911e-06
were O 0 8.579595487390179e-07
determined O 0 8.954729651122761e-07
using O 0 5.866919536856585e-07
reverse O 0 1.7285947251366451e-06
transcriptase O 0 3.697384727274766e-06
polymerase O 0 3.963159088016255e-06
chain O 0 1.8688318732529297e-06
reaction O 0 4.3198321009185747e-07
of O 0 4.6938936293372535e-07
total O 0 6.621406782869599e-07
RNA O 0 3.748053131857887e-06
from O 0 1.3622617416331195e-06
keratinocytes O 0 1.0617854968586471e-05
incubated O 0 1.176530531665776e-05
for O 0 3.9746355469105765e-06
2 O 0 7.521641964558512e-05
. O 0 4.140080272918567e-05

5 O 0 7.553556497441605e-05
h O 0 3.0463275834335946e-05
in O 0 2.0165537080174545e-06
the O 0 1.9200920178263914e-06
presence O 0 1.8869448012992507e-06
or O 0 1.3343851605895907e-06
absence O 0 1.6724711713322904e-06
of O 0 2.270287723149522e-06
10 O 0 5.912426331633469e-06
microg O 0 0.0004157171933911741
cycloheximide O 0 0.0004808272351510823
per O 0 2.9478163924068213e-05
ml O 0 0.00044797404552809894
. O 0 8.54349200380966e-05

Using O 0 1.371883899992099e-05
this O 0 2.669552031875355e-06
approach O 0 3.1534352729067905e-06
, O 0 9.007060839394398e-07
an O 0 9.061806167665054e-07
abnormally O 0 7.940483556012623e-06
spliced O 0 1.2087921277270652e-05
transcript O 0 1.5741135939606465e-05
was O 0 8.207993232645094e-06
identified O 0 6.562884209415643e-07
that O 0 8.584181188098228e-08
contains O 0 3.821003531356837e-07
an O 0 2.610790090784576e-07
extra O 0 9.251626238437893e-07
264 O 0 2.508018042135518e-06
bases O 0 1.0315650342818117e-06
upstream O 0 2.2397289285436273e-06
from O 0 4.433794060787477e-07
exon O 0 5.244731255515944e-06
32 O 0 1.596187757968437e-06
, O 0 4.098032775345928e-07
resulting O 0 6.149252840259578e-07
in O 0 3.1437434699910227e-07
a O 0 1.4850464822302456e-06
premature O 0 4.810782229469623e-06
termination O 0 5.496346147992881e-06
codon O 0 1.6194746422115713e-05
27 O 0 7.393997748295078e-06
bp O 0 1.6532747395103797e-05
downstream O 0 7.628546882187948e-06
from O 0 2.7025912459066603e-06
the O 0 6.671305527561344e-06
cryptic O 0 0.00019519224588293582
splice O 0 0.0003608214610721916
site O 0 0.00023761080228723586
. O 0 0.00010822856711456552

Three O 0 1.2825064004573505e-05
other O 0 1.5114304687813274e-06
splice O 0 2.1640775230480358e-05
variants O 0 5.344966211850988e-06
, O 0 8.035899554670323e-07
including O 0 5.110512688588642e-07
one O 0 3.3204358373950527e-07
derived O 0 2.723313059505017e-07
from O 0 1.7908497795815492e-07
the O 0 3.116020081961324e-07
skipping O 0 2.716767994570546e-06
of O 0 1.0205011449215817e-06
exon O 0 1.0307585398550145e-05
32 O 0 3.3571143376320833e-06
, O 0 6.857762286927027e-07
were O 0 7.674069024687924e-07
also O 0 2.1866403585590888e-06
identified O 0 6.143880909803556e-06
. O 0 2.1950265363557264e-05

These O 0 1.404830709361704e-05
results O 0 3.742916533155949e-06
indicate O 0 2.133718908226001e-06
the O 0 1.3259747220217832e-06
usefulness O 0 8.369592251256108e-06
of O 0 7.230655683088116e-06
cycloheximide O 1 0.9642267823219299
treatment O 0 3.084939635300543e-06
in O 0 3.162814721235918e-07
evaluating O 0 9.726405778565095e-07
the O 0 4.6841182665957604e-07
abnormal O 0 5.702754037884006e-07
processing O 0 4.483551663270191e-07
of O 0 3.004043378496135e-07
mRNA O 0 8.69191239871725e-07
due O 0 2.406677879207564e-07
to O 0 1.4817204885275714e-07
splice O 0 3.934553205908742e-06
- O 0 3.710220653374563e-06
site O 0 1.7313500393356662e-06
mutations O 0 2.036207860101058e-07
, O 0 1.6114077538986749e-07
because O 0 1.403219300755154e-07
( O 0 3.342931336192123e-07
i O 0 1.6604104757789173e-06
) O 0 5.984659878777165e-07
aberrant O 0 2.627738695082371e-06
splicing O 0 1.3933289437773055e-06
often O 0 4.507637925144081e-07
generates O 0 8.255678380919562e-07
a O 0 5.848869477631524e-07
premature O 0 1.4420108982449165e-06
termination O 0 1.697909851827717e-06
codon O 0 3.926333192794118e-06
, O 0 5.175816113478504e-07
( O 0 4.0166318626688735e-07
ii O 0 2.158413735742215e-05
) O 0 5.210086442275497e-07
transcripts O 0 1.5968150819389848e-06
with O 0 4.5767893652737257e-07
premature O 0 4.731385615741601e-06
termination O 0 5.045300895289984e-06
codons O 0 1.004587011266267e-05
can O 0 2.800469474095735e-07
occur O 0 1.55742583274332e-07
at O 0 1.1344909580657259e-06
low O 0 3.1923352707963204e-06
or O 0 9.181101177091477e-07
undetectable O 0 1.096738014894072e-05
levels O 0 5.125565962771361e-07
due O 0 2.4458879011035606e-07
to O 0 2.974195183469419e-07
nonsense O 0 4.897335657005897e-06
- O 0 2.0738782495755004e-06
mediated O 0 1.0603237114992226e-06
mRNA O 0 1.4805482351221144e-06
decay O 0 1.008441927297099e-06
, O 0 1.7588651246569498e-07
and O 0 9.86551071946451e-08
( O 0 3.083322894781304e-07
iii O 0 0.0002645146450959146
) O 0 3.6696363281407685e-07
the O 0 1.8035999005405756e-07
levels O 0 1.6247990686224512e-07
of O 0 1.4127985537015775e-07
these O 0 3.761685007930282e-08
transcripts O 0 5.352238190425851e-07
can O 0 1.7699844079288596e-07
be O 0 2.9849840643692005e-07
increased O 0 1.1153184686918394e-06
by O 0 2.359298605369986e-06
cycloheximide O 0 0.0006288705626502633
. O 0 6.413702794816345e-05

A O 0 0.0001693711819825694
deletion O 0 9.414804662810639e-05
mutation O 0 1.0283686606271658e-05
in O 0 2.3767076982039725e-06
COL17A1 O 1 0.9998080134391785
in O 0 1.7380468761984957e-06
five O 0 2.091411488436279e-06
Austrian O 0 3.805604501394555e-05
families O 0 8.062828555921442e-07
with O 0 2.2201852516445797e-06
generalized O 0 0.0012296681525185704
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999995231628418
represents O 0 3.179448685841635e-05
propagation O 0 2.1914416720392182e-05
of O 0 6.064409717509989e-06
an O 0 6.303281224973034e-06
ancestral O 0 9.676191984908655e-05
allele O 0 8.871048339642584e-05
. O 0 7.748643838567659e-05

Patients O 0 0.00039789205766282976
with O 0 2.466318619553931e-05
generalized O 1 0.7736735939979553
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 7.022600766504183e-05
a O 0 1.3641462828672957e-05
usually O 0 2.7339638108969666e-06
nonlethal O 0 4.311980228521861e-05
form O 0 2.656077640494914e-06
of O 0 2.6759507818496786e-05
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 1.2803337085642852e-05
have O 0 1.8716928025241941e-06
generalized O 0 1.231168153026374e-05
blistering B-Disease 0 0.39554619789123535
, O 0 4.483238444663584e-05
nail B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 1 0.5310444831848145
patchy B-Disease 1 0.9999998807907104
alopecia I-Disease 1 1.0
, O 1 0.857750415802002
and O 0 0.0031252093613147736
dental B-Disease 1 1.0
abnormalities I-Disease 1 0.9999998807907104
. O 0 0.0010627092560753226

Skin B-Disease 1 1.0
fragility I-Disease 1 0.999880313873291
in O 0 6.2019971664994955e-06
most O 0 1.7633103652769933e-06
cases O 0 5.79149343593599e-07
is O 0 3.7314222822715237e-07
due O 0 4.188194679954904e-07
to O 0 3.274017501553317e-07
mutations O 0 3.7863614466004947e-07
in O 0 1.900091319839703e-07
the O 0 4.068181738148269e-07
gene O 0 8.279624239548866e-07
encoding O 0 3.623727934609633e-06
type O 0 0.00254087639041245
XVII O 1 1.0
collagen O 1 0.9999998807907104
( O 0 0.0002590453368611634
COL17A1 O 1 0.9999997615814209
) O 0 4.876300954492763e-05
. O 0 7.08924635546282e-05

Recently O 0 0.0002371472801314667
, O 0 8.887264812074136e-06
we O 0 1.5334702538893907e-06
reported O 0 1.0343853773520095e-06
five O 0 1.332503188677947e-06
Austrian O 0 2.1458919945871457e-05
families O 0 1.1411175364628434e-06
with O 0 2.279092996104737e-06
generalized O 0 0.0026857785414904356
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
who O 0 0.0001643073046579957
share O 0 1.4456445569521748e-05
the O 0 1.043074644258013e-05
same O 0 1.4895945241732989e-05
COL17A1 O 1 0.9994910955429077
mutation O 0 0.0001631744235055521
. O 0 7.825037755537778e-05

Affected O 0 4.998875010642223e-05
individuals O 0 1.562394572829362e-06
in O 0 9.340902806798113e-07
three O 0 5.860773626409355e-07
families O 0 1.0887743684406814e-07
are O 0 6.037836186578716e-08
homozygous O 0 7.207808039311203e-07
for O 0 3.329799938001088e-07
4003delTC O 0 0.00012856049579568207
, O 0 8.453914688288933e-07
whereas O 0 4.6349936155820615e-07
those O 0 1.1532333843433662e-07
in O 0 1.4586400709504233e-07
two O 0 2.999803712100402e-07
others O 0 1.2877626431873068e-06
are O 0 9.8362909284333e-07
compound O 0 4.4806351070292294e-05
heterozygotes O 0 0.00019776212866418064
. O 0 0.00010500045027583838

To O 0 1.0959224709949922e-05
determine O 0 2.3931931991683086e-06
if O 0 4.5890314481766836e-07
the O 0 7.166484010667773e-07
occurrence O 0 1.965505816770019e-06
of O 0 1.3897101780457888e-06
4003delTC O 0 1.6412635886808857e-05
in O 0 4.30566728937265e-07
these O 0 1.6417268966506526e-07
unrelated O 0 6.219163424248109e-07
families O 0 8.994856415256436e-08
signifies O 0 1.2356557590464945e-06
propagation O 0 1.2564796634251252e-06
of O 0 6.698347192468646e-07
an O 0 7.050064141367329e-07
ancestral O 0 3.87353202313534e-06
allele O 0 1.8484654447092908e-06
or O 0 4.527196608705708e-07
a O 0 1.8413048792353948e-06
mutational O 0 8.840097871143371e-05
hot O 0 0.00021319609368219972
spot O 0 2.0857765775872394e-05
, O 0 9.139378107647644e-07
haplotypes O 0 2.562538156780647e-06
were O 0 3.9120192241171026e-07
determined O 0 5.486953114086646e-07
for O 0 2.902606297539023e-07
polymorphisms O 0 1.1638716159723117e-06
both O 0 4.944160991726676e-07
within O 0 1.464544766349718e-06
and O 0 3.7548290947597707e-06
flanking O 1 0.9864596128463745
COL17A1 O 1 1.0
. O 0 0.00015639518096577376

Five O 0 0.00013291032519191504
intragenic O 0 0.000555208942387253
polymorphisms O 0 4.2970139475073665e-05
were O 0 5.704490376956528e-06
chosen O 0 7.66229732107604e-06
based O 0 3.2454411211801926e-06
on O 0 7.070135779940756e-06
their O 0 6.428692358895205e-06
informativeness O 0 0.004063472617417574
. O 0 0.00011568214540602639

One O 0 1.9330162103869952e-05
of O 0 4.2846395444939844e-06
these O 0 3.8570732385778683e-07
, O 0 4.094384280506347e-07
not O 0 1.3526310738143366e-07
previously O 0 9.797989832804888e-07
reported O 0 3.9528325146420684e-07
, O 0 4.0378321841672005e-07
was O 0 2.1738073883170728e-06
2988 O 0 1.9363076717127115e-05
A O 0 3.4608337955432944e-06
or O 0 6.597240940209304e-07
C O 0 4.287852789275348e-06
that O 0 2.1480012435404205e-07
introduces O 0 2.0348968519101618e-06
a O 0 3.704701327933435e-07
new O 0 4.7631988309149165e-07
restriction O 0 1.0741063078967272e-06
site O 0 5.070392489869846e-06
for O 0 2.97992642117606e-06
Eco0109 O 0 0.00019606371643021703
I O 0 0.0002515194355510175
. O 0 6.827126344433054e-05

All O 0 3.055638444493525e-05
the O 0 1.4682836990687065e-05
4003delTC O 0 0.00012558515300042927
alleles O 0 7.601356628583744e-06
showed O 0 2.1433165784401353e-06
the O 0 1.1310438594591687e-06
same O 0 8.235445534410246e-07
haplotype O 0 6.614303856622428e-06
for O 0 7.563442068203585e-07
these O 0 6.404665100490092e-07
five O 0 2.5491031010460574e-06
polymorphic O 0 7.169715536292642e-05
markers O 0 0.00025445487699471414
. O 0 9.64961654972285e-05

Fourteen O 0 0.000580795924179256
microsatellite O 0 0.0005370324361138046
polymorphisms O 0 2.6488976800465025e-05
were O 0 2.9390109830274014e-06
selected O 0 2.724489604588598e-06
based O 0 7.250918656609429e-07
on O 0 8.31988074878609e-07
their O 0 2.6068269676216005e-07
high O 0 1.0575976375548635e-05
heterozygosity O 0 0.0001751274976413697
and O 0 6.707257966809266e-07
their O 0 2.711234685648378e-07
location O 0 2.9060038286843337e-06
within O 0 1.361300633107021e-06
10q23 O 0 8.951008931035176e-05
- O 0 8.01540954853408e-05
q25 O 0 0.0007393709965981543
near O 0 0.0002592210366856307
COL17A1 O 1 0.9895275235176086
. O 0 0.00017778732581064105

Three O 0 4.510103099164553e-05
families O 0 5.586974566540448e-06
shared O 0 6.670465154456906e-06
microsatellite O 0 8.458004595013335e-05
polymorphisms O 0 7.87990848039044e-06
covering O 0 2.75981510640122e-05
at O 0 5.696406333299819e-06
most O 0 4.740861356822279e-07
19 O 0 1.6086991081465385e-06
cM O 0 8.793885172053706e-06
, O 0 8.144980938595836e-07
whereas O 0 5.403667842074356e-07
the O 0 5.297465008879954e-07
others O 0 3.9955426700544194e-07
shared O 0 2.441364586047712e-07
smaller O 0 5.393767423811369e-07
regions O 0 3.287756555891974e-07
consistent O 0 4.002636444511154e-07
with O 0 1.2937915983002313e-07
cross O 0 7.307970122383267e-07
- O 0 1.8769086409520241e-06
over O 0 4.237701602960442e-07
events O 0 2.3915245606076496e-07
during O 0 2.542169283969997e-07
passage O 0 2.2660925935724663e-07
of O 0 1.7495436566150602e-07
this O 0 9.769785691560173e-08
mutation O 0 2.772622167412919e-07
through O 0 5.130583531354205e-07
several O 0 1.8385360363026848e-06
generations O 0 1.0292477782058995e-05
. O 0 2.671496258699335e-05

These O 0 2.284472247993108e-05
results O 0 6.4241203290293925e-06
indicate O 0 2.0035606667079264e-06
that O 0 7.600361300319491e-07
4003delTC O 0 2.364939973631408e-05
occurs O 0 4.3464532950565626e-07
on O 0 5.049191713624168e-07
a O 0 9.26730933770159e-07
single O 0 1.5026090522951563e-06
ancestral O 0 1.2577883353515062e-05
allele O 0 6.748797659383854e-06
. O 0 4.42457076132996e-06
. O 0 2.6859703211812302e-05

The O 0 0.00015456073742825538
haptoglobin O 0 0.0013359719887375832
- O 0 0.00014546852617058903
gene O 0 1.949053694261238e-05
deletion O 0 4.0372895455220714e-05
responsible O 0 1.9529050405253656e-05
for O 0 1.526883352198638e-05
anhaptoglobinemia B-Disease 1 0.9965749382972717
. O 0 0.0002067553432425484

We O 0 2.3003480237093754e-05
have O 0 1.991570343307103e-06
found O 0 9.287871876040299e-07
an O 0 1.1252629974478623e-06
allelic O 0 1.6431707990705036e-05
deletion O 0 8.18232638266636e-06
of O 0 4.472231466934318e-06
the O 0 4.818431534658885e-06
haptoglobin O 0 0.0006400737911462784
( O 0 2.4879809643607587e-06
Hp O 0 1.9301902284496464e-05
) O 0 6.267970888984564e-07
gene O 0 3.4822832617464883e-07
from O 0 3.557961747446825e-07
an O 0 7.263266184054373e-07
individual O 0 8.473900834360393e-07
with O 0 4.183542841929011e-06
anhaptoglobinemia B-Disease 0 0.48609358072280884
. O 0 7.308264321181923e-05

The O 0 8.264220377895981e-05
Hp O 0 0.0003825027961283922
gene O 0 1.438010349374963e-05
cluster O 0 3.432111407164484e-05
consists O 0 2.366712806178839e-06
of O 0 1.2976025800526259e-06
coding O 0 5.490583134815097e-06
regions O 0 6.682828939119645e-07
of O 0 1.803271402422979e-06
the O 0 1.267071070287784e-06
alpha O 0 9.268385838367976e-06
chain O 0 1.7333541109110229e-06
and O 0 3.1308420034292794e-07
beta O 0 2.572842049630708e-06
chain O 0 1.5953310139593668e-06
of O 0 8.25164022444369e-07
the O 0 9.860654017757042e-07
haptoglobin O 0 2.280980334035121e-05
gene O 0 9.485865462011134e-07
( O 0 5.615984832729737e-07
Hp O 0 5.136711479281075e-06
) O 0 3.109506678811158e-07
and O 0 2.3551301353563758e-07
of O 0 6.125401910139772e-07
the O 0 8.035362952796277e-07
alpha O 0 6.7186674641561694e-06
chain O 0 1.6695804561095429e-06
and O 0 3.029583126590296e-07
beta O 0 1.911668960019597e-06
chain O 0 1.1710260423569707e-06
of O 0 7.033249289634114e-07
the O 0 1.3998057966091437e-06
haptoglobin O 0 3.942363036912866e-05
- O 0 6.038324499968439e-06
related O 0 1.343843109680165e-06
gene O 0 7.345757921939366e-07
( O 0 9.92596369542298e-07
Hpr O 0 2.9480581360985525e-05
) O 0 8.66827917889168e-07
, O 0 5.01621400417207e-07
in O 0 3.921566644748964e-07
tandem O 0 3.158846993756015e-06
from O 0 8.077128086370067e-07
the O 0 1.926462118717609e-06
5 O 0 1.511511618446093e-05
side O 0 2.5950794224627316e-05
. O 0 3.933639527531341e-05

Southern O 0 0.0003628737758845091
blot O 0 0.0003330344916321337
and O 0 6.010460765537573e-06
PCR O 0 1.5521160094067454e-05
analyses O 0 3.707214091264177e-06
have O 0 3.1874628803052474e-07
indicated O 0 4.3700401874957606e-07
that O 0 7.798087153787492e-08
the O 0 2.1008598594107752e-07
individual O 0 1.1257111509621609e-07
with O 0 1.802269196105044e-07
anhaptoglobinemia B-Disease 0 0.00044681274448521435
was O 0 6.644624136242783e-06
homozygous O 0 9.071178510566824e-07
for O 0 1.7604644142465986e-07
the O 0 3.107393240497913e-07
gene O 0 3.600870002173906e-07
deletion O 0 5.856169309481629e-07
and O 0 2.0302917391745723e-07
that O 0 7.137293067671635e-08
the O 0 1.9236463799643388e-07
gene O 0 2.459508436913893e-07
deletion O 0 6.535123020512401e-07
was O 0 1.39933194986952e-06
included O 0 3.510043882215541e-07
at O 0 6.761551958334167e-07
least O 0 1.2900977708341088e-07
from O 0 1.302915819678674e-07
the O 0 3.781572672778566e-07
promoter O 0 4.940860526403412e-05
region O 0 2.5794927296374226e-06
of O 0 1.8269095107825706e-06
Hp O 0 3.2222251320490614e-05
to O 0 2.4477574243064737e-06
Hpr O 0 6.991496047703549e-05
alpha O 0 5.554541075980524e-06
but O 0 3.4469954357518873e-07
not O 0 1.765309747270294e-07
to O 0 6.599292987630179e-07
Hpr O 0 5.2593106374843046e-05
beta O 0 2.2460762920673005e-05
( O 0 5.870524091733387e-06
Hpdel O 0 0.02168637327849865
) O 0 2.8341548386379145e-05
. O 0 6.141940684756264e-05

In O 0 1.1280876606178936e-05
addition O 0 5.079006768937688e-06
, O 0 1.43707131883275e-06
we O 0 3.177265739395807e-07
found O 0 2.4692616307220305e-07
seven O 0 1.6200581853809126e-07
individuals O 0 3.320606367651635e-08
with O 0 1.3176619972909975e-07
hypohaptoglobinemia B-Disease 0 0.019262511283159256
in O 0 4.753737243845535e-07
three O 0 1.9451080390808784e-07
families O 0 7.808147728383119e-08
, O 0 1.0188037435909791e-07
and O 0 9.028941860833584e-08
the O 0 2.5839887030087993e-07
genotypes O 0 1.1041954621759942e-06
of O 0 5.347238243302854e-07
six O 0 2.3652995650991215e-07
of O 0 4.5615033172907715e-07
the O 0 2.8329833412499283e-07
seven O 0 3.2095110213958833e-07
individuals O 0 6.222491322205315e-08
were O 0 1.5560776489564887e-07
found O 0 1.761527528287843e-07
to O 0 3.0857088972879865e-07
be O 0 1.9291924218123313e-06
Hp2 O 1 0.8649842143058777
/ O 1 0.7997515201568604
Hpdel O 1 0.9879156351089478
. O 0 0.0001408418465871364

The O 0 5.8590812841430306e-05
phenotypes O 0 3.576849849196151e-05
and O 0 2.274873850183212e-06
genotypes O 0 1.1700521099555772e-05
in O 0 5.80087430535059e-07
one O 0 5.292224045660987e-07
of O 0 4.350857523149898e-07
these O 0 8.016031216584452e-08
three O 0 1.0188018251255926e-07
families O 0 8.366971826490044e-08
showed O 0 3.0687377261529036e-07
the O 0 3.277879159213626e-07
father O 0 5.446049726742785e-07
to O 0 1.973259173837505e-07
be O 0 3.602999640861526e-07
hypohaptoglobinemic B-Disease 0 2.519707595638465e-05
( O 0 1.3532752518585767e-06
Hp2 O 0 0.0001186227091238834
) O 0 1.2346886251179967e-06
and O 0 1.011317749544105e-06
Hp2 O 0 0.0016962449299171567
/ O 0 0.00012353881902527064
Hpdel O 1 0.8953718543052673
, O 0 2.710836270125583e-06
the O 0 1.1774943686759798e-06
mother O 0 1.159849375653721e-06
to O 0 2.284214275505292e-07
be O 0 2.0235648889865843e-07
Hp2 O 0 2.088137080136221e-05
- O 0 3.102393975495943e-06
1 O 0 2.94917776955117e-06
and O 0 5.440847985482833e-07
Hp1 O 0 0.00018682991503737867
/ O 0 2.3958622477948666e-05
Hp2 O 0 0.024670111015439034
, O 0 5.393083597482473e-07
one O 0 1.469801276243743e-07
of O 0 1.693285298642877e-07
the O 0 1.8635374487985246e-07
two O 0 6.924103246319646e-08
children O 0 6.613480962869289e-08
to O 0 5.301103911392602e-08
be O 0 1.973266705590504e-07
hypohaptoglobinemic B-Disease 0 2.589453106338624e-05
( O 0 7.24257063211553e-07
Hp2 O 0 6.956261495361105e-05
) O 0 3.9297765397350304e-07
and O 0 2.722952103795251e-07
Hp2 O 0 0.007804352790117264
/ O 0 0.00036119899596087635
Hpdel O 1 0.9709752798080444
, O 0 8.218874540943943e-07
and O 0 2.1271105765663378e-07
the O 0 2.3063994092353823e-07
other O 0 9.546126733539495e-08
child O 0 3.3528993981235544e-07
to O 0 2.2349018991008052e-07
be O 0 3.999865896275878e-07
Hp1 O 0 0.0002111114008584991
and O 0 1.8781134940581978e-06
Hp1 O 1 0.98874831199646
/ O 0 0.009314117021858692
Hpdel O 1 0.8885404467582703
, O 0 1.8102842886946746e-06
showing O 0 1.834875206441211e-06
an O 0 1.0341033203076222e-06
anomalous O 0 1.1610309229581617e-05
inheritance O 0 6.139699053164804e-06
of O 0 5.251727998256683e-06
Hp O 0 0.10276307910680771
phenotypes O 0 1.0410404684080277e-05
in O 0 1.2474807817852707e-06
the O 0 3.4050283375108847e-06
child O 0 7.491978976759128e-06
with O 0 7.414439551212126e-06
Hp1 O 1 0.9978207349777222
. O 0 0.00014582266157958657

The O 0 0.00020798458717763424
Hp2 O 1 0.9999176263809204
/ O 1 0.935766875743866
Hpdel O 1 0.9976438879966736
individuals O 0 2.4908229079301236e-06
had O 0 1.9736307876883075e-06
an O 0 6.682179218842066e-07
extremely O 0 1.273398197554343e-06
low O 0 2.4279727313114563e-06
level O 0 2.2178742256073747e-06
of O 0 1.6124620287882863e-06
Hp O 0 3.680539157357998e-05
( O 0 1.1176502994203474e-06
mean O 0 1.1135329032185837e-06
+ O 0 2.6716304546425818e-06
/ O 0 6.130864676379133e-06
- O 0 1.1903831364179496e-05
SD O 0 0.0003432581142988056
= O 0 3.7333234104153235e-06
0 O 0 2.103754013660364e-06
. O 0 6.056620236449817e-07
049 O 0 3.636080145952292e-05
+ O 0 5.401728685683338e-06
/ O 0 7.1669542194285896e-06
- O 0 6.565810053871246e-06
0 O 0 2.8552890398714226e-06
. O 0 1.1603052598729846e-06
043 O 0 5.034760761191137e-05
mg O 0 1.9485891243675724e-05
/ O 0 1.4104501133260783e-05
ml O 0 1.601291478436906e-05
; O 0 6.012278959133255e-07
n O 0 8.45139993543853e-07
= O 0 4.7590896201654687e-07
6 O 0 6.894668445056595e-07
) O 0 3.036896032426739e-07
, O 0 1.321259617270698e-07
compared O 0 2.8223368531143933e-07
with O 0 9.816670143436568e-08
the O 0 3.6239103451407573e-07
level O 0 8.850691983752768e-07
( O 0 3.223271107799519e-07
1 O 0 7.367029297711269e-07
. O 0 1.5716240397978254e-07
64 O 0 1.1572860785236116e-06
+ O 0 1.5364946648332989e-06
/ O 0 2.725648528212332e-06
- O 0 2.276062787132105e-06
1 O 0 1.8038319922197843e-06
. O 0 5.919699788137223e-07
07 O 0 2.941335151263047e-05
mg O 0 3.3259395422646776e-05
/ O 0 1.7462880350649357e-05
ml O 0 3.4286011214135215e-05
) O 0 7.368898309323413e-07
obtained O 0 4.19582278254893e-07
from O 0 3.389750986571016e-07
52 O 0 2.077205408568261e-06
healthy O 0 1.0426024346088525e-06
volunteers O 0 1.3615759826279827e-06
having O 0 1.299217274208786e-06
phenotype O 0 2.8322640446276637e-06
Hp2 O 0 0.0017436740454286337
, O 0 1.196333755615342e-06
whereas O 0 4.793800485458632e-07
the O 0 6.157756615721155e-07
serum O 0 2.6068767056131037e-06
Hp O 0 6.36799813946709e-06
level O 0 1.1922210205739248e-06
of O 0 7.730128572802641e-07
an O 0 5.723496769860503e-07
individual O 0 2.7648459877127607e-07
with O 0 7.126042760319251e-07
Hp1 O 1 0.8120473027229309
/ O 0 0.0030357621144503355
Hpdel O 1 0.6383257508277893
was O 0 6.709314038744196e-05
0 O 0 5.691567275789566e-05
. O 0 5.2029314247192815e-05

50 O 0 0.00015841446293052286
mg O 0 0.00075148994801566
/ O 0 0.004819327965378761
ml O 0 0.4239934980869293
, O 0 3.5733423828787636e-06
which O 0 4.0470615658705356e-07
was O 0 1.501629071753996e-06
approximately O 0 3.853525356589671e-07
half O 0 2.866150907721021e-07
the O 0 2.6285405851922405e-07
level O 0 8.928065540203534e-07
of O 0 1.2850758821514319e-06
Hp O 0 2.674024653970264e-05
in O 0 7.076793622218247e-07
control O 0 4.008896212326363e-06
sera O 0 0.003894830122590065
from O 0 1.3171058981242822e-06
the O 0 1.3721776213060366e-06
Hp1 O 0 8.352398435818031e-05
phenotype O 0 1.0970621815431514e-06
( O 0 3.242243735712691e-07
1 O 0 9.689806574897375e-07
. O 0 2.1376362724367937e-07
26 O 0 7.013911726971855e-07
+ O 0 1.0116312978425412e-06
/ O 0 2.409328544672462e-06
- O 0 1.5127990309338202e-06
0 O 0 1.1540281548150233e-06
. O 0 3.444340279656899e-07
33 O 0 2.4136131742125144e-06
mg O 0 8.184386388165876e-06
/ O 0 8.301925845444202e-06
ml O 0 1.4156056749925483e-05
; O 0 4.08369146498444e-07
n O 0 9.894764616547036e-07
= O 0 7.599695095450443e-07
9 O 0 9.984122470996226e-07
) O 0 3.790928246871772e-07
, O 0 3.96550404957452e-07
showing O 0 7.309977831937431e-07
a O 0 1.3020180631428957e-06
gene O 0 4.1863368096528575e-06
- O 0 4.695471216109581e-05
dosage O 0 0.00010410735558252782
effect O 0 3.241444574086927e-05
. O 0 6.250159640330821e-05

The O 0 3.489280425128527e-05
other O 0 3.4758506899379427e-06
allele O 0 7.018614269327372e-06
( O 0 2.8049298634869047e-06
Hp2 O 0 0.0009338684030808508
) O 0 9.285843702855345e-07
of O 0 8.32156331398437e-07
individuals O 0 2.4132717157954175e-07
with O 0 4.252798646575684e-07
Hp2 O 1 0.9999943971633911
/ O 1 0.9976295232772827
Hpdel O 1 0.9999948740005493
was O 0 8.208384315366857e-06
found O 0 1.4736625075784104e-07
to O 0 8.946486218519567e-08
have O 0 4.07514768596684e-08
, O 0 8.290545139288952e-08
in O 0 5.3008914591146095e-08
all O 0 6.327501722580564e-08
exons O 0 1.309358594880905e-06
, O 0 3.951087705900136e-07
no O 0 4.4950172650715103e-07
mutation O 0 5.101066449242353e-07
, O 0 5.020229423280398e-07
by O 0 8.374249773623887e-07
DNA O 0 7.79613128543133e-06
sequencing O 0 3.921807001461275e-05
. O 0 4.6197164920158684e-05

On O 0 2.2892396373208612e-05
the O 0 3.1376916922454257e-06
basis O 0 9.319956006947905e-07
of O 0 8.530040531695704e-07
the O 0 5.002660259378899e-07
present O 0 2.001214483016156e-07
study O 0 2.195314721120667e-07
, O 0 1.5356155813606165e-07
the O 0 2.712791626890976e-07
mechanism O 0 2.3139473626088147e-07
of O 0 6.98724647918425e-07
anhaptoglobinemia B-Disease 0 0.004400553647428751
and O 0 4.6158714894772856e-07
the O 0 6.218101589183789e-07
mechanism O 0 7.424399086630729e-07
of O 0 1.3258936633064877e-06
anomalous O 0 1.27835601233528e-05
inheritance O 0 9.342040357296355e-06
of O 0 1.250068180524977e-05
Hp O 0 0.13833032548427582
phenotypes O 0 2.241856236651074e-05
were O 0 4.422288384375861e-06
well O 0 5.2280520321801305e-06
explained O 0 3.459064828348346e-05
. O 0 5.123277151142247e-05

However O 0 2.3809659978724085e-05
, O 0 6.273021426750347e-06
the O 0 2.6145025913137943e-06
mechanism O 0 5.883128324057907e-06
of O 0 2.3524356947746128e-05
hypohaptoglobinemia B-Disease 1 0.9997183680534363
remains O 0 0.0037097479216754436
unknown O 0 0.00038488878635689616

ATM O 0 0.4393630027770996
mutations O 0 4.009388794656843e-05
and O 0 9.448664059164003e-06
phenotypes O 0 3.704738264787011e-05
in O 0 1.1188019925612025e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.3598862551589264e-06
in O 0 5.11729695062968e-07
the O 0 5.284220492285385e-07
British O 0 1.030460680340184e-06
Isles O 0 1.605338297849812e-06
: O 0 1.675880128004792e-07
expression O 0 2.055848966620033e-07
of O 0 4.019697428248037e-07
mutant O 0 4.161041943007149e-06
ATM O 0 5.3067185945110396e-05
and O 0 1.696081284308093e-07
the O 0 1.9800643258349737e-07
risk O 0 5.285843371893861e-07
of O 0 4.187111244391417e-06
leukemia B-Disease 1 1.0
, O 1 0.9664214849472046
lymphoma B-Disease 1 1.0
, O 0 0.010411527007818222
and O 0 0.0021745646372437477
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 8.372910087928176e-05

We O 0 2.9588058168883435e-05
report O 0 4.265843926987145e-06
the O 0 1.788439817573817e-06
spectrum O 0 4.443031684786547e-06
of O 0 1.9823951333819423e-06
59 O 0 1.4803315934841521e-05
ATM O 0 0.0001303983444813639
mutations O 0 1.691504735390481e-06
observed O 0 1.0521665672058589e-06
in O 0 1.0881717571464833e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.03637363761663437
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.990953134940355e-06
patients O 0 8.675043545736116e-07
in O 0 4.207350627893902e-07
the O 0 1.8440427993482444e-06
British O 0 2.0706387658719905e-05
Isles O 0 9.131505066761747e-05
. O 0 3.4838445571949705e-05

Of O 0 0.00014987069880589843
51 O 0 0.00019095349125564098
ATM O 0 0.008277329616248608
mutations O 0 7.682221621507779e-06
identified O 0 1.4671575172542362e-06
in O 0 4.123318433357781e-07
families O 0 1.005621541594337e-07
native O 0 4.0493546293873806e-07
to O 0 1.3714617352889036e-07
the O 0 3.826521037808561e-07
British O 0 8.510118050253368e-07
Isles O 0 1.6874380435183411e-06
, O 0 3.783203226248588e-07
11 O 0 1.026376821755548e-06
were O 0 5.211994675846654e-07
founder O 0 1.2887434422736987e-05
mutations O 0 4.863907747676421e-07
, O 0 2.2936532673156762e-07
and O 0 1.4990406782544596e-07
2 O 0 7.305420126613171e-07
of O 0 5.015587589696224e-07
these O 0 8.763027636859988e-08
11 O 0 7.334796237046248e-07
conferred O 0 1.4269600114857894e-06
a O 0 1.289620740863029e-06
milder O 0 8.077689017227385e-06
clinical O 0 1.0190084140049294e-05
phenotype O 0 1.3899725672672503e-06
with O 0 2.3251406844337907e-07
respect O 0 3.6918558521392697e-07
to O 0 7.497529850297724e-07
both O 0 3.6389928936841898e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 1 0.9147951006889343
cellular O 0 0.1542937308549881
features O 0 0.00031698099337518215
. O 0 0.00010335075785405934

We O 0 1.469603375880979e-05
report O 0 3.535580390234827e-06
, O 0 1.068303731699416e-06
in O 0 3.8082055198174203e-07
two O 0 2.2819826028808166e-07
A B-Disease 1 0.9707034826278687
- I-Disease 1 0.9999363422393799
T I-Disease 1 0.9999992847442627
families O 0 2.725347201248951e-07
, O 0 1.4832106387530075e-07
an O 0 1.938937117529349e-07
ATM O 0 1.827539199439343e-05
mutation O 0 1.1647665587588563e-06
( O 0 8.752709845794016e-07
7271T O 0 2.4441269488306716e-05
- O 0 7.495380032196408e-06
- O 0 7.4792574196180794e-06
> O 0 3.0094367957644863e-06
G O 0 5.302729732648004e-06
) O 0 1.4428813699396414e-07
that O 0 5.028134708595644e-08
may O 0 6.639226057814085e-08
be O 0 4.0947977453242856e-08
associated O 0 5.618980836175069e-08
with O 0 3.1828211177753474e-08
an O 0 1.4578014884136792e-07
increased O 0 3.291612529210397e-07
risk O 0 1.683448658695852e-06
of O 0 1.8592023479868658e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.9445478916168213
in O 0 4.3001600147363206e-07
both O 0 4.868734322371893e-07
homozygotes O 0 1.932960731210187e-05
and O 0 7.981594762895838e-07
heterozygotes O 0 7.6277460721030366e-06
( O 0 9.751464631335693e-07
relative O 0 1.3707233392779017e-06
risk O 0 7.037556883915386e-07
12 O 0 4.184138617802091e-07
. O 0 1.1179173498021555e-07
7 O 0 7.064359124342445e-07
; O 0 2.7469059205031954e-07
P O 0 3.707189307533554e-06
= O 0 7.245872666317155e-07
. O 0 2.3635813306555065e-07
0025 O 0 1.2235914255143143e-05
) O 0 4.874513592767471e-07
, O 0 2.780123509182886e-07
although O 0 1.1773086328048521e-07
there O 0 9.86844668204867e-08
is O 0 1.0290353458231039e-07
a O 0 2.2723099846189143e-07
less O 0 3.603676361763064e-07
severe O 0 6.526952347485349e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 1.947537384694442e-06
in O 0 1.850270194836412e-07
terms O 0 1.779604872353957e-07
of O 0 5.934768978477223e-07
the O 0 1.354804112452257e-06
degree O 0 1.1746370546461549e-05
of O 0 8.016700303414837e-05
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 0.34545251727104187

This O 0 2.717838106036652e-05
mutation O 0 1.355737003905233e-05
( O 0 3.5688706248038216e-06
7271T O 0 0.00010182063851971179
- O 0 2.656005381140858e-05
- O 0 2.7297061024000868e-05
> O 0 1.5557894585072063e-05
G O 0 1.7674350601737387e-05
) O 0 6.187294729897985e-07
also O 0 2.553638012159354e-07
allows O 0 1.6347401299299236e-07
expression O 0 2.6604610070535273e-07
of O 0 4.3475768052303465e-07
full O 0 7.229638185890508e-07
- O 0 2.274561438753153e-06
length O 0 9.166980134978076e-07
ATM O 0 6.316670805972535e-06
protein O 0 4.263466735210386e-07
at O 0 5.968302048131591e-07
a O 0 3.3818915312622266e-07
level O 0 7.51002403376333e-07
comparable O 0 1.5894431726337643e-06
with O 0 2.569659045548178e-07
that O 0 2.4196964432121604e-07
in O 0 1.1657779168672278e-06
unaffected O 0 1.9217048247810453e-05
individuals O 0 2.960057145173778e-06
. O 0 2.7782420147559606e-05

In O 0 1.4507488231174648e-05
addition O 0 5.956161203357624e-06
, O 0 1.5743978565296857e-06
we O 0 3.0020646590855904e-07
have O 0 7.13869496848929e-08
studied O 0 1.1562578947632574e-06
18 O 0 1.8551073708295007e-06
A B-Disease 1 0.9999865293502808
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.5571019957860699e-06
, O 0 2.1604161304367153e-07
in O 0 5.924319523842314e-08
15 O 0 2.2029654189736902e-07
families O 0 3.674853843449455e-08
, O 0 1.0288665919233608e-07
who O 0 4.286509351913992e-07
developed O 0 2.0648178178817034e-05
leukemia B-Disease 1 1.0
, O 1 0.9136303663253784
lymphoma B-Disease 1 1.0
, O 0 0.0011250382522121072
preleukemic O 1 0.9999984502792358
T O 1 0.9997743964195251
- O 0 0.12114478647708893
cell O 0 0.0007118996581993997
proliferation O 1 0.5345925092697144
, O 0 3.773596517930855e-06
or O 0 0.2750338315963745
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 6.551965634571388e-05
mostly O 0 2.924545015048352e-06
in O 0 5.567246716964291e-06
childhood O 0 0.00018338474910706282
. O 0 7.296488183783367e-05

A O 0 0.00016011377738323063
wide O 0 3.814585943473503e-05
variety O 0 5.578695436270209e-06
of O 0 6.124179435573751e-06
ATM O 0 0.01607045717537403
mutation O 0 3.1875711101747584e-06
types O 0 7.381390219052264e-07
, O 0 4.346826472101384e-07
including O 0 4.980135486221116e-07
missense O 0 9.734712875797413e-06
mutations O 0 5.204980766393419e-07
and O 0 3.109572048742848e-07
in O 0 3.496146234738262e-07
- O 0 8.701667866262142e-06
frame O 0 6.098494395700982e-06
deletions O 0 4.742018973047379e-06
, O 0 7.221238433885446e-07
were O 0 4.776313176080293e-07
seen O 0 1.5344855910370825e-06
in O 0 8.652057772451371e-07
these O 0 1.7766300288712955e-06
patients O 0 1.2857260117016267e-05
. O 0 4.049334893352352e-05

We O 0 1.4635165825893637e-05
also O 0 2.7805631361843552e-06
show O 0 1.6710059753677342e-06
that O 0 2.386393873621273e-07
25 O 0 8.720906521375582e-07
% O 0 2.0419443558239436e-07
of O 0 4.392984465084737e-07
all O 0 3.419450251840317e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.8606229989236454e-06
carried O 0 8.431771902905894e-07
in O 0 3.20795038533106e-07
- O 0 3.899112016370054e-06
frame O 0 2.775677785393782e-06
deletions O 0 2.8718877729261294e-06
or O 0 6.64953574869287e-07
missense O 0 4.255847215972608e-06
mutations O 0 3.9643202853767434e-07
, O 0 1.8973426563206885e-07
many O 0 6.431829291386748e-08
of O 0 2.1838050656697305e-07
which O 0 7.728183959443413e-08
were O 0 6.335641700161432e-08
also O 0 8.473062251823649e-08
associated O 0 7.910441013336822e-08
with O 0 1.323647040862852e-07
expression O 0 6.653931450273376e-07
of O 0 4.625849214789923e-06
mutant O 0 6.821998977102339e-05
ATM O 0 0.003465039888396859
protein O 0 5.801038787467405e-05
. O 0 6.296763604041189e-05

The O 0 0.00013474663137458265
DMPK O 1 0.9999927282333374
gene O 0 4.868328323937021e-05
of O 0 0.00034659725497476757
severely O 1 0.9999998807907104
affected O 1 0.9996135830879211
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9996732473373413
is O 0 2.4920653231674805e-05
hypermethylated O 1 0.9698370099067688
proximal O 0 0.0001381115143885836
to O 0 2.5078074941120576e-06
the O 0 5.369607606553473e-06
largely O 0 9.010823305288795e-06
expanded O 0 3.3686428650980815e-05
CTG O 1 0.9611632227897644
repeat O 0 0.0002714184520300478
. O 0 0.00012245825200807303

Using O 0 5.672791667166166e-05
methylation O 0 7.148564327508211e-05
- O 0 6.955102435313165e-05
sensitive O 0 1.5556768630631268e-05
restriction O 0 3.7271722703735577e-06
enzymes O 0 6.367800438056292e-07
, O 0 2.722095189255924e-07
we O 0 1.791604944401115e-07
characterized O 0 4.226739065416041e-07
the O 0 3.6217960541762295e-07
methylation O 0 1.3299601278049522e-06
pattern O 0 7.555324259556073e-07
on O 0 4.277410994291131e-07
the O 0 1.9053753419484565e-07
5 O 0 3.584861758554325e-07
side O 0 3.443099103606073e-07
of O 0 2.87211577187918e-07
the O 0 9.918336445480236e-07
CTG O 1 0.9298060536384583
repeat O 0 4.9177838263858575e-06
in O 0 3.51266606912759e-07
the O 0 9.067554742614448e-07
DMPK O 1 0.7626290917396545
gene O 0 6.23818948497501e-07
of O 0 7.83349037192238e-07
normal O 0 4.664255186526134e-07
individuals O 0 5.704092842506725e-08
and O 0 1.8066228335555934e-07
of O 0 2.0209586182318162e-06
patients O 0 2.00405747818877e-06
affected O 0 9.323689482698683e-07
with O 0 4.378710855235113e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 4.343660475569777e-05
showing O 0 1.199511007143883e-05
expansions O 0 1.1138687113998458e-05
of O 0 7.030082997516729e-06
the O 0 7.149921657401137e-06
repetitive O 0 9.433415834791958e-05
sequence O 0 3.8040729123167694e-05
. O 0 5.7907422160496935e-05

The O 0 0.00010266622848575935
gene O 0 1.852563764259685e-05
segment O 0 2.1098310753586702e-05
analyzed O 0 3.2377497518609744e-06
corresponds O 0 3.072077333854395e-06
to O 0 7.225592071335996e-07
the O 0 1.7481138456787448e-06
genomic O 0 1.9182662072125822e-05
SacI O 0 0.0002873084449674934
- O 0 2.8528194889076985e-05
HindIII O 0 0.00014459548401646316
fragment O 0 1.2573879757837858e-05
carrying O 0 4.686264219344594e-06
exons O 0 1.964510556717869e-05
11 O 0 8.234069355239626e-06
- O 0 4.132309550186619e-05
15 O 0 6.607281102333218e-05
. O 0 8.036257349886e-05

There O 0 4.84465308545623e-05
is O 0 1.0962276974169072e-05
constitutive O 0 1.7281470718444325e-05
methylation O 0 1.082666221918771e-05
in O 0 2.4385728920606198e-06
intron O 0 7.611531327711418e-05
12 O 0 4.867888947046595e-06
at O 0 3.1554086490359623e-06
restriction O 0 1.2427476576704066e-06
sites O 0 8.518821914549335e-07
of O 0 1.023044433168252e-06
SacII O 0 0.00018783340055961162
and O 0 2.152448132619611e-06
HhaI O 0 0.004768627695739269
, O 0 1.9134929516440025e-06
localized O 0 4.197730049781967e-06
1 O 0 2.4419939563813386e-06
, O 0 6.497749041045608e-07
159 O 0 1.0540014727666858e-06
- O 0 1.1725771855708444e-06
1 O 0 1.8021778487309348e-06
, O 0 4.0311604720955074e-07
232 O 0 1.4014835869602393e-06
bp O 0 2.1159071366128046e-06
upstream O 0 1.5210085848593735e-06
of O 0 4.937860467180144e-07
the O 0 9.242755254490476e-07
CTG O 1 0.8164873123168945
repeat O 0 2.9498726235033246e-06
, O 0 2.6426309318594576e-07
whereas O 0 1.2093886425645906e-07
most O 0 7.099331611470916e-08
, O 0 7.680455382796936e-08
if O 0 3.8993022144495626e-08
not O 0 2.3046267116910713e-08
all O 0 3.6986147478046405e-08
, O 0 8.951026586601074e-08
of O 0 1.2246158576090238e-07
the O 0 1.8169069448958908e-07
other O 0 7.097963816704578e-08
sites O 0 2.326231793858824e-07
of O 0 4.4989110392634757e-07
SacII O 0 0.004442664794623852
, O 0 5.513873588824936e-07
HhaI O 0 0.00026896066265180707
, O 0 6.102545171415841e-07
and O 0 3.536689519023639e-07
HpaII O 0 4.962364619132131e-05
in O 0 2.7898758503397403e-07
this O 0 1.653145744739959e-07
region O 0 3.444524452334008e-07
are O 0 7.865921247685037e-08
unmethylated O 0 1.8749940863926895e-05
, O 0 4.1822954699455295e-07
in O 0 1.6075550490768364e-07
normal O 0 1.8258072032040218e-07
individuals O 0 5.16033971109664e-08
and O 0 1.9716244992196152e-07
most O 0 3.7608245406772767e-07
of O 0 3.6459889543039026e-06
the O 0 1.579644413141068e-05
patients O 0 2.169205981772393e-05
. O 0 2.6035671908175573e-05

In O 0 9.004604180518072e-06
a O 0 3.2440545965073397e-06
number O 0 7.604828056173574e-07
of O 0 3.4356999094597995e-06
young O 0 5.687970042345114e-05
and O 0 5.003871137887472e-06
severely O 1 0.9941224455833435
affected O 0 1.3483399925462436e-06
patients O 0 4.757565079671622e-07
, O 0 1.3047124980403169e-07
however O 0 1.0025878793840093e-07
, O 0 1.1371670893822738e-07
complete O 0 1.5672311803882621e-07
methylation O 0 3.935353447559464e-07
of O 0 3.079505859204801e-07
these O 0 5.5703317514144146e-08
restriction O 0 2.404379131348833e-07
sites O 0 6.250039632504922e-07
was O 0 2.0357099401735468e-06
found O 0 3.7027234611741733e-07
in O 0 4.194982352601073e-07
the O 0 2.2382876068149926e-06
mutated O 0 3.171844218741171e-05
allele O 0 3.814229421550408e-05
. O 0 4.072555748280138e-05

In O 0 1.5310273738577962e-05
most O 0 2.4103603664116235e-06
of O 0 1.9980061551905237e-06
these O 0 3.3353680350955983e-07
patients O 0 6.355108439493051e-07
, O 0 3.5446956303530897e-07
the O 0 8.526502597305807e-07
onset O 0 5.832512761116959e-05
of O 0 0.0007119376678019762
the O 1 0.9320792555809021
disease O 1 1.0
was O 1 0.9999990463256836
congenital O 1 1.0
. O 0 0.0012002656003460288

Preliminary O 0 0.00010915890015894547
in O 0 1.907481419038959e-05
vivo O 0 0.0001115899722208269
footprinting O 0 0.00036795748746953905
data O 0 1.8579526113171596e-06
gave O 0 2.2390861431631492e-06
evidence O 0 8.684107797307661e-07
for O 0 2.928162814441748e-07
protein O 0 8.62552155922458e-07
- O 0 2.5132328573818086e-06
DNA O 0 9.327656584900978e-07
contact O 0 3.089961069235869e-07
in O 0 2.4750190164013475e-07
normal O 0 3.830511730029684e-07
genes O 0 1.895507040217126e-07
at O 0 9.236912887899962e-07
an O 0 1.2652428722503828e-06
Sp1 O 0 0.0002765831886790693
consensus O 0 3.0852045256324345e-06
binding O 0 5.856035727447306e-07
site O 0 1.9208173398510553e-06
upstream O 0 1.641743892832892e-06
of O 0 4.936142090627982e-07
the O 0 7.329467734962236e-07
CTG O 0 0.0923244059085846
repeat O 0 1.860012730503513e-06
and O 0 2.270600845122317e-07
for O 0 1.227427901540068e-07
a O 0 2.3282804306745675e-07
significant O 0 2.0246727672201814e-07
reduction O 0 5.676291721101734e-07
of O 0 4.6284517907224654e-07
this O 0 8.324009570515045e-08
interaction O 0 2.1550474116338592e-07
in O 0 2.094294586640899e-07
cells O 0 2.835540442447382e-07
with O 0 2.43247285425241e-07
a O 0 4.534630079433555e-06
hypermethylated O 0 0.09447062015533447
DMPK O 1 0.9999773502349854
gene O 0 2.610702722449787e-05
. O 0 1.5515728591708466e-05
. O 0 6.108261732151732e-05

The O 0 0.0003999928885605186
hemochromatosis B-Disease 1 0.9999997615814209
gene O 0 1.628895006433595e-05
product O 0 7.262466624524677e-06
complexes O 0 6.319025942502776e-06
with O 0 1.0460255452926503e-06
the O 0 5.134208549861796e-06
transferrin O 0 8.251817052951083e-05
receptor O 0 6.720256351400167e-06
and O 0 1.453574441256933e-06
lowers O 0 1.4345231647894252e-05
its O 0 9.811519703362137e-07
affinity O 0 2.819700057443697e-06
for O 0 2.188645339629147e-06
ligand O 0 2.397599382675253e-05
binding O 0 1.9417588191572577e-05
. O 0 5.528615292860195e-05

We O 0 3.820196070591919e-05
recently O 0 1.6489573681610636e-05
reported O 0 4.129254648432834e-06
the O 0 1.4387552482730825e-06
positional O 0 1.258565862372052e-05
cloning O 0 5.456569397210842e-06
of O 0 1.6276167116302531e-06
a O 0 1.942918288477813e-06
candidate O 0 5.040578344051028e-06
gene O 0 2.4921580461523263e-06
for O 0 7.823702617315575e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 1.0
. O 0 0.0011359023628756404

The O 0 3.427293631830253e-05
gene O 0 4.6866930460964795e-06
product O 0 1.781484229468333e-06
, O 0 7.670249715374666e-07
a O 0 5.719006139770499e-07
member O 0 4.598192049343197e-07
of O 0 9.366682434119866e-07
the O 0 9.28101883346244e-07
major O 0 3.187150650774129e-05
histocompatibility O 1 0.9999998807907104
complex O 0 0.00022146051924210042
class O 0 1.9327978861838346e-06
I O 0 1.0113378266396467e-05
- O 0 2.233739223811426e-06
like O 0 3.4991282404917e-07
family O 0 3.9944796981217223e-07
, O 0 2.3068790255820204e-07
was O 0 8.56066662890953e-07
found O 0 1.1946517020078318e-07
to O 0 1.391137942619025e-07
have O 0 7.145233382743754e-08
a O 0 3.6691884020001453e-07
mutation O 0 1.1506323289722786e-06
, O 0 1.2996808891330147e-06
Cys O 0 0.3711645305156708
- O 0 1.9890188923454843e-05
282 O 0 2.2599711883231066e-05
- O 0 2.9050506782368757e-05
- O 0 2.0354640582809225e-05
> O 0 1.6274076187983155e-05
Tyr O 0 0.0014845527475699782
( O 0 9.317680564890907e-07
C282Y O 0 1.0828655831573997e-05
) O 0 4.639093162950303e-07
, O 0 3.5224948646828125e-07
in O 0 2.3300285079130845e-07
85 O 0 2.732629127422115e-06
% O 0 1.1491760005810647e-06
of O 0 4.675978289014893e-06
patient O 0 1.967129355762154e-05
chromosomes O 0 1.1914188689843286e-05
. O 0 2.3865377443144098e-05

This O 0 2.7553001928026788e-05
mutation O 0 1.648426041356288e-05
eliminates O 0 2.7466401661513373e-05
the O 0 2.923468628068804e-06
ability O 0 1.3279386621434242e-06
of O 0 3.1586544082529144e-06
HFE O 1 0.9887415766716003
to O 0 2.514076868465054e-06
associate O 0 4.672189334087307e-06
with O 0 5.645180181090836e-07
beta2 O 1 0.5798579454421997
- O 0 0.08644894510507584
microglobulin O 1 0.9248034358024597
( O 0 3.505180984575418e-06
beta2m O 0 0.00022641298710368574
) O 0 1.1934916983591393e-06
and O 0 7.637096928192477e-07
prevents O 0 4.9727732402971014e-06
cell O 0 1.225721734954277e-05
- O 0 7.31107356841676e-05
surface O 0 4.217049354338087e-05
expression O 0 2.1497326088137925e-05
. O 0 4.7067776904441416e-05

A O 0 0.00021538659348152578
second O 0 2.2308387997327372e-05
mutation O 0 3.9657716115470976e-06
that O 0 4.283321857201372e-07
has O 0 4.025551447739417e-07
no O 0 2.547542408137815e-07
effect O 0 3.5039801105085644e-07
on O 0 5.7374484185857e-07
beta2m O 0 9.128814417636022e-05
association O 0 1.303271687902452e-06
, O 0 1.0588333907435299e-06
H63D O 1 0.9999891519546509
, O 0 9.683885764388833e-07
was O 0 2.0432801193237538e-06
found O 0 1.3652318386903062e-07
in O 0 5.41476019577658e-08
eight O 0 1.3485428951298672e-07
out O 0 1.3916582020101487e-07
of O 0 3.013256844042189e-07
nine O 0 8.762924608163303e-07
patients O 0 5.542067356145708e-07
heterozygous O 0 1.10894745830592e-06
for O 0 6.240069296836737e-07
the O 0 4.3422955968708266e-06
C282Y O 0 0.000491661427076906
mutant O 0 0.00020347663667052984
. O 0 5.998366032144986e-05

In O 0 1.363551928079687e-05
this O 0 2.0937463887094054e-06
report O 0 1.5721457202744205e-06
, O 0 9.710556696518324e-07
we O 0 4.1137894868370495e-07
demonstrate O 0 7.017370649009536e-07
in O 0 5.739265134252491e-07
cultured O 0 6.464911621151259e-06
293 O 0 2.7500578653416596e-05
cells O 0 5.599814357992727e-06
overexpressing O 0 0.0001020886775222607
wild O 0 1.166782749351114e-05
- O 0 1.475958833907498e-05
type O 0 3.2840507628861815e-06
or O 0 7.69814050727291e-07
mutant O 0 8.827822966850363e-06
HFE O 0 0.3777848780155182
proteins O 0 2.0503938458205084e-07
that O 0 5.641316747073688e-08
both O 0 6.856618739448095e-08
the O 0 2.834213148616982e-07
wild O 0 2.3002978650765726e-06
- O 0 6.0938496062590275e-06
type O 0 3.2069544886326184e-06
and O 0 1.0970139783239574e-06
H63D O 1 0.9999957084655762
HFE O 1 0.9978955984115601
proteins O 0 1.0283931715093786e-06
form O 0 4.309216592446319e-07
stable O 0 9.843488442129456e-07
complexes O 0 1.081670006897184e-06
with O 0 3.2993528975566733e-07
the O 0 2.0497518562478945e-06
transferrin O 0 9.64304999797605e-05
receptor O 0 3.0371900720638223e-05
( O 0 1.5480138245038688e-05
TfR O 0 0.0026540905237197876
) O 0 2.5830257072811946e-05
. O 0 6.443975144065917e-05

The O 0 0.0001444197987439111
C282Y O 0 0.0007141740061342716
mutation O 0 1.22897563414881e-05
nearly O 0 4.886092938249931e-06
completely O 0 3.832707534456858e-06
prevents O 0 1.2695870736934012e-06
the O 0 7.872178002799046e-07
association O 0 5.096583208796801e-07
of O 0 9.943623808794655e-07
the O 0 2.0760703591804486e-06
mutant O 0 4.543321119854227e-05
HFE O 1 0.9715142846107483
protein O 0 5.8589575928635895e-06
with O 0 1.8267875248056953e-06
the O 0 1.960359441000037e-05
TfR O 1 0.5163639783859253
. O 0 8.284331852337345e-05

Studies O 0 7.126077252905816e-05
on O 0 1.5166375305852853e-05
cell O 0 2.8894761271658354e-05
- O 0 2.0859237338299863e-05
associated O 0 4.250736765243346e-06
transferrin O 0 4.2955554818036035e-05
at O 0 6.460394160967553e-06
37 O 0 4.725919552583946e-06
degrees O 0 3.8282655623333994e-06
C O 0 5.698726454284042e-06
suggest O 0 7.19795082204655e-07
that O 0 1.0011852680236188e-07
the O 0 5.224061965236615e-07
overexpressed O 0 3.0172794140526094e-05
wild O 0 9.560989383317064e-06
- O 0 1.692907972028479e-05
type O 0 7.617176834173733e-06
HFE O 0 0.0012847400503233075
protein O 0 1.1118268048448954e-06
decreases O 0 8.216617288780981e-07
the O 0 4.824524353352899e-07
affinity O 0 1.078149807653972e-06
of O 0 1.6183116713364143e-06
the O 0 4.485695626499364e-06
TfR O 0 0.0003210935101378709
for O 0 1.755900120770093e-05
transferrin O 0 0.0005258166347630322
. O 0 9.284212137572467e-05

The O 0 0.0001698659179965034
overexpressed O 0 0.005450122989714146
H63D O 1 0.9995933175086975
protein O 0 8.502593118464574e-06
does O 0 9.954297865988337e-07
not O 0 1.3804226739466685e-07
have O 0 5.1008132828656016e-08
this O 0 4.829564659303287e-08
effect O 0 1.0762293101151954e-07
, O 0 1.296592984090239e-07
providing O 0 1.7341216107524815e-07
the O 0 2.282944819853583e-07
first O 0 2.134969605549486e-07
direct O 0 2.3204796661957516e-07
evidence O 0 2.491905775059422e-07
for O 0 1.6264547753053193e-07
a O 0 8.328327112394618e-07
functional O 0 1.7792497146729147e-06
consequence O 0 5.267538654152304e-06
of O 0 4.1730590965016745e-06
the O 0 1.7491976905148476e-05
H63D O 1 0.9999370574951172
mutation O 0 6.55689145787619e-05
. O 0 5.3012758144177496e-05

Addition O 0 0.00011310994887026027
of O 0 3.5939738154411316e-05
soluble O 0 0.00012819276889786124
wild O 0 6.742332334397361e-05
- O 0 0.0008971162606030703
type O 0 0.0211001168936491
HFE O 1 1.0
/ O 1 0.9998629093170166
beta2m O 1 0.998036801815033
heterodimers O 0 0.00023662828607484698
to O 0 2.1857897536392557e-06
cultured O 0 8.360003448615316e-06
cells O 0 7.887447850407625e-07
also O 0 4.767630343849305e-07
decreased O 0 1.0738124274212169e-06
the O 0 3.2801119687064784e-07
apparent O 0 9.666096048022155e-07
affinity O 0 5.437559593701735e-07
of O 0 8.983889756564167e-07
the O 0 8.908801873985794e-07
TfR O 0 1.8471633666194975e-05
for O 0 1.4662577996205073e-07
its O 0 1.4631218903105037e-07
ligand O 0 6.04791637215385e-07
under O 0 5.944341978647572e-07
steady O 0 3.1773006412549876e-06
- O 0 2.352466026422917e-06
state O 0 3.8703532823092246e-07
conditions O 0 3.528604111124878e-07
, O 0 1.6379783573938766e-07
both O 0 1.1051019299657128e-07
in O 0 2.8028847509631305e-07
293 O 0 4.945914497511694e-06
cells O 0 6.556084599651513e-07
and O 0 6.877430109852867e-07
in O 0 4.7640396587667055e-06
HeLa O 1 0.9924328327178955
cells O 0 2.7469075575936586e-05
. O 0 3.930470847990364e-05

Furthermore O 0 8.048144081840292e-05
, O 0 7.283636023203144e-06
at O 0 4.3716427171602845e-06
4 O 0 4.365988843346713e-06
degrees O 0 3.849793301924365e-06
C O 0 6.597703304578317e-06
, O 0 2.95138477213186e-07
the O 0 3.304602387288469e-07
added O 0 7.429115953527798e-07
soluble O 0 2.336183797524427e-06
complex O 0 2.6623924895829987e-06
of O 0 5.893904926779214e-06
HFE O 1 0.9999991655349731
/ O 0 0.08625516295433044
beta2m O 0 0.0002559029671829194
inhibited O 0 8.02576687419787e-06
binding O 0 7.582002012895828e-07
of O 0 1.703526663732191e-06
transferrin O 0 1.6333438907167874e-05
to O 0 3.747045184354647e-06
HeLa O 1 0.9485004544258118
cell O 0 4.43497410742566e-05
TfR O 0 0.00016648441669531167
in O 0 1.4674737940367777e-06
a O 0 4.742208602692699e-06
concentration O 0 4.593990161083639e-05
- O 0 7.545190601376817e-05
dependent O 0 1.0362700777477585e-05
manner O 0 1.650968442845624e-05
. O 0 4.6582128561567515e-05

Scatchard O 0 0.0011998265981674194
plots O 0 9.490041702520102e-05
of O 0 9.318674528913107e-06
these O 0 9.514186558590154e-07
data O 0 9.505190519121243e-07
indicate O 0 3.459836364072544e-07
that O 0 1.958637056986845e-07
the O 0 6.190234103087278e-07
added O 0 2.3278657863556873e-06
heterodimer O 0 1.2469509783841204e-05
substantially O 0 1.126452730204619e-06
reduced O 0 9.502905982117227e-07
the O 0 5.871044663763314e-07
affinity O 0 2.670107051017112e-06
of O 0 4.668670499086147e-06
TfR O 0 0.00038754171691834927
for O 0 1.0881119123951066e-05
transferrin O 0 0.000498918117955327
. O 0 7.411750266328454e-05

These O 0 1.8827793610398658e-05
results O 0 5.3193170970189385e-06
establish O 0 3.35011031893373e-06
a O 0 2.62529374595033e-06
molecular O 0 1.0122535059053916e-05
link O 0 5.030944976169849e-06
between O 0 9.431579996999062e-07
HFE O 1 0.999984860420227
and O 0 9.54393044594326e-07
a O 0 1.1340300716256024e-06
key O 0 1.6763739267844358e-06
protein O 0 4.4864003712064005e-07
involved O 0 2.8828617359977216e-07
in O 0 1.6214740128361882e-07
iron O 0 4.447111859917641e-05
transport O 0 7.536211796832504e-07
, O 0 2.7955914561061945e-07
the O 0 6.381113735187682e-07
TfR O 0 0.001027481397613883
, O 0 4.6609025616817235e-07
and O 0 1.7212060754445702e-07
raise O 0 5.63671278541733e-07
the O 0 3.0491776215058053e-07
possibility O 0 5.048277103014698e-07
that O 0 7.037167648604736e-08
alterations O 0 7.18315959602478e-07
in O 0 1.5663405861232604e-07
this O 0 1.2204816357552772e-07
regulatory O 0 5.762442469858797e-07
mechanism O 0 4.81396739360207e-07
may O 0 2.9495924991351785e-07
play O 0 4.774409489982645e-07
a O 0 7.256633125507506e-07
role O 0 9.122432516051049e-07
in O 0 6.016799147801066e-07
the O 0 2.676873918971978e-06
pathogenesis O 1 0.9995406866073608
of O 1 0.9984663724899292
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9993981122970581
. O 0 0.0005045753787271678

Genomic O 0 0.0003040799347218126
organization O 0 3.371136699570343e-05
of O 0 1.4107514289207757e-05
the O 0 1.5783614799147472e-05
UBE3A O 1 0.9999998807907104
/ O 1 0.9999836683273315
E6 O 1 1.0
- O 0 0.028594089671969414
AP O 0 7.594877388328314e-05
gene O 0 5.289879936754005e-06
and O 0 3.850527718896046e-06
related O 0 1.2839321243518498e-05
pseudogenes O 0 0.0002117383264703676
. O 0 8.049925236264244e-05

The O 0 0.0003665888507384807
UBE3A O 0 0.008414282463490963
gene O 0 4.0705446735955775e-05
encodes O 0 3.805597225436941e-05
the O 0 1.3345047591428738e-05
E6 O 1 0.9969983100891113
- O 0 9.599095210433006e-05
AP O 0 3.4840999433072284e-05
ubiquitin O 0 1.6148294889717363e-05
- O 0 5.578343916567974e-06
protein O 0 1.61536490850267e-06
ligase O 0 6.809706064814236e-06
and O 0 5.248045908956556e-07
has O 0 5.568971346292528e-07
recently O 0 7.676221116525994e-07
been O 0 2.3493154799325566e-07
shown O 0 1.1189349891083111e-07
to O 0 1.2192113274522853e-07
be O 0 2.1635831615185452e-07
mutated O 0 7.779309271427337e-06
in O 0 0.0003115209692623466
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.02529066801071167
who O 0 1.2526471437013242e-05
lack O 0 1.528719258203637e-05
15q11 O 1 0.8520827293395996
- O 0 0.001983199268579483
q13 O 0 0.00021403239225037396
deletions O 0 2.79421110462863e-05
or O 0 7.41698568162974e-06
chromosome O 0 1.465326567995362e-05
15 O 0 2.9477994758053683e-05
paternal O 0 0.0001571399043314159
uniparental B-Disease 1 0.9999535083770752
disomy I-Disease 1 0.9995334148406982
. O 0 0.0005525985034182668

Previous O 0 0.0004033254226669669
UBE3A O 0 0.007785994093865156
cDNA O 0 0.00011326278035994619
analysis O 0 8.296923624584451e-06
has O 0 1.8390024933978566e-06
shown O 0 5.112501639814582e-07
a O 0 1.2203529422549764e-06
coding O 0 8.499423529428896e-06
region O 0 3.4749493806884857e-06
of O 0 5.685415999323595e-06
approximately O 0 1.2781243640347384e-05
2 O 0 6.056661004549824e-05
. O 0 5.5505381169496104e-05

6 O 0 0.0002657945442479104
kb O 0 0.0008678692393004894
and O 0 5.327709004632197e-06
a O 0 4.185897523711901e-06
3 O 0 7.294250281120185e-06
- O 0 1.8273040041094646e-05
untranslated O 0 0.03708038479089737
region O 0 4.345651177573018e-06
( O 0 2.195357637901907e-06
UTR O 0 0.009112505242228508
) O 0 1.123440142691834e-06
of O 0 1.1284816991974367e-06
< O 0 5.541831797017949e-06
50 O 0 2.0374443465698278e-06
bp O 0 3.1527135888609337e-06
, O 0 5.300325938151218e-07
whereas O 0 4.5521599645326205e-07
Northern O 0 8.784780334281095e-07
analysis O 0 3.111046282811003e-07
has O 0 2.778872101316665e-07
indicated O 0 3.733493940671906e-07
mRNA O 0 8.023279178814846e-07
sizes O 0 3.6371574196891743e-07
of O 0 4.3573518837547454e-07
5 O 0 1.9175338366039796e-06
- O 0 1.3326910448085982e-05
8 O 0 2.3291329853236675e-05
kb O 0 0.00025863692280836403
. O 0 4.720663127955049e-05

We O 0 2.871327342290897e-05
have O 0 1.643319819777389e-06
analyzed O 0 2.767631485767197e-06
additional O 0 1.122643311646243e-06
cDNA O 0 1.0646408554748632e-05
clones O 0 9.015731848194264e-06
and O 0 4.7024786908878013e-07
provide O 0 3.265514010308834e-07
evidence O 0 5.218081469138269e-07
for O 0 4.6351573246283806e-07
an O 0 9.695963854028378e-07
additional O 0 4.20756578023429e-06
0 O 0 2.2219637685338967e-05
. O 0 3.643966556410305e-05

5 O 0 0.00012097681610612199
kb O 0 0.0005179256550036371
of O 0 2.554146158217918e-05
5 O 0 3.345253935549408e-05
- O 0 6.398722325684503e-05
UTR O 0 0.08910378068685532
and O 0 3.6024539440404624e-06
> O 0 1.5203735529212281e-05
2 O 0 1.0595822459436022e-05
kb O 0 6.592937279492617e-05
of O 0 8.397342753596604e-06
3 O 0 4.0522365452488884e-05
- O 0 0.0011284330394119024
UTR O 1 0.998019814491272
. O 0 0.00011868425644934177

We O 0 2.88734954665415e-05
have O 0 2.11135966310394e-06
established O 0 1.6314802451233845e-06
the O 0 1.5180146419879748e-06
genomic O 0 2.9851000817870954e-06
organization O 0 1.1788067695306381e-06
of O 0 2.6737509415397653e-06
UBE3A O 1 0.995354413986206
and O 0 1.4225032600734266e-06
the O 0 1.5533095165665145e-06
sequence O 0 1.501351334809442e-06
of O 0 4.626149348041508e-06
intron O 0 0.009819845668971539
- O 0 0.2484433948993683
exon O 0 0.001134349498897791
borders O 0 9.565551590640098e-05
. O 0 8.409333531744778e-05

We O 0 3.243191531510092e-05
have O 0 2.076644705084618e-06
also O 0 2.6524830900598317e-06
mapped O 0 7.763426765450276e-06
two O 0 5.130006002218579e-07
highly O 0 1.7418832385374117e-06
homologous O 0 1.2130566346968408e-06
processed O 0 1.2213146192152635e-06
pseudogenes O 0 4.297407031117473e-06
, O 0 1.1462121847216622e-06
UBE3AP1 O 1 0.9213201403617859
and O 0 1.9736457943508867e-06
UBE3AP2 O 1 0.9995761513710022
, O 0 1.0813853350555291e-06
to O 0 2.4422402589152625e-07
chromosomes O 0 1.9772207338064618e-07
2 O 0 6.399237690857262e-07
and O 0 9.229210462535775e-08
21 O 0 9.661636113378336e-07
, O 0 2.9359836162257125e-07
respectively O 0 9.141941745838267e-07
, O 0 4.6207472337300715e-07
and O 0 4.982805421605008e-07
determined O 0 1.3364992810238618e-06
their O 0 8.170920295924589e-07
genomic O 0 2.5807212296058424e-05
organization O 0 1.8714497855398804e-05
. O 0 5.3906216635368764e-05

These O 0 5.868424977961695e-06
results O 0 1.6533711004740326e-06
will O 0 3.8797472257101617e-07
form O 0 1.824303410558059e-07
the O 0 2.10144293077974e-07
basis O 0 2.2003472111009614e-07
for O 0 1.4597894448797888e-07
studies O 0 3.024208012902818e-07
of O 0 3.6767335132026346e-07
mutation O 0 7.611168939547497e-07
and O 0 1.2724125326712965e-06
imprinting O 0 6.81139063090086e-05
of O 0 0.00011724825162673369
UBE3A O 1 0.9999963045120239
. O 0 0.0002584025205578655

Mutation O 0 0.00021386818843893707
spectrum O 0 7.298826676560566e-05
and O 0 1.2038728527841158e-05
genotype O 0 3.646066033979878e-05
- O 0 4.733650712296367e-05
phenotype O 0 1.1341489880578592e-05
analyses O 0 5.068632617621915e-06
in O 0 3.7856893868593033e-06
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9982143640518188
and O 0 1.3218613275967073e-05
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.2020648682664614e-05
two O 0 7.288937467819778e-06
hamartoma B-Disease 1 0.9999998807907104
syndromes I-Disease 1 0.9999562501907349
with O 0 0.000225811279960908
germline O 1 0.9999966621398926
PTEN O 1 1.0
mutation O 0 0.0004002799396403134
. O 0 9.761100227478892e-05

The O 0 0.0008763791411183774
tumour B-Disease 1 1.0
suppressor O 1 0.9999997615814209
gene O 0 0.001054463442414999
PTEN O 1 0.9999996423721313
, O 0 1.5247849660227075e-05
which O 0 3.9209485294122715e-06
maps O 0 1.608429738553241e-05
to O 0 1.6884130673133768e-05
10q23 O 0 0.0014915995998308063
. O 0 0.00012541713658720255

3 O 0 9.813365613808855e-05
and O 0 1.5041780898172874e-05
encodes O 0 1.81774466909701e-05
a O 0 6.349132945615565e-06
403 O 0 1.4431209820031654e-05
amino O 0 3.772812078750576e-06
acid O 0 3.062360292460653e-06
dual O 0 4.7347707550216e-06
specificity O 0 5.651839728670893e-06
phosphatase O 0 0.00012922515452373773
( O 0 3.115603021797142e-06
protein O 0 3.6539115626510466e-06
tyrosine O 0 5.275652711134171e-06
phosphatase O 0 1.7937651136890054e-05
; O 0 3.819684764039266e-07
PTPase O 0 3.1891049729892984e-05
) O 0 3.103892254330276e-07
, O 0 2.446732310090738e-07
was O 0 8.769587793722167e-07
shown O 0 1.1692345225355893e-07
recently O 0 3.163010831030988e-07
to O 0 1.3512347152300208e-07
play O 0 6.598556296921743e-07
a O 0 8.528202215529745e-07
broad O 0 3.6904446005792124e-06
role O 0 4.138756139582256e-06
in O 0 3.111814066869556e-06
human O 0 1.200432325276779e-05
malignancy B-Disease 1 0.9999839067459106
. O 0 0.0001240943092852831

Somatic O 0 0.4267902970314026
PTEN O 1 0.9999386072158813
deletions O 0 0.0001228264154633507
and O 0 4.483462817006512e-06
mutations O 0 2.628265065141022e-06
were O 0 9.056293492903933e-07
observed O 0 5.746840088249883e-07
in O 0 3.462559732270165e-07
sporadic B-Disease 0 0.00011428006109781563
breast I-Disease 1 1.0
, I-Disease 0 0.000428374158218503
brain I-Disease 1 0.9961943626403809
, I-Disease 0 8.194160182029009e-05
prostate I-Disease 1 1.0
and I-Disease 1 0.9986421465873718
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.0004080489743500948
lines O 0 4.6105216711112007e-07
and O 0 1.2914789238038793e-07
in O 0 9.404654832678716e-08
several O 0 2.282376527773522e-07
primary O 0 1.616188274056185e-05
tumours B-Disease 1 1.0
such O 0 1.7711151940602576e-06
as O 0 0.0019908982794731855
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 1.0
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.5093544125556946

In O 0 2.5621036911616102e-05
addition O 0 1.501764290878782e-05
, O 0 1.1073781024606433e-05
PTEN O 1 0.9999675750732422
was O 0 2.1392250346252695e-05
identified O 0 1.2819494941140874e-06
as O 0 7.337467877732706e-07
the O 0 1.0149165063921828e-06
susceptibility O 0 6.44670581095852e-06
gene O 0 1.4631389149144525e-06
for O 0 1.2837479062000057e-06
two O 0 6.8426397774601355e-06
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.0406105250003748e-05
CD B-Disease 1 0.9999722242355347
; O 0 2.9641250876011327e-06
MIM O 1 0.992715060710907
158350 O 0 0.00013626925647258759
) O 0 1.4130655472399667e-06
and O 0 1.5122782315302175e-06
Bannayan B-Disease 0 0.002268916228786111
- I-Disease 0 0.0020849797874689102
Zonana I-Disease 1 0.9998297691345215
( I-Disease 0 1.3498747648554854e-05
BZS I-Disease 1 0.8649826049804688
) I-Disease 0 2.726043931033928e-06
or I-Disease 0 2.2722761059412733e-06
Ruvalcaba I-Disease 0 0.0003998358442913741
- I-Disease 0 7.643602293683216e-05
Riley I-Disease 0 0.08827590942382812
- I-Disease 1 0.9899430274963379
Smith I-Disease 1 0.8447591662406921
syndrome I-Disease 1 0.9999991655349731
( O 0 4.0339033148484305e-05
MIM O 1 0.9999998807907104
153480 O 1 0.9783958792686462
) O 0 7.111034210538492e-05
. O 0 0.00016011820116546005

Constitutive O 0 0.0004921190557070076
DNA O 0 2.9890521545894444e-05
from O 0 2.664566636667587e-06
37 O 0 1.155267636931967e-05
CD B-Disease 0 0.003946313634514809
families O 0 9.550385584589094e-07
and O 0 8.117088441395026e-07
seven O 0 3.3385390452167485e-06
BZS B-Disease 0 0.3872300386428833
families O 0 2.3597733616043115e-06
was O 0 9.115171451412607e-06
screened O 0 1.763816544553265e-05
for O 0 9.226637303072494e-06
germline O 0 0.0006250371807254851
PTEN O 1 0.9999822378158569
mutations O 0 0.00021014439698774368
. O 0 0.00010076011676574126

PTEN O 1 0.9990769624710083
mutations O 0 3.12899355776608e-05
were O 0 3.1046047297422774e-06
identified O 0 1.1389735163902515e-06
in O 0 3.5125083286402514e-07
30 O 0 6.723716978740413e-07
of O 0 3.6888224030917627e-07
37 O 0 1.217297153743857e-06
( O 0 2.7898946086679643e-07
81 O 0 1.8386587044005864e-06
% O 0 2.9549758551183913e-07
) O 0 2.3067293852818693e-07
CD B-Disease 0 2.517917710065376e-05
families O 0 1.6411101455560129e-07
, O 0 2.9891859298913914e-07
including O 0 1.9919528426726174e-07
missense O 0 3.36324796990084e-06
and O 0 7.69988844240288e-07
nonsense O 0 2.264758586534299e-05
point O 0 1.0478953299752902e-05
mutations O 0 9.548746220389148e-07
, O 0 5.509022003025166e-07
deletions O 0 1.9285116650280543e-06
, O 0 7.423662395922292e-07
insertions O 0 9.273160685552284e-06
, O 0 1.3929156921221875e-06
a O 0 1.8566489643490058e-06
deletion O 0 1.0752464731922373e-05
/ O 0 2.757484617177397e-05
insertion O 0 1.1184030881850049e-05
and O 0 3.0185080959199695e-06
splice O 0 7.176261715358123e-05
site O 0 5.277381933410652e-05
mutations O 0 1.8343645933782682e-05
. O 0 2.3338643586612307e-05

These O 0 1.4021269635122735e-05
mutations O 0 4.713209364126669e-06
were O 0 1.1096414027633728e-06
scattered O 0 1.6240489912888734e-06
over O 0 9.267371297028149e-07
the O 0 6.096461220295168e-07
entire O 0 8.186551099242934e-07
length O 0 3.4067068099830067e-07
of O 0 1.4260170928537264e-06
PTEN O 1 0.9938143491744995
, O 0 4.2224525031997473e-07
with O 0 1.2266438886854303e-07
the O 0 1.8093643916472502e-07
exception O 0 2.680892521311762e-07
of O 0 2.454049194966501e-07
the O 0 2.481050103142479e-07
first O 0 6.172984967633965e-07
, O 0 7.15778242010856e-07
fourth O 0 4.674609499488724e-06
and O 0 1.6104472706501838e-06
last O 0 1.7513311831862666e-05
exons O 0 0.00014897790970280766
. O 0 6.946504436200485e-05

A O 0 0.0003751790209207684
hot O 0 0.00025659363018348813
spot O 0 5.701709596905857e-05
for O 0 4.757283932121936e-06
PTEN O 1 0.8381614089012146
mutation O 0 2.4375499378948007e-06
in O 0 4.811332701137871e-07
CD B-Disease 0 0.062135398387908936
was O 0 6.9171069299045485e-06
identified O 0 5.89189824040659e-07
in O 0 1.9151785579651914e-07
exon O 0 3.5746647881751414e-06
5 O 0 7.350411124207312e-07
that O 0 7.377562383226177e-08
contains O 0 3.075948313835397e-07
the O 0 3.2157979035218887e-07
PTPase O 0 8.352877193829045e-05
core O 0 1.7592084986972623e-05
motif O 0 5.222674644755898e-06
, O 0 3.1085104978956224e-07
with O 0 1.1085811024713621e-07
13 O 0 1.039405788105796e-06
of O 0 5.283696395963489e-07
30 O 0 9.884342944133095e-07
( O 0 2.9282631430760375e-07
43 O 0 1.4466087350228918e-06
% O 0 4.066839665028965e-07
) O 0 7.38617814022291e-07
CD B-Disease 0 3.214254684280604e-05
mutations O 0 1.7197913848576718e-06
identified O 0 9.622473271519993e-07
in O 0 9.97044026007643e-07
this O 0 2.2394556253857445e-06
exon O 0 0.00024945384939201176
. O 0 4.9465455958852544e-05

Seven O 0 3.228936839150265e-05
of O 0 6.4901460063993e-06
30 O 0 4.566318693832727e-06
( O 0 8.195979717129376e-07
23 O 0 1.0452088190504583e-06
% O 0 2.5277464033024444e-07
) O 0 1.297125891142059e-07
were O 0 9.706004533427404e-08
within O 0 6.792148354861638e-08
the O 0 2.0488633367676812e-07
core O 0 8.024880116863642e-06
motif O 0 4.230008016747888e-06
, O 0 2.3041987162741862e-07
the O 0 1.6077881070941658e-07
majority O 0 6.040220767999926e-08
( O 0 6.126966667352463e-08
five O 0 7.476296559616458e-08
of O 0 1.4662101932572114e-07
seven O 0 1.6887825893263653e-07
) O 0 1.40131490411477e-07
of O 0 1.9483681512610929e-07
which O 0 1.1093572993559064e-07
were O 0 2.741569744557637e-07
missense O 0 2.9691666441067355e-06
mutations O 0 4.2118350052078313e-07
, O 0 3.472629259704263e-07
possibly O 0 6.725089178871713e-07
pointing O 0 7.349275961132662e-07
to O 0 1.666604134697991e-07
the O 0 3.7817059705957945e-07
functional O 0 8.746326898290135e-07
significance O 0 3.336941290399409e-06
of O 0 3.0985709145170404e-06
this O 0 2.101484142258414e-06
region O 0 2.2452453777077608e-05
. O 0 3.4087792300852016e-05

Germline O 1 0.994253933429718
PTEN O 1 0.999974250793457
mutations O 0 2.117549411195796e-05
were O 0 2.679269528016448e-06
identified O 0 1.0844607913895743e-06
in O 0 3.230071570214932e-07
four O 0 2.7895302423530666e-07
of O 0 5.881900051463163e-07
seven O 0 4.392121297769336e-07
( O 0 5.059526415607252e-07
57 O 0 4.637081474356819e-06
% O 0 1.143471649811545e-06
) O 0 2.922336989286123e-06
BZS B-Disease 0 0.003939957823604345
families O 0 5.608916580968071e-06
studied O 0 6.489449879154563e-05
. O 0 6.816938548581675e-05

Interestingly O 0 0.00035054449108429253
, O 0 1.4155300050333608e-05
none O 0 4.545307547232369e-06
of O 0 1.2445077572920127e-06
these O 0 2.5169336481667415e-07
mutations O 0 9.202990440826397e-07
was O 0 3.1314023090089904e-06
observed O 0 6.507485181828088e-07
in O 0 6.134586101325112e-07
the O 0 4.431301476870431e-06
PTPase O 1 0.9874293208122253
core O 0 0.17265957593917847
motif O 0 0.0006007790798321366
. O 0 0.00011077140516135842

It O 0 2.0327364836703055e-05
is O 0 2.180393266826286e-06
also O 0 1.2865890539615066e-06
worthy O 0 8.12281905382406e-06
of O 0 2.298574372616713e-06
note O 0 1.2286476476219832e-06
that O 0 1.08466409187713e-07
a O 0 3.274560924637626e-07
single O 0 4.778531774718431e-07
nonsense O 0 4.848452590522356e-06
point O 0 3.707072892211727e-06
mutation O 0 5.835152592226223e-07
, O 0 4.4734636617249635e-07
R233X O 0 8.724036888452247e-06
, O 0 5.602263968285115e-07
was O 0 1.8830869521480054e-06
observed O 0 3.00987920809348e-07
in O 0 2.3675879390339105e-07
the O 0 5.293975391396089e-07
germline O 0 3.4846161724999547e-06
DNA O 0 5.306951607053634e-07
from O 0 2.9643689458680456e-07
two O 0 2.2942221278299257e-07
unrelated O 0 3.3565318062755978e-06
CD B-Disease 0 0.02080850675702095
families O 0 9.294021197092661e-07
and O 0 1.5611046819685725e-06
one O 0 9.166165000351612e-06
BZS B-Disease 1 0.9998656511306763
family O 0 7.461206405423582e-05
. O 0 7.15421192580834e-05

Genotype O 0 0.0007062329677864909
- O 0 0.00020999819389544427
phenotype O 0 1.903354495880194e-05
studies O 0 1.3566841516876593e-06
were O 0 3.074387961987668e-07
not O 0 7.863806672503415e-08
performed O 0 4.95457300075941e-07
on O 0 2.9203320650594833e-07
this O 0 1.6664785107423086e-07
small O 0 7.379179578492767e-07
group O 0 1.3484262808560743e-06
of O 0 8.431278729403857e-06
BZS B-Disease 1 0.9997714161872864
families O 0 1.4334566003526561e-05
. O 0 5.312490611686371e-05

However O 0 6.164814112707973e-05
, O 0 1.6312113075400703e-05
genotype O 0 3.2156069210032e-05
- O 0 2.6173436708631925e-05
phenotype O 0 5.603799763775896e-06
analysis O 0 1.0075103773488081e-06
inthe O 0 1.1015913514711428e-05
group O 0 1.0173692999160266e-06
of O 0 1.3112467058817856e-06
CD B-Disease 1 0.9983713030815125
families O 0 4.1041107579076197e-07
revealed O 0 5.719027740269667e-07
two O 0 6.44030038188248e-08
possible O 0 1.495714911925461e-07
associations O 0 2.3087937961463467e-07
worthy O 0 6.057809059711872e-06
of O 0 2.0991165001760237e-06
follow O 0 6.230662279449461e-07
- O 0 3.3178635021613445e-06
up O 0 2.897909098464879e-06
in O 0 1.3437894494927605e-06
independent O 0 3.6240699046174996e-06
analyses O 0 1.298651477554813e-05
. O 0 3.116539301117882e-05

The O 0 3.203000596840866e-05
first O 0 6.0177444538567215e-06
was O 0 7.556530363217462e-06
an O 0 1.1064554428230622e-06
association O 0 8.652726251057175e-07
noted O 0 8.789992875790631e-07
in O 0 1.950894983338003e-07
the O 0 5.113452630212123e-07
group O 0 5.189605758459948e-07
of O 0 1.2261824622328277e-06
CD B-Disease 1 0.9970619082450867
families O 0 8.713208217159263e-07
with O 0 5.319382580637466e-06
breast B-Disease 1 1.0
disease I-Disease 1 0.9999836683273315
. O 0 6.852211663499475e-05

A O 0 0.00015538290608674288
correlation O 0 2.8369782739900984e-05
was O 0 1.45573267218424e-05
observed O 0 1.8034312461168156e-06
between O 0 4.371937052383146e-07
the O 0 8.081642590695992e-07
presence O 0 1.2851530755142448e-06
/ O 0 1.5380222976091318e-05
absence O 0 2.9759505650872597e-06
of O 0 3.4132344808313064e-06
a O 0 8.737374628253747e-06
PTEN O 1 0.9997217059135437
mutation O 0 9.499607358520734e-07
and O 0 1.8734736784153938e-07
the O 0 4.6784489882156777e-07
type O 0 2.3366558252746472e-06
of O 0 7.406602435366949e-06
breast O 1 0.9999918937683105
involvement O 0 0.00040847496711649
( O 0 4.921832896798151e-06
unaffected O 0 2.4255925382021815e-05
versus O 0 0.0014692791737616062
benign O 1 0.9995391368865967
versus O 1 0.9995176792144775
malignant O 1 1.0
) O 0 4.1727809730218723e-05
. O 0 6.323745037661865e-05

Specifically O 0 4.083031672053039e-05
and O 0 3.236743168599787e-06
more O 0 4.413510623635375e-07
directly O 0 6.289766929512552e-07
, O 0 3.1528287536275457e-07
an O 0 4.904525212623412e-07
association O 0 7.0410141006505e-07
was O 0 4.164896836300613e-06
also O 0 3.923998121990735e-07
observed O 0 1.4993150898590102e-07
between O 0 1.1331572125072853e-07
the O 0 3.631715514984535e-07
presence O 0 5.346289526642067e-07
of O 0 1.087109694708488e-06
a O 0 5.358016096579377e-06
PTEN O 1 0.9999973773956299
mutation O 0 2.5643332264735363e-05
and O 0 5.90569106861949e-05
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 0.0001521761587355286

Secondly O 0 0.00015921129670459777
, O 0 6.192942691995995e-06
there O 0 1.5192022146948148e-06
appeared O 0 1.4856130974294501e-06
to O 0 3.0581762189285655e-07
be O 0 2.918316397426679e-07
an O 0 7.868260354371159e-07
interdependent O 0 4.479466952034272e-06
association O 0 9.86044710771239e-07
between O 0 3.4471435128580197e-07
mutations O 0 6.143678774606087e-07
upstream O 0 1.5302548490581103e-06
and O 0 3.1306569781008875e-07
within O 0 2.7995241680400795e-07
the O 0 8.04023784439778e-07
PTPase O 1 0.8876689076423645
core O 0 0.005024979822337627
motif O 0 1.7793512597563677e-05
, O 0 9.562461400491884e-07
the O 0 5.578177706411225e-07
core O 0 6.552699232997838e-06
motif O 0 4.090632501174696e-06
containing O 0 8.106869699986419e-07
the O 0 2.941519028354378e-07
majority O 0 1.3010421184844745e-07
of O 0 4.011222642930079e-07
missense O 0 4.097065811947687e-06
mutations O 0 5.102365321363322e-07
, O 0 2.575326334408601e-07
and O 0 1.49508025515388e-07
the O 0 1.9953162677666114e-07
involvement O 0 6.569640618181438e-07
of O 0 6.525364142362378e-07
all O 0 2.3672131987950706e-07
major O 0 4.705368337454274e-05
organ O 1 0.9999991655349731
systems O 1 0.9986863732337952
( O 0 8.973786862043198e-06
central O 0 0.00020219363796059042
nervous O 0 1.7924176063388586e-05
system O 0 5.042472821514821e-06
, O 0 6.362831754813669e-06
thyroid O 1 1.0
, O 0 0.010083506815135479
breast O 1 1.0
, O 0 0.00023755554866511375
skin O 1 0.9999740123748779
and O 0 0.017866896465420723
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 0.0009822146967053413
. O 0 0.00016507142572663724

However O 0 3.247044878662564e-05
, O 0 4.092622475582175e-06
these O 0 4.955825829711102e-07
observations O 0 1.1557660855032736e-06
would O 0 4.2304733938181016e-07
need O 0 2.3448299657502503e-07
to O 0 1.9701357700796507e-07
be O 0 1.8666038670289709e-07
confirmed O 0 2.109172783093527e-07
by O 0 1.0794445870487834e-07
studying O 0 8.21032017483958e-07
a O 0 7.707191116423928e-07
larger O 0 5.609855975308164e-07
number O 0 7.018575161055196e-07
of O 0 3.908617145498283e-06
CD B-Disease 1 0.7500726580619812
families O 0 8.826239536574576e-06
. O 0 2.2202184482011944e-05

Molecular O 1 0.9990251064300537
defects O 1 0.9942522644996643
leading O 0 0.00025159353390336037
to O 0 6.127953838586109e-06
human O 0 5.810635229863692e-06
complement B-Disease 0 0.03103073686361313
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.966602773492923e-06
an O 0 3.6592400647350587e-06
African O 0 4.943476596963592e-06
- O 0 6.935014971531928e-05
American O 0 3.7880650779698044e-05
family O 0 2.8363612727844156e-05
. O 0 4.14163623645436e-05

Complement B-Disease 1 0.5089110136032104
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.0011767154792323709
C6D B-Disease 1 1.0
) O 0 1.528101165604312e-05
was O 0 0.0011115241795778275
diagnosed O 0 4.47097590949852e-05
in O 0 2.3566265383578866e-07
a O 0 4.2316071358072804e-07
16 O 0 1.334313992629177e-06
- O 0 4.544813236861955e-06
year O 0 1.4538752566295443e-06
- O 0 5.634838544210652e-06
old O 0 8.475327376800124e-06
African O 0 8.2459763461884e-07
- O 0 5.105006493977271e-06
American O 0 3.710584906002623e-06
male O 0 3.671151944217854e-06
with O 0 5.539227004192071e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.0003956753353122622

The O 0 8.848498691804707e-05
patients O 0 1.3709042832488194e-05
father O 0 5.528534529730678e-06
and O 0 5.933014790571178e-07
two O 0 2.7819638148685044e-07
brothers O 0 4.481449195736786e-06
also O 0 6.187330541251868e-07
had O 0 1.922899400597089e-06
C6D B-Disease 1 0.9999985694885254
, O 0 8.300052627419063e-07
but O 0 1.1886331208188494e-07
gave O 0 3.966854364989558e-07
no O 0 2.3732077636395843e-07
history O 0 7.938529620332702e-07
of O 0 3.8900716390344314e-06
meningitis B-Disease 1 0.9999710321426392
or O 0 4.150875611230731e-06
other O 0 2.8565202683239477e-06
neisserial B-Disease 1 0.9999966621398926
infection I-Disease 0 0.0033079455606639385
. O 0 5.7823162933345884e-05

By O 0 2.4307841158588417e-05
using O 0 1.5478750356123783e-05
exon O 0 6.586532981600612e-05
- O 0 1.3991242667543702e-05
specific O 0 1.5181188928181655e-06
polymerase O 0 6.150329681986477e-06
chain O 0 5.165301445231307e-06
reaction O 0 7.610370857946691e-07
( O 0 5.096874247101368e-07
PCR O 0 2.890307996494812e-06
) O 0 7.183844559222052e-07
/ O 0 4.525272743194364e-06
single O 0 7.353825708378281e-07
- O 0 1.6893993688427145e-06
strand O 0 9.98629388959671e-07
conformation O 0 6.136686465652019e-07
polymorphism O 0 2.904500036038371e-07
as O 0 1.4173586748711386e-07
a O 0 3.185627690527326e-07
screening O 0 7.649678650523128e-07
step O 0 5.410350922829821e-07
and O 0 2.114171167022505e-07
nucleotide O 0 3.0801459161011735e-07
sequencing O 0 4.80178925954533e-07
of O 0 2.979043642881152e-07
target O 0 7.402792903121735e-07
exons O 0 1.3384714065978187e-06
, O 0 1.9383436722364422e-07
we O 0 8.298867015810174e-08
determined O 0 1.8362021592110978e-07
that O 0 7.264887358360284e-08
the O 0 3.727876105585892e-07
proband O 0 4.972908936906606e-05
was O 0 6.711911282764049e-06
a O 0 2.350400791328866e-06
compound O 0 8.748856089368928e-06
heterozygote O 0 2.212946674262639e-05
for O 0 1.9673657334351446e-06
two O 0 4.541268936009146e-06
C6 O 1 0.9999995231628418
gene O 0 3.175134042976424e-05
mutations O 0 2.4533648684155196e-05
. O 0 3.9126920455601066e-05

The O 0 3.3831234759418294e-05
first O 0 1.0398645827081054e-05
, O 0 6.101886356191244e-06
1195delC O 0 3.7342502764659e-05
located O 0 6.690700047329301e-06
in O 0 7.983300633895851e-07
exon O 0 7.339410785789369e-06
7 O 0 2.610812543935026e-06
, O 0 4.1258596183979535e-07
is O 0 2.022044753857699e-07
a O 0 2.3494007450608478e-07
novel O 0 9.561221077092341e-07
mutation O 0 2.0881479656509327e-07
, O 0 1.4275069304403587e-07
while O 0 1.5048360069158662e-07
the O 0 2.0742368178616744e-07
second O 0 8.806430287222611e-07
, O 0 4.6497811467816064e-07
1936delG O 0 6.270305675570853e-06
in O 0 3.615218417962751e-07
exon O 0 4.66751771455165e-06
12 O 0 1.1860371387228952e-06
, O 0 2.9570225024144747e-07
has O 0 1.5726840274510323e-07
been O 0 1.6250562850927963e-07
described O 0 1.5051459456572047e-07
before O 0 1.400284901365012e-07
to O 0 2.102898406519671e-07
cause O 0 1.0728491588452016e-06
C6D B-Disease 1 0.9853358864784241
in O 0 4.1506993397888436e-07
an O 0 6.802026177865628e-07
unrelated O 0 2.614168579384568e-06
African O 0 1.6228707409027265e-06
- O 0 1.4562741853296757e-05
American O 0 1.1715215805452317e-05
individual O 0 6.847888471384067e-06
. O 0 2.410051820334047e-05

Both O 0 2.3675031115999445e-05
mutations O 0 1.0527414815442171e-05
result O 0 2.9962177450215677e-06
in O 0 1.351095988866291e-06
premature O 0 1.2037856322422158e-05
termination O 0 1.7015901903505437e-05
codons O 0 4.725893086288124e-05
and O 0 1.2733939911413472e-05
C6 O 1 0.9999990463256836
null O 0 0.0002386249543633312
alleles O 0 6.960515747778118e-05
. O 0 8.209691441152245e-05

Allele O 0 0.00018942676251754165
- O 0 4.820146205020137e-05
specific O 0 3.6313872442406137e-06
PCR O 0 9.591921298124362e-06
indicated O 0 1.5392137129310868e-06
that O 0 2.225700512781259e-07
the O 0 7.718680876678263e-07
probands O 0 0.00011722979979822412
two O 0 7.123977638912038e-07
brothers O 0 7.442472906404873e-06
also O 0 1.3994107348480611e-06
inherited O 0 1.0016233318310697e-05
the O 0 1.6406952454417478e-06
1195delC O 0 3.063376061618328e-05
mutation O 0 1.4564120647264645e-06
from O 0 3.6647156775870826e-07
their O 0 1.7374622984789312e-07
heterozygous O 0 9.810902383833309e-07
mother O 0 8.985997510535526e-07
and O 0 2.2276287836575648e-07
the O 0 6.919455586285039e-07
1936delG O 0 1.6641768525005318e-05
mutation O 0 9.498139661445748e-07
from O 0 3.9731924061925383e-07
their O 0 3.030724542441021e-07
homozygous O 0 6.506307272502454e-06
father O 0 7.12707469574525e-06
. O 0 7.532657946285326e-06
. O 0 3.153860961901955e-05

PAX6 O 1 0.9982874989509583
mutations O 0 0.0006834277301095426
reviewed O 0 0.0007711127982474864
. O 0 0.0004484713717829436

Mutations O 0 8.893170888768509e-05
in O 0 1.0230610314465594e-05
PAX6 O 1 0.9934266805648804
are O 0 1.2396970987538225e-06
responsible O 0 1.7492944834884838e-06
for O 0 7.389996881101979e-07
human O 0 2.4449204829579685e-06
aniridia B-Disease 1 1.0
and O 0 1.9310496099933516e-06
have O 0 2.1900534363794577e-07
also O 0 3.082429316236812e-07
been O 0 2.409716159945674e-07
found O 0 1.6375221889575187e-07
in O 0 1.4388194813363953e-07
patients O 0 2.4614794824628916e-07
with O 0 2.9928969524917193e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 0.0004244439478497952
with O 1 0.9274572730064392
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 1 0.9983600974082947
with O 0 0.0022328365594148636
autosomal B-Disease 1 0.9999996423721313
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 0.0005176212289370596
and O 0 6.999244305916363e-06
with O 0 1.6102194422273897e-05
isolated B-Disease 1 0.9959535598754883
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.05738038942217827

No O 0 7.408358214888722e-05
locus O 0 0.00014788020052947104
other O 0 1.8868745428335387e-06
than O 0 1.5014429664006457e-06
chromosome O 0 4.0477125367033295e-06
11p13 O 0 7.598565571242943e-05
has O 0 8.164906830643304e-07
been O 0 4.436556366727018e-07
implicated O 0 2.7521291485754773e-06
in O 0 5.45772763871355e-07
aniridia B-Disease 1 1.0
, O 0 1.581434162289952e-06
and O 0 7.671918069718231e-07
PAX6 O 1 0.9999922513961792
is O 0 1.7080457155316253e-06
clearly O 0 7.797750072313647e-07
the O 0 2.562858014698577e-07
major O 0 1.3394328561844304e-06
, O 0 2.4682256594132923e-07
if O 0 1.1790154275104214e-07
not O 0 1.1045307957147088e-07
only O 0 2.026832675028345e-07
, O 0 1.1349302440066822e-06
gene O 0 4.353349140728824e-06
responsible O 0 2.0016655980725773e-05
. O 0 4.515649925451726e-05

Twenty O 0 0.0002654486452229321
- O 0 4.694512972491793e-05
eight O 0 7.222688964247936e-06
percent O 0 4.159712261753157e-06
of O 0 2.1642631509166677e-06
identified O 0 2.800645461320528e-06
PAX6 O 1 0.9708368182182312
mutations O 0 1.6171067045434029e-06
are O 0 2.9355078368098475e-07
C O 0 3.0520386644639075e-05
- O 0 0.00010704025044105947
T O 0 3.237656710552983e-05
changes O 0 4.995004019292537e-07
at O 0 2.939941850854666e-06
CpG O 0 1.9099788914900273e-05
dinucleotides O 0 3.582475983421318e-05
, O 0 6.286001053013024e-07
20 O 0 4.7273849190787587e-07
% O 0 9.099167641579697e-08
are O 0 2.018529698943894e-08
splicing O 0 5.877453190805682e-07
errors O 0 1.8332239051233046e-06
, O 0 3.4516799019002065e-07
and O 0 1.4636481182606076e-07
more O 0 8.067445378401317e-08
than O 0 7.659710377083684e-08
30 O 0 3.368970169503882e-07
% O 0 1.9879638557540602e-07
are O 0 7.95334642589296e-08
deletion O 0 2.002361043196288e-06
or O 0 1.267706920771161e-06
insertion O 0 1.2149520443927031e-05
events O 0 1.4724005268362816e-05
. O 0 3.733032281161286e-05

There O 0 3.8155758375069126e-05
is O 0 7.047442522889469e-06
a O 0 6.296894753177185e-06
noticeably O 0 3.3655156585155055e-05
elevated O 0 0.00021588971139863133
level O 0 3.711685849339119e-06
of O 0 1.560872533445945e-06
mutation O 0 5.153523261469672e-07
in O 0 1.8140778479391884e-07
the O 0 4.1062560285354266e-07
paired O 0 1.0625366257954738e-06
domain O 0 4.962101343153336e-07
compared O 0 4.7412592607543047e-07
with O 0 1.2214817957101332e-07
the O 0 6.516949611068412e-07
rest O 0 1.3314322586666094e-06
of O 0 1.3181022495700745e-06
the O 0 3.5243467664258787e-06
gene O 0 6.981890237511834e-06
. O 0 1.804517705750186e-05

Increased O 0 5.2330655307741836e-05
mutation O 0 9.713468898553401e-06
in O 0 1.478677177146892e-06
the O 0 2.883785327867372e-06
homeodomain O 0 0.0001047773112077266
is O 0 1.5071339021233143e-06
accounted O 0 1.541736196486454e-06
for O 0 4.21580097054175e-07
by O 0 3.7603618352477497e-07
the O 0 4.720604920294136e-06
hypermutable O 0 0.00039866697625257075
CpG O 0 0.00023773453722242266
dinucleotide O 0 0.0002810671867337078
in O 0 1.3665654478245415e-05
codon O 0 0.0001562559773446992
240 O 0 0.00013614405179396272
. O 0 5.910806794418022e-05

Very O 0 3.148302130284719e-05
nearly O 0 1.1445734344306402e-05
all O 0 1.5064887293192442e-06
mutations O 0 2.3222362415253883e-06
appear O 0 9.678363994680694e-07
to O 0 5.433557817013934e-07
cause O 0 2.89805825559597e-06
loss O 0 8.996674296213314e-06
of O 0 1.4235332628231845e-06
function O 0 3.9104560300984303e-07
of O 0 5.708565709028335e-07
the O 0 9.009483505906246e-07
mutant O 0 4.158728643233189e-06
allele O 0 6.640707397309598e-07
, O 0 1.7266263796500425e-07
and O 0 9.838095138547942e-08
more O 0 5.989227247482631e-08
than O 0 1.1454828552359686e-07
80 O 0 8.308843462145887e-07
% O 0 3.514833792905847e-07
of O 0 8.210256510210456e-07
exonic O 0 3.36012126354035e-05
substitutions O 0 5.814327323605539e-06
result O 0 1.7136943597506615e-06
in O 0 3.923761596524855e-06
nonsense O 0 0.0001407531090080738
codons O 0 0.00032847028342075646
. O 0 9.893258538795635e-05

In O 0 1.3789630429528188e-05
a O 0 5.227004749031039e-06
gene O 0 1.5273139979399275e-06
with O 0 3.83540992743292e-07
such O 0 5.686006261385046e-07
extraordinarily O 0 5.791178864456015e-06
high O 0 5.1188667384849396e-06
sequence O 0 5.640982294607966e-07
conservation O 0 1.1630482958935318e-06
throughout O 0 2.5218665200554824e-07
evolution O 0 5.299840495354147e-07
, O 0 2.8330535428722214e-07
there O 0 2.9717708116550057e-07
are O 0 1.1156934931477736e-07
presumed O 0 3.203265350748552e-06
undiscovered O 0 9.336050425190479e-05
missense O 0 9.992762898036744e-06
mutations O 0 5.997469543217449e-07
, O 0 2.666620844138379e-07
these O 0 5.4927443926544584e-08
are O 0 3.782693980269869e-08
hypothesized O 0 6.017487521603471e-07
to O 0 9.358846142504262e-08
exist O 0 9.323123606463923e-08
in O 0 1.3563888501266774e-07
as O 0 4.4825640088674845e-07
- O 0 8.881232133717276e-06
yet O 0 2.456569291098276e-06
unidentified O 0 1.2962969776708633e-05
phenotypes O 0 1.6527355910511687e-05
. O 0 5.988804332446307e-06
. O 0 2.342857806070242e-05

Genetic O 0 0.0002565390896052122
heterogeneity O 0 0.0002250847319373861
and O 0 7.85487918619765e-06
penetrance O 0 7.202203414635733e-05
analysis O 0 2.297715127497213e-06
of O 0 3.6717158309329534e-06
the O 0 4.003478352387901e-06
BRCA1 O 0 0.00015667967090848833
and O 0 3.35454774358368e-06
BRCA2 O 0 0.004168531391769648
genes O 0 3.1697525173512986e-06
in O 0 7.139448825910222e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
families O 0 1.139704545494169e-05
. O 0 4.2109531932510436e-05

The O 1 0.6908789873123169
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9968158602714539
Consortium O 0 0.003331678919494152
. O 0 0.0001779637241270393

The O 0 2.2616592104895972e-05
contribution O 0 2.1625901354127564e-05
of O 0 2.1699879653169774e-05
BRCA1 O 0 0.0012084345798939466
and O 0 4.3775544327218086e-06
BRCA2 O 1 0.9610116481781006
to O 0 1.229324971063761e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.08686015754938126
assessed O 0 2.9096920570736984e-06
by O 0 1.4905955936228565e-07
linkage O 0 1.2443474588508252e-06
and O 0 2.7959916337749746e-07
mutation O 0 2.970963350890088e-07
analysis O 0 1.1298045166086013e-07
in O 0 1.490897005851366e-07
237 O 0 1.4987018630563398e-06
families O 0 7.271098212413563e-08
, O 0 1.0364081504121714e-07
each O 0 2.7307946126597926e-08
with O 0 5.281403758772285e-08
at O 0 5.198511985327059e-07
least O 0 1.0936112460058212e-07
four O 0 7.727520312528213e-08
cases O 0 9.573751924563112e-08
of O 0 3.603013965403079e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9879077076911926
, O 0 2.969660499729798e-07
collected O 0 5.38740835054341e-07
by O 0 2.129574738773954e-07
the O 0 6.752634817530634e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.1648496836423874
Consortium O 0 0.00023599332780577242
. O 0 6.521658360725269e-05

Families O 0 1.1325990271870978e-05
were O 0 3.6222970720700687e-06
included O 0 1.945376652656705e-06
without O 0 5.509237439582648e-07
regard O 0 1.565404318171204e-06
to O 0 4.814586986867653e-07
the O 0 7.583578849335026e-07
occurrence O 0 5.0138837650592905e-06
of O 0 0.0003136400773655623
ovarian B-Disease 1 1.0
or I-Disease 0 3.346019730088301e-05
other I-Disease 0 1.0527915947022848e-05
cancers I-Disease 1 0.9999487400054932
. O 0 9.052090172190219e-05

Overall O 0 0.12553495168685913
, O 0 0.00011869784066220745
disease O 0 0.37317347526550293
was O 0 3.3914056984940544e-05
linked O 0 6.810634658904746e-06
to O 0 1.3306604387253174e-06
BRCA1 O 0 9.231619515048806e-06
in O 0 3.047851748760877e-07
an O 0 3.4573429275042145e-07
estimated O 0 4.525202541572071e-07
52 O 0 7.083694981702138e-07
% O 0 1.0268178840533437e-07
of O 0 1.7218577852418093e-07
families O 0 5.385251711231831e-08
, O 0 1.1197270310958629e-07
to O 0 1.5823802357317618e-07
BRCA2 O 0 2.1285666207404574e-06
in O 0 6.323568868538132e-08
32 O 0 4.770458872371819e-07
% O 0 1.4008566040502046e-07
of O 0 2.0114586618547037e-07
families O 0 4.632002159610238e-08
, O 0 9.385624366586853e-08
and O 0 6.155219267611756e-08
to O 0 1.2124628767651302e-07
neither O 0 3.099993364230613e-07
gene O 0 1.569235337228747e-07
in O 0 1.0844531317388828e-07
16 O 0 5.660026545228902e-07
% O 0 1.5704358702350874e-07
( O 0 1.8639320842339657e-07
95 O 0 1.2596409533216502e-06
% O 0 2.724746934745781e-07
confidence O 0 1.1016531971108634e-06
interval O 0 4.032958258903818e-06
[ O 0 7.428616299876012e-06
CI O 1 0.9999920129776001
] O 0 2.3721199795545544e-06
6 O 0 1.121940158554935e-06
% O 0 1.4336586673380225e-07
- O 0 4.115618423838896e-07
28 O 0 7.029004791547777e-07
% O 0 2.9559876679741137e-07
) O 0 3.0669906436742167e-07
, O 0 5.029851877225155e-07
suggesting O 0 2.106729425577214e-06
other O 0 1.933450676006032e-06
predisposition O 0 0.00014782859943807125
genes O 0 2.2784368411521427e-05
. O 0 3.428025229368359e-05

The O 0 4.14113856095355e-05
majority O 0 4.392948540044017e-06
( O 0 1.8556894474386354e-06
81 O 0 6.05159584665671e-06
% O 0 5.156492761670961e-07
) O 0 3.7149968079575046e-07
of O 0 8.808907523416565e-07
the O 0 9.816079909796827e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.5149515775192413e-07
were O 0 8.143616270217535e-08
due O 0 1.36063704303524e-07
to O 0 1.1499101759682162e-07
BRCA1 O 0 2.839598892023787e-06
, O 0 1.4048220009499346e-07
with O 0 6.258628815203338e-08
most O 0 7.778092481203203e-08
others O 0 1.0827933749624208e-07
( O 0 1.2718807340661442e-07
14 O 0 6.466370336966065e-07
% O 0 2.552308728809294e-07
) O 0 3.9817041397327557e-07
due O 0 1.7059685433196137e-06
to O 0 5.736349976359634e-06
BRCA2 O 0 0.00044254271779209375
. O 0 4.6522996854037046e-05

Conversely O 0 8.668411464896053e-05
, O 0 3.5709440453501884e-06
the O 0 1.2124113482059329e-06
majority O 0 2.8994330136811186e-07
of O 0 6.419806481972046e-07
families O 0 8.799354844768459e-08
with O 0 2.0617528662114637e-07
male B-Disease 0 3.422866711844108e-06
and I-Disease 0 2.4603039037174312e-06
female I-Disease 0 0.4312252402305603
breast I-Disease 1 1.0
cancer I-Disease 1 0.9999105930328369
were O 0 4.917620231026376e-07
due O 0 5.014735506847501e-07
to O 0 6.20529419848026e-07
BRCA2 O 0 1.6753168893046677e-05
( O 0 1.0680001878426992e-06
76 O 0 1.1692144653352443e-05
% O 0 1.9543620055628708e-06
) O 0 5.575663180934498e-06
. O 0 2.9715985874645412e-05

The O 0 7.212079071905464e-05
largest O 0 3.573968933778815e-05
proportion O 0 5.936642082815524e-06
( O 0 1.000119937089039e-06
67 O 0 3.677389258882613e-06
% O 0 2.69522530516042e-07
) O 0 2.5809518433561607e-07
of O 0 2.665420595349133e-07
families O 0 4.059879188389459e-08
due O 0 9.243833432037718e-08
to O 0 6.729875678956887e-08
other O 0 6.842508781801371e-08
genes O 0 1.4341904375214654e-07
was O 0 1.1391874750188435e-06
found O 0 1.4537613424181473e-07
in O 0 5.9220823800387734e-08
families O 0 2.778182484064473e-08
with O 0 5.2047028020751895e-08
four O 0 1.3613573912607535e-07
or O 0 1.6182237061457272e-07
five O 0 3.0917942694941303e-07
cases O 0 3.697740567076835e-07
of O 0 1.066457753040595e-05
female O 1 0.7712920904159546
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
only O 0 1.5553654520772398e-05
. O 0 3.7488291127374396e-05

These O 0 1.3643050806422252e-05
estimates O 0 7.763226676615886e-06
were O 0 1.243397264261148e-06
not O 0 3.544583933035028e-07
substantially O 0 9.72505176832783e-07
affected O 0 2.2189014714513178e-07
either O 0 1.6281386194805236e-07
by O 0 9.868050909744852e-08
changing O 0 3.0373246318049496e-07
the O 0 3.4776900292854407e-07
assumed O 0 1.8099873386745458e-06
penetrance O 0 5.349612365534995e-06
model O 0 4.778377160619129e-07
for O 0 4.077916173628182e-07
BRCA1 O 0 7.254845513671171e-06
or O 0 2.8314653377492505e-07
by O 0 1.6486885101585358e-07
including O 0 7.216907533802441e-07
or O 0 1.5329965208366048e-06
excluding O 0 1.9128152416669764e-05
BRCA1 O 0 8.35190512589179e-05
mutation O 0 1.338500533165643e-05
data O 0 1.0136155651707668e-05
. O 0 4.1058701754081994e-05

Among O 0 4.765063931699842e-05
those O 0 3.5092648431600537e-06
families O 0 9.099667863665672e-07
with O 0 7.163464488257887e-07
disease O 0 0.35267725586891174
due O 0 1.1038648608518997e-06
to O 0 7.03632167642354e-07
BRCA1 O 0 1.5680454453104176e-05
that O 0 7.136516444461449e-08
were O 0 9.071613504829656e-08
tested O 0 6.725731083179198e-08
by O 0 1.8874288798542693e-08
one O 0 4.5668222981021245e-08
of O 0 1.1462390148153645e-07
the O 0 8.749282898179445e-08
standard O 0 3.258070080391917e-07
screening O 0 4.181657402568817e-07
methods O 0 2.1954947726499086e-07
, O 0 1.7308634880919271e-07
mutations O 0 1.0989599985578025e-07
were O 0 7.54380593548376e-08
detected O 0 2.0457277116747719e-07
in O 0 8.559118214179762e-08
the O 0 2.1110524528467067e-07
coding O 0 1.0640535492711933e-06
sequence O 0 2.773846574655181e-07
or O 0 1.7706528865346627e-07
splice O 0 1.5900891412456986e-06
sites O 0 2.6726624469119997e-07
in O 0 6.91373074346302e-08
an O 0 1.3719430569381075e-07
estimated O 0 4.707962091288209e-07
63 O 0 1.9470435290713795e-06
% O 0 4.5751485799883085e-07
( O 0 4.4850787617178867e-07
95 O 0 5.802185569336871e-06
% O 0 3.907278824044624e-06
CI O 1 0.9969995617866516
51 O 0 1.2000763490505051e-05
% O 0 1.6444014363514725e-06
- O 0 9.808462891669478e-06
77 O 0 1.593438719282858e-05
% O 0 4.215462013235083e-06
) O 0 8.791645996097941e-06
. O 0 3.0874190997565165e-05

The O 0 4.567980067804456e-05
estimated O 0 1.7862215827335604e-05
sensitivity O 0 1.0518712770135608e-05
was O 0 5.036446509620873e-06
identical O 0 7.708183602517238e-07
for O 0 2.997404351390287e-07
direct O 0 4.4803886112276814e-07
sequencing O 0 1.150382217929291e-06
and O 0 5.026179223932559e-07
other O 0 1.2354977343420614e-06
techniques O 0 1.3556050362240057e-05
. O 0 3.333045242470689e-05

The O 0 0.000104800499684643
penetrance O 0 0.0005537104443646967
of O 0 6.775797373848036e-05
BRCA2 O 0 0.024269670248031616
was O 0 1.4786454812565353e-05
estimated O 0 2.1407793155958643e-06
by O 0 5.393320066104934e-07
maximizing O 0 1.2631893696379848e-05
the O 0 3.2972720873658545e-06
LOD O 1 0.9998868703842163
score O 0 5.38400081495638e-06
in O 0 1.8992502646142384e-06
BRCA2 O 0 4.707882180809975e-05
- O 0 9.065281119546853e-06
mutation O 0 9.560117177898064e-07
families O 0 1.1583599501818753e-07
, O 0 2.1816693163145828e-07
over O 0 6.856395202703425e-07
all O 0 9.438706456421642e-07
possible O 0 3.6905641991324956e-06
penetrance O 0 0.00025670204195193946
functions O 0 3.0165339921950363e-05
. O 0 6.44000101601705e-05

The O 0 4.419909600983374e-05
estimated O 0 1.521638569101924e-05
cumulative O 0 3.218042547814548e-05
risk O 0 1.4568117876478937e-05
of O 0 3.524697240209207e-05
breast B-Disease 1 0.9999998807907104
cancer I-Disease 0 0.3398827910423279
reached O 0 1.224437710334314e-06
28 O 0 1.4116500324234948e-06
% O 0 2.647787482601416e-07
( O 0 3.3738061233634653e-07
95 O 0 1.618811666048714e-06
% O 0 9.131084652835852e-07
CI O 1 0.995686948299408
9 O 0 4.883093424723484e-06
% O 0 3.6339952202979475e-07
- O 0 8.851687880451209e-07
44 O 0 1.0686053428798914e-06
% O 0 2.036811821426454e-07
) O 0 1.2578796315665386e-07
by O 0 8.406659190995924e-08
age O 0 5.026605549574015e-07
50 O 0 5.273567467156681e-07
years O 0 3.713176113251393e-07
and O 0 2.814477682022698e-07
84 O 0 3.85396651836345e-06
% O 0 3.9491138181801944e-07
( O 0 3.139321336220746e-07
95 O 0 3.124582917735097e-06
% O 0 1.6320699387506465e-06
CI O 1 0.9890338182449341
43 O 0 4.826203621632885e-06
% O 0 5.828556481901614e-07
- O 0 1.5800820847289287e-06
95 O 0 1.545252757750859e-06
% O 0 3.1083237672646646e-07
) O 0 3.4487513289604976e-07
by O 0 2.3415182681674196e-07
age O 0 2.8375739020702895e-06
70 O 0 8.435878044110723e-06
years O 0 1.8779914171318524e-05
. O 0 4.8354355385527015e-05

The O 0 0.000153368353494443
corresponding O 1 0.8763279318809509
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.27413612604141235
were O 0 1.8544546037446707e-05
0 O 0 8.849755977280438e-05
. O 0 9.264614345738664e-05

4 O 0 0.00010584580013528466
% O 0 1.2001391951343976e-05
( O 0 4.787267243955284e-06
95 O 0 1.6155165212694556e-05
% O 0 3.453817498666467e-06
CI O 1 0.9947174191474915
0 O 0 2.7072528610005975e-06
% O 0 4.989814783584734e-07
- O 0 8.692940127730253e-07
1 O 0 1.3264957487990614e-06
% O 0 2.3554176209472644e-07
) O 0 1.1095287533180453e-07
by O 0 7.200175389243668e-08
age O 0 1.8955429936795554e-07
50 O 0 2.57976580542163e-07
years O 0 1.5660866381494998e-07
and O 0 9.715690652001285e-08
27 O 0 4.785203486790124e-07
% O 0 1.1884041839493875e-07
( O 0 1.5883583159848058e-07
95 O 0 1.7818954347603722e-06
% O 0 6.657746212113125e-07
CI O 1 0.952568531036377
0 O 0 1.611774791854259e-06
% O 0 3.594337556478422e-07
- O 0 1.0992719126079464e-06
47 O 0 9.672421583672985e-07
% O 0 1.5625077764980233e-07
) O 0 1.9496525283102528e-07
by O 0 2.510822412205016e-07
age O 0 2.6473730940779205e-06
70 O 0 1.1599121535255108e-05
years O 0 1.6794698240119033e-05
. O 0 4.685434396378696e-05

The O 0 4.258967601344921e-05
lifetime O 0 9.060294541995972e-05
risk O 0 9.440029680263251e-05
of O 0 0.013046177104115486
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
appears O 0 1.418720671608753e-06
similar O 0 7.05245923882103e-08
to O 0 7.443186689215509e-08
the O 0 2.2157465195959958e-07
risk O 0 1.033332409861032e-06
in O 0 3.248167388392176e-07
BRCA1 O 0 8.868122677085921e-06
carriers O 0 5.772067765974498e-07
, O 0 2.813382877775439e-07
but O 0 8.928655859108403e-08
there O 0 1.3049626090833044e-07
was O 0 4.117471235076664e-07
some O 0 6.755661274837621e-08
suggestion O 0 4.856936470787332e-07
of O 0 3.0664438099847757e-07
a O 0 6.157497978165338e-07
lower O 0 1.066516233549919e-06
risk O 0 9.912492942021345e-07
in O 0 5.517029535440088e-07
BRCA2 O 0 1.1003314284607768e-05
carriers O 0 7.315124435081088e-07
< O 0 3.0160333608364454e-06
50 O 0 1.0853827916434966e-06
years O 0 1.3423560858427663e-06
of O 0 5.8587452258507255e-06
age O 0 2.926525667135138e-05
. O 0 6.295178172877058e-05

Eye B-Disease 1 0.9999997615814209
movement I-Disease 0 0.00047533816541545093
abnormalities I-Disease 0 0.0011024299310520291
correlate O 0 2.458044036757201e-05
with O 0 4.060626451973803e-06
genotype O 0 3.995586666860618e-05
in O 0 6.867278443678515e-06
autosomal O 1 0.6498249173164368
dominant O 1 0.9999997615814209
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 0.0002983837330248207

We O 0 4.867483221460134e-05
compared O 0 2.3797447283868678e-05
horizontal O 0 5.9162939578527585e-05
eye O 0 0.003917885944247246
movements O 0 4.937130597681971e-06
( O 0 2.9529853691201424e-06
visually O 0 8.993002666102257e-06
guided O 0 2.2423995687859133e-05
saccades O 0 8.786605758359656e-05
, O 0 2.6010654892161256e-06
antisaccades O 0 7.974529580678791e-05
, O 0 1.1435720352892531e-06
and O 0 7.791632015141658e-07
smooth O 0 2.2113545128377154e-06
pursuit O 0 5.951051662123064e-06
) O 0 5.138388701197982e-07
in O 0 1.7043637967617542e-07
control O 0 7.882740646891762e-07
subjects O 0 9.916805083776126e-07
( O 0 5.148119726072764e-07
n O 0 1.028081442200346e-06
= O 0 8.582737791584805e-07
14 O 0 9.335496429230261e-07
) O 0 3.966082715578523e-07
and O 0 2.0684925061686954e-07
patients O 0 1.392268842437261e-07
with O 0 5.408030645526196e-08
three O 0 1.6856192530667613e-07
forms O 0 4.439684175849834e-07
of O 0 1.2431373761501163e-05
autosomal O 0 0.13017959892749786
dominant O 1 0.9999673366546631
cerebellar B-Disease 1 1.0
ataxias I-Disease 1 1.0
type I-Disease 1 0.9942050576210022
I I-Disease 1 0.992007851600647
spinocerebellar B-Disease 1 0.9999979734420776
ataxias I-Disease 0 0.003528764471411705
1 I-Disease 0 4.622061169357039e-06
and I-Disease 0 2.631284417020652e-07
2 I-Disease 0 1.2952880297234515e-06
( O 0 9.167443408841791e-07
SCA1 B-Disease 0 0.011425127275288105
, O 0 5.576539479079656e-07
n O 0 5.297525831338135e-07
= O 0 5.686255803993845e-07
11 O 0 5.050935101280629e-07
; O 0 2.4364661044273817e-07
SCA2 B-Disease 0 7.44838107493706e-05
, O 0 5.510445930667629e-07
n O 0 5.474852287079557e-07
= O 0 5.2605730616051e-07
10 O 0 3.861563584450778e-07
) O 0 3.8739977981094853e-07
and O 0 1.0072030818264466e-06
SCA3 B-Disease 1 1.0
/ O 0 0.00038922022213228047
Machado B-Disease 0 0.0004298033600207418
- I-Disease 0 0.00029594244551844895
Joseph I-Disease 0 0.07167418301105499
disease I-Disease 0 0.10602667927742004
( O 0 2.8726876735163387e-06
MJD B-Disease 1 1.0
) O 0 1.908612148326938e-06
( O 0 1.1013348739652429e-06
n O 0 2.698372782106162e-06
= O 0 4.945046839566203e-06
16 O 0 7.140681645978475e-06
) O 0 9.679725735622924e-06
. O 0 4.1318999137729406e-05

In O 0 0.00010190474858973175
SCA1 B-Disease 1 0.9142640829086304
, O 0 2.2982385416980833e-05
saccade O 0 0.00011116556561319157
amplitude O 0 2.524746196286287e-05
was O 0 1.9928202164010145e-05
significantly O 0 2.5716474283399293e-06
increased O 0 1.8737913478616974e-06
, O 0 2.483114485585247e-06
resulting O 0 7.978375833772589e-06
in O 0 1.0765290426206775e-05
hypermetria B-Disease 0 0.0072947111912071705
. O 0 0.00014655335689894855

The O 0 0.0002144721947843209
smooth O 0 0.0002628160291351378
pursuit O 0 0.00044246326433494687
gain O 0 0.0002027790033025667
was O 0 0.0005155439721420407
decreased O 0 0.00036029110196977854
. O 0 0.0001581275719217956

In O 0 0.00014405229012481868
SCA2 B-Disease 1 0.9802440404891968
, O 0 5.167172275832854e-05
saccade O 0 0.0005705796647816896
velocity O 0 0.0001297707058256492
was O 0 0.0001441828499082476
markedly O 0 0.00013254127406980842
decreased O 0 0.00010978544742101803
. O 0 8.235017594415694e-05

The O 0 3.7488578527700156e-05
percentage O 0 1.3709212907997426e-05
of O 0 4.762331627716776e-06
errors O 0 3.104342249571346e-05
in O 0 2.73360387836874e-06
antisaccades O 1 0.9999818801879883
was O 0 0.001079736975952983
greatly O 0 1.224563902724185e-06
increased O 0 5.03504452353809e-07
and O 0 3.357807827342185e-07
was O 0 2.8968036076548742e-06
significantly O 0 9.194770882459125e-07
correlated O 0 7.79930473981949e-07
with O 0 3.025910189080605e-07
age O 0 6.358391601679614e-06
at O 0 0.00011670013918774202
disease O 0 0.4190419018268585
onset O 0 0.01406340952962637
. O 0 0.00015260848158504814

In O 0 9.522405889583752e-06
addition O 0 5.139886525284965e-06
, O 0 1.1820218333014054e-06
a O 0 1.0651206139300484e-06
correlation O 0 1.3996216239320347e-06
between O 0 5.53496874999837e-07
smooth O 0 3.603560344345169e-06
pursuit O 0 7.602414825669257e-06
gain O 0 1.8365627738603507e-06
and O 0 4.089826290964993e-07
the O 0 4.7449503881580313e-07
number O 0 7.787665481373551e-07
of O 0 4.9109830797533505e-06
trinucleotide O 0 0.030464444309473038
repeats O 0 2.245084942842368e-05
was O 0 4.4659343984676525e-05
found O 0 1.4839911273156758e-05
. O 0 1.765964407240972e-05

In O 0 0.00015823074500076473
SCA3 B-Disease 1 1.0
, O 0 4.965507105225697e-05
gaze B-Disease 0 0.00036102236481383443
- I-Disease 0 0.00458512594923377
evoked I-Disease 0 0.00018729385919868946
nystagmus I-Disease 0 0.010986989364027977
was O 0 9.843227417150047e-06
often O 0 3.9293007603191654e-07
present O 0 3.5262053188489517e-07
as O 0 4.203492380838725e-07
was O 0 4.921049367112573e-06
saccade O 0 3.8905611290829256e-05
hypometria O 0 0.00012619688641279936
and O 0 3.241558943045675e-06
smooth O 0 9.101776413444895e-06
pursuit O 0 2.8439233574317768e-05
gain O 0 1.0788371582748368e-05
was O 0 3.539086537784897e-05
markedly O 0 2.80982148979092e-05
decreased O 0 8.620353764854372e-05
. O 0 4.5389380829874426e-05

Three O 0 2.939540172519628e-05
major O 0 2.3901979147922248e-05
criteria O 0 1.6094945749500766e-05
, O 0 3.865472535835579e-06
saccade O 0 6.069746086723171e-05
amplitude O 0 1.346167209703708e-05
, O 0 2.710386524995556e-06
saccade O 0 2.9989569156896323e-05
velocity O 0 5.1127826736774296e-06
, O 0 5.539784524444258e-07
and O 0 2.5497908495708543e-07
presence O 0 6.735525630574557e-07
of O 0 1.803068471417646e-06
gaze B-Disease 0 0.00012545469508040696
- I-Disease 0 0.001381763257086277
evoked I-Disease 0 2.5405324777239002e-05
nystagmus I-Disease 0 3.709461816470139e-05
, O 0 5.719987825614226e-07
permitted O 0 4.290239132842544e-07
the O 0 2.3861480258347e-07
correct O 0 3.7326037727325456e-07
assignment O 0 8.525323664798634e-07
of O 0 2.721820067108638e-07
90 O 0 3.535043902047619e-07
% O 0 1.0482789747356946e-07
of O 0 1.785309819979375e-07
the O 0 5.171040129425819e-07
SCA1 B-Disease 0 0.2121068239212036
, O 0 4.107932625174726e-07
90 O 0 4.3511562353160116e-07
% O 0 1.0369321046255209e-07
of O 0 2.1332375865767972e-07
the O 0 4.561103423839086e-07
SCA2 B-Disease 1 0.9993337988853455
, O 0 4.2559673829600797e-07
and O 0 1.20785230706133e-07
93 O 0 1.271847168027307e-06
% O 0 1.708186090354502e-07
of O 0 2.679468877886393e-07
the O 0 5.262379545456497e-07
patients O 0 2.6645031425687193e-07
with O 0 1.9448853549874912e-07
SCA3 B-Disease 1 1.0
to O 0 1.0378932984167477e-06
their O 0 1.9853530375257833e-07
genetically O 0 1.0731449719969532e-06
confirmed O 0 2.795501075070206e-07
patient O 0 3.1656819032832573e-07
group O 0 1.1731437155049207e-07
and O 0 1.5063581315644115e-07
, O 0 3.2111762493514107e-07
therefore O 0 1.7091539916691545e-07
, O 0 2.1319766574379173e-07
may O 0 2.3105558000224846e-07
help O 0 5.372990585783555e-07
orient O 0 2.575245889602229e-05
diagnoses O 0 4.526196789811365e-06
of O 0 6.024875801813323e-06
SCA1 B-Disease 1 1.0
, O 0 5.599579253612319e-06
SCA2 B-Disease 1 0.9999951124191284
, O 0 1.8989713908013073e-06
and O 0 1.529789415144478e-06
SCA3 B-Disease 1 1.0
at O 0 9.537566256767605e-06
early O 0 2.0866400518571027e-06
clinical O 0 5.02775992572424e-06
stages O 0 2.934832536993781e-06
of O 0 3.851485871564364e-06
the O 0 2.0672021491918713e-05
diseases O 1 0.9966201782226562
. O 0 8.104728294711094e-06
. O 0 3.749290408450179e-05

Genetic O 0 8.174381946446374e-05
basis O 0 1.014017834677361e-05
and O 0 2.385575498919934e-06
molecular O 0 2.200337257818319e-05
mechanism O 0 2.236163527413737e-05
for O 0 0.059745486825704575
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.998235821723938

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 3.6185490898787975e-05
more O 0 1.0256840141664725e-06
than O 0 8.39267102037411e-07
300 O 0 2.1379025838541565e-06
, O 0 9.233293667421094e-07
000 O 0 3.985833700426156e-06
sudden O 0 3.763461336347973e-06
deaths O 0 5.65297057164571e-07
each O 0 1.4020849903317867e-07
year O 0 5.295510732139519e-07
in O 0 4.429778925896244e-07
the O 0 3.018329380211071e-06
USA O 0 0.00010967076377710328
alone O 0 2.4509819922968745e-05
. O 0 2.641292303451337e-05

In O 0 2.4034323359956034e-05
approximately O 0 7.852137059671804e-06
5 O 0 4.014405476482352e-06
- O 0 3.3796131901908666e-06
12 O 0 1.1751048987207469e-06
% O 0 3.4930067727145797e-07
of O 0 3.087898789999599e-07
these O 0 7.097233378772216e-08
cases O 0 1.3355459316244378e-07
, O 0 1.4108449875038787e-07
there O 0 1.1784072739828844e-07
are O 0 5.983677908716345e-08
no O 0 6.354424044729967e-07
demonstrable O 1 0.9999635219573975
cardiac O 1 1.0
or O 0 0.0003823775623459369
non O 1 0.7445700764656067
- O 1 0.9999945163726807
cardiac O 1 0.9999587535858154
causes O 0 5.657522592628084e-07
to O 0 6.359697835023326e-08
account O 0 6.127645235665113e-08
for O 0 3.779376456236605e-08
the O 0 1.4405632953184977e-07
episode O 0 1.3793832067676703e-06
, O 0 1.8792123057664867e-07
which O 0 9.528609012932066e-08
is O 0 1.974898964363092e-07
therefore O 0 1.7566121357504016e-07
classified O 0 2.1585863123618765e-06
as O 0 1.6153160686371848e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9998341798782349
IVF B-Disease 1 1.0
) O 0 6.194690649863333e-05
. O 0 8.206624625017866e-05

A O 0 0.00011879170779138803
distinct O 0 9.620531272958033e-06
group O 0 4.41685551777482e-06
of O 0 2.4324537662323564e-05
IVF B-Disease 1 1.0
patients O 0 1.973141661437694e-05
has O 0 8.003120228750049e-07
been O 0 3.4282695082765713e-07
found O 0 1.237705049561555e-07
to O 0 6.442671462991711e-08
present O 0 1.5583543699904112e-07
with O 0 1.656981254427592e-07
a O 0 4.759839157486567e-06
characteristic O 0 0.00010819709132192656
electrocardiographic O 1 0.9930225014686584
pattern O 0 0.00028418831061571836
. O 0 0.0001390442776028067

Because O 0 1.7922260667546652e-05
of O 0 5.344899818737758e-06
the O 0 2.4248256522696465e-06
small O 0 8.857430202624528e-07
size O 0 9.119614787778119e-07
of O 0 5.787667305412469e-07
most O 0 2.658467508354079e-07
pedigrees O 0 1.1525455647642957e-06
and O 0 2.1652407156125264e-07
the O 0 4.3586942410911433e-07
high O 0 8.524416443833616e-06
incidence O 0 8.634413461550139e-06
of O 0 3.1244696856447263e-06
sudden B-Disease 0 1.0860963811865076e-05
death I-Disease 0 2.1529983769141836e-06
, O 0 2.5817544724304753e-07
however O 0 1.6282457693250763e-07
, O 0 1.7589304945886397e-07
molecular O 0 9.327042675977282e-07
genetic O 0 3.561485755199101e-07
studies O 0 3.627336866429687e-07
of O 0 1.1605376357692876e-06
IVF B-Disease 1 0.9823211431503296
have O 0 2.6997116719940095e-07
not O 0 1.36806136197265e-07
yet O 0 4.6621204319308163e-07
been O 0 1.4707351283504977e-06
done O 0 4.853740847465815e-06
. O 0 1.901598443510011e-05

Because O 0 0.0005318477051332593
IVF B-Disease 1 1.0
causes O 1 0.9994109869003296
cardiac O 1 1.0
rhythm O 1 1.0
disturbance O 1 0.9999998807907104
, O 0 2.8528886559797684e-06
we O 0 6.250098749660538e-07
investigated O 0 2.117760232067667e-06
whether O 0 5.201249564379395e-07
malfunction O 0 0.009886677376925945
of O 0 1.123551555792801e-06
ion O 0 7.509024271712406e-06
channels O 0 1.0741944151959615e-06
could O 0 3.777813049055112e-07
cause O 0 1.288364501306205e-06
the O 0 1.0487024155736435e-06
disorder O 0 2.6073588742292486e-05
by O 0 2.4033542445067724e-07
studying O 0 1.395966478412447e-06
mutations O 0 4.1571763631509384e-07
in O 0 2.7272295710645267e-07
the O 0 1.4699220400871127e-06
cardiac O 0 0.0001298922870773822
sodium O 0 8.151328984240536e-06
channel O 0 2.7857871828018688e-05
gene O 0 3.2983462006086484e-05
SCN5A O 1 0.9959768652915955
. O 0 0.0001530973386252299

We O 0 2.4080805815174244e-05
have O 0 3.3634273677307647e-06
now O 0 3.5765199299930828e-06
identified O 0 2.3604170564794913e-06
a O 0 1.6045055417635012e-06
missense O 0 1.075383806892205e-05
mutation O 0 9.546606634103227e-07
, O 0 3.5297685485602415e-07
a O 0 6.17945204339776e-07
splice O 0 2.1085357730044052e-05
- O 0 1.207196601171745e-05
donor O 0 9.640338021199568e-07
mutation O 0 3.2963058060886397e-07
, O 0 2.6654410589799227e-07
and O 0 2.1908054748109862e-07
a O 0 1.0235870604446973e-06
frameshift O 0 7.026724688330432e-06
mutation O 0 4.584875910040864e-07
in O 0 1.458531500020399e-07
the O 0 2.5685224613880564e-07
coding O 0 3.198082140443148e-06
region O 0 1.1917231859115418e-06
of O 0 4.153734607825754e-06
SCN5A O 1 0.9999988079071045
in O 0 2.8595729872904485e-06
three O 0 4.478749360714573e-06
IVF B-Disease 1 0.6017354130744934
families O 0 5.325808615452843e-06
. O 0 3.789120455621742e-05

We O 0 1.5149737009778619e-05
show O 0 3.6561841625371017e-06
that O 0 2.816512960635009e-07
sodium O 0 1.3179540019336855e-06
channels O 0 4.247249876243586e-07
with O 0 2.066867494932012e-07
the O 0 1.205493731504248e-06
missense O 0 1.2933766811329406e-05
mutation O 0 1.6890642200451111e-06
recover O 0 1.4643632084698766e-06
from O 0 4.151926304984954e-07
inactivation O 0 2.1523172108572908e-05
more O 0 1.631413510949642e-07
rapidly O 0 3.55429250475936e-07
than O 0 9.76961871401727e-08
normal O 0 1.5711714240751462e-07
and O 0 7.307176019821782e-08
that O 0 6.97841002761379e-08
the O 0 3.8626981790912396e-07
frameshift O 0 6.385322649293812e-06
mutation O 0 4.386110958876088e-07
causes O 0 2.889994448196376e-07
the O 0 1.3841308543760533e-07
sodium O 0 6.225767492651357e-07
channel O 0 5.279258630253025e-07
to O 0 2.6052808266285865e-07
be O 0 5.872926180927607e-07
non O 0 6.50954734737752e-06
- O 0 5.4660271416651085e-05
functional O 0 4.760886076837778e-05
. O 0 4.856976374867372e-05

Our O 0 3.2132033084053546e-05
results O 0 5.245131433184724e-06
indicate O 0 1.4893438446961227e-06
that O 0 2.9140056767573697e-07
mutations O 0 6.71182590394892e-07
in O 0 4.416508545546094e-07
cardiac O 0 0.11466022580862045
ion O 0 2.4234794182120822e-05
- O 0 5.162586603546515e-05
channel O 0 3.908781309291953e-06
genes O 0 4.5680027938033163e-07
contribute O 0 3.667883277103101e-07
to O 0 2.1456794740970508e-07
the O 0 6.593743933080987e-07
risk O 0 1.943060851772316e-06
of O 0 2.7750425033445936e-06
developing O 0 1.066058121068636e-05
IVF B-Disease 1 0.9987792372703552
. O 0 2.3325226720771752e-05
. O 0 6.0571004723897204e-05

Molecular O 0 0.0004045655659865588
heterogeneity O 0 0.0004201039846520871
in O 0 1.968619653780479e-05
mucopolysaccharidosis B-Disease 1 0.9999414682388306
IVA I-Disease 1 1.0
in O 0 7.3041769610426854e-06
Australia O 0 1.6671588127792347e-06
and O 0 6.726423293912376e-07
Northern O 0 1.3109454357618233e-06
Ireland O 0 1.0870163578147185e-06
: O 0 3.7687627241211885e-07
nine O 0 7.443462664014078e-07
novel O 0 2.1951400412945077e-06
mutations O 0 3.20527135500015e-07
including O 0 3.8300660776258155e-07
T312S O 0 0.002637590514495969
, O 0 1.042117446559132e-06
a O 0 8.641114845886477e-07
common O 0 5.298728638081229e-07
allele O 0 1.1178123031641007e-06
that O 0 3.208574241853057e-07
confers O 0 7.960865332279354e-06
a O 0 9.535692697681952e-06
mild O 0 0.00023471383610740304
phenotype O 0 8.845402771839872e-05
. O 0 6.690006557619199e-05

Mucopolysaccharidosis B-Disease 1 0.999997615814209
IVA I-Disease 1 1.0
( O 1 0.8847601413726807
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 4.252258804626763e-05
is O 0 4.923570031678537e-06
an O 0 6.080996172386222e-06
autosomal B-Disease 1 0.8700986504554749
recessive I-Disease 1 0.9999985694885254
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.011253831908106804
by O 0 8.009884595594485e-07
a O 0 1.0010408004745841e-05
genetic B-Disease 1 0.9999209642410278
defect I-Disease 1 0.9999866485595703
in O 0 2.2047595393814845e-06
N O 0 4.067866757395677e-05
- O 0 4.505155447986908e-05
acetylgalactosamine O 0 0.006148127838969231
- O 0 1.988920303119812e-05
6 O 0 1.1836997146019712e-05
- O 0 3.3104148315032944e-05
sulfate O 0 4.0212515159510076e-05
sulfatase O 1 0.6673772931098938
( O 0 2.5689834728837013e-05
GALNS O 1 0.9999860525131226
) O 0 3.209201167919673e-05
. O 0 5.2517629228532314e-05

Previous O 0 5.6623823184054345e-05
studies O 0 1.0085899702971801e-05
of O 0 4.393061317387037e-06
patients O 0 6.318607006505772e-07
from O 0 2.6074187076119415e-07
a O 0 7.317077574953146e-07
British O 0 1.6826813862280687e-06
- O 0 9.813048563955817e-06
Irish O 0 1.1147538316436112e-05
population O 0 1.7876949698347744e-07
showed O 0 2.1088712287564704e-07
that O 0 5.592549356947529e-08
the O 0 3.117993685464171e-07
I113F O 0 2.3303728085011244e-05
mutation O 0 5.213446456764359e-07
is O 0 1.9611117352269503e-07
the O 0 1.7272654417865851e-07
most O 0 1.621671970042371e-07
common O 0 1.8183126826443186e-07
single O 0 3.166158535350405e-07
mutation O 0 1.0908775038842577e-06
among O 0 1.7871013824333204e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 1 0.596355140209198
and O 0 2.2446131424658233e-06
produces O 0 5.412072823673952e-06
a O 0 8.760795935813803e-06
severe O 0 0.003788901027292013
clinical O 1 0.9253336787223816
phenotype O 0 0.0002429088781354949
. O 0 7.631475455127656e-05

We O 0 1.803261875465978e-05
studied O 0 1.876996066130232e-05
mutations O 0 1.8272579609401873e-06
in O 0 4.734093295155617e-07
the O 0 1.213413042933098e-06
GALNS O 0 0.4094485342502594
gene O 0 5.908672733312414e-07
from O 0 4.962688535670168e-07
23 O 0 1.8206445702162455e-06
additional O 0 2.5755227852641838e-06
MPS B-Disease 1 0.9999548196792603
IVA I-Disease 1 1.0
patients O 0 1.0710237802413758e-05
( O 0 4.1109737480837794e-07
15 O 0 3.5048759627898107e-07
from O 0 1.6169434502444346e-07
Australia O 0 8.009902785488521e-08
, O 0 7.807641111412522e-08
8 O 0 2.453286356285389e-07
from O 0 1.4527938674291363e-07
Northern O 0 4.899989676232508e-07
Ireland O 0 4.0686396118871926e-07
) O 0 2.3159651618698263e-07
, O 0 1.4000178794049134e-07
with O 0 6.69500082040031e-08
various O 0 3.028210926458996e-07
clinical O 0 0.00036751703009940684
phenotypes O 0 0.0064792269840836525
( O 0 1.2379247891658451e-05
severe O 0 0.05812365561723709
, O 0 5.345361842046259e-07
16 O 0 5.256039798950951e-07
cases O 0 6.576499345101183e-08
; O 0 6.998617863018808e-08
intermediate O 0 1.2422026429703692e-06
, O 0 1.9639902859580616e-07
4 O 0 8.149199857143685e-07
cases O 0 1.8362372600222443e-07
; O 0 3.401084427423484e-07
mild O 0 4.07710194849642e-06
, O 0 8.907187520890147e-07
3 O 0 3.8105192743387306e-06
cases O 0 1.657861503190361e-06
) O 0 7.132119208108634e-06
. O 0 3.4505119401728734e-05

We O 0 1.6451764167868532e-05
found O 0 2.8501826818683185e-06
two O 0 4.5651154323422816e-07
common O 0 6.097774871705042e-07
mutations O 0 4.975331080459e-07
that O 0 1.201551782514798e-07
together O 0 2.2034404878468195e-07
accounted O 0 8.441049317298166e-07
for O 0 1.8231381204714125e-07
32 O 0 9.683977850727388e-07
% O 0 2.563192822435667e-07
of O 0 3.9745566482451977e-07
the O 0 6.390156954694248e-07
44 O 0 2.777944700937951e-06
unrelated O 0 2.596896592876874e-06
alleles O 0 1.161826730822213e-06
in O 0 1.085713051907078e-06
these O 0 1.664378828536428e-06
patients O 0 1.2958939805685077e-05
. O 0 3.58343604602851e-05

One O 0 4.5174550905358046e-05
is O 0 6.819330792495748e-06
the O 0 2.507233602955239e-06
T312S O 0 6.4325678977184e-05
mutation O 0 2.8642782581300708e-06
, O 0 8.558544095649268e-07
a O 0 1.0104935199706233e-06
novel O 0 7.500171250285348e-06
mutation O 0 1.411780658600037e-06
found O 0 7.344328878389206e-07
exclusively O 0 1.726137156765617e-06
in O 0 2.035438228631392e-06
milder O 0 5.885485006729141e-05
patients O 0 3.136157101835124e-05
. O 0 4.990648085367866e-05

The O 0 2.4536691853427328e-05
other O 0 1.720815134831355e-06
is O 0 1.2139755654061446e-06
the O 0 1.3211642908572685e-06
previously O 0 3.070806087634992e-06
described O 0 2.6662494292395422e-06
I113F O 0 3.704710252350196e-05
that O 0 8.29530449664162e-07
produces O 0 5.502681688085431e-06
a O 0 1.5968202205840498e-05
severe O 0 0.0005551001522690058
phenotype O 0 0.00019194472406525165
. O 0 9.510415839031339e-05

The O 0 0.0001296464033657685
I113F O 0 0.00032752027618698776
and O 0 1.0917977306235116e-05
T312S O 0 0.00010758607095340267
mutations O 0 3.832320089713903e-06
accounted O 0 2.189451151934918e-06
for O 0 3.328380842049228e-07
8 O 0 1.1260359542575316e-06
( O 0 2.2848919911666599e-07
18 O 0 4.3050553699686134e-07
% O 0 1.0353905821602893e-07
) O 0 1.0883528744898285e-07
and O 0 7.367353305198776e-08
6 O 0 7.899206480033172e-07
( O 0 2.4548123178647074e-07
14 O 0 5.760574595115031e-07
% O 0 1.8271902035849052e-07
) O 0 2.4253915853478247e-07
of O 0 5.136781169312599e-07
44 O 0 2.68796065938659e-06
unrelated O 0 4.301757599023404e-06
alleles O 0 2.249112867502845e-06
, O 0 4.9317332013743e-06
respectively O 0 2.247670454380568e-05
. O 0 6.228638085303828e-05

The O 0 7.27065053069964e-05
relatively O 0 2.0636543922591954e-05
high O 0 2.7794876586995088e-05
residual O 0 0.009045735001564026
GALNS O 1 0.9999978542327881
activity O 0 9.207456969306804e-06
seen O 0 2.712894911383046e-06
when O 0 1.1102354164904682e-06
the O 0 1.981627519853646e-06
T312S O 0 4.5190277887741104e-05
mutant O 0 1.973243161046412e-05
cDNA O 0 2.5955892851925455e-05
is O 0 2.499655693100067e-06
overexpressed O 0 2.570664946688339e-05
in O 0 9.70498376773321e-07
mutant O 0 1.3881332961318549e-05
cells O 0 6.19289153291902e-07
provides O 0 3.1570408509651315e-07
an O 0 2.0747630458117783e-07
explanation O 0 4.1447222542956297e-07
for O 0 2.0960028734862135e-07
the O 0 5.764080128756177e-07
mild O 0 1.7927270164364018e-05
phenotype O 0 3.879742052959045e-06
in O 0 6.843343385298795e-07
patients O 0 7.592552151436394e-07
with O 0 5.686554231942864e-07
this O 0 3.937421297450783e-06
mutation O 0 2.07127468456747e-05
. O 0 2.5296196326962672e-05

The O 0 2.6094929125974886e-05
distribution O 0 3.906683105014963e-06
and O 0 9.65321760304505e-07
relative O 0 8.200686352211051e-07
frequencies O 0 5.310292863214272e-07
of O 0 7.395637453555537e-07
the O 0 7.720344683548319e-07
I113F O 0 2.512130231480114e-05
and O 0 7.856982051634986e-07
T312S O 0 2.710109947656747e-05
mutations O 0 9.033900028043718e-07
in O 0 2.151917612991383e-07
Australia O 0 2.886975210003584e-07
corresponded O 0 3.7951821241222206e-07
to O 0 1.145854326978224e-07
those O 0 6.094623472563399e-08
observed O 0 1.0153448926075725e-07
in O 0 9.44447222650524e-08
Northern O 0 5.669069764735468e-07
Ireland O 0 5.731279770770925e-07
and O 0 1.4154122141007974e-07
are O 0 5.525855684140879e-08
unique O 0 1.271508551781153e-07
to O 0 6.249776873801238e-08
these O 0 3.4667355208739536e-08
two O 0 6.491777782002828e-08
populations O 0 9.44807538871828e-08
, O 0 1.5092626881596516e-07
suggesting O 0 3.0137741191538225e-07
that O 0 4.148110122059734e-08
both O 0 9.9809078335511e-08
mutations O 0 2.3472262000723276e-07
were O 0 2.0364777242320997e-07
probably O 0 6.407017849596741e-07
introduced O 0 2.5605470455047907e-07
to O 0 2.1872774880193901e-07
Australia O 0 2.0118079646636033e-07
by O 0 1.1149085565875794e-07
Irish O 0 1.6366103636755724e-06
migrants O 0 5.705016974388855e-07
during O 0 7.268005788318987e-07
the O 0 1.7536724499223055e-06
19th O 0 2.3758628231007606e-05
century O 0 4.3410680518718436e-05
. O 0 4.210394763504155e-05

Haplotype O 0 0.0005140182911418378
analysis O 0 1.1460458154033404e-05
using O 0 3.82284360966878e-06
6 O 0 1.7524838767712936e-05
RFLPs O 0 0.00020923848205711693
provides O 0 1.6089431937871268e-06
additional O 0 5.152501216798555e-07
data O 0 5.177237767384213e-07
that O 0 1.290961648692246e-07
the O 0 4.7546166115353117e-07
I113F O 0 1.318944850936532e-05
mutation O 0 9.949941386366845e-07
originated O 0 8.886332238944306e-07
from O 0 5.938573508501577e-07
a O 0 2.875231302823522e-06
common O 0 4.91055698148557e-06
ancestor O 0 3.807608300121501e-05
. O 0 5.7598237617639825e-05

The O 0 2.848581425496377e-05
other O 0 3.061916459046188e-06
9 O 0 1.118230284191668e-05
novel O 0 1.0162289981963113e-05
mutations O 0 1.2159290463387151e-06
identified O 0 3.6846839179816016e-07
in O 0 9.204599393797253e-08
these O 0 7.053401418488647e-08
23 O 0 1.3389386595008546e-06
patients O 0 2.3100007240373088e-07
were O 0 8.863888467658398e-08
each O 0 7.891001274629161e-08
limited O 0 1.4961985073114192e-07
to O 0 2.2777385311201215e-07
a O 0 2.2802430521551287e-06
single O 0 4.491658728511538e-06
family O 0 1.3643649253936019e-05
. O 0 2.1132384063093923e-05

These O 0 1.0819509043358266e-05
data O 0 5.16206091560889e-06
provide O 0 9.56356529968616e-07
further O 0 8.116074354802549e-07
evidence O 0 4.7038511752361956e-07
for O 0 3.3773503105294367e-07
extensive O 0 3.1748168112244457e-06
allelic O 0 3.953152918256819e-05
heterogeneity O 0 7.759298023302108e-05
in O 0 3.057615231227828e-06
MPS B-Disease 1 0.9996587038040161
IVA I-Disease 1 1.0
in O 0 4.044841716677183e-06
British O 0 1.1897043805220164e-05
- O 0 0.0005190784577280283
Irish O 0 8.17197360447608e-05
patients O 0 5.940794380876468e-07
and O 0 1.151140125443817e-07
provide O 0 1.0128768224149098e-07
evidence O 0 1.2078626809852722e-07
for O 0 7.872045415524553e-08
their O 0 5.690379012435187e-08
transmission O 0 1.4583298479919904e-07
to O 0 1.4239309109598253e-07
Australia O 0 2.530633480546385e-07
by O 0 1.3514241459233745e-07
British O 0 2.1623507109325146e-06
- O 0 8.76129706739448e-06
Irish O 0 1.6995874830172397e-05
migrants O 0 4.866124982072506e-06
. O 0 7.632381311850622e-06
. O 0 4.081802035216242e-05

Identification O 0 7.608797022840008e-05
of O 0 2.4949689759523608e-05
constitutional O 0 0.00010614113125484437
WT1 O 1 1.0
mutations O 0 1.6819076336105354e-05
, O 0 2.229551000709762e-06
in O 0 9.818521675697411e-07
patients O 0 1.2405308780216728e-06
with O 0 9.161509524346911e-07
isolated O 1 0.9376252889633179
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.0731313017895445e-05
and O 0 9.63299498835113e-07
analysis O 0 6.171207473926188e-07
of O 0 2.2158067167765694e-06
genotype O 0 1.0377079888712615e-05
/ O 0 3.947675577364862e-05
phenotype O 0 4.955195890943287e-06
correlations O 0 3.4673914797167527e-06
by O 0 4.3196590127081436e-07
use O 0 5.307518335939676e-07
of O 0 1.832989710237598e-06
a O 0 5.877027433598414e-06
computerized O 0 0.00016578503709752113
mutation O 0 2.3401293219649233e-05
database O 0 4.1154118662234396e-05
. O 0 9.302148828282952e-05

Constitutional O 0 0.00012469972716644406
mutations O 0 1.0209653737547342e-05
of O 0 8.231369065470062e-06
the O 0 7.026932962617138e-06
WT1 O 1 0.9999921321868896
gene O 0 2.272232904942939e-06
, O 0 8.561956406083482e-07
encoding O 0 2.0221038994350238e-06
a O 0 2.377440068812575e-06
zinc O 0 0.010709801688790321
- O 0 8.025451825233176e-05
finger O 0 3.6576071579474956e-05
transcription O 0 1.0719435522332788e-05
factor O 0 6.55023768558749e-06
involved O 0 7.957121965773695e-07
in O 0 1.2717016488750232e-06
renal O 1 1.0
and O 0 4.5761938963551074e-05
gonadal O 1 0.9999998807907104
development O 0 4.791885203303536e-06
, O 0 6.367150717778713e-07
are O 0 7.644545263474356e-08
found O 0 1.4390391811502923e-07
in O 0 1.1885514794585106e-07
most O 0 2.2001185584485938e-07
patients O 0 3.411733473512868e-07
with O 0 4.131482000957476e-07
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.19189102947711945
DDS B-Disease 1 1.0
) O 0 8.443806109426077e-06
, O 0 2.1384653337008785e-06
or O 0 5.499733561009634e-06
diffuse B-Disease 1 0.999996542930603
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 1 0.9856982827186584
DMS B-Disease 1 1.0
) O 0 1.664556521063787e-06
associated O 0 3.436203712681163e-07
with O 0 3.7657881080122024e-07
pseudohermaphroditism B-Disease 1 1.0
and O 0 9.055862392415293e-06
/ O 1 0.9982383251190186
or O 0 0.0014074536738917232
Wilms B-Disease 1 1.0
tumor I-Disease 1 1.0
( O 0 0.00011086376616731286
WT B-Disease 1 0.9999998807907104
) O 0 5.520375998457894e-05
. O 0 8.066114969551563e-05

Most O 0 4.784397970070131e-05
mutations O 0 3.548291715560481e-05
in O 0 1.956827509275172e-05
DDS B-Disease 1 1.0
patients O 0 7.596594514325261e-05
lie O 0 1.2083841284038499e-05
in O 0 9.070348028217268e-07
exon O 0 1.6328329365933314e-05
8 O 0 3.2478435514349258e-06
or O 0 7.904865810814954e-07
exon O 0 4.167097813478904e-06
9 O 0 1.1857068784593139e-06
, O 0 4.3098575019939744e-07
encoding O 0 2.330731604160974e-06
zinc O 0 2.5669562091934495e-05
finger O 0 3.7664129195036367e-05
2 O 0 1.273984344152268e-05
or O 0 1.140641984420654e-06
zinc O 0 1.352699564449722e-05
finger O 0 7.066394118737662e-06
3 O 0 2.147461827917141e-06
, O 0 2.903060192238627e-07
respectively O 0 3.4635735346455476e-07
, O 0 1.1978562497461098e-07
with O 0 8.29147879244374e-08
a O 0 6.958479161767173e-07
hot O 0 1.6069547200459056e-05
spot O 0 8.712961971468758e-06
( O 0 1.5554634273939882e-06
R394W O 0 2.520858652133029e-05
) O 0 1.528750885881891e-06
in O 0 1.1891472695424454e-06
exon O 0 5.115608291816898e-05
9 O 0 4.563808033708483e-05
. O 0 4.576001811074093e-05

We O 0 2.514455081836786e-05
analyzed O 0 7.577284122817218e-06
a O 0 3.3207188607775606e-06
series O 0 1.5048432260300615e-06
of O 0 1.4222550817066804e-06
24 O 0 5.044184945290908e-06
patients O 0 7.024789852039248e-07
, O 0 2.0777609677224973e-07
10 O 0 5.845423061145993e-07
with O 0 3.4561728057269647e-07
isolated B-Disease 0 1.3960562682768796e-05
DMS I-Disease 1 1.0
( O 0 1.0733715498645324e-05
IDMS B-Disease 1 1.0
) O 0 1.316863404099422e-06
, O 0 4.278602148133359e-07
10 O 0 4.4093121687183157e-07
with O 0 3.855050749734801e-07
DDS B-Disease 1 1.0
, O 0 2.4206483431044035e-06
and O 0 6.076423915146734e-07
4 O 0 3.546613243088359e-06
with O 0 1.218917645928741e-06
urogenital B-Disease 1 1.0
abnormalities I-Disease 1 0.9999982118606567
and O 0 0.001341941300779581
/ O 1 0.9999998807907104
or O 0 0.4109393060207367
WT B-Disease 1 1.0
. O 0 0.00013914470036979765

We O 0 5.606481136055663e-05
report O 0 3.5620596463559195e-05
WT1 O 0 0.14288268983364105
heterozygous O 0 1.2010288628516719e-05
mutations O 0 1.410281470271002e-06
in O 0 3.9182617683763965e-07
16 O 0 2.1436151200759923e-06
patients O 0 5.508281333277409e-07
, O 0 2.6286107868145336e-07
4 O 0 9.126070494858141e-07
of O 0 8.662072445986269e-07
whom O 0 1.1895543821083265e-06
presented O 0 5.400245299824746e-06
with O 0 1.0745135114120785e-05
IDMS B-Disease 1 1.0
. O 0 0.00027707486879080534

One O 0 7.77661771280691e-05
male O 0 1.570203312439844e-05
and O 0 1.7240182614841615e-06
two O 0 1.4550681726177572e-06
female O 0 7.023069338174537e-05
IDMS B-Disease 1 1.0
patients O 0 0.00020090490579605103
with O 0 1.390523357258644e-05
WT1 O 1 1.0
mutations O 0 0.008231001906096935
underwent O 1 0.9998063445091248
normal O 0 6.879632564960048e-05
puberty O 0 0.00017813754675444216
. O 0 3.8725309423170984e-05

Two O 0 2.414422488072887e-05
mutations O 0 1.0099171959154774e-05
associated O 0 1.7989136722462717e-06
with O 0 1.8304602917851298e-06
IDMS B-Disease 1 1.0
are O 0 8.356587386515457e-07
different O 0 1.530806486016445e-07
from O 0 3.0003101869624516e-07
those O 0 2.9164743864384945e-07
described O 0 2.344647100471775e-06
in O 0 1.128818348661298e-05
DDS B-Disease 1 1.0
patients O 0 0.005738494452089071
. O 0 0.00012687209527939558

No O 0 0.0003133976715616882
WT1 O 1 0.9999558925628662
mutations O 0 2.238284287159331e-05
were O 0 2.323984290342196e-06
detected O 0 2.3942636744322954e-06
in O 0 3.1026345936879807e-07
the O 0 5.194596610635926e-07
six O 0 7.482329351660155e-07
other O 0 2.0526431399048306e-06
IDMS B-Disease 1 1.0
patients O 0 1.1673949302348774e-05
, O 0 1.2712117722912808e-06
suggesting O 0 2.29532815865241e-06
genetic O 0 2.392341912127449e-06
heterogeneity O 0 3.302034383523278e-05
of O 0 4.178554445388727e-05
this O 0 1.0544033102632966e-05
disease O 1 0.8030486106872559
. O 0 5.797909034299664e-05

We O 0 5.2422161388676614e-05
analyzed O 0 3.536177973728627e-05
genotype O 0 2.717096867854707e-05
/ O 0 5.0892158469650894e-05
phenotype O 0 7.803377229720354e-06
correlations O 0 4.806838205695385e-06
, O 0 8.461287279715179e-07
on O 0 4.0984588167702896e-07
the O 0 2.711229569740681e-07
basis O 0 2.8912018024129793e-07
of O 0 4.4272704258219164e-07
the O 0 5.346014404494781e-07
constitution O 0 4.586821944485564e-07
of O 0 1.2874972981080646e-06
a O 0 4.8427964429720305e-06
WT1 O 1 0.59041827917099
mutation O 0 2.5028784875757992e-06
database O 0 1.727158064568357e-06
of O 0 1.4015183751325822e-06
84 O 0 2.3153846996137872e-05
germ O 1 0.9521210193634033
- O 0 0.00015163575881160796
line O 0 3.666442580652074e-06
mutations O 0 4.365878680800961e-07
, O 0 1.5749130000131117e-07
to O 0 1.295615135177286e-07
compare O 0 2.2029466606454662e-07
the O 0 1.9119009664336772e-07
distribution O 0 1.3900054796067707e-07
and O 0 6.84133425465916e-08
type O 0 6.003180601510394e-07
of O 0 4.661978323383664e-07
mutations O 0 2.684410560505057e-07
, O 0 1.88978702908571e-07
according O 0 7.995508610747493e-08
to O 0 1.7905834681641863e-07
the O 0 1.0075660838992917e-06
different O 0 1.2231936352691264e-06
symptoms O 0 2.785447213682346e-05
. O 0 2.964448503917083e-05

This O 0 8.55962480272865e-06
demonstrated O 0 7.046743576211156e-06
( O 0 1.4317363365989877e-06
1 O 0 3.656473609225941e-06
) O 0 7.055283504087129e-07
the O 0 5.343109137356805e-07
association O 0 3.279348845808272e-07
between O 0 1.7819094466631213e-07
mutations O 0 1.9039350718230708e-07
in O 0 1.4011959592608036e-07
exons O 0 2.1662663129973225e-06
8 O 0 1.3630699413624825e-06
and O 0 2.3200637144782377e-07
9 O 0 1.0124699656444136e-06
and O 0 2.75989862075221e-07
DMS B-Disease 1 0.843384861946106
; O 0 3.511362933750206e-07
( O 0 2.7809028324554674e-07
2 O 0 1.2325333500484703e-06
) O 0 3.9239455418282887e-07
among O 0 3.0023622343833267e-07
patients O 0 3.0813507123639283e-07
with O 0 1.86014261771561e-07
DMS B-Disease 1 1.0
, O 0 1.303731551161036e-06
a O 0 4.1263317029915925e-07
higher O 0 2.8955506081729254e-07
frequency O 0 2.94414604695703e-07
of O 0 5.055600240666536e-07
exon O 0 4.490065293794032e-06
8 O 0 2.1349483176891226e-06
mutations O 0 3.869533884426346e-07
among O 0 1.8476075069884246e-07
46 O 0 2.1678099528799066e-06
, O 0 1.4444705129790236e-06
XY O 1 0.7196125388145447
patients O 0 5.866997412340424e-07
with O 0 1.9514345694915392e-07
female O 0 1.2180646535853157e-06
phenotype O 0 8.690403774380684e-07
than O 0 1.7567178645094828e-07
among O 0 3.3210565675290127e-07
46 O 0 5.057151156506734e-06
, O 0 2.473221456966712e-06
XY O 1 0.9227815866470337
patients O 0 7.651867690583458e-07
with O 0 2.507525209693995e-07
sexual O 0 9.304255286224361e-07
ambiguity O 0 1.0620407010719646e-05
or O 0 8.411821568188316e-07
male O 0 1.1112691709058709e-06
phenotype O 0 5.87026647735911e-07
; O 0 1.1123426446602025e-07
and O 0 1.9117368310617167e-07
( O 0 4.112440308290388e-07
3 O 0 1.1101866448370856e-06
) O 0 3.177568714818335e-07
statistically O 0 3.1009602707854356e-07
significant O 0 2.6605118819134077e-07
evidence O 0 2.2757147633001296e-07
that O 0 9.864269401305137e-08
mutations O 0 1.8435102333569375e-07
in O 0 1.9402652640110318e-07
exons O 0 3.216642653569579e-06
8 O 0 3.087523964495631e-06
and O 0 5.596667733698268e-07
9 O 0 2.5136068870779127e-06
preferentially O 0 8.821248798085435e-07
affect O 0 2.4861188308022975e-07
amino O 0 3.1914478881844843e-07
acids O 0 1.5007513809450757e-07
with O 0 1.1030761015717871e-07
different O 0 1.454594951155741e-07
functions O 0 1.3984260931465542e-06
. O 0 5.3775866035721265e-06
. O 0 4.426680243341252e-05

The O 0 9.526408393867314e-05
185delAG O 0 0.0005469740717671812
BRCA1 O 0 8.670048555359244e-05
mutation O 0 5.130023964738939e-06
originated O 0 1.2617738320841454e-06
before O 0 2.185784353514464e-07
the O 0 2.434636030557158e-07
dispersion O 0 1.3910996585764224e-06
of O 0 8.187113280655467e-07
Jews O 0 9.026640555021004e-07
in O 0 1.467330719151505e-07
the O 0 3.036713565052196e-07
diaspora O 0 4.5781951030221535e-07
and O 0 3.4305458029848523e-07
is O 0 5.786011456621054e-07
not O 0 3.046915821869334e-07
limited O 0 1.2162607845311868e-06
to O 0 5.895164122193819e-06
Ashkenazim O 0 0.0004406770458444953
. O 0 9.328868327429518e-05

The O 0 8.788969716988504e-05
185delAG O 0 0.00017882545944303274
mutation O 0 6.018123713147361e-06
in O 0 1.0906674106081482e-06
BRCA1 O 0 1.5556561265839264e-05
is O 0 6.664054126304109e-07
detected O 0 7.316638175325352e-07
in O 0 2.3844285124141607e-07
Ashkenazi O 0 7.784719855408184e-06
Jews O 0 1.0126158258572104e-06
both O 0 2.6957957288686885e-07
in O 0 5.723076128560933e-07
familial B-Disease 1 0.9999328851699829
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.0494578646103037e-06
in O 0 4.87057320697204e-07
the O 0 1.7515079662189237e-06
general O 0 4.890111540589714e-06
population O 0 4.97078190164757e-06
. O 0 2.8012813345412724e-05

All O 0 3.763432687264867e-05
tested O 0 3.770269177039154e-05
Ashkenazi O 0 9.383846918353811e-05
mutation O 0 7.3454957600915805e-06
carriers O 0 2.7511844109540107e-06
share O 0 1.681819981058652e-06
the O 0 9.520921935290971e-07
same O 0 7.793267400302284e-07
allelic O 0 4.076239201822318e-05
pattern O 0 8.436054486082867e-06
at O 0 1.8734623154159635e-05
the O 0 2.8833132091676816e-05
BRCA1 O 0 0.0006353792268782854
locus O 0 0.0015058352146297693
. O 0 0.00011194135004188865

Our O 0 4.302500019548461e-05
previous O 0 1.5574343706248328e-05
study O 0 3.517580580592039e-06
showed O 0 1.328931944044598e-06
that O 0 1.463278209712371e-07
this O 0 2.0845170922711986e-07
Ashkenazi O 0 1.021438765747007e-05
mutation O 0 1.090875343834341e-06
also O 0 4.613802957464941e-07
occurs O 0 1.0398197503036499e-07
in O 0 2.2135205313134065e-07
Iraqi O 0 9.745959914653213e-07
Jews O 0 1.3969838619232178e-06
with O 0 5.13067107021925e-07
a O 0 2.9646903385582846e-06
similar O 0 3.5063073937635636e-06
allelic O 0 0.0003451855154708028
pattern O 0 0.00014257045404519886
. O 0 5.83032779104542e-05

We O 0 1.7458483853260987e-05
extended O 0 4.5550623326562345e-06
our O 0 9.655630037741503e-07
analysis O 0 2.5813557158471667e-07
to O 0 1.7150958342426748e-07
other O 0 2.946367771983205e-07
non O 0 1.990704504351015e-06
- O 0 8.721790436538868e-06
Ashkenazi O 0 1.0742173799371812e-05
subsets O 0 4.658819307223894e-06
354 O 0 8.941067790146917e-06
of O 0 2.47341267822776e-06
Moroccan O 0 1.5902249288046733e-05
origin O 0 7.746127153041016e-07
, O 0 8.065858310146723e-07
200 O 0 2.5773017569008516e-06
Yemenites O 0 2.0759061953867786e-05
and O 0 1.7432627146263258e-06
150 O 0 9.824677363212686e-06
Iranian O 0 2.6562283892417327e-05
Jews O 0 2.3933547709020786e-05
. O 0 4.374387935968116e-05

Heteroduplex O 0 0.0026452834717929363
analysis O 0 2.8568296329467557e-05
complemented O 0 4.1092975152423605e-05
by O 0 1.5328679410231416e-06
direct O 0 1.5312372170228628e-06
DNA O 0 1.7663398921285989e-06
sequencing O 0 2.0934469375788467e-06
of O 0 3.125405328319175e-06
abnormally O 0 1.0530286090215668e-05
migrating O 0 4.42124655819498e-06
bands O 0 1.170018640550552e-05
were O 0 5.324829089659033e-06
employed O 0 3.242811362724751e-05
. O 0 4.420752884470858e-05

Four O 0 1.3895582014811225e-05
of O 0 5.721783963963389e-06
Moroccan O 0 2.4539500373066403e-05
origin O 0 8.033584890654311e-07
( O 0 2.9183914307395753e-07
1 O 0 7.229306788758549e-07
. O 0 8.901857029286475e-08
1 O 0 5.67036749998806e-07
% O 0 1.1967155444381206e-07
) O 0 1.4897244682288147e-07
and O 0 1.0478471779151732e-07
none O 0 1.6261569157904887e-07
of O 0 3.184151466939511e-07
the O 0 5.658828285959316e-07
Yemenites O 0 3.885948535753414e-05
or O 0 5.086580472379865e-07
Iranians O 0 1.8670184545044322e-06
was O 0 2.650091118994169e-06
a O 0 9.264437039746554e-07
carrier O 0 2.5488307073828764e-06
of O 0 2.2233973595575662e-06
the O 0 4.476605681702495e-06
185delAG O 0 0.00024162551562767476
mutation O 0 3.0211982448236085e-05
. O 0 4.271967918612063e-05

BRCA1 O 0 0.0025090135168284178
allelic O 0 0.0003992627316620201
patterns O 0 7.089438440743834e-06
were O 0 1.3770292071058066e-06
determined O 0 8.181977477761393e-07
for O 0 2.0580871762376773e-07
four O 0 1.8637952337030583e-07
of O 0 3.083464150677173e-07
these O 0 4.758418015171628e-08
individuals O 0 3.2528973292755836e-08
and O 0 5.8367781718970946e-08
for O 0 1.1622007889400265e-07
12 O 0 3.3495948059680813e-07
additional O 0 3.2446502018501633e-07
non O 0 1.229030772265105e-06
- O 0 7.779109182592947e-06
Ashkenazi O 0 1.559785960125737e-05
185delAG O 0 2.7673686417983845e-05
mutation O 0 1.849872660386609e-06
carriers O 0 6.174491886667965e-07
who O 0 1.7575081301401951e-06
had O 0 2.25002095248783e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00017594410746823996

Six O 0 5.409571895143017e-05
non O 0 5.6303015298908576e-05
- O 0 0.0001582586410222575
Ashkenazi O 0 6.909902731422335e-05
individuals O 0 7.819085681148863e-07
shared O 0 9.037674999490264e-07
the O 0 1.0022797596320743e-06
common O 0 1.1419568863857421e-06
Ashkenazi O 0 0.00024068326456472278
haplotype O 0 3.801429193117656e-05
, O 0 1.0405890407128027e-06
four O 0 3.4592230235830357e-07
had O 0 4.975985916644277e-07
a O 0 4.753129871915007e-07
closely O 0 3.5601476611191174e-07
related O 0 4.0672119894225034e-07
pattern O 0 1.0329401902708923e-06
, O 0 2.603902373721212e-07
and O 0 1.0436625075271877e-07
the O 0 2.69236068106693e-07
rest O 0 8.15645478269289e-07
( O 0 2.55432979656689e-07
n O 0 5.40320456821064e-07
= O 0 5.497926736097725e-07
6 O 0 9.702929446575581e-07
) O 0 4.958042723046674e-07
displayed O 0 2.3286631858354667e-06
a O 0 3.2057741918833926e-06
distinct O 0 4.2069559640367515e-06
BRCA1 O 0 0.00015259305655490607
allelic O 0 0.0009473621612414718
pattern O 0 0.0001755770790623501
. O 0 7.360517338383943e-05

We O 0 3.196333273081109e-05
conclude O 0 1.1753843864426017e-05
that O 0 9.302214039053069e-07
the O 0 2.1662765448127175e-06
185delAG O 0 0.00011659492156468332
BRCA1 O 0 7.011172419879586e-05
mutation O 0 1.7638922145124525e-06
occurs O 0 2.0696960234545259e-07
in O 0 1.7298749810379377e-07
some O 0 2.2421431822294835e-07
non O 0 1.7164848031825386e-06
- O 0 3.938312875106931e-05
Ashkenazi O 0 2.7790210879174992e-05
populations O 0 5.175085675546143e-07
at O 0 1.6211290585488314e-06
rates O 0 4.560015725019184e-07
comparable O 0 5.074660975878942e-07
with O 0 2.5664311920081673e-07
that O 0 7.088519851095043e-07
of O 0 1.0090055184264202e-05
Ashkenazim O 0 0.0009441695874556899
. O 0 5.385010808822699e-05

The O 0 4.1710543882800266e-05
majority O 0 8.934785910241771e-06
of O 0 7.74513046053471e-06
Jewish O 0 1.8578268281999044e-05
185delAG O 0 0.00013852499250788242
mutation O 0 3.5197685974708293e-06
carriers O 0 1.1806248494394822e-06
have O 0 2.696937713153602e-07
a O 0 6.189054033711727e-07
common O 0 7.202359597613395e-07
allelic O 0 1.837591662479099e-05
pattern O 0 3.911962267011404e-06
, O 0 5.354269774215936e-07
supporting O 0 9.30912790408911e-07
the O 0 7.256571166180947e-07
founder O 0 2.105124258378055e-05
effect O 0 9.44101032018807e-07
notion O 0 1.8276588207299937e-06
, O 0 3.351511566052068e-07
but O 0 1.9692849662078515e-07
dating O 0 5.071603368378419e-07
the O 0 3.149393705825787e-07
mutations O 0 1.7337430335828685e-07
origin O 0 6.033841515318272e-08
to O 0 5.875828534840366e-08
an O 0 1.4450199614657322e-07
earlier O 0 3.11272600583834e-07
date O 0 6.440503170779266e-07
than O 0 5.640466724798898e-07
currently O 0 3.4290060284547508e-06
estimated O 0 8.857329703459982e-06
. O 0 3.221278893761337e-05

However O 0 3.932660547434352e-05
, O 0 5.362852334656054e-06
the O 0 2.024836248892825e-06
different O 0 4.980192329639976e-07
allelic O 0 1.2179346413176972e-05
pattern O 0 3.7636191336787306e-06
at O 0 4.508486199483741e-06
the O 0 2.469125774950953e-06
BRCA1 O 0 3.103637936874293e-05
locus O 0 2.549142845964525e-05
even O 0 4.4264598386689613e-07
in O 0 2.0351575358290575e-07
some O 0 1.507501963260438e-07
Jewish O 0 8.129073307827639e-07
mutation O 0 4.297835403122008e-07
carriers O 0 5.757432859354594e-07
, O 0 4.0030334957918967e-07
might O 0 5.371360884964815e-07
suggest O 0 4.145675234212831e-07
that O 0 1.3628186934511177e-07
the O 0 6.674026735709049e-07
mutation O 0 1.7906036191561725e-06
arose O 0 2.3743493784422753e-06
independently O 0 1.4101040051173186e-06
. O 0 5.3673652473662514e-06
. O 0 2.370422225794755e-05

Crystal O 0 0.0012393230572342873
structure O 0 4.477038237382658e-05
of O 0 2.57599022006616e-05
the O 0 5.721666821045801e-05
hemochromatosis B-Disease 1 1.0
protein O 0 0.00010619540262268856
HFE O 1 0.9999984502792358
and O 0 4.7308440116466954e-06
characterization O 0 1.7288986782659777e-05
of O 0 4.3130416997883e-06
its O 0 1.888345423139981e-06
interaction O 0 2.1125599687366048e-06
with O 0 3.088098083026125e-06
transferrin O 0 0.00031320619746111333
receptor O 0 0.00016639982641208917
. O 0 7.102759991539642e-05

HFE O 1 0.9999614953994751
is O 0 4.183499186183326e-05
an O 0 1.460081784898648e-05
MHC O 0 0.014964913949370384
- O 0 2.5405299311387353e-05
related O 0 1.972298832697561e-06
protein O 0 5.997572429805587e-07
that O 0 1.1104030761543981e-07
is O 0 2.1242644265839772e-07
mutated O 0 9.196085670737375e-07
in O 0 2.6960452714774874e-07
the O 0 2.2260260266193654e-06
iron B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.999990701675415

HFE O 0 0.32614946365356445
binds O 0 0.00012662216613534838
to O 0 1.8964821720146574e-05
transferrin O 0 0.00029555504443123937
receptor O 0 5.562534715863876e-05
( O 0 1.0522877346375026e-05
TfR O 0 0.0005444944836199284
) O 0 1.610321419320826e-06
and O 0 4.4014259970026615e-07
reduces O 0 1.1233352097406168e-06
its O 0 2.7403334001974144e-07
affinity O 0 9.852212770056212e-07
for O 0 6.156241738608514e-07
iron O 0 0.00012694434553850442
- O 0 2.9437316698022187e-05
loaded O 0 9.214818419422954e-06
transferrin O 0 4.277066909708083e-05
, O 0 5.411463916971115e-06
implicating O 0 0.02816026285290718
HFE O 1 1.0
in O 0 0.0001134734702645801
iron O 1 0.9999957084655762
metabolism O 0 0.0010641544358804822
. O 0 0.0001492272858740762

The O 0 0.0007158938096836209
2 O 0 0.0011184068862348795
. O 0 0.0004764309851452708

6 O 0 0.00019176762725692242
A O 0 9.18293881113641e-05
crystal O 0 0.00011924965656362474
structure O 0 2.0555682567646727e-05
of O 0 3.672534876386635e-05
HFE O 1 0.9999998807907104
reveals O 0 3.357033710926771e-05
the O 0 2.1774342258140678e-06
locations O 0 1.6682022305758437e-06
of O 0 5.3171102081250865e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 6.7529567786550615e-06
and O 0 9.084155863092747e-07
a O 0 4.05179116569343e-06
patch O 1 0.9999939203262329
of O 0 0.21969309449195862
histidines O 1 0.9999589920043945
that O 0 6.510620096378261e-07
could O 0 3.5320448432685225e-07
be O 0 1.5020056309822394e-07
involved O 0 5.67383494853857e-07
in O 0 7.55216888137511e-07
pH O 0 6.866995681775734e-05
- O 0 7.027524407021701e-05
dependent O 0 5.41878671356244e-06
interactions O 0 5.316887381923152e-06
. O 0 2.361856786592398e-05

We O 0 4.863836511503905e-05
also O 0 1.1495945727801882e-05
demonstrate O 0 6.295579623838421e-06
that O 0 2.7099779345007846e-06
soluble O 0 5.926509038545191e-05
TfR O 0 0.03046584315598011
and O 0 5.471796612255275e-06
HFE O 1 0.9999066591262817
bind O 0 2.6445823095855303e-06
tightly O 0 3.9787769310350996e-06
at O 0 2.610190222185338e-06
the O 0 5.570639132201904e-07
basic O 0 1.2897929764221772e-06
pH O 0 5.257821612758562e-06
of O 0 1.0406486126157688e-06
the O 0 7.45632974030741e-07
cell O 0 1.2895175132143777e-06
surface O 0 1.6841504475451075e-06
, O 0 2.57320522223381e-07
but O 0 1.0884421897117136e-07
not O 0 1.0488169266409386e-07
at O 0 1.4885202972436673e-06
the O 0 1.310606648985413e-06
acidic O 0 2.420855344098527e-05
pH O 0 3.772750642383471e-05
of O 0 1.2379531654005405e-05
intracellular O 0 8.414780313614756e-05
vesicles O 0 0.0002658700686879456
. O 0 9.475853585172445e-05

TfR O 0 0.25969043374061584
HFE O 1 0.9601805806159973
stoichiometry O 0 0.00039442142588086426
( O 0 1.609849277883768e-05
2 O 0 1.2491993402363732e-05
1 O 0 8.370773684873711e-06
) O 0 1.3893524055674789e-06
differs O 0 2.0156498976575676e-06
from O 0 1.7152902955785976e-06
TfR O 0 7.390153768938035e-05
transferrin O 0 2.2614694898948073e-05
stoichiometry O 0 7.919006748124957e-06
( O 0 9.644328429203597e-07
2 O 0 1.7973754893318983e-06
2 O 0 1.7727459180605365e-06
) O 0 4.168240366198006e-07
, O 0 3.4402006576783606e-07
implying O 0 7.288808205885289e-07
a O 0 2.083578891642901e-07
different O 0 3.58797365151986e-08
mode O 0 5.147256274540268e-07
of O 0 2.735685313837166e-07
binding O 0 2.5808535042415315e-07
for O 0 4.3082880551992275e-07
HFE O 1 0.9801509380340576
and O 0 1.4900713267707033e-06
transferrin O 0 1.858666837506462e-05
to O 0 2.221754584752489e-06
TfR O 0 0.0026216991245746613
, O 0 8.246306606451981e-07
consistent O 0 7.027000492598745e-07
with O 0 1.8619422803567431e-07
our O 0 3.340076091262745e-07
demonstration O 0 3.86854071621201e-06
that O 0 8.144515390995366e-07
HFE O 1 0.9793463945388794
, O 0 3.4504464565543458e-06
transferrin O 0 3.375856613274664e-05
, O 0 2.5558802008163184e-06
and O 0 2.9247262318676803e-06
TfR O 0 0.00019414945563767105
form O 0 4.50085235570441e-06
a O 0 1.3889753063267563e-05
ternary O 0 0.0003019756404682994
complex O 0 0.0005466166185215116
. O 0 0.00011701436596922576

Identification O 0 3.221027145627886e-05
of O 0 8.575933861720841e-06
three O 0 1.2664876294365968e-06
novel O 0 7.403057225019438e-06
mutations O 0 6.305658644123469e-07
and O 0 2.62824471519707e-07
a O 0 6.630139637309185e-07
high O 0 2.421412546027568e-06
frequency O 0 7.44852570733201e-07
of O 0 5.435863954517117e-07
the O 0 1.0018917464549304e-06
Arg778Leu O 0 0.011943978257477283
mutation O 0 1.584195160830859e-06
in O 0 5.570958023781714e-07
Korean O 0 1.3765902622253634e-05
patients O 0 1.1105795465482515e-06
with O 0 1.4025919199411874e-06
Wilson B-Disease 1 0.9999469518661499
disease I-Disease 1 0.992130696773529
. O 0 4.2839208617806435e-05

Four O 0 3.63229846698232e-05
mutations O 0 9.78612297330983e-06
- O 0 1.9831059034913778e-05
- O 0 3.267583088018e-05
R778L O 0 0.00013610458699986339
, O 0 2.4133921669999836e-06
A874V O 0 3.504520282149315e-05
, O 0 1.4662846297142096e-06
L1083F O 0 2.6801875719684176e-05
, O 0 7.895380349509651e-07
and O 0 5.45888326541899e-07
2304delC O 0 1.6351830709027126e-05
- O 0 7.360761628660839e-06
- O 0 4.206041012366768e-06
in O 0 3.157185233249038e-07
the O 0 3.8852343209327955e-07
copper O 0 3.247664153605001e-06
- O 0 2.8097838367102668e-06
transporting O 0 2.387762833677698e-06
enzyme O 0 1.2802366882169736e-06
, O 0 7.390856922029343e-07
P O 0 9.479114851274062e-06
- O 0 8.185847036656924e-06
type O 0 6.657462563453009e-06
ATPase O 0 4.2565025069052354e-05
( O 0 1.6197536751860753e-06
ATP7B O 1 0.999258816242218
) O 0 7.109534294613695e-07
, O 0 3.2355839607589587e-07
were O 0 1.593360536844557e-07
identified O 0 3.7609680703099e-07
in O 0 2.8278009267523885e-07
Korean O 0 1.5281302694347687e-05
Patients O 0 2.1351640953071183e-06
with O 0 1.618947635506629e-06
Wilson B-Disease 1 0.9999899864196777
disease I-Disease 1 0.992994487285614
. O 0 6.43791863694787e-05

Arg778Leu O 1 0.9967781901359558
, O 0 2.422236320853699e-05
the O 0 7.0595438046439085e-06
most O 0 1.0976900739478879e-06
frequently O 0 9.402840532857226e-07
reported O 0 3.53909854311496e-07
mutation O 0 1.7378283700963948e-07
of O 0 1.7506317817606032e-07
this O 0 6.517558404084411e-08
enzyme O 0 1.7403111485236877e-07
, O 0 1.1801346033735172e-07
was O 0 6.277404622778704e-07
found O 0 9.13075695052612e-08
in O 0 5.5276370147794296e-08
six O 0 1.0198827737895044e-07
of O 0 2.584646665582113e-07
eight O 0 5.610081075246853e-07
unrelated O 0 1.737214915920049e-06
patients O 0 2.8836785759267514e-07
studied O 0 8.269129239124595e-07
, O 0 3.669958346108615e-07
an O 0 4.0280514213009155e-07
allele O 0 8.559474622416019e-07
frequency O 0 1.501626229583053e-06
of O 0 4.350677045295015e-06
37 O 0 4.368760346551426e-05
. O 0 3.546076186466962e-05

5 O 0 3.303023549960926e-05
% O 0 4.761395757668652e-06
, O 0 1.7783913790481165e-06
which O 0 3.2578154218754207e-07
is O 0 2.657760092006356e-07
considerably O 0 3.7029846566838387e-07
higher O 0 3.419352196942782e-07
than O 0 1.1832067059458495e-07
those O 0 1.0179607556892734e-07
in O 0 2.8739734148075513e-07
other O 0 6.060520263417857e-07
Asian O 0 8.84168275661068e-06
populations O 0 9.778408639249392e-06
. O 0 2.5356237529194914e-05

The O 0 6.354939978336915e-05
novel O 0 3.218576603103429e-05
single O 0 4.810424798051827e-06
nucleotide O 0 5.550145942834206e-06
deletion O 0 5.63995718039223e-06
, O 0 1.729590849208762e-06
2304delC O 0 3.9081463910406455e-05
, O 0 2.286601784362574e-06
was O 0 7.181123692134861e-06
found O 0 1.164786681329133e-06
in O 0 8.911180771065119e-07
one O 0 9.156721716863103e-06
patient O 0 3.6294768506195396e-05
. O 0 4.719587741419673e-05

Since O 0 5.1509465265553445e-05
a O 0 2.878395389416255e-05
mutation O 0 1.0826362085936125e-05
at O 0 7.083193850121461e-06
cDNA O 0 4.044248998980038e-05
nucleotide O 0 1.8905411707237363e-05
2302 O 0 0.00030540337320417166
( O 0 4.398720648168819e-06
2302insC O 0 3.38374957209453e-05
) O 0 1.1436003433118458e-06
had O 0 6.70962492677063e-07
been O 0 3.0356449087776127e-07
previously O 0 7.209725936263567e-07
described O 0 3.6170601447338413e-07
, O 0 1.8302631588085205e-07
this O 0 1.3363408868372062e-07
region O 0 3.297547550573654e-07
of O 0 5.751045364377205e-07
the O 0 1.6889193830138538e-06
ATP7B O 1 0.9999997615814209
gene O 0 1.0382734672020888e-06
may O 0 3.213829415926739e-07
be O 0 2.4498214656887285e-07
susceptible O 0 1.9242093003413174e-06
to O 0 8.372924185096053e-07
gene O 0 5.639010851155035e-06
rearrangements O 1 0.9026686549186707
causing O 1 0.9992998838424683
Wilson B-Disease 1 0.9999988079071045
disease I-Disease 1 0.9948522448539734
. O 0 6.14621676504612e-05

Disruption O 0 0.00019697642710525542
of O 0 1.2753993360092863e-05
splicing O 0 1.2875346328655723e-05
regulated O 0 3.26735994349292e-06
by O 0 7.315207994906814e-07
a O 0 2.863729378077551e-06
CUG O 1 0.9062056541442871
- O 0 3.029752588190604e-05
binding O 0 5.625700396194588e-06
protein O 0 1.310611787630478e-05
in O 0 1.3642010344483424e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.005894538015127182

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999961853027344
DM B-Disease 1 1.0
) O 0 0.001016391208395362
is O 0 3.8831703932373784e-06
caused O 0 2.06088134291349e-06
by O 0 5.128118232278212e-07
a O 0 6.2023218561080284e-06
CTG O 1 0.9995865225791931
expansion O 0 1.9859542589983903e-05
in O 0 1.1262378620813251e-06
the O 0 9.906784725899342e-07
3 O 0 5.5368500397889875e-06
untranslated O 0 0.00013605112326331437
region O 0 5.111851351102814e-06
of O 0 7.371396804956021e-06
the O 0 2.493786632840056e-05
DM B-Disease 1 1.0
gene O 0 0.0002586203918326646
. O 0 0.00010638633830239996

One O 0 6.445505277952179e-05
model O 0 3.167754039168358e-05
of O 0 0.00012097034777980298
DM B-Disease 1 1.0
pathogenesis O 1 1.0
suggests O 0 9.128122655965853e-06
that O 0 7.236764076878899e-07
RNAs O 0 7.773517609166447e-06
from O 0 5.110396159579977e-07
the O 0 4.697798772212991e-07
expanded O 0 9.664612434789888e-07
allele O 0 1.0106244872076786e-06
create O 0 7.569099125248613e-07
a O 0 7.148559575398394e-07
gain O 0 1.4190982255968265e-06
- O 0 3.711183126142714e-06
of O 0 2.11918268178124e-06
- O 0 5.247842636890709e-06
function O 0 4.807902200809622e-07
mutation O 0 2.6788302420754917e-07
by O 0 6.412757613816211e-08
the O 0 1.8665166123810195e-07
inappropriate O 0 5.425707740869257e-07
binding O 0 1.87968367981739e-07
of O 0 7.079973443069321e-07
proteins O 0 2.798755360799987e-07
to O 0 6.378764965120354e-07
the O 0 6.951793693588115e-06
CUG O 1 0.9993507266044617
repeats O 0 0.00010969984577968717
. O 0 9.665328252594918e-05

Data O 0 3.521972757880576e-05
presented O 0 2.3924307242850773e-05
here O 0 3.394627128727734e-06
indicate O 0 2.2013116449670633e-06
that O 0 5.747393743149587e-07
the O 0 1.431064788448566e-06
conserved O 0 1.2178660654171836e-05
heterogeneous O 0 1.5043257917568553e-05
nuclear O 0 3.798696707235649e-05
ribonucleoprotein O 0 0.003120811190456152
, O 0 2.485507593519287e-06
CUG O 0 0.0001355540007352829
- O 0 4.431132310855901e-06
binding O 0 7.607366114825709e-07
protein O 0 7.590351174258103e-07
( O 0 8.42124507016706e-07
CUG O 1 0.9940296411514282
- O 0 4.312300734454766e-05
BP O 0 0.00011972078209510073
) O 0 8.274350875581149e-07
, O 0 8.069674777289038e-07
may O 0 4.698179907336453e-07
mediate O 0 3.5069163004664006e-06
the O 0 1.3192567394071375e-06
trans O 0 9.987084013118874e-06
- O 0 1.2520213203970343e-05
dominant O 0 8.847334356687497e-06
effect O 0 1.5731866369605996e-06
of O 0 4.336253368819598e-06
the O 0 8.650153176859021e-06
RNA O 0 0.00010591919271973893
. O 0 6.441628647735342e-05

CUG O 1 0.9999967813491821
- O 0 0.22802968323230743
BP O 0 0.01771523803472519
was O 0 1.6226609659497626e-05
found O 0 6.336342153190344e-07
to O 0 2.0267128775230958e-07
bind O 0 2.8604137014554e-07
to O 0 3.901288891938748e-07
the O 0 1.3073920399619965e-06
human O 0 5.5925079323060345e-06
cardiac O 1 0.9999998807907104
troponin O 1 1.0
T O 1 0.9996411800384521
( O 0 3.63703588845965e-06
cTNT O 0 4.906274989480153e-05
) O 0 9.860541467787698e-07
pre O 0 8.965411325334571e-06
- O 0 9.123884410655592e-06
messenger O 0 6.9155044002400246e-06
RNA O 0 4.247745891916566e-06
and O 0 5.822533921673312e-07
regulate O 0 1.6711796888557728e-06
its O 0 1.4313841347757261e-06
alternative O 0 8.32171099318657e-06
splicing O 0 4.657404133467935e-05
. O 0 4.801080285687931e-05

Splicing O 0 0.00019008407252840698
of O 0 4.0885686757974327e-05
cTNT O 1 0.8132925629615784
was O 0 0.0007819496677257121
disrupted O 0 8.691189577803016e-05
in O 0 2.018369013967458e-05
DM B-Disease 1 1.0
striated O 1 1.0
muscle O 1 0.8484541773796082
and O 0 2.749170107563259e-06
in O 0 1.7238243117390084e-06
normal O 0 2.4684570689714747e-06
cells O 0 1.0284716154274065e-06
expressing O 0 1.7457347212257446e-06
transcripts O 0 9.184322152577806e-06
that O 0 1.9647616227302933e-06
contain O 0 1.6640402463963255e-05
CUG O 1 0.9835739135742188
repeats O 0 0.00013534991012420505
. O 0 7.718333654338494e-05

Altered O 0 0.00013323669554665685
expression O 0 1.691809120529797e-05
of O 0 9.514707926427945e-06
genes O 0 3.554309614628437e-06
regulated O 0 4.944688498653704e-06
posttranscriptionally O 0 5.66823837289121e-05
by O 0 2.192062765971059e-06
CUG O 1 0.9999997615814209
- O 1 0.721005916595459
BP O 0 0.03951835259795189
therefore O 0 1.8269059864906012e-06
may O 0 8.706331300345482e-07
contribute O 0 1.6110049045892083e-06
to O 0 4.8005804273998365e-06
DM B-Disease 1 1.0
pathogenesis O 1 1.0
. O 0 6.091461546020582e-05
. O 0 0.00013535314064938575

Identification O 0 7.172163168434054e-05
of O 0 1.854198308137711e-05
a O 0 1.0245079465676099e-05
novel O 0 2.5607114366721362e-05
nonsense O 0 3.309376916149631e-05
mutation O 0 1.2778629070453462e-06
and O 0 4.647684193059831e-07
a O 0 8.469400540889183e-07
missense O 0 6.315887276286958e-06
substitution O 0 1.888637029878737e-06
in O 0 5.368441975406313e-07
the O 0 1.0806585351019748e-06
vasopressin O 0 2.4435395971522667e-05
- O 0 5.306870298227295e-05
neurophysin O 1 0.6966297626495361
II O 1 0.9999978542327881
gene O 0 1.074380861609825e-06
in O 0 2.7480484732222976e-07
two O 0 2.7695620019585476e-07
Spanish O 0 7.027080300758826e-06
kindreds O 0 4.625791552825831e-05
with O 0 5.835881893290207e-06
familial B-Disease 1 0.9999855756759644
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 0.0004920042119920254

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.9992188215255737
FNDI B-Disease 1 1.0
) O 0 9.864653293334413e-06
is O 0 2.869938271032879e-06
an O 0 2.6203786092082737e-06
autosomal B-Disease 1 0.9999289512634277
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.950626015663147
by O 0 6.339392257359577e-06
deficiency O 1 0.9999991655349731
in O 0 2.7856910946866265e-06
the O 0 1.4700336578243878e-05
antidiuretic O 1 0.7575758099555969
hormone O 0 1.2473696187953465e-05
arginine O 0 1.4727783309353981e-05
vasopressin O 0 3.210777504136786e-05
( O 0 3.5122980079904664e-06
AVP O 0 0.017978236079216003
) O 0 8.136006499626092e-07
encoded O 0 2.7669454993883846e-07
by O 0 1.361208177286244e-07
the O 0 1.0926224831564468e-06
AVP O 1 0.999996542930603
- O 0 0.04124639928340912
neurophysin O 1 0.999796450138092
II O 1 1.0
( O 0 2.092965405608993e-05
AVP O 1 1.0
- O 0 0.2515747845172882
NPII O 1 0.9997218251228333
) O 0 4.34638059232384e-06
gene O 0 2.387664835623582e-06
on O 0 5.493296612257836e-06
chromosome O 0 3.4853695979109034e-05
20p13 O 0 0.0005553687806241214
. O 0 9.535405843053013e-05

In O 0 1.20300292110187e-05
this O 0 2.105239218508359e-06
study O 0 1.1747396229111473e-06
, O 0 6.542817914123589e-07
we O 0 1.8106193522271496e-07
analyzed O 0 5.533395892598492e-07
two O 0 1.7189341861012508e-07
families O 0 9.659409272444464e-08
with O 0 2.767302191841736e-07
FNDI B-Disease 1 0.9999994039535522
using O 0 8.165630447365402e-07
direct O 0 5.654998176396475e-07
automated O 0 4.982699465472251e-06
fluorescent O 0 1.0954229765047785e-05
, O 0 1.0802535825860105e-06
solid O 0 2.2569597604160663e-06
phase O 0 2.790945472952444e-06
, O 0 5.237560571913491e-07
single O 0 7.431432891280565e-07
- O 0 1.9635217540781014e-06
stranded O 0 1.7076679341698764e-06
DNA O 0 4.476852097923256e-07
sequencing O 0 1.0186818144575227e-06
of O 0 1.7745795730661484e-06
PCR O 0 1.985868948395364e-05
- O 0 7.40756731829606e-05
amplified O 0 0.00012472351954784244
AVP O 1 0.9999961853027344
- O 0 0.029463650658726692
NPII O 1 0.9964041709899902
DNA O 0 0.00010114034375874326
. O 0 5.6221459090011194e-05

In O 0 7.4995564318669494e-06
one O 0 2.3335473997576628e-06
of O 0 1.3840440260537434e-06
the O 0 9.799886129258084e-07
families O 0 1.606185122682291e-07
, O 0 2.956238631668384e-07
affected O 0 1.618936806835336e-07
individuals O 0 5.792571045049044e-08
presented O 0 4.885292241851857e-07
a O 0 7.510253681175527e-07
novel O 0 2.612023081383086e-06
nonsense O 0 4.726884526462527e-06
mutation O 0 3.1282394274967373e-07
in O 0 1.2897336887363053e-07
exon O 0 2.272061465191655e-06
3 O 0 5.211855409470445e-07
of O 0 2.984272384765063e-07
the O 0 1.606353521310666e-07
gene O 0 1.6253787293862842e-07
, O 0 1.5640016215456853e-07
consisting O 0 2.4754959326855897e-07
in O 0 8.430712483686875e-08
a O 0 6.352254899866239e-07
G O 0 7.206974714790704e-06
to O 0 6.156106451271626e-07
T O 0 1.1696371075231582e-05
transition O 0 8.758680110076966e-07
at O 0 1.8860146155930124e-06
nucleotide O 0 1.886020072561223e-06
2101 O 0 3.248697976232506e-05
, O 0 7.340912020481483e-07
which O 0 1.1763804508291287e-07
produces O 0 3.407788824461022e-07
a O 0 4.48039315870119e-07
stop O 0 8.924014309741324e-07
signal O 0 1.5835441899980651e-06
in O 0 6.832896701780555e-07
codon O 0 9.119040441873949e-06
82 O 0 1.1843602806038689e-05
( O 0 5.205792604101589e-06
Glu O 1 0.9408355951309204
) O 0 9.33269075176213e-06
of O 0 4.471419379115105e-05
NPII O 1 0.9999009370803833
. O 0 0.0001949632860487327

The O 0 9.4998387794476e-05
premature O 0 6.289609154919162e-05
termination O 0 3.0131930543575436e-05
eliminates O 0 2.7518677597981878e-05
part O 0 3.1201341244013747e-06
of O 0 2.0039522041770397e-06
the O 0 1.5104188832992804e-06
C O 0 1.839741162257269e-05
- O 0 7.350996838795254e-06
terminal O 0 5.40828568773577e-06
domain O 0 1.011288759400486e-06
of O 0 1.678480657574255e-06
NPII O 1 0.9999239444732666
, O 0 7.72959026562603e-07
including O 0 2.925622766269953e-07
a O 0 4.4505705432129616e-07
cysteine O 0 7.045977667985426e-07
residue O 0 1.3345786555873929e-06
in O 0 1.1382932996184536e-07
position O 0 3.5020525501749944e-07
85 O 0 1.3400626812654082e-06
, O 0 2.2343093064591812e-07
which O 0 1.0550709816925519e-07
could O 0 1.1070174110727748e-07
be O 0 8.84868498474134e-08
involved O 0 1.405540217547241e-07
in O 0 1.4654665392299648e-07
the O 0 4.653476253224653e-07
correct O 0 1.3548403785534902e-06
folding O 0 1.9802069800789468e-05
of O 0 9.32429338718066e-06
the O 0 5.665380012942478e-05
prohormone O 1 0.9994580149650574
. O 0 8.964804146671668e-05

In O 0 2.0945506548741832e-05
the O 0 6.881274657644099e-06
second O 0 5.334496108844178e-06
family O 0 2.1076095890748547e-06
, O 0 8.880350605977583e-07
a O 0 1.0064867410619627e-06
G279A O 0 1.0235498848487623e-05
substitution O 0 1.722852971397515e-06
at O 0 1.5905137615845888e-06
position O 0 1.1162974260514602e-06
- O 0 1.2169684850960039e-06
1 O 0 1.2744587820634479e-06
of O 0 5.157850182513357e-07
the O 0 4.226214969094144e-07
signal O 0 1.5669428421460907e-06
peptide O 0 2.043088898062706e-06
was O 0 2.5455974537180737e-06
observed O 0 5.592249863184406e-07
in O 0 2.3849742092352244e-07
all O 0 3.8036392879803316e-07
affected O 0 1.2433688425517175e-06
individuals O 0 1.0540125003899448e-06
. O 0 1.7639897123444825e-05

This O 0 3.0053015507292002e-05
missense O 0 0.00010744726023403928
mutation O 0 8.096832971205004e-06
, O 0 2.348908537896932e-06
which O 0 1.0533332215345581e-06
replaces O 0 6.385154119925573e-05
Ala O 1 0.8819352984428406
with O 0 4.3105337681481615e-06
Thr O 1 0.9999998807907104
, O 0 6.599257176276296e-06
is O 0 1.1027369737348636e-06
frequent O 0 2.713132971621235e-06
among O 0 8.51923232403351e-06
FNDI B-Disease 1 1.0
patients O 0 3.8306006899802014e-05
and O 0 9.353185532745556e-07
is O 0 6.798264848839608e-07
thought O 0 6.183177561069897e-07
to O 0 1.6462642804526695e-07
reduce O 0 5.910752634008531e-07
the O 0 6.632998292843695e-07
efficiency O 0 1.5790697034390178e-06
of O 0 9.409873200638685e-07
cleavage O 0 4.3125564843649045e-06
by O 0 8.92637217475567e-07
signal O 0 1.8592943888506852e-05
peptidases O 0 0.0001460709172533825
. O 0 1.0045389899460133e-05
. O 0 4.718813215731643e-05

Genetic O 0 0.00015536528371740133
heterogeneity O 0 0.0002541767607908696
of O 0 0.00031065967050381005
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.4729548588074977e-06
due O 0 2.2039459963707486e-06
to O 0 2.1961325273878174e-06
TWIST O 0 0.0018250617431476712
and O 0 1.3837384358339477e-05
FGFR O 1 0.9999967813491821
mutations O 0 8.754439477343112e-05
. O 0 6.782307173125446e-05

Thirty O 0 0.0005179232102818787
- O 0 0.00014399133215192705
two O 0 3.771696810872527e-06
unrelated O 0 1.634649743209593e-05
patients O 0 1.2640332442970248e-06
with O 0 1.7808511643124803e-07
features O 0 3.0614726256317226e-06
of O 0 0.0009311074973084033
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.14260318595916e-06
a O 0 6.064525678084465e-06
common O 0 2.159274481527973e-05
autosomal B-Disease 1 0.8704021573066711
dominant I-Disease 1 0.999638557434082
condition I-Disease 0 0.10760648548603058
of O 1 0.9978482723236084
craniosynostosis B-Disease 1 1.0
and O 1 0.9790448546409607
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9999704360961914
, O 0 1.1032250313292025e-06
were O 0 2.5436241912757396e-07
screened O 0 9.305496746492281e-07
for O 0 2.0437700243292056e-07
mutations O 0 3.029149411304388e-07
in O 0 4.853648647440423e-07
TWIST O 0 0.00037722158594988286
, O 0 5.617583610728616e-06
FGFR2 O 1 0.999988317489624
, O 0 1.2634833183255978e-05
and O 0 2.6388477635919116e-05
FGFR3 O 1 0.9998373985290527
. O 0 0.00035539318923838437

Nine O 0 0.0001262130099348724
novel O 0 9.580165351508185e-05
and O 0 4.809961410501273e-06
three O 0 3.388178356544813e-06
recurrent O 1 0.801235556602478
TWIST O 1 0.9894997477531433
mutations O 0 4.9844484237837605e-06
were O 0 6.292394800766488e-07
found O 0 6.21251842858328e-07
in O 0 9.102965918827977e-07
12 O 0 6.279569333855761e-06
families O 0 3.893612756655784e-06
. O 0 2.006749673455488e-05

Seven O 0 5.6425891671096906e-05
families O 0 2.3928987502586097e-06
were O 0 9.212517966261657e-07
found O 0 3.558284049631766e-07
to O 0 1.6901280730508006e-07
have O 0 1.2908866153793497e-07
the O 0 7.142766662582289e-07
FGFR3 O 1 0.9999047517776489
P250R O 0 0.00024286715779453516
mutation O 0 1.1879785688506672e-06
, O 0 2.9157013159419876e-07
and O 0 1.5464217995031504e-07
one O 0 2.3148523098370788e-07
individual O 0 9.372099896154396e-08
was O 0 1.5047713759486214e-06
found O 0 2.5214214360858023e-07
to O 0 1.715912247846063e-07
have O 0 2.7221366849516926e-07
an O 0 2.3493832941312576e-06
FGFR2 O 1 0.8763989210128784
VV269 O 0 0.0002853108453564346
- O 0 7.241547427838668e-05
270 O 0 8.927923045121133e-05
deletion O 0 9.955395216820762e-05
. O 0 8.674033597344533e-05

To O 0 1.6258192772511393e-05
date O 0 7.09821870259475e-06
, O 0 1.30733099013014e-06
our O 0 3.3771277685445966e-07
detection O 0 2.0015800146211404e-06
rate O 0 2.722134126997844e-07
for O 0 2.4861517999852367e-07
TWIST O 0 3.2032599847298115e-05
or O 0 1.1824976127172704e-06
FGFR O 1 0.9323145151138306
mutations O 0 8.632038657196972e-07
is O 0 2.097790599009386e-07
68 O 0 1.619135900909896e-06
% O 0 2.653713124800561e-07
in O 0 2.2167060365063662e-07
our O 0 6.437991260099807e-07
Saethre B-Disease 1 0.9999909400939941
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 9.261600098398048e-06
, O 0 8.387262369069504e-07
including O 0 5.271078862278955e-07
our O 0 9.069319162335887e-07
five O 0 1.0159740213566693e-06
patients O 0 8.24767482754396e-07
elsewhere O 0 5.42119778401684e-07
reported O 0 8.679537017997063e-07
with O 0 1.3784786005999194e-06
TWIST O 0 0.0013991917949169874
mutations O 0 4.390067988424562e-05
. O 0 5.8007455663755536e-05

More O 0 7.301516234292649e-06
than O 0 1.4579503613276756e-06
35 O 0 1.916601377160987e-06
different O 0 2.423396097128716e-07
TWIST O 0 8.917572813516017e-06
mutations O 0 4.879876769336988e-07
are O 0 1.0232283642608309e-07
now O 0 5.397415634433855e-07
known O 0 8.522210350747628e-07
in O 0 6.766493356735737e-07
the O 0 3.2223042580881156e-06
literature O 0 2.341441904718522e-05
. O 0 2.7785863494500518e-05

The O 0 5.06949691043701e-05
most O 0 6.4570676840958185e-06
common O 0 2.709719638005481e-06
phenotypic O 0 4.7111334424698725e-06
features O 0 4.771924523083726e-06
, O 0 1.1027664186258335e-06
present O 0 3.2632539159749285e-07
in O 0 1.0912899739423665e-07
more O 0 3.828085937129799e-08
than O 0 6.89525450070505e-08
a O 0 2.2088876505677035e-07
third O 0 4.980373091711954e-07
of O 0 4.96056827614666e-07
our O 0 3.0854380383971147e-07
patients O 0 1.8405992818770756e-07
with O 0 1.6436349881132628e-07
TWIST O 0 0.00014326108794193715
mutations O 0 9.950853154805372e-07
, O 0 5.913965992476733e-07
are O 0 4.881566155745531e-07
coronal B-Disease 0 0.004030674230307341
synostosis I-Disease 1 0.6053350567817688
, O 0 4.953059942636173e-06
brachycephaly B-Disease 0 0.003635549917817116
, O 0 4.6567533900088165e-06
low B-Disease 0 5.745078669860959e-05
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 7.463767542503774e-05
facial B-Disease 1 0.9995015859603882
asymmetry I-Disease 1 0.9445058703422546
, O 0 2.8432777980924584e-05
ptosis B-Disease 1 0.9999984502792358
, O 0 1.075695672625443e-05
hypertelorism B-Disease 1 0.9987311959266663
, O 0 1.0714304153225385e-05
broad B-Disease 0 4.1993036575149745e-05
great I-Disease 0 0.003825642867013812
toes I-Disease 1 0.87836092710495
, O 0 1.4644282600784209e-05
and O 0 1.647992030484602e-05
clinodactyly B-Disease 0 0.3957761824131012
. O 0 0.0001838420721469447

Significant O 0 0.00023219772265292704
intra O 0 0.0008205464109778404
- O 0 0.00013405585195869207
and O 0 5.820840669912286e-06
interfamilial O 0 0.00014720686885993928
phenotypic O 0 2.436753857182339e-05
variability O 0 2.0124145521549508e-05
is O 0 9.552353503750055e-07
present O 0 3.2354483892049757e-07
for O 0 5.64738797947939e-07
either O 0 8.193799772016064e-07
TWIST O 0 0.00012911112571600825
mutations O 0 5.904548743274063e-06
or O 0 8.549345693609212e-06
FGFR O 1 0.9999895095825195
mutations O 0 6.880682485643774e-05
. O 0 5.5847202020231634e-05

The O 0 2.7535847038961947e-05
overlap O 0 1.0628583368088584e-05
in O 0 2.02574415197887e-06
clinical O 0 9.145515832642559e-06
features O 0 2.6887812509812647e-06
and O 0 6.53200743272464e-07
the O 0 1.0747272654043627e-06
presence O 0 1.3116143691149773e-06
, O 0 2.834929375694628e-07
in O 0 9.706763393069195e-08
the O 0 1.250595147439526e-07
same O 0 6.328057366999928e-08
genes O 0 7.917746813745907e-08
, O 0 8.000482409897813e-08
of O 0 1.9362946090950572e-07
mutations O 0 8.27417920845619e-08
for O 0 7.353482800454003e-08
more O 0 5.578657180649316e-08
than O 0 9.153442448450733e-08
one O 0 4.80731500829279e-07
craniosynostotic B-Disease 0 0.0007919050403870642
condition I-Disease 0 1.2732913319268846e-06
- O 0 2.1172998003748944e-06
such O 0 2.9330595907595125e-07
as O 0 1.0047651812783442e-06
Saethre B-Disease 0 0.11602377146482468
- I-Disease 0 0.0002169052604585886
Chotzen I-Disease 1 0.639962375164032
, I-Disease 0 2.045594328592415e-06
Crouzon I-Disease 0 0.005990673787891865
, I-Disease 0 2.0834208953601774e-06
and I-Disease 0 1.985846438401495e-06
Pfeiffer I-Disease 1 0.9999988079071045
syndromes I-Disease 1 0.8499062061309814
- O 0 2.8213646146468818e-05
support O 0 1.3062890502624214e-06
the O 0 1.1625759270827984e-06
hypothesis O 0 1.266746039618738e-06
that O 0 1.759084966579394e-07
TWIST O 0 1.2509602129284758e-05
and O 0 5.427611995401094e-07
FGFRs O 0 0.00021671610011253506
are O 0 1.1741623495709064e-07
components O 0 3.5779828522208845e-07
of O 0 3.7174598332967435e-07
the O 0 3.0057543654038454e-07
same O 0 1.8069708573875687e-07
molecular O 0 1.196849552798085e-06
pathway O 0 1.0641946346368059e-06
involved O 0 2.780348893338669e-07
in O 0 1.0307993392189019e-07
the O 0 4.2060628402396105e-07
modulation O 0 9.197707186103798e-06
of O 0 0.00026549166068434715
craniofacial O 1 1.0
and O 0 0.2881110608577728
limb O 1 0.9999998807907104
development O 0 6.881406079628505e-06
in O 0 2.7076787318947027e-06
humans O 0 2.3581737877975684e-06
. O 0 2.287735924255685e-06
. O 0 1.5872918083914556e-05

Mutation O 0 7.006626401562244e-05
analysis O 0 1.2790756045433227e-05
of O 0 2.904621396737639e-05
UBE3A O 1 1.0
in O 1 0.9999957084655762
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9998111128807068
. O 0 0.0004055459576193243

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9918952584266663
AS B-Disease 1 1.0
) O 0 1.2271895684534684e-05
is O 0 1.970024186448427e-06
caused O 0 1.3554167708207387e-06
by O 0 3.6093172184337163e-07
chromosome O 0 3.892669610650046e-06
15q11 O 0 6.76256458973512e-05
- O 0 2.3020051230560057e-05
q13 O 0 5.174321631784551e-05
deletions O 0 7.851717782614287e-06
of O 0 2.765800672932528e-06
maternal O 0 2.036339083133498e-06
origin O 0 4.2080688444912084e-07
, O 0 3.9013931996123574e-07
by O 0 4.5597897724292125e-07
paternal O 0 1.4544948498951271e-05
uniparental B-Disease 1 0.9999997615814209
disomy I-Disease 1 0.9999998807907104
( O 0 0.00012654128659050912
UPD B-Disease 1 1.0
) O 0 2.3197371774585918e-06
15 O 0 1.7998316934608738e-06
, O 0 3.241619310756505e-07
by O 0 2.345858831631631e-07
imprinting O 0 4.2387484427308664e-05
defects O 0 0.004093716852366924
, O 0 1.255738084182667e-06
and O 0 5.52196183889464e-07
by O 0 4.3904589119847515e-07
mutations O 0 1.0606737532725674e-06
in O 0 2.111734147547395e-06
the O 0 1.5994784916983917e-05
UBE3A O 1 0.999990701675415
gene O 0 0.00013770400255452842
. O 0 8.702152990736067e-05

UBE3A O 1 0.5062891244888306
encodes O 0 0.00036485324380919337
a O 0 5.064524521003477e-05
ubiquitin O 0 0.00014396235928870738
- O 0 5.561229772865772e-05
protein O 0 9.44077328313142e-06
ligase O 0 2.2121321308077313e-05
and O 0 2.3558854991279077e-06
shows O 0 5.430104920378653e-06
brain O 0 3.971695332438685e-05
- O 0 5.3664127335650846e-05
specific O 0 1.1173753591720015e-05
imprinting O 0 0.0003492767282295972
. O 0 8.028718730201945e-05

Here O 0 3.5846798709826544e-05
we O 0 1.2193536349514034e-05
describe O 0 1.8308934158994816e-05
UBE3A O 1 0.7000111937522888
coding O 0 0.00012829131446778774
- O 0 0.0005126887117512524
region O 0 9.197136023431085e-06
mutations O 0 1.592529429217393e-06
detected O 0 9.222891321769566e-07
by O 0 2.0930744426550518e-07
SSCP O 0 0.054783571511507034
analysis O 0 4.2501753227952577e-07
in O 0 2.9475171459125704e-07
13 O 0 3.4195161333627766e-06
AS B-Disease 0 0.4181971549987793
individuals O 0 5.424512892204802e-07
or O 0 3.546853349689627e-06
families O 0 5.0170074246125296e-06
. O 0 1.981034074560739e-05

Two O 0 3.584146543289535e-05
identical O 0 1.8077196727972478e-05
de O 0 9.578036406310275e-05
novo O 0 0.00013390560343395919
5 O 0 3.3510714274598286e-05
- O 0 3.224364627385512e-05
bp O 0 2.5173609174089506e-05
duplications O 0 3.344571086927317e-05
in O 0 1.6460803635709453e-06
exon O 0 3.4021282772300765e-05
16 O 0 1.2565751603688113e-05
were O 0 6.025070888426853e-06
found O 0 1.1624579201452434e-05
. O 0 3.1573970773024485e-05

Among O 0 2.4758579456829466e-05
the O 0 5.191820946492953e-06
other O 0 1.0792608691190253e-06
11 O 0 1.7729116734699346e-06
unique O 0 9.373447369398491e-07
mutations O 0 5.018166007175751e-07
, O 0 3.610470571402402e-07
8 O 0 1.3473002127284417e-06
were O 0 3.5430429079497117e-07
small O 0 6.343089467009122e-07
deletions O 0 2.842476305886521e-06
or O 0 7.628377147739229e-07
insertions O 0 9.029869943333324e-06
predicted O 0 2.68041958406684e-06
to O 0 5.494692345564545e-07
cause O 0 1.7592623180462397e-06
frameshifts O 0 4.134079426876269e-05
, O 0 6.226255209185183e-07
1 O 0 1.2528098523034714e-06
was O 0 2.200220251324936e-06
a O 0 6.547462021444517e-07
mutation O 0 3.068055889343668e-07
to O 0 1.1260826937586899e-07
a O 0 3.3433329349463747e-07
stop O 0 6.10693575708865e-07
codon O 0 1.4622963817600976e-06
, O 0 2.0024438640575681e-07
1 O 0 6.2018392554819e-07
was O 0 1.21038613087876e-06
a O 0 7.066529406074551e-07
missense O 0 4.166588951193262e-06
mutation O 0 7.839079785298964e-07
, O 0 2.7998925133942976e-07
and O 0 1.358808674467582e-07
1 O 0 1.4986304677222506e-06
was O 0 2.187096924899379e-06
predicted O 0 5.708391199732432e-07
to O 0 2.0843420145411073e-07
cause O 0 5.215554210735718e-07
insertion O 0 1.2613046465048683e-06
of O 0 8.034443226279109e-07
an O 0 5.765015202996437e-07
isoleucine O 0 2.4569848392275162e-05
in O 0 3.75075245528933e-07
the O 0 6.816026711931045e-07
hect O 0 1.4918052329448983e-05
domain O 0 1.0094839808516554e-06
of O 0 7.506916404054209e-07
the O 0 1.283476194657851e-06
UBE3A O 1 0.8703432083129883
protein O 0 9.727241376822349e-07
, O 0 2.0084110019524815e-07
which O 0 1.1110026321148325e-07
functions O 0 1.4071470388898888e-07
in O 0 2.5430929895264853e-07
E2 O 0 2.9684377295779996e-05
binding O 0 1.0011295898948447e-06
and O 0 1.292637421101972e-06
ubiquitin O 0 5.654434426105581e-05
transfer O 0 4.1016945033334196e-05
. O 0 5.0182232371298596e-05

Eight O 0 2.043715176114347e-05
of O 0 4.939310656482121e-06
the O 0 2.2188114598975517e-06
cases O 0 7.380516535704373e-07
were O 0 9.060509569280839e-07
familial O 0 0.04161226376891136
, O 0 5.803529802506091e-06
and O 0 9.741963822307298e-07
five O 0 2.6904021979134995e-06
were O 0 3.534609277267009e-06
sporadic O 0 4.974948751623742e-05
. O 0 4.920030914945528e-05

In O 0 2.698043863347266e-05
two O 0 4.452032044355292e-06
familial O 0 5.2235274779377505e-05
cases O 0 2.3056525151332607e-06
and O 0 1.5645446183043532e-06
one O 0 1.8008825009019347e-06
sporadic O 0 1.037284528138116e-05
case O 0 2.7950741241511423e-06
, O 0 1.6572925005675643e-06
mosaicism O 0 0.00016706738097127527
for O 0 2.5240321974706603e-06
UBE3A O 1 0.9999967813491821
mutations O 0 2.0146812858001795e-06
was O 0 3.546772177287494e-06
detected O 0 5.761409624938096e-07
in O 0 1.4993865704582277e-07
the O 0 2.2058478066355747e-07
mother O 0 3.0947560958338727e-07
of O 0 1.9916072346859437e-07
three O 0 1.641456037759781e-07
AS B-Disease 1 0.9862139821052551
sons O 0 4.8657630031812005e-06
, O 0 2.056295898000826e-07
in O 0 5.737000918770718e-08
the O 0 1.7294675558332528e-07
maternal O 0 4.437542315827159e-07
grandfather O 0 1.9032646605410264e-06
of O 0 5.786872634416795e-07
two O 0 1.2347551603397733e-07
AS B-Disease 1 0.5431171655654907
first O 0 1.0065904234579648e-06
cousins O 0 1.6881430155990529e-06
, O 0 3.4649579561119026e-07
and O 0 1.0395699234777567e-07
in O 0 1.0405955208625528e-07
the O 0 2.415081041817757e-07
mother O 0 6.714182632094889e-07
of O 0 9.243953513760061e-07
an O 0 2.100898882417823e-06
AS B-Disease 1 0.9998283386230469
daughter O 0 0.0004531146551016718
. O 0 8.476616494590417e-05

The O 0 2.3068065274856053e-05
frequencies O 0 7.041100616334006e-06
with O 0 4.684829093548615e-07
which O 0 3.189056201335916e-07
we O 0 3.1199121508507233e-07
detected O 0 6.029883934388636e-07
mutations O 0 1.948773160620476e-07
were O 0 1.1799613730545389e-07
5 O 0 4.7131553060353326e-07
( O 0 1.9414201801737363e-07
14 O 0 3.305485165583377e-07
% O 0 1.0804910033357373e-07
) O 0 1.0230156277657443e-07
of O 0 2.5985389129346004e-07
35 O 0 1.126469896917115e-06
in O 0 1.514095089305556e-07
sporadic O 0 1.000119937089039e-06
cases O 0 1.3802541332097462e-07
and O 0 1.237067692727578e-07
8 O 0 6.434762553908513e-07
( O 0 2.0047481541496381e-07
80 O 0 4.4869480575471243e-07
% O 0 8.131587492243852e-08
) O 0 1.0637943148594786e-07
of O 0 3.672514310437691e-07
10 O 0 1.0292291108271456e-06
in O 0 1.05680453543755e-06
familial O 0 2.41982579609612e-05
cases O 0 4.2962187762896065e-06
. O 0 8.838934263621923e-06
. O 0 3.531941547407769e-05

The O 0 0.0006871343939565122
hemochromatosis B-Disease 1 1.0
845 O 1 0.9997803568840027
G O 1 0.924730658531189
- O 0 0.0035309132654219866
- O 0 8.182165765902027e-05
> O 0 1.7163298252853565e-05
A O 0 7.621318673045607e-06
and O 0 7.092901910255023e-07
187 O 0 4.923043888993561e-06
C O 0 1.4612823179049883e-05
- O 0 1.378216256853193e-05
- O 0 2.0269042579457164e-05
> O 0 1.374965904687997e-05
G O 0 2.794989268295467e-05
mutations O 0 9.059576200343145e-07
: O 0 4.834707283407624e-07
prevalence O 0 1.9001325881617959e-06
in O 0 5.630700457004423e-07
non O 0 1.3574058357335161e-05
- O 0 0.10073473304510117
Caucasian O 0 0.04134877398610115
populations O 0 2.2106265532784164e-05
. O 0 2.5116009055636823e-05

Hemochromatosis B-Disease 1 1.0
, O 0 0.00020576242241077125
the O 0 0.04808352142572403
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.9997715353965759
, O 0 1.0141454367840197e-05
leads O 0 1.1233652003284078e-05
, O 0 5.76377260586014e-07
if O 0 5.22393747814931e-07
untreated O 0 0.03180864825844765
, O 0 6.30971328519081e-07
to O 0 6.536257046718674e-07
progressive O 1 0.9932616353034973
iron B-Disease 1 1.0
overload I-Disease 1 0.9999991655349731
and O 0 7.08920561010018e-05
premature B-Disease 0 0.000492826453410089
death I-Disease 0 0.00017856477643363178
. O 0 7.226468733279034e-05

The O 0 0.00031888572266325355
hemochromatosis B-Disease 1 1.0
gene O 0 4.6698838559677824e-05
, O 0 1.901299401652068e-05
HFE O 1 1.0
, O 0 1.2960830645170063e-05
recently O 0 6.421413218049565e-06
has O 0 7.111019613148528e-07
been O 0 4.242505440288369e-07
identified O 0 2.7077825848209613e-07
, O 0 1.5365165495495603e-07
and O 0 1.0499397973262603e-07
characterization O 0 1.047998580361309e-06
of O 0 7.3691933266673e-07
this O 0 2.1104324332554825e-07
gene O 0 2.657547213402722e-07
has O 0 1.8824786707227759e-07
shown O 0 1.3738873860802414e-07
that O 0 4.8897479842935354e-08
it O 0 5.470296926546325e-08
contains O 0 1.5145600684718374e-07
two O 0 6.508490457690641e-08
mutations O 0 1.5327493940731074e-07
that O 0 3.672492354667156e-08
result O 0 1.0738957456624121e-07
in O 0 1.6779719658188696e-07
amino O 0 3.13220368752809e-07
acid O 0 5.44338092822727e-07
substitutions O 0 1.6012343166948995e-06
- O 0 3.711554882102064e-06
cDNA O 0 1.0880766240006778e-05
nucleotides O 0 3.947588083974551e-06
845 O 0 2.6038453142973594e-05
G O 0 1.5177429304458201e-05
- O 0 9.74577596934978e-06
- O 0 8.36078470456414e-06
> O 0 3.9802989704185165e-06
A O 0 3.846556410280755e-06
( O 0 1.0065538162962184e-06
C282Y O 0 8.989847628981806e-06
) O 0 3.899823468600516e-07
and O 0 2.187068872672171e-07
187 O 0 2.667042963366839e-06
C O 0 7.391318831651006e-06
- O 0 8.804156095720828e-06
- O 0 1.7892425603349693e-05
> O 0 2.196142668253742e-05
G O 0 7.83900250098668e-05
( O 0 8.195360351237468e-06
H63D O 1 0.9980419874191284
) O 0 3.40735241479706e-05
. O 0 8.185826300177723e-05

Although O 0 0.0005867262370884418
hemochromatosis B-Disease 1 1.0
is O 0 2.6893918402493e-05
common O 0 4.651692961488152e-06
in O 0 1.8302507669432089e-06
Caucasians O 0 0.0009166411473415792
, O 0 1.89670538475184e-06
affecting O 0 2.4040978132688906e-06
> O 0 6.9110146796447225e-06
= O 0 1.825140202527109e-06
1 O 0 2.3421173409587936e-06
/ O 0 2.2877316041558515e-06
300 O 0 5.149966568751552e-07
individuals O 0 5.1257703859164394e-08
of O 0 2.4800755227261106e-07
northern O 0 3.1639069675293285e-07
European O 0 2.847746145562269e-07
origin O 0 8.83226149994698e-08
, O 0 8.858260258648443e-08
it O 0 4.3942243621586385e-08
has O 0 9.393773581223286e-08
not O 0 4.19163086462504e-08
been O 0 1.6137929037540744e-07
recognized O 0 3.4099895174222183e-07
in O 0 3.8408123259614513e-07
other O 0 1.2962667597093969e-06
populations O 0 6.385700544342399e-06
. O 0 2.59840799117228e-05

The O 0 3.2151223422260955e-05
present O 0 4.9102059165306855e-06
study O 0 1.2839095688832458e-06
used O 0 4.855940574088891e-07
PCR O 0 2.7828286874864716e-06
and O 0 4.800726856046822e-07
restriction O 0 1.5067904541865573e-06
- O 0 4.010624707007082e-06
enzyme O 0 8.387893899453047e-07
digestion O 0 1.0267116294926382e-06
to O 0 1.5515210805006063e-07
analyze O 0 6.010203605910647e-07
the O 0 2.428465393222723e-07
frequency O 0 3.2228376767307054e-07
of O 0 4.2071377492902684e-07
the O 0 6.503042868644116e-07
845 O 0 3.050973464269191e-05
G O 0 1.924789830809459e-05
- O 0 5.679357855115086e-06
- O 0 6.654840490227798e-06
> O 0 3.2713635391701246e-06
A O 0 2.7029600460082293e-06
and O 0 4.0904035358835245e-07
187 O 0 2.9160203212086344e-06
C O 0 8.646277819934767e-06
- O 0 1.0568928701104596e-05
- O 0 1.4012553947395645e-05
> O 0 9.829869668465108e-06
G O 0 2.6104886273969896e-05
mutations O 0 7.111833042472426e-07
in O 0 5.676481578120729e-07
HLA O 0 0.02874848246574402
- O 0 1.2602401511685457e-05
typed O 0 3.130052846245235e-06
samples O 0 2.6964181643052143e-07
from O 0 1.8658919032077392e-07
non O 0 9.264322216040455e-07
- O 0 8.656194950162899e-06
Caucasian O 0 2.3140557459555566e-05
populations O 0 4.502842898546078e-07
, O 0 2.882897547351604e-07
comprising O 0 5.297021061778651e-07
Australian O 0 1.4440944369198405e-06
Aboriginal O 0 2.3356312794931e-06
, O 0 7.458107234015188e-07
Chinese O 0 1.8856620727092377e-06
, O 0 1.5550867829006165e-06
and O 0 2.109495881086332e-06
Pacific O 0 5.15390420332551e-05
Islanders O 0 0.000226761243538931
. O 0 7.001037010923028e-05

Results O 0 3.046641177206766e-05
showed O 0 9.02594365470577e-06
that O 0 9.301238037551229e-07
the O 0 2.941021193691995e-06
845 O 0 0.00017563214350957423
G O 0 0.00034208805300295353
- O 0 8.056913793552667e-05
- O 0 4.778032598551363e-05
> O 0 9.460674846195616e-06
A O 0 3.955282863898901e-06
mutation O 0 4.8341496494686e-07
was O 0 6.585341907339171e-07
present O 0 1.2153965656125365e-07
in O 0 4.459483804453157e-08
these O 0 2.7469157615200857e-08
populations O 0 3.317700603133744e-08
( O 0 7.298986304249411e-08
allele O 0 1.1587897574827366e-07
frequency O 0 9.192317662609639e-08
0 O 0 1.9328004441376834e-07
. O 0 4.7023263505252544e-08
32 O 0 2.559367544563429e-07
% O 0 7.058434192686036e-08
) O 0 9.395888156404908e-08
, O 0 1.1708591074466312e-07
and O 0 6.452399503587003e-08
, O 0 1.2652138536850543e-07
furthermore O 0 2.749810050772794e-07
, O 0 2.1147802442555985e-07
it O 0 1.6740624175781704e-07
was O 0 1.8479014443073538e-06
always O 0 1.0418411875434685e-06
seen O 0 8.563908409087162e-07
in O 0 2.465891952851962e-07
conjunction O 0 1.1152568504257943e-06
with O 0 7.292222221622069e-07
HLA O 1 0.9999897480010986
haplotypes O 0 2.2218155208975077e-05
common O 0 1.3560943443735596e-06
in O 0 7.056669915073144e-07
Caucasians O 0 2.116699397447519e-05
, O 0 1.2837039093938074e-06
suggesting O 0 1.3225849215814378e-06
that O 0 4.266264568286715e-07
845 O 0 3.710565943038091e-05
G O 0 3.941363320336677e-05
- O 0 2.5775090762181208e-05
- O 0 5.9408364904811606e-05
> O 0 1.278553554584505e-05
A O 0 1.393631100654602e-05
may O 0 2.965330452298076e-07
have O 0 7.476067764855543e-08
been O 0 1.3824528366512823e-07
introduced O 0 2.495982300843025e-07
into O 0 3.425890042763058e-07
these O 0 2.367698641592142e-07
populations O 0 6.425276524169021e-07
by O 0 1.0239901939712581e-06
Caucasian O 0 0.00020855112234130502
admixture O 0 0.00030580867314711213
. O 0 0.00014025178097654134

187 O 0 0.00031537588802166283
C O 0 0.00016061471251305193
- O 0 6.385178858181462e-05
- O 0 3.3191085094586015e-05
> O 0 1.7938677046913654e-05
G O 0 2.836945714079775e-05
was O 0 3.6311967051005922e-06
present O 0 4.006176652637805e-07
at O 0 7.795140390953748e-07
an O 0 3.4673246318561723e-07
allele O 0 7.541100330854533e-07
frequency O 0 1.340024368801096e-06
of O 0 4.023036581202177e-06
2 O 0 7.083273521857336e-05
. O 0 5.057107046013698e-05

68 O 0 0.00016912877617869526
% O 0 6.846922133263433e-06
in O 0 8.678163112563198e-07
the O 0 7.460625397470722e-07
two O 0 1.545012651149591e-07
populations O 0 1.8942131418953068e-07
analyzed O 0 5.684011057383032e-07
( O 0 6.271641836974595e-07
Australian O 0 5.0279422794119455e-06
Aboriginal O 0 5.361338480724953e-06
and O 0 2.9001207622059155e-06
Chinese O 0 1.1441576134529896e-05
) O 0 2.524404408177361e-05
. O 0 7.340161391766742e-05

In O 0 2.3917804355733097e-05
the O 0 5.9339254221413285e-06
Australian O 0 7.229483799164882e-06
Aboriginal O 0 4.382642146083526e-06
samples O 0 8.642136890557595e-07
, O 0 6.903182452333567e-07
187 O 0 2.7703567866410594e-06
C O 0 8.340667591255624e-06
- O 0 1.1308936336718034e-05
- O 0 1.8254802853334695e-05
> O 0 9.901467819872778e-06
G O 0 3.2109368476085365e-05
was O 0 1.7041375031112693e-06
found O 0 1.3191885273045045e-07
to O 0 6.300801658198907e-08
be O 0 8.307466003998343e-08
associated O 0 1.4841741347026982e-07
with O 0 3.500830416669487e-07
HLA O 1 0.9999998807907104
haplotypes O 0 5.809116191812791e-05
common O 0 1.2000474498563563e-06
in O 0 7.837689395273628e-07
Caucasians O 0 2.406354178674519e-05
, O 0 4.269105602361378e-07
suggesting O 0 2.8216641112521756e-07
that O 0 8.40513649791319e-08
it O 0 1.6640994715544366e-07
was O 0 1.5412290395033779e-06
introduced O 0 5.2188283916621e-07
by O 0 5.578932587013696e-07
recent O 0 7.381526756944368e-06
admixture O 0 0.00010213999485131353
. O 0 7.758292485959828e-05

In O 0 2.5635459678596817e-05
the O 0 5.774463716079481e-06
Chinese O 0 3.4971637887792895e-06
samples O 0 7.45795091461332e-07
analyzed O 0 9.412224812876957e-07
, O 0 6.2744658180236e-07
187 O 0 3.0045819130464224e-06
C O 0 1.0093077435158193e-05
- O 0 9.39023811952211e-06
- O 0 1.2871688340965193e-05
> O 0 5.7556885622034315e-06
G O 0 2.1159929019631818e-05
was O 0 2.1901839772908716e-06
present O 0 2.736891246968298e-07
in O 0 1.542039171908982e-07
association O 0 2.1777196934635867e-07
with O 0 1.349038143416692e-07
a O 0 5.420029083325062e-07
wide O 0 2.7839034828502918e-06
variety O 0 1.7035461041814415e-06
of O 0 8.469040949421469e-06
HLA O 1 1.0
haplotypes O 0 1.7518590539111756e-05
, O 0 5.44909426025697e-07
showing O 0 4.7334432906609436e-07
this O 0 6.351273640348154e-08
mutation O 0 9.146985036068145e-08
to O 0 8.67199361209714e-08
be O 0 7.988953854010106e-08
widespread O 0 4.944736247125547e-07
and O 0 2.0474746520449116e-07
likely O 0 2.8246526539987826e-07
to O 0 1.775221534217053e-07
predate O 0 2.469591890985612e-06
the O 0 4.1664637251415115e-07
more O 0 3.1209714279611944e-07
genetically O 0 1.2679161045525689e-06
restricted O 0 1.0600467703625327e-06
845 O 0 5.1331462600501254e-05
G O 0 8.851004531607032e-05
- O 0 6.434076931327581e-05
- O 0 5.675183274433948e-05
> O 0 3.977141386712901e-05
A O 0 4.4413944124244153e-05
mutation O 0 2.8175656552775763e-05
. O 0 2.438073897792492e-05

Genotype O 0 0.0016670972108840942
- O 0 0.00047650589840486646
phenotype O 0 0.00010124013351742178
correlations O 0 0.00011517671373439953
in O 0 3.9190330426208675e-05
attenuated B-Disease 1 0.9928061366081238
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.0021934686228632927

Germ O 1 0.9997460246086121
- O 0 0.0003818943223450333
line O 0 2.443008270347491e-05
mutations O 0 2.729534799073008e-06
of O 0 2.718525138334371e-06
the O 0 8.045192771533038e-06
tumor B-Disease 1 1.0
suppressor O 1 1.0
APC O 1 0.998301088809967
are O 0 1.7607073914405191e-06
implicated O 0 4.964957770425826e-05
in O 0 4.871901637670817e-06
attenuated B-Disease 1 0.9997057318687439
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9989845156669617
AAPC B-Disease 1 1.0
) O 0 4.6803329496469814e-06
, O 0 1.4130305316939484e-06
a O 0 2.241094307464664e-06
variant O 0 1.3568623216997366e-05
of O 0 2.5303819711552933e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999971389770508
FAP B-Disease 1 1.0
) O 0 0.0004952771123498678
. O 0 0.0001978956861421466

AAPC B-Disease 1 1.0
is O 0 3.842377554974519e-05
recognized O 0 1.058029374689795e-05
by O 0 8.142449701153964e-07
the O 0 1.6283868262689793e-06
occurrence O 0 2.812110778904753e-06
of O 0 3.6467574773269007e-06
< O 0 5.1376417104620486e-05
100 O 0 3.179891427862458e-05
colonic B-Disease 1 0.9999991655349731
adenomas I-Disease 1 0.9613165855407715
and O 0 9.612787152946112e-07
a O 0 9.613071370040416e-07
later O 0 1.1585239008127246e-06
onset O 0 1.1807727787527256e-05
of O 1 0.820480465888977
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.1613552639319096e-06
age O 0 2.468009824951878e-06
> O 0 2.0537711407087045e-06
40 O 0 2.5482768251094967e-06
years O 0 2.4115515770972706e-06
) O 0 6.267561275308253e-06
. O 0 2.5494735382380895e-05

The O 0 3.552608905010857e-05
aim O 0 2.4278373530250974e-05
of O 0 3.7473669181053992e-06
this O 0 6.33710328656889e-07
study O 0 1.0131557246495504e-06
was O 0 1.9190229068044573e-06
to O 0 5.274317231851455e-07
assess O 0 4.402246304380242e-06
genotype O 0 1.7416077753296122e-05
- O 0 4.086740591446869e-05
phenotype O 0 1.4892962099111173e-05
correlations O 0 2.1417601601569913e-05
in O 0 2.71226090262644e-05
AAPC B-Disease 1 1.0
families O 0 5.0881724746432155e-05
. O 0 9.576010779710487e-05

By O 0 2.057968777080532e-05
protein O 0 1.0599401321087498e-05
- O 0 1.826730658649467e-05
truncation O 0 4.817420995095745e-05
test O 0 2.7453788788989186e-06
( O 0 2.4520165879948763e-06
PTT O 0 0.00013595061318483204
) O 0 1.1477982297947165e-06
assay O 0 1.475979047427245e-06
, O 0 4.754009523821878e-07
the O 0 4.889085971626628e-07
entire O 0 1.8774385353026446e-06
coding O 0 3.530082040015259e-06
region O 0 1.5864931128817261e-06
of O 0 1.1702122719725594e-06
the O 0 2.5121785256487783e-06
APC B-Disease 0 0.0016084465896710753
gene O 0 1.4216909676179057e-06
was O 0 4.294523023418151e-06
screened O 0 2.1242046841507545e-06
in O 0 4.112895339858369e-07
affected O 0 2.738648277045286e-07
individuals O 0 9.330915418104269e-08
from O 0 5.60267039872997e-07
11 O 0 2.8343683879938908e-05
AAPC B-Disease 1 1.0
kindreds O 0 0.009430416859686375
, O 0 2.228791800007457e-06
and O 0 7.24263998108654e-07
their O 0 4.369061059605883e-07
phenotypic O 0 1.2666986549447756e-05
differences O 0 5.115972271596547e-06
were O 0 4.5360488911683206e-06
examined O 0 4.365549102658406e-05
. O 0 5.133763261255808e-05

Five O 0 6.773898348910734e-05
novel O 0 0.00011793156591011211
germ O 1 0.8804231286048889
- O 0 0.0012231383007019758
line O 0 5.422008689492941e-05
APC B-Disease 0 0.007883916608989239
mutations O 0 2.6390976017864887e-06
were O 0 7.349499924202973e-07
identified O 0 8.292346365124104e-07
in O 0 9.184298050968209e-07
seven O 0 1.1963260476477444e-05
kindreds O 0 0.0010893474100157619
. O 0 8.311021520057693e-05

Mutations O 0 4.95975291414652e-05
were O 0 4.669240752264159e-06
located O 0 4.684289251599694e-06
in O 0 4.644223565719585e-07
three O 0 1.6636694510907546e-07
different O 0 5.0798320216927095e-08
regions O 0 1.7584693523531314e-07
of O 0 5.606342483588378e-07
the O 0 7.486890467589546e-07
APC B-Disease 0 7.445817755069584e-05
gene O 0 3.889104789323028e-07
( O 0 2.0304079839661426e-07
1 O 0 9.021433697853354e-07
) O 0 1.6480957754083647e-07
at O 0 4.97397934395849e-07
the O 0 2.651754869020806e-07
5 O 0 5.15733859174361e-07
end O 0 3.14099821707714e-07
spanning O 0 1.1704678399837576e-06
exons O 0 1.8380170558884856e-06
4 O 0 1.1318929864501115e-06
and O 0 1.8392762513030902e-07
5 O 0 5.125203870193218e-07
, O 0 1.8629617670740117e-07
( O 0 9.621346919175267e-08
2 O 0 3.792403617808304e-07
) O 0 1.400963469677663e-07
within O 0 1.281639896433262e-07
exon O 0 9.909156233334215e-07
9 O 0 5.855706035617914e-07
, O 0 1.9105067394775688e-07
and O 0 7.497001064393771e-08
( O 0 9.371689202453126e-08
3 O 0 4.1450425669609103e-07
) O 0 1.3235107587661332e-07
at O 0 4.749776678636408e-07
the O 0 2.264694813902679e-07
3 O 0 1.7647538470555446e-06
distal O 0 7.423616352753015e-06
end O 0 1.5354531797129312e-06
of O 0 2.302273060195148e-06
the O 0 4.85872442368418e-06
gene O 0 1.958634857146535e-05
. O 0 3.0994404369266704e-05

Variability O 0 0.00020689242228399962
in O 0 4.291464847483439e-06
the O 0 2.454405375829083e-06
number O 0 2.490799033694202e-06
of O 0 0.14826327562332153
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.9999876022338867
most O 0 1.3579137885244563e-06
apparent O 0 2.722474164329469e-06
in O 0 1.887182747850602e-07
individuals O 0 4.2922280840684834e-08
with O 0 8.494664882618963e-08
mutations O 0 2.494040813871834e-07
in O 0 1.6894915688681067e-07
region O 0 3.30109998003536e-07
1 O 0 3.0620769848610507e-06
, O 0 5.756774044129997e-07
and O 0 5.386483508118545e-07
upper O 0 6.505806231871247e-05
- O 1 0.9999305009841919
gastrointestinal O 1 1.0
manifestations O 1 0.9829871654510498
were O 0 3.131880248474772e-06
more O 0 6.517832389363321e-07
severe O 0 2.0249392036930658e-05
in O 0 2.7797041184385307e-06
them O 0 5.781952040706528e-06
. O 0 3.6186040233587846e-05

In O 0 9.568851965013891e-06
individuals O 0 8.584473221162625e-07
with O 0 4.5357708700066723e-07
mutations O 0 4.2693986301856057e-07
in O 0 1.7432481058676785e-07
either O 0 2.528619233999052e-07
region O 0 4.792213985638227e-07
2 O 0 2.5005213046824792e-06
or O 0 3.952376630422805e-07
region O 0 3.5964870903626434e-07
3 O 0 8.990789410745492e-07
, O 0 2.0146916313024121e-07
the O 0 2.2905929597527575e-07
average O 0 2.889167376451951e-07
number O 0 2.2662504761683522e-07
of O 0 1.8469132783138775e-06
adenomas B-Disease 1 0.9984099864959717
tended O 0 3.6554381495079724e-06
to O 0 3.8898906495887786e-07
be O 0 1.530939357508032e-07
lower O 0 2.494245450179733e-07
than O 0 8.162199094385869e-08
those O 0 4.3665696836114876e-08
in O 0 5.897745580796254e-08
individuals O 0 3.0572831377639886e-08
with O 0 4.707531076064697e-08
mutations O 0 1.5907733086351072e-07
in O 0 1.0736193445382014e-07
region O 0 3.330120534883463e-07
1 O 0 1.1606615544224042e-06
, O 0 2.357422346221938e-07
although O 0 1.3099040074848745e-07
age O 0 7.114091999937955e-07
at O 0 4.003783942607697e-06
diagnosis O 0 1.3441441296890844e-05
was O 0 1.242964299308369e-05
similar O 0 7.963408279465511e-06
. O 0 4.24388526880648e-05

In O 0 5.0615359214134514e-05
all O 0 2.3955835786182433e-05
AAPC B-Disease 1 1.0
kindreds O 0 0.0011569138150662184
, O 0 4.34912544733379e-06
a O 0 3.4521449379099067e-06
predominance O 0 2.7421281629358418e-05
of O 0 1.552034700580407e-05
right O 0 0.00029758227174170315
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.999432384967804
rectal B-Disease 1 1.0
polyp I-Disease 1 1.0
sparing O 1 0.5011574029922485
was O 0 0.00035134851350449026
observed O 0 4.302015804569237e-05
. O 0 4.0136346797226e-05

No O 0 0.0019347009947523475
desmoid B-Disease 1 1.0
tumors I-Disease 1 1.0
were O 0 8.673358024680056e-06
found O 0 3.3913138395291753e-06
in O 0 1.8386236888545682e-06
these O 0 2.5370277398906182e-06
kindreds O 0 0.0004241353599354625
. O 0 9.513681288808584e-05

Our O 0 3.93939481000416e-05
data O 0 1.0469104381627403e-05
suggest O 0 3.200831315552932e-06
that O 0 4.960549517818436e-07
, O 0 8.373691002816486e-07
in O 0 8.99941937859694e-07
AAPC B-Disease 1 1.0
families O 0 6.47351498628268e-07
, O 0 3.99375977622185e-07
the O 0 3.241733566028415e-07
location O 0 8.126546617859276e-07
of O 0 8.261546327048563e-07
the O 0 1.880235345197434e-06
APC B-Disease 0 0.42723920941352844
mutation O 0 5.796201548946556e-06
may O 0 1.746277689562703e-06
partially O 0 9.781504559214227e-06
predict O 0 3.639524038590025e-06
specific O 0 1.4083178712098743e-06
phenotypic O 0 2.772384868876543e-05
expression O 0 2.3926657377160154e-05
. O 0 5.0746140914270654e-05

This O 0 1.043027987179812e-05
should O 0 1.5488099052163307e-06
help O 0 6.622746013817959e-07
in O 0 2.3274743909951212e-07
the O 0 3.34135023649651e-07
design O 0 2.070076334348414e-06
of O 0 1.6933062170210178e-06
tailored O 0 4.448254912858829e-06
clinical O 0 8.77237253007479e-05
- O 0 0.00793005246669054
management O 0 1.0066210052173119e-05
protocols O 0 2.2273829927144106e-06
in O 0 4.5801206738360634e-07
this O 0 3.0870745604261174e-07
subset O 0 2.740058789640898e-06
of O 0 9.104701348405797e-06
FAP B-Disease 1 1.0
patients O 0 5.678615707438439e-05
. O 0 7.695390195294749e-06
. O 0 4.6520421165041625e-05

Wilms B-Disease 1 1.0
' I-Disease 0 0.017057064920663834
tumor I-Disease 1 0.9995750784873962
1 O 0 5.455107384477742e-05
and O 0 7.341370746871689e-06
Dax O 1 0.9999994039535522
- O 0 1.7215017578564584e-05
1 O 0 6.518841018987587e-06
modulate O 0 8.064142093644477e-06
the O 0 1.5681251852583955e-06
orphan O 0 1.3911493624618743e-05
nuclear O 0 8.384899047086947e-06
receptor O 0 8.5152769315755e-06
SF O 1 0.9999998807907104
- O 0 2.0392877559061162e-05
1 O 0 7.823329724487849e-06
in O 0 9.029465104504197e-07
sex O 0 1.0418839337944519e-06
- O 0 3.3817732401075773e-06
specific O 0 1.0892453019550885e-06
gene O 0 5.574089755100431e-06
expression O 0 1.4951808225305285e-05
. O 0 4.1126299038296565e-05

Products O 0 9.536324796499684e-05
of O 0 2.6087316655321047e-05
steroidogenic O 0 0.04427170753479004
factor O 0 3.4108405088773e-05
1 O 0 1.9532963051460683e-05
( O 0 3.99335112888366e-06
SF O 1 1.0
- O 0 2.3447890271199867e-05
1 O 0 7.074141649354715e-06
) O 0 1.2149369013059186e-06
and O 0 1.7181552038891823e-06
Wilms B-Disease 1 1.0
tumor I-Disease 1 0.9999550580978394
1 O 0 2.9772374546155334e-05
( O 0 4.74457920063287e-06
WT1 O 1 0.9763994812965393
) O 0 7.647140591870993e-07
genes O 0 2.0405796874456428e-07
are O 0 4.340802561841883e-08
essential O 0 2.8885338565487473e-07
for O 0 4.2484569462430954e-07
mammalian O 0 8.233967491833027e-06
gonadogenesis O 0 0.00012956497084815055
prior O 0 2.1911032490606885e-06
to O 0 2.3682955543335993e-06
sexual O 0 6.822355771873845e-06
differentiation O 0 6.714960181852803e-05
. O 0 8.692947449162602e-05

In O 0 3.6154931876808405e-05
males O 0 1.0389616363681853e-05
, O 0 9.830919225350954e-06
SF O 1 1.0
- O 0 0.003028215141966939
1 O 0 2.8720613045152277e-05
participates O 0 4.4000803427479696e-06
in O 0 4.4313296143627667e-07
sexual O 0 2.828804213095282e-07
development O 0 2.0734991323934082e-07
by O 0 2.0222799435032357e-07
regulating O 0 2.1606335849355673e-06
expression O 0 9.703335308586247e-07
of O 0 1.1838064892799594e-06
the O 0 1.8609460994412075e-06
polypeptide O 0 6.22501756879501e-05
hormone O 0 1.8852913854061626e-05
Mullerian O 0 0.11807161569595337
inhibiting O 0 3.1158531783148646e-05
substance O 0 1.959595101652667e-05
( O 0 1.2647865332837682e-05
MIS O 1 0.9999983310699463
) O 0 1.998598236241378e-05
. O 0 3.967231896240264e-05

Here O 0 4.734309914056212e-05
, O 0 7.986689524841495e-06
we O 0 1.0818556575031835e-06
show O 0 3.369363412275561e-06
that O 0 1.7070686908482458e-06
WT1 O 1 0.9768487811088562
- O 0 0.0003962115151807666
KTS O 1 0.9997921586036682
isoforms O 0 1.2701799278147519e-05
associate O 0 1.3491102436091751e-05
and O 0 2.5184010610246332e-06
synergize O 0 0.0001014886365737766
with O 0 4.294514383218484e-06
SF O 1 1.0
- O 0 0.004315218422561884
1 O 0 1.9881084881490096e-05
to O 0 3.144917855024687e-06
promote O 0 1.916198198159691e-05
MIS O 1 0.9998617172241211
expression O 0 9.311821486335248e-05
. O 0 0.00011734131840057671

In O 0 4.029481715406291e-05
contrast O 0 3.678426946862601e-05
, O 0 2.4103459509206004e-05
WT1 O 1 0.9998571872711182
missense O 0 0.00022792657546233386
mutations O 0 7.4763693191925995e-06
, O 0 1.430389374945662e-06
associated O 0 8.331410299433628e-07
with O 0 8.253284704551334e-07
male B-Disease 0 1.4911465768818744e-05
pseudohermaphroditism I-Disease 1 1.0
in O 0 1.0444492545502726e-05
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.066631729278015e-06
fail O 0 4.494675522437319e-06
to O 0 3.053643467865186e-06
synergize O 0 0.00027392609626986086
with O 0 9.988883903133683e-06
SF O 1 1.0
- O 1 0.998524010181427
1 O 0 0.000837477738969028
. O 0 8.550404891138896e-05

Additionally O 0 0.00012143357162130997
, O 0 8.010503734112717e-06
the O 0 3.3997716855083127e-06
X O 0 3.3481806894997135e-05
- O 0 1.885559322545305e-05
linked O 0 7.014346010691952e-06
, O 0 8.689061132827192e-07
candidate O 0 1.4857406540613738e-06
dosage O 0 6.551611932081869e-06
- O 0 5.299408257997129e-06
sensitive O 0 2.772312654997222e-06
sex O 0 6.63600985717494e-07
- O 0 2.9020352485531475e-06
reversal O 0 2.1816786102135666e-06
gene O 0 6.88823433847574e-07
, O 0 1.0926339655270567e-06
Dax O 1 0.9999988079071045
- O 0 1.700248867564369e-05
1 O 0 9.528238479106221e-06
, O 0 2.0346967630757717e-06
antagonizes O 0 1.8901591829489917e-05
synergy O 0 1.811248694139067e-05
between O 0 2.0146371753071435e-06
SF O 1 1.0
- O 0 4.69996448373422e-05
1 O 0 1.4425568224396557e-05
and O 0 1.3788546766591026e-06
WT1 O 1 0.9953879714012146
, O 0 1.2538282589957817e-06
most O 0 7.079534611875715e-07
likely O 0 6.396912795025855e-07
through O 0 2.0711374304482888e-07
a O 0 6.168359618641261e-07
direct O 0 7.47063552353211e-07
interaction O 0 9.633591844249167e-07
with O 0 2.1827690943609923e-06
SF O 1 1.0
- O 1 0.9290245771408081
1 O 0 0.00035166883026249707
. O 0 6.450073851738125e-05

We O 0 2.2629968952969648e-05
propose O 0 2.723039870033972e-05
that O 0 4.899437954009045e-06
WT1 O 1 0.9980514049530029
and O 0 2.5554032617947087e-05
Dax O 1 1.0
- O 0 0.000188701887964271
1 O 0 1.7696545910439454e-05
functionally O 0 8.643556611787062e-06
oppose O 0 1.6966456541922526e-06
each O 0 2.9095735953887925e-07
other O 0 2.2955680378800025e-07
in O 0 4.792981940227037e-07
testis O 0 1.745728513924405e-05
development O 0 1.165295543614775e-06
by O 0 5.904436761738907e-07
modulating O 0 6.854787352494895e-05
SF O 1 1.0
- O 0 0.0777226984500885
1 O 0 6.199951167218387e-05
- O 0 5.5377437092829496e-05
mediated O 0 2.495485205145087e-05
transactivation O 0 0.00029468192951753736
. O 0 2.3168644474935718e-05
. O 0 9.425952157471329e-05

A O 0 0.00036107920459471643
mouse O 0 8.414756302954629e-05
model O 0 1.4910441677784547e-05
for O 0 9.276839591620956e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999998807907104
- O 1 0.9999998807907104
centre O 1 0.994800329208374
mutations O 0 0.00016701595450285822
. O 0 0.00010767856292659417

Imprinting O 0 0.0010557580972090364
in O 0 1.5220477507682517e-05
the O 0 1.1783283298427705e-05
15q11 O 0 0.0003581213823053986
- O 0 0.00015495059778913856
q13 O 0 0.00019138146308250725
region O 0 3.353006150064175e-06
involves O 0 1.4771084124731715e-06
an O 0 7.614232799824094e-07
imprinting O 0 1.9495926608215086e-05
centre O 0 1.83348311111331e-05
( O 0 1.5113843119252124e-06
IC O 0 0.05066303163766861
) O 0 1.0004539490182651e-06
, O 0 3.1762994012751733e-07
mapping O 0 3.7224441484795534e-07
in O 0 1.565352079069271e-07
part O 0 3.6480304288488696e-07
to O 0 1.801906392984165e-07
the O 0 6.646866381743166e-07
promoter O 0 4.1414230508962646e-05
and O 0 1.7217737422470236e-06
first O 0 5.651123046845896e-06
exon O 0 8.95921402843669e-05
of O 0 6.408297485904768e-05
SNRPN O 1 0.9999979734420776
. O 0 0.00010524012759560719

Deletion O 0 0.0002561106812208891
of O 0 3.2042746170191094e-05
this O 0 6.866525382065447e-06
IC O 1 0.769855797290802
abolishes O 0 0.00019395445997361094
local O 0 8.376331606996246e-06
paternally O 0 3.245270636398345e-05
derived O 0 1.316444013355067e-06
gene O 0 6.946802955098974e-07
expression O 0 5.711233939109661e-07
and O 0 3.3440281299590424e-07
results O 0 4.069644887749746e-07
in O 0 3.0116591460682685e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999998807907104
PWS B-Disease 1 1.0
) O 0 0.0004931144649162889
. O 0 0.00017043229308910668

We O 0 2.7139529265696183e-05
have O 0 1.6657825199217768e-06
created O 0 2.870261369025684e-06
two O 0 5.699084226762352e-07
deletion O 0 6.224287517397897e-06
mutations O 0 1.2210094837428187e-06
in O 0 6.038757760506996e-07
mice O 0 2.812529373841244e-06
to O 0 9.444486295251409e-07
understand O 0 6.132794624136295e-06
PWS B-Disease 1 1.0
and O 0 3.3745729979273165e-06
the O 0 3.3185153824888403e-06
mechanism O 0 3.07794857690169e-06
of O 0 5.280202913127141e-06
this O 0 1.0916228347923607e-05
IC O 1 0.9991705417633057
. O 0 0.0001340080489171669

Mice O 0 0.008704774081707
harbouring O 0 0.11325245350599289
an O 0 2.4110910089802928e-05
intragenic O 0 0.017856629565358162
deletion O 0 6.772322376491502e-05
in O 0 6.2288127082865685e-06
Snrpn O 1 0.9982870221138
are O 0 1.3632312629852095e-06
phenotypically O 0 1.7511340047349222e-05
normal O 0 1.077947217709152e-06
, O 0 5.680943786501302e-07
suggesting O 0 5.747152158619429e-07
that O 0 1.5080541970746708e-07
mutations O 0 5.223035373091989e-07
of O 0 1.5792172689543804e-06
SNRPN O 1 0.999990701675415
are O 0 3.03764295495057e-07
not O 0 2.2759014939310873e-07
sufficient O 0 1.0618234682624461e-06
to O 0 5.384950782172382e-06
induce O 0 0.00019314924429636449
PWS B-Disease 1 1.0
. O 0 0.0004251744830980897

Mice O 0 0.0001369069068459794
with O 0 3.2069392545963638e-06
a O 0 3.685302772282739e-06
larger O 0 2.852649004125851e-06
deletion O 0 5.661345312546473e-06
involving O 0 2.2250519577937666e-06
both O 0 7.470863465641742e-07
Snrpn O 1 0.8251365423202515
and O 0 1.6048361430875957e-06
the O 0 3.279988050053362e-06
putative O 0 0.45274627208709717
PWS O 1 1.0
- O 1 0.9999982118606567
IC O 1 0.9999997615814209
lack O 0 9.653415872890037e-06
expression O 0 1.5963795476636733e-06
of O 0 1.684987410044414e-06
the O 0 2.8254278277017875e-06
imprinted O 0 1.7845375623437576e-05
genes O 0 2.5385063509020256e-06
Zfp127 O 0 0.0013801436871290207
( O 0 3.405703637326951e-06
mouse O 0 1.300836811424233e-05
homologue O 0 2.776382643787656e-05
of O 0 3.9439751162717585e-06
ZNF127 O 1 0.9999909400939941
) O 0 2.5488429855613504e-06
, O 0 1.864918658611714e-06
Ndn O 0 0.019824616611003876
and O 0 2.007898729061708e-06
Ipw O 0 0.0001362510520266369
, O 0 2.6574205094220815e-06
and O 0 9.158539455711434e-07
manifest O 0 3.197490514139645e-06
several O 0 9.824702829064336e-07
phenotypes O 0 1.36201442728634e-05
common O 0 6.6029215304297395e-06
to O 0 5.723162030335516e-05
PWS B-Disease 1 1.0
infants O 1 0.6992297768592834
. O 0 0.00018964959599543363

These O 0 7.327759703912307e-06
data O 0 2.6823986445378978e-06
demonstrate O 0 1.833566784625873e-06
that O 0 2.579965041604737e-07
both O 0 1.6719721429581114e-07
the O 0 3.346835910633672e-07
position O 0 9.13952703740506e-07
of O 0 6.628521305174218e-07
the O 0 6.572248025804583e-07
IC O 1 0.9885517358779907
and O 0 5.262891136226244e-07
its O 0 3.193067357187829e-07
role O 0 5.449770128507225e-07
in O 0 1.2036012719818245e-07
the O 0 2.651163129030465e-07
coordinate O 0 4.361974959010695e-07
expression O 0 2.3730042642000626e-07
of O 0 4.3178633291063306e-07
genes O 0 1.956178579121115e-07
is O 0 1.1771727770337748e-07
conserved O 0 5.033734282733349e-07
between O 0 1.557956039732744e-07
mouse O 0 3.204731910955161e-06
and O 0 1.9463364253624604e-07
human O 0 2.259090763345739e-07
, O 0 1.2585682895860373e-07
and O 0 1.2247934932929638e-07
indicate O 0 1.4606557385832275e-07
that O 0 5.587431672893217e-08
the O 0 1.9833564124382974e-07
mouse O 0 1.7091929294110741e-06
is O 0 1.8060751472148695e-07
a O 0 1.523972059658263e-07
suitable O 0 2.71258983275402e-07
model O 0 1.6512674960722507e-07
system O 0 1.4135304127194104e-07
in O 0 6.957079534686272e-08
which O 0 9.596439554115932e-08
to O 0 1.6786746925845364e-07
investigate O 0 6.126681455498328e-07
the O 0 4.773089585796697e-07
molecular O 0 1.0457752068759874e-06
mechanisms O 0 4.752812685637764e-07
of O 0 1.0281960385327693e-06
imprinting O 0 5.7979486882686615e-06
in O 0 3.5682850807461364e-07
this O 0 1.7672924457201589e-07
region O 0 1.1119985856566927e-06
of O 0 1.4297523875939078e-06
the O 0 3.163314204357448e-06
genome O 0 8.373503987968434e-06
. O 0 5.415046416601399e-06
. O 0 2.2767642803955823e-05

Mutations O 0 3.90575805795379e-05
of O 0 1.1164379429828841e-05
the O 0 5.480423624248942e-06
ATM O 1 0.5823837518692017
gene O 0 5.323757250152994e-06
detected O 0 3.858253876387607e-06
in O 0 1.3592147070085048e-06
Japanese O 0 0.021223224699497223
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 2.4786904759821482e-05
: O 0 1.2332200185483089e-06
possible O 0 8.941246392168978e-07
preponderance O 0 2.0053110347362235e-05
of O 0 2.271595803904347e-06
the O 0 1.2329425089774304e-06
two O 0 6.370254368448514e-07
founder O 0 0.00014236885181162506
mutations O 0 2.0177187252556905e-05
4612del165 O 0 0.00047000221093185246
and O 0 3.93779446312692e-05
7883del5 O 0 0.0026330796536058187
. O 0 0.00024851117632351816

The O 0 7.566050044260919e-05
ATM O 1 0.8480663299560547
( O 0 2.3511347535531968e-05
A O 1 0.9999921321868896
- O 1 0.9999970197677612
T O 1 1.0
, O 0 4.315329078963259e-06
mutated O 0 4.071398052474251e-06
) O 0 1.1888013204952586e-06
gene O 0 1.046905708790291e-06
on O 0 2.1597477370960405e-06
human O 0 3.2572361305938102e-06
chromosome O 0 4.076254481333308e-05
11q22 O 0 0.0009710582671687007
. O 0 6.439293792936951e-05

3 O 0 0.00010596527135930955
has O 0 1.00621991805383e-05
recently O 0 4.070652721566148e-06
been O 0 5.847028887728811e-07
identified O 0 2.2573698288397281e-07
as O 0 1.6812283831768582e-07
the O 0 1.887400600253386e-07
gene O 0 1.8991366346199356e-07
responsible O 0 2.9977732651786937e-07
for O 0 2.910972511926957e-07
the O 0 1.3921480785938911e-06
human O 0 7.639962859684601e-06
recessive B-Disease 1 0.9993079900741577
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9659082293510437
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.2688723624451086e-05
. O 0 4.7733919927850366e-05

In O 0 1.5666168110328726e-05
order O 0 3.4857030186685733e-06
to O 0 7.080155910443864e-07
define O 0 9.993543699238217e-07
the O 0 6.776005534447904e-07
types O 0 1.0181621519222972e-06
of O 0 4.424227881827392e-05
disease O 1 0.9997819066047668
- O 1 0.9472087025642395
causing O 0 0.00031372110242955387
ATM O 0 0.25116705894470215
mutations O 0 6.637706633227936e-07
in O 0 4.491280662932695e-07
Japanese O 0 1.2917877029394731e-05
A B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.2576795143104391e-06
as O 0 2.0022470437197626e-07
well O 0 1.3440080692816991e-07
as O 0 1.220802943180388e-07
to O 0 9.748379881102665e-08
look O 0 2.468437685365643e-07
for O 0 2.3495979917242948e-07
possible O 0 1.1677150268951664e-06
mutational O 0 5.013210102333687e-05
hotspots O 0 2.60290689766407e-05
, O 0 1.0044327609648462e-06
reverse O 0 9.88454075923073e-07
- O 0 1.9247340787842404e-06
transcribed O 0 1.3275993069328251e-06
RNA O 0 1.6383748970838496e-06
derived O 0 3.2496140534021833e-07
from O 0 1.7074189884169755e-07
ten O 0 8.08142715413851e-07
patients O 0 2.5438814077460847e-07
belonging O 0 5.730503858103475e-07
to O 0 2.1070819400392793e-07
eight O 0 8.67398455284274e-07
unrelated O 0 4.840917426918168e-06
Japanese O 0 1.689361670287326e-05
A B-Disease 1 0.9999953508377075
- I-Disease 1 0.9999884366989136
T I-Disease 1 0.9999934434890747
families O 0 3.1618557727597363e-07
was O 0 1.0414904636490974e-06
analyzed O 0 3.577167433377326e-07
for O 0 1.4404520243260777e-07
mutations O 0 1.835510659020656e-07
by O 0 1.7207710811817378e-07
the O 0 1.243596557287674e-06
restriction O 0 4.315115347708343e-06
endonuclease O 0 9.333869820693508e-05
fingerprinting O 0 5.039198731537908e-05
method O 0 2.64717273239512e-05
. O 0 3.3768705179682e-05

As O 0 3.8267116906354204e-05
has O 0 4.654382792068645e-06
been O 0 1.2648147276195232e-06
reported O 0 4.111946338980488e-07
by O 0 1.372474400795909e-07
others O 0 2.2204744709597435e-07
, O 0 2.085413797203728e-07
mutations O 0 1.3977980017898517e-07
that O 0 6.939268359928974e-08
lead O 0 7.344615937654453e-07
to O 0 9.160740432889725e-07
exon O 0 4.6913442929508165e-05
skipping O 0 2.5135894247796386e-05
or O 0 1.2077974815838388e-06
premature O 0 1.7038922806023038e-06
protein O 0 4.78037804896303e-07
truncation O 0 4.362771505839191e-06
were O 0 5.225302857070346e-07
also O 0 7.654444402760419e-07
predominant O 0 6.096290690038586e-06
in O 0 2.7381647669244558e-06
our O 0 6.5694052864273544e-06
mutants O 0 8.26005925773643e-05
. O 0 4.7400830226251855e-05

Six O 0 1.9345136024639942e-05
different O 0 1.0864463320103823e-06
mutations O 0 1.1327718993925373e-06
were O 0 3.590562016597687e-07
identified O 0 3.667914825200569e-07
on O 0 4.964013555763813e-07
12 O 0 1.5982532204361632e-06
of O 0 1.8752197092908318e-06
the O 0 2.169764684367692e-06
16 O 0 9.5464383775834e-06
alleles O 0 7.590092991449637e-06
examined O 0 4.716671901405789e-05
. O 0 5.5506228818558156e-05

Four O 0 4.975613046553917e-05
were O 0 7.98396285972558e-06
deletions O 0 2.0740004401886836e-05
involving O 0 7.272954007930821e-06
a O 0 4.931182502332376e-06
loss O 0 2.3887307179393247e-05
of O 0 3.6794240259041544e-06
a O 0 2.810743353620637e-06
single O 0 2.931168182840338e-06
exon O 0 2.7748208594857715e-05
exon O 0 2.1855310478713363e-05
7 O 0 7.2391981120745186e-06
, O 0 1.585927520864061e-06
exon O 0 1.1408093087084126e-05
16 O 0 3.6089631976210512e-06
, O 0 1.9371309463167563e-06
exon O 0 2.9820339477737434e-05
33 O 0 1.654443440202158e-05
or O 0 5.160461114428472e-06
exon O 0 0.0001316644047619775
35 O 0 6.1851525970269e-05
. O 0 6.997512537054718e-05

The O 0 5.150907236384228e-05
others O 0 8.261693437816575e-06
were O 0 1.8474523812983534e-06
minute O 0 1.5096907191036735e-05
deletions O 0 2.8348631531116553e-05
, O 0 6.772563210688531e-06
4649delA O 0 4.8110392526723444e-05
in O 0 2.750155999819981e-06
exon O 0 3.1518378818873316e-05
33 O 0 1.621446426725015e-05
and O 0 4.149497726757545e-06
7883del5 O 0 0.00010094225581269711
in O 0 1.1480477041914128e-05
exon O 0 0.00032942264806479216
55 O 0 0.00024018831027206033
. O 0 0.00011748148244805634

The O 0 5.594426693278365e-05
mutations O 0 1.8203551007900387e-05
4612del165 O 0 0.00010215879592578858
and O 0 3.111985961368191e-06
7883del5 O 0 0.0001080672736861743
were O 0 7.54259644963895e-07
found O 0 2.449031910600752e-07
in O 0 1.0883839962616548e-07
more O 0 3.7652021944722947e-08
than O 0 5.8571529848450155e-08
two O 0 6.570104460479342e-08
unrelated O 0 5.130231102157268e-07
families O 0 5.6204168430440404e-08
; O 0 5.239444078597444e-08
44 O 0 3.295972419437021e-07
% O 0 1.0223251933894062e-07
( O 0 7.299431104001997e-08
7 O 0 2.0041689197114465e-07
of O 0 7.781090261005374e-08
16 O 0 2.541415540235903e-07
) O 0 1.0685956652878303e-07
of O 0 2.27565635668725e-07
the O 0 3.295764940958179e-07
mutant O 0 1.7375264178554062e-06
alleles O 0 3.1601797445546254e-07
had O 0 3.961255572448863e-07
one O 0 2.5353756427648477e-07
of O 0 9.037674999490264e-07
the O 0 1.1986520576101611e-06
two O 0 1.5649625311198179e-06
mutations O 0 6.945637323951814e-06
. O 0 1.912565312522929e-05

The O 0 0.00011981729039689526
4612del165 O 0 0.000840271299239248
mutations O 0 6.751398359483574e-06
in O 0 5.477301669998269e-07
three O 0 3.9407314034178853e-07
different O 0 8.173883259132708e-08
families O 0 7.075337293827033e-08
were O 0 8.760336811519664e-08
all O 0 7.976589699865144e-08
ascribed O 0 1.1051098454117891e-06
to O 0 2.2691591539114597e-07
the O 0 5.239354550212738e-07
same O 0 5.656594339598087e-07
T O 0 2.4531427698093466e-05
- O 0 1.1085160622315016e-05
- O 0 1.15819320853916e-05
> O 0 5.046446403866867e-06
A O 0 2.4926289370341692e-06
substitution O 0 1.44831483339658e-06
at O 0 1.681677076703636e-06
the O 0 1.2120043493268895e-06
splice O 0 1.725070978864096e-05
donor O 0 2.2507326775667025e-06
site O 0 1.1351088687661104e-05
in O 0 4.2455430957488716e-06
intron O 0 0.00037752435309812427
33 O 0 0.00019089467241428792
. O 0 0.00011173744860570878

Microsatellite O 0 0.0030666429083794355
genotyping O 0 0.0003475597477518022
around O 0 2.206203862442635e-05
the O 0 7.746386472717859e-06
ATM O 0 0.1296602487564087
locus O 0 0.0008894822676666081
also O 0 1.5366733805421973e-06
indicated O 0 1.0882444030357874e-06
that O 0 1.7008110830829537e-07
a O 0 3.433894164572848e-07
common O 0 4.380325435704435e-07
haplotype O 0 4.219853963149944e-06
was O 0 2.5418642053409712e-06
shared O 0 3.06832475871488e-07
by O 0 1.260930275748251e-07
the O 0 6.528657081616984e-07
mutant O 0 6.55893791190465e-06
alleles O 0 7.965276722643466e-07
in O 0 9.852494713413762e-07
both O 0 2.2033489130990347e-06
mutations O 0 1.3421599760476965e-05
. O 0 2.5703804567456245e-05

This O 0 1.4478630873782095e-05
suggests O 0 8.14944814919727e-06
that O 0 3.588008326005365e-07
these O 0 1.1617496653570925e-07
two O 0 1.518001653266765e-07
founder O 0 4.182006887276657e-05
mutations O 0 1.4264375067796209e-06
may O 0 5.398094913289242e-07
be O 0 6.063456794436206e-07
predominant O 0 8.31572924653301e-06
among O 0 2.6907514438789804e-06
Japanese O 0 3.969956742366776e-05
ATM O 0 0.003347994526848197
mutant O 0 0.00025439250748604536
alleles O 0 5.019166201236658e-05
. O 0 7.21011238056235e-05

W474C O 0 0.001910772523842752
amino O 0 7.036336319288239e-05
acid O 0 1.815577343222685e-05
substitution O 0 9.971115105145145e-06
affects O 0 1.6762523955549113e-06
early O 0 6.992219709900382e-07
processing O 0 8.909260600376001e-07
of O 0 7.021333203738322e-07
the O 0 5.1500938980098e-07
alpha O 0 1.749735019984655e-06
- O 0 1.6865211591721163e-06
subunit O 0 1.5643804545106832e-06
of O 0 6.221257535798941e-07
beta O 0 3.592710072553018e-06
- O 0 1.3951697837910615e-05
hexosaminidase O 0 0.0001347078214166686
A O 0 4.685481599153718e-06
and O 0 4.5187510977484635e-07
is O 0 3.223430837806518e-07
associated O 0 3.0832259767521464e-07
with O 0 8.307449093081232e-07
subacute O 1 0.9999938011169434
G B-Disease 1 0.9998795986175537
( I-Disease 0 4.189535684417933e-05
M2 I-Disease 1 1.0
) I-Disease 0 4.9719088565325364e-05
gangliosidosis I-Disease 0 0.0016598632792010903
. O 0 0.0001512490416644141

Mutations O 0 5.5078922741813585e-05
in O 0 4.484874352783663e-06
the O 0 4.833315415453399e-06
HEXA O 0 0.4143028259277344
gene O 0 2.0967756881873356e-06
, O 0 6.795555691496702e-07
encoding O 0 7.699550224060658e-07
the O 0 5.709088100047666e-07
alpha O 0 2.3918491933727637e-06
- O 0 2.0087568373128306e-06
subunit O 0 1.9211031485610874e-06
of O 0 5.867674985893245e-07
beta O 0 2.527351171011105e-06
- O 0 3.922107680409681e-06
hexosaminidase O 0 4.001870547654107e-05
A O 0 5.5743075790815055e-06
( O 0 1.0151730975849205e-06
Hex O 0 8.435965719399974e-05
A O 0 4.235848791722674e-06
) O 0 5.241998337623954e-07
, O 0 3.5205169979235507e-07
that O 0 2.3076270849742286e-07
abolish O 0 5.906283604417695e-06
Hex O 0 0.00019978285126853734
A O 0 1.3755246982327662e-05
enzyme O 0 4.158014689892298e-06
activity O 0 4.2603628571669105e-06
cause O 0 0.00010146957356482744
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999992847442627
( O 0 1.8701564840739593e-05
TSD B-Disease 1 0.9999996423721313
) O 0 1.7160919014713727e-06
, O 0 9.88848228189454e-07
the O 0 1.1013223684130935e-06
fatal O 0 3.61374877684284e-05
infantile B-Disease 0 4.667514804168604e-05
form I-Disease 0 9.137208962783916e-07
of I-Disease 0 8.559885827708058e-06
G I-Disease 1 0.656894862651825
( I-Disease 0 3.0177366170391906e-06
M2 I-Disease 1 0.9999983310699463
) I-Disease 0 3.2971904602163704e-06
gangliosidosis I-Disease 0 8.479163079755381e-05
, I-Disease 0 4.03004014515318e-06
Type I-Disease 0 1.9180759409209713e-05
1 I-Disease 0 7.605554128531367e-05
. O 0 6.008322088746354e-05

Less O 0 0.0001369325036648661
severe O 1 0.7952496409416199
, O 0 4.2978907003998756e-05
subacute O 1 1.0
( O 0 0.002006493043154478
juvenile O 1 1.0
- O 1 0.9999841451644897
onset O 1 0.9976540207862854
) O 0 4.880737833445892e-06
and O 0 3.5911482427763985e-06
chronic O 1 1.0
( O 0 8.95254470378859e-06
adult O 0 8.479571079078596e-06
- O 0 0.030834179371595383
onset O 0 0.00011997550609521568
) O 0 4.882376742898487e-07
variants O 0 5.887731049369904e-07
are O 0 8.058233902374923e-08
characterized O 0 2.2177168546022585e-07
by O 0 7.906956511760654e-08
a O 0 3.55405148866339e-07
broad O 0 1.2685389947364456e-06
spectrum O 0 2.823730710588279e-06
of O 0 1.950494606717257e-06
clinical O 0 0.02234600856900215
manifestations O 0 0.0015296661294996738
and O 0 5.730853445129469e-07
are O 0 1.0312339782103663e-07
associated O 0 1.3717533420276595e-07
with O 0 1.8773619103740202e-07
residual O 0 0.000311951880576089
levels O 0 1.5643640836060513e-06
of O 0 3.224942247470608e-06
Hex O 0 0.10626455396413803
A O 0 5.718600732507184e-05
enzyme O 0 1.3824893358105328e-05
activity O 0 1.825097388064023e-05
. O 0 2.7321542802383192e-05

We O 0 5.012789188185707e-05
identified O 0 1.453687855246244e-05
a O 0 1.2323088412813377e-05
1422 O 0 0.09201783686876297
G O 0 0.011438233777880669
- O 0 0.0015906533226370811
- O 0 0.00012773906928487122
> O 0 1.852931200119201e-05
C O 0 1.7418817151337862e-05
( O 0 8.826078783386038e-07
amino O 0 6.599544235541543e-07
acid O 0 1.1889499091921607e-06
W474C O 0 7.097961315594148e-06
) O 0 3.7313472489586275e-07
substitution O 0 6.176206284180807e-07
in O 0 1.8843161342374515e-07
the O 0 2.6846586820283846e-07
first O 0 2.778572820716363e-07
position O 0 4.070184331794735e-07
of O 0 9.255509212380275e-07
exon O 0 7.61427145334892e-06
13 O 0 2.0725337890326045e-06
of O 0 2.6680706923798425e-06
HEXA O 1 0.9736594557762146
of O 0 3.365018756085192e-06
a O 0 2.1195262434048345e-06
non O 0 2.6683660507842433e-06
- O 0 9.11458846530877e-06
Jewish O 0 4.486769284994807e-06
proband O 0 4.9536643928149715e-05
who O 0 2.885991762013873e-06
manifested O 0 4.001741672254866e-06
a O 0 3.5502509945217753e-06
subacute O 0 0.32866424322128296
variant O 0 3.38873578584753e-05
of O 0 3.8099107769085094e-05
G B-Disease 1 0.990535318851471
( I-Disease 0 2.4049228159128688e-05
M2 I-Disease 1 0.9999995231628418
) I-Disease 0 3.677792119560763e-05
gangliosidosis I-Disease 0 0.0009354045614600182
. O 0 5.876085924683139e-05

On O 0 5.5377437092829496e-05
the O 0 1.111982601287309e-05
second O 0 1.9022569176740944e-05
maternally O 0 7.665930752409622e-05
inherited O 0 5.010252061765641e-05
allele O 0 4.698830252891639e-06
, O 0 1.1986405752395513e-06
we O 0 3.302791071746469e-07
identified O 0 5.505791591531306e-07
the O 0 7.166839850469842e-07
common O 0 7.884734259278048e-06
infantile O 1 1.0
disease O 1 0.9999998807907104
- O 1 0.9059281349182129
causing O 0 1.2317612345214002e-05
4 O 0 5.970976872049505e-06
- O 0 6.5118197198899e-06
bp O 0 4.859790351474658e-06
insertion O 0 3.2698787890694803e-06
, O 0 1.4654193591923104e-06
+ O 0 1.4388307135959622e-05
TATC O 0 0.1666167974472046
1278 O 0 0.06189296022057533
, O 0 4.5288566070667e-06
in O 0 4.434425591171021e-06
exon O 0 0.00012902298476547003
11 O 0 6.606260285479948e-05
. O 0 8.381937368540093e-05

Pulse O 0 0.001609554048627615
- O 0 0.00024664969532750547
chase O 0 6.082882100599818e-05
analysis O 0 4.208737664157525e-06
using O 0 3.215704282411025e-06
proband O 0 0.00014926429139450192
fibroblasts O 0 1.7500588000984862e-05
revealed O 0 4.334492132329615e-06
that O 0 5.012230417378305e-07
the O 0 1.2623263501154725e-06
W474C O 0 2.1278350686770864e-05
- O 0 3.14363433062681e-06
containing O 0 1.7006534562824527e-06
alpha O 0 3.532190021360293e-06
- O 0 2.768550302789663e-06
subunit O 0 4.106148935534293e-06
precursor O 0 3.4273448363819625e-06
was O 0 1.5444173868672806e-06
normally O 0 2.3845873897698766e-07
synthesized O 0 7.303086135834747e-07
, O 0 1.4201066278474173e-07
but O 0 8.264006368108312e-08
not O 0 7.31158209532623e-08
phosphorylated O 0 1.1381711146896123e-06
or O 0 3.098063530160289e-07
secreted O 0 8.982099188870052e-07
, O 0 3.2966670460155e-07
and O 0 2.594017871615506e-07
the O 0 6.105863690208935e-07
mature O 0 2.6153829821851104e-06
lysosomal O 0 4.6786477469140664e-05
alpha O 0 1.3009411304665264e-05
- O 0 1.5100189557415433e-05
subunit O 0 1.943166716955602e-05
was O 0 1.3300451428222004e-05
not O 0 2.1499167814909015e-06
detected O 0 3.1237639632308856e-05
. O 0 2.9720802558586e-05

When O 0 3.387737524462864e-05
the O 0 1.218302804772975e-05
W474C O 0 8.884559792932123e-05
- O 0 1.5479738067369908e-05
containing O 0 7.061368705763016e-06
alpha O 0 9.687842975836247e-06
- O 0 8.958522812463343e-06
subunit O 0 7.913043191365432e-06
was O 0 9.650028005125932e-06
transiently O 0 2.4197681341320276e-05
co O 0 4.7270827963075135e-06
- O 0 3.996143277618103e-06
expressed O 0 6.992225962676457e-07
with O 0 1.6068116792666842e-07
the O 0 4.6941804043854063e-07
beta O 0 1.5450848422915442e-06
- O 0 1.4792977935940144e-06
subunit O 0 1.3631610045194975e-06
to O 0 1.9863738032199763e-07
produce O 0 6.614060907850217e-07
Hex O 0 5.3975967603037134e-05
A O 0 6.889035830681678e-06
( O 0 1.815432597140898e-06
alphabeta O 0 3.786764500546269e-05
) O 0 7.252786531353195e-07
in O 0 7.455731747540995e-07
COS O 0 0.0715269222855568
- O 0 8.858562978275586e-06
7 O 0 4.150867425778415e-06
cells O 0 3.565169208741281e-07
, O 0 1.9233748105307313e-07
the O 0 2.4319254521287803e-07
mature O 0 4.6313218149407476e-07
alpha O 0 1.193537173094228e-06
- O 0 7.089263363013742e-07
subunit O 0 8.971218790065905e-07
was O 0 6.586516292372835e-07
present O 0 1.4412916016226518e-07
, O 0 1.0951475104548081e-07
but O 0 5.2790269933211675e-08
its O 0 9.618263874244803e-08
level O 0 5.06789490373194e-07
was O 0 1.5171968925642432e-06
much O 0 4.3083616674266523e-07
lower O 0 4.650087248592172e-07
than O 0 6.483710279781008e-08
that O 0 2.3275092075891735e-08
from O 0 8.236232673652921e-08
normal O 0 3.6478076026469353e-07
alpha O 0 1.749411239870824e-06
- O 0 2.113337814080296e-06
subunit O 0 5.2973919082432985e-06
transfections O 0 2.817355743900407e-05
, O 0 4.7025321237015305e-07
although O 0 1.3597147585642233e-07
higher O 0 1.8997833706180245e-07
than O 0 1.2020160511383438e-07
in O 0 1.3539191456857225e-07
those O 0 1.9576697241063812e-07
cells O 0 3.4481988109291706e-07
transfected O 0 1.9823592083412223e-06
with O 0 9.940250578210907e-08
an O 0 4.914989517601498e-07
alpha O 0 5.0437711252016015e-06
- O 0 4.975818683305988e-06
subunit O 0 9.222273547493387e-06
associated O 0 1.788566009963688e-06
with O 0 5.851039531989954e-06
infantile O 1 0.9662055373191833
TSD B-Disease 1 0.9999998807907104
. O 0 0.0002540827263146639

Furthermore O 0 0.00011166522745043039
, O 0 9.343698366137687e-06
the O 0 4.178869403403951e-06
precursor O 0 1.6027917808969505e-05
level O 0 4.1960056478274055e-06
of O 0 2.314498033229029e-06
the O 0 1.8146953379982733e-06
W474C O 0 1.6748888810980134e-05
alpha O 0 4.560582510748645e-06
- O 0 3.0282103580248076e-06
subunit O 0 2.9873388029955095e-06
was O 0 1.4206893865775783e-06
found O 0 1.39247845254431e-07
to O 0 1.449006816756082e-07
accumulate O 0 1.018478769765352e-06
in O 0 2.7393798518460244e-07
comparison O 0 4.878178287981427e-07
to O 0 2.8770145377166045e-07
the O 0 5.998899723635986e-07
normal O 0 9.14289216780162e-07
alpha O 0 5.810879429191118e-06
- O 0 7.941089279484004e-06
subunit O 0 2.7646306989481673e-05
precursor O 0 3.55894590029493e-05
levels O 0 1.3603113075078e-05
. O 0 2.456858055666089e-05

We O 0 3.566359737305902e-05
conclude O 0 1.2389996300044004e-05
that O 0 1.765683123267081e-06
the O 0 3.930075763491914e-06
1422 O 0 0.006760084070265293
G O 0 0.00042334262980148196
- O 0 9.805610170587897e-05
- O 0 5.449887612485327e-05
> O 0 1.5124111996556167e-05
C O 0 1.1134332453366369e-05
mutation O 0 8.485318971906963e-07
is O 0 2.3086309397513105e-07
the O 0 2.7669034352584276e-07
cause O 0 5.438959647108277e-07
of O 0 2.4912408207455883e-06
Hex B-Disease 1 0.9999949932098389
A I-Disease 1 0.9988687634468079
enzyme I-Disease 1 0.999751627445221
deficiency I-Disease 1 0.9999998807907104
in O 0 4.9079026211984456e-06
the O 0 1.675954626989551e-05
proband O 0 0.48817193508148193
. O 0 9.324510756414384e-05

The O 0 7.429951801896095e-05
resulting O 0 3.508034933474846e-05
W474C O 0 0.0001980973029276356
substitution O 0 1.9475841327221133e-05
clearly O 0 5.3876838137512095e-06
interferes O 0 3.940392616641475e-06
with O 0 4.3386839365666674e-07
alpha O 0 5.549129582504975e-06
- O 0 3.1200509056361625e-06
subunit O 0 2.271595803904347e-06
processing O 0 9.610266715753824e-07
, O 0 2.5776901679819275e-07
but O 0 1.0389474169869573e-07
because O 0 1.1849049741385898e-07
the O 0 3.036785756194149e-07
base O 0 1.372212977912568e-06
substitution O 0 1.927509629240376e-06
falls O 0 7.367882972175721e-06
at O 0 9.707686103865854e-07
the O 0 3.88578996535216e-07
first O 0 4.5616687316396565e-07
position O 0 4.699797386820137e-07
of O 0 8.084479645731335e-07
exon O 0 5.614455403701868e-06
13 O 0 8.851848178892396e-07
, O 0 3.1536586675429135e-07
aberrant O 0 1.0252205129290815e-06
splicing O 0 8.885925808499451e-07
may O 0 1.9860895861256722e-07
also O 0 3.1389859600494674e-07
contribute O 0 5.246754426480038e-07
to O 0 4.6754425397921295e-07
Hex B-Disease 1 0.9999798536300659
A I-Disease 1 0.9680668711662292
deficiency I-Disease 1 0.9886272549629211
in O 0 1.416941358911572e-06
this O 0 1.8442643749949639e-06
proband O 0 0.0017601035069674253
. O 0 9.093984772334807e-06
. O 0 4.2150786612182856e-05

Two O 0 5.3194864449324086e-05
frequent O 0 0.00011076633381890133
missense O 0 0.0003485480847302824
mutations O 0 5.488335955305956e-05
in O 0 0.00010078643390443176
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.005354007240384817

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.00015505036571994424
an O 0 0.05637752637267113
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999927282333374
by O 0 4.981100937584415e-05
early O 1 0.9762939810752869
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 1.0
goiter B-Disease 1 1.0
. O 1 0.9998996257781982

A O 0 0.00010013626888394356
century O 0 1.0216530426987447e-05
after O 0 1.8505292018744512e-06
its O 0 3.189606729847583e-07
recognition O 0 7.245182018777996e-07
as O 0 6.782418608963781e-07
a O 0 7.004038707236759e-06
syndrome O 1 0.9438618421554565
by O 0 5.600304007202794e-07
Vaughan O 0 0.24461247026920319
Pendred O 1 0.9999980926513672
, O 0 2.35240099755174e-06
the O 0 2.1679816200048663e-06
disease O 0 0.0006552044069394469
gene O 0 2.4999037577799754e-06
( O 0 3.6744727367477026e-06
PDS O 1 0.9999992847442627
) O 0 2.891018993977923e-06
was O 0 8.332368452101946e-06
mapped O 0 8.856459317030385e-06
to O 0 2.6072048058267683e-06
chromosome O 0 3.680468944367021e-05
7q22 O 0 0.0005656949942931533
- O 0 0.0006201979704201221
q31 O 0 0.0018127926159650087
. O 0 0.00011499432002892718

1 O 0 9.365555888507515e-05
and O 0 9.014415809360798e-06
, O 0 4.136463758186437e-06
recently O 0 7.546707365690963e-06
, O 0 1.3990237448524567e-06
found O 0 5.752723382101976e-07
to O 0 8.065919701039093e-07
encode O 0 3.6761023238796042e-06
a O 0 7.78183948568767e-06
putative O 0 0.0001534114999230951
sulfate O 0 0.00033840449759736657
transporter O 0 0.2713961601257324
. O 0 0.000159243936650455

We O 0 1.5873281881795265e-05
performed O 0 6.189228770381305e-06
mutation O 0 1.218766556121409e-06
analysis O 0 4.25227142386575e-07
of O 0 5.292627633934899e-07
the O 0 1.6575137351537705e-06
PDS B-Disease 1 1.0
gene O 0 2.2445829017669894e-06
in O 0 7.784071271998982e-07
patients O 0 4.574773413423827e-07
from O 0 3.152461829358799e-07
14 O 0 1.790634428289195e-06
Pendred B-Disease 0 0.0011198512511327863
families O 0 1.263802857920382e-07
originating O 0 2.2264816834649537e-07
from O 0 1.4542605697442923e-07
seven O 0 1.728099050524179e-07
countries O 0 2.509112739801367e-08
and O 0 3.0046595611565863e-07
identified O 0 1.063274453372287e-06
all O 0 1.3986075373395579e-06
mutations O 0 9.746437171997968e-06
. O 0 2.5356914193253033e-05

The O 0 4.297120904084295e-05
mutations O 0 5.411463916971115e-06
include O 0 2.179482635256136e-06
three O 0 7.978399025887484e-07
single O 0 1.3141460613042e-06
base O 0 4.307546078052837e-06
deletions O 0 5.98755923419958e-06
, O 0 1.6366477666451829e-06
one O 0 1.5014057908047107e-06
splice O 0 1.6003265045583248e-05
site O 0 9.420717105967924e-06
mutation O 0 2.695232751648291e-06
and O 0 1.441232711840712e-06
10 O 0 1.0110397852258757e-05
missense O 0 0.00019282041466794908
mutations O 0 4.210949191474356e-05
. O 0 7.20545940566808e-05

One O 0 0.00010050945274997503
missense O 0 0.00016551556473132223
mutation O 0 1.0790677151817363e-05
( O 0 2.6816494482773123e-06
L236P O 0 5.4750009439885616e-05
) O 0 1.4560552017428563e-06
was O 0 3.6307224036136176e-06
found O 0 3.5099432693641575e-07
in O 0 1.2051886244535126e-07
a O 0 4.335796859322727e-07
homozygous O 0 8.753887072998623e-07
state O 0 1.718108109116656e-07
in O 0 1.4508347589980986e-07
two O 0 1.399729541162742e-07
consanguineous O 0 5.456985945784254e-06
families O 0 1.0383135418123857e-07
and O 0 1.5358266125531372e-07
in O 0 1.860091174421541e-07
a O 0 5.301457690620737e-07
heterozygous O 0 5.161703597877931e-07
state O 0 1.0288272989100733e-07
in O 0 1.1261192156553079e-07
five O 0 2.1959094453904981e-07
additional O 0 9.880874358714209e-07
non O 0 8.040958164201584e-06
- O 0 0.00013238943938631564
consanguineous O 0 0.00019121986406389624
families O 0 7.196535534603754e-06
. O 0 4.143398109590635e-05

Another O 0 0.00015247160627041012
missense O 0 0.00027709812275134027
mutation O 0 1.7379907149006613e-05
( O 0 3.354694854351692e-06
T416P O 0 5.489251998369582e-05
) O 0 1.143903659794887e-06
was O 0 2.79632718047651e-06
found O 0 2.845872870693711e-07
in O 0 1.0964244978595161e-07
a O 0 2.941255274890864e-07
homozygous O 0 4.847302079724614e-07
state O 0 1.7211698377650464e-07
in O 0 1.262530702206277e-07
one O 0 2.707426176584704e-07
family O 0 2.7859144324793306e-07
and O 0 1.2667483417772019e-07
in O 0 1.847864865567317e-07
a O 0 5.359552233130671e-07
heterozygous O 0 7.909744681455777e-07
state O 0 3.3600758797547314e-07
in O 0 6.388603424056782e-07
four O 0 2.275025508424733e-06
families O 0 4.416965111886384e-06
. O 0 3.12979900627397e-05

Pendred B-Disease 1 0.9999935626983643
patients O 0 2.7622640118352138e-05
in O 0 1.2797922863683198e-06
three O 0 1.1224827858313802e-06
non O 0 9.24237428989727e-06
- O 0 0.0003431520890444517
consanguineous O 0 3.119652683380991e-05
families O 0 2.758935409019614e-07
were O 0 1.2893733014607278e-07
shown O 0 1.0358903068663494e-07
to O 0 2.0580067427999893e-07
be O 0 4.3259089466118894e-07
compound O 0 5.468436938826926e-06
heterozygotes O 0 1.6873103959369473e-05
for O 0 3.2767338780104183e-06
L236P O 0 0.00028476814622990787
and O 0 1.3229332580522168e-05
T416P O 0 0.0008451213943772018
. O 0 6.800732808187604e-05

In O 0 1.1994423402938992e-05
total O 0 4.495661414694041e-06
, O 0 1.5591199371556286e-06
one O 0 6.38655023976753e-07
or O 0 2.3745978694478254e-07
both O 0 7.018696379645917e-08
of O 0 3.5138219800501247e-07
these O 0 8.288395036970542e-08
mutations O 0 1.227761572408781e-07
were O 0 1.4238032974844828e-07
found O 0 1.4298163364401262e-07
in O 0 1.1680108258360633e-07
nine O 0 4.24872467874593e-07
of O 0 4.4054280579075566e-07
the O 0 7.286216145985236e-07
14 O 0 2.129161430275417e-06
families O 0 6.789142616980826e-07
analyzed O 0 8.888298907550052e-06
. O 0 2.3869135475251824e-05

The O 0 3.777066740440205e-05
identification O 0 8.140624231600668e-06
of O 0 4.573064416035777e-06
two O 0 1.1205938790226355e-06
frequent O 0 8.412748684349936e-06
PDS B-Disease 1 1.0
mutations O 0 3.047246082132915e-06
will O 0 5.477417062138557e-07
facilitate O 0 1.0658867495294544e-06
the O 0 1.6095383443825995e-06
molecular O 0 2.2503641957882792e-05
diagnosis O 0 0.0055776131339371204
of O 1 0.9993504881858826
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.001573687419295311

Insertional O 0 0.002852359088137746
mutation O 0 2.8337117328192107e-05
by O 0 4.8643851187080145e-06
transposable O 0 0.0005988993216305971
element O 0 6.82132231304422e-05
, O 0 6.460603344748961e-06
L1 O 1 0.9825656414031982
, O 0 2.132762574547087e-06
in O 0 7.59139368256001e-07
the O 0 2.677022166608367e-06
DMD B-Disease 1 1.0
gene O 0 2.3091051843948662e-06
results O 0 7.857477157813264e-07
in O 0 1.0795490652526496e-06
X B-Disease 1 0.9993054866790771
- I-Disease 1 0.9999938011169434
linked I-Disease 1 0.9990623593330383
dilated I-Disease 1 0.9793713092803955
cardiomyopathy I-Disease 1 1.0
. O 0 0.0005587938358075917

X B-Disease 1 0.9999905824661255
- I-Disease 1 0.9999959468841553
linked I-Disease 1 0.9999929666519165
dilated I-Disease 1 0.9999945163726807
cardiomyopathy I-Disease 1 1.0
( O 0 0.07651553303003311
XLDCM B-Disease 1 1.0
) O 0 3.063131316594081e-06
is O 0 6.927405138412723e-07
a O 0 8.229196168940689e-07
clinical O 0 4.714620899903821e-06
phenotype O 0 1.5902725181149435e-06
of O 0 2.604106157377828e-06
dystrophinopathy B-Disease 1 0.9992057681083679
which O 0 7.669167416679556e-07
is O 0 5.466202424031508e-07
characterized O 0 1.0740592415459105e-06
by O 0 4.334548009410355e-07
preferential O 0 1.1396916306694038e-05
myocardial B-Disease 1 0.9999997615814209
involvement I-Disease 0 2.204289921792224e-05
without O 0 7.335586360568414e-07
any O 0 6.506244289994356e-07
overt O 0 8.623706889920868e-06
clinical O 0 0.000239847824559547
signs O 0 0.0015119992895051837
of O 1 0.9961104989051819
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.9621676802635193

To O 0 1.1960363735852297e-05
date O 0 8.30586941447109e-06
, O 0 1.695804598966788e-06
several O 0 6.855362926216912e-07
mutations O 0 6.955341405046056e-07
in O 0 5.390965043261531e-07
the O 0 1.4286879377323203e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 1 0.9977684020996094
, O 1 0.6101806163787842
DMD O 1 1.0
, O 0 4.948980858898722e-06
have O 0 2.359279989150309e-07
been O 0 4.658965053749853e-07
identified O 0 3.640988666120393e-07
in O 0 2.157630234478347e-07
patients O 0 3.0411214879677573e-07
with O 0 3.636394296790968e-07
XLDCM B-Disease 1 1.0
, O 0 1.2154793012086884e-06
but O 0 2.5619024768275267e-07
a O 0 6.103278451519145e-07
pathogenic O 0 1.668077970862214e-06
correlation O 0 5.648594765261805e-07
of O 0 7.188469908214756e-07
these O 0 2.685419246972742e-07
cardiospecific O 0 2.95692134386627e-05
mutations O 0 1.3426032410279731e-06
in O 0 6.627983566431794e-07
DMD O 1 1.0
with O 0 1.249195065611275e-06
the O 0 1.0964075045194477e-05
XLDCM B-Disease 1 1.0
phenotype O 0 1.303216049564071e-05
has O 0 2.9327591164474143e-06
remained O 0 8.151662768796086e-06
to O 0 1.7213108094438212e-06
be O 0 4.374895979708526e-06
elucidated O 0 0.00019757854170165956
. O 0 7.082908268785104e-05

We O 0 4.152963447268121e-05
report O 0 1.0473358997842297e-05
here O 0 1.0257641633870662e-06
the O 0 4.66377485963676e-07
identification O 0 5.559409146371763e-07
of O 0 9.02088402199297e-07
a O 0 1.3468453516907175e-06
unique O 0 1.8699050770010217e-06
de O 0 2.5802242817007937e-05
novo O 0 6.871921505080536e-05
L1 O 0 0.0002105786552419886
insertion O 0 5.369935479393462e-06
in O 0 7.016728318376408e-07
the O 0 1.0747231726782047e-06
muscle O 0 4.424722192197805e-06
exon O 0 2.2534481104230508e-05
1 O 0 8.815808541839942e-06
in O 0 1.4624580444433377e-06
DMD O 1 1.0
in O 0 1.1355689366610022e-06
three O 0 1.1580235650399118e-06
XLDCM B-Disease 1 1.0
patients O 0 8.563230267100153e-07
from O 0 4.3531071014513145e-07
two O 0 4.92593756007409e-07
unrelated O 0 1.266178151126951e-05
Japanese O 0 3.3206084481207654e-05
families O 0 4.768312464875635e-06
. O 0 2.6848358174902387e-05

The O 0 4.2231382394675165e-05
insertion O 0 4.029862247989513e-05
was O 0 1.572604014654644e-05
a O 0 3.3991461805271683e-06
5 O 0 4.471596184885129e-06
- O 0 5.187861461308785e-06
truncated O 0 6.3915126702340785e-06
form O 0 5.71811142435763e-07
of O 0 1.401897861796897e-06
human O 0 2.1206624296610244e-06
L1 O 0 0.006429349072277546
inversely O 0 7.002595793892397e-06
integrated O 0 3.6578651361196535e-06
in O 0 3.417679863559897e-07
the O 0 4.195950680241367e-07
5 O 0 1.8045511751552112e-06
- O 0 6.878374733787496e-06
untranslated O 0 0.0031580314971506596
region O 0 1.383716721647943e-06
in O 0 2.927313857981062e-07
the O 0 5.326431846697233e-07
muscle O 0 1.1045219707739307e-06
exon O 0 7.432591701217461e-06
1 O 0 7.428183835145319e-06
, O 0 4.3527583670766035e-07
which O 0 8.158121289625342e-08
affected O 0 6.818836340016787e-08
the O 0 1.0120387372580808e-07
transcription O 0 8.336210726156423e-07
or O 0 2.2976620073222875e-07
the O 0 4.314479724598641e-07
stability O 0 1.31821923332609e-06
of O 0 1.153944594989298e-06
the O 0 1.02565070392302e-06
muscle O 0 1.1225405387449428e-06
form O 0 2.490114638931118e-07
of O 0 1.3437817187877954e-06
dystrophin O 0 1.2378610335872509e-05
transcripts O 0 3.480189207039075e-06
but O 0 1.74207642089641e-07
not O 0 4.936217479212246e-08
that O 0 3.9180445554620746e-08
of O 0 2.424727938432625e-07
the O 0 8.388925607505371e-07
brain O 0 0.0134609155356884
or O 0 1.6613846582913538e-06
Purkinje O 1 0.9990290403366089
cell O 0 3.796076271100901e-06
form O 0 2.3675517013543868e-07
, O 0 2.2316687875445496e-07
probably O 0 3.2678971706445736e-07
due O 0 1.577057560098183e-07
to O 0 2.277399744343711e-07
its O 0 3.5894595384888817e-07
unique O 0 1.3326200587471249e-06
site O 0 6.352251602947945e-06
of O 0 8.877235813997686e-06
integration O 0 3.675586776807904e-05
. O 0 6.342589040286839e-05

We O 0 3.531257971189916e-05
speculate O 0 1.926383629324846e-05
that O 0 7.016366794232454e-07
this O 0 2.5057514108084433e-07
insertion O 0 1.5932479300317937e-06
of O 0 7.978528060448298e-07
an O 0 1.057550662153517e-06
L1 O 0 0.0009829533519223332
sequence O 0 9.359932278130145e-07
in O 0 7.266702368724509e-07
DMD O 1 1.0
is O 0 6.221173975973215e-07
responsible O 0 5.096723612041387e-07
for O 0 1.0842193631788177e-07
some O 0 1.0204743716712983e-07
of O 0 3.8784523326285125e-07
the O 0 3.6048143670086574e-07
population O 0 1.2252502301635104e-07
of O 0 7.922171221252938e-07
Japanese O 0 9.334133210359141e-06
patients O 0 1.1641291166597512e-06
with O 0 1.4427591850108001e-06
XLDCM B-Disease 1 0.9999998807907104
. O 0 1.8205617379862815e-05
. O 0 5.083409996586852e-05

Severe O 1 0.9868001937866211
early O 0 8.5991712694522e-05
- O 1 0.9999939203262329
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.9999943971633911
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.99265056848526
red O 1 0.9999997615814209
hair O 1 0.9993867874145508
pigmentation O 1 0.9999599456787109
caused O 0 0.00012029282515868545
by O 0 5.242965471552452e-06
POMC O 1 1.0
mutations O 0 1.4119466868578456e-05
in O 0 4.966218966728775e-06
humans O 0 1.0883952199947089e-05
. O 0 2.775196662696544e-05

Sequential O 0 0.000280103093245998
cleavage O 0 0.00012702049571089447
of O 0 1.4252449545892887e-05
the O 0 6.619489795411937e-06
precursor O 0 1.5812964193173684e-05
protein O 0 2.3348738977801986e-06
pre O 0 2.2351316147251055e-05
- O 0 5.699448229279369e-05
pro O 0 0.025157006457448006
- O 0 0.005510601215064526
opiomelanocortin O 0 0.1548774540424347
( O 0 4.733249170385534e-06
POMC O 0 0.0023689959198236465
) O 0 1.5600837741658324e-06
generates O 0 1.6153232991200639e-06
the O 0 1.1920790257136105e-06
melanocortin O 0 9.405418677488342e-05
peptides O 0 3.868858129862929e-06
adrenocorticotrophin O 0 7.349673251155764e-05
( O 0 3.3225908282474848e-06
ACTH O 0 8.305585652124137e-05
) O 0 1.6015749224607134e-06
, O 0 2.1313007891876623e-06
melanocyte O 0 0.0002208637451985851
- O 0 0.00010304158058715984
stimulating O 0 6.142866186564788e-05
hormones O 0 4.073697255080333e-06
( O 0 2.2909978270035936e-06
MSH O 1 0.9122351408004761
) O 0 1.2790089840564178e-06
alpha O 0 4.806343440577621e-06
, O 0 6.576711939487723e-07
beta O 0 1.7019109463944915e-06
and O 0 4.3003731775570486e-07
gamma O 0 2.149502506654244e-06
as O 0 2.828178367053624e-07
well O 0 1.8298548809525528e-07
as O 0 2.1808227756991982e-07
the O 0 7.011417437752243e-07
opioid O 0 1.3225497241364792e-05
- O 0 1.5876488760113716e-05
receptor O 0 1.0010293408413418e-05
ligand O 0 1.0416263648949098e-05
beta O 0 4.1985305870184675e-05
- O 0 0.00033084306051023304
endorphin O 0 0.008946017362177372
. O 0 8.765917300479487e-05

While O 0 4.395865471451543e-05
a O 0 8.496497684973292e-06
few O 0 3.0959890864323825e-06
cases O 0 1.2590140840984532e-06
of O 0 3.0096036425675265e-05
isolated O 1 0.9999852180480957
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
have O 0 6.410935498024628e-07
been O 0 1.2137927569710882e-06
reported O 0 1.3310666417964967e-06
( O 0 2.2393062408809783e-06
OMIM O 1 0.9999207258224487
201400 O 0 0.0023771733976900578
) O 0 1.3425801625999156e-06
, O 0 8.3291064356672e-07
an O 0 2.414699565633782e-06
inherited O 1 0.9997860789299011
POMC O 1 1.0
defect O 1 0.9999474287033081
has O 0 4.414926934259711e-06
not O 0 4.784337193086685e-07
been O 0 1.0344583643018268e-06
described O 0 3.0976193556853104e-06
so O 0 2.3759439500281587e-06
far O 0 1.0774513611977454e-05
. O 0 3.414033562876284e-05

Recent O 0 6.54319956083782e-05
studies O 0 9.389415026817005e-06
in O 0 1.430966449333937e-06
animal O 0 4.145234470342984e-06
models O 0 2.014158781094011e-06
elucidated O 0 1.1633163012447767e-05
a O 0 1.5425317769768299e-06
central O 0 2.5103513507929165e-06
role O 0 1.239646280737361e-06
of O 0 1.9159178918926045e-06
alpha O 0 3.075787753914483e-05
- O 0 0.011532824486494064
MSH O 1 0.9999964237213135
in O 0 7.046280074973765e-07
the O 0 4.7238921752068563e-07
regulation O 0 4.809901383850956e-07
of O 0 4.333961101110617e-07
food O 0 2.862263670522225e-07
intake O 0 4.5858334374315746e-07
by O 0 6.143689290638576e-08
activation O 0 5.462090939545305e-07
of O 0 1.3237382745501236e-06
the O 0 2.383271748840343e-06
brain O 0 1.580513890075963e-05
melanocortin O 0 0.007216978818178177
- O 0 8.444796549156308e-06
4 O 0 4.611938493326306e-06
- O 0 3.462213953753235e-06
receptor O 0 2.032660404438502e-06
( O 0 8.622536142866011e-07
MC4 O 0 0.005721732974052429
- O 0 9.393964319315273e-06
R O 0 1.4747924069524743e-05
; O 0 3.9039312582644925e-07
refs O 0 4.878578238276532e-06
3 O 0 9.73945589066716e-07
- O 0 8.240818942795158e-07
5 O 0 5.536330149880087e-07
) O 0 1.3140993360138964e-07
and O 0 1.0312162856962459e-07
the O 0 1.9140409790452395e-07
linkage O 0 1.9842714209517e-06
of O 0 1.7272767536269384e-06
human O 0 2.0886807305942057e-06
obesity B-Disease 1 0.9999819993972778
to O 0 6.976426902838284e-07
chromosome O 0 8.420345238846494e-07
2 O 0 8.865753784448316e-07
in O 0 1.205155228944932e-07
close O 0 6.837165642537002e-07
proximity O 0 8.185739375221601e-07
to O 0 3.0324272870529967e-07
the O 0 1.4308873232948827e-06
POMC O 1 0.6205378174781799
locus O 0 4.7305100451922044e-05
, O 0 1.164697664535197e-06
led O 0 8.862922413754859e-07
to O 0 2.0979007331334287e-07
the O 0 2.452437399824703e-07
proposal O 0 2.0746286111261725e-07
of O 0 2.557188736318494e-07
an O 0 2.717758320613939e-07
association O 0 5.400051463766431e-07
of O 0 6.515907898574369e-06
POMC O 1 1.0
with O 0 1.250189779966604e-05
human O 0 0.00010375225974712521
obesity B-Disease 1 1.0
. O 0 0.00014272496628109366

The O 0 3.655591353890486e-05
dual O 0 4.2241616029059514e-05
role O 0 1.675914609222673e-05
of O 0 1.4791673493164126e-05
alpha O 0 0.002253474434837699
- O 1 0.9979504942893982
MSH O 1 1.0
in O 0 1.6940135765253217e-06
regulating O 0 3.0106023132248083e-06
food O 0 9.077496088139014e-07
intake O 0 2.041815150732873e-06
and O 0 2.9627412345689663e-07
influencing O 0 5.072975454822881e-06
hair O 0 3.0443006835412234e-05
pigmentation O 0 0.0012132041156291962
predicts O 0 5.3467656471184455e-06
that O 0 2.9655961952812504e-07
the O 0 5.205496904636675e-07
phenotype O 0 1.002524527393689e-06
associated O 0 1.9400431483518332e-07
with O 0 2.2873119576161116e-07
a O 0 2.540984269217006e-06
defect O 0 0.00789335835725069
in O 0 2.4658827442181064e-06
POMC O 1 0.9999995231628418
function O 0 1.6240009017565171e-06
would O 0 6.628565643040929e-07
include O 0 3.0893679650034755e-06
obesity B-Disease 1 1.0
, O 0 3.1434785796591314e-06
alteration O 0 3.8163401768542826e-05
in O 0 5.729198619519593e-06
pigmentation O 1 0.9999468326568604
and O 0 0.018427791073918343
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
. O 0 0.00022874560090713203

The O 0 6.364958971971646e-05
observation O 0 0.00012326710566412657
of O 0 1.2048319149471354e-05
these O 0 1.576710360495781e-06
symptoms O 0 8.743559192225803e-06
in O 0 5.543896577364649e-07
two O 0 7.20892842309695e-07
probands O 0 0.04794394597411156
prompted O 0 3.143382400594419e-06
us O 0 8.91420654625108e-07
to O 0 3.477982204458385e-07
search O 0 1.3626463442051318e-06
for O 0 5.059207524027443e-07
mutations O 0 1.2605662504938664e-06
within O 0 9.166193422061042e-07
their O 0 2.1621299310936593e-06
POMC O 1 0.991557240486145
genes O 0 3.571253182599321e-05
. O 0 6.085806307964958e-05

Patient O 0 0.0001025504752760753
1 O 0 2.411748755548615e-05
was O 0 7.878104952396825e-06
found O 0 5.140471444065042e-07
to O 0 1.8832831472082034e-07
be O 0 1.922336849702333e-07
a O 0 5.758619181506219e-07
compound O 0 3.026157628482906e-06
heterozygote O 0 6.371308245434193e-06
for O 0 4.187372155683988e-07
two O 0 2.639457648001553e-07
mutations O 0 3.3609828165026556e-07
in O 0 2.0726827187900199e-07
exon O 0 6.730024324497208e-06
3 O 0 2.724528485487099e-06
( O 0 9.46387160638551e-07
G7013T O 0 1.5993136912584305e-05
, O 0 8.032328651097487e-07
C7133delta O 0 3.441579974605702e-05
) O 0 4.286460182356677e-07
which O 0 8.781180582673187e-08
interfere O 0 2.12056434634178e-07
with O 0 7.874853480416277e-08
appropriate O 0 3.177065650561417e-07
synthesis O 0 1.804093471946544e-06
of O 0 3.4078286716976436e-06
ACTH O 0 0.0003574306902009994
and O 0 4.764285222336184e-06
alpha O 0 0.00017993137589655817
- O 0 0.4582703709602356
MSH O 1 0.9999966621398926
. O 0 0.0003039944567717612

Patient O 0 0.0002033622149610892
2 O 0 4.361853643786162e-05
was O 0 1.737354432407301e-05
homozygous O 0 4.7002554310893174e-06
for O 0 3.9531681750304415e-07
a O 0 7.956553531585087e-07
mutation O 0 5.147923616277694e-07
in O 0 3.6544130921356555e-07
exon O 0 1.1669674677250441e-05
2 O 0 9.148115168500226e-06
( O 0 2.407654164926498e-06
C3804A O 0 4.840386100113392e-05
) O 0 2.649899215612095e-06
which O 0 4.197930138616357e-06
abolishes O 0 0.0002647762594278902
POMC O 1 0.815483033657074
translation O 0 0.0001929686841322109
. O 0 0.00011313918366795406

These O 0 1.5202228496491443e-05
findings O 0 4.698211796494434e-06
represent O 0 9.636017921366147e-07
the O 0 6.274142947404471e-07
first O 0 7.962345307532814e-07
examples O 0 9.423955589227262e-07
of O 0 2.2244705633056583e-06
a O 0 1.0186158760916442e-05
genetic B-Disease 1 0.9999923706054688
defect I-Disease 1 0.9999986886978149
within O 0 2.0631821371353e-06
the O 0 5.3001917876827065e-06
POMC O 1 0.9904272556304932
gene O 0 1.164255763796973e-06
and O 0 2.99255759728112e-07
define O 0 7.38674145850382e-07
a O 0 9.872491091300617e-07
new O 0 3.57363546754641e-06
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 1.0
resulting O 0 9.671235602581874e-06
in O 0 7.318710686377017e-07
early O 0 2.944476136690355e-06
- O 1 0.9908360242843628
onset O 1 0.9999991655349731
obesity B-Disease 1 1.0
, O 1 0.9976170659065247
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.7516995668411255
red O 1 0.9999992847442627
hair O 1 0.9947565793991089
pigmentation O 1 0.9914071559906006
. O 0 2.5557494154782034e-05
. O 0 4.988583532394841e-05

A O 0 0.0004973104223608971
European O 0 9.674235479906201e-05
multicenter O 0 0.0016501073259860277
study O 0 1.5780395187903196e-05
of O 0 3.860131255351007e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.642573003366124e-06
classification O 0 4.721532150142593e-06
of O 0 1.8014493434748147e-06
105 O 0 6.678887075395323e-06
mutations O 0 3.681101361507899e-07
and O 0 1.7310846089912957e-07
a O 0 2.838137618255132e-07
general O 0 4.065311998147081e-07
system O 0 3.909497650056437e-07
for O 0 3.8598403762080125e-07
genotype O 0 1.5263822206179611e-06
- O 0 3.923716576537117e-06
based O 0 1.606483806426695e-06
prediction O 0 2.9684575565624982e-05
of O 0 2.6068042643601075e-05
metabolic O 0 0.19454243779182434
phenotype O 0 0.0001282217272091657
. O 0 8.382719533983618e-05

Phenylketonuria B-Disease 1 0.9999994039535522
( O 0 0.004487962927669287
PKU B-Disease 1 1.0
) O 0 2.279958425788209e-05
and O 0 9.382181815453805e-06
mild B-Disease 1 0.9992815852165222
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9999955892562866
MHP B-Disease 1 1.0
) O 0 7.878369797253981e-05
are O 0 2.9866237127862405e-06
allelic B-Disease 1 0.9999996423721313
disorders I-Disease 1 1.0
caused O 0 3.700163142639212e-05
by O 0 4.795940071744553e-07
mutations O 0 3.5997609870719316e-07
in O 0 2.573347614998056e-07
the O 0 5.876276532035263e-07
gene O 0 1.297209223594109e-06
encoding O 0 4.087411070941016e-06
phenylalanine O 0 8.868629083735868e-05
hydroxylase O 1 0.5371909737586975
( O 0 0.00020931771723553538
PAH O 1 1.0
) O 0 0.00011324150545988232
. O 0 9.256029443349689e-05

Previous O 0 0.00010416225268272683
studies O 0 1.1367131264705677e-05
have O 0 1.1091113947259146e-06
suggested O 0 1.9628514564828947e-06
that O 0 2.9137027013348415e-07
the O 0 5.911552989346092e-07
highly O 0 2.6390625862404704e-06
variable O 0 2.5837396151473513e-06
metabolic O 0 0.00023318319290410727
phenotypes O 0 4.140309465583414e-05
of O 1 0.9984267950057983
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.00023382640210911632
with O 0 0.0011743719223886728
PAH O 1 1.0
genotypes O 1 0.9999898672103882
. O 0 0.000498008681461215

We O 0 2.9579819965874776e-05
identified O 0 8.563355549995322e-06
both O 0 2.3009342839941382e-06
causative O 0 6.397673132596537e-05
mutations O 0 4.745086243929109e-06
in O 0 1.969081267816364e-06
686 O 1 0.9844915270805359
patients O 0 3.8134021451696754e-06
from O 0 1.2608693396032322e-06
seven O 0 3.387028073120746e-06
European O 0 1.3167669749236666e-05
centers O 0 3.829464549198747e-05
. O 0 5.6571196182630956e-05

On O 0 2.583045352366753e-05
the O 0 4.106054802832659e-06
basis O 0 1.0224025572824758e-06
of O 0 1.0214768053629086e-06
the O 0 9.696194638308953e-07
phenotypic O 0 5.5454052017012145e-06
characteristics O 0 1.4029544672666816e-06
of O 0 2.4220939849328715e-06
297 O 0 0.00019657173834275454
functionally O 0 0.013388463295996189
hemizygous O 1 0.9744275212287903
patients O 0 1.5657685707992641e-06
, O 0 4.1327274402647163e-07
105 O 0 1.9561725821404252e-06
of O 0 7.66169648613868e-07
the O 0 6.087119004405395e-07
mutations O 0 2.666363911885128e-07
were O 0 1.194788410430192e-07
assigned O 0 6.975016049182159e-07
to O 0 1.9699386655247508e-07
one O 0 4.6338138304236054e-07
of O 0 1.2016816981486045e-06
four O 0 1.3799372027278878e-06
arbitrary O 0 3.654594593172078e-06
phenotype O 0 1.833423630159814e-05
categories O 0 1.4780787751078606e-05
. O 0 5.0878810725407675e-05

We O 0 1.4477719560090918e-05
proposed O 0 5.678924480889691e-06
and O 0 1.4733464013261255e-06
tested O 0 1.4821615650362219e-06
a O 0 8.318182835864718e-07
simple O 0 6.589079362129269e-07
model O 0 6.630177722399822e-07
for O 0 3.1363347829937993e-07
correlation O 0 1.3104491927151685e-06
between O 0 9.636036111260182e-07
genotype O 0 4.866385097557213e-06
and O 0 3.997587555204518e-06
phenotypic O 0 4.811741382582113e-05
outcome O 0 5.751667413278483e-05
. O 0 8.687443914823234e-05

The O 0 6.404644955182448e-05
observed O 0 1.7906902940012515e-05
phenotype O 0 1.5020822502265219e-05
matched O 0 4.545792762655765e-06
the O 0 1.6421104191977065e-06
predicted O 0 3.2503351121704327e-06
phenotype O 0 1.459040959161939e-06
in O 0 2.1318852816420986e-07
79 O 0 1.4706412230225396e-06
% O 0 1.785260366204966e-07
of O 0 2.8397755613696063e-07
the O 0 2.471111031354667e-07
cases O 0 1.7971544252759486e-07
, O 0 1.9266811079887702e-07
and O 0 5.322644014427169e-08
in O 0 8.165157794337574e-08
only O 0 8.547877428100037e-08
5 O 0 4.2570309233269654e-07
of O 0 4.067126724294212e-07
184 O 0 2.3031868749967543e-06
patients O 0 3.8363612020475557e-07
was O 0 1.1779335409300984e-06
the O 0 3.9373168192469166e-07
observed O 0 2.4353883532057807e-07
phenotype O 0 1.759787977562155e-07
more O 0 2.995738057620656e-08
than O 0 7.281354186261524e-08
one O 0 2.691095346563088e-07
category O 0 1.0815380164785893e-06
away O 0 1.0795799880725099e-06
from O 0 6.515967925224686e-07
that O 0 6.61570140891854e-07
expected O 0 6.905112059030216e-06
. O 0 2.9445625841617584e-05

Among O 0 3.5537574149202555e-05
the O 0 4.478885784919839e-06
seven O 0 2.5115414246101864e-06
contributing O 0 4.508722668106202e-06
centers O 0 1.2792846746378927e-06
, O 0 2.008552684173992e-07
the O 0 2.013639033293657e-07
proportion O 0 4.23264452820149e-07
of O 0 8.516531124769244e-07
patients O 0 2.2529803800352965e-07
for O 0 1.2304880669944396e-07
whom O 0 4.961287345395249e-07
the O 0 3.8053303796914406e-07
observed O 0 3.731621518454631e-07
phenotype O 0 4.849475203627662e-07
did O 0 1.8149205516237998e-07
not O 0 7.696306880689008e-08
match O 0 4.5122700953470485e-07
the O 0 5.302378554006282e-07
predicted O 0 1.8342539078730624e-06
phenotype O 0 6.743965172972821e-07
was O 0 1.0659568943083286e-06
4 O 0 9.412287909071892e-07
% O 0 2.939171963589615e-07
- O 0 1.0636325669111102e-06
23 O 0 1.4700090105179697e-06
% O 0 5.560883096222824e-07
( O 0 4.410901510709664e-07
P O 0 6.7665587266674265e-06
< O 0 2.5283300146838883e-06
. O 0 2.2032217827927525e-07
0001 O 0 6.464128546213033e-06
) O 0 4.5458088493433024e-07
, O 0 2.7492961862662924e-07
suggesting O 0 3.6851935192316887e-07
that O 0 4.331423753001218e-08
differences O 0 8.426935238503575e-08
in O 0 7.784489497453251e-08
methods O 0 1.5415920984196418e-07
used O 0 1.172729895415614e-07
for O 0 1.5690541488311283e-07
mutation O 0 4.905544415123586e-07
detection O 0 2.8975111945328536e-06
or O 0 8.33644890008145e-07
phenotype O 0 1.5143332348088734e-06
classification O 0 2.653186584211653e-06
may O 0 2.2250361553233233e-07
account O 0 1.4046800345113297e-07
for O 0 1.672402731855982e-07
a O 0 7.448575161106419e-07
considerable O 0 1.538013407298422e-06
proportion O 0 1.888363385660341e-06
of O 0 3.475771336525213e-06
genotype O 0 1.8955059204017743e-05
- O 0 0.00014089625619817525
phenotype O 0 4.846963565796614e-05
inconsistencies O 0 0.00016060553025454283
. O 0 9.94144138530828e-05

Our O 0 5.256593067315407e-05
data O 0 6.423269041988533e-06
indicate O 0 2.8439540074032266e-06
that O 0 4.913105726700451e-07
the O 0 3.586808134059538e-06
PAH O 1 1.0
- O 0 0.16963227093219757
mutation O 0 5.246892214927357e-06
genotype O 0 3.212479668945889e-06
is O 0 4.922067660118046e-07
the O 0 4.5171097440288577e-07
main O 0 4.321292635722784e-06
determinant O 0 5.3262578148860484e-05
of O 0 1.279622119909618e-05
metabolic O 1 0.9981873631477356
phenotype O 0 3.676302185340319e-06
in O 0 4.1100327052845387e-07
most O 0 8.512471936228394e-07
patients O 0 4.0390209505858365e-06
with O 0 0.0032860550563782454
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 1 0.6240705847740173

In O 0 1.7217858840012923e-05
the O 0 4.658157195081003e-06
present O 0 1.1645888662314974e-06
study O 0 7.706750011493568e-07
, O 0 5.290674494062841e-07
the O 0 2.556698746047914e-07
classification O 0 1.4261844398788526e-06
of O 0 1.7920490336109651e-06
105 O 0 0.4500642716884613
PAH O 1 1.0
mutations O 0 2.2163751509651775e-06
may O 0 3.4718976849035244e-07
allow O 0 1.7364119742069306e-07
the O 0 3.8117954659355746e-07
prediction O 0 3.174732228217181e-06
of O 0 7.832623509784753e-07
the O 0 7.989454502421722e-07
biochemical O 0 4.647667083190754e-06
phenotype O 0 6.443187317017873e-07
in O 0 1.9775374937580636e-07
> O 0 1.106214995161281e-06
10 O 0 3.7076631542731775e-07
, O 0 3.371856678313634e-07
000 O 0 1.7018995777107193e-06
genotypes O 0 4.105620519112563e-06
, O 0 4.069679562235251e-07
which O 0 1.266220408524532e-07
may O 0 1.3492015682459169e-07
be O 0 7.802817947322183e-08
useful O 0 2.0201056827318098e-07
for O 0 1.3051580083356384e-07
the O 0 5.752470997322234e-07
management O 0 4.137280029681278e-06
of O 0 1.4674466001451947e-05
hyperphenylalaninemia B-Disease 1 1.0
in O 0 2.040649633272551e-05
newborns O 0 7.000556797720492e-05
. O 0 3.4081163903465495e-05

Somatic O 0 0.0017539698164910078
instability O 0 0.0002738741459324956
of O 0 8.630420052213594e-05
the O 0 7.732861558906734e-05
CTG O 1 0.9999990463256836
repeat O 0 6.920275336597115e-05
in O 0 3.8089208374003647e-06
mice O 0 5.890943612030242e-06
transgenic O 0 6.6369107116770465e-06
for O 0 8.757544947002316e-07
the O 0 3.7562545912805945e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.28385522961616516
is O 0 2.727070977925905e-06
age O 0 1.5030074109745328e-06
dependent O 0 2.7646851208373846e-07
but O 0 1.1116936349253592e-07
not O 0 5.276872627746343e-08
correlated O 0 2.8480775426942273e-07
to O 0 1.3760575257038e-07
the O 0 6.140972459434124e-07
relative O 0 2.0561853943945607e-06
intertissue O 0 8.356940088560805e-05
transcription O 0 2.7714044335880317e-05
levels O 0 1.2370785952953156e-05
and O 0 1.7199889043695293e-05
proliferative O 1 0.9998905658721924
capacities O 0 0.0008599741850048304
. O 0 0.00021628486865665764

A O 0 0.00048317157779820263
( O 0 4.230502599966712e-05
CTG O 1 0.9952914714813232
) O 0 1.2522924407676328e-05
nexpansion O 0 9.508820221526548e-05
in O 0 2.4522153125872137e-06
the O 0 2.295207650604425e-06
3 O 0 6.9257021095836535e-06
- O 0 2.227127151854802e-05
untranslated O 0 0.004394807852804661
region O 0 4.477356924326159e-06
( O 0 2.400134690105915e-06
UTR O 0 0.003457621904090047
) O 0 1.2276437928449013e-06
of O 0 1.4391794138646219e-06
the O 0 1.7694151210889686e-06
DM O 1 1.0
protein O 0 9.117822628468275e-06
kinase O 0 1.025974597723689e-05
gene O 0 1.3583464806288248e-06
( O 0 1.0119381386175519e-06
DMPK O 1 0.9992702603340149
) O 0 1.0908744343396393e-06
is O 0 3.844924378881842e-07
responsible O 0 6.896674449308193e-07
for O 0 1.2758633829434984e-06
causing O 1 0.9130358099937439
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999995231628418
DM B-Disease 1 1.0
) O 0 0.0001977757056010887
. O 0 8.964855805970728e-05

Major O 1 0.501752495765686
instability O 0 0.11716748028993607
, O 0 6.096906872699037e-06
with O 0 1.154312144535652e-06
very O 0 7.82000995513954e-07
large O 0 1.9137191884510685e-06
expansions O 0 4.620174877345562e-06
between O 0 4.8982286671162e-07
generations O 0 8.153110684361309e-07
and O 0 2.565364525253244e-07
high O 0 2.003243480430683e-06
levels O 0 5.836049012941658e-07
of O 0 1.100171743928513e-06
somatic O 0 1.315191821049666e-05
mosaicism O 1 0.9257980585098267
, O 0 2.055783397736377e-06
is O 0 1.0516339443711331e-06
observed O 0 1.4687871043861378e-06
in O 0 2.3254251573234797e-06
patients O 0 6.662403848167742e-06
. O 0 2.282569039380178e-05

There O 0 2.2860105673316866e-05
is O 0 5.280565346765798e-06
a O 0 2.42926989812986e-06
good O 0 1.3285188060763176e-06
correlation O 0 1.1728456001947052e-06
between O 0 3.05388027754816e-07
repeat O 0 1.9730925941985333e-06
size O 0 9.540954124531709e-07
( O 0 3.061514632918261e-07
at O 0 6.67628057726688e-07
least O 0 1.2031158291847532e-07
in O 0 1.8235346033179667e-07
leucocytes O 0 1.2898302884423174e-05
) O 0 9.180890856441692e-07
, O 0 7.487954576390621e-07
clinical O 0 3.115368144790409e-06
severity O 0 8.034741767914966e-06
and O 0 1.2394052646413911e-06
age O 0 8.594880455348175e-06
of O 0 2.7431509806774557e-05
onset O 0 0.1464444398880005
. O 0 0.0001391545229125768

The O 0 0.0003545649233274162
trinucleotide O 1 0.9999299049377441
repeat O 0 0.00044424840598367155
instability O 0 0.00010801083408296108
mechanisms O 0 1.3719022717850748e-05
involved O 0 3.9808719520806335e-06
in O 0 4.598516625264892e-06
DM B-Disease 1 1.0
and O 0 2.4695147658349015e-05
other O 0 2.7930916530749528e-06
human O 0 3.251791713410057e-05
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 4.260115019860677e-06
unknown O 0 4.261819049133919e-05
. O 0 4.910989082418382e-05

We O 0 4.5415363274514675e-05
studied O 0 4.7384743083966896e-05
somatic O 0 3.3308657293673605e-05
instability O 0 1.1688109225360677e-05
by O 0 1.1225469052078552e-06
measuring O 0 3.3271957363467664e-05
the O 0 7.476062819478102e-06
CTG O 1 0.9995276927947998
repeat O 0 4.457299837667961e-06
length O 0 5.889899057365255e-07
at O 0 6.697094931951142e-07
several O 0 1.7022746590100724e-07
ages O 0 3.3851054581646167e-07
in O 0 1.0654371607188295e-07
various O 0 1.3311792201875505e-07
tissues O 0 6.176282454362081e-07
of O 0 1.2639223996302462e-06
transgenic O 0 2.6416979380883276e-05
mice O 0 2.36797018260404e-06
carrying O 0 8.793514325589058e-07
a O 0 6.938221872587746e-07
( O 0 1.0277500450683874e-06
CTG O 0 0.4622745215892792
) O 0 2.064142563540372e-06
55expansion O 0 3.0519862775690854e-05
surrounded O 0 8.121022801788058e-06
by O 0 2.7592540163823287e-07
45 O 0 1.1667855233099544e-06
kb O 0 1.5628607798134908e-05
of O 0 1.7448594462621259e-06
the O 0 1.3696869700652314e-06
human O 0 3.854539500025567e-06
DM B-Disease 1 1.0
region O 0 1.4010629456606694e-05
, O 0 9.072182365343906e-07
using O 0 5.596705250354717e-07
small O 0 2.516221229598159e-06
- O 0 3.587412356864661e-05
pool O 0 6.567116361111403e-05
PCR O 0 6.224038224900141e-05
. O 0 2.641370338096749e-05

These O 0 3.1579122151015326e-05
mice O 0 2.358498386456631e-05
have O 0 6.290571263889433e-07
been O 0 6.038700917088136e-07
shown O 0 2.4131611553457333e-07
to O 0 1.936464570917451e-07
reproduce O 0 5.314284976520867e-07
the O 0 4.917530986858765e-07
intergenerational O 0 4.679261564888293e-06
and O 0 5.979416641821445e-07
somatic O 0 4.08162668463774e-06
instability O 0 2.389083874732023e-06
of O 0 1.2728518186122528e-06
the O 0 1.7851185702966177e-06
55 O 0 1.3397737347986549e-05
CTG O 1 0.9992237091064453
repeat O 0 6.750452030246379e-06
suggesting O 0 1.0600953146422398e-06
that O 0 1.4844700046978687e-07
surrounding O 0 1.00308682249306e-06
sequences O 0 3.14644609034076e-07
and O 0 1.670490092919863e-07
the O 0 2.780330135010445e-07
chromatin O 0 2.6677475943870377e-06
environment O 0 8.097481440927368e-07
are O 0 1.4920236424131872e-07
involved O 0 8.065004521995434e-07
in O 0 1.3002685363971977e-06
instability O 0 6.538970046676695e-05
mechanisms O 0 3.8306257920339704e-05
. O 0 6.581648631254211e-05

As O 0 2.5806622943491675e-05
observed O 0 2.708964984776685e-06
in O 0 7.730142783657357e-07
some O 0 4.435697462668031e-07
of O 0 1.4688864666823065e-06
the O 0 1.8317908825338236e-06
tissues O 0 4.9901559577847365e-06
of O 0 0.06813029199838638
DM B-Disease 1 1.0
patients O 0 0.009790041483938694
, O 0 6.070562221793807e-07
there O 0 1.6175910388938064e-07
is O 0 2.0715127391213173e-07
a O 0 2.59693621273982e-07
tendency O 0 5.859845941813546e-07
for O 0 1.8419319758322672e-07
repeat O 0 9.571621149007115e-07
length O 0 6.279997251112945e-07
and O 0 3.462216398020246e-07
somatic O 0 4.209941835142672e-06
mosaicism O 0 3.339962859172374e-05
to O 0 3.1453447491003317e-07
increase O 0 1.9117223359899072e-07
with O 0 1.235582089975651e-07
the O 0 5.021660740567313e-07
age O 0 1.420686658093473e-06
of O 0 2.617489144540741e-06
the O 0 1.0527323865971994e-05
mouse O 0 0.00018400198314338923
. O 0 4.0160317439585924e-05

Furthermore O 0 0.0001687507174210623
, O 0 1.088753379008267e-05
we O 0 1.2714153854176402e-06
observed O 0 1.274732312595006e-06
no O 0 6.440337187996192e-07
correlation O 0 7.490454549952119e-07
between O 0 2.3977455043677764e-07
the O 0 7.934722816571593e-07
somatic O 0 6.068100901757134e-06
mutation O 0 2.1095199826959288e-06
rate O 0 1.356323309664731e-06
and O 0 2.4633866360090906e-06
tissue O 0 4.3149830162292346e-05
proliferation O 0 0.0005478676757775247
capacity O 0 6.397795368684456e-05
. O 0 5.669178790412843e-05

The O 0 8.018688822630793e-05
somatic O 0 0.00014508399181067944
mutation O 0 5.615794179902878e-06
rates O 0 4.938722781844262e-07
in O 0 1.3178116375911486e-07
different O 0 5.8457022333868736e-08
tissues O 0 3.501083938317606e-07
were O 0 1.3450724622998678e-07
also O 0 1.6966313864941185e-07
not O 0 9.400226019806723e-08
correlated O 0 3.4909118085124646e-07
to O 0 2.6583177259453805e-07
the O 0 7.005174325058761e-07
relative O 0 1.3150186077837134e-06
inter O 0 8.418785000685602e-05
- O 0 0.00084156624507159
tissue O 0 2.622308556965436e-06
difference O 0 8.502038326696493e-07
in O 0 1.4004758952523844e-07
transcriptional O 0 6.928706852704636e-07
levels O 0 2.6604863023749203e-07
of O 0 1.818787893625995e-07
the O 0 1.3477290394803276e-07
three O 0 1.3652721975176974e-07
genes O 0 1.842696377707398e-07
( O 0 3.886197816882486e-07
DMAHP O 1 0.9976917505264282
, O 0 1.1239095556447865e-06
DMPK O 0 0.014781893230974674
and O 0 8.021075927899801e-07
59 O 0 7.720661415078212e-06
) O 0 1.5060319356052787e-06
surrounding O 0 4.597148745233426e-06
the O 0 2.730081632762449e-06
repeat O 0 1.4541411474056076e-05
. O 0 7.261850441864226e-06
. O 0 3.078702138736844e-05

A O 0 0.0004679962294176221
novel O 0 0.0002809583966154605
missense O 0 0.000207827179110609
mutation O 0 8.372473530471325e-06
in O 0 1.399893903908378e-06
patients O 0 1.230319639944355e-06
from O 0 5.329694090505654e-07
a O 0 3.888098490278935e-06
retinoblastoma B-Disease 1 0.9769394993782043
pedigree O 0 0.0023032526951283216
showing O 0 6.307923740678234e-06
only O 0 1.0036485491582425e-06
mild O 0 3.6127892144577345e-06
expression O 0 1.4112151802692097e-06
of O 0 2.3342552140093176e-06
the O 0 1.4911423932062462e-05
tumor B-Disease 1 0.9999977350234985
phenotype O 0 6.29876958555542e-05
. O 0 4.9964488425757736e-05

We O 0 3.2505016861250624e-05
have O 0 2.096999651257647e-06
used O 0 1.486171413489501e-06
single O 0 1.3633741673402255e-06
strand O 0 4.623070708476007e-06
conformation O 0 1.3518795185518684e-06
polymorphism O 0 6.270290668908274e-07
analysis O 0 3.171749654029554e-07
to O 0 3.0280261853476986e-07
study O 0 3.921185225408408e-07
the O 0 4.0998310169015895e-07
27 O 0 1.5153793810895877e-06
exons O 0 3.5694051803147886e-06
of O 0 2.004904445129796e-06
the O 0 3.6698672829516e-06
RB1 O 1 0.9999599456787109
gene O 0 7.720491908003169e-07
in O 0 1.65362820325754e-07
individuals O 0 9.462412720040447e-08
from O 0 2.722796068610478e-07
a O 0 1.3770606983598555e-06
family O 0 2.1686805666831788e-06
showing O 0 2.4922342163335998e-06
mild O 0 8.137968507071491e-06
expression O 0 2.0599891286110505e-06
of O 0 5.451129254652187e-06
the O 0 1.9199498638045043e-05
retinoblastoma B-Disease 1 0.9801806807518005
phenotype O 0 0.00015325023559853435
. O 0 9.491897071711719e-05

In O 0 2.1183834178373218e-05
this O 0 2.9090235784678953e-06
family O 0 3.536430313033634e-06
affected O 0 8.500124977217638e-07
individuals O 0 1.92942451349154e-07
developed O 0 1.9010986989087542e-06
unilateral B-Disease 0 0.37241509556770325
tumors I-Disease 1 1.0
and O 0 2.9463974442478502e-06
, O 0 5.303602392814355e-07
as O 0 2.3762424916640157e-07
a O 0 2.7475033448354225e-07
result O 0 1.8126216616565216e-07
of O 0 3.5534247899704496e-07
linkage O 0 2.0603447410394438e-06
analysis O 0 5.256942472442461e-07
, O 0 5.136257072990702e-07
unaffected O 0 2.235158490293543e-06
mutation O 0 6.730940640409244e-07
carriers O 0 3.829134698207781e-07
were O 0 2.5188714403157064e-07
also O 0 4.211887016936089e-07
identified O 0 9.445567457078141e-07
within O 0 1.1224474292248487e-06
the O 0 7.10587255525752e-06
pedigree O 0 0.00021936003759037703
. O 0 0.00011595338582992554

A O 0 0.00013603710976894945
single O 0 1.1110953892057296e-05
band O 0 1.566822720633354e-05
shift O 0 2.787631046885508e-06
using O 0 1.8935063508251915e-06
SSCP O 1 0.9241664409637451
was O 0 8.541684110241476e-06
identified O 0 7.801878609825508e-07
in O 0 4.784920974998386e-07
exon O 0 9.152058737527113e-06
21 O 0 1.6439341834484367e-06
which O 0 2.861041252799623e-07
resulted O 0 7.275515372384689e-07
in O 0 3.131307835246844e-07
a O 0 1.6048452380346134e-06
missense O 0 9.917704119288828e-06
mutation O 0 2.359226755288546e-06
converting O 0 5.744101599702844e-06
a O 0 5.669724941981258e-06
cys O 1 0.9876124262809753
- O 0 0.00013558722275774926
- O 0 4.959657962899655e-05
> O 0 1.9162056560162455e-05
arg O 0 9.178770415019244e-05
at O 0 4.221830749884248e-06
nucleotide O 0 2.197548610638478e-06
position O 0 2.2005772279953817e-06
28 O 0 4.5460183173418045e-06
in O 0 2.6813811473402893e-06
the O 0 1.7009915609378368e-05
exon O 0 0.0005287126987241209
. O 0 0.00014389936404768378

The O 0 8.738876204006374e-05
mutation O 0 4.206012454233132e-05
destroyed O 0 8.258665184257552e-05
an O 0 1.0199104508501478e-05
NdeI O 0 0.0006137595628388226
restriction O 0 2.757713446044363e-05
enzyme O 0 3.577293682610616e-05
site O 0 9.894606773741543e-05
. O 0 5.260424950392917e-05

Analysis O 0 1.3288180525705684e-05
of O 0 7.6165956670593005e-06
all O 0 1.2349146345513873e-06
family O 0 1.6846644257384469e-06
members O 0 3.4985274055543414e-07
demonstrated O 0 1.212369625136489e-06
that O 0 2.3757350220421358e-07
the O 0 8.743174362280115e-07
missense O 0 1.1938051102333702e-05
mutation O 0 2.4223340915341396e-06
co O 0 1.7008520444505848e-05
- O 0 0.0005184487672522664
segregated O 0 5.815336407977156e-06
with O 0 2.6502934247218946e-07
patients O 0 5.735906256632006e-07
with O 0 7.938128305795544e-07
tumors B-Disease 1 1.0
or O 0 7.741317676845938e-05
who O 0 2.1029397885286016e-06
, O 0 3.1253884458237735e-07
as O 0 2.2191767357071512e-07
a O 0 2.057800685406619e-07
result O 0 1.6432917959718907e-07
of O 0 4.2251792820025e-07
linkage O 0 1.4654962114946102e-06
analysis O 0 5.515120165000553e-07
had O 0 5.454054416986764e-07
been O 0 4.470180101634469e-07
predicted O 0 1.098228267437662e-06
to O 0 6.689575684504234e-07
carry O 0 1.7715154854158754e-06
the O 0 4.680306119553279e-06
predisposing O 0 0.00015856589016038924
mutation O 0 4.176368020125665e-05
. O 0 3.675341577036306e-05

These O 0 1.2249528481333982e-05
observations O 0 1.4965572518121917e-05
point O 0 5.721265097236028e-06
to O 0 6.973659196773951e-07
another O 0 1.6925343970797257e-06
region O 0 1.8710859421844361e-06
of O 0 3.2068201107904315e-06
the O 0 7.265258318511769e-06
RB1 O 1 0.9999991655349731
gene O 0 2.040347453657887e-06
where O 0 6.382616675182362e-07
mutations O 0 2.5771592504497676e-07
only O 0 7.668685952921805e-08
modify O 0 1.7233149662843061e-07
the O 0 1.0769685587774802e-07
function O 0 7.086762821018056e-08
of O 0 2.8126476081524743e-07
the O 0 2.3129589976633724e-07
gene O 0 2.0455678395592258e-07
and O 0 2.2347697381519538e-07
raise O 0 8.246542506640253e-07
important O 0 3.4948126881317876e-07
questions O 0 3.749633208371961e-07
for O 0 2.610244962397701e-07
genetic O 0 1.0341022971260827e-06
counseling O 0 8.317358037857048e-07
in O 0 2.3233008050738135e-07
families O 0 1.3213477245699323e-07
with O 0 1.7249608674774208e-07
these O 0 3.8267435797934013e-07
distinctive O 0 1.1939622709178366e-05
phenotypes O 0 2.5689492758829147e-05
. O 0 1.0224562174698804e-05
. O 0 3.242452658014372e-05

Maternal B-Disease 0 0.0020865160040557384
disomy I-Disease 1 0.9350075125694275
and O 0 0.0003641511721070856
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.15580280125141144
with O 0 2.035110810538754e-05
gamete O 0 0.4791812002658844
complementation O 1 0.9699153900146484
in O 0 1.8387920590612339e-06
a O 0 2.466148771418375e-06
case O 0 1.6935224493863643e-06
of O 0 2.1575717710220488e-06
familial O 0 0.00010632062912918627
translocation O 0 1.0756341907836031e-05
( O 0 7.79061451794405e-07
3 O 0 1.4209224445949076e-06
; O 0 1.8818271030340838e-07
15 O 0 3.938713746265421e-07
) O 0 3.3210181982212816e-07
( O 0 6.889160886203172e-07
p25 O 0 2.456907350278925e-05
; O 0 8.483337410325476e-07
q11 O 0 2.080583362840116e-05
. O 0 9.101090654439759e-07
2 O 0 8.030926437641028e-06
) O 0 9.308318112744018e-06
. O 0 2.9657834602403454e-05

Maternal B-Disease 0 0.009822659194469452
uniparental I-Disease 1 0.9999990463256836
disomy I-Disease 1 0.9999995231628418
( I-Disease 0 0.009890207089483738
UPD I-Disease 1 1.0
) I-Disease 0 7.139605258998927e-06
for I-Disease 0 8.265596989076585e-07
chromosome I-Disease 0 1.8665376728677074e-06
15 I-Disease 0 8.983409998108982e-07
is O 0 2.413204924778256e-07
responsible O 0 2.9299252446435275e-07
for O 0 1.03742863188927e-07
an O 0 1.9674641293931927e-07
estimated O 0 3.519838571719447e-07
30 O 0 2.6211807835352374e-07
% O 0 1.5131062980344723e-07
of O 0 2.5156688820970885e-07
cases O 0 3.1569445013701625e-07
of O 0 5.811045411974192e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999998807907104
PWS B-Disease 1 1.0
) O 0 0.0009330475004389882
. O 0 0.00017068666056729853

We O 0 2.099076118611265e-05
report O 0 3.088887524427264e-06
on O 0 9.849291018326767e-07
an O 0 7.820920018275501e-07
unusual O 0 1.6400726963183843e-06
case O 0 9.406320486959885e-07
of O 0 2.1124551494722255e-06
maternal B-Disease 0 6.447462510550395e-06
disomy I-Disease 0 0.11389687657356262
15 I-Disease 0 7.272925813595066e-06
in O 0 1.8219263893115567e-06
PWS B-Disease 1 1.0
that O 0 6.151276465971023e-07
is O 0 4.617368460912985e-07
most O 0 2.542634831570467e-07
consistent O 0 3.8829008985885594e-07
with O 0 2.04935588499211e-07
adjacent O 0 3.1307811241276795e-06
- O 0 3.3482288017694373e-06
1 O 0 3.3287851692875847e-06
segregation O 0 2.575075995991938e-06
of O 0 4.6974403744570736e-07
a O 0 6.398816481123504e-07
paternal O 0 2.6318566597183235e-06
t O 0 1.8883489474319504e-06
( O 0 3.025921557764377e-07
3 O 0 6.113846779953747e-07
; O 0 1.3102862794767134e-07
15 O 0 2.893055182084936e-07
) O 0 1.6879742759101646e-07
( O 0 2.502288793948537e-07
p25 O 0 1.1803516827058047e-05
; O 0 2.52737038408668e-07
q11 O 0 6.163411853776779e-06
. O 0 1.5967313515830028e-07
2 O 0 7.334683687076904e-07
) O 0 1.6696363047685736e-07
with O 0 1.1558417867263415e-07
simultaneous O 0 1.3908370419812854e-06
maternal O 0 6.526342986035161e-06
meiotic O 0 0.00017501147522125393
nondisjunction O 0 0.03291545435786247
for O 0 8.327832802024204e-06
chromosome O 0 2.269433025503531e-05
15 O 0 2.8379063223837875e-05
. O 0 4.6567380195483565e-05

The O 0 6.998353637754917e-05
patient O 0 2.2195006749825552e-05
( O 0 3.0840483304928057e-06
J O 0 0.00031988872797228396
. O 0 9.480429525865475e-07
B O 0 4.8953183977573644e-06
. O 0 1.1031644220338421e-07
) O 0 1.3092657979996147e-07
, O 0 1.5773102290950192e-07
a O 0 2.5474793119428796e-07
17 O 0 8.042476906666707e-07
- O 0 1.5321517139454954e-06
year O 0 7.087884341672179e-07
- O 0 7.79234051151434e-06
old O 0 1.2815687114198226e-05
white O 0 2.648843064889661e-06
male O 0 8.933405979405507e-07
with O 0 5.579832418334263e-07
PWS B-Disease 1 1.0
, O 0 6.315254722721875e-06
was O 0 6.74722059557098e-06
found O 0 3.404910557947005e-07
to O 0 1.6549344650229614e-07
have O 0 8.150220764946425e-08
47 O 0 6.123585762907169e-07
chromosomes O 0 1.2256978720870393e-07
with O 0 7.124331347085899e-08
a O 0 8.398852173741034e-07
supernumerary O 0 0.002596068661659956
, O 0 1.2750143696393934e-06
paternal O 0 3.651800398074556e-06
der O 0 0.010234173387289047
( O 0 4.4756743022844603e-07
15 O 0 6.092137141422427e-07
) O 0 1.5626537219759484e-07
consisting O 0 1.7076909841762244e-07
of O 0 1.6638853139738785e-07
the O 0 2.305137201119578e-07
short O 0 7.864913982302824e-07
arm O 0 2.9431032544380287e-06
and O 0 2.7159134674548113e-07
the O 0 8.672743661009008e-07
proximal O 0 0.010921446606516838
long O 0 3.0056678497203393e-06
arm O 0 6.246158591238782e-06
of O 0 1.5174719010246918e-06
chromosome O 0 2.2420113054977264e-06
15 O 0 2.2229521619010484e-06
, O 0 1.3856420082447585e-06
and O 0 2.437972852931125e-06
distal O 0 0.07992587983608246
chromosome O 0 0.0006642088992521167
arm O 0 0.10669735074043274
3p O 1 0.9999369382858276
. O 0 0.00021967651264276356

The O 0 7.547508721472695e-05
t O 0 3.272915637353435e-05
( O 0 2.1240832666080678e-06
3 O 0 2.574015297795995e-06
; O 0 3.158407935188734e-07
15 O 0 5.487235625878384e-07
) O 0 2.2043147396288987e-07
was O 0 1.0291790886185481e-06
present O 0 1.750040894421545e-07
in O 0 9.053775329448399e-08
the O 0 2.1190238896906521e-07
balanced O 0 2.473598499364016e-07
state O 0 7.867527074267855e-08
in O 0 1.0977637288078768e-07
the O 0 5.852250524185365e-07
patients O 0 4.825973292099661e-07
father O 0 1.4864422155369539e-06
and O 0 1.4863528576825047e-06
a O 0 1.3508792108041234e-05
sister O 0 0.00014171277871355414
. O 0 6.047421265975572e-05

Fluorescent O 0 0.0006729672313667834
in O 0 1.7347021639579907e-05
situ O 0 8.353737212019041e-05
hybridization O 0 9.553516065352596e-06
analysis O 0 9.595037226972636e-07
demonstrated O 0 1.3059801631243317e-06
that O 0 2.734942086135561e-07
the O 0 3.123897613477311e-06
PWS B-Disease 1 1.0
critical O 0 0.0005537283141165972
region O 0 6.114235475251917e-06
resided O 0 5.105098807689501e-06
on O 0 7.888456252658216e-07
the O 0 5.4192537390918e-07
derivative O 0 1.3536392771129613e-06
chromosome O 0 4.303204264033411e-07
3 O 0 5.56728821266006e-07
and O 0 1.0623323731806522e-07
that O 0 2.9327004824608593e-08
there O 0 5.933173596872621e-08
was O 0 6.725115326844389e-07
no O 0 1.841659695855924e-07
deletion O 0 7.135495252441615e-07
of O 0 9.129691420639574e-07
the O 0 8.421153324889019e-06
PWS B-Disease 1 1.0
region O 0 4.910899406240787e-06
on O 0 1.1536628790054237e-06
the O 0 8.521373047187808e-07
normal O 0 3.7911090089437494e-07
pair O 0 7.595405122629018e-07
of O 0 1.137580738941324e-06
15s O 0 7.108140562195331e-05
present O 0 3.6968415315641323e-06
in O 0 7.362881660810672e-06
J O 0 0.03542632237076759
. O 0 5.232316834735684e-05

B O 1 0.828041136264801
. O 0 0.0013257665559649467

Methylation O 0 6.85358390910551e-05
analysis O 0 6.1752734836773016e-06
at O 0 6.9891184466541745e-06
exon O 0 1.942047856573481e-05
alpha O 0 5.016657723899698e-06
of O 0 1.4443602367464337e-06
the O 0 1.3037476946919924e-06
small O 0 2.1848643427802017e-06
nuclear O 0 8.560293281334452e-06
ribonucleoprotein O 0 0.00039241943159140646
- O 0 1.1548876500455663e-05
associated O 0 1.7324204009128152e-06
polypeptide O 0 2.729211701080203e-05
N O 0 1.8130993339582346e-05
( O 0 1.794340505512082e-06
SNRPN O 0 0.4630774259567261
) O 0 1.4033024626769475e-06
gene O 0 6.501920211121615e-07
showed O 0 6.262712304305751e-07
a O 0 6.376307624123001e-07
pattern O 0 1.1148654266435187e-06
characteristic O 0 1.6994439420159324e-06
of O 0 1.5757511846459238e-06
only O 0 5.929055078013334e-07
the O 0 1.0566423043201212e-06
maternal O 0 2.6892018922808347e-06
chromosome O 0 4.150273980485508e-06
15 O 0 5.382435574574629e-06
in O 0 5.234487161942525e-06
J O 0 0.007622152101248503
. O 0 4.8029673052951694e-05

B O 1 0.6082019209861755
. O 0 0.0011813202872872353

Maternal B-Disease 0 0.0009114961721934378
disomy I-Disease 0 0.4528581202030182
was O 0 8.53771052788943e-05
confirmed O 0 3.7055774555483367e-06
by O 0 5.232712965153041e-07
polymerase O 0 4.276956588000758e-06
chain O 0 2.463621740389499e-06
reaction O 0 4.775366164722072e-07
analysis O 0 2.786791526432353e-07
of O 0 9.097029760596342e-07
microsatellite O 0 3.007239502039738e-05
repeats O 0 3.1933402624417795e-06
at O 0 2.810255864460487e-06
the O 0 1.531690031697508e-06
gamma O 0 1.2888417586509604e-05
- O 0 1.3206566109147388e-05
aminobutyric O 0 4.330392403062433e-05
acid O 0 4.738285042549251e-06
receptor O 0 4.533852006716188e-06
beta3 O 0 3.0455201340373605e-05
subunit O 0 1.3132016647432465e-05
( O 0 5.507228252099594e-06
GABRB3 O 1 0.9676754474639893
) O 0 2.3167252948042005e-05
locus O 0 0.00036980706499889493
. O 0 8.853823965182528e-05

A O 0 0.0005550970090553164
niece O 0 0.0015437786933034658
( O 0 8.660142157168593e-06
B O 0 4.190230538370088e-05
. O 0 7.673937147956167e-07
B O 0 4.017377250420395e-06
. O 0 1.155694064891577e-07
) O 0 1.3030735601660126e-07
with O 0 8.945394114334704e-08
45 O 0 6.643285814789124e-07
chromosomes O 0 1.5745479231554782e-07
and O 0 7.990325201490123e-08
the O 0 1.6943174330208421e-07
derivative O 0 4.738619452382409e-07
3 O 0 4.3714368302971707e-07
but O 0 6.821984044336205e-08
without O 0 4.850742740813985e-08
the O 0 1.966102303185835e-07
der O 0 0.00013599314843304455
( O 0 3.457728610101185e-07
15 O 0 7.100089192135783e-07
) O 0 2.0958110269475583e-07
demonstrated O 0 3.949057258978428e-07
a O 0 4.1194115851794777e-07
phenotype O 0 7.657269520677801e-07
consistent O 0 4.4283260081101616e-07
with O 0 1.2864892084962776e-07
that O 0 1.1986287518084282e-07
reported O 0 3.2094280300043465e-07
for O 0 2.98887812277826e-07
haploinsufficiency O 0 5.579514254350215e-05
of O 0 1.0134396688954439e-05
distal O 0 0.003891262924298644
3 O 0 0.00020216220582369715
p O 0 7.45643992559053e-05
. O 0 3.980017208959907e-05

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999997615814209
associated O 0 2.9695927878492512e-05
with O 0 5.6021858654276e-06
unbalanced O 0 0.00010076722537633032
segregation O 0 5.2222429076209664e-05
of O 0 2.3818882255000062e-05
non O 0 0.0017997750546783209
- O 1 0.9423025250434875
Robertsonian O 1 0.9999841451644897
translocations O 0 3.0352501198649406e-05
has O 0 1.2351856639725156e-06
been O 0 3.2582909170741914e-07
reported O 0 3.438268834088376e-07
previously O 0 3.9888493574835593e-07
but O 0 1.0407324424477338e-07
has O 0 1.2852629538429028e-07
not O 0 4.100737527323872e-08
, O 0 4.58660309732295e-08
to O 0 8.046054489341259e-08
our O 0 1.0376522396882137e-07
knowledge O 0 3.4043034702335717e-07
, O 0 2.1972920194457402e-07
been O 0 1.6448895223675208e-07
observed O 0 1.9340707524406753e-07
in O 0 2.1406454209227377e-07
a O 0 1.5484125697184936e-06
case O 0 6.447075065807439e-06
of O 0 3.582595309126191e-05
PWS B-Disease 1 1.0
. O 0 0.0005499218823388219

Furthermore O 0 0.00013792424579150975
, O 0 1.0623790331010241e-05
our O 0 1.2056224250045489e-06
findings O 0 8.281314194391598e-07
are O 0 1.3825410860590637e-07
best O 0 9.486281555837195e-07
interpreted O 0 9.406984418092179e-07
as O 0 9.525117548037088e-07
true O 0 5.634580702462699e-06
gamete O 0 8.122120925690979e-05
complementation O 0 0.01107777003198862
resulting O 0 1.7869915609480813e-05
in O 0 1.2036501175316516e-05
maternal B-Disease 0 0.00016668836178723723
UPD I-Disease 1 1.0
15 I-Disease 0 0.0015728439902886748
and O 0 0.0004328921786509454
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9998997449874878
- I-Disease 1 0.9999997615814209
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
type I-Disease 0 0.00023500516545027494
2 I-Disease 0 6.871253572171554e-05
and O 0 3.954422936658375e-06
Stuve B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999996423721313
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.999998927116394
: O 0 1.3186730711822747e-06
a O 0 9.986998747990583e-07
case O 0 8.461084917144035e-07
for O 0 5.981013941891433e-07
" O 0 5.97110783928656e-06
lumping O 0 5.530698399525136e-05
" O 0 2.5069921321119182e-05
. O 0 3.4822398447431624e-05

Recent O 0 5.015639544581063e-05
studies O 0 6.7855321503884625e-06
demonstrated O 0 4.798896043212153e-06
the O 0 1.193484877148876e-06
existence O 0 9.230898854184488e-07
of O 0 9.390724926561234e-07
a O 0 1.0296886330252164e-06
genetically O 0 1.190331772704667e-06
distinct O 0 4.453746385024715e-07
, O 0 2.461606243286951e-07
usually O 0 9.307594694973886e-08
lethal O 0 2.215869159272188e-07
form O 0 4.03815505478633e-08
of O 0 3.0170582476785057e-07
the O 0 1.0585001746221678e-06
Schwartz B-Disease 1 0.9952527284622192
- I-Disease 1 0.9999998807907104
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 3.07622758555226e-05
SJS B-Disease 1 1.0
) O 0 8.558514309697784e-06
of O 0 1.8209402696811594e-05
myotonia B-Disease 1 0.9999998807907104
and O 0 5.432836042018607e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 7.25607096683234e-05
which O 0 2.260332621517591e-06
we O 0 1.3474068509822246e-06
called O 0 1.250027708010748e-05
SJS B-Disease 1 1.0
type I-Disease 0 0.001424493151716888
2 I-Disease 0 0.00035221874713897705
. O 0 9.514334669802338e-05

This O 0 4.0753606299404055e-05
disorder O 1 0.9995352029800415
is O 0 6.184998255776009e-06
reminiscent O 0 4.1449944546911865e-05
of O 0 9.567675988364499e-06
another O 0 1.2399003026075661e-05
rare O 0 5.2958062042307574e-06
condition O 0 1.8096593521477189e-06
, O 0 8.139203941937012e-07
the O 0 1.5797927517269272e-06
Stuve B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999998807907104
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00030460546258836985
SWS B-Disease 1 1.0
) O 0 2.236729869764531e-06
, O 0 4.537059794529341e-07
which O 0 2.061281065834919e-07
comprises O 0 1.6284132016153308e-06
campomelia B-Disease 0 8.754723967285827e-05
at O 0 7.056118192849681e-06
birth O 0 2.5449592158111045e-06
with O 0 1.1371251957825734e-06
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 1 0.8879663348197937
contractures B-Disease 1 1.0
, O 0 9.521607353235595e-06
and O 0 2.5905444545060163e-06
early B-Disease 0 1.2948463336215355e-05
death I-Disease 0 7.273688243003562e-05
. O 0 3.943013507523574e-05

To O 0 1.801713187887799e-05
test O 0 4.461561275093118e-06
for O 0 1.1311936987112858e-06
possible O 0 2.4382450192206306e-06
nosologic O 0 0.004057547077536583
identity O 0 1.2799022215403966e-06
between O 0 3.374835841896129e-07
these O 0 3.152642307213682e-07
disorders O 1 0.945620596408844
, O 0 8.023784516808519e-07
we O 0 2.6017156073976366e-07
reviewed O 0 3.5646897345031903e-07
the O 0 2.1374040670707473e-07
literature O 0 3.2982771358547325e-07
and O 0 7.818833580586215e-08
obtained O 0 8.378262350561272e-08
a O 0 1.8296978510079498e-07
follow O 0 1.576143517922901e-07
- O 0 5.288066518005508e-07
up O 0 4.1900804603756114e-07
of O 0 2.5302304607066617e-07
the O 0 1.4571578788036277e-07
only O 0 5.735141073159866e-08
two O 0 5.855779150465423e-08
surviving O 0 1.9620449620560976e-06
patients O 0 2.2062411630940915e-07
, O 0 1.0475954326238934e-07
one O 0 1.3789660613383603e-07
with O 0 2.2622856477028108e-07
SJS B-Disease 1 1.0
type I-Disease 0 1.36393300635973e-05
2 I-Disease 0 3.5518121421773685e-06
at O 0 1.7868677559818025e-06
age O 0 6.356842163768306e-07
10 O 0 2.2198582882992923e-07
years O 0 1.749683775642552e-07
and O 0 1.325038994082206e-07
another O 0 5.537872880267969e-07
with O 0 6.363156330735364e-07
SWS B-Disease 1 0.999923825263977
at O 0 2.212085746577941e-05
age O 0 7.883832040533889e-06
7 O 0 1.5405503290821798e-05
years O 0 1.817063457565382e-05
. O 0 5.133058220962994e-05

Patients O 0 0.00023177589173428714
reported O 0 1.6465686712763272e-05
as O 0 3.967462816945044e-06
having O 0 7.790556992404163e-06
either O 0 4.891715889243642e-06
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.3032926917076111
SWS B-Disease 1 0.9999990463256836
presented O 0 4.121468919038307e-06
a O 0 8.750280926506093e-07
combination O 0 5.576337116508512e-07
of O 0 8.268624469565111e-07
a O 0 3.0629182674601907e-06
severe O 0 0.0035387014504522085
, O 0 2.0103132101212395e-06
prenatal O 0 0.00015231726865749806
- O 1 0.9999997615814209
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999630451202393
with O 1 0.9997748732566833
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999998807907104
respiratory O 1 1.0
and O 0 0.00028486427618190646
feeding O 0 0.017614981159567833
difficulties O 0 5.5432701628888026e-05
, O 0 1.5001577367002028e-06
tendency O 0 2.222797547801747e-06
to O 0 1.408829689353297e-06
hyperthermia B-Disease 1 0.999994158744812
, O 0 1.045861949933169e-06
and O 0 3.447584049354191e-07
frequent O 0 1.1116836731162039e-06
death O 0 1.7472772242399515e-06
in O 0 3.69946178579994e-07
infancy O 0 1.8615530734678032e-06
) O 0 2.952801025912777e-07
with O 0 2.2423590451126074e-07
a O 0 2.807726787068532e-06
distinct O 0 4.931652711093193e-06
campomelic B-Disease 1 0.9998880624771118
- I-Disease 1 0.9999964237213135
metaphyseal I-Disease 1 1.0
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.007887326180934906

The O 0 4.1270013753091916e-05
similarity O 0 1.6207324733841233e-05
of O 0 7.087585800036322e-06
the O 0 4.435918526723981e-06
clinical O 0 4.030581112601794e-05
and O 0 2.080629428746761e-06
radiographic O 1 0.5824813842773438
findings O 0 3.0079963835305534e-06
is O 0 6.355108439493051e-07
so O 0 1.8557803116436844e-07
extensive O 0 1.1204549537069397e-06
that O 0 1.4226971245534514e-07
these O 0 2.276033939097033e-07
disorders O 1 0.5469776391983032
appear O 0 1.161586169473594e-06
to O 0 8.331235221703537e-07
be O 0 7.445599408129056e-07
a O 0 3.348864311192301e-06
single O 0 6.831776317994809e-06
entity O 0 3.348663085489534e-05
. O 0 4.51309751952067e-05

The O 0 6.627815309911966e-05
follow O 0 9.449547178519424e-06
- O 0 1.2952193173987325e-05
up O 0 3.59033333552361e-06
observation O 0 9.997223060054239e-06
of O 0 1.0308864375474514e-06
an O 0 3.653015880900057e-07
identical O 0 3.53909854311496e-07
and O 0 2.4387327357544564e-07
unique O 0 5.813390089315362e-07
pattern O 0 3.4329846130276565e-06
of O 0 0.0009681678493507206
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 3.917248250218108e-06
the O 0 2.1850996745342854e-06
two O 0 2.0963827296327509e-07
patients O 0 2.787267305848218e-07
( O 0 2.0877119766282703e-07
one O 0 2.740495403941168e-07
with O 0 3.278263704942219e-07
SJS B-Disease 1 1.0
type I-Disease 0 6.360056431731209e-05
2 I-Disease 0 7.648243808944244e-06
, O 0 4.76540265026415e-07
one O 0 2.4697655476302316e-07
with O 0 3.209431440609478e-07
SWS B-Disease 1 0.9998190999031067
) O 0 3.283634441686445e-06
surviving O 0 1.0413144991616718e-05
beyond O 0 2.6689053811423946e-06
infancy O 0 2.5990175345214084e-06
adds O 0 5.719780347135384e-07
to O 0 1.604514778819066e-07
the O 0 3.5298188549859333e-07
evidence O 0 4.3135995042575814e-07
in O 0 5.434646368485119e-07
favor O 0 1.7639024463278474e-06
of O 0 5.642124506266555e-06
identity O 0 2.3362650608760305e-05
. O 0 4.328748764237389e-05

The O 0 4.511755105340853e-05
hypothesis O 0 2.291406417498365e-05
that O 0 2.071628614430665e-06
SWS B-Disease 1 0.9999557733535767
and O 0 1.3527459486795124e-05
SJS B-Disease 1 1.0
type I-Disease 0 0.0019528208067640662
2 I-Disease 0 9.681017218099441e-06
are O 0 1.4299253336957918e-07
the O 0 4.7458556196033896e-07
same O 0 5.300608449942956e-07
disorder O 0 0.0007881171768531203
should O 0 4.2351237539151043e-07
be O 0 3.4415165828249883e-07
testable O 0 3.2401342195953475e-06
by O 0 3.6359122645990283e-07
molecular O 0 3.939351699955296e-06
methods O 0 2.1335924884624546e-06
. O 0 3.471683385214419e-06
. O 0 2.413138463452924e-05

A O 0 0.0005226957146078348
mouse O 0 0.00013129532453604043
model O 0 9.660819159762468e-06
of O 0 1.932260420289822e-05
severe O 1 0.9999998807907104
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9114637970924377
defects O 1 0.9999841451644897
in O 0 4.8757432523416355e-05
hemostasis O 1 1.0
and O 0 0.00845735426992178
thrombosis B-Disease 1 0.9999995231628418
. O 0 0.00025059067411348224

von B-Disease 1 0.9999852180480957
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.9937480688095093
( I-Disease 0 0.0006482746102847159
vWf I-Disease 1 1.0
) I-Disease 1 0.5964086651802063
deficiency I-Disease 1 1.0
causes O 1 0.9997358918190002
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.004732108674943447
humans O 0 2.3922779291751795e-05
. O 0 3.739495514309965e-05

We O 0 2.674925053725019e-05
generated O 0 1.0060040040116291e-05
a O 0 3.968530108977575e-06
mouse O 0 6.9283178163459525e-06
model O 0 1.3911951555201085e-06
for O 0 3.5604057302407455e-07
this O 0 6.980446300985932e-07
disease O 0 2.250219949928578e-06
by O 0 3.8471617358482035e-07
using O 0 1.7813040358305443e-06
gene O 0 9.247557500202674e-06
targeting O 0 4.84693591715768e-05
. O 0 5.302408317220397e-05

vWf B-Disease 1 0.9999284744262695
- I-Disease 1 0.9999804496765137
deficient I-Disease 1 0.999985933303833
mice O 0 5.749128831666894e-05
appeared O 0 5.687108114216244e-06
normal O 0 8.461771017209685e-07
at O 0 9.007696348817262e-07
birth O 0 2.7751539732889796e-07
; O 0 1.6898361820949503e-07
they O 0 1.4131961734165088e-07
were O 0 7.24487790648709e-07
viable O 0 6.030532404111e-06
and O 0 5.826439064549049e-06
fertile O 0 0.00017109044711105525
. O 0 9.494303958490491e-05

Neither O 0 0.0011911182664334774
vWf O 0 0.005851346999406815
nor O 0 0.0002262502966914326
vWf O 0 0.003337604459375143
propolypeptide O 0 0.004869556054472923
( O 0 3.221162114641629e-05
von B-Disease 1 0.9926241636276245
Willebrand I-Disease 1 1.0
antigen O 1 0.9959633350372314
II O 1 1.0
) O 0 2.63229594565928e-06
were O 0 8.22859931304265e-07
detectable O 0 5.348627382772975e-06
in O 0 4.946391527482774e-07
plasma O 0 2.068660978693515e-05
, O 0 1.3120672974764602e-06
platelets O 0 1.0539539289311506e-05
, O 0 7.44901569760259e-07
or O 0 1.203788769998937e-06
endothelial O 0 1.2577667803270742e-05
cells O 0 5.528901851903356e-07
of O 0 1.6023311673052376e-06
the O 0 4.869096301263198e-06
homozygous O 0 4.133716720389202e-05
mutant O 0 0.00024789117742329836
mice O 0 7.971540617290884e-05
. O 0 3.894897236023098e-05

The O 0 0.00018910445214714855
mutant O 1 0.6533814072608948
mice O 0 0.022317850962281227
exhibited O 0 0.007600464858114719
defects O 0 0.49104711413383484
in O 0 4.5277943172550295e-06
hemostasis O 1 0.9979155659675598
with O 0 1.797171421458188e-06
a O 0 8.9887162175728e-06
highly O 0 0.0006335536600090563
prolonged O 1 0.9711183905601501
bleeding O 1 0.9999480247497559
time O 0 1.9335539036546834e-06
and O 0 1.5006098692538217e-06
spontaneous O 0 1.3583564395958092e-05
bleeding O 0 0.10152129083871841
events O 0 7.51809352550481e-07
in O 0 3.0601540856878273e-07
approximately O 0 6.426998311326315e-07
10 O 0 9.825190545598161e-07
% O 0 1.0974064252877724e-06
of O 0 7.268280569405761e-06
neonates O 0 0.0001762133906595409
. O 0 4.56848501926288e-05

As O 0 2.2187410650076345e-05
in O 0 2.4047260467341403e-06
the O 0 2.658966877788771e-06
human O 0 2.0867455532425083e-06
disease O 0 0.008095698431134224
, O 0 5.542236749533913e-07
the O 0 1.127872678807762e-06
factor O 0 1.9565102775231935e-05
VIII O 1 0.9999958276748657
level O 0 3.348251311763306e-06
in O 0 2.577995132924116e-07
these O 0 1.6565908822485653e-07
mice O 0 1.510804963800183e-06
was O 0 1.955180323420791e-06
reduced O 0 5.515635734809621e-07
strongly O 0 3.026146657703066e-07
as O 0 2.0794102795207436e-07
a O 0 3.3357784445797733e-07
result O 0 2.4051772129496385e-07
of O 0 4.6486727001138206e-07
the O 0 5.108203140480327e-07
lack O 0 7.59595536692359e-07
of O 0 1.8876053218264133e-06
protection O 0 7.496895705116913e-06
provided O 0 2.813816990965279e-06
by O 0 4.956868906447198e-06
vWf O 0 0.0013202531263232231
. O 0 0.0001053456508088857

Defective O 1 0.9999990463256836
thrombosis B-Disease 1 0.9999856948852539
in O 0 1.6412228433182463e-05
mutant O 0 0.09432120621204376
mice O 0 2.4538237994420342e-05
was O 0 1.1048179658246227e-05
also O 0 5.796505320176948e-07
evident O 0 9.909147138387198e-07
in O 0 1.9285545249658753e-07
an O 0 2.7914887823499157e-07
in O 0 3.783946453950193e-07
vivo O 0 5.214239536144305e-06
model O 0 3.284517333668191e-06
of O 0 0.0003278548829257488
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 0.0005252287955954671

In O 0 2.108511580445338e-05
this O 0 2.9368509331106907e-06
model O 0 3.623119482654147e-06
, O 0 1.7627723991608946e-06
the O 0 4.785085820913082e-06
exteriorized O 0 0.0011645578779280186
mesentery O 0 0.17595241963863373
was O 0 6.58599310554564e-05
superfused O 0 0.00031636119820177555
with O 0 4.485708359425189e-06
ferric O 1 0.9933492541313171
chloride O 0 5.001873796572909e-05
and O 0 2.071059725494706e-06
the O 0 3.4260183383594267e-06
accumulation O 0 1.9274566511739977e-05
of O 0 1.5403460565721616e-05
fluorescently O 1 0.9966161847114563
labeled O 0 0.002468519378453493
platelets O 0 4.401041951496154e-05
was O 0 1.2014504136459436e-05
observed O 0 2.7227831651543966e-06
by O 0 1.7906960465552402e-06
intravital O 0 0.0002672307309694588
microscopy O 0 8.314587466884404e-05
. O 0 6.648692215094343e-05

We O 0 4.0471113607054576e-05
conclude O 0 1.631774466659408e-05
that O 0 1.159895873570349e-06
these O 0 5.749388947151601e-07
mice O 0 4.089594767719973e-06
very O 0 6.665248974968563e-07
closely O 0 1.5232556052069413e-06
mimic O 0 0.006051886361092329
severe O 1 0.9512116312980652
human O 0 0.303874135017395
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 2.4087335077638272e-06
will O 0 2.2687697764922632e-07
be O 0 9.797572175784808e-08
very O 0 7.673352797610278e-08
useful O 0 8.212232671667152e-08
for O 0 9.124106270519405e-08
investigating O 0 3.3116756981144135e-07
the O 0 2.655566220255423e-07
role O 0 6.244129622245964e-07
of O 0 1.0899738072112086e-06
vWf O 0 0.0018312364118173718
in O 0 6.950010060791101e-07
normal O 0 9.365735991195834e-07
physiology O 0 5.934927230555331e-06
and O 0 5.60526757453772e-07
in O 0 1.764023522810021e-06
disease O 0 0.0001917087793117389
models O 0 7.876918061811011e-06
. O 0 7.669206752325408e-06
. O 0 3.236150951124728e-05

Oral O 0 0.0007247363100759685
contraceptives O 0 0.00041632974171079695
and O 0 8.91968284122413e-06
the O 0 8.431245987594593e-06
risk O 0 5.521850107470527e-05
of O 1 0.9832983613014221
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.173987478017807

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.9999958276748657
Study O 0 0.00023307093943003565
Group O 0 0.00015580665785819292
. O 0 8.935351070249453e-05

BACKGROUND O 0 0.000499996414873749
Women O 0 6.522914645756828e-06
with O 0 8.917846230360738e-07
mutations O 0 1.0192833315159078e-06
in O 0 2.99977784834482e-07
either O 0 3.384288618235587e-07
the O 0 7.331312872338458e-07
BRCA1 O 0 1.7493714040028863e-05
or O 0 9.461489298701053e-07
the O 0 1.332810711573984e-06
BRCA2 O 0 3.5837914765579626e-05
gene O 0 3.9618637970306736e-07
have O 0 7.761197906575035e-08
a O 0 6.028009806868795e-07
high O 0 7.3391870500927325e-06
lifetime O 0 1.0253993423248176e-05
risk O 0 2.153795685444493e-05
of O 1 0.719054639339447
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00012830675404984504

Oral O 0 0.0019509622361510992
contraceptives O 1 0.885794460773468
protect O 0 0.03431041166186333
against O 1 0.9999998807907104
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.772559342811292e-07
general O 0 5.827122890877945e-07
, O 0 2.473532276781043e-07
but O 0 7.404671009680897e-08
it O 0 5.027568761306611e-08
is O 0 7.76901813992481e-08
not O 0 3.247280844220768e-08
known O 0 2.737809836617089e-07
whether O 0 1.1758432094666205e-07
they O 0 9.484276120019786e-08
also O 0 2.586037339824543e-07
protect O 0 8.588501714257291e-07
against O 0 2.872561708500143e-06
hereditary B-Disease 1 0.986430287361145
forms I-Disease 0 6.947776273591444e-05
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002491367922630161

METHODS O 0 7.718687265878543e-05
We O 0 8.00190719019156e-06
enrolled O 0 1.639670881559141e-05
207 O 0 1.1095304216723889e-05
women O 0 1.0067939228974865e-06
with O 0 1.7828166392064304e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.985168521263404e-06
161 O 0 3.760096205951413e-06
of O 0 9.788697070689523e-07
their O 0 1.727729994627225e-07
sisters O 0 3.2566397294431226e-06
as O 0 5.03000535445608e-07
controls O 0 2.0511226921371417e-06
in O 0 4.7097944388951873e-07
a O 0 1.4283840528150904e-06
case O 0 2.585874426586088e-06
- O 0 3.034283326996956e-05
control O 0 1.526066625956446e-05
study O 0 1.4607946468458977e-05
. O 0 1.8684164388105273e-05

All O 0 2.2164547772263177e-05
the O 0 1.117618285206845e-05
patients O 0 2.9790085136482958e-06
carried O 0 9.599154964234913e-07
a O 0 8.055749844970705e-07
pathogenic O 0 1.985445123864338e-06
mutation O 0 5.851848641214019e-07
in O 0 2.5772257572498347e-07
either O 0 6.505970873149636e-07
BRCA1 O 0 5.197508016863139e-06
( O 0 5.148405080035445e-07
179 O 0 2.8014198960590875e-06
women O 0 2.2105859898147173e-07
) O 0 4.197735847810691e-07
or O 0 1.1662760925901239e-06
BRCA2 O 0 8.74510224093683e-05
( O 0 1.564786430208187e-06
28 O 0 9.83077916316688e-06
women O 0 1.4281444009611732e-06
) O 0 5.2280365707702e-06
. O 0 1.9148610590491444e-05

The O 0 6.417433905880898e-05
control O 0 2.5241492039640434e-05
women O 0 1.5804798749741167e-06
were O 0 6.793197258048167e-07
enrolled O 0 2.5025467493833276e-06
regardless O 0 4.03935757731233e-07
of O 0 4.302584386550734e-07
whether O 0 2.0200556605232123e-07
or O 0 2.2670890587050962e-07
not O 0 1.0464411559496511e-07
they O 0 2.392674502971204e-07
had O 0 1.9893077478627674e-06
either O 0 4.929104306938825e-06
mutation O 0 2.6283043553121388e-05
. O 0 3.5866185498889536e-05

Lifetime O 0 0.0003493236727081239
histories O 0 5.726273957407102e-05
of O 0 1.6396834325860254e-05
oral O 0 2.2097201508586295e-05
- O 0 0.0002922157582361251
contraceptive O 0 1.781888204277493e-05
use O 0 4.856565851696359e-07
were O 0 1.9284698282717727e-07
obtained O 0 1.6646741585191194e-07
by O 0 8.098540860146386e-08
interview O 0 6.058584176571458e-07
or O 0 7.625236264630075e-08
by O 0 4.929123420538417e-08
written O 0 1.1767563279363458e-07
questionnaire O 0 2.8815344421673217e-07
and O 0 6.877797886772896e-08
were O 0 1.0383669746261148e-07
compared O 0 2.6917189188679913e-07
between O 0 1.853102702398246e-07
patients O 0 3.6164908578939503e-07
and O 0 1.896210193308434e-07
control O 0 2.0686436528194463e-06
women O 0 1.522454056157585e-07
, O 0 9.877956586024084e-08
after O 0 1.4310016638319212e-07
adjustment O 0 5.334911179488699e-07
for O 0 1.6663577184772294e-07
year O 0 5.898347694710537e-07
of O 0 1.3244227830000455e-06
birth O 0 2.6049083317047916e-06
and O 0 2.4815899450914003e-06
parity O 0 0.00010355832637287676
. O 0 5.462463741423562e-05

RESULTS O 0 0.0001184325956273824
The O 0 2.7845149816130288e-05
adjusted O 0 3.289628875791095e-05
odds O 0 3.876983464579098e-05
ratio O 0 1.0762374586192891e-05
for O 0 5.4261159675661474e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 5.522156811821333e-07
with O 0 1.5420479826389055e-07
any O 0 3.805453445693274e-07
past O 0 5.161600142855605e-07
use O 0 4.436331835222518e-07
of O 0 2.3497957499785116e-06
oral O 0 1.5740115486551076e-05
contraceptives O 0 6.195565219968557e-05
was O 0 2.7831585612148046e-05
0 O 0 3.5852099244948477e-05
. O 0 4.052085932926275e-05

5 O 0 7.357639697147533e-05
( O 0 1.0150666639674455e-05
95 O 0 2.149400461348705e-05
percent O 0 6.683729225187562e-06
confidence O 0 2.770499577309238e-06
interval O 0 1.8834389265975915e-06
, O 0 4.3979437691632484e-07
0 O 0 6.281817945819057e-07
. O 0 1.972521630477786e-07
3 O 0 6.172148800942523e-07
to O 0 2.4052530989138177e-07
0 O 0 1.0523170885790023e-06
. O 0 5.871004873370111e-07
8 O 0 7.526711669925135e-06
) O 0 8.29762029752601e-06
. O 0 3.0782350222580135e-05

The O 0 0.00015689048450440168
risk O 0 3.782282510655932e-05
decreased O 0 3.598395551307476e-06
with O 0 1.8328972828385304e-07
increasing O 0 2.61716934346623e-07
duration O 0 4.911723863187945e-07
of O 0 2.8440226174097916e-07
use O 0 1.8476586660653993e-07
( O 0 3.0838467068861064e-07
P O 0 2.21645336750953e-06
for O 0 1.5704537759120285e-07
trend O 0 8.639319162284664e-07
, O 0 1.5599840708091506e-07
< O 0 1.8140930251320242e-06
0 O 0 5.500506858879817e-07
. O 0 9.132062928074447e-08
001 O 0 2.0804229734494584e-06
) O 0 7.232163312664852e-08
; O 0 2.1633409730270614e-08
use O 0 3.152966598918283e-08
for O 0 5.634671040866124e-08
six O 0 8.841936960379826e-08
or O 0 7.598406170927774e-08
more O 0 5.021138349547982e-08
years O 0 1.3896158179704798e-07
was O 0 6.820617386438244e-07
associated O 0 8.764315140297185e-08
with O 0 5.114218026847084e-08
a O 0 3.464075746251183e-07
60 O 0 9.92840568869724e-07
percent O 0 1.4242394854591112e-06
reduction O 0 3.1265203688235488e-06
in O 0 3.7983866150170797e-06
risk O 0 2.1320638552424498e-05
. O 0 2.7723133825929835e-05

Oral O 0 0.0002348871057620272
- O 0 0.0001796713040675968
contraceptive O 0 8.450281893601641e-05
use O 0 3.635808980106958e-06
protected O 0 0.03559347242116928
against O 1 0.9999288320541382
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 2.8746504199261835e-07
for O 0 2.2955897804877168e-07
carriers O 0 3.6279561754781753e-07
of O 0 5.766125923400978e-07
the O 0 1.0987866971845506e-06
BRCA1 O 0 2.012606455537025e-05
mutation O 0 6.210889296198729e-07
( O 0 2.5225975264220324e-07
odds O 0 3.3772739698179066e-06
ratio O 0 6.91496325089247e-07
, O 0 1.1012051004399837e-07
0 O 0 1.8410294444493047e-07
. O 0 4.910618045528281e-08
5 O 0 1.9872889822636353e-07
; O 0 6.48968594418875e-08
95 O 0 7.194738600446726e-07
percent O 0 5.270515543998044e-07
confidence O 0 2.600259563223517e-07
interval O 0 5.55403630642104e-07
, O 0 1.540749963169219e-07
0 O 0 2.30818187674231e-07
. O 0 4.8127368756922806e-08
3 O 0 1.6709010708382266e-07
to O 0 5.2734616673433266e-08
0 O 0 1.192640155522895e-07
. O 0 3.252549873877797e-08
9 O 0 2.034870192346716e-07
) O 0 7.246647726333322e-08
and O 0 6.297017307588249e-08
for O 0 1.2070634625160892e-07
carriers O 0 3.7317568057915196e-07
of O 0 4.688390902174433e-07
the O 0 1.1071616654589889e-06
BRCA2 O 0 1.5921976228128187e-05
mutation O 0 7.924188594188308e-07
( O 0 4.5390333980321884e-07
odds O 0 3.4152988064306555e-06
ratio O 0 5.913266818424745e-07
, O 0 1.671611897791081e-07
0 O 0 1.6891644349925627e-07
. O 0 8.524366990059207e-08
4 O 0 5.805456453344959e-07
; O 0 1.8755062569653091e-07
95 O 0 1.2483614000302623e-06
percent O 0 1.0911376193689648e-06
confidence O 0 7.321713155761245e-07
interval O 0 7.26143809970381e-07
, O 0 3.0635763437203423e-07
0 O 0 4.4566607471097086e-07
. O 0 1.3503266416137194e-07
2 O 0 5.17495209351182e-07
to O 0 2.532084408812807e-07
1 O 0 2.2703657123201992e-06
. O 0 4.629741283679323e-07
1 O 0 6.924565695953788e-06
) O 0 6.920135547261452e-06
. O 0 2.3705757485004142e-05

CONCLUSIONS O 0 0.0004641170089598745
Oral O 0 0.00023085907741915435
- O 0 0.00017707471852190793
contraceptive O 0 4.2853880586335436e-05
use O 0 1.4196816664480139e-06
may O 0 3.9103628068914986e-07
reduce O 0 5.883420044483501e-07
the O 0 7.559100936305185e-07
risk O 0 6.264944204303902e-06
of O 1 0.9993288516998291
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.177889192964358e-07
women O 0 1.1624256757158946e-07
with O 0 6.262808227575078e-08
pathogenic O 0 7.781637236803363e-07
mutations O 0 4.028216551432706e-07
in O 0 4.948788614456134e-07
the O 0 3.001291361215408e-06
BRCA1 O 0 0.00019995223556179553
or O 0 2.1662704966729507e-05
BRCA2 O 0 0.0013666871236637235
gene O 0 0.00018007382459472865

A O 0 0.0010953544406220317
Japanese O 0 0.00018015368550550193
family O 0 1.9749866623897105e-05
with O 0 5.5093296396080405e-06
adrenoleukodystrophy B-Disease 1 1.0
with O 0 4.421744506544201e-06
a O 0 7.551675025752047e-06
codon O 0 9.548887646815274e-06
291 O 0 6.445950020861346e-06
deletion O 0 2.4740706976444926e-06
: O 0 5.121197546031908e-07
a O 0 5.878798106095928e-07
clinical O 0 4.146230367041426e-06
, O 0 4.965235120835132e-07
biochemical O 0 5.720572062273277e-06
, O 0 1.1875741847688914e-06
pathological O 0 0.004511633887887001
, O 0 2.5384242690051906e-06
and O 0 2.412892627035035e-06
genetic O 0 1.590168903931044e-05
report O 0 1.090299520001281e-05
. O 0 3.5078708606306463e-05

We O 0 4.59293914900627e-05
report O 0 5.204899025557097e-06
a O 0 3.46309889209806e-06
Japanese O 0 1.0647524504747707e-05
family O 0 3.0721478196937824e-06
with O 0 2.5951067073037848e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.9999734163284302
ALD B-Disease 1 1.0
) O 0 2.1199566617724486e-06
with O 0 3.259916354636516e-07
a O 0 7.0444320954266e-07
three O 0 3.4364725820523745e-07
base O 0 1.727825406305783e-06
pair O 0 1.8544935755926417e-06
deletion O 0 4.819396508537466e-06
( O 0 2.1429689240903826e-06
delGAG O 0 3.693260077852756e-05
291 O 0 7.4100930760323536e-06
) O 0 1.4593985042665736e-06
in O 0 1.3536237020161934e-06
the O 0 1.0851088518393226e-05
ALD B-Disease 1 1.0
gene O 0 0.0001615818327991292
. O 0 8.677889127284288e-05

A O 0 9.014223178382963e-05
variety O 0 1.1962861208303366e-05
of O 0 8.003509719856083e-06
phenotypes O 0 1.88325357157737e-05
were O 0 1.7916353272084962e-06
observed O 0 1.9723627247003606e-06
within O 0 1.0864712294278434e-06
this O 0 2.2260326204559533e-06
family O 0 1.8996121070813388e-05
. O 0 4.66054116259329e-05

While O 0 4.547889329842292e-05
the O 0 1.2849390259361826e-05
proband O 0 0.008054238744080067
( O 0 3.7964018702041358e-06
patient O 0 2.738175226113526e-06
1 O 0 3.726145450855256e-06
) O 0 7.352065267696162e-07
was O 0 3.608960014389595e-06
classified O 0 1.4869157212160644e-06
as O 0 3.171284106429084e-07
having O 0 4.2239548747602385e-07
a O 0 4.033244920265133e-07
rare O 0 8.487844525006949e-07
intermediate O 0 6.4228343035210855e-06
type O 0 1.4278025446401443e-06
of O 0 1.9907824935216922e-06
adult O 0 8.450000677839853e-06
cerebral O 0 0.0003588824765756726
and O 0 1.2674674962909194e-06
cerebello O 1 0.9999992847442627
- O 1 0.9998067021369934
brain O 0 0.0010276454268023372
stem O 0 1.7288981553065241e-06
forms O 0 4.056810780639353e-07
, O 0 3.190756956428231e-07
his O 0 6.853898071312869e-07
younger O 0 1.2151015198469395e-06
brother O 0 4.505473043536767e-06
( O 0 7.446806762345659e-07
patient O 0 4.619174376330193e-07
2 O 0 1.4128581824479625e-06
) O 0 2.721773455505172e-07
and O 0 3.8799618096163613e-07
nephew O 0 0.00012478824646677822
( O 0 9.132216405305371e-07
patient O 0 1.0146484328288352e-06
3 O 0 1.028235374178621e-06
) O 0 4.407399103456555e-07
had O 0 1.554128971292812e-06
a O 0 4.502715455600992e-06
childhood O 0 0.03784777596592903
ALD B-Disease 1 1.0
type O 1 0.9942697286605835
. O 0 0.00013853504788130522

Another O 0 0.00048654613783583045
nephew O 1 0.5974469780921936
( O 0 1.6352172679034993e-05
patient O 0 9.38007087825099e-06
4 O 0 4.713299404102145e-06
) O 0 7.280922886820917e-07
of O 0 8.055595799305593e-07
patient O 0 1.1790540384026826e-06
1 O 0 3.905781341018155e-06
was O 0 7.199130322987912e-06
classified O 0 3.071910668950295e-06
as O 0 7.73524618580268e-07
having O 0 1.766093987498607e-06
an O 0 3.1111608223000076e-06
adolescent O 0 0.00021513229876291007
form O 0 1.6469832189613953e-05
. O 0 5.2144845540169626e-05

The O 0 5.974025043542497e-05
tau O 0 0.00022056637681089342
level O 0 8.619028449174948e-06
in O 0 1.1336538818795816e-06
the O 0 2.9049592740193475e-06
cerebrospinal O 0 0.03854728490114212
fluid O 0 0.00017258866864722222
( O 0 1.3324598512554076e-05
CSF O 1 1.0
) O 0 1.1590864232857712e-06
in O 0 4.0826753888723033e-07
patient O 0 5.779614298262459e-07
1 O 0 1.145070427810424e-06
was O 0 1.3198181250118068e-06
as O 0 2.058022374740176e-07
high O 0 8.550834422749176e-07
as O 0 1.7063413793039217e-07
that O 0 8.501099557634006e-08
of O 0 7.439935529873765e-07
patients O 0 1.0007172477344284e-06
with O 0 3.4626759770617355e-06
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
( O 0 6.226555797184119e-06
AD B-Disease 0 0.00016148634313140064
) O 0 1.1962667485931888e-05
. O 0 2.718224459385965e-05

His O 0 0.000563437701202929
brain O 0 0.0024647226091474295
magnetic O 0 4.868142423219979e-05
resonance O 0 3.532740447553806e-05
image O 0 0.00014396633196156472
( O 0 1.0323333299311344e-05
MRI O 1 0.896316409111023
) O 0 2.9251530122564873e-06
showed O 0 4.048152732138988e-06
abnormalities B-Disease 0 1.0798788935062476e-05
in I-Disease 0 5.568068672801019e-07
the I-Disease 0 1.5742837149446132e-06
bilateral I-Disease 0 3.364430813235231e-05
cerebellar I-Disease 1 1.0
hemispheres I-Disease 0 0.006548223085701466
and O 0 5.6247827160404995e-06
brain O 0 0.4994252622127533
stem O 0 4.829666067962535e-06
, O 0 4.047323898248578e-07
but O 0 1.2882117061963072e-07
not O 0 4.523269581113709e-08
in O 0 1.2458764331313432e-07
the O 0 6.24046833763714e-07
cerebral O 0 0.000271216151304543
white O 0 1.9399001303099794e-06
matter O 0 6.562665362253028e-07
, O 0 2.2863763149416627e-07
where O 0 1.8589118155887263e-07
marked O 0 3.96348866615881e-07
reductions O 0 1.1031997928512283e-06
of O 0 8.13167844171403e-07
the O 0 1.446528585802298e-06
cerebral O 0 0.0051737213507294655
blood O 0 1.9660569705592934e-06
flow O 0 7.759361437820189e-07
and O 0 3.91658801390804e-07
oxygen O 0 6.740987714692892e-07
metabolism O 0 6.630411348851339e-07
were O 0 2.1059349819552153e-07
clearly O 0 9.479172717874462e-07
demonstrated O 0 4.80371284083958e-07
by O 0 3.495586042845389e-07
positron O 0 6.5644012465782e-06
emission O 0 4.4868720578961074e-06
tomography O 0 1.2811606211471371e-05
( O 0 8.976003300631419e-06
PET O 0 0.0012470352230593562
) O 0 1.742325366649311e-05
. O 0 6.929811206646264e-05

In O 0 1.678704393270891e-05
patients O 0 2.716141125347349e-06
2 O 0 2.8029244276694953e-06
and O 0 3.669135821837699e-07
3 O 0 2.9807988539687358e-06
, O 0 7.615902859470225e-07
the O 0 6.508801106974715e-07
autopsy O 0 2.532133066779352e-06
findings O 0 6.312234859251475e-07
showed O 0 1.7589165963727282e-06
massive O 0 0.05124058946967125
demyelination B-Disease 1 1.0
of I-Disease 0 0.03877396136522293
the I-Disease 0 0.0002003685076488182
cerebral I-Disease 0 0.3495333790779114
white I-Disease 0 3.7338431866373867e-06
matter I-Disease 0 4.3745811240114563e-07
with O 0 1.5018825649804057e-07
sparing O 0 2.5846318294497905e-06
of O 0 1.4194271216183552e-06
the O 0 2.526604248487274e-06
U O 1 0.9995624423027039
- O 1 0.5493864417076111
fibers O 0 1.0118722457264084e-05
, O 0 4.930834620608948e-07
compatible O 0 1.327523364125227e-06
with O 0 2.916452217505139e-07
the O 0 1.3149045798854786e-06
findings O 0 1.9652245555334957e-06
of O 0 1.0626982657413464e-05
childhood O 1 0.99467933177948
ALD B-Disease 1 1.0
. O 0 0.0004799123271368444

Oleic O 0 0.11914509534835815
and O 0 6.110847607487813e-05
erucic O 1 0.6771093010902405
acids O 0 1.0991441740770824e-05
( O 0 4.798758709512185e-06
Lorenzos O 0 0.011678190901875496
Oil O 0 8.811816769593861e-06
) O 0 7.739585043964325e-07
were O 0 4.319065851632331e-07
administered O 0 2.972737718209828e-07
to O 0 1.7290652465362655e-07
patients O 0 2.006768227147404e-07
1 O 0 8.091197969406494e-07
and O 0 1.4100702117048058e-07
4 O 0 1.406028559358674e-06
, O 0 3.4067588217112643e-07
but O 0 1.6122208990054787e-07
sufficient O 0 5.223832886258606e-07
effectiveness O 0 2.5609674594306853e-06
was O 0 6.047845545253949e-06
not O 0 1.2107266229577363e-06
obtained O 0 8.501279808115214e-06
. O 0 3.6474637454375625e-05

The O 0 3.968723103753291e-05
findings O 0 9.531455361866392e-06
in O 0 8.090372034530446e-07
this O 0 4.624785390205943e-07
family O 0 6.079965260141762e-07
suggest O 0 3.0321672284117085e-07
that O 0 8.762475545154302e-08
delGAG291 O 0 7.058567916828906e-06
is O 0 3.0209105261747027e-07
part O 0 5.476910587276507e-07
of O 0 5.986874498375983e-07
the O 0 9.412081567461428e-07
cause O 0 1.466497224100749e-06
of O 0 5.508935373654822e-06
Japanese O 0 0.0014888281002640724
ALD B-Disease 1 1.0
with O 0 8.539769623894244e-06
phenotypic O 0 0.0001001007403829135
variations O 0 0.00010261317220283672
. O 0 6.999394099693745e-05

Moreover O 0 5.989449709886685e-05
, O 0 6.755507456546184e-06
although O 0 1.6101140545288217e-06
the O 0 8.762373227000353e-07
scale O 0 1.985448761843145e-06
of O 0 1.5431792235176545e-06
the O 0 7.607293923683756e-07
study O 0 2.7623104870144743e-07
is O 0 1.1986391257323703e-07
limited O 0 9.595908778692319e-08
, O 0 9.197123063131585e-08
there O 0 8.808220997025273e-08
is O 0 1.3945384580438258e-07
a O 0 2.597768400391942e-07
possibility O 0 9.55375639932754e-07
that O 0 1.9310961363316892e-07
PET O 0 1.2247682207089383e-05
can O 0 1.7506884830709168e-07
detect O 0 1.4205646721165976e-06
an O 0 1.1607590977291693e-06
insidious B-Disease 1 0.8204129934310913
lesion I-Disease 1 0.9276428818702698
which O 0 5.6440393336743e-07
is O 0 4.915781914860418e-07
undetectable O 0 2.699415063034394e-06
by O 0 1.0217637225196086e-07
computed O 0 6.603346491829143e-07
tomogram O 0 3.858246418531053e-05
( O 0 7.636092504981207e-07
CT O 0 0.0024004492443054914
) O 0 3.1655036991651286e-07
or O 0 2.3038099072891782e-07
MRI O 0 2.0216662051097956e-06
analysis O 0 1.4226468181277596e-07
, O 0 1.1069182193068627e-07
and O 0 5.1357133656892984e-08
that O 0 3.744418819451312e-08
the O 0 1.7337794133709394e-07
higher O 0 3.062489781768818e-07
level O 0 8.596319389653218e-07
of O 0 1.0958513030345785e-06
tau O 0 1.0365527487010695e-05
reflects O 0 1.9055459006267483e-06
the O 0 6.425637479878787e-07
process O 0 3.565710073871742e-07
of O 0 3.783513193411636e-06
neuronal B-Disease 0 0.04291475564241409
degeneration I-Disease 1 1.0
in O 0 0.337396502494812
ALD B-Disease 1 1.0
. O 0 0.0015050022630020976

Lorenzos O 0 0.1828959584236145
Oil O 0 6.544996722368523e-05
should O 0 1.816868461901322e-06
be O 0 2.554702689394617e-07
given O 0 1.4117360080945218e-07
in O 0 1.6049617101998592e-07
the O 0 4.3521936277102213e-07
early O 0 1.2471762147470145e-06
stage O 0 1.3558791579271201e-05
. O 0 6.663585736532696e-06
. O 0 3.5123928682878613e-05

Nonsense O 0 0.0006703271064907312
mutation O 0 2.348156886000652e-05
in O 0 2.4676003249624046e-06
exon O 0 2.427453000564128e-05
4 O 0 1.0491713510418776e-05
of O 0 3.2693299090169603e-06
human O 0 1.0719470537878806e-06
complement O 0 5.907128524995642e-06
C9 O 1 0.9999992847442627
gene O 0 1.8721997321335948e-06
is O 0 4.829315685128677e-07
the O 0 4.894226890428399e-07
major O 0 3.154036676278338e-06
cause O 0 4.226072178425966e-06
of O 0 1.1129215636174195e-05
Japanese O 0 0.0029221612494438887
complement B-Disease 0 0.03401564434170723
C9 I-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00040837429696694016

Deficiency B-Disease 1 0.9999996423721313
of I-Disease 0 0.0002270134718855843
the I-Disease 0 3.8512254832312465e-05
ninth I-Disease 0 0.09063079208135605
component I-Disease 0 0.0013242679415270686
of I-Disease 0 5.282761321723228e-06
human I-Disease 0 8.032183131945203e-07
complement I-Disease 0 4.395676569401985e-06
( O 0 3.9422607187589165e-06
C9 O 1 1.0
) O 0 1.475883436796721e-06
is O 0 3.6577847595253843e-07
the O 0 3.0452571309069754e-07
most O 0 2.4629304107293137e-07
common O 0 1.2842377827837481e-06
complement B-Disease 1 0.9999996423721313
deficiency I-Disease 1 1.0
in O 0 2.0027239315822953e-06
Japan O 0 3.0641365356132155e-06
but O 0 2.2712353597853507e-07
is O 0 2.644244716520916e-07
rare O 0 5.12901749516459e-07
in O 0 4.10624437563456e-07
other O 0 5.843427857143979e-07
countries O 0 8.21058563360566e-07
. O 0 2.2297392206382938e-05

We O 0 3.1254327041096985e-05
studied O 0 1.9212868210161105e-05
the O 0 2.2804169930168428e-06
molecular O 0 4.603211891662795e-06
basis O 0 2.087099801428849e-06
of O 0 6.678985664620996e-05
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
in O 0 2.680159013834782e-06
four O 0 3.7650411286449526e-06
Japanese O 0 0.006529446225613356
C9 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 0.9999998807907104
patients O 0 5.19597451784648e-05
who O 0 5.580451215791982e-06
had O 0 3.0699091439601034e-05
suffered O 1 0.9990322589874268
from O 0 0.016294389963150024
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.0003552057023625821

Direct O 0 0.00012248277198523283
sequencing O 0 5.253907147562131e-05
of O 0 3.179375926265493e-05
amplified O 0 0.00011503293353598565
C9 O 0 0.007129886653274298
cDNA O 0 7.43260097806342e-05
and O 0 2.0008776573376963e-06
DNA O 0 2.711384240683401e-06
revealed O 0 2.920971382991411e-06
a O 0 1.5033687077448121e-06
nonsense O 0 1.0102996384375729e-05
substitution O 0 3.5170473893231247e-06
( O 0 3.0461942515103146e-06
CGA O 0 0.00017864427354652435
- O 0 5.004974809708074e-05
- O 0 4.952729432261549e-05
> O 0 2.0254026821930893e-05
TGA O 0 9.912909445120022e-05
) O 0 1.3022316807109746e-06
at O 0 2.1850642042409163e-06
codon O 0 3.919928076356882e-06
95 O 0 2.1597415980068035e-06
in O 0 3.9775142113285256e-07
exon O 0 5.7951847338699736e-06
4 O 0 1.6714698176656384e-06
in O 0 4.538055407010688e-07
the O 0 1.0310093330190284e-06
four O 0 3.037477199541172e-06
C9 B-Disease 1 0.9999998807907104
- I-Disease 1 0.9996166229248047
deficient I-Disease 0 0.059340909123420715
individuals O 0 1.1673370863718446e-05
. O 0 4.446399907465093e-05

An O 0 9.116365981753916e-05
allele O 0 5.5772696214262396e-05
- O 0 2.4294029572047293e-05
specific O 0 2.3577736101287883e-06
polymerase O 0 9.450213838135824e-06
chain O 0 3.3357257507304894e-06
reaction O 0 7.778521080581413e-07
system O 0 3.511349575546774e-07
designed O 0 8.378915481443983e-07
to O 0 2.0973786263311922e-07
detect O 0 5.855667382093088e-07
exclusively O 0 5.091695811643149e-07
only O 0 1.1818894307680239e-07
one O 0 1.462261280948951e-07
of O 0 2.530609322093369e-07
the O 0 2.0237327191807708e-07
normal O 0 1.911355838046802e-07
and O 0 1.632123058925572e-07
mutant O 0 2.4114915504469536e-06
alleles O 0 3.789092204442568e-07
indicated O 0 1.788852728168422e-07
that O 0 3.934700032459659e-08
all O 0 5.9564865040329096e-08
the O 0 1.3572713442044915e-07
four O 0 1.3172096657854127e-07
patients O 0 9.926154831418899e-08
were O 0 7.257325762566325e-08
homozygous O 0 3.3070298854909197e-07
for O 0 9.421477642490572e-08
the O 0 2.5269173420383595e-07
mutation O 0 1.1194985205520425e-07
in O 0 8.923701244611948e-08
exon O 0 2.7752541882364312e-06
4 O 0 9.385102544001711e-07
and O 0 1.8766566256545048e-07
that O 0 8.506565762900209e-08
the O 0 2.6163758093389333e-07
parents O 0 1.74677282416269e-07
of O 0 8.827695410218439e-07
patient O 0 1.6878951782928198e-06
2 O 0 6.254599611565936e-06
were O 0 4.541979251371231e-06
heterozygous O 0 2.6101526600541547e-05
. O 0 2.4298107746290043e-05

The O 0 4.821254333364777e-05
common O 0 1.1036375326511916e-05
mutation O 0 4.044000434078043e-06
at O 0 4.5997535380593035e-06
codon O 0 9.254800716007594e-06
95 O 0 2.5857609671220416e-06
in O 0 5.139966674505558e-07
exon O 0 6.83390089761815e-06
4 O 0 3.0569212867703754e-06
might O 0 4.803731030733616e-07
be O 0 1.2934189896895987e-07
responsible O 0 3.71827184153517e-07
for O 0 4.0853743143998145e-07
most O 0 1.498580445513653e-06
Japanese O 0 0.00044603360584005713
C9 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.323814962641336e-05
. O 0 7.464415830327198e-05

BRCA1 O 0 0.0003889364597853273
required O 0 9.474145372223575e-06
for O 0 3.916859895980451e-06
transcription O 0 5.530471389647573e-05
- O 0 0.002182033145800233
coupled O 0 2.2974758394411765e-05
repair O 0 5.638285801978782e-05
of O 0 1.587835322425235e-05
oxidative O 0 6.898427818669006e-05
DNA O 0 8.294401777675375e-05
damage O 0 0.00286225788295269
. O 0 0.00010402646148577332

The O 0 0.0003422536246944219
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9721797108650208
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.8367270827293396
gene O 0 2.3358372345683165e-05
BRCA1 O 0 8.77995480550453e-05
encodes O 0 6.952761395950802e-06
a O 0 5.052321284892969e-06
zinc O 0 4.934362368658185e-05
finger O 0 2.1687508706236258e-05
protein O 0 1.7126845932580181e-06
of O 0 2.135736394848209e-06
unknown O 0 6.653603577433387e-06
function O 0 6.0953957472520415e-06
. O 0 2.764259079413023e-05

Association O 0 5.195840640226379e-05
of O 0 1.6754494936321862e-05
the O 0 8.882418114808388e-06
BRCA1 O 0 2.454759851389099e-05
protein O 0 1.3792872550766333e-06
with O 0 2.916630137406173e-07
the O 0 1.1165647038069437e-06
DNA O 0 1.8002540400630096e-06
repair O 0 1.0808453225763515e-05
protein O 0 2.1504824871954042e-06
Rad51 O 0 4.400722900754772e-05
and O 0 3.2756605605754885e-07
changes O 0 9.24626633036496e-08
in O 0 5.9467012647473894e-08
the O 0 1.7499841931112314e-07
phosphorylation O 0 3.5592140079643286e-07
and O 0 2.239217735677812e-07
cellular O 0 8.071414185906178e-07
localization O 0 2.3413088001689175e-06
of O 0 9.409909580426756e-07
the O 0 4.1718828924786067e-07
protein O 0 3.5549024346437363e-07
after O 0 2.796546141325962e-07
exposure O 0 7.36858908112481e-07
to O 0 1.5294990873826464e-07
DNA O 0 9.824057087826077e-07
- O 0 6.023497007845435e-06
damaging O 0 5.085021712147864e-06
agents O 0 3.4982105034941924e-07
are O 0 4.1269135664379064e-08
consistent O 0 2.0073788675745163e-07
with O 0 5.338626607453989e-08
a O 0 4.149860330926458e-07
role O 0 9.386784540765802e-07
for O 0 8.793313099886291e-07
BRCA1 O 0 1.7962813217309304e-05
in O 0 1.484417794017645e-06
DNA O 0 1.590165811649058e-05
repair O 0 0.0003494004486128688
. O 0 6.91003369865939e-05

Here O 0 2.3506976503995247e-05
, O 0 4.1541620703355875e-06
it O 0 1.2121083727834048e-06
is O 0 1.1021249974874081e-06
shown O 0 5.923652679484803e-07
that O 0 6.553665912178985e-07
mouse O 0 5.388036515796557e-05
embryonic O 0 0.00015871654613874853
stem O 0 0.0002102432044921443
cells O 0 2.29507418225694e-06
deficient B-Disease 0 1.4528895007970277e-05
in I-Disease 0 6.717846190440468e-07
BRCA1 I-Disease 0 8.127452929329593e-06
are O 0 1.5496726746278e-07
defective O 0 3.0689559480379103e-06
in O 0 1.9859268718391831e-07
the O 0 4.374722948341514e-07
ability O 0 1.7591034406905237e-07
to O 0 1.338873119038908e-07
carry O 0 1.819268504732463e-07
out O 0 3.6118274238106096e-07
transcription O 0 3.99755754187936e-06
- O 0 1.2521956705313642e-05
coupled O 0 4.125357918383088e-06
repair O 0 5.7809543250186834e-06
of O 0 1.6216501990129473e-06
oxidative O 0 2.9645573249581503e-06
DNA O 0 1.4717286376253469e-06
damage O 0 7.495165846194141e-06
, O 0 6.22205845957069e-07
and O 0 2.963447798265406e-07
are O 0 2.2796987764195364e-07
hypersensitive O 0 2.5971245122491382e-05
to O 0 1.771704774000682e-06
ionizing O 0 0.00036953340168111026
radiation O 0 7.888698019087315e-05
and O 0 3.1565823519486003e-06
hydrogen O 0 1.9589298972277902e-05
peroxide O 0 0.0001362800394417718
. O 0 4.2811112507479265e-05

These O 0 1.1868713045259938e-05
results O 0 2.931704784714384e-06
suggest O 0 2.8946358270331984e-06
that O 0 5.403255727287615e-07
BRCA1 O 0 1.3892004972149152e-05
participates O 0 4.060385890625184e-06
, O 0 8.349839504262491e-07
directly O 0 3.5570593581724097e-07
or O 0 3.9149003328020626e-07
indirectly O 0 1.3020317055634223e-06
, O 0 3.481200678834284e-07
in O 0 3.1172800163403735e-07
transcription O 0 7.639678187842946e-06
- O 0 3.550938708940521e-05
coupled O 0 3.1133811262407107e-06
repair O 0 9.168167707684916e-06
of O 0 3.2307727906299988e-06
oxidative O 0 8.718197932466865e-06
DNA O 0 9.435192623641342e-06
damage O 0 4.2446463339729235e-05
. O 0 8.626955604995601e-06
. O 0 4.615410580299795e-05

Truncation O 0 0.002087471541017294
mutations O 0 4.205587538308464e-05
in O 0 4.571983026835369e-06
the O 0 7.632454071426764e-06
transactivation O 0 0.00019424314086791128
region O 0 1.0302867849532049e-05
of O 0 1.589651765243616e-05
PAX6 O 1 0.9999996423721313
result O 0 3.2053217182692606e-06
in O 0 1.5824738284209161e-06
dominant O 0 4.596272992785089e-05
- O 0 0.0007932622102089226
negative O 0 1.9928715119021945e-05
mutants O 0 8.472341141896322e-05
. O 0 2.5435483621549793e-05

PAX6 O 1 0.9997609257698059
is O 0 4.075376273249276e-05
a O 0 7.898002877482213e-06
transcription O 0 2.0373596271383576e-05
factor O 0 3.1644246973883128e-06
with O 0 2.129976905962394e-07
two O 0 2.2893807738455507e-07
DNA O 0 6.445535518651013e-07
- O 0 1.2247670611031936e-06
binding O 0 3.7545891018453403e-07
domains O 0 9.62483113653434e-07
( O 0 8.98561211215565e-07
paired O 0 3.3409151001251303e-06
box O 0 1.1352094588801265e-05
and O 0 9.221677146342699e-07
homeobox O 0 0.0002113204391207546
) O 0 9.954762845154619e-07
and O 0 7.398317620754824e-07
a O 0 3.2970647225738503e-06
proline O 0 2.2799365979153663e-05
- O 0 1.557348332426045e-05
serine O 0 1.7740698240231723e-05
- O 0 1.7791306163417175e-05
threonine O 0 2.3208138372865506e-05
( O 0 4.2109136302315164e-06
PST O 1 0.9968724846839905
) O 0 1.0636807928676717e-05
- O 0 6.586834933841601e-05
rich O 0 2.1911760995863006e-05
transactivation O 0 0.00041565007995814085
domain O 0 0.00011954042565776035
. O 0 9.951760148396716e-05

PAX6 O 1 0.9999998807907104
regulates O 0 0.026070138439536095
eye O 1 0.9901845455169678
development O 0 7.915307833172847e-06
in O 0 2.0218801637383876e-06
animals O 0 9.638021083446802e-07
ranging O 0 2.2126350813778117e-06
from O 0 1.7906889979713014e-06
jellyfish O 0 5.466455149871763e-06
to O 0 1.0007220225816127e-06
Drosophila O 0 1.3593749827123247e-05
to O 0 3.8777670852141455e-06
humans O 0 8.853900908434298e-06
. O 0 3.46121632901486e-05

Heterozygous O 0 0.00031565106473863125
mutations O 0 2.4475695681758225e-05
in O 0 1.548507157167478e-06
the O 0 2.27981036005076e-06
human O 0 2.657805907801958e-06
PAX6 O 1 0.9999955892562866
gene O 0 1.9130989130644593e-06
result O 0 3.44481975389499e-07
in O 0 1.552702286744534e-07
various O 0 1.3547818866754824e-07
phenotypes O 0 1.3245262380223721e-06
, O 0 3.6075451248507306e-07
including O 0 1.3607944993054844e-06
aniridia B-Disease 1 1.0
, O 0 6.362312706187367e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.4146298528648913e-05
autosomal B-Disease 0 0.2927189767360687
dominant I-Disease 1 0.9999772310256958
keratitis I-Disease 1 1.0
, O 0 0.0017823524540290236
and O 0 4.6961613406892866e-05
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.43882471323013306

It O 0 3.385182571946643e-05
is O 0 6.644681434408994e-06
believed O 0 3.383802550160908e-06
that O 0 2.147534274854479e-07
the O 0 7.551996077381773e-07
mutated O 0 2.41159750657971e-06
allele O 0 1.3241789247331326e-06
of O 0 1.2231073469592957e-06
PAX6 O 1 0.9997885823249817
produces O 0 1.8759315025818069e-06
an O 0 5.052765459367947e-07
inactive O 0 4.538385383057175e-06
protein O 0 7.608592795804725e-07
and O 0 5.450029902931419e-07
aniridia B-Disease 1 1.0
is O 0 1.9753897504415363e-06
caused O 0 2.655928028616472e-06
due O 0 1.6037466821217095e-06
to O 0 2.891016492867493e-06
genetic O 0 2.042168125626631e-05
haploinsufficiency O 0 0.1414836347103119
. O 0 9.736818174133077e-05

However O 0 1.8508419088902883e-05
, O 0 2.8092213142372202e-06
several O 0 8.617020057499758e-07
truncation O 0 3.4379427233943716e-05
mutations O 0 1.378901856696757e-06
have O 0 2.165651551422343e-07
been O 0 3.8231178223213647e-07
found O 0 1.8462725392964785e-07
to O 0 1.0441542741546073e-07
occur O 0 5.0268592843849547e-08
in O 0 1.2792965264907252e-07
the O 0 3.38686220402451e-07
C O 0 1.1083057870564517e-05
- O 0 4.448802428669296e-06
terminal O 0 3.3197245556948474e-06
half O 0 6.6846524759967e-07
of O 0 1.5042016912047984e-06
PAX6 O 1 0.9999440908432007
in O 0 1.164144691756519e-06
patients O 0 7.50852109376865e-07
with O 0 2.3781446145676455e-07
Aniridia B-Disease 1 1.0
resulting O 0 2.3260283796844305e-06
in O 0 5.692994591299794e-07
mutant O 0 2.266367800984881e-06
proteins O 0 1.2889994138731709e-07
that O 0 7.284187830691735e-08
retain O 0 4.268584632427519e-07
the O 0 2.4493587602592015e-07
DNA O 0 3.2803811222947843e-07
- O 0 9.694863365439232e-07
binding O 0 2.3114111513677926e-07
domains O 0 5.010614927414281e-07
but O 0 1.80056488829905e-07
have O 0 1.3819558830618917e-07
lost O 0 2.3985442112461897e-06
most O 0 4.406125526656979e-07
of O 0 1.8373195871390635e-06
the O 0 1.17279805635917e-05
transactivation O 0 0.0006030009244568646
domain O 0 0.00016196223441511393
. O 0 0.000102657126262784

It O 0 1.0936547369055916e-05
is O 0 1.6464477994304616e-06
not O 0 2.9460531436598103e-07
clear O 0 6.558373115694849e-07
whether O 0 3.5460547564980516e-07
such O 0 4.525672920863144e-07
mutants O 0 1.2006029464828316e-05
really O 0 2.401160145382164e-06
behave O 0 3.9636285009692074e-07
as O 0 3.5051934332841483e-07
loss O 0 2.5556510081514716e-06
- O 0 4.409666871652007e-06
of O 0 2.0746022073581116e-06
- O 0 9.359215255244635e-06
function O 0 8.072029800132441e-07
mutants O 0 3.2233065212494694e-06
as O 0 1.073885073310521e-06
predicted O 0 5.8118994274991564e-06
by O 0 3.7174067983869463e-06
haploinsufficiency O 0 0.0008983384468592703
. O 0 7.1719718107488e-05

Contrary O 0 4.7305551561294124e-05
to O 0 2.6730015179055044e-06
this O 0 8.515833087585634e-07
theory O 0 1.9139783944410738e-06
, O 0 3.3920986197699676e-07
our O 0 1.623634204861446e-07
data O 0 2.8382621053424373e-07
showed O 0 3.0992868005341734e-07
that O 0 8.577863042091849e-08
these O 0 5.71729437126578e-08
mutants O 0 1.1254218179601594e-06
are O 0 1.212842164477479e-07
dominant O 0 2.7689147827913985e-06
- O 0 4.685825842898339e-06
negative O 0 9.108176186600758e-07
in O 0 4.4482024463832204e-07
transient O 0 2.9618076951010153e-06
transfection O 0 6.824770025559701e-06
assays O 0 1.1081937145718257e-06
when O 0 4.576933463340538e-07
they O 0 1.379301437509639e-07
are O 0 1.5015861265510466e-07
coexpressed O 0 1.6885402146726847e-05
with O 0 1.5360330962721491e-06
wild O 0 3.8380047044483945e-05
- O 0 0.0003926477220375091
type O 0 0.00027541484450921416
PAX6 O 1 0.9998852014541626
. O 0 0.0001789453817764297

We O 0 2.1701351215597242e-05
found O 0 3.936369921575533e-06
that O 0 3.834773281141679e-07
the O 0 9.162802143691806e-07
dominant O 0 8.189094842236955e-06
- O 0 1.191421142721083e-05
negative O 0 8.570223144488409e-07
effects O 0 8.970525300355803e-07
result O 0 1.350267382349557e-07
from O 0 1.5266617481302092e-07
the O 0 2.1300988350958505e-07
enhanced O 0 6.174562940941541e-07
DNA O 0 6.116616759754834e-07
binding O 0 3.144747893202293e-07
ability O 0 4.2562879798424547e-07
of O 0 2.1256555555737577e-06
these O 0 1.2859143225796288e-06
mutants O 0 5.352184234652668e-05
. O 0 3.9867642044555396e-05

Kinetic O 0 0.00021244247909635305
studies O 0 8.566149517719168e-06
of O 0 3.6322392134024994e-06
binding O 0 1.5062789771036478e-06
and O 0 9.210514804181003e-07
dissociation O 0 2.0446132111828774e-06
revealed O 0 1.4759959867660655e-06
that O 0 1.6880210296221776e-07
various O 0 3.4709509577623976e-07
truncation O 0 3.003043821081519e-05
mutants O 0 7.441407433361746e-06
have O 0 1.5907004069504183e-07
3 O 0 1.3498943189915735e-06
- O 0 2.68849407802918e-06
5 O 0 1.7812819805840263e-06
- O 0 2.1124351405887865e-06
fold O 0 1.254201379197184e-06
higher O 0 3.18183225544999e-07
affinity O 0 2.830374796758406e-07
to O 0 1.3642231522226211e-07
various O 0 1.720106581615255e-07
DNA O 0 3.936779933155776e-07
- O 0 6.38449193957058e-07
binding O 0 1.6297713045787532e-07
sites O 0 2.674811980796221e-07
when O 0 1.3537537313368375e-07
compared O 0 2.655882838098478e-07
with O 0 1.8650487731974863e-07
the O 0 9.101299269786978e-07
wild O 0 1.7627386114327237e-05
- O 0 0.00022611701569985598
type O 0 0.00018338457448408008
PAX6 O 1 0.9994303584098816
. O 0 9.1627320216503e-05

These O 0 1.1265503417234868e-05
results O 0 2.121354327755398e-06
provide O 0 5.181011601962382e-07
a O 0 9.762816262082197e-07
new O 0 6.342520464386325e-07
insight O 0 1.63660399721266e-06
into O 0 2.6737075131677557e-07
the O 0 3.8829674053886265e-07
role O 0 1.3897910093874088e-06
of O 0 2.982607156809536e-06
mutant O 0 0.00021111984096933156
PAX6 O 1 0.9999985694885254
in O 0 1.3375843991525471e-05
causing O 0 0.0085732601583004
aniridia B-Disease 1 0.9999998807907104
. O 0 3.6916968383593485e-05
. O 0 7.078606722643599e-05

Reversal O 0 0.0008829986909404397
of O 0 0.21232591569423676
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 1 0.8009001612663269
excellent O 1 0.9431307911872864
neuropsychologic O 1 0.9995723366737366
outcome O 0 7.595951046823757e-06
in O 0 1.0551327704888536e-06
very B-Disease 0 9.936504739016527e-07
- I-Disease 0 1.2688918104686309e-05
long I-Disease 0 6.425566880352562e-06
- I-Disease 0 3.117163578281179e-05
chain I-Disease 0 1.357110795652261e-05
acyl I-Disease 0 2.002784276555758e-05
- I-Disease 0 2.9114187782397494e-05
coenzyme I-Disease 0 9.400452654517721e-06
A I-Disease 0 0.00027425066218711436
dehydrogenase I-Disease 0 0.049819812178611755
deficiency I-Disease 1 0.9988157749176025
. O 0 0.0001769269147189334

Very B-Disease 0 4.032276410725899e-05
- I-Disease 0 8.108237670967355e-05
long I-Disease 0 1.6598025467828847e-05
- I-Disease 0 3.6719851777888834e-05
chain I-Disease 0 9.308336302638054e-06
acyl I-Disease 0 1.2240582691447344e-05
- I-Disease 0 1.171021085610846e-05
coenzyme I-Disease 0 5.4509519031853415e-06
A I-Disease 0 1.7939739336725324e-05
dehydrogenase I-Disease 0 5.4134528909344226e-05
( I-Disease 0 7.813740921847057e-06
VLCAD I-Disease 1 1.0
) I-Disease 0 0.0001720502186799422
deficiency I-Disease 1 0.9999901056289673
is O 0 2.399772938588285e-06
a O 0 4.826295935345115e-06
disorder O 1 0.6563589572906494
of O 0 9.58465170697309e-06
fatty O 0 1.762308420438785e-05
acid O 0 2.5114502477663336e-06
beta O 0 1.7828336922320887e-06
oxidation O 0 6.918644430697896e-07
that O 0 2.0287318136524846e-07
reportedly O 0 4.974946023139637e-06
has O 0 4.263698372142244e-07
high O 0 2.021187810896663e-06
rates O 0 5.636207447423658e-07
of O 0 2.3089135083864676e-06
morbidity O 0 0.00011523031571414322
and O 0 1.3156484783394262e-05
mortality O 0 0.00012547695951070637
. O 0 5.7036784710362554e-05

We O 0 2.0410037905094214e-05
describe O 0 9.566853805154096e-06
the O 0 2.4232076611951925e-06
outcome O 0 1.295600668527186e-06
of O 0 1.1078249144702568e-06
a O 0 6.700103654111444e-07
5 O 0 1.6152863508978044e-06
- O 0 2.1160321921342984e-06
year O 0 5.5018449529598e-07
- O 0 4.119688583159586e-06
old O 0 6.953418051125482e-06
girl O 0 2.6712327780842315e-06
with O 0 8.505428468197351e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 2.0236499040038325e-05
was O 0 2.6389583581476472e-05
first O 0 5.563779836847971e-07
seen O 0 4.824514689971693e-07
at O 0 4.3567078478190524e-07
5 O 0 4.843568603973836e-07
months O 0 1.659916648577564e-07
of O 0 1.8837322102172038e-07
age O 0 7.036442752905714e-07
with O 0 6.6063574877262e-07
severe O 1 0.9999910593032837
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 1.0
hepatomegaly B-Disease 1 1.0
, O 1 0.9999998807907104
encephalopathy B-Disease 1 1.0
, O 0 9.955746645573527e-05
and O 0 6.651077274000272e-05
hypotonia B-Disease 1 0.9903255701065063
. O 0 0.00029265432385727763

Biochemical O 0 0.0016064858064055443
studies O 0 9.657110786065459e-05
indicated O 1 0.9037678837776184
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.16361114382743835
by O 0 7.113330411812058e-06
a O 0 2.0453682736842893e-05
stable O 0 1.2366079317871481e-05
yet O 0 8.092942152870819e-06
inactive O 0 7.317210838664323e-05
enzyme O 0 2.63956517301267e-05
. O 0 2.5668239686638117e-05

Molecular O 0 0.00018294011533726007
genetic O 0 1.6232103007496335e-05
analysis O 0 3.042951220777468e-06
of O 0 7.036663646431407e-06
her O 0 8.974282536655664e-06
VLCAD O 1 0.9999927282333374
gene O 0 5.257621523924172e-06
revealed O 0 4.373289812065195e-06
a O 0 3.3830572192528052e-06
T1372C O 0 0.00012298191722948104
( O 0 3.3546884878887795e-06
F458L O 0 3.587402170524001e-05
) O 0 1.8052844552585157e-06
missense O 0 2.183960168622434e-05
mutation O 0 3.976804237026954e-06
and O 0 2.151563649022137e-06
a O 0 1.6302999938488938e-05
1668 O 0 0.24921852350234985
ACAG O 1 0.9999583959579468
1669 O 0 0.008476214483380318
splice O 0 0.001074040774255991
site O 0 0.0003145728842355311
mutation O 0 0.00016041513299569488
. O 0 0.00012346047151368111

After O 0 7.230086339404806e-05
initial O 0 2.3533151761512272e-05
treatment O 0 7.038280728011159e-06
with O 0 1.051070398716547e-06
intravenous O 0 3.209442729712464e-05
glucose O 0 2.0781801140401512e-05
and O 0 1.9235999388911296e-06
carnitine O 0 0.414960116147995
, O 0 1.9353728930582292e-06
the O 0 1.3842077351000626e-06
patient O 0 2.604411520223948e-06
has O 0 1.0321189165551914e-06
thrived O 0 3.5271409615234006e-06
on O 0 6.156077461128007e-07
a O 0 1.112467316488619e-06
low O 0 3.318217750347685e-06
- O 0 4.376627657620702e-06
fat O 0 1.0415370525151957e-05
diet O 0 2.6901147975877393e-06
supplemented O 0 1.293022137360822e-06
with O 0 4.2329756411163544e-07
medium O 0 6.490010036941385e-06
- O 0 1.5043444363982417e-05
chain O 0 9.510126801615115e-06
triglyceride O 0 2.615786979731638e-05
oil O 0 8.57591749081621e-06
and O 0 2.538184389777598e-06
carnitine O 0 8.240014722105116e-05
and O 0 7.121747785276966e-06
avoidance O 0 0.001157305552624166
of O 0 0.00010144151747226715
fasting O 0 0.00015535093552898616
. O 0 6.186444079503417e-05

Her O 0 0.10729201883077621
ventricular O 1 1.0
hypertrophy O 1 0.9999147653579712
resolved O 0 3.331170591991395e-05
significantly O 0 2.5726017156557646e-06
over O 0 9.70269752542663e-07
1 O 0 2.9162677037675167e-06
year O 0 9.25219126202137e-07
, O 0 5.333497483661631e-07
and O 0 3.5467212455841945e-07
cognitively O 0 1.0367801223765127e-05
, O 0 4.387968317587365e-07
she O 0 5.393134756559448e-07
is O 0 2.274215660236223e-07
in O 0 1.2359699042008288e-07
the O 0 3.858177137772145e-07
superior O 0 4.779065875482047e-06
range O 0 5.924052857153583e-06
for O 0 5.917937414778862e-06
age O 0 4.499239366850816e-05
. O 0 4.895460369880311e-05

Clinical O 0 0.0013355750124901533
recognition O 0 5.506663364940323e-05
of O 1 0.999998927116394
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 0.0002452665939927101
important O 0 1.6335601458195015e-06
because O 0 2.406537760180072e-07
it O 0 1.0576883369139978e-07
is O 0 1.1335765748299309e-07
one O 0 1.0931690752613576e-07
of O 0 3.156607704113412e-07
the O 0 3.838527504740341e-07
few O 0 4.822053938369208e-07
directly O 0 1.791157160369039e-06
treatable O 1 0.995594322681427
causes O 0 1.1244691449974198e-05
of O 0 0.21170271933078766
cardiomyopathy B-Disease 1 1.0
in O 0 4.966908454662189e-05
children O 0 1.4667863069917075e-05
. O 0 8.946970410761423e-06
. O 0 2.2712214558850974e-05

Cloning O 0 8.26158793643117e-05
of O 0 7.4127929110545665e-06
a O 0 4.604642981576035e-06
novel O 0 8.448969310848042e-06
member O 0 1.3697967915504705e-06
of O 0 1.253063260264753e-06
the O 0 1.2784723821823718e-06
low O 0 6.845805273769656e-06
- O 0 1.8420356354909018e-05
density O 0 8.90000410436187e-06
lipoprotein O 1 0.9422910213470459
receptor O 0 8.566204633098096e-05
family O 0 3.0731487640878186e-05
. O 0 3.0458857509074733e-05

A O 0 0.00010625152208376676
gene O 0 6.221356215974083e-06
encoding O 0 6.788464361306978e-06
a O 0 4.2309920900152065e-06
novel O 0 1.2620780580618884e-05
transmembrane O 0 1.000658085104078e-05
protein O 0 1.9145809346809983e-06
was O 0 2.07698940357659e-06
identified O 0 2.3057836529005726e-07
by O 0 6.269010555115528e-08
DNA O 0 2.487498989012238e-07
sequence O 0 1.3848385549408704e-07
analysis O 0 1.192844933939341e-07
within O 0 1.9235582726651046e-07
the O 0 7.467245382031251e-07
insulin B-Disease 0 2.7283920644549653e-05
- I-Disease 1 0.9068883061408997
dependent I-Disease 0 5.198978033149615e-05
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 5.723560752812773e-05
IDDM B-Disease 1 0.9999996423721313
) O 0 1.1197371350135654e-05
locus O 0 0.00020326799130998552
IDDM4 O 1 0.987740695476532
on O 0 4.231115599395707e-05
chromosome O 0 0.00010542735981289297
11q13 O 0 0.0008180427248589694
. O 0 9.774532372830436e-05

Based O 0 1.9063429135712795e-05
on O 0 3.1068025236891117e-06
its O 0 1.6648724567858153e-06
chromosomal O 0 1.0762108104245272e-05
position O 0 3.5283587749290746e-06
, O 0 6.393119065251085e-07
this O 0 2.0005943213163846e-07
gene O 0 3.234806627006037e-07
is O 0 2.956906826057093e-07
a O 0 2.86593490272935e-07
candidate O 0 7.449249892488297e-07
for O 0 3.6279422488405544e-07
conferring O 0 1.013890141621232e-05
susceptibility O 0 0.0014941469999030232
to O 0 5.440571840154007e-05
diabetes B-Disease 1 1.0
. O 0 0.00018168574024457484

The O 0 5.96516219957266e-05
gene O 0 1.4217453099263366e-05
, O 0 5.625646281259833e-06
termed O 0 1.2254505236342084e-05
low O 0 7.69610869610915e-06
- O 0 1.4677965737064369e-05
density O 0 5.413079179561464e-06
lipoprotein O 0 0.00016304767632391304
receptor O 0 4.6281793402158655e-06
related O 0 9.719915396999568e-07
protein O 0 5.629696602227341e-07
5 O 0 1.1192416877747746e-06
( O 0 9.799942972676945e-07
LRP5 O 1 0.7619542479515076
) O 0 8.06038315204205e-07
, O 0 6.588985570488148e-07
encodes O 0 1.2171287835371913e-06
a O 0 6.998096750976401e-07
protein O 0 5.843182862008689e-07
of O 0 1.1445823702160851e-06
1615 O 0 9.552713891025633e-06
amino O 0 6.45303884994064e-07
acids O 0 2.402066741069575e-07
that O 0 7.676983670990012e-08
contains O 0 4.136063296300563e-07
conserved O 0 9.050698395185464e-07
modules O 0 1.5544047755611246e-06
which O 0 1.2454843556497508e-07
are O 0 4.5928359782010375e-08
characteristic O 0 4.511908855420188e-07
of O 0 5.365135962165368e-07
the O 0 5.548931767407339e-07
low O 0 3.4052068258461077e-06
- O 0 6.984014817135176e-06
density O 0 2.5787621780182235e-06
lipoprotein O 0 0.18403275310993195
( O 0 7.071274922054727e-06
LDL O 1 0.9999998807907104
) O 0 8.404601430811454e-06
receptor O 0 3.2923155231401324e-05
family O 0 1.9437782611930743e-05
. O 0 3.5022552765440196e-05

These O 0 1.7666330677457154e-05
modules O 0 3.877493509207852e-05
include O 0 6.89670105202822e-06
a O 0 6.633923931076424e-06
putative O 0 2.20964866457507e-05
signal O 0 6.20776017967728e-06
peptide O 0 1.914498625410488e-06
for O 0 2.5921261226358183e-07
protein O 0 3.9800943341106176e-07
export O 0 7.817161531420425e-07
, O 0 7.02162822108221e-07
four O 0 8.976687126960314e-07
epidermal O 0 0.367104172706604
growth O 0 4.025085672765272e-06
factor O 0 1.4736001503479201e-05
( O 0 3.178640326950699e-06
EGF O 1 0.9623818397521973
) O 0 1.0509351113796583e-06
repeats O 0 1.5153706272030831e-06
with O 0 2.0757170204888098e-07
associated O 0 7.377287261078891e-07
spacer O 0 8.329556294484064e-06
domains O 0 2.5886527055263286e-06
, O 0 1.0669749599401257e-06
three O 0 7.590712698402058e-07
LDL O 1 0.9999998807907104
- O 0 0.007010763045400381
receptor O 0 9.062290700967424e-06
( O 0 2.165543264709413e-06
LDLR O 1 0.9830096364021301
) O 0 1.4429133443627506e-06
repeats O 0 1.9495832930260804e-06
, O 0 4.361845924449881e-07
a O 0 6.299401889009459e-07
single O 0 8.042269996622053e-07
transmembrane O 0 5.559077180805616e-06
spanning O 0 6.99606698617572e-06
domain O 0 4.257406089891447e-06
, O 0 1.6895895669222227e-06
and O 0 1.4197601103660418e-06
a O 0 9.889426110021304e-06
cytoplasmic O 0 5.78496401431039e-05
domain O 0 7.214198558358476e-05
. O 0 6.592409044969827e-05

The O 0 4.300084037822671e-05
encoded O 0 1.2661044820561074e-05
protein O 0 3.124279146504705e-06
has O 0 8.759866432228591e-07
a O 0 8.380193889934162e-07
unique O 0 9.032970069711155e-07
organization O 0 9.546733963361476e-07
of O 0 2.3564450657431735e-06
EGF O 1 0.9999951124191284
and O 0 3.73869261238724e-06
LDLR O 1 0.9999847412109375
repeats O 0 5.1193355830037035e-06
; O 0 6.333834789984394e-07
therefore O 0 8.031562401811243e-07
, O 0 8.294956046484003e-07
LRP5 O 0 0.01213892176747322
likely O 0 9.243362910638098e-07
represents O 0 4.001666980002483e-07
a O 0 3.167058650888066e-07
new O 0 3.2796427262837824e-07
category O 0 1.5894614762146375e-06
of O 0 2.4992173166538123e-06
the O 0 7.67453275329899e-06
LDLR O 1 0.9999988079071045
family O 0 5.324789890437387e-05
. O 0 5.151742516318336e-05

Both O 0 3.854503302136436e-05
human O 0 9.523405424261e-06
and O 0 5.912685537623474e-06
mouse O 1 0.8419799208641052
LRP5 O 1 1.0
cDNAs O 1 0.999858021736145
have O 0 1.7424415545974625e-06
been O 0 1.3834832088832627e-06
isolated O 0 1.5199066183413379e-06
and O 0 2.475543112723244e-07
the O 0 4.0175666526920395e-07
encoded O 0 5.628730264106707e-07
mature O 0 3.3650528052930895e-07
proteins O 0 7.976286298116975e-08
are O 0 2.680194022275373e-08
95 O 0 5.13279076130857e-07
% O 0 1.6852655448929e-07
identical O 0 2.198235193873188e-07
, O 0 1.7642662442085566e-07
indicating O 0 4.6187514612938685e-07
a O 0 6.472699851656216e-07
high O 0 3.7025645269750385e-06
degree O 0 2.768463218671968e-06
of O 0 2.0647646579163847e-06
evolutionary O 0 9.77376475930214e-06
conservation O 0 1.9480206901789643e-05
. O 0 6.826507615187438e-06
. O 0 3.738653686014004e-05

The O 0 0.00010927471157629043
APC B-Disease 0 0.001408363925293088
variants O 0 6.015872349962592e-05
I1307K O 0 0.0020503855776041746
and O 0 3.646941877377685e-06
E1317Q O 0 9.005854371935129e-05
are O 0 2.869068964628241e-07
associated O 0 6.760043333997601e-07
with O 0 0.0833214521408081
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0007750334916636348
but O 0 4.0732052752900927e-07
not O 0 1.334358046278794e-07
always O 0 5.35959372882644e-07
with O 0 2.7209841846342897e-07
a O 0 2.1637617919623153e-06
family O 0 4.721712230093544e-06
history O 0 2.382581078563817e-05
. O 0 3.830107016256079e-05

Classical O 0 0.0770936831831932
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999493360519409
FAP B-Disease 1 1.0
) O 0 3.127829768345691e-05
is O 0 3.3990713745879475e-06
a O 0 4.213022293697577e-06
high O 0 0.017035221680998802
- O 1 0.9999904632568359
penetrance O 1 1.0
autosomal B-Disease 1 0.9999995231628418
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999725818634033
that O 0 8.530886930202541e-07
predisposes O 0 2.3571401470690034e-05
to O 0 5.285555744194426e-07
hundreds O 0 8.873442993717617e-07
or O 0 3.982866303431365e-07
thousands O 0 1.542005293231341e-06
of O 0 0.311170369386673
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 2.6337440431234427e-05
that O 0 3.864179234369658e-07
results O 0 2.721368446145789e-07
from O 0 3.196571185526409e-07
truncating O 0 6.1535447457572445e-06
mutations O 0 6.907429792590847e-07
in O 0 5.528437441171263e-07
the O 0 3.353089141455712e-06
APC B-Disease 0 0.030392862856388092
gene O 0 2.7899612177861854e-05
. O 0 4.461375647224486e-05

A O 0 0.00030230055563151836
variant O 0 0.00020541955018416047
of O 0 7.196868682513013e-05
FAP B-Disease 1 1.0
is O 0 0.0002983948215842247
attenuated B-Disease 1 0.999962329864502
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 1.0271434803144075e-05
which O 0 6.60986131606478e-07
results O 0 3.969806243731e-07
from O 0 7.510840873692359e-07
germ O 0 0.0008030292228795588
- O 0 1.2936391613038722e-05
line O 0 3.0861961022310425e-06
mutations O 0 2.2504205787754472e-07
in O 0 6.954359577093783e-08
the O 0 1.2851207031872036e-07
5 O 0 4.138714757573325e-07
and O 0 1.3446530999772222e-07
3 O 0 6.764235536138585e-07
regions O 0 2.4976205281745933e-07
of O 0 1.0037356332759373e-06
the O 0 3.2082241432362935e-06
APC B-Disease 0 0.006057547405362129
gene O 0 3.9493137592216954e-05
. O 0 4.584038470056839e-05

Attenuated B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 0.024680912494659424
have O 0 8.395544455197523e-07
" O 0 2.232044153060997e-06
multiple O 0 4.177626124146627e-06
" O 1 0.9999921321868896
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 4.9483154725749046e-05
typically O 0 5.698948370991275e-07
fewer O 0 2.0916257881253841e-07
than O 0 1.0077624068571822e-07
100 O 0 6.199934432515875e-07
) O 0 1.8202402429778886e-07
without O 0 1.65659713502464e-07
the O 0 1.0657607845132588e-06
florid O 0 5.839329969603568e-05
phenotype O 0 1.3733671039517503e-05
of O 0 1.1042101505154278e-05
classical O 0 0.00041181041160598397
FAP B-Disease 1 0.999997615814209
. O 0 0.0003005300532095134

Another O 0 0.00012694785255007446
group O 0 1.3790892808174249e-05
of O 0 5.02287639392307e-06
patients O 0 1.4914388657416566e-06
with O 0 4.75111335163092e-07
multiple O 0 0.0004362281470093876
adenomas B-Disease 1 1.0
has O 0 6.975694304856006e-06
no O 0 8.780692724030814e-07
mutations O 0 2.2705314961513068e-07
in O 0 1.5573620260056487e-07
the O 0 5.776759621767269e-07
APC B-Disease 0 0.017064934596419334
gene O 0 9.015328146233514e-07
, O 0 5.222024697104644e-07
and O 0 1.7076536096283235e-07
their O 0 1.335002082214487e-07
phenotype O 0 8.084410865194513e-07
probably O 0 2.853308274097799e-07
results O 0 5.1914668119934504e-08
from O 0 8.47189909336521e-08
variation O 0 5.239913889454328e-07
at O 0 8.898196028894745e-07
a O 0 5.637497793031798e-07
locus O 0 1.0144462976313662e-05
, O 0 5.952948072263098e-07
or O 0 5.558184739129501e-07
loci O 0 3.975791969423881e-06
, O 0 1.0747415899459156e-06
elsewhere O 0 1.26467716654588e-06
in O 0 9.583194469087175e-07
the O 0 7.250570433825487e-06
genome O 0 4.1762206819839776e-05
. O 0 4.597364750225097e-05

Recently O 0 0.0001703721791272983
, O 0 8.70108760864241e-06
however O 0 1.5780219655425753e-06
, O 0 9.437247854293673e-07
a O 0 1.8086931277139229e-06
missense O 0 1.079359935829416e-05
variant O 0 7.3988221629406326e-06
of O 0 8.836498636810575e-06
APC B-Disease 1 0.999390721321106
( O 0 4.51465166406706e-06
I1307K O 0 0.0004944693064317107
) O 0 1.2250613963260548e-06
was O 0 3.277527866885066e-06
described O 0 6.360086786116881e-07
that O 0 1.2813197258765285e-07
confers O 0 1.1979046803389792e-06
an O 0 5.311624704518181e-07
increased O 0 7.17460807209136e-07
risk O 0 7.870790796005167e-06
of O 1 0.9991174340248108
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 4.432479545357637e-05
including O 0 2.9620960049214773e-06
multiple O 0 1.7513109924038872e-05
adenomas B-Disease 1 1.0
, O 0 1.9225077267037705e-05
in O 0 2.037072044913657e-05
Ashkenazim O 0 0.00211360864341259
. O 0 0.0001706602779449895

We O 0 1.9404038539505564e-05
have O 0 1.660538828218705e-06
studied O 0 3.6705221191368764e-06
a O 0 1.2509594853327144e-06
set O 0 9.178501159112784e-07
of O 0 1.092904994948185e-06
164 O 0 7.078994258336024e-06
patients O 0 1.2211166904307902e-06
with O 0 4.900630301563069e-07
multiple O 1 0.999975323677063
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999397993087769
/ I-Disease 1 1.0
or I-Disease 1 0.9538103938102722
carcinoma I-Disease 1 1.0
and O 0 6.098058292991482e-06
analyzed O 0 5.398957910074387e-06
codons O 0 1.858751966210548e-05
1263 O 0 0.00015341049584094435
- O 0 2.5628442017477937e-05
1377 O 0 0.00012796191731467843
( O 0 4.297886789572658e-06
exon O 0 2.2165459085954353e-05
15G O 0 3.053616819670424e-05
) O 0 5.666831839334918e-07
of O 0 1.013295559459948e-06
the O 0 1.1452046919657732e-06
APC B-Disease 0 6.243785901460797e-05
gene O 0 1.9380399862711783e-06
for O 0 3.417149400775088e-06
germ O 1 0.9992768168449402
- O 0 0.3629078269004822
line O 0 0.00014624960022047162
variants O 0 0.00011632017412921414
. O 0 7.272134098457173e-05

Three O 0 4.6395933168241754e-05
patients O 0 6.19174988969462e-06
with O 0 7.540129445260391e-07
the O 0 2.035356601481908e-06
I1307K O 0 0.00011826355330413207
allele O 0 2.826384388754377e-06
were O 0 7.340603929151257e-07
detected O 0 1.366008405057073e-06
, O 0 5.820257911182125e-07
each O 0 3.70954467143747e-07
of O 0 4.490673745749518e-06
Ashkenazi O 0 0.0001837207964854315
descent O 0 7.024295337032527e-05
. O 0 5.9594472986645997e-05

Four O 0 0.0001296551781706512
patients O 0 2.2815895135863684e-05
had O 0 1.0630753422447015e-05
a O 0 1.2051847079419531e-05
germ O 1 0.9938924312591553
- O 0 0.0008986399043351412
line O 0 1.7592890799278393e-05
E1317Q O 0 4.749209983856417e-05
missense O 0 1.2217585208418313e-05
variant O 0 2.4615362690383336e-06
of O 0 1.1986018080278882e-06
APC O 0 0.013382997363805771
that O 0 2.2376401886958774e-07
was O 0 1.1444949450378772e-06
not O 0 4.347414872540867e-08
present O 0 5.390204549371447e-08
in O 0 5.2387846949386585e-08
controls O 0 2.735633017891814e-07
; O 0 8.693025677075639e-08
one O 0 9.80976366804498e-08
of O 0 1.2748972721965401e-07
these O 0 4.302851053239465e-08
individuals O 0 2.8149116815257003e-08
had O 0 1.4552844618265226e-07
an O 0 1.636768018897783e-07
unusually O 0 7.460426445504709e-07
large O 0 4.785751457347942e-07
number O 0 3.870567013564141e-07
of O 0 1.9759850147238467e-06
metaplastic B-Disease 0 0.1160125732421875
polyps I-Disease 0 0.00040755720692686737
of I-Disease 0 1.3048713299212977e-05
the I-Disease 0 2.7437288736109622e-05
colorectum I-Disease 0 0.02662065625190735
. O 0 0.00011514333891682327

There O 0 3.223700696253218e-05
is O 0 6.321871296677273e-06
increasing O 0 3.035117515537422e-06
evidence O 0 1.0818340570040164e-06
that O 0 1.8373495436208032e-07
there O 0 3.4978000940100173e-07
exist O 0 4.6982066237433173e-07
germ O 0 8.069577597780153e-05
- O 0 6.9096968218218535e-06
line O 0 2.3863262867962476e-06
variants O 0 9.62930243986193e-07
of O 0 1.2935771565025789e-06
the O 0 1.2401382036841824e-06
APC B-Disease 0 0.0006438000127673149
gene O 0 7.266369834724173e-07
that O 0 3.0214349067136936e-07
predispose O 0 2.7512053293321515e-06
to O 0 2.3851697505961056e-07
the O 0 4.422877282195259e-07
development O 0 4.2218925955239683e-07
of O 0 2.8757465315720765e-06
multiple O 1 0.9994170665740967
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 2.4424398361588828e-05
but O 0 5.810829293295683e-07
without O 0 2.6446127776580397e-07
the O 0 5.159306510904571e-07
florid O 0 1.8891860236180946e-05
phenotype O 0 1.2125315151934046e-06
of O 0 7.745935590719455e-07
classical O 0 1.9993474779766984e-05
FAP B-Disease 1 0.9999998807907104
, O 0 1.0113370763065177e-06
and O 0 2.6271320052728697e-07
possibly O 0 4.0123589428731066e-07
with O 0 1.0888740575865086e-07
importance O 0 2.4877983832993777e-06
for O 0 0.003756100544705987
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0005051384214311838
in O 0 4.756277007800236e-07
the O 0 5.980244282000058e-07
general O 0 1.6412210470662103e-06
population O 0 9.261301556762191e-07
. O 0 2.6152383725275286e-06
. O 0 1.9300245185149834e-05

Genomic O 0 0.00013145554112270474
structure O 0 3.098923116340302e-05
of O 0 1.4490065950667486e-05
the O 0 6.627120455959812e-05
human O 1 0.9923478364944458
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999985694885254
CLD B-Disease 1 1.0
) O 0 0.00015345583960879594
gene O 0 6.893390673212707e-05
. O 0 7.631927292095497e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999997615814209
CLD B-Disease 1 1.0
) O 0 0.00016611162573099136
is O 0 2.9537291084125172e-06
caused O 0 1.0142180144612212e-06
by O 0 1.4104253409641387e-07
mutations O 0 2.3941672111504886e-07
in O 0 2.1366498970110115e-07
a O 0 9.300333658757154e-07
gene O 0 5.551599997488665e-07
which O 0 4.705089224898984e-07
encodes O 0 5.468702966027195e-06
an O 0 9.296200005337596e-06
intestinal O 1 0.9999634027481079
anion O 1 0.7203008532524109
transporter O 1 0.9634748101234436
. O 0 0.0001855867449194193

We O 0 1.8547181753092445e-05
report O 0 3.2868676953512477e-06
here O 0 6.142929009911313e-07
the O 0 5.074516025160847e-07
complete O 0 5.921099841543764e-07
genomic O 0 2.1003640995331807e-06
organization O 0 9.237758149538422e-07
of O 0 1.4987276699685026e-06
the O 0 1.7217064396390924e-06
human O 0 1.3492983725882368e-06
CLD B-Disease 1 0.9998278617858887
gene O 0 1.6066522903201985e-06
which O 0 4.713209023066156e-07
spans O 0 3.7489969599846518e-06
approximately O 0 1.5696617765570409e-06
39kb O 0 2.9383356377366e-05
, O 0 1.050377022693283e-06
and O 0 1.2023086810586392e-06
comprises O 0 8.067988346738275e-06
21 O 0 2.9970102332299575e-05
exons O 0 0.0003278673975728452
. O 0 0.0001347941579297185

All O 0 9.253770986106247e-05
exon O 0 0.0005538389086723328
/ O 0 0.00020945868163835257
intron O 0 0.0002665531064849347
boundaries O 0 1.0619636668707244e-05
conform O 0 3.2973350698739523e-06
to O 0 1.8939543906526524e-06
the O 0 6.303557711362373e-06
GT O 1 0.9999523162841797
/ O 1 0.9999963045120239
AG O 1 1.0
rule O 0 0.00023526811855845153
. O 0 0.0001989965239772573

An O 0 1.6095622413558885e-05
analysis O 0 4.737223207484931e-06
of O 0 3.7756051369797206e-06
the O 0 3.542330205164035e-06
putative O 0 4.2043120629386976e-05
promoter O 0 0.00855032354593277
region O 0 5.878938281966839e-06
sequence O 0 1.1113539812868112e-06
shows O 0 1.2585254580699257e-06
a O 0 1.4544660871251835e-06
putative O 0 5.224708729656413e-05
TATA O 1 0.9999202489852905
box O 0 0.0007194421486929059
and O 0 2.763759539448074e-06
predicts O 0 1.0373656550655141e-05
multiple O 0 2.260733708681073e-06
transcription O 0 1.1813787750725169e-05
factor O 0 9.534310265735257e-06
binding O 0 3.372317678440595e-06
sites O 0 2.2742013243259862e-05
. O 0 4.056640318594873e-05

The O 0 4.994056871510111e-05
genomic O 0 2.9151358830858953e-05
structure O 0 9.644949386711232e-06
was O 0 4.643830834538676e-06
determined O 0 6.921633826095785e-07
using O 0 1.8556758618615277e-07
DNA O 0 2.910950342993601e-07
from O 0 2.0229069264132704e-07
several O 0 1.059976497685966e-07
sources O 0 1.6828533944135415e-07
including O 0 3.03821678926397e-07
multiple O 0 4.836921334572253e-07
large O 0 2.831729261743021e-06
- O 0 0.00025348339113406837
insert O 0 2.504501935618464e-05
libaries O 0 1.9475153749226592e-05
and O 0 3.3720817782523227e-07
genomic O 0 1.8295737618245766e-06
DNA O 0 1.6310227692883927e-06
from O 0 1.7086910020225332e-06
Finnish O 1 0.9988262057304382
CLD B-Disease 1 1.0
patients O 0 3.428529089433141e-05
and O 0 1.3513122212316375e-05
controls O 0 0.00025358976563438773
. O 0 9.348156891064718e-05

Exon O 0 0.0011923789279535413
- O 0 6.470366497524083e-05
specific O 0 3.74123192159459e-06
primers O 0 1.820185025280807e-05
developed O 0 2.1113153252372285e-06
in O 0 3.058698325730802e-07
this O 0 1.2284021977393422e-07
study O 0 2.1322125576261897e-07
will O 0 7.108287292112436e-08
facilitate O 0 2.0822123758534872e-07
mutation O 0 2.9119303235347616e-07
screening O 0 4.863416052103275e-07
studies O 0 3.151016301217169e-07
of O 0 9.925139465849497e-07
patients O 0 9.32109344375931e-07
with O 0 9.518924457552203e-07
the O 0 7.752486999379471e-05
disease O 1 0.998924195766449
. O 0 6.343169661704451e-05

Genomic O 0 0.0001632341736694798
sequencing O 0 3.749351162696257e-05
of O 0 1.2543242519313935e-05
a O 0 3.315565118100494e-05
BAC O 1 1.0
clone O 1 0.9995582699775696
H O 1 0.9999997615814209
_ O 0 8.259787136921659e-06
RG364P16 O 0 6.592604040633887e-05
revealed O 0 2.452149828968686e-06
the O 0 5.973153065497172e-07
presence O 0 5.145022896613227e-07
of O 0 7.252295404214237e-07
another O 0 2.176836233047652e-06
, O 0 4.87890417844028e-07
highly O 0 9.119971196014376e-07
homologous O 0 4.842081011702248e-07
gene O 0 2.665199474449764e-07
3 O 0 7.64427511512622e-07
of O 0 8.119512244775251e-07
the O 0 1.3529527222999604e-06
CLD B-Disease 1 0.9685841202735901
gene O 0 9.263297329198394e-07
, O 0 2.7345274133949715e-07
with O 0 9.145449553216167e-08
a O 0 5.242052907306061e-07
similar O 0 1.635462183458003e-07
genomic O 0 1.375614374410361e-06
structure O 0 1.3654562280862592e-06
, O 0 5.390363639889983e-07
recently O 0 7.667178465453617e-07
identified O 0 3.9275397512028576e-07
as O 0 2.999780690515763e-07
the O 0 2.623812179081142e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.484687345509883e-05
( O 0 4.7459721827181056e-05
PDS B-Disease 1 1.0
) O 0 2.172230597352609e-05
. O 0 1.5708323189755902e-05
. O 0 5.42683555977419e-05

The O 0 0.00010811995161930099
APCI1307K O 1 0.9999721050262451
allele O 0 8.368232374778017e-05
and O 0 1.7318376194452867e-05
cancer B-Disease 1 0.9998828172683716
risk O 0 2.171252890548203e-05
in O 0 9.997700090025319e-07
a O 0 1.4624441746491357e-06
community O 0 6.651342800978455e-07
- O 0 2.7693133688444505e-06
based O 0 1.2574985248647863e-06
study O 0 1.4725372921020607e-06
of O 0 4.209319740766659e-06
Ashkenazi O 0 0.00017619879508856684
Jews O 0 8.230308594647795e-05
. O 0 7.207548333099112e-05

Mutations O 0 0.0002400266967015341
in O 0 1.6014517314033583e-05
APC O 0 0.017494209110736847
are O 0 3.2411294341727626e-06
classically O 0 0.00012164379586465657
associated O 0 3.5187413232051767e-06
with O 0 8.7052376329666e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999948740005493
FAP B-Disease 1 1.0
) O 0 7.664321856282186e-06
, O 0 1.5588672113153734e-06
a O 0 3.5430532534519443e-06
highly O 0 0.011705569922924042
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9972535967826843
by O 0 7.879878467065282e-06
multiple O 1 0.9953241944313049
intestinal O 1 1.0
polyps B-Disease 1 1.0
and O 0 7.420070232910803e-06
, O 0 7.303844995476538e-07
without O 0 2.7180328743270366e-07
surgical O 0 0.08356258273124695
intervention O 0 2.627027015478234e-06
, O 0 4.3254425463601365e-07
the O 0 2.770235596472048e-07
development O 0 9.649369303588173e-07
of O 0 0.18676723539829254
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.015414214693009853
CRC B-Disease 1 0.9999995231628418
) O 0 3.329068567836657e-05
. O 0 6.411292997654527e-05

APC B-Disease 1 0.6488398909568787
is O 0 4.980977610102855e-05
a O 0 6.339274841593578e-05
tumour O 1 1.0
- O 1 0.9990542531013489
suppressor O 1 0.9999994039535522
gene O 0 6.764390946045751e-06
, O 0 1.1382666116332985e-06
and O 0 1.3784969041807926e-06
somatic O 0 5.226114080869593e-05
loss O 0 0.305027037858963
occurs O 0 4.792036179424031e-06
in O 0 1.585628888278734e-05
tumours B-Disease 1 1.0
. O 0 0.0002850329619832337

The O 0 0.00014035103959031403
germline O 0 0.000745620985981077
T O 0 0.006777510978281498
- O 0 2.645045424287673e-05
to O 0 1.935402451636037e-06
- O 0 1.2105131645512301e-05
A O 0 1.1029851521016099e-05
transversion O 0 4.798461668542586e-05
responsible O 0 1.8765649656415917e-06
for O 0 4.405966080867074e-07
the O 0 1.4762789533051546e-06
APC O 0 9.415540262125432e-05
I1307K O 0 9.318519732914865e-05
allele O 0 2.7109808797831647e-06
converts O 0 1.4757089275008184e-06
the O 0 5.052307869846118e-07
wild O 0 1.9317255919304444e-06
- O 0 1.7393352891303948e-06
type O 0 6.437475690290739e-07
sequence O 0 1.9933877126732114e-07
to O 0 1.5206560988190176e-07
a O 0 2.0654185846069595e-06
homopolymer O 1 0.9938347339630127
tract O 1 0.99912029504776
( O 0 7.991702659637667e-06
A8 O 1 0.9999994039535522
) O 0 1.0223656090602162e-06
that O 0 2.8419157160897157e-07
is O 0 8.683775831741514e-07
genetically O 0 4.568792064674199e-06
unstable O 0 7.835769793018699e-06
and O 0 1.5177193972704117e-06
prone O 0 4.7252622607629746e-05
to O 0 1.3463880350172985e-05
somatic O 0 0.00023084630083758384
mutation O 0 5.2935065468773246e-05
. O 0 5.237649384071119e-05

The O 0 0.00012632210564333946
I1307K O 0 0.0008324648952111602
allele O 0 4.187522426946089e-05
was O 0 2.6850686481338926e-05
found O 0 5.9291792240401264e-06
in O 0 3.506521579765831e-06
6 O 0 5.634335320792161e-05
. O 0 6.324264541035518e-05

1 O 0 4.478054688661359e-05
% O 0 5.438490461529e-06
of O 0 6.964487965888111e-06
unselected O 0 0.28074559569358826
Ashkenazi O 0 0.0019448688253760338
Jews O 0 5.34401306140353e-06
and O 0 6.268173819989897e-07
higher O 0 7.866054261285171e-07
proportions O 0 2.7002829483535606e-06
of O 0 4.366088887763908e-06
Ashkenazim O 0 0.003289637854322791
with O 0 7.250760063470807e-07
family O 0 1.803183636184258e-06
or O 0 1.0281991080773878e-06
personal O 0 3.080614987993613e-06
histories O 0 2.6444361083122203e-06
of O 0 1.0350689990445971e-05
CRC B-Disease 1 0.9999997615814209
( O 0 6.707361990265781e-06
ref O 0 0.0005089357728138566
. O 0 1.8810515030054376e-06
2 O 0 8.881384928827174e-06
) O 0 8.882994734449312e-06
. O 0 3.595323869376443e-05

To O 0 1.8957787688123062e-05
evaluate O 0 1.2249644896655809e-05
the O 0 1.8636242202774156e-06
role O 0 2.3317097657127306e-06
of O 0 3.1313993531512097e-06
I1307K O 0 0.4841466248035431
in O 0 1.5145673160077422e-06
cancer B-Disease 0 0.015264853835105896
, O 0 5.097671760267986e-07
we O 0 3.2761445822870883e-07
genotyped O 0 9.892369234876242e-06
5 O 0 3.930281764041865e-06
, O 0 2.7970313567493577e-06
081 O 0 0.00014225582708604634
Ashkenazi O 0 3.594340159907006e-05
volunteers O 0 7.236740657390328e-06
in O 0 2.016688313233317e-06
a O 0 6.2610797613160685e-06
community O 0 5.435824732558103e-06
survey O 0 1.7790254787541926e-05
. O 0 2.901318839576561e-05

Risk O 0 0.00016683641297277063
of O 0 2.8838794605690055e-05
developing O 0 0.4899199604988098
colorectal B-Disease 1 1.0
, I-Disease 1 0.999829888343811
breast I-Disease 1 1.0
and I-Disease 0 3.059067921640235e-06
other I-Disease 0 8.150327062139695e-07
cancers I-Disease 1 0.502577006816864
were O 0 5.63615344617574e-07
compared O 0 1.1286700782875414e-06
between O 0 5.146593480276351e-07
genotyped O 0 0.0721890926361084
I1307K O 0 0.00019602631800808012
carriers O 0 7.503953156628995e-07
and O 0 2.721856446896709e-07
non O 0 1.3992479352964438e-06
- O 0 5.365174729377031e-06
carriers O 0 6.886486971779959e-07
and O 0 2.2990448655946238e-07
their O 0 1.3487152727975626e-07
first O 0 1.0762513511508587e-06
- O 0 2.546169162087608e-05
degree O 0 2.5478428142378107e-05
relatives O 0 1.7628310160944238e-05
. O 0 3.910312443622388e-05

Sperm O 0 9.073245746549219e-05
DNA O 0 1.8812932466971688e-05
analysis O 0 3.985825969721191e-06
in O 0 2.991215751535492e-06
a O 0 2.0858600692008622e-05
Friedreich B-Disease 1 0.9999996423721313
ataxia I-Disease 1 1.0
premutation O 1 0.9999997615814209
carrier O 0 0.0001719487045193091
suggests O 0 6.54013183520874e-06
both O 0 1.8505573962102062e-06
meiotic O 0 7.049210398690775e-05
and O 0 3.820460278802784e-06
mitotic O 0 1.59845676535042e-05
expansion O 0 1.4855484550935216e-05
in O 0 2.6511477244639536e-06
the O 0 1.1895603165612556e-05
FRDA B-Disease 1 0.9994227886199951
gene O 0 0.00010653334902599454
. O 0 0.00010265555465593934

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 0.0011939610121771693
usually O 0 5.166946266399464e-06
caused O 0 3.897454007528722e-06
by O 0 4.230449235365086e-07
an O 0 9.783489076653495e-07
expansion O 0 7.871083653299138e-06
of O 0 5.821173544973135e-06
a O 0 6.894734724482987e-06
GAA O 0 0.0008236548164859414
trinucleotide O 0 0.0023344983346760273
repeat O 0 1.449023238819791e-05
in O 0 2.2079302652855404e-06
intron O 0 4.7615762014174834e-05
1 O 0 8.62891465658322e-06
of O 0 5.489813702297397e-06
the O 0 1.0427803317725193e-05
FRDA B-Disease 1 0.9986177682876587
gene O 0 4.9994134315056726e-05
. O 0 5.4694010032108054e-05

Occasionally O 0 0.00014907396689523011
, O 0 1.0123451829713304e-05
a O 0 5.4792217270005494e-06
fully O 0 4.696912583312951e-06
expanded O 0 2.3650047751289094e-06
allele O 0 1.626384687369864e-06
has O 0 6.541894777001289e-07
been O 0 4.264036022050277e-07
found O 0 3.3821785905274737e-07
to O 0 2.0774103859366733e-07
arise O 0 2.8910804417137115e-07
from O 0 2.1393168481154134e-07
a O 0 9.253426469513215e-07
premutation O 0 3.975200161221437e-05
of O 0 3.564047801773995e-06
100 O 0 5.858990789420204e-06
or O 0 1.276513330594753e-06
less O 0 3.405593361094361e-06
triplet O 0 7.2414506576024e-05
repeats O 0 3.167273825965822e-05
. O 0 3.195047247572802e-05

We O 0 3.240814112359658e-05
have O 0 2.3702250473434106e-06
examined O 0 4.43106500824797e-06
the O 0 1.0923391755568446e-06
sperm O 0 1.0793288538479828e-06
DNA O 0 1.1588499546633102e-06
of O 0 2.2160136268212227e-06
a O 0 1.549960688862484e-05
premutation O 0 0.35259881615638733
carrier O 0 0.00013506950926966965
. O 0 6.952383409952745e-05

This O 0 4.235418964526616e-05
mans O 0 0.00027064295136369765
leucocyte O 0 0.000417904753703624
DNA O 0 1.1978811016888358e-05
showed O 0 1.830566816352075e-06
one O 0 6.58080921311921e-07
normal O 0 4.989810236111225e-07
allele O 0 5.670194695994724e-07
and O 0 2.4867873094081006e-07
one O 0 5.070878046353755e-07
allele O 0 1.07897471934848e-06
of O 0 1.762580723152496e-06
approximately O 0 3.5577484140958404e-06
100 O 0 1.9041843188460916e-05
repeats O 0 2.2549098503077403e-05
. O 0 3.317829759907909e-05

His O 0 0.00013523007510229945
sperm O 0 1.059004534909036e-05
showed O 0 3.952070073864888e-06
an O 0 1.1131846804346424e-06
expanded O 0 2.310349600520567e-06
allele O 0 1.8321054540137993e-06
in O 0 5.453294988910784e-07
a O 0 1.5989957091733231e-06
tight O 0 6.1856112552050035e-06
range O 0 4.480774350668071e-06
centering O 0 7.952146006573457e-06
on O 0 1.4066173434912344e-06
a O 0 1.4376498711499153e-06
size O 0 2.0693105398095213e-06
of O 0 2.2888621060701553e-06
approximately O 0 7.804418601153884e-06
320 O 0 5.900253017898649e-05
trinucleotide O 0 0.0014971679775044322
repeats O 0 0.00018800256657414138
. O 0 0.00012130174582125619

His O 0 0.0001950266887433827
affected O 0 3.0191415135050192e-05
son O 0 0.00010385065252194181
has O 0 5.061845968157286e-06
repeat O 0 7.380625902442262e-06
sizes O 0 2.5773854304134147e-06
of O 0 3.258012611695449e-06
1040 O 0 7.136305066524073e-05
and O 0 1.2748934750561602e-05
540 O 0 0.0003083133779000491
. O 0 8.602549496572465e-05

These O 0 1.964579860214144e-05
data O 0 6.013149686623365e-06
suggest O 0 2.9624209219036857e-06
that O 0 3.6844062378804665e-07
expansion O 0 2.178350086978753e-06
occurs O 0 2.137705763516351e-07
in O 0 1.5620383919667802e-07
two O 0 7.560645087778539e-08
stages O 0 8.020892323656881e-07
, O 0 3.0220863322938385e-07
the O 0 3.9833827258917154e-07
first O 0 4.805912681149493e-07
during O 0 6.183578875607054e-07
meiosis O 0 2.6253790110786213e-06
followed O 0 1.231036776516703e-06
by O 0 5.903620490244066e-07
a O 0 3.780483439186355e-06
second O 0 1.4035637832421344e-05
mitotic O 0 6.0563146689673886e-05
expansion O 0 0.00017496506916359067
. O 0 9.265744301956147e-05

We O 0 2.2253141651162878e-05
also O 0 5.758845418313285e-06
show O 0 2.6995878670277307e-06
that O 0 2.1849298548204388e-07
in O 0 1.7967670373764122e-07
all O 0 1.409672165664233e-07
informative O 0 2.0903028143948177e-06
carrier O 0 1.728766278574767e-06
father O 0 8.85606141309836e-07
to O 0 2.8834477916461765e-07
affected O 0 4.035707092953089e-07
child O 0 6.399365588549699e-07
transmissions O 0 8.251782332990842e-07
, O 0 1.8287627767676895e-07
with O 0 1.6972009575511038e-07
the O 0 5.8060930996362e-07
notable O 0 1.4267421875047148e-06
exception O 0 9.365333539790299e-07
of O 0 9.584382496541366e-07
the O 0 1.9370531845197547e-06
premutation O 0 0.02179512195289135
carrier O 0 4.773390173795633e-06
, O 0 8.347698212674004e-07
the O 0 1.5416583210026147e-06
expansion O 0 7.459511380147887e-06
size O 0 1.081717709894292e-05
decreases O 0 8.781264114077203e-06
. O 0 5.742644589190604e-06
. O 0 3.6660647310782224e-05

The O 0 0.00010600862879073247
R496H O 0 0.0005324799567461014
mutation O 0 2.276479972351808e-05
of O 0 1.4278107300924603e-05
arylsulfatase O 1 0.9708296656608582
A O 0 0.00031675471109338105
does O 0 3.3065614388760878e-06
not O 0 3.2158575322682736e-06
cause O 0 0.0001268616906600073
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 0.0005845437990501523

Deficiency B-Disease 1 0.9999929666519165
of I-Disease 0 0.00030993722612038255
arylsulfatase I-Disease 1 0.999977707862854
A I-Disease 1 0.911137044429779
( O 0 4.0734568756306544e-05
ARSA O 1 0.9999979734420776
) O 0 1.1690572137013078e-05
enzyme O 0 1.08913964140811e-05
activity O 0 5.368471192923607e-06
causes O 0 3.649896461865865e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0222471896559
MLD B-Disease 1 1.0
) O 0 0.0001494651078246534
. O 0 0.0001373281847918406

A O 0 0.0001301166630582884
number O 0 1.2754164345096797e-05
of O 0 2.1662663129973225e-05
ARSA O 1 0.9999668598175049
gene O 0 8.098832950054202e-06
mutations O 0 2.5615902359277243e-06
responsible O 0 3.940328497265e-06
for O 0 6.369656148308422e-06
MLD B-Disease 1 1.0
have O 0 5.676461114489939e-06
been O 0 6.411646609194577e-06
identified O 0 2.1409634427982382e-05
. O 0 2.5582314265193418e-05

Recently O 0 0.00011221355816815048
, O 0 7.587284926557913e-06
the O 0 4.1201128624379635e-06
R496H O 0 4.187702143099159e-05
mutation O 0 2.119114014931256e-06
of O 0 5.0688645387708675e-06
ARSA O 1 0.999994158744812
was O 0 1.70265011547599e-05
proposed O 0 8.235869586314948e-07
to O 0 2.673659196261724e-07
be O 0 1.318735627364731e-07
a O 0 4.403789830575988e-07
cause O 0 1.1338050853737514e-06
of O 0 5.787673217128031e-06
MLD B-Disease 1 1.0
( O 0 8.060789696173742e-06
Draghia O 0 0.02497648075222969
et O 0 1.655676169320941e-05
al O 0 8.756954230193514e-06
. O 0 6.742248501723225e-07
, O 0 1.5557958477074862e-06
1997 O 0 1.0900624147325289e-05
) O 0 1.3065160601399839e-05
. O 0 3.9673304854659364e-05

We O 0 1.6132316886796616e-05
have O 0 1.7732988908392144e-06
investigated O 0 7.105370968929492e-06
the O 0 1.6997454395095701e-06
R496H O 0 6.873717211419716e-05
mutation O 0 1.3156884506315691e-06
and O 0 2.402071288543084e-07
found O 0 1.5198210689959524e-07
this O 0 1.0654167681423132e-07
mutation O 0 1.5422949672938557e-07
at O 0 5.250328740658006e-07
a O 0 4.138730389513512e-07
relatively O 0 2.683202353637171e-07
high O 0 7.585242656205082e-07
frequency O 0 2.054570984455495e-07
in O 0 7.360779363807524e-08
an O 0 1.7692114795408997e-07
African O 0 2.5290580651926575e-07
American O 0 5.609401227957278e-07
population O 0 1.1855176040853621e-07
( O 0 1.3992730885092897e-07
f O 0 9.078309517462912e-07
= O 0 4.782904738931393e-07
0 O 0 7.170743288043013e-07
. O 0 3.155280126065918e-07
09 O 0 1.0115403711097315e-05
, O 0 1.2040138699376257e-06
n O 0 1.9964536477345973e-06
= O 0 2.2552555947186192e-06
61 O 0 1.0677174941520207e-05
subjects O 0 1.2445927495718934e-05
) O 0 1.0121366358362138e-05
. O 0 4.061370054841973e-05

The O 0 0.00022511498536914587
ARSA O 1 0.9998964071273804
enzyme O 0 4.197770249447785e-05
activity O 0 4.750342668558005e-06
in O 0 5.873110922038904e-07
subjects O 0 9.223884944731253e-07
with O 0 1.6788924028787733e-07
and O 0 3.0410751605813857e-07
without O 0 2.732095367719012e-07
the O 0 1.1868314686580561e-06
R496H O 0 3.3608997910050675e-05
mutation O 0 1.403082933393307e-06
was O 0 2.3737425181025174e-06
determined O 0 5.359981969377259e-07
and O 0 2.577001794179523e-07
found O 0 2.798451248509082e-07
to O 0 4.6462039904326957e-07
be O 0 1.4343467000799137e-06
normal O 0 8.388978130824398e-06
. O 0 2.385493462497834e-05

It O 0 1.9065482774749398e-05
is O 0 6.1458908930944744e-06
therefore O 0 1.5092626881596516e-06
concluded O 0 1.1162122746100067e-06
that O 0 1.4910889944985684e-07
the O 0 7.572145932499552e-07
R496H O 0 2.493190004315693e-05
mutation O 0 2.0347608824522467e-06
of O 0 2.8362674129311927e-06
ARSA O 1 0.9999741315841675
does O 0 8.039854151320469e-07
not O 0 2.52242898568511e-07
negatively O 0 4.2440672132215695e-07
influence O 0 4.396853228172404e-07
the O 0 2.783664854177914e-07
activity O 0 3.6385551993589615e-07
of O 0 9.690462547951029e-07
ARSA O 1 0.9999948740005493
and O 0 1.3618902130474453e-06
is O 0 6.99756242283911e-07
not O 0 4.4657909370471316e-07
a O 0 4.6932186705817e-06
cause O 0 2.1383315470302477e-05
of O 0 0.00022652353800367564
MLD B-Disease 1 1.0

Down O 0 0.0003113392158411443
- O 0 4.932131923851557e-05
regulation O 0 8.962898391473573e-06
of O 0 6.706172371195862e-06
transmembrane O 0 0.00011847687710542232
carbonic O 1 0.9755069613456726
anhydrases O 1 0.9999773502349854
in O 0 0.00011272802657913417
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9995356798171997
lines O 0 1.0168446351599414e-05
by O 0 1.4782217476749793e-06
wild O 0 1.253603204531828e-05
- O 0 8.011596219148487e-05
type O 0 7.534694304922596e-05
von B-Disease 1 0.8121858835220337
Hippel I-Disease 1 0.9999690055847168
- I-Disease 1 0.9596850275993347
Lindau I-Disease 1 0.8492938876152039
transgenes O 0 0.0038193929940462112
. O 0 0.0002981297730002552

To O 0 4.7551140596624464e-05
discover O 0 3.95528732042294e-05
genes O 0 2.8968315746169537e-06
involved O 0 1.1385901643734542e-06
in O 0 8.712842713975988e-07
von B-Disease 0 0.021503178402781487
Hippel I-Disease 1 0.9999984502792358
- I-Disease 1 0.9999243021011353
Lindau I-Disease 1 0.9999994039535522
( O 0 1.9058812540606596e-05
VHL B-Disease 1 0.9999866485595703
) O 0 5.218338628765196e-06
- O 0 3.286151695647277e-05
mediated O 0 1.5397277820738964e-05
carcinogenesis O 1 0.9999933242797852
, O 0 2.25592020797194e-06
we O 0 8.065119914135721e-07
used O 0 7.896413080743514e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999977350234985
lines O 0 5.4425276175606996e-05
stably O 0 7.648224709555507e-05
transfected O 0 2.027979280683212e-05
with O 0 7.913773742984631e-07
wild O 0 1.480228456784971e-05
- O 0 0.0003595504676923156
type O 0 0.0005503036081790924
VHL O 1 0.9999995231628418
- O 0 0.21974721550941467
expressing O 0 5.079736729385331e-05
transgenes O 0 0.0009306130814366043
. O 0 7.877715688664466e-05

Large O 0 0.00012235436588525772
- O 0 5.1827417337335646e-05
scale O 0 2.0911918909405358e-05
RNA O 0 1.5065985280671157e-05
differential O 0 6.810076229157858e-06
display O 0 9.955778295989148e-06
technology O 0 3.41109966939257e-06
applied O 0 7.947566587063193e-07
to O 0 2.606414284400671e-07
these O 0 9.614962692694462e-08
cell O 0 6.917238692949468e-07
lines O 0 4.795954282599268e-07
identified O 0 3.2386958537244936e-07
several O 0 1.9871487211275962e-07
differentially O 0 2.788365009109839e-06
expressed O 0 4.5273952764546266e-07
genes O 0 2.5194481168000493e-07
, O 0 2.5793477220759087e-07
including O 0 4.3535513327697117e-07
an O 0 1.6939876559263212e-06
alpha O 0 2.986211438837927e-05
carbonic O 0 0.00018848161562345922
anhydrase O 0 0.004790510982275009
gene O 0 1.4918293345544953e-05
, O 0 1.2206312021589838e-05
termed O 0 0.0001676305109867826
CA12 O 1 0.9999594688415527
. O 0 0.00029908091528341174

The O 0 4.2404059058753774e-05
deduced O 0 2.5629102310631424e-05
protein O 0 2.370304173382465e-06
sequence O 0 1.173929945252894e-06
was O 0 2.9942555102024926e-06
classified O 0 2.015146264966461e-06
as O 0 3.879636096826289e-07
a O 0 5.698839800061251e-07
one O 0 5.859220095771889e-07
- O 0 6.002406735206023e-06
pass O 0 3.5443918022792786e-06
transmembrane O 0 2.3722857804386877e-05
CA O 0 4.086428816663101e-05
possessing O 0 5.621431228064466e-06
an O 0 1.43122576901078e-06
apparently O 0 1.9984615846624365e-06
intact O 0 3.6334447486296995e-06
catalytic O 0 5.043300006946083e-06
domain O 0 3.150801830997807e-06
in O 0 1.898955133583513e-06
the O 0 6.784134711779188e-06
extracellular O 0 9.844134910963476e-05
CA O 1 0.5692865252494812
module O 0 0.0014001401141285896
. O 0 0.00012526867794804275

Reintroduced O 0 0.0014729327522218227
wild O 0 0.0003656999615486711
- O 0 0.004384467378258705
type O 0 0.0007815153803676367
VHL B-Disease 1 0.9993557333946228
strongly O 0 1.2333033737377264e-05
inhibited O 0 7.497503702325048e-06
the O 0 1.8004496951107285e-06
overexpression O 0 9.642162694945e-06
of O 0 1.4936507568563684e-06
the O 0 2.4423338800261263e-06
CA12 O 1 0.9997407793998718
gene O 0 7.249356599459134e-07
in O 0 2.8872366897303436e-07
the O 0 1.5191500324363005e-06
parental O 0 0.0002921948616858572
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999997615814209
lines O 0 0.0007394799031317234
. O 0 0.00013421906623989344

Similar O 0 2.8739355911966413e-05
results O 0 3.88830630981829e-06
were O 0 1.1070899290643865e-06
obtained O 0 1.22352378184587e-06
with O 0 8.173086598617374e-07
CA9 O 1 0.9986799359321594
, O 0 2.41342877416173e-06
encoding O 0 2.0181410036457237e-06
another O 0 3.6952483242203016e-06
transmembrane O 0 2.708983447519131e-05
CA O 0 3.454113902989775e-05
with O 0 9.431094554201991e-07
an O 0 2.9427749268506886e-06
intact O 0 1.8244532839162275e-05
catalytic O 0 6.833489896962419e-05
domain O 0 5.379837239161134e-05
. O 0 4.2411338654346764e-05

Although O 0 3.896576163242571e-05
both O 0 3.8997441151877865e-06
domains O 0 6.306624527496751e-06
of O 0 6.275648502196418e-06
the O 0 1.1929355423490051e-05
VHL B-Disease 1 0.9999898672103882
protein O 0 2.5845774871413596e-06
contribute O 0 8.320118922711117e-07
to O 0 2.992272243318439e-07
regulation O 0 1.2881445172752137e-06
of O 0 2.506000328139635e-06
CA12 O 1 0.9999970197677612
expression O 0 1.7700428998068674e-06
, O 0 6.804108920732688e-07
the O 0 7.875647156652121e-07
elongin O 0 1.724998583085835e-05
binding O 0 1.294524963668664e-06
domain O 0 2.573408892203588e-06
alone O 0 2.696697947612847e-06
could O 0 1.8875962268793955e-06
effectively O 0 7.229518359963549e-06
regulate O 0 3.105875657638535e-05
CA9 O 1 0.9999281167984009
expression O 0 7.23191405995749e-05
. O 0 8.128737681545317e-05

We O 0 7.722884038230404e-05
mapped O 0 0.0002465365978423506
CA12 O 1 0.9791672229766846
and O 0 5.1423576223896816e-05
CA9 O 1 0.9994634985923767
loci O 0 0.00011197038838872686
to O 0 1.0739101526269224e-05
chromosome O 0 4.692275251727551e-05
bands O 0 0.00010203680722042918
15q22 O 0 0.006200736854225397
and O 0 5.1267379603814334e-05
17q21 O 0 0.009343042969703674
. O 0 0.0002418294461676851

2 O 0 0.00011278781312284991
respectively O 0 3.090512109338306e-05
, O 0 4.679216999647906e-06
regions O 0 3.5866507914761314e-06
prone O 0 1.017863269225927e-05
to O 0 1.011741233014618e-06
amplification O 0 7.806815119693056e-06
in O 0 1.1069166703236988e-06
some O 0 3.162062512274133e-06
human O 0 1.2380286534607876e-05
cancers B-Disease 1 0.9998940229415894
. O 0 5.350683568394743e-05

Additional O 0 2.29522047447972e-05
experiments O 0 7.2655493568163365e-06
are O 0 3.6323319818620803e-07
needed O 0 2.7380710321267543e-07
to O 0 2.6698728561314056e-07
define O 0 3.9439424881493323e-07
the O 0 2.6140511977246206e-07
role O 0 9.020058087116922e-07
of O 0 3.7488034649868496e-06
CA O 1 0.7359958291053772
IX O 1 1.0
and O 0 4.279257154848892e-06
CA O 0 0.21728894114494324
XII O 1 0.9999998807907104
enzymes O 0 6.327694563879049e-07
in O 0 2.2470173632882506e-07
the O 0 2.562246947945823e-07
regulation O 0 6.322404146885674e-07
of O 0 1.0636365459504304e-06
pH O 0 6.1755381466355175e-06
in O 0 3.6721883134305244e-07
the O 0 6.4390843590445e-07
extracellular O 0 4.152831024839543e-06
microenvironment O 0 1.1896068826899864e-05
and O 0 2.671080210348009e-07
its O 0 2.4449528268633003e-07
potential O 0 8.243247862083081e-07
impact O 0 2.423262912998325e-06
on O 0 7.497482329199556e-06
cancer B-Disease 1 0.999776303768158
cell O 0 6.365007720887661e-05
growth O 0 2.5976372853619978e-05
. O 0 7.679320697207004e-05

A O 0 0.00012207875261083245
gene O 0 1.1149664715048857e-05
encoding O 0 8.525473276677076e-06
a O 0 3.431217237448436e-06
transmembrane O 0 2.893311648222152e-05
protein O 0 3.4695881367952097e-06
is O 0 1.2089267329429276e-06
mutated O 0 2.3226416487887036e-06
in O 0 4.193390168438782e-07
patients O 0 1.2485543265938759e-06
with O 0 8.303715731017292e-06
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999998807907104
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 1.0
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 0.0002127878979081288
. O 0 0.00012132523261243477

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9917866587638855
WFS B-Disease 1 1.0
; O 0 6.057481368770823e-05
OMIM O 1 1.0
222300 O 1 0.9942933320999146
) O 0 6.150998615339631e-06
is O 0 2.4633773136883974e-06
an O 0 5.577759111474734e-06
autosomal B-Disease 1 0.9999048709869385
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 0.00015858266851864755
by O 0 3.298190677014645e-06
young O 0 0.0008562668808735907
- O 1 0.9970912933349609
onset O 1 0.9998319149017334
non O 1 0.9509473443031311
- O 1 0.9999995231628418
immune O 1 0.9992497563362122
insulin B-Disease 1 0.570839524269104
- I-Disease 1 0.9999953508377075
dependent I-Disease 0 0.002286853501573205
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.7449009418487549
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 1 0.5790221095085144

Linkage O 0 0.0005795197212137282
to O 0 2.3234248146764003e-05
markers O 0 8.787310071056709e-05
on O 0 1.1583633749978617e-05
chromosome O 0 3.569081673049368e-05
4p O 1 0.9992272853851318
was O 0 2.4921746444306336e-05
confirmed O 0 2.4984665287774988e-06
in O 0 8.209254929170129e-07
five O 0 3.162421535307658e-06
families O 0 2.933701807705802e-06
. O 0 2.992426379933022e-05

On O 0 3.632621155702509e-05
the O 0 6.881989975227043e-06
basis O 0 2.9974867175042164e-06
of O 0 8.687572517374065e-06
meiotic O 1 0.9945496916770935
recombinants O 1 0.9999998807907104
and O 0 0.00022446087677963078
disease O 1 0.9860949516296387
- O 0 0.0003164239169564098
associated O 0 2.6560344394965796e-06
haplotypes O 0 7.950273356982507e-06
, O 0 1.2719999631372048e-06
the O 0 2.657278628248605e-06
WFS B-Disease 1 0.9999970197677612
gene O 0 3.144353968309588e-06
was O 0 3.790338951148442e-06
localized O 0 3.860175183945103e-06
to O 0 7.053675972201745e-07
a O 0 4.2665269575081766e-06
BAC O 1 0.9999958276748657
/ O 0 0.00266686431132257
P1 O 1 0.9998347759246826
contig O 0 0.0002470012695994228
of O 0 5.7151305554725695e-06
less O 0 2.082320406771032e-06
than O 0 2.789093514365959e-06
250 O 0 3.0376968425116502e-05
kb O 0 0.0009763061534613371
. O 0 8.003990660654381e-05

Mutations O 0 6.295142520684749e-05
in O 0 5.319996489561163e-06
a O 0 6.98946496413555e-06
novel O 0 1.6712830984033644e-05
gene O 0 1.9882227206835523e-06
( O 0 1.3079919654046535e-06
WFS1 O 1 0.6885946989059448
) O 0 1.1786290770032792e-06
encoding O 0 1.359673660772387e-06
a O 0 9.381826657772763e-07
putative O 0 9.480090739089064e-06
transmembrane O 0 4.3493450903042685e-06
protein O 0 6.475799523286696e-07
were O 0 2.2243148123379797e-07
found O 0 1.429827278798257e-07
in O 0 7.444435823344975e-08
all O 0 7.817909164486991e-08
affected O 0 1.4178914398144116e-07
individuals O 0 3.945167748042877e-08
in O 0 1.6548524683912547e-07
six O 0 1.8757581301542814e-06
WFS B-Disease 1 1.0
families O 0 2.2847851255392015e-07
, O 0 1.8133080459392659e-07
and O 0 7.376464594699428e-08
these O 0 6.132356844545939e-08
mutations O 0 1.7004330743475293e-07
were O 0 1.3086740580092737e-07
associated O 0 2.6669869157558423e-07
with O 0 4.0105229004439025e-07
the O 0 4.625111978384666e-05
disease O 1 0.999559223651886
phenotype O 0 8.952169446274638e-05
. O 0 6.1947968788445e-05

WFS1 O 1 0.9999823570251465
appears O 0 6.0462512919912115e-05
to O 0 2.1240932710497873e-06
function O 0 1.4182255654304754e-06
in O 0 4.923570600112726e-07
survival O 0 4.859864020545501e-06
of O 0 4.503110176301561e-06
islet O 1 0.992250382900238
beta O 0 0.00025952173746190965
- O 0 0.23143264651298523
cells O 0 2.0835759642068297e-06
and O 0 9.909600748869707e-07
neurons O 0 5.865163075213786e-06
. O 0 4.495189841691172e-06
. O 0 2.2973707018536516e-05

Stable O 0 0.00015591751434840262
interaction O 0 1.1282630111963954e-05
between O 0 2.9095783702359768e-06
the O 0 1.9921897091990104e-06
products O 0 1.6806350231490796e-06
of O 0 1.968307742572506e-06
the O 0 4.010662905784557e-06
BRCA1 O 0 0.0001876272144727409
and O 0 4.631561296264408e-06
BRCA2 O 1 0.9978526830673218
tumor B-Disease 1 0.9999997615814209
suppressor O 1 0.9998588562011719
genes O 0 3.82408006771584e-06
in O 0 2.2305100628727814e-06
mitotic O 0 3.186797766829841e-05
and O 0 1.2846620847994927e-05
meiotic O 1 0.9173923134803772
cells O 0 9.56899966695346e-05
. O 0 9.586389205651358e-05

BRCA1 O 0 0.014071675017476082
and O 0 3.47017303283792e-05
BRCA2 O 0 0.00022236396034713835
account O 0 1.7388293827025336e-06
for O 0 5.976822876618826e-07
most O 0 3.631625702382735e-07
cases O 0 2.710870035116386e-07
of O 0 1.549139369672048e-06
familial O 1 0.7519199252128601
, O 0 3.921591996913776e-06
early O 0 3.4135011901526013e-06
onset O 1 0.9502614736557007
breast B-Disease 1 0.9999973773956299
and I-Disease 0 8.651688403915614e-06
/ I-Disease 1 1.0
or I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 9.549091828375822e-07
encode O 0 1.3097619557811413e-06
products O 0 8.000128559615405e-07
that O 0 1.6953907788774814e-07
each O 0 4.3309614738973323e-07
interact O 0 7.900675882410724e-07
with O 0 2.4670118818903575e-06
hRAD51 O 0 0.0006073515978641808
. O 0 9.417336696060374e-05

Results O 0 1.473983775213128e-05
presented O 0 6.899924755998654e-06
here O 0 1.1447766610217514e-06
show O 0 1.6958077821982442e-06
that O 0 5.488266765496519e-07
BRCA1 O 0 1.9402852558414452e-05
and O 0 1.987422820093343e-06
BRCA2 O 0 0.000254484242759645
coexist O 0 3.334491793793859e-06
in O 0 4.741015402487392e-07
a O 0 1.3828117744196788e-06
biochemical O 0 1.0051149729406461e-05
complex O 0 5.566827894654125e-06
and O 0 1.4881654806231381e-06
colocalize O 0 0.0004956700722686946
in O 0 3.3720634746714495e-06
subnuclear O 0 0.0018187956884503365
foci O 0 7.385003846138716e-05
in O 0 1.8049641994366539e-06
somatic O 0 1.0997469871654175e-05
cells O 0 5.121129333929275e-07
and O 0 1.7531111495827645e-07
on O 0 4.909672952635447e-07
the O 0 3.8990719986031763e-07
axial O 0 4.14321084463154e-06
elements O 0 1.4323454706755001e-06
of O 0 3.34217702402384e-06
developing O 0 7.87494263931876e-06
synaptonemal O 0 0.0841716006398201
complexes O 0 0.00017559583648107946
. O 0 8.158776472555473e-05

Like O 0 0.0002469791506882757
BRCA1 O 0 0.0007104746764525771
and O 0 2.169706749555189e-05
RAD51 O 1 0.9999973773956299
, O 0 4.39093892055098e-05
BRCA2 O 0 0.00020058354130014777
relocates O 0 6.227623816812411e-05
to O 0 6.868843684060266e-06
PCNA O 0 0.017232244834303856
+ O 0 1.6211621186812408e-05
replication O 0 5.089354090159759e-06
sites O 0 2.361698307140614e-06
following O 0 7.332389486691682e-07
exposure O 0 5.601758402917767e-06
of O 0 3.643358013505349e-06
S O 0 0.0017279956955462694
phase O 0 1.0991567251039669e-05
cells O 0 1.6050473732320825e-06
to O 0 2.158592678824789e-06
hydroxyurea O 0 0.00013878018944524229
or O 0 1.484107178839622e-05
UV O 1 0.9998873472213745
irradiation O 0 0.000557245803065598
. O 0 0.00012114997662138194

Thus O 0 3.912147803930566e-05
, O 0 1.0228131941403262e-05
BRCA1 O 0 2.7754029360949062e-05
and O 0 1.6310942783093196e-06
BRCA2 O 0 2.805371696013026e-05
participate O 0 6.838411650278431e-07
, O 0 3.0954586804909923e-07
together O 0 1.5584642198973597e-07
, O 0 1.394334958604304e-07
in O 0 1.1631632190756136e-07
a O 0 3.6709104733745335e-07
pathway O 0 1.6783542378107086e-06
( O 0 3.6411830706128967e-07
s O 0 9.170425414595229e-07
) O 0 1.555638533545789e-07
associated O 0 4.864111602387311e-08
with O 0 3.2419837481256764e-08
the O 0 1.9070989765168633e-07
activation O 0 3.8596860463258054e-07
of O 0 8.214995546040882e-07
double O 0 2.148530938939075e-06
- O 0 1.8989616364706308e-05
strand O 0 5.579908247455023e-06
break O 0 3.489588152660872e-06
repair O 0 1.1266695764788892e-05
and O 0 1.4104294905337156e-06
/ O 0 3.242613092879765e-05
or O 0 6.361242412822321e-06
homologous O 0 1.851731758506503e-05
recombination O 0 3.488564834697172e-05
. O 0 5.067046367912553e-05

Dysfunction O 1 0.9999566078186035
of O 0 6.1025668401271105e-05
this O 0 2.4533849227736937e-06
pathway O 0 1.1458949302323163e-05
may O 0 5.908802336307417e-07
be O 0 1.8676793445138173e-07
a O 0 2.7792802370640857e-07
general O 0 2.997190051701182e-07
phenomenon O 0 8.007876317606133e-07
in O 0 1.2647673486299027e-07
the O 0 1.8698126780236635e-07
majority O 0 6.721114687024965e-08
of O 0 1.8311799010461982e-07
cases O 0 1.8923027766959422e-07
of O 0 5.649075319524854e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.8521261811256409
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.626922130526509e-05
. O 0 3.077019937336445e-05

A O 0 0.0005333732115104795
novel O 0 0.00024747391580604017
Arg362Ser O 0 0.0008516483358107507
mutation O 0 8.630256161268335e-06
in O 0 9.895113635138841e-07
the O 0 1.4170033182381303e-06
sterol O 0 2.3207163394545205e-05
27 O 0 7.3688383963599335e-06
- O 0 1.7044860214809887e-05
hydroxylase O 0 6.633216253248975e-05
gene O 0 3.0091096050455235e-06
( O 0 1.8718819774221629e-06
CYP27 O 1 0.9947817921638489
) O 0 9.983065183405415e-07
: O 0 3.561560504294903e-07
its O 0 2.126561042814501e-07
effects O 0 6.379890464813798e-07
on O 0 6.968560342102137e-07
pre O 0 4.8546203288424294e-06
- O 0 2.7636278900899924e-06
mRNA O 0 1.96647329175903e-06
splicing O 0 2.09913264370698e-06
and O 0 6.018899512127973e-07
enzyme O 0 5.996444997435901e-06
activity O 0 8.397495548706502e-06
. O 0 2.6209603674942628e-05

A O 0 0.00013785295595880598
novel O 0 5.3022467909613624e-05
C O 0 2.1255635147099383e-05
to O 0 1.40428232953127e-06
A O 0 4.9311497605231125e-06
mutation O 0 6.261828389142465e-07
in O 0 2.9702496817662905e-07
the O 0 7.788215157233935e-07
sterol O 0 1.7011863747029565e-05
27 O 0 6.478817340394016e-06
- O 0 1.4579222806787584e-05
hydroxylase O 0 3.930913226213306e-05
gene O 0 1.6117794530146057e-06
( O 0 1.8565056052466389e-06
CYP27 O 1 0.9932540059089661
) O 0 1.4207150798029033e-06
was O 0 2.629215032357024e-06
identified O 0 3.029617516858707e-07
by O 0 9.504829989737118e-08
sequencing O 0 1.7180667555294349e-06
amplified O 0 1.2319374036451336e-05
CYP27 O 1 0.9701401591300964
gene O 0 1.8765757658911753e-06
products O 0 7.610937018398545e-07
from O 0 5.067078632237099e-07
a O 0 8.122067924887233e-07
patient O 0 1.02117485312192e-06
with O 0 1.1975346296821954e-06
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 0.0009901328012347221
CTX B-Disease 1 1.0
) O 0 5.045695434091613e-05
. O 0 7.909480336820707e-05

The O 0 7.049096166156232e-05
mutation O 0 1.7760217815521173e-05
changed O 0 5.3058552111906465e-06
the O 0 2.346179371670587e-06
adrenodoxin O 0 5.169089126866311e-05
cofactor O 0 2.5031124096130952e-05
binding O 0 3.2045516036305344e-06
residue O 0 1.1813144737971015e-05
362Arg O 0 1.982266257982701e-05
to O 0 2.146057340723928e-06
362Ser O 0 5.591605804511346e-05
( O 0 6.493433374998858e-06
CGT O 0 0.04289877414703369
362Arg O 0 0.00011489041935419664
to O 0 5.773549673904199e-06
AGT O 1 1.0
362Ser O 0 0.05775687098503113
) O 0 2.458289372953004e-06
, O 0 7.653444527022657e-07
and O 0 3.475313121725776e-07
was O 0 2.9699058359256014e-06
responsible O 0 1.4375333421412506e-06
for O 0 1.2057557796651963e-06
deficiency O 1 0.808654248714447
in O 0 1.1105551038781414e-06
the O 0 2.0704396774817724e-06
sterol O 0 2.2042100681574084e-05
27 O 0 6.2744215938437264e-06
- O 0 1.1748420547519345e-05
hydroxylase O 0 2.6430256184539758e-05
activity O 0 1.039164885696664e-06
, O 0 3.1749152640259126e-07
as O 0 2.6812810460796754e-07
confirmed O 0 2.79162179595005e-07
by O 0 1.2503328150614834e-07
expression O 0 4.401052535740746e-07
of O 0 1.3568990198109532e-06
mutant O 0 8.754340342420619e-06
cDNA O 0 1.9170336599927396e-05
into O 0 4.474301022128202e-06
COS O 0 0.027161678299307823
- O 0 8.165268081938848e-05
1 O 0 6.479320290964097e-05
cells O 0 1.8604934666655026e-05
. O 0 2.910544390033465e-05

Quantitative O 0 0.0001111451128963381
analysis O 0 9.472520105191506e-06
showed O 0 4.50594143330818e-06
that O 0 5.644534439852578e-07
the O 0 8.645088200864848e-07
expression O 0 6.370163418978336e-07
of O 0 1.7987094906857237e-06
CYP27 O 0 0.42632657289505005
gene O 0 1.1943535582759068e-06
mRNA O 0 2.349719579797238e-06
in O 0 7.891383120295359e-07
the O 0 2.567555156929302e-06
patient O 0 6.290802048170008e-06
represented O 0 6.069987648515962e-06
52 O 0 6.699915684293956e-05
. O 0 8.130396599881351e-05

5 O 0 5.354368840926327e-05
% O 0 7.585859293612884e-06
of O 0 5.578631316893734e-06
the O 0 6.589987151528476e-06
normal O 0 1.2907889868074562e-05
level O 0 7.184690184658393e-05
. O 0 8.522142161382362e-05

As O 0 5.6578315707156435e-05
the O 0 1.4344451301440131e-05
mutation O 0 5.600273652817123e-06
occurred O 0 2.7370892894396093e-06
at O 0 5.518584202945931e-06
the O 0 1.6917435914365342e-06
penultimate O 0 9.324978236691095e-06
nucleotide O 0 1.883936533886299e-06
of O 0 1.824085757107241e-06
exon O 0 7.107946203177562e-06
6 O 0 2.6865307063417276e-06
( O 0 6.598744448638172e-07
- O 0 1.3772945521850488e-06
2 O 0 1.0651439197317814e-06
position O 0 1.2070617003701045e-06
of O 0 1.1102724783995654e-06
exon O 0 1.0796894457598682e-05
6 O 0 5.9182762015552726e-06
- O 0 7.0911896727920976e-06
intron O 0 4.23914025304839e-05
6 O 0 5.191335731069557e-06
splice O 0 8.768711268203333e-06
site O 0 1.3401752312347526e-06
) O 0 1.689710558139268e-07
of O 0 2.263802940660753e-07
the O 0 1.0687607243653474e-07
gene O 0 1.6934501445575734e-07
, O 0 2.0611238937817689e-07
we O 0 1.7619257164369628e-07
hypothesized O 0 1.4077954801905435e-06
that O 0 1.0395302041388277e-07
the O 0 4.5824671701666375e-07
mutation O 0 1.2831959566028672e-06
may O 0 4.936066488880897e-07
partially O 0 2.1139485397725366e-06
affect O 0 1.8028741521902703e-07
the O 0 2.1091629776037735e-07
normal O 0 1.3768293172233825e-07
splicing O 0 4.6806979980829055e-07
efficiency O 0 6.552921831826097e-07
in O 0 2.3697565154634503e-07
exon O 0 4.561356490739854e-06
6 O 0 1.8891774971052655e-06
and O 0 4.3319778342265636e-07
cause O 0 5.884621145924029e-07
alternative O 0 3.8684086689499964e-07
splicing O 0 7.656934144506522e-07
elsewhere O 0 4.62112154764327e-07
, O 0 4.2412554535076197e-07
which O 0 2.1561430685324012e-07
resulted O 0 6.788637278987153e-07
in O 0 5.51728192021983e-07
decreased O 0 3.312760554763372e-06
transcript O 0 7.4445028985792305e-06
in O 0 2.181156560254749e-06
the O 0 8.051232725847512e-06
patient O 0 3.166228998452425e-05
. O 0 3.530591493472457e-05

Transfection O 0 0.0008099264232441783
of O 0 3.2416301110060886e-05
constructed O 0 7.592495967401192e-05
minigenes O 0 0.009466320276260376
, O 0 1.4816754401181242e-06
with O 0 2.3398663984153245e-07
or O 0 2.5654694013610424e-07
without O 0 1.8121447453722794e-07
the O 0 4.430607134509046e-07
mutation O 0 5.351748200155271e-07
, O 0 3.910981831722893e-07
into O 0 6.040417019903543e-07
COS O 1 0.7777528166770935
- O 0 1.1392786291253287e-05
1 O 0 4.920218543702504e-06
cells O 0 2.3433702267539047e-07
confirmed O 0 1.1222606843830363e-07
that O 0 2.750984329225048e-08
the O 0 1.3222415873315185e-07
mutant O 0 3.0237920327635948e-06
minigene O 0 5.407116987043992e-05
was O 0 2.668472689038026e-06
responsible O 0 4.915922886539192e-07
for O 0 2.2498241492030502e-07
a O 0 7.550534064648673e-07
mRNA O 0 2.8469960398069816e-06
species O 0 4.0936660639090405e-07
alternatively O 0 1.3843291526427492e-06
spliced O 0 3.6514102248474956e-06
at O 0 2.0951226815668633e-06
an O 0 1.1568072295631282e-06
activated O 0 1.0625320101098623e-05
cryptic O 0 1.848404099291656e-05
5 O 0 3.941023805964505e-06
splice O 0 1.7085580111597665e-05
site O 0 7.855477633711416e-06
88 O 0 6.558187578775687e-06
bp O 0 5.626365691568935e-06
upstream O 0 1.8304375544175855e-06
from O 0 3.4351094768680923e-07
the O 0 3.93475687587852e-07
3 O 0 1.6933578308453434e-06
end O 0 1.5041788401504164e-06
of O 0 3.0743372008146252e-06
exon O 0 7.730016659479588e-05
6 O 0 6.986031075939536e-05
. O 0 5.108611730975099e-05

Our O 0 2.500392474757973e-05
data O 0 5.3980415941623505e-06
suggest O 0 1.9293356672278605e-06
that O 0 2.578093472038745e-07
the O 0 4.404142828207114e-07
C O 0 2.657476215972565e-06
to O 0 3.9245745142579835e-07
A O 0 1.817402221604425e-06
mutation O 0 3.8004486668796744e-07
at O 0 9.472576039115665e-07
the O 0 8.79379115303891e-07
penultimate O 0 5.6884150581026915e-06
nucleotide O 0 7.997679745130881e-07
of O 0 7.727710453764303e-07
exon O 0 5.353133474272909e-06
6 O 0 1.330019813394756e-06
of O 0 6.991905934228271e-07
the O 0 7.305573035409907e-07
CYP27 O 1 0.9958406090736389
gene O 0 4.7569392336299643e-07
not O 0 7.972786875143356e-08
only O 0 1.2902798118830106e-07
causes O 0 9.399846021551639e-07
the O 0 1.06051993498113e-06
deficiency B-Disease 0 0.01807883195579052
in I-Disease 0 4.610882626820967e-07
the I-Disease 0 7.769061198814597e-07
sterol I-Disease 0 1.0117593774339184e-05
27 I-Disease 0 3.6082406040804926e-06
- I-Disease 0 8.11185691418359e-06
hydroxylase I-Disease 0 2.4343313270946965e-05
activity I-Disease 0 1.0753977903732448e-06
, O 0 4.7000304448374663e-07
but O 0 3.3559862799847906e-07
also O 0 6.474070914919139e-07
partially O 0 2.502265260773129e-06
leads O 0 7.574341225335957e-07
to O 0 1.9610818924320483e-07
alternative O 0 7.664290819775488e-07
pre O 0 2.084506149913068e-06
- O 0 2.2269880446401658e-06
mRNA O 0 1.6979357724267174e-06
splicing O 0 2.265348030050518e-06
of O 0 3.0050775876588887e-06
the O 0 7.888871550676413e-06
gene O 0 2.268444404762704e-05
. O 0 4.941543375025503e-05

To O 0 1.8213691873825155e-05
our O 0 4.5225633584777825e-06
knowledge O 0 2.5739759621501435e-06
, O 0 4.832531317333633e-07
this O 0 1.4643516976775572e-07
is O 0 2.8853125400019053e-07
the O 0 2.870990272185736e-07
first O 0 4.2030873714793415e-07
report O 0 3.2487372436662554e-07
regarding O 0 3.0290803465504723e-07
effects O 0 6.87796784859529e-07
on O 0 7.0537231522394e-07
pre O 0 3.2270586416416336e-06
- O 0 1.7737537518769386e-06
mRNA O 0 7.508334078920598e-07
splicing O 0 6.191149282130937e-07
of O 0 4.2702293967522564e-07
a O 0 3.292372241503472e-07
mutation O 0 2.5136833414762805e-07
at O 0 5.27335146216501e-07
the O 0 2.467590434207523e-07
- O 0 1.1870962453031098e-06
2 O 0 1.4529077816405334e-06
position O 0 9.795261348699569e-07
of O 0 8.079454119069851e-07
a O 0 1.840576260292437e-06
5 O 0 9.761953151610214e-06
splice O 0 9.468600183026865e-05
site O 0 7.317601557588205e-05
. O 0 3.712831312441267e-05

ATM O 0 0.23985514044761658
germline O 0 0.0008376117912121117
mutations O 0 3.530477260937914e-05
in O 0 5.068033260613447e-06
classical O 0 0.275668740272522
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.006150583736598492
in O 0 2.130020675394917e-06
the O 0 4.568282747641206e-06
Dutch O 0 0.0032048176508396864
population O 0 7.588536846014904e-06
. O 0 3.310367537778802e-05

Germline O 0 0.0010937298648059368
mutations O 0 1.333904128841823e-05
in O 0 1.6357021195290145e-06
the O 0 1.810888534237165e-06
ATM O 0 0.00025412760442122817
gene O 0 1.1381429203538573e-06
are O 0 1.57579478354819e-07
responsible O 0 5.996989216328075e-07
for O 0 4.786166982739815e-07
the O 0 3.0385430363821797e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999880790710449
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.9457634557038546e-05
. O 0 7.742269372101873e-05

In O 0 1.3824022971675731e-05
our O 0 4.152673227508785e-06
study O 0 1.3234430298325606e-06
, O 0 6.379294177349948e-07
we O 0 1.4308298545984144e-07
have O 0 5.367429523062128e-08
determined O 0 1.532600322207145e-07
the O 0 3.381394719781383e-07
ATM O 0 1.263009926333325e-05
mutation O 0 7.012366722847219e-07
spectrum O 0 1.3887469094697735e-06
in O 0 2.205605937888322e-07
19 O 0 1.3047451830061618e-06
classical O 0 5.4756487770646345e-06
A B-Disease 1 0.9997277855873108
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 6.721921863572788e-07
, O 0 1.5958254095949087e-07
including O 0 1.270524165875031e-07
some O 0 1.6456739615478e-07
immigrant O 0 4.705435117102752e-07
populations O 0 1.5391418628496467e-07
, O 0 1.626656427333728e-07
as O 0 9.872852757553119e-08
well O 0 2.5440391482334235e-07
as O 0 2.7309854999657546e-07
12 O 0 9.003264267448685e-07
of O 0 1.4854515484330477e-06
Dutch O 0 2.8432834369596094e-05
ethnic O 0 1.1656527931336313e-05
origin O 0 1.2252063243067823e-05
. O 0 3.2574840588495135e-05

Both O 0 1.8850791093427688e-05
the O 0 8.695205906406045e-06
protein O 0 4.21426011598669e-06
truncation O 0 2.08527926588431e-05
test O 0 1.8997467350345687e-06
( O 0 2.181533091061283e-06
PTT O 0 0.00045596022391691804
) O 0 1.319620423601009e-06
and O 0 4.783164513355587e-07
the O 0 6.404054602171527e-07
restriction O 0 2.151811941075721e-06
endonuclease O 0 2.1228001060080715e-05
fingerprinting O 0 1.595864159753546e-05
( O 0 2.8436584216251504e-06
REF O 0 0.25974348187446594
) O 0 5.170138024368498e-07
method O 0 1.889911374064468e-07
were O 0 7.513391864222285e-08
used O 0 5.8869339625289285e-08
and O 0 6.793185036713112e-08
compared O 0 9.934640843312081e-08
for O 0 4.0176043825113084e-08
their O 0 2.603636062303849e-08
detection O 0 6.446642260016233e-07
efficiency O 0 6.198421829139988e-07
, O 0 2.590705037164298e-07
identifying O 0 4.371086390619894e-07
76 O 0 1.0201129043707624e-06
% O 0 1.0787365312125985e-07
and O 0 8.206689727785488e-08
60 O 0 4.302367244690686e-07
% O 0 2.088761448248988e-07
of O 0 4.535087327894871e-07
the O 0 7.423478791679372e-07
mutations O 0 2.2666358745482285e-06
, O 0 3.2005780212784884e-06
respectively O 0 2.6482384782866575e-05
. O 0 5.124122617417015e-05

Most O 0 9.722733375383541e-05
patients O 0 2.0075918655493297e-05
were O 0 2.8798249331885017e-06
found O 0 1.3488918284565443e-06
to O 0 1.3562623735197121e-06
be O 0 4.7041121433721855e-06
compound O 0 0.00010263793228659779
heterozygote O 0 0.0008924778085201979
. O 0 0.00011594012175919488

Seventeen O 0 0.00024935920373536646
mutations O 0 9.165099982055835e-06
were O 0 9.039295036927797e-07
distinct O 0 9.579804327586317e-07
, O 0 5.010538757233007e-07
of O 0 8.888993647815369e-07
which O 0 2.675812140751077e-07
10 O 0 8.514745104548638e-07
were O 0 5.593055334429664e-07
not O 0 4.301316778310138e-07
reported O 0 3.7492040974029806e-06
previously O 0 1.9304370653117076e-05
. O 0 3.306954022264108e-05

Mutations O 0 0.00010797652794281021
are O 0 3.501558921925607e-06
small O 0 9.235247489414178e-06
deletions O 0 2.194197804783471e-05
or O 0 5.276282081467798e-06
point O 0 3.4773747756844386e-05
mutations O 0 4.48351829618332e-06
frequently O 0 3.7781048831675434e-06
affecting O 0 7.767263014102355e-06
splice O 0 9.941706957761198e-05
sites O 0 4.4855984015157446e-05
. O 0 4.496716792345978e-05

Moreover O 0 0.0005168266361579299
, O 0 6.057470091036521e-05
a O 0 6.683464016532525e-05
16 O 0 0.0001508456189185381
. O 0 0.00012070843513356522

7 O 0 0.00015372764028143138
- O 0 8.404058462474495e-05
kb O 0 0.00017935379582922906
genomic O 0 1.1328129403409548e-05
deletion O 0 6.403238330676686e-06
of O 0 2.286183189426083e-06
the O 0 7.478348607037333e-07
3 O 0 1.234318915521726e-06
end O 0 4.891380740446039e-07
of O 0 3.4410308558108227e-07
the O 0 2.0290450208904076e-07
gene O 0 2.2796616860887298e-07
, O 0 1.342990856301185e-07
most O 0 1.3390032904680993e-07
likely O 0 1.5397981201203947e-07
a O 0 1.2292659334889322e-07
result O 0 8.509470461603996e-08
of O 0 1.913489882099384e-07
recombination O 0 3.1295942903852847e-07
between O 0 1.1236871699793483e-07
two O 0 9.514516108311e-08
LINE O 0 7.26298640074674e-06
elements O 0 1.4607073808292625e-06
, O 0 1.4625306903326418e-06
was O 0 1.2779781172866933e-05
identified O 0 1.4756758901057765e-05
. O 0 3.419099448365159e-05

The O 0 2.733017026912421e-05
most O 0 2.97057704301551e-06
frequently O 0 1.92751690519799e-06
found O 0 7.467231171176536e-07
mutation O 0 6.290930514296633e-07
, O 0 2.997981880525913e-07
identified O 0 1.9911837512154307e-07
in O 0 9.401875900039158e-08
three O 0 1.4829036842911592e-07
unrelated O 0 8.657307262183167e-07
Turkish O 0 2.8822703370678937e-06
A B-Disease 1 0.9999916553497314
- I-Disease 1 0.9999903440475464
T I-Disease 1 0.9999997615814209
individuals O 0 2.254398907552968e-07
, O 0 3.5327457226230763e-07
was O 0 2.3383145162370056e-06
previously O 0 1.1223286264794297e-06
described O 0 5.218156502451166e-07
to O 0 2.5130935910055996e-07
be O 0 2.330761930124936e-07
a O 0 6.681044624201604e-07
Turkish O 0 8.1030893852585e-06
A B-Disease 1 0.9994656443595886
- I-Disease 1 0.9999942779541016
T I-Disease 1 1.0
founder O 1 0.8655079007148743
mutation O 0 9.512256656307727e-05
. O 0 6.198668415891007e-05

The O 0 3.7331141356844455e-05
presence O 0 8.713227543921676e-06
of O 0 5.1334786803636234e-06
a O 0 6.7106243477610406e-06
founder O 0 0.021023878827691078
mutation O 0 2.3147827050706837e-06
among O 0 5.202410306992533e-07
relatively O 0 4.129067576741363e-07
small O 0 4.840548513129761e-07
ethnic O 0 4.937634230373078e-07
population O 0 8.427015529832715e-08
groups O 0 3.8251229739216797e-08
in O 0 1.0290529672829507e-07
Western O 0 1.1355018614267465e-06
Europe O 0 7.947127187435399e-07
could O 0 2.1522930637729587e-07
indicate O 0 1.9309284482460498e-07
a O 0 4.43375199665752e-07
high O 0 2.3067609618010465e-06
carrier O 0 2.6975546916219173e-06
frequency O 0 1.439136894987314e-06
in O 0 1.2393225006235298e-06
such O 0 2.5520123472233536e-06
communities O 0 1.1186696610820945e-05
. O 0 4.393271592562087e-05

In O 0 1.7723990822560154e-05
patients O 0 3.4424660952936392e-06
of O 0 2.3690477064519655e-06
Dutch O 0 2.9654778700205497e-05
ethnic O 0 1.485498387410189e-06
origin O 0 5.022441200708272e-07
, O 0 4.4488390926744614e-07
however O 0 3.289917742677062e-07
, O 0 3.606602376748924e-07
no O 0 4.1808678474808403e-07
significant O 0 1.3594064967037411e-06
founder O 0 6.762526027159765e-05
effect O 0 1.9956580672442215e-06
could O 0 1.3148995776646188e-06
be O 0 1.7530120430819807e-06
identified O 0 8.041472938202787e-06
. O 0 1.603724194865208e-05

The O 0 5.332646469469182e-05
observed O 0 1.3706376194022596e-05
genetic O 0 3.7962136048008688e-06
heterogeneity O 0 1.4014558473718353e-05
including O 0 1.7283625766140176e-06
the O 0 1.7626949784244061e-06
relative O 0 1.2446441814972786e-06
high O 0 5.060856437921757e-06
percentage O 0 2.055393451882992e-06
of O 0 2.0409233911777847e-06
splice O 0 4.6227836719481274e-05
- O 0 1.9755139874177985e-05
site O 0 5.313511337590171e-06
mutations O 0 8.973999570116575e-07
had O 0 7.024106025710353e-07
no O 0 4.054791702401417e-07
reflection O 0 2.3031823275232455e-06
on O 0 2.118839120157645e-06
the O 0 5.1162555791961495e-06
phenotype O 0 4.003603680757806e-05
. O 0 3.176115205860697e-05

All O 0 3.571082925191149e-05
patients O 0 1.5089939552126452e-05
manifested O 0 1.0235587069473695e-05
classical O 0 4.684643499786034e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
and O 0 4.4481444092525635e-06
increased O 0 6.585564278793754e-06
cellular O 0 1.6675925508025102e-05
radioresistant O 0 0.0002600993902888149
DNA O 0 4.876654566032812e-05
synthesis O 0 6.470897642429918e-05
. O 0 4.3380387069191784e-05

Determination O 0 9.986877557821572e-05
of O 0 1.3022196071688086e-05
the O 0 4.423693098942749e-06
genomic O 0 4.905665718979435e-06
structure O 0 2.0625684555852786e-06
of O 0 2.0268146272428567e-06
the O 0 1.8034949107459397e-06
COL4A4 O 1 0.9999821186065674
gene O 0 8.633026595816773e-07
and O 0 2.824243381382985e-07
of O 0 1.4135184756014496e-06
novel O 0 0.00011615125549724326
mutations O 0 2.0315817891969346e-05
causing O 0 0.01318611390888691
autosomal B-Disease 1 0.9999923706054688
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.5774145722389221

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.02146468497812748
a O 0 0.002245415700599551
progressive O 1 0.9999997615814209
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.9908876419067383
by O 0 2.1597810700768605e-05
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.7715811133384705
abnormalities I-Disease 0 0.043619848787784576
and O 0 6.306200361905212e-07
associated O 0 4.5833675699213927e-07
with O 0 2.0946521317455336e-07
mutations O 0 4.4485037165031827e-07
in O 0 2.4763269834693347e-07
either O 0 3.20580028301265e-07
the O 0 9.996917924581794e-07
COL4A3 O 1 0.9999985694885254
or O 0 1.1982440355495783e-06
the O 0 1.7419131381757325e-06
COL4A4 O 1 0.9982374906539917
gene O 0 7.939566444292723e-07
, O 0 3.17020152351688e-07
which O 0 1.3326031478300138e-07
encode O 0 3.4036673923765193e-07
the O 0 1.131834778789198e-06
alpha3 O 0 7.900661148596555e-05
and O 0 4.288503077987116e-06
alpha4 O 0 0.4851825535297394
type O 1 0.7841633558273315
IV O 1 1.0
collagen O 1 0.9999998807907104
chains O 0 0.003979863133281469
, O 0 1.659622103034053e-05
respectively O 0 3.4894597774837166e-05
. O 0 6.972094706725329e-05

To O 0 1.2661575055972207e-05
date O 0 8.10818346508313e-06
, O 0 1.7508767768958933e-06
mutation O 0 9.074250328922062e-07
screening O 0 7.296590638361522e-07
in O 0 1.5650863360860967e-07
the O 0 3.3277777333751146e-07
two O 0 1.5152708954246918e-07
genes O 0 3.8546869518540916e-07
has O 0 4.511762199399527e-07
been O 0 4.037073608742503e-07
hampered O 0 3.4244828839291586e-06
by O 0 2.586444054486492e-07
the O 0 6.717423275404144e-07
lack O 0 8.676375955474214e-07
of O 0 3.080194801441394e-06
genomic O 0 7.426661341014551e-06
structure O 0 1.1806917427747976e-05
information O 0 9.778445928532165e-06
. O 0 3.694979386636987e-05

We O 0 1.2254716239112895e-05
report O 0 1.7286409956795978e-06
here O 0 4.6554472987736517e-07
the O 0 3.672832917800406e-07
complete O 0 4.620245022124436e-07
characterization O 0 1.6415842765127309e-06
of O 0 5.41958456778957e-07
the O 0 4.5922143954157946e-07
48 O 0 7.325526212298428e-07
exons O 0 1.0696371646190528e-06
of O 0 5.827055815643689e-07
the O 0 9.568491350364638e-07
COL4A4 O 1 0.9978533387184143
gene O 0 4.3356973833397205e-07
, O 0 2.428703851364844e-07
a O 0 3.389130256437056e-07
comprehensive O 0 5.864496870344738e-07
gene O 0 2.5869130126920936e-07
screen O 0 1.4911686321283923e-06
, O 0 2.738342743668909e-07
and O 0 7.321880701738337e-08
the O 0 1.2907979396459268e-07
subsequent O 0 1.4835062245310837e-07
detection O 0 5.324836820363998e-07
of O 0 3.233436984828586e-07
10 O 0 3.625583246957831e-07
novel O 0 1.2248289067429141e-06
mutations O 0 2.4058334702203865e-07
in O 0 1.8253544453727955e-07
eight O 0 2.176313046220457e-06
patients O 0 5.765538389823632e-06
diagnosed O 0 0.47186803817749023
with O 0 1.3887211025576107e-05
autosomal B-Disease 1 0.9999991655349731
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.6657245755195618

Furthermore O 0 0.00023302229237742722
, O 0 2.4628869141452014e-05
we O 0 4.126743078813888e-06
identified O 0 3.0306111966638127e-06
a O 0 1.8828570773621323e-06
glycine O 0 4.5121296352590434e-06
to O 0 7.52383130020462e-07
alanine O 0 5.615381724055624e-06
substitution O 0 1.8870347275878885e-06
in O 0 4.012596548363945e-07
the O 0 7.846738867556269e-07
collagenous O 0 6.402226426871493e-05
domain O 0 1.3946489616500912e-06
that O 0 3.4530427228673943e-07
is O 0 5.159626539352757e-07
apparently O 0 9.50215337525151e-07
silent O 0 2.7098358259536326e-06
in O 0 2.9445726568155806e-07
the O 0 6.030804229339992e-07
heterozygous O 0 1.6469377897010418e-06
carriers O 0 1.0164178547711344e-06
, O 0 1.4077043033466907e-06
in O 0 1.4827963923380594e-06
11 O 0 1.9405777493375354e-05
. O 0 5.4046016884967685e-05

5 O 0 3.0425882869167253e-05
% O 0 3.5644659419631353e-06
of O 0 2.0981478883186355e-06
all O 0 4.797070118911506e-07
control O 0 1.5524462924076943e-06
individuals O 0 1.4699485006985924e-07
, O 0 3.8417098835452634e-07
and O 0 2.1241996250864759e-07
in O 0 1.976809613779551e-07
one O 0 3.3930174936358526e-07
control O 0 9.441658903597272e-07
individual O 0 3.200567277872324e-07
homozygous O 0 1.034706997415924e-06
for O 0 7.741770673419524e-07
this O 0 1.1333889915476902e-06
glycine O 0 2.6736755899037234e-05
substitution O 0 2.355495234951377e-05
. O 0 3.474179902696051e-05

There O 0 2.6800238629220985e-05
has O 0 3.573499043341144e-06
been O 0 6.16824195276422e-07
no O 0 4.617236584181228e-07
previous O 0 5.998876986268442e-07
finding O 0 5.59044735837233e-07
of O 0 5.716236159969412e-07
a O 0 6.034555326550617e-07
glycine O 0 1.4734840760866064e-06
substitution O 0 5.458310852191062e-07
that O 0 9.649612309203803e-08
is O 0 1.199488650627245e-07
not O 0 5.340765696359995e-08
associated O 0 7.386024236666344e-08
with O 0 1.1265628785395165e-07
any O 0 6.300633117461985e-07
obvious O 0 4.855555744143203e-06
phenotype O 0 2.3536622393294238e-06
in O 0 1.2134165672250674e-06
homozygous O 0 1.2213135050842538e-05
individuals O 0 5.2563777899194974e-06
. O 0 5.2925272029824555e-05

Founder O 1 0.9895059466362
BRCA1 O 0 0.00206124410033226
and O 0 1.9942423023167066e-05
BRCA2 O 0 0.0002142202138202265
mutations O 0 3.479552106000483e-06
in O 0 1.5959822121658362e-06
French O 0 0.0027892962098121643
Canadian O 0 0.1927316039800644
breast B-Disease 1 1.0
and I-Disease 1 0.999883770942688
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.8735408957581967e-05
. O 0 3.381097849342041e-05

We O 0 2.4375394787057303e-05
have O 0 1.3927589179729694e-06
identified O 0 1.0586212511043414e-06
four O 0 2.8400626206348534e-07
mutations O 0 1.9019024932731554e-07
in O 0 9.750462481861177e-08
each O 0 8.435747389512471e-08
of O 0 8.037823135964572e-07
the O 0 4.843817350774771e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.9996128678321838
- O 0 5.398080247687176e-05
susceptibility O 0 6.243603820621502e-06
genes O 0 5.228403097135015e-07
, O 0 6.437795150304737e-07
BRCA1 O 0 5.358159341994906e-06
and O 0 5.621906211672467e-07
BRCA2 O 0 1.8349141100770794e-05
, O 0 3.211375485534518e-07
in O 0 3.8177546457518474e-07
French O 0 2.047247653536033e-05
Canadian O 0 0.0001224699371960014
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999957084655762
and O 0 5.2865452744299546e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.6782095119415317e-06
from O 0 8.91600939212367e-06
Quebec O 0 0.00023450175649486482
. O 0 4.7100915253395215e-05

To O 0 5.460406464408152e-05
identify O 0 3.065889541176148e-05
founder O 0 0.0013194209896028042
effects O 0 4.240850830683485e-05
, O 0 2.5838628516794415e-06
we O 0 6.942100867490808e-07
examined O 0 1.6208014130825177e-06
independently O 0 4.0086030139718787e-07
ascertained O 0 3.850068424071651e-06
French O 0 1.384935876558302e-05
Canadian O 0 1.1889082088600844e-05
cancer B-Disease 0 2.3300106477108784e-05
families O 0 5.18273068905728e-08
for O 0 6.371341498834227e-08
the O 0 1.3603126092220919e-07
distribution O 0 2.0080508988939982e-07
of O 0 7.078778025970678e-07
these O 0 2.4473135340485896e-07
eight O 0 3.867050509143155e-06
mutations O 0 9.32699731492903e-06
. O 0 2.2488475224236026e-05

Mutations O 0 5.9164463891647756e-05
were O 0 7.823015948815737e-06
found O 0 2.4336197839147644e-06
in O 0 8.588354489802441e-07
41 O 0 1.0746611224021763e-05
of O 0 1.0771143024612684e-05
97 O 0 0.0001369358942611143
families O 0 1.1659985830192454e-05
. O 0 3.2811538403620943e-05

Six O 0 2.9789016480208375e-05
of O 0 7.451534202118637e-06
eight O 0 4.327164788264781e-06
mutations O 0 1.2446216715034097e-06
were O 0 7.596709110657685e-07
observed O 0 9.79704509518342e-07
at O 0 5.290202807373134e-06
least O 0 2.3278259959624847e-06
twice O 0 1.5244882888509892e-05
. O 0 3.209693750250153e-05

The O 0 0.00011937638191739097
BRCA1 O 0 0.00045649733510799706
C4446T O 0 0.0003142925852444023
mutation O 0 6.411004960682476e-06
was O 0 4.948178684571758e-06
the O 0 5.893606953577546e-07
most O 0 3.991954713455925e-07
common O 0 3.672044783797901e-07
mutation O 0 3.4125304182452965e-07
found O 0 1.8340408303174627e-07
, O 0 2.1696868657272717e-07
followed O 0 5.14538101015205e-07
by O 0 4.652952725336945e-07
the O 0 7.843679668440018e-06
BRCA2 O 0 0.00030134429107420146
8765delAG O 0 0.0009688228601589799
mutation O 0 0.0001579000527272001
. O 0 0.00012712107854895294

Together O 0 1.6630567188258283e-05
, O 0 4.9041500460589305e-06
these O 0 7.566558792859723e-07
mutations O 0 1.401529061695328e-06
were O 0 2.461812584897416e-07
found O 0 3.131618484530918e-07
in O 0 1.414290977663768e-07
28 O 0 6.777640351174341e-07
of O 0 5.723174467675562e-07
41 O 0 2.495026137694367e-06
families O 0 1.2781964642272214e-07
identified O 0 2.1700738273011666e-07
to O 0 2.631530264807225e-07
have O 0 3.606908762776584e-07
a O 0 4.348918082541786e-06
mutation O 0 1.2962945220351685e-05
. O 0 2.7283347662887536e-05

The O 0 5.628347571473569e-05
odds O 0 5.276602314552292e-05
of O 0 5.100403541291598e-06
detection O 0 8.145454557961784e-06
of O 0 1.5484199593629455e-06
any O 0 3.9975321897145477e-07
of O 0 6.548080477841722e-07
the O 0 5.716999567084713e-07
four O 0 7.490532993870147e-07
BRCA1 O 0 1.4575302884622943e-05
mutations O 0 1.6844733181642368e-06
was O 0 1.2723404324788135e-05
18 O 0 2.519431109249126e-05
. O 0 3.0501763831125572e-05

7x O 1 0.9962195754051208
greater O 0 3.574613219825551e-05
if O 0 2.5248361907870276e-06
one O 0 8.618039259999932e-07
or O 0 3.4510543400756433e-07
more O 0 1.2094025692022115e-07
cases O 0 2.684558921828284e-07
of O 1 0.9889230728149414
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.3103216360832448e-06
also O 0 2.576298925305309e-07
present O 0 1.8557767589300056e-07
in O 0 2.283567397398656e-07
the O 0 1.7303019603787106e-06
family O 0 1.0076534636027645e-05
. O 0 2.17073320527561e-05

The O 0 5.011136090615764e-05
odds O 0 6.020440923748538e-05
of O 0 5.3181956900516525e-06
detection O 0 1.0496006325411145e-05
of O 0 2.417895984763163e-06
any O 0 8.46680848098913e-07
of O 0 1.1956710750382626e-06
the O 0 1.0244551731375395e-06
four O 0 1.282130597246578e-06
BRCA2 O 0 2.9930028176750056e-05
mutations O 0 1.8835467017197516e-06
was O 0 1.4098771316639613e-05
5 O 0 2.5681387342046946e-05
. O 0 4.030604031868279e-05

3x O 0 0.0047238897532224655
greater O 0 3.764663779293187e-05
if O 0 3.84472241421463e-06
there O 0 1.2564809139803401e-06
were O 0 4.08002847507305e-07
at O 0 1.3476470712703303e-06
least O 0 1.9691478314598498e-07
five O 0 1.7639213467646186e-07
cases O 0 2.8339238156149804e-07
of O 0 1.2228168088768143e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999880790710449
in O 0 1.701795554254204e-06
the O 0 6.457942163251573e-06
family O 0 1.6027917808969505e-05
. O 0 2.5967481633415446e-05

Interestingly O 0 0.00016565449186600745
, O 0 5.451321612781612e-06
the O 0 2.512624178052647e-06
presence O 0 1.3541402950068004e-06
of O 0 2.011678589042276e-06
a O 0 5.661280738422647e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.9823858141899109
case O 0 8.73065971518372e-07
< O 0 2.1636772089550504e-06
36 O 0 8.517408787156455e-07
years O 0 2.454554817177268e-07
of O 0 2.281686732885646e-07
age O 0 3.888355308845348e-07
was O 0 5.261817364043964e-07
strongly O 0 1.8804350077061827e-07
predictive O 0 5.159975557944563e-07
of O 0 3.796876626438461e-07
the O 0 3.2867754384824366e-07
presence O 0 2.375619345684754e-07
of O 0 2.5323549834865844e-07
any O 0 3.52684111248891e-07
of O 0 7.988936090441712e-07
the O 0 1.6441255183963221e-06
eight O 0 3.353089141455712e-06
mutations O 0 9.72243014984997e-06
screened O 0 5.968785990262404e-05
. O 0 3.71689056919422e-05

Carriers O 0 3.852827285300009e-05
of O 0 6.588918495253893e-06
the O 0 1.794525473997055e-06
same O 0 6.056637289475475e-07
mutation O 0 4.7093899979699927e-07
, O 0 2.084401558022364e-07
from O 0 8.666850703775708e-08
different O 0 3.1379020271060654e-08
families O 0 5.693549098850781e-08
, O 0 1.2614198396931897e-07
shared O 0 2.2564552182302577e-07
similar O 0 1.982987782866985e-07
haplotypes O 0 2.1272576304909308e-06
, O 0 3.9041697164066136e-07
indicating O 0 6.376216674652824e-07
that O 0 1.0682369833148186e-07
the O 0 3.4546499705356837e-07
mutant O 0 2.4367711830564076e-06
alleles O 0 1.9266884976332221e-07
were O 0 1.2481311273404572e-07
likely O 0 7.780155186765114e-08
to O 0 5.5073574145581006e-08
be O 0 5.609664555095151e-08
identical O 0 1.1322606496833032e-07
by O 0 6.771038130182205e-08
descent O 0 3.463494238076237e-07
for O 0 1.5887870574715635e-07
a O 0 7.803225798852509e-07
mutation O 0 7.104098926902225e-07
in O 0 4.953930670126283e-07
the O 0 3.039421926587238e-06
founder O 0 0.000336856726789847
population O 0 1.1534776604094077e-05
. O 0 4.336628262535669e-05

The O 0 1.773460826370865e-05
identification O 0 5.574855549639324e-06
of O 0 2.8337690309854224e-06
common O 0 5.094200787425507e-06
BRCA1 O 0 0.008956585079431534
and O 0 3.5239402222941862e-06
BRCA2 O 0 0.004268787335604429
mutations O 0 1.0473951306266827e-06
will O 0 2.930134996859124e-07
facilitate O 0 4.225239820243587e-07
carrier O 0 1.7019254983097198e-06
detection O 0 1.9758306279982207e-06
in O 0 5.355618100111315e-07
French O 0 3.5385528462938964e-05
Canadian O 0 0.0001709113857941702
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999970197677612
and O 0 5.900377072975971e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.330725172010716e-05
. O 0 2.7179210519534536e-05

Are O 0 9.365502774016932e-05
Dp71 O 1 0.924597442150116
and O 0 8.263777999673039e-05
Dp140 O 1 0.9861522912979126
brain O 0 0.037510260939598083
dystrophin O 0 0.00033943765447475016
isoforms O 0 1.9883438653778285e-05
related O 0 7.356873993558111e-06
to O 0 3.987578566011507e-06
cognitive B-Disease 1 0.9381971955299377
impairment I-Disease 1 1.0
in O 1 0.9372765421867371
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999974966049194

Molecular O 0 0.00023633561795577407
study O 0 1.1672992513922509e-05
and O 0 3.0168619105097605e-06
neuropsychological O 0 2.0265581042622216e-05
analysis O 0 5.625156518362928e-07
were O 0 2.9119553346390603e-07
performed O 0 1.1945052165174275e-06
concurrently O 0 1.2515585012806696e-06
on O 0 7.930470928840805e-07
49 O 0 4.533722403721185e-06
patients O 0 1.3208253903940204e-06
with O 0 2.4754963305895217e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 1.0
DMD B-Disease 1 1.0
) O 0 2.2828237433714094e-06
in O 0 3.2986454812089505e-07
order O 0 2.5106453449552646e-07
to O 0 1.987688875715321e-07
find O 0 3.387960418876901e-07
a O 0 3.6078097309655277e-07
molecular O 0 9.057088163899607e-07
explanation O 0 5.013033614886808e-07
for O 0 1.8846864691113296e-07
the O 0 9.85487190519052e-07
cognitive B-Disease 0 4.3376290705055e-05
impairment I-Disease 1 0.7090173363685608
observed O 0 3.4657086871447973e-06
in O 0 2.891832536988659e-06
most O 0 2.443082667014096e-05
DMD B-Disease 1 1.0
patients O 0 0.00018718761566560715
. O 0 7.063044176902622e-05

Complete O 0 4.751895903609693e-05
analysis O 0 8.942015483626164e-06
of O 0 6.571065569005441e-06
the O 0 5.107967353978893e-06
dystrophin O 0 5.022244658903219e-05
gene O 0 3.4661716199479997e-06
was O 0 4.125357918383088e-06
performed O 0 1.0584304845906445e-06
to O 0 2.9317115490812284e-07
define O 0 5.311630388860067e-07
the O 0 4.7507370481980615e-07
localization O 0 2.942337005151785e-06
of O 0 1.3628256283482187e-06
deletions O 0 6.707643024128629e-06
and O 0 1.2436107681423891e-06
duplications O 0 1.646124292165041e-05
in O 0 8.909566417969472e-07
relation O 0 1.1591891961870715e-06
to O 0 6.376934038598847e-07
the O 0 2.687499318199116e-06
different O 0 3.51436210621614e-06
DMD B-Disease 1 1.0
promoters O 1 0.945792555809021
. O 0 0.00016457510355394334

Qualitative O 0 0.00016629674064461142
analysis O 0 7.081924195517786e-06
of O 0 3.7232289287203457e-06
the O 0 3.188829850842012e-06
Dp71 O 0 0.023152418434619904
transcript O 0 6.408981334971031e-06
and O 0 4.787184479937423e-07
testing O 0 3.453536692177295e-07
for O 0 1.3398310727552598e-07
the O 0 2.719080498536641e-07
specific O 0 1.3643246177252877e-07
first O 0 6.618238330702297e-07
exon O 0 6.277389729802962e-06
of O 0 2.0355857941467548e-06
Dp140 O 0 5.951859930064529e-05
were O 0 1.0475009730726015e-06
also O 0 1.2028638138872338e-06
carried O 0 2.713458798098145e-06
out O 0 6.504954853880918e-06
. O 0 2.7847858291352168e-05

Neuropsychological O 0 0.0012710412265732884
analysis O 0 2.7040689019486308e-05
assessed O 0 3.885551996063441e-05
verbal O 0 2.5290553821832873e-05
and O 0 2.7174676233698847e-06
visuospatial O 0 0.0008887621806934476
intelligence O 0 1.019935734802857e-05
, O 0 3.6468861708272016e-06
verbal O 0 3.673582250485197e-05
memory O 1 0.9993059635162354
, O 0 7.030780579952989e-06
and O 0 3.64213497050514e-06
reading O 0 6.562339694937691e-05
skills O 0 7.530440780101344e-05
. O 0 4.634931974578649e-05

Comparison O 0 0.0001163554479717277
of O 0 3.428561467444524e-05
molecular O 0 1.8833183276001364e-05
and O 0 3.1231052162183914e-06
psychometric O 0 8.702468767296523e-05
findings O 0 1.991872522921767e-06
demonstrated O 0 1.91799836102291e-06
that O 0 2.8605938950931886e-07
deletions O 0 2.355265451114974e-06
and O 0 4.902102546111564e-07
duplications O 0 1.3865720575267915e-05
that O 0 3.373587276200851e-07
were O 0 3.5917571494792355e-07
localized O 0 1.9505412183207227e-06
in O 0 2.140425010566105e-07
the O 0 4.956411885359557e-07
distal O 0 1.7433527318644337e-05
part O 0 2.404611450401717e-06
of O 0 1.4442611018239404e-06
the O 0 9.926758366418653e-07
gene O 0 7.82856147907296e-07
seemed O 0 7.298316404558136e-07
to O 0 1.793370643099479e-07
be O 0 2.786238439966837e-07
preferentially O 0 9.579777042745263e-07
associated O 0 5.673364285030402e-07
with O 0 1.7719852394293412e-06
cognitive B-Disease 0 0.15863999724388123
impairment I-Disease 1 0.9999978542327881
. O 0 0.0003163478977512568

Two O 0 2.2043152057449333e-05
altered O 0 3.328303500893526e-05
Dp71 O 0 0.0003356651577632874
transcripts O 0 1.6297233742079698e-05
and O 0 2.117542180712917e-06
two O 0 5.432552825368475e-07
deleted O 0 7.5065972851007245e-06
Dp140 O 0 2.12211198231671e-05
DNA O 0 9.489973535892204e-07
sequences O 0 3.380401949470979e-07
were O 0 1.0890693147302954e-07
found O 0 1.7583319333880354e-07
in O 0 9.622209518056479e-08
four O 0 3.672542163712933e-07
patients O 0 1.1075608199462295e-06
with O 0 2.4313580979651306e-06
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.49318239092826843

These O 0 2.0936880900990218e-05
findings O 0 8.588226592110004e-06
suggest O 0 2.296711727467482e-06
that O 0 1.3943908072633349e-07
some O 0 1.0156121277304919e-07
sequences O 0 1.6006008252134052e-07
located O 0 6.695906904496951e-07
in O 0 1.0117144455534799e-07
the O 0 2.2206671701496816e-07
distal O 0 4.092817562195705e-06
part O 0 7.064076612550707e-07
of O 0 5.447940907288285e-07
the O 0 3.3873209304147167e-07
gene O 0 1.3738690540776588e-07
and O 0 1.3159164780063293e-07
, O 0 1.7900967463901907e-07
in O 0 1.0917334236637544e-07
particular O 0 1.9749347757169744e-07
, O 0 2.4634519490973616e-07
some O 0 2.6307347411602677e-07
DMD B-Disease 1 0.9999998807907104
isoforms O 0 1.314346604885941e-06
expressed O 0 3.123088561096665e-07
in O 0 2.9767008413728036e-07
the O 0 2.3343998236668995e-06
brain O 0 0.009935405105352402
may O 0 2.7462405682854296e-07
be O 0 9.939227396671413e-08
related O 0 2.3412368932440586e-07
to O 0 2.805479084599938e-07
the O 0 1.1729820243999711e-06
cognitive B-Disease 0 0.0004181578115094453
impairment I-Disease 1 0.9696290493011475
associated O 0 5.246111413725885e-06
with O 0 2.1884048692299984e-05
DMD B-Disease 1 1.0
. O 0 7.108817953849211e-05
. O 0 8.091515337582678e-05

I1307K O 0 0.004750647582113743
APC O 0 0.0021185744553804398
and O 0 1.6783489627414383e-05
hMLH1 O 0 0.00014902294788043946
mutations O 0 2.4011694677028572e-06
in O 0 5.736693537983228e-07
a O 0 2.323266244275146e-06
non O 0 5.880160642846022e-06
- O 0 4.423805876285769e-05
Jewish O 0 6.029991709510796e-06
family O 0 1.3377094774114084e-06
with O 0 9.885228564598947e-07
hereditary B-Disease 1 0.9999884366989136
non I-Disease 1 0.9999998807907104
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.004271396901458502

We O 0 2.6759200409287587e-05
describe O 0 1.6848276573000476e-05
a O 0 8.227162652474362e-06
French O 0 5.4468320740852505e-05
Canadian O 0 5.805616456200369e-05
hereditary B-Disease 1 0.9999961853027344
non I-Disease 1 0.9999992847442627
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9998824596405029
HNPCC B-Disease 1 1.0
) O 0 6.111075890657958e-06
kindred O 0 6.0761802160413936e-05
which O 0 1.0233391094516264e-06
carries O 0 4.414614977577003e-06
a O 0 3.1968138500815257e-06
novel O 0 1.7239624867215753e-05
truncating O 0 7.194857607828453e-05
mutation O 0 1.7535405277158134e-05
in O 0 1.0540484254306648e-05
hMLH1 O 0 0.0007259518606588244
. O 0 0.00013504194794222713

Interestingly O 0 0.0003065848723053932
, O 0 1.903704833239317e-05
the O 0 1.1255613571847789e-05
I1307K O 0 0.00021911087969783694
APC O 0 0.00010750116052804515
polymorphism O 0 6.658999154751655e-06
, O 0 1.6246112863882445e-06
associated O 0 3.6868107144982787e-07
with O 0 1.2052471731749392e-07
an O 0 2.556586764512758e-07
increased O 0 6.599796051887097e-07
risk O 0 6.563255738001317e-06
of O 1 0.9978132247924805
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.693950364118791e-06
is O 0 3.485752131382469e-07
also O 0 1.905202822172214e-07
present O 0 2.5297384809164214e-07
in O 0 3.415382821003732e-07
this O 0 8.584800639255263e-07
family O 0 1.013339169730898e-05
. O 0 1.937448905664496e-05

The O 0 5.632804095512256e-05
I1307K O 0 0.00013341721205506474
polymorphism O 0 6.60935984342359e-06
has O 0 1.7261635321119684e-06
previously O 0 2.034196313616121e-06
only O 0 2.0827503988130047e-07
been O 0 2.8398108042893e-07
identified O 0 2.610974263461685e-07
in O 0 1.3033620405167312e-07
individuals O 0 1.3101225704303943e-07
of O 0 1.7598529211682035e-06
self O 0 2.37791446124902e-05
- O 0 0.009021793492138386
reported O 0 8.442702892352827e-06
Ashkenazi O 0 5.57597195438575e-05
Jewish O 0 2.2406893549486995e-05
origins O 0 4.353704571258277e-05
. O 0 2.9659502615686506e-05

In O 0 1.0817806469276547e-05
addition O 0 3.964720690419199e-06
, O 0 1.2041953141306294e-06
in O 0 3.482143711153185e-07
this O 0 1.6033905581025465e-07
family O 0 3.347553843013884e-07
, O 0 2.2315708747555618e-07
there O 0 1.568567853382774e-07
appears O 0 2.9309620686035487e-07
to O 0 8.96510599091016e-08
be O 0 8.083618041609952e-08
no O 0 1.6893464760414645e-07
relationship O 0 1.2603352672613255e-07
between O 0 1.3428858380848396e-07
the O 0 5.346157081476122e-07
I1307K O 0 5.243930900178384e-06
polymorphism O 0 3.538703765570972e-07
and O 0 1.6501513755429187e-07
the O 0 3.20199603720539e-07
presence O 0 6.689523956993071e-07
or O 0 6.771632001800754e-07
absence O 0 2.631031065902789e-06
of O 0 2.447210135869682e-05
cancer B-Disease 1 0.9997501969337463
. O 0 1.1982293472101446e-05
. O 0 3.635223401943222e-05

Identification O 0 5.1498656830517575e-05
of O 0 1.3097222108626738e-05
a O 0 4.531820195552427e-06
novel O 0 1.152823278971482e-05
mutation O 0 1.349934109384776e-06
of O 0 1.249267711500579e-06
the O 0 2.086439053528011e-06
CPO O 0 0.44336774945259094
gene O 0 1.586263238095853e-06
in O 0 9.646996659284923e-07
a O 0 4.46766716777347e-06
Japanese O 0 9.468194184591994e-05
hereditary B-Disease 1 0.9999946355819702
coproporphyria I-Disease 1 0.9999997615814209
family O 0 0.00038574979407712817
. O 0 0.00012123642227379605

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999997615814209
( O 0 0.008685956709086895
HCP B-Disease 1 1.0
) O 0 1.710821015876718e-05
is O 0 3.6145709145785077e-06
an O 0 4.2091551222256385e-06
autosomal B-Disease 1 0.9996871948242188
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999988079071045
characterized O 0 2.7657435566652566e-05
by O 0 1.066001686922391e-06
a O 0 1.9754499589907937e-05
deficiency B-Disease 1 0.9997972846031189
of I-Disease 0 0.011720582842826843
coproporphyrinogen I-Disease 1 0.9999996423721313
oxidase I-Disease 0 4.52167478215415e-05
( O 0 1.6262080180240446e-06
CPO O 1 0.9758436679840088
) O 0 8.64188962168555e-07
caused O 0 6.284964229053003e-07
by O 0 1.1890639939338143e-07
a O 0 6.928158313712629e-07
mutation O 0 5.566560616898641e-07
in O 0 6.633745215367526e-07
the O 0 4.463442564883735e-06
CPO O 1 0.7534184455871582
gene O 0 4.618580351234414e-05
. O 0 7.100389484548941e-05

Only O 0 1.1625576007645577e-05
11 O 0 5.1143529162800405e-06
mutations O 0 1.4941508652555058e-06
of O 0 1.3351261713978602e-06
the O 0 1.1631093457253883e-06
gene O 0 1.0386447684140876e-06
have O 0 3.1743007866680273e-07
been O 0 7.860325013098191e-07
reported O 0 2.0880911506537814e-06
in O 0 4.821759375772672e-06
HCP B-Disease 1 1.0
patients O 0 0.00011867089779116213
. O 0 5.632975808111951e-05

We O 0 2.137134833901655e-05
report O 0 6.371308245434193e-06
another O 0 4.335343874117825e-06
mutation O 0 1.8548739717516582e-06
in O 0 7.445883056789171e-07
a O 0 3.823937731795013e-06
Japanese O 0 5.029625026509166e-05
family O 0 3.339344766573049e-05
. O 0 4.731213994091377e-05

Polymerase O 0 0.0006237921770662069
chain O 0 0.00010587224824121222
reaction O 0 1.3615664101962466e-05
- O 0 1.4459120393439662e-05
single O 0 2.1681305497622816e-06
strand O 0 3.741649607036379e-06
conformational O 0 1.0305236628482817e-06
polymorphism O 0 5.408689958130708e-07
and O 0 2.6257771423843224e-07
direct O 0 2.9422318448268925e-07
sequence O 0 3.915079389571474e-07
analyses O 0 8.967480198407429e-07
demonstrated O 0 8.196159342332976e-07
a O 0 6.319613135019608e-07
C O 0 3.961722995882155e-06
to O 0 4.716977173302439e-07
T O 0 4.2568622120597865e-06
substitution O 0 1.0531965699556167e-06
in O 0 2.3574941110382497e-07
exon O 0 4.598481609718874e-06
1 O 0 1.4727563666383503e-06
of O 0 7.658591130166315e-07
the O 0 9.407110042047861e-07
CPO O 0 8.74092584126629e-05
gene O 0 5.844586894454551e-07
at O 0 9.816199053602759e-07
nucleotide O 0 6.152989726615488e-07
position O 0 1.013714154396439e-06
85 O 0 1.8591294974612538e-06
, O 0 3.54215131892488e-07
which O 0 1.6969728733329248e-07
lies O 0 1.1291157306914101e-06
in O 0 1.6672876768097922e-07
the O 0 7.104370070010191e-07
putative O 0 8.075994628597982e-06
presequence O 0 5.9669302572729066e-05
for O 0 1.9581473225116497e-06
targeting O 0 7.044237463560421e-06
to O 0 7.249685495480662e-06
mitochondria O 0 5.15625870320946e-05
. O 0 7.847275264794007e-05

This O 0 2.0380086425575428e-05
mutation O 0 7.369218565145275e-06
changes O 0 8.309033319164882e-07
the O 0 1.1700046798068797e-06
codon O 0 6.037841103534447e-06
for O 0 1.116299586101377e-06
glutamine O 0 6.5557987909414805e-06
to O 0 9.064900154953648e-07
a O 0 1.862345015979372e-06
termination O 0 5.595025868387893e-06
codon O 0 1.2537190741568338e-05
at O 0 5.045666512160096e-06
amino O 0 2.913988055297523e-06
acid O 0 5.892634817428188e-06
position O 0 1.1291500413790345e-05
29 O 0 5.252474147710018e-05
. O 0 6.258856592467055e-05

MaeI O 0 0.0025595289189368486
restriction O 0 5.741594577557407e-05
analysis O 0 5.797594440082321e-06
showed O 0 1.968433480215026e-06
two O 0 2.619416648030892e-07
other O 0 3.550755138803652e-07
carriers O 0 9.203859576700779e-07
in O 0 7.081600870151306e-07
the O 0 5.837624030391453e-06
family O 0 2.552315163484309e-05
. O 0 4.089032518095337e-05

The O 0 0.00010658110841177404
C O 0 0.036654844880104065
- O 1 0.8549899458885193
T O 0 0.20686429738998413
mutation O 0 4.7394150897162035e-06
is O 0 1.092187062567973e-06
located O 0 1.5406117199745495e-06
within O 0 3.050346606414678e-07
a O 0 5.385312533690012e-07
recently O 0 1.0132725947187282e-06
proposed O 0 5.264507763058646e-07
putative O 0 3.0777696338191163e-06
alternative O 0 7.914951538623427e-07
translation O 0 1.0229233566860785e-06
initiation O 0 2.580454747658223e-06
codon O 0 3.7813886137882946e-06
( O 0 7.496064426959492e-07
TIC O 0 2.5394230760866776e-05
- O 0 2.2968565644987393e-06
1 O 0 1.4736837101736455e-06
) O 0 3.284444289874955e-07
, O 0 2.653363821991661e-07
supporting O 0 4.5315942998058745e-07
that O 0 3.115812035048293e-07
TIC O 0 0.0005995321553200483
- O 0 7.455130798916798e-06
1 O 0 5.146159764990443e-06
is O 0 7.620741939717846e-07
the O 0 9.125512860919116e-07
real O 0 3.38325708071352e-06
TIC O 0 0.0010445918887853622
rather O 0 9.492978847447375e-07
than O 0 8.527169370609045e-07
TIC O 0 0.4677802324295044
- O 0 8.058857201831415e-05
2 O 0 3.083438059547916e-05
. O 0 6.782646778447088e-06
. O 0 2.847799078153912e-05

Human B-Disease 0 7.845816435292363e-05
complement I-Disease 0 0.0003967858210671693
factor I-Disease 1 0.9999791383743286
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.0008070074836723506
with O 1 0.9999856948852539
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.999981164932251

This O 0 1.4041595022717956e-05
study O 0 3.863518941216171e-06
reports O 0 1.0715955340856453e-06
on O 0 6.687789095849439e-07
six O 0 3.641349621830159e-07
cases O 0 3.6347577747619653e-07
of O 0 2.130978464265354e-05
deficiency B-Disease 1 0.9999992847442627
in I-Disease 0 1.1688058521031053e-06
the I-Disease 0 8.239279054578219e-07
human I-Disease 0 3.495246119200601e-07
complement I-Disease 0 9.560719718137989e-07
regulatory I-Disease 0 1.5605510270688683e-06
protein I-Disease 0 2.449116436764598e-06
Factor I-Disease 0 7.529665163019672e-05
H I-Disease 1 0.9990843534469604
( O 0 1.8704668036662042e-06
FH O 1 0.74714595079422
) O 0 2.717981146815873e-07
in O 0 9.487007446296047e-08
the O 0 1.7223915449449123e-07
context O 0 3.2993875720421784e-07
of O 0 1.014481085803709e-06
an O 0 3.0103294193395413e-05
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.41135627031326294

Five O 0 1.9710356355062686e-05
of O 0 5.354644599719904e-06
the O 0 2.0386087271617725e-06
cases O 0 5.408030006037734e-07
were O 0 3.7656982954104024e-07
observed O 0 3.7984884215802595e-07
in O 0 2.7761782916968514e-07
children O 0 4.388780325825792e-07
presenting O 0 2.7395624329074053e-06
with O 0 1.6610945749562234e-05
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.021858610212802887
. O 0 0.0001286406914005056

Two O 0 9.229805073118769e-06
of O 0 9.18922796699917e-06
the O 0 2.5604642814869294e-06
children O 0 1.1342680181769538e-06
exhibited O 0 5.469260941026732e-06
a O 0 5.273680926620727e-06
homozygous O 0 0.0025593291502445936
deficiency O 1 0.999995231628418
characterized O 0 4.569271823129384e-06
by O 0 4.2762363250403723e-07
the O 0 1.102549731513136e-06
absence O 0 1.6042272363847587e-06
of O 0 1.508918671788706e-06
the O 0 7.827933927728736e-07
150 O 0 1.3451356153382221e-06
- O 0 3.0367157251021126e-06
kD O 0 0.0001361939066555351
form O 0 3.1456747251468187e-07
of O 0 1.0166970696445787e-06
Factor O 0 8.8561384472996e-05
H O 0 0.47694864869117737
and O 0 2.7370580824026547e-07
the O 0 3.3497735785203986e-07
presence O 0 2.7092960408481304e-07
, O 0 1.7377158201270504e-07
upon O 0 2.352037142827612e-07
immunoblotting O 0 4.756335329147987e-06
, O 0 3.144007223454537e-07
of O 0 7.386784091067966e-07
the O 0 8.010198371266597e-07
42 O 0 4.033516233903356e-06
- O 0 1.4005901903146878e-05
kD O 1 0.9827683568000793
Factor O 0 2.559710446803365e-05
H O 0 0.00027624741778708994
- O 0 2.2828016881248914e-06
like O 0 4.630994965282298e-07
protein O 0 3.187852257724444e-07
1 O 0 1.0253525033476762e-06
( O 0 5.800508802167315e-07
FHL O 0 0.00023969600442796946
- O 0 2.7862965907843318e-06
1 O 0 2.023224396907608e-06
) O 0 2.2659477849629184e-07
and O 0 1.6813615388855396e-07
other O 0 3.8473086760859587e-07
FH O 0 0.10661978274583817
- O 0 8.8545684775454e-06
related O 0 1.5940214552756515e-06
protein O 0 2.4424457478744444e-06
( O 0 2.1084379113744944e-06
FHR O 1 0.9967393279075623
) O 0 6.8844515226373915e-06
bands O 0 6.0989365010755137e-05
. O 0 3.382807335583493e-05

Southern O 0 0.00029427907429635525
blot O 0 0.0002743756922427565
and O 0 3.797930276050465e-06
PCR O 0 8.465390237688553e-06
analysis O 0 5.868760126759298e-07
of O 0 4.761831746691314e-07
DNA O 0 5.915416068091872e-07
of O 0 9.529142630526621e-07
one O 0 8.06333559921768e-07
patient O 0 1.2563970130941016e-06
with O 0 4.34871282095628e-07
homozygous O 0 0.00042091833893209696
deficiency O 1 0.999738872051239
ruled O 0 2.5473800633335486e-06
out O 0 4.509323332513304e-07
the O 0 2.5366185241182393e-07
presence O 0 2.585366303264891e-07
of O 0 3.6954210713702196e-07
a O 0 3.8985365335975075e-07
large O 0 4.494742995575507e-07
deletion O 0 1.5725536286481656e-06
of O 0 1.088042040464643e-06
the O 0 1.4011534403834958e-06
FH O 1 0.9999814033508301
gene O 0 7.112572575351805e-07
as O 0 3.6252620816412673e-07
the O 0 1.1191755220352206e-06
underlying O 0 0.0051221298053860664
defect O 0 0.000414858921431005
for O 0 3.932955223717727e-06
the O 0 0.0009687172714620829
deficiency O 1 0.9999995231628418
. O 0 0.00015659334894735366

The O 0 2.0395891624502838e-05
other O 0 1.8507091681385646e-06
four O 0 8.128491799652693e-07
children O 0 6.201992732712824e-07
presented O 0 1.858622567851853e-06
with O 0 1.0233702596451622e-06
heterozygous O 0 0.00010090240539284423
deficiency O 1 0.9999994039535522
and O 0 4.6988529902591836e-06
exhibited O 0 3.502552499412559e-05
a O 0 2.6955642624670872e-06
normal O 0 6.438955324483686e-07
immunoblotting O 0 1.3264781955513172e-05
pattern O 0 1.1757617812691024e-06
of O 0 9.139204735220119e-07
proteins O 0 2.2130475940684846e-07
of O 0 9.82037590802065e-07
the O 0 1.1138591617054772e-05
FH O 1 0.9999998807907104
family O 0 0.00010127024870598689
. O 0 7.119245128706098e-05

Factor B-Disease 1 1.0
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.0463214493938722e-05
the O 0 5.947000772721367e-06
only O 0 3.771171577682253e-06
complement B-Disease 1 0.9999963045120239
deficiency I-Disease 1 1.0
associated O 0 7.032712892396376e-05
with O 0 0.0009307815344072878
HUS B-Disease 1 1.0
. O 0 0.004341619089245796

These O 0 1.1384401659597643e-05
observations O 0 1.2856058674515225e-05
suggest O 0 4.185534180578543e-06
a O 0 1.7123580846600817e-06
role O 0 2.9692516818613512e-06
for O 0 1.8326471717955428e-06
FH O 1 1.0
and O 0 5.952163974143332e-06
/ O 1 0.9849098324775696
or O 0 1.1366241778887343e-05
FH O 1 0.9999958276748657
receptors O 0 2.824468765538768e-06
in O 0 6.340796971926466e-07
the O 0 2.464951876390842e-06
pathogenesis O 1 0.9995276927947998
of O 1 0.9677046537399292
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 0.035529445856809616
. O 0 0.00022568147687707096

Further O 0 3.2345928048016503e-05
evidence O 0 7.432613074342953e-06
for O 0 1.1448399845903623e-06
a O 0 2.4239700451289536e-06
major O 0 6.942266281839693e-06
ancient O 0 0.00010807232320075855
mutation O 0 0.0001488643029006198
underlying O 1 0.9999988079071045
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 7.957884372444823e-05
linkage O 0 0.0003755665384232998
disequilibrium O 0 0.0003945767821278423
studies O 0 3.797531689997413e-06
in O 0 1.670991764513019e-06
the O 0 5.821018476126483e-06
Japanese O 0 4.7242392611224204e-05
population O 0 9.828332622419111e-06
. O 0 3.638619091361761e-05

The O 0 0.12499719858169556
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997219443321228
DM B-Disease 1 1.0
) O 0 1.7851503798738122e-05
mutation O 0 2.078455509035848e-06
is O 0 6.157979441923089e-07
an O 0 5.817416877107462e-07
unstable O 0 4.3724558054236695e-06
( O 0 1.2234199857630301e-06
CTG O 1 0.9434973001480103
) O 0 9.335167305835057e-07
n O 0 8.54520123994007e-07
repeat O 0 9.099215958485729e-07
, O 0 3.5532349329514545e-07
present O 0 2.6687069976105704e-07
at O 0 6.173997917358065e-07
a O 0 3.8181914874257927e-07
copy O 0 6.799224365749978e-07
number O 0 1.4397338077287714e-07
of O 0 4.2247401665918005e-07
5 O 0 1.052989773597801e-06
- O 0 2.231095095339697e-06
37 O 0 1.6499183175255894e-06
repeats O 0 5.843695021212625e-07
on O 0 3.7394732999018743e-07
normal O 0 2.729415484736819e-07
chromosomes O 0 1.7469626811816852e-07
but O 0 1.1895959062258044e-07
amplified O 0 8.639895554551913e-07
to O 0 2.697287300179596e-07
50 O 0 1.7031725292326882e-06
- O 0 4.593196081259521e-06
3000 O 0 7.766004273435101e-06
copies O 0 3.5353646126168314e-06
on O 0 1.1974116205237806e-05
DM B-Disease 1 1.0
chromosomes O 0 5.269300891086459e-05
. O 0 4.9786172894528136e-05

Previous O 0 8.40062930365093e-05
findings O 0 1.5396042726933956e-05
in O 0 4.611296390066855e-06
Caucasian O 0 6.138825119705871e-05
populations O 0 1.765551701282675e-06
of O 0 3.6286037357058376e-06
a O 0 6.509766535600647e-05
DM B-Disease 1 1.0
founder O 1 0.9999997615814209
chromosome O 0 7.865507541282568e-06
raise O 0 1.7990149672186817e-06
a O 0 7.028240815998288e-07
question O 0 5.058971055404982e-07
about O 0 1.9500598114063905e-07
the O 0 2.8656998551923607e-07
molecular O 0 1.0639460015227087e-06
events O 0 5.321309117789497e-07
involved O 0 6.479345415755233e-07
in O 0 5.287895419314737e-07
the O 0 2.3343552584265126e-06
expansion O 0 3.282888064859435e-05
mutation O 0 3.0085187972872518e-05
. O 0 3.1195308110909536e-05

To O 0 4.586237628245726e-05
investigate O 0 2.6756215447676368e-05
whether O 0 3.867131908918964e-06
a O 0 4.7879434532660525e-06
founder O 0 3.368366742506623e-05
chromosome O 0 2.0400050289026694e-06
for O 0 7.932362109386304e-07
the O 0 3.980386281909887e-06
DM B-Disease 1 1.0
mutation O 0 4.96085567647242e-06
exists O 0 6.468997639785812e-07
in O 0 1.942127454412912e-07
the O 0 4.194190523776342e-07
Japanese O 0 2.3989766759768827e-06
population O 0 2.0420164048573497e-07
, O 0 1.819171160377664e-07
we O 0 3.373529295913613e-07
genotyped O 0 7.926517355372198e-06
families O 0 1.3944719512437587e-07
using O 0 2.986564311413531e-07
polymorphic O 0 3.2453667699883226e-06
markers O 0 3.5688467505679e-06
near O 0 4.195057044853456e-06
the O 0 7.153974479479075e-07
( O 0 1.2187292668386362e-06
CTG O 0 0.028197765350341797
) O 0 1.0585717973299325e-06
n O 0 1.9448239072517026e-06
repeat O 0 4.8480596888111904e-06
region O 0 2.5093627300520893e-06
and O 0 2.463527835061541e-06
constructed O 0 5.609025902231224e-05
haplotypes O 0 0.0002007306757150218
. O 0 7.196113438112661e-05

Six O 0 4.211294435663149e-05
different O 0 2.122450950992061e-06
haplotypes O 0 9.828820111579262e-06
were O 0 1.0318295835531899e-06
found O 0 7.24579706457007e-07
and O 0 1.4587793657483417e-06
DM B-Disease 1 1.0
alleles O 0 2.012829099840019e-05
were O 0 5.778000286227325e-06
always O 0 1.54312056110939e-05
haplotype O 0 0.00011358616757206619
A O 0 0.0002711432462092489
. O 0 9.223763481713831e-05

To O 0 1.400515429850202e-05
find O 0 4.300235559639987e-06
an O 0 1.0052127663584542e-06
origin O 0 4.224099541261239e-07
of O 0 6.828493042121409e-07
the O 0 7.038415787974373e-07
( O 0 1.9211524886486586e-06
CTG O 1 0.8221568465232849
) O 0 9.329150998382829e-07
n O 0 1.4976645843489678e-06
repeat O 0 1.9536912532203132e-06
mutation O 0 2.9256449352033087e-07
and O 0 1.2540084526335704e-07
to O 0 1.1423998103055055e-07
investigate O 0 3.4577814744807256e-07
the O 0 2.6164656219407334e-07
mechanism O 0 2.605079600925819e-07
of O 0 3.2758541124167095e-07
the O 0 3.520362383824249e-07
expansion O 0 1.1504963595143636e-06
mutation O 0 2.975727397824812e-07
in O 0 9.856351113057826e-08
the O 0 2.336280999770679e-07
Japanese O 0 1.8272091892868048e-06
population O 0 1.182854703074554e-07
we O 0 8.91650486778417e-08
have O 0 8.969399090119623e-08
studied O 0 1.1850037253680057e-06
90 O 0 2.448910890961997e-06
Japanese O 0 1.2602234164660331e-05
DM B-Disease 1 1.0
families O 0 9.601233159628464e-07
comprising O 0 1.8494441746952361e-06
190 O 0 4.867735697189346e-06
affected O 0 7.708698035457928e-07
and O 0 9.59616272666608e-07
130 O 0 1.64413340826286e-05
unaffected O 0 4.484281816985458e-05
members O 0 1.1683672710205428e-05
. O 0 4.9971444241236895e-05

The O 0 5.9757916460512206e-05
results O 0 7.443771664839005e-06
suggest O 0 2.643357220222242e-06
that O 0 4.515769660429214e-07
a O 0 9.287357443099609e-07
few O 0 8.284639534394955e-07
common O 0 8.164735163518344e-07
ancestral O 0 4.054875716974493e-06
mutations O 0 6.317335987660044e-07
in O 0 2.3468344068078295e-07
both O 0 2.1745218248270248e-07
Caucasian O 0 0.0002740285126492381
and O 0 8.944470550886763e-07
Japanese O 0 5.571889687416842e-06
populations O 0 2.0969386582692096e-07
have O 0 6.107156025336735e-08
originated O 0 2.612207197216776e-07
by O 0 6.028238885846804e-08
expansion O 0 1.04151229152194e-06
of O 0 7.409078648379364e-07
an O 0 7.644486572644382e-07
ancestral O 0 4.30968657383346e-06
n O 0 2.2329468265525065e-06
= O 0 1.7035882819982362e-06
5 O 0 1.483898358856095e-06
repeat O 0 1.7206444908879348e-06
to O 0 4.63467983990995e-07
n O 0 1.6792636188256438e-06
= O 0 2.1295613805705216e-06
19 O 0 2.482039690221427e-06
- O 0 5.584337486652657e-06
37 O 0 1.517233522463357e-05
copies O 0 1.1042544429074042e-05
. O 0 3.315451249363832e-05

These O 0 1.4720918443344999e-05
data O 0 5.0556272981339134e-06
support O 0 2.426407945677056e-06
multistep O 0 1.722105844237376e-05
models O 0 3.919849405065179e-06
of O 0 4.3797176658699755e-06
triplet O 0 6.291745376074687e-05
repeat O 0 6.080561433918774e-06
expansion O 0 3.631982963270275e-06
that O 0 1.7425132625703554e-07
have O 0 8.186975009039088e-08
been O 0 1.1489411377851866e-07
proposed O 0 2.0245086318482208e-07
for O 0 2.2067105476253346e-07
both O 0 1.0179001037613489e-06
DM B-Disease 1 1.0
and O 0 0.000574470148421824
Friedreichs B-Disease 1 1.0
ataxia I-Disease 1 0.9999996423721313
. O 0 9.084267367143184e-05
. O 0 8.001654350664467e-05

The O 0 3.893185203196481e-05
molecular O 0 3.447687049629167e-05
basis O 0 8.0912905104924e-06
of O 1 0.9965307116508484
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.599871772370534e-06
the O 0 2.6804809749592096e-06
western O 0 4.570744749798905e-06
Cape O 0 1.9705845261341892e-05
, O 0 2.2827844077255577e-06
South O 0 1.0337746971345041e-05
Africa O 0 1.1092870408901945e-05
. O 0 2.9403141525108367e-05

Deficiency B-Disease 1 0.9999980926513672
of I-Disease 0 0.00019251511548645794
the I-Disease 0 4.1098541259998456e-05
sixth I-Disease 0 0.01213911548256874
component I-Disease 0 0.00045818666694685817
of I-Disease 0 4.240112957631936e-06
human I-Disease 0 6.446875318033563e-07
complement I-Disease 0 6.989785106270574e-06
( O 0 2.710901026148349e-05
C6 O 1 1.0
) O 0 1.058999941960792e-06
has O 0 3.2530468274671875e-07
been O 0 2.0201383676976548e-07
reported O 0 1.5085490190358541e-07
in O 0 6.431547916463387e-08
a O 0 1.0814105166900845e-07
number O 0 5.147893844537066e-08
of O 0 1.6641835998143506e-07
families O 0 3.102243439911945e-08
from O 0 5.8251448109558623e-08
the O 0 3.0120213523332495e-07
western O 0 1.0681366120479652e-06
Cape O 0 1.0828820450115018e-05
, O 0 1.645989414100768e-06
South O 0 8.229979357565753e-06
Africa O 0 8.396847078984138e-06
. O 0 2.4494844183209352e-05

Meningococcal B-Disease 1 1.0
disease I-Disease 1 0.9999959468841553
is O 0 1.2580114344018511e-05
endemic O 0 1.3224261238065083e-05
in O 0 5.50018683043163e-07
the O 0 8.89208024545951e-07
Cape O 0 6.469456820923369e-06
and O 0 2.749490306541702e-07
almost O 0 1.8643906685156253e-07
all O 0 1.1115282205764743e-07
pedigrees O 0 2.0499355741776526e-06
of O 0 5.2249120017222594e-06
total O 1 0.9846571087837219
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.00043054434354417026
C6Q0 O 1 1.0
) O 0 1.4724417951583746e-06
have O 0 3.06487379475584e-07
been O 0 3.614101444782136e-07
ascertained O 0 4.3007607928302605e-06
because O 0 9.884266773951822e-07
of O 0 1.0267183824907988e-05
recurrent O 1 1.0
disease O 1 0.9999995231628418
. O 0 0.00024545908672735095

We O 0 2.4991264581331052e-05
have O 0 1.4604512443838757e-06
sequenced O 0 3.965730229538167e-06
the O 0 9.304148420596903e-07
expressed O 0 3.5636804796013166e-07
exons O 0 2.932683628387167e-06
of O 0 1.930066446220735e-06
the O 0 4.81538199892384e-06
C6 O 1 1.0
gene O 0 8.520106007381401e-07
from O 0 3.506537495923112e-07
selected O 0 4.495214227517863e-07
cases O 0 1.0169458164455136e-07
and O 0 1.507299174363652e-07
have O 0 6.803804808441782e-08
found O 0 1.587103071187812e-07
three O 0 2.5153090632556996e-07
molecular O 0 0.006425241008400917
defects O 0 0.3297828137874603
leading O 0 0.00024301680969074368
to O 0 8.619929303677054e-07
total O 0 1.11990366349346e-05
deficiency O 1 0.9999954700469971
879delG O 1 0.9383392930030823
, O 0 9.868575716609485e-07
which O 0 3.6685025861515896e-07
is O 0 3.76291609427426e-07
the O 0 6.064416879780765e-07
common O 0 7.651167379663093e-07
defect O 0 1.2164429790573195e-05
in O 0 5.437777303995972e-07
the O 0 1.5939212971716188e-06
Cape O 0 1.0870528967643622e-05
and O 0 4.846872343478026e-07
hitherto O 0 4.151924258621875e-06
unreported O 0 6.761837084923172e-06
, O 0 7.268837407536921e-07
and O 0 4.848125172429718e-07
1195delC O 0 1.7065322026610374e-05
and O 0 7.668238595215371e-07
1936delG O 0 3.5824006772600114e-05
, O 0 7.678271458644303e-07
which O 0 2.184556961992712e-07
have O 0 1.336171493449001e-07
been O 0 2.4517123620171333e-07
previously O 0 1.0335166962249787e-06
reported O 0 7.438069360432564e-07
in O 0 7.061369160510367e-07
African O 0 2.4445218969049165e-06
- O 0 4.3389816710259765e-05
Americans O 0 1.1168192031618673e-05
. O 0 3.521912367432378e-05

We O 0 2.489936741767451e-05
also O 0 4.5789820433128625e-06
show O 0 2.3264367428055266e-06
that O 0 4.906798380943656e-07
the O 0 1.324168920291413e-06
879delG O 0 5.580520155490376e-05
and O 0 2.2366468783729943e-06
1195delC O 0 0.4339004158973694
defects O 0 0.0001789987727534026
are O 0 3.6765194977306237e-07
associated O 0 5.885855784981686e-07
with O 0 1.387636302752071e-06
characteristic O 1 0.9999991655349731
C6 O 1 1.0
/ O 1 1.0
C7 O 1 1.0
region O 0 2.304139889020007e-05
DNA O 0 9.899890756059904e-06
marker O 0 4.592001641867682e-05
haplotypes O 0 8.851166057866067e-06
, O 0 9.944078556145541e-07
although O 0 7.209106911432173e-07
small O 0 1.7806705727707595e-06
variations O 0 6.422246315196389e-06
were O 0 3.999380169261713e-06
observed O 0 1.0647789167705923e-05
. O 0 3.0058861739235e-05

The O 0 0.00013949953427072614
1936delG O 0 0.42123734951019287
defect O 0 0.0635128766298294
was O 0 2.1968380679027177e-05
observed O 0 1.421179945282347e-06
only O 0 2.348061229895393e-07
once O 0 6.426667482628545e-07
in O 0 1.5477408510378154e-07
the O 0 2.572577102455398e-07
Cape O 0 2.874315441658837e-06
, O 0 2.0269060030386754e-07
but O 0 7.501564169842823e-08
its O 0 2.087536756789632e-07
associated O 0 7.042377205834782e-07
haplotype O 0 1.3787894204142503e-05
could O 0 2.116811174346367e-06
be O 0 3.833073151326971e-06
deduced O 0 5.579104617936537e-05
. O 0 3.674633626360446e-05

The O 0 3.199944694642909e-05
data O 0 5.269769189908402e-06
from O 0 1.844668986450415e-06
the O 0 2.954247520392528e-06
haplotypes O 0 7.880750672484282e-06
indicate O 0 7.528374794674164e-07
that O 0 1.3422686606645584e-07
these O 0 8.35330595805317e-08
three O 0 2.4392375053139403e-07
molecular O 0 1.5870358765823767e-05
defects O 0 0.00018981657922267914
account O 0 4.211939312881441e-07
for O 0 4.849142101193138e-07
the O 0 1.8742183556241798e-06
defects O 0 1.207817331305705e-05
in O 0 2.640398975017888e-07
all O 0 1.7540327235110453e-07
the O 0 3.6779746892534604e-07
38 O 0 2.0404563656484243e-06
unrelated O 0 5.3793205552210566e-06
C6Q0 O 1 0.9996457099914551
individuals O 0 2.472612550263875e-07
we O 0 1.895447354627322e-07
have O 0 1.1840510438787533e-07
studied O 0 1.8983449763254612e-06
from O 0 1.2060893368470715e-06
the O 0 3.8853891055623535e-06
Cape O 0 9.631727880332619e-05
. O 0 4.01547658839263e-05

We O 0 2.7164389393874444e-05
have O 0 1.900607458082959e-06
also O 0 2.7557007342693396e-06
observed O 0 1.9048571857638308e-06
the O 0 2.5666467990959063e-06
879delG O 0 0.00017609480710234493
defect O 0 3.1619954825146124e-05
in O 0 1.274528131034458e-06
two O 0 2.2183141936693573e-06
Dutch O 1 0.999998927116394
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 0.006368082948029041
, O 0 1.711215304567304e-06
but O 0 2.987458742609306e-07
the O 0 5.874191515431448e-07
879delG O 0 5.153103484190069e-05
defect O 0 8.557567525713239e-06
in O 0 5.992284286548966e-07
the O 0 8.671676710036991e-07
Cape O 0 1.4896854736434761e-05
probably O 0 7.307273222068034e-07
did O 0 2.1239503666947712e-07
not O 0 5.318107909602077e-08
come O 0 1.3234009088591847e-07
from O 0 3.551222675923782e-07
The O 0 2.145472080883337e-06
Netherlands O 0 3.2488653232576326e-05
. O 0 9.123998097493313e-06
. O 0 3.565577571862377e-05

Complement B-Disease 1 1.0
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.5167077183141373e-05
seven O 0 7.66556513553951e-06
further O 0 2.9403734060906572e-06
molecular O 0 0.001313996035605669
defects O 0 0.0035176086239516735
and O 0 1.834600425354438e-06
their O 0 1.685791062300268e-06
associated O 0 1.2494794646045193e-05
marker O 0 0.02981303632259369
haplotypes O 0 0.00046534015564247966
. O 0 0.0001285788748646155

Seven O 0 4.704879393102601e-05
further O 0 1.0483821824891493e-05
molecular O 0 1.3202762602304574e-05
bases O 0 1.8695929611567408e-05
of O 1 0.9824333190917969
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.2708576580043882e-05
described O 0 0.00016355951083824039
. O 0 8.57731283758767e-05

All O 0 1.1757319043681491e-05
these O 0 1.2212749425088987e-06
new O 0 1.9304436591482954e-06
molecular O 0 3.0147797588142566e-05
defects O 0 8.273018465843052e-05
involve O 0 1.5400065649373573e-06
single O 0 1.1259286338827224e-06
- O 0 5.287857675284613e-06
nucleotide O 0 1.2538341707113432e-06
events O 0 4.5219155708764447e-07
, O 0 2.7411803671384405e-07
deletions O 0 6.812718424953346e-07
and O 0 2.0296411662457103e-07
substitutions O 0 1.0890687462961068e-06
, O 0 2.6313747980566404e-07
some O 0 1.2075159361302212e-07
of O 0 3.2835831120792136e-07
which O 0 2.644466405854473e-07
alter O 0 2.2755029931431636e-06
splice O 0 9.957031579688191e-06
sites O 0 2.5226702291547554e-06
, O 0 1.0585031304799486e-06
and O 0 1.0413752988824854e-06
others O 0 7.1136155384010635e-06
codons O 0 0.00017231078527402133
. O 0 7.243453001137823e-05

They O 0 8.888027878128923e-06
are O 0 8.049383382058295e-07
distributed O 0 1.070219809662376e-06
along O 0 1.5703086546636769e-06
the O 0 3.0212470392143587e-06
C7 O 1 0.9998612403869629
gene O 0 1.5463702993656625e-06
, O 0 4.0973060322357924e-07
but O 0 1.7183441514134756e-07
predominantly O 0 4.96378618208837e-07
towards O 0 9.054514862327778e-07
the O 0 8.45046486119827e-07
3 O 0 7.091155566740781e-06
end O 0 2.578839303168934e-05
. O 0 4.52895910711959e-05

All O 0 1.7011636373354122e-05
were O 0 4.233776962792035e-06
found O 0 1.6970243450487033e-06
in O 0 1.0793329465741408e-06
compound O 0 1.6294232409563847e-05
heterozygous O 0 1.8395376173430122e-05
individuals O 0 5.699422217730898e-06
. O 0 3.7023157346993685e-05

The O 0 0.15651708841323853
C6 O 1 1.0
/ O 1 0.9999998807907104
C7 O 1 1.0
marker O 1 0.8817948698997498
haplotypes O 0 7.46932128095068e-05
associated O 0 2.293699935762561e-06
with O 0 1.3936996765551157e-06
most O 0 8.100779086817056e-05
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999706745147705
are O 0 3.0571079605579143e-06
tabulated O 0 1.1831556548713706e-05
. O 0 8.050771612033714e-06
. O 0 3.404113886062987e-05

A O 0 0.0002741186472121626
genome O 0 3.080831447732635e-05
- O 0 2.16494663618505e-05
wide O 0 9.202611181535758e-06
search O 0 4.176980837655719e-06
for O 0 1.948722911038203e-06
chromosomal O 0 7.992929749889299e-05
loci O 0 0.00014463148545473814
linked O 0 5.3200346883386374e-05
to O 0 2.7741587018681457e-06
mental O 1 0.9999518394470215
health O 0 0.01721043698489666
wellness O 1 0.9454498887062073
in O 0 6.932547194082872e-07
relatives O 0 4.7044252937666897e-07
at O 0 6.925502589183452e-07
high O 0 4.511320639721816e-06
risk O 0 1.9564020021789474e-06
for O 0 2.9989050744916312e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 0.05357583239674568
the O 0 8.112304931273684e-05
Old O 0 0.39109185338020325
Order O 0 2.4706125259399414e-05
Amish O 0 0.0001348769583273679
. O 0 4.617215017788112e-05

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 1.0
BPAD B-Disease 1 1.0
; O 1 0.9998107552528381
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 1.3525061149266548e-05
is O 0 7.927552019282302e-07
characterized O 0 5.057780185779848e-07
by O 0 1.491235508410682e-07
episodes O 0 2.1722159999626456e-06
of O 0 0.0012327124131843448
mania B-Disease 1 1.0
and O 0 2.3272768885362893e-05
/ O 1 0.9999024868011475
or O 0 2.577445047791116e-05
hypomania B-Disease 1 0.9946869611740112
interspersed O 0 2.7416888769948855e-05
with O 0 2.5534875476296293e-06
periods O 0 1.185553537652595e-05
of O 0 5.425763811217621e-05
depression B-Disease 1 0.9929574728012085
. O 0 0.00011102764256065711

Compelling O 0 0.00024835957447066903
evidence O 0 1.3085709724691696e-05
supports O 0 1.1405678378650919e-05
a O 0 2.6082118438353064e-06
significant O 0 2.37922267842805e-06
genetic O 0 2.2598628675041255e-06
component O 0 6.987845154071692e-06
in O 0 5.481775247062615e-07
the O 0 2.0364827832963783e-06
susceptibility O 0 3.621220821514726e-05
to O 0 1.1117843314423226e-05
develop O 0 0.00047433716827072203
BPAD B-Disease 1 1.0
. O 0 0.0005742785870097578

To O 0 8.782854820310604e-06
date O 0 4.389417881611735e-06
, O 0 1.2239310080985888e-06
however O 0 5.323364575815503e-07
, O 0 1.1445714562796638e-06
linkage O 0 4.845961029786849e-06
studies O 0 8.747210813453421e-07
have O 0 1.8368835696946917e-07
attempted O 0 1.2959046671312535e-06
only O 0 1.255578467862506e-07
to O 0 2.4298299194924766e-07
identify O 0 6.140890036476776e-07
chromosomal O 0 1.1303739483992103e-05
loci O 0 1.2321395843173377e-05
that O 0 3.0576191534237296e-07
cause O 0 1.126394749917381e-06
or O 0 3.4788311609190714e-07
increase O 0 3.770031753447256e-07
the O 0 1.3833709999744315e-06
risk O 0 3.4094377951987553e-06
of O 0 5.642539235850563e-06
developing O 0 3.0817387596471235e-05
BPAD B-Disease 1 1.0
. O 0 0.0002620158775243908

To O 0 1.3911945643485524e-05
determine O 0 3.3402779990865383e-06
whether O 0 8.470644274893857e-07
there O 0 5.466718562274764e-07
could O 0 4.3778322833532e-07
be O 0 2.493393935765198e-07
protective O 0 2.674449888218078e-06
alleles O 0 4.1404715034332185e-07
that O 0 1.1325187188049313e-07
prevent O 0 4.651936649224808e-07
or O 0 1.908426980889999e-07
reduce O 0 4.1409967366234923e-07
the O 0 2.8005655394736095e-07
risk O 0 3.590506878481392e-07
of O 0 5.184767815080704e-07
developing O 0 1.1301499398541637e-06
BPAD B-Disease 1 1.0
, O 0 3.5329074421497353e-07
similar O 0 7.628261755598942e-08
to O 0 5.2470245037739005e-08
what O 0 9.599533257187431e-08
is O 0 9.610892703904028e-08
observed O 0 8.551415930924122e-08
in O 0 5.920715651086539e-08
other O 0 1.583701276786087e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.0246251804346684e-05
we O 0 4.758037164265261e-07
used O 0 2.102345888488344e-06
mental O 1 0.9705143570899963
health O 0 7.576648204121739e-05
wellness O 1 0.9128819108009338
( O 0 1.1588742836465826e-06
absence O 0 1.3947779962109053e-06
of O 0 1.533069507786422e-06
any O 0 3.1422134725289652e-06
psychiatric B-Disease 1 1.0
disorder I-Disease 1 0.9999996423721313
) O 0 1.7371602325511049e-06
as O 0 7.250918656609429e-07
the O 0 1.1525521586008836e-06
phenotype O 0 1.233871785188967e-06
in O 0 3.0751681379115325e-07
our O 0 5.700350698134571e-07
genome O 0 1.8515160036258749e-06
- O 0 4.515004548011348e-06
wide O 0 6.180304808367509e-06
linkage O 0 9.668718121247366e-06
scan O 0 5.662494913849514e-06
of O 0 1.8879636627389118e-06
several O 0 1.1172239737788914e-06
large O 0 4.926702786178794e-06
multigeneration O 0 0.00012639777560252696
Old O 0 3.345936784171499e-05
Order O 0 3.8133257476147264e-06
Amish O 0 1.005225203698501e-05
pedigrees O 0 8.483356396027375e-06
exhibiting O 0 2.6310585781175178e-06
an O 0 1.0242509915769915e-06
extremely O 0 3.422599320401787e-06
high O 0 1.669366793066729e-05
incidence O 0 0.00013317621778696775
of O 0 0.0003885669575538486
BPAD B-Disease 1 1.0
. O 0 0.000383808248443529

We O 0 2.4874636437743902e-05
have O 0 1.7117702100222232e-06
found O 0 1.3583489817392547e-06
strong O 0 5.891488399356604e-07
evidence O 0 5.054182565800147e-07
for O 0 2.409504702427512e-07
a O 0 1.0745612826212891e-06
locus O 0 1.2404526387399528e-05
on O 0 1.7997665509028593e-06
chromosome O 0 4.8185602281591855e-06
4p O 0 0.00036597566213458776
at O 0 6.090456736274064e-06
D4S2949 O 0 2.4975897758849896e-05
( O 0 1.8562152490630979e-06
maximum O 0 5.006448645872297e-06
GENEHUNTER O 0 0.00051710638217628
- O 0 1.6908172256080434e-05
PLUS O 0 2.713572575885337e-05
nonparametric O 0 2.6107749363291077e-05
linkage O 0 5.482148935698206e-06
score O 0 1.447576096325065e-06
= O 0 8.794067980488762e-07
4 O 0 9.054152201315446e-07
. O 0 2.944718744402053e-07
05 O 0 1.937123670359142e-05
, O 0 8.973212288765353e-07
P O 0 3.4802058053173823e-06
= O 0 5.084941108179919e-07
5 O 0 7.358912057497946e-07
. O 0 1.2239679847425577e-07
22 O 0 4.691817139246268e-07
x O 0 3.125597345388087e-07
10 O 0 4.206471828638314e-07
( O 0 3.1306268510888913e-07
- O 0 1.0876862006625743e-06
4 O 0 1.303761337112519e-06
) O 0 4.928954240313033e-07
; O 0 4.5653462166228564e-07
SIBPAL O 0 0.00010098548955284059
Pempirical O 0 2.8033015041728504e-05
value O 0 1.402574525855016e-06
< O 0 2.771117806332768e-06
3 O 0 8.773770332481945e-07
x O 0 4.5640140911018534e-07
10 O 0 2.683120499114011e-07
( O 0 1.5205111481009226e-07
- O 0 6.769204219381209e-07
5 O 0 4.0009038571042765e-07
) O 0 2.4339300352949067e-07
) O 0 1.3609574978090677e-07
and O 0 1.4160832506604493e-07
suggestive O 0 1.1293030865999754e-06
evidence O 0 3.4185859476565383e-07
for O 0 2.8180014055578795e-07
a O 0 1.3038769566264818e-06
locus O 0 3.341740375617519e-05
on O 0 5.150480319571216e-06
chromosome O 0 1.3217250852903817e-05
4q O 0 0.00016626660362817347
at O 0 9.414520718564745e-06
D4S397 O 0 5.676796718034893e-05
( O 0 2.2738890947948676e-06
maximum O 0 4.8168421926675364e-06
GENEHUNTER O 0 0.0006350384210236371
- O 0 1.946082011272665e-05
PLUS O 0 2.6832563889911398e-05
nonparametric O 0 2.5068773538805544e-05
linkage O 0 4.341641215432901e-06
score O 0 1.7886546856971108e-06
= O 0 1.1255206118221395e-06
3 O 0 1.0821054274856579e-06
. O 0 2.5809274006860505e-07
29 O 0 1.467398078602855e-06
, O 0 5.694819265045226e-07
P O 0 2.8862366434623254e-06
= O 0 4.573970500132418e-07
2 O 0 5.477970717038261e-07
. O 0 1.251109296163122e-07
57 O 0 4.7417930204574077e-07
x O 0 3.094298506312043e-07
10 O 0 2.2940973565255263e-07
( O 0 1.9627582048542536e-07
- O 0 9.773193596629426e-07
3 O 0 1.2853797670686617e-06
) O 0 3.6266138181417773e-07
; O 0 3.322203099287435e-07
SIBPAL O 0 7.744735921733081e-05
Pempirical O 0 1.840778350015171e-05
value O 0 9.078717084776144e-07
< O 0 2.259009534100187e-06
1 O 0 7.173349558797781e-07
x O 0 3.684719160901295e-07
10 O 0 1.934781010959341e-07
( O 0 1.360403416583722e-07
- O 0 4.3775528979494993e-07
3 O 0 5.403946943260962e-07
) O 0 1.0806970607291078e-07
) O 0 1.5009776177521417e-07
that O 0 8.74621193247549e-08
are O 0 1.7744683589171473e-07
linked O 0 2.572807716205716e-06
to O 0 3.041909394596587e-06
mental O 1 0.9996980428695679
health O 0 0.1454324573278427
wellness O 1 0.9996993541717529
. O 0 0.00014161686704028398

These O 0 1.7253918485948816e-05
findings O 0 5.42534280612017e-06
are O 0 3.357955336014129e-07
consistent O 0 6.688835583190667e-07
with O 0 1.3785111718789267e-07
the O 0 4.94124776651006e-07
hypothesis O 0 5.083176120024291e-07
that O 0 5.821102178060755e-08
certain O 0 1.7247978689738375e-07
alleles O 0 3.6206114373271703e-07
could O 0 1.5393942476293887e-07
prevent O 0 4.391501704503753e-07
or O 0 3.2055095289251767e-07
modify O 0 4.923147685076401e-07
the O 0 5.379727667786938e-07
clinical O 0 3.010091177202412e-06
manifestations O 0 1.0370441486884374e-05
of O 0 0.01780862733721733
BPAD B-Disease 1 1.0
and O 0 6.434795977838803e-06
perhaps O 0 2.4011717414396117e-06
other O 0 9.115467491938034e-07
related O 0 0.00038418496842496097
affective B-Disease 1 1.0
disorders I-Disease 1 1.0
. O 1 0.6444867253303528

Segregation O 0 0.3910340368747711
distortion O 1 0.9999388456344604
in O 0 0.0110378572717309
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.6446486711502075

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999990463256836
DM B-Disease 1 1.0
) O 0 0.00014801349607296288
is O 0 4.107629138161428e-06
an O 0 5.147656793269562e-06
autosomal B-Disease 1 0.9963323473930359
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999985694885254
which O 0 6.337454010463262e-07
, O 0 3.544401465660485e-07
in O 0 2.018353200128331e-07
the O 0 3.145560754092003e-07
typical O 0 1.1474633083707886e-06
pedigree O 0 4.781983079737984e-06
, O 0 4.839689609070774e-07
shows O 0 5.332403816282749e-07
a O 0 9.051165079654311e-07
three O 0 1.1365788168404833e-06
generation O 0 1.6421181499026716e-05
anticipation O 0 0.00010375582496635616
cascade O 0 0.002497101668268442
. O 0 8.57771301525645e-05

This O 0 3.397858017706312e-05
results O 0 1.0906572242674883e-05
in O 0 9.649273124523461e-06
infertility B-Disease 1 0.9999833106994629
and O 1 0.9999314546585083
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999921321868896
CDM B-Disease 1 1.0
) O 0 1.3960476508145803e-06
with O 0 2.2624584516961477e-07
the O 0 8.081303803919582e-07
disappearance O 0 6.39436575511354e-06
of O 0 1.952998172782827e-05
DM B-Disease 1 1.0
in O 0 2.7427768145571463e-05
that O 0 1.0571800885372795e-05
pedigree O 0 0.00031998357735574245
. O 0 8.326560782734305e-05

The O 0 4.270264980732463e-05
concept O 0 1.5065266779856756e-05
of O 0 9.516232239548117e-06
segregation O 0 7.392169936792925e-05
distortion O 1 0.9691183567047119
, O 0 2.2081028419052018e-06
where O 0 7.03385921951849e-07
there O 0 2.358317061634807e-07
is O 0 2.2218999617962254e-07
preferential O 0 5.299496592670039e-07
transmission O 0 5.84417477966781e-07
of O 0 5.159168949830928e-07
the O 0 4.5961050432197226e-07
larger O 0 6.255095854612591e-07
allele O 0 6.693020964121388e-07
at O 0 1.3276386425786768e-06
the O 0 3.253014028814505e-06
DM B-Disease 1 1.0
locus O 1 0.6819660663604736
, O 0 8.850117865222273e-07
has O 0 3.845833873583615e-07
been O 0 2.602884308089415e-07
put O 0 6.547799102918361e-07
forward O 0 4.3778950953310414e-07
to O 0 1.9135900686251262e-07
explain O 0 3.8387875633816293e-07
partially O 0 1.328363055108639e-06
the O 0 3.1484239571000217e-07
maintenance O 0 8.182552846847102e-06
of O 0 1.3779560504190158e-05
DM B-Disease 1 1.0
in O 0 5.931684881943511e-06
the O 0 1.3069746273686178e-05
population O 0 8.070835974649526e-06
. O 0 2.4183538698707707e-05

In O 0 2.9522498152800836e-05
a O 0 1.1475375686131883e-05
survey O 0 6.6173688537674025e-06
of O 0 1.1413208085286897e-05
DM B-Disease 1 1.0
in O 0 8.125321983243339e-06
Northern O 0 1.9260971384937875e-05
Ireland O 0 5.266217158350628e-06
, O 0 4.094082669325871e-06
59 O 0 2.9807832106598653e-05
pedigrees O 0 4.296145561966114e-05
were O 0 1.9570534277590923e-05
ascertained O 0 0.00020535393559839576
. O 0 9.500898158876225e-05

Sibships O 0 0.016252297908067703
where O 0 1.109750519390218e-05
the O 0 1.9326321307744365e-06
status O 0 1.2004514928776189e-06
of O 0 6.682943762825744e-07
all O 0 1.6129375524087664e-07
the O 0 3.9992482925299555e-07
members O 0 1.1746954697855472e-07
had O 0 2.9529363132496655e-07
been O 0 1.5865765590206138e-07
identified O 0 1.2734732024455298e-07
were O 0 8.098649573184957e-08
examined O 0 1.8602082718643942e-07
to O 0 7.247421507372565e-08
determine O 0 6.612333436351037e-08
the O 0 1.0046821330433886e-07
transmission O 0 2.0835213376813044e-07
of O 0 3.9312797639468045e-07
the O 0 2.800629545163247e-06
DM B-Disease 1 1.0
expansion O 0 8.819646609481424e-05
from O 0 1.218238935507543e-06
affected O 0 8.460382900921104e-07
parents O 0 5.649499712490069e-07
to O 0 9.980924460251117e-07
their O 0 1.948890030689654e-06
offspring O 0 3.1274717912310734e-05
. O 0 3.1521205528406426e-05

Where O 0 5.28015625604894e-05
the O 0 1.684304152149707e-05
transmitting O 0 0.00011849654401885346
parent O 0 2.2629537852481008e-05
was O 0 4.892049400950782e-05
male O 0 1.2550542123790365e-05
, O 0 1.130729742726544e-05
58 O 0 0.0001262133737327531
. O 0 0.00010427794040879235

3 O 0 4.980398080078885e-05
% O 0 4.545471711026039e-06
of O 0 2.429765572742326e-06
the O 0 2.3675909233134007e-06
offspring O 0 1.2210165323267574e-06
were O 0 4.1337364109494956e-07
affected O 0 3.173159370817302e-07
, O 0 2.0001651535039855e-07
and O 0 8.644926197121094e-08
in O 0 1.4931366365544818e-07
the O 0 3.963927213135321e-07
case O 0 4.50666647111575e-07
of O 0 8.411228122895409e-07
a O 0 2.319582335985615e-06
female O 0 2.1720441054640105e-06
transmitting O 0 2.0969253455405124e-05
parent O 0 3.6863571040157694e-06
, O 0 4.556765361485304e-06
68 O 0 7.569665467599407e-05
. O 0 4.342997635831125e-05

7 O 0 0.00035281124291941524
% O 0 3.561540142982267e-05
were O 0 2.581452099548187e-05
affected O 0 4.007343522971496e-05
. O 0 9.499485167907551e-05

Studies O 0 3.841626676148735e-05
on O 0 1.3882286111766007e-05
meiotic O 0 0.00020919140661135316
drive O 0 3.288929656264372e-05
in O 0 4.947329671267653e-06
DM B-Disease 1 1.0
have O 0 1.1227011782466434e-06
shown O 0 4.54125029136776e-07
increased O 0 3.090848110787192e-07
transmission O 0 5.024309643886227e-07
of O 0 4.1734026012818504e-07
the O 0 4.865216283178597e-07
larger O 0 7.732760423095897e-07
allele O 0 7.402891242236365e-07
at O 0 1.6902503148230608e-06
the O 0 2.8070146527170436e-06
DM B-Disease 1 1.0
locus O 0 0.0010266065364703536
in O 0 4.140011697018053e-06
non O 0 3.6444253055378795e-05
- O 1 0.985509991645813
DM O 1 1.0
heterozygotes O 0 0.0008626130875200033
for O 0 2.8669604944298044e-05
CTGn O 1 0.9771984815597534
. O 0 0.00011995790555374697

This O 0 1.653981234994717e-05
study O 0 5.5795467233110685e-06
provides O 0 1.7072704849852016e-06
further O 0 9.381164431943034e-07
evidence O 0 5.862740977136127e-07
that O 0 2.556513436502428e-07
the O 0 3.3487558539491147e-06
DM B-Disease 1 1.0
expansion O 0 0.015172881074249744
tends O 0 8.764555786910933e-06
to O 0 1.7839595329860458e-06
be O 0 2.3400032205245225e-06
transmitted O 0 9.572449016559403e-06
preferentially O 0 3.642757292254828e-05
. O 0 4.4889358832733706e-05

Diagnosis O 1 0.9997548460960388
of O 1 0.9468424916267395
hemochromatosis B-Disease 1 1.0
. O 0 0.19242368638515472

If O 0 0.0003107295779045671
untreated O 1 0.9999998807907104
, O 0 0.1783323884010315
hemochromatosis B-Disease 1 1.0
can O 0 0.000806241063401103
cause O 1 0.9997064471244812
serious O 1 1.0
illness O 1 0.9997392296791077
and O 0 6.925053526174452e-07
early B-Disease 0 1.0618781516313902e-06
death I-Disease 0 2.6657612579583656e-06
, O 0 3.4193098485957307e-07
but O 0 2.0927552668581484e-07
the O 0 1.2528325896710157e-06
disease O 0 0.006120355799794197
is O 0 6.802403049732675e-07
still O 0 7.28461770904687e-07
substantially O 0 2.090998577841674e-06
under O 0 7.572660706500756e-06
- O 1 0.9995287656784058
diagnosed O 1 0.9906438589096069
. O 0 7.114432810340077e-05

The O 0 7.262737199198455e-05
cornerstone O 0 0.0010353315155953169
of O 0 9.105275239562616e-06
screening O 0 6.141350240795873e-06
and O 0 9.159289788840397e-07
case O 0 1.003044758363103e-06
detection O 0 4.749450454255566e-06
is O 0 5.489376349032682e-07
the O 0 5.23901462656795e-07
measurement O 0 2.9369323328864994e-06
of O 0 2.6048337531392463e-06
serum O 0 1.3373000001593027e-05
transferrin O 0 2.4568136723246425e-05
saturation O 0 1.9771274310187437e-05
and O 0 2.225518983323127e-06
the O 0 5.649581908073742e-06
serum O 0 4.606071161106229e-05
ferritin O 0 0.0002305023226654157
level O 0 6.161198689369485e-05
. O 0 8.38938940432854e-05

Once O 0 9.722010145196691e-05
the O 0 1.4106088201515377e-05
diagnosis O 0 0.00012389635958243161
is O 0 2.745685378613416e-06
suspected O 0 1.874284316727426e-05
, O 0 1.6579278963035904e-06
physicians O 0 2.416943743810407e-06
must O 0 4.0870111206459114e-07
use O 0 5.677666763403977e-07
serum O 0 8.482587873004377e-06
ferritin O 0 9.560827311361209e-05
levels O 0 2.444990514050005e-06
and O 0 1.5752658555356902e-06
hepatic O 1 0.9999998807907104
iron O 1 0.9999418258666992
stores O 0 7.279767942236504e-06
on O 0 3.698304908539285e-06
liver O 1 0.9457561373710632
biopsy O 0 5.137436164659448e-05
specimens O 0 1.8146520233131014e-06
to O 0 3.1308599091062206e-07
assess O 0 1.0607141120999586e-06
patients O 0 3.006637427915848e-07
for O 0 2.2532124432927958e-07
the O 0 1.0454830317030428e-06
presence O 0 2.4327355276909657e-06
of O 0 4.599039311870001e-05
iron B-Disease 1 0.9999996423721313
overload I-Disease 1 0.999602735042572
. O 0 0.00015353632625192404

Liver O 1 1.0
biopsy O 1 0.9827659130096436
is O 0 9.142760063696187e-06
also O 0 1.2916294735987321e-06
used O 0 5.346244051906979e-07
to O 0 3.3469092386440025e-07
establish O 0 6.631638598264544e-07
the O 0 5.442674932965019e-07
presence O 0 7.047873396004434e-07
or O 0 4.537614017863234e-07
absence O 0 1.0864794148801593e-06
of O 0 2.011290234804619e-05
cirrhosis B-Disease 1 1.0
, O 0 3.2969326184684178e-06
which O 0 5.394996946961328e-07
can O 0 2.8362356374600495e-07
affect O 0 3.2568011647526873e-06
prognosis O 1 0.7488057613372803
and O 0 5.890196462132735e-06
management O 0 0.00030669974512420595
. O 0 5.326278187567368e-05

A O 0 6.510598177555948e-05
DNA O 0 8.223145414376631e-06
- O 0 5.54515145267942e-06
based O 0 7.554740477644373e-07
test O 0 1.9659297834095923e-07
for O 0 1.6246224276983412e-07
the O 0 9.204246111949033e-07
HFE O 1 0.9491880536079407
gene O 0 1.2206276096549118e-06
is O 0 4.234146615544887e-07
commercially O 0 5.875771762475779e-07
available O 0 8.020803221597816e-08
, O 0 1.4902629175139737e-07
but O 0 5.4645823865939747e-08
its O 0 8.942203777451141e-08
place O 0 2.654355739650782e-07
in O 0 1.0731299937560834e-07
the O 0 3.069908416364342e-07
diagnosis O 0 5.754409357905388e-06
of O 0 6.324361311271787e-05
hemochromatosis B-Disease 1 1.0
is O 0 6.652155570918694e-05
still O 0 8.111470378935337e-06
being O 0 7.732878657407127e-06
evaluated O 0 1.7519025277579203e-05
. O 0 2.370094443904236e-05

Currently O 0 8.092479401966557e-05
, O 0 5.3391431720228866e-06
the O 0 1.8481571260053897e-06
most O 0 7.689013727940619e-07
useful O 0 5.446470936476544e-07
role O 0 5.323710183802177e-07
for O 0 1.6509999056779634e-07
this O 0 7.328363693659412e-08
test O 0 7.643276944691024e-08
is O 0 9.519525434598108e-08
in O 0 5.738390385090497e-08
the O 0 1.6446165318484418e-07
detection O 0 2.1408588963822694e-06
of O 0 5.945594693912426e-06
hemochromatosis B-Disease 1 1.0
in O 0 1.8347963077758322e-06
the O 0 1.88625574537582e-06
family O 0 7.723518251623318e-07
members O 0 1.9990133637293184e-07
of O 0 5.186211637919769e-07
patients O 0 2.5229201128240675e-07
with O 0 1.390437773807207e-07
a O 0 1.2689927189057926e-06
proven O 0 7.144700248318259e-06
case O 0 1.5322276567530935e-06
of O 0 4.481193172978237e-06
the O 0 3.817271863226779e-05
disease O 1 0.5651219487190247
. O 0 5.0508457206888124e-05

It O 0 2.7566406060941517e-05
is O 0 8.497308044752572e-06
crucial O 0 1.0804124940477777e-05
to O 0 1.1238174010941293e-05
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 0.999967098236084
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 1 0.9998425245285034
because O 0 3.014710637216922e-05
phlebotomy O 1 0.9999996423721313
therapy O 0 0.0021110414527356625
can O 0 1.5994181694622966e-06
avert O 1 0.9534915685653687
serious O 1 1.0
chronic O 1 1.0
disease O 1 1.0
and O 0 1.4015038686920889e-05
can O 0 3.9323370515376155e-07
even O 0 5.819237003379385e-07
lead O 0 1.3952662811789196e-06
to O 0 6.744460279151099e-07
normal O 0 1.988871417779592e-06
life O 0 4.472099590202561e-06
expectancy O 0 9.544426575303078e-06
. O 0 5.141386736795539e-06
. O 0 2.5139588615274988e-05

Prevalence O 0 0.0005514398799277842
of O 0 2.409082298981957e-05
the O 0 1.1051266483264044e-05
I1307K O 0 0.003775190794840455
APC B-Disease 0 0.001026006182655692
gene O 0 2.7238297661824618e-06
variant O 0 2.575085773059982e-06
in O 0 2.997452952513413e-07
Israeli O 0 1.469183530389273e-06
Jews O 0 1.2801120874428307e-06
of O 0 6.896411264278868e-07
differing O 0 3.460301911673014e-07
ethnic O 0 6.836090165052155e-07
origin O 0 5.362527986108034e-07
and O 0 6.377931640599854e-07
risk O 0 1.2190605957584921e-05
for O 0 0.01083005778491497
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00043309174361638725

BACKGROUND O 0 0.0002739049377851188
& O 0 0.00013535030302591622
AIMS O 0 0.00013769033830612898
Israeli O 0 1.5693320165155455e-05
Jews O 0 5.201623935136013e-06
of O 0 1.5036181366667734e-06
European O 0 1.41883708693058e-06
birth O 0 7.594202884320111e-07
, O 0 4.330069316438312e-07
i O 0 6.100706855249882e-07
. O 0 1.2449594066765712e-07
e O 0 3.103102130808111e-07
. O 0 1.1193341009629876e-07
, O 0 3.355278863637068e-07
Ashkenazim O 0 6.910659067216329e-06
, O 0 2.438730462017702e-07
have O 0 8.016596808602117e-08
the O 0 3.916020432370715e-07
highest O 1 0.9992790818214417
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.16217373311519623
of O 0 4.540905592875788e-06
any O 0 9.356415375805227e-07
Israeli O 0 7.3654659900057595e-06
ethnic O 0 9.023851816891693e-06
group O 0 1.9564955437090248e-05
. O 0 2.4987453798530623e-05

The O 0 0.00019965505634900182
I1307K O 0 0.0016122658271342516
APC B-Disease 0 0.002558827633038163
gene O 0 2.3509846869274043e-05
variant O 0 6.911392119945958e-05
was O 0 4.702959267888218e-05
found O 0 2.341134631933528e-06
in O 0 2.2748042738385266e-06
6 O 0 4.128260843572207e-05
. O 0 3.427738192840479e-05

1 O 0 3.8214602682273835e-05
% O 0 2.3655213681195164e-06
of O 0 2.0115060124226147e-06
American O 0 2.9444170195347397e-06
Jews O 0 2.029383267654339e-06
, O 0 3.050093653200747e-07
28 O 0 6.942113941477146e-07
% O 0 2.4513360585842747e-07
of O 0 4.1920631588254764e-07
their O 0 6.593259627152293e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.6171719835256226e-05
, O 0 4.41309822463154e-07
but O 0 1.0616214041192507e-07
not O 0 8.052394662172446e-08
in O 0 2.5167344119836343e-07
non O 0 3.643687932708417e-06
- O 0 8.117706602206454e-05
Jews O 0 3.2516487408429384e-05
. O 0 3.144956281175837e-05

We O 0 4.016062666778453e-05
assessed O 0 5.547188993659802e-05
the O 0 8.84267774381442e-06
I1307K O 0 0.0001198230020236224
prevalence O 0 1.6585619960096665e-05
in O 0 1.0549326816544635e-06
Israeli O 0 2.5633346467657248e-06
Jews O 0 1.1517500979607576e-06
of O 0 5.365852189243014e-07
differing O 0 2.3257614145677508e-07
ethnic O 0 6.850395379842666e-07
origin O 0 3.753894475266861e-07
and O 0 4.925993835058762e-07
risk O 0 8.366192560060881e-06
for O 0 0.0012366264127194881
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0005238932790234685

METHODS O 0 7.400393951684237e-05
DNA O 0 9.194698577630334e-06
samples O 0 1.377312855765922e-06
from O 0 6.34028879176185e-07
500 O 0 2.152308525182889e-06
unrelated O 0 2.366103444728651e-06
Jews O 0 8.956335477705579e-07
of O 0 5.343731004359142e-07
European O 0 6.964580734347692e-07
or O 0 3.2191547916227137e-07
non O 0 8.079608164734964e-07
- O 0 1.7621133565626224e-06
European O 0 4.5402629211821477e-07
origin O 0 1.0807156058945111e-07
, O 0 5.151832738192752e-08
with O 0 1.9138960638542812e-08
or O 0 6.680650699308899e-08
without O 0 5.491811805313773e-08
a O 0 2.679803685623483e-07
personal O 0 9.623399819247425e-07
and O 0 3.6294304095463303e-07
/ O 0 5.592699017142877e-05
or O 0 5.086376404506154e-07
family O 0 4.356612350875366e-07
history O 0 6.990245537963347e-07
of O 0 1.5145195675358991e-06
neoplasia B-Disease 1 0.9999585151672363
, O 0 7.308751150958415e-07
were O 0 2.652199952990486e-07
examined O 0 4.3156569518032484e-07
for O 0 1.6539183889108244e-07
the O 0 4.929377155349357e-07
I1307K O 0 1.1910689863725565e-05
variant O 0 1.2269134685993777e-06
by O 0 1.754074361315361e-07
the O 0 4.02665705223626e-07
allele O 0 8.049721031966328e-07
- O 0 2.4693940758879762e-06
specific O 0 4.900830958831648e-07
oligonucleotide O 0 1.8370850739302114e-05
( O 0 5.28106420460972e-06
ASO O 1 0.9675514101982117
) O 0 1.6228605090873316e-05
method O 0 1.900770075735636e-05
. O 0 3.72610375052318e-05

RESULTS O 0 6.850774661870673e-05
In O 0 6.254933396121487e-06
persons O 0 1.8762857507681474e-06
at O 0 2.6193417852482526e-06
average O 0 2.3787304144207155e-06
risk O 0 2.55314671449014e-06
for O 0 8.409115253016353e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.194466550368816e-06
I1307K O 0 0.0006011103978380561
was O 0 9.028844942804426e-06
found O 0 1.1858336392833735e-06
in O 0 1.2005374401269364e-06
5 O 0 1.9177650756319053e-05
. O 0 2.9722137696808204e-05

0 O 0 4.51593441539444e-05
% O 0 6.99979136697948e-06
of O 0 4.828118562727468e-06
120 O 0 1.2966826943738852e-05
European O 0 6.917199698364129e-06
and O 0 5.770202733401675e-06
1 O 0 7.424299110425636e-05
. O 0 5.363567834137939e-05

6 O 0 5.033776324125938e-05
% O 0 5.1321085265954025e-06
of O 0 3.564805865607923e-06
188 O 0 8.496303053107113e-06
non O 0 4.210780844005058e-06
- O 0 1.3035192750976421e-05
European O 0 3.266699195592082e-06
Jews O 0 3.4541997138148872e-06
( O 0 1.5190167914624908e-06
P O 0 1.0782840035972185e-05
= O 0 1.8190999071521219e-06
0 O 0 1.7345463447782095e-06
. O 0 1.5852257320148055e-06
08 O 0 6.995857256697491e-05
) O 0 1.8574335626908578e-05
. O 0 5.27559568581637e-05

It O 0 4.319825166021474e-05
occurred O 0 3.734136407729238e-05
in O 0 7.6274700404610485e-06
15 O 0 4.33775749115739e-05
. O 0 9.731268073664978e-05

4 O 0 5.840889934916049e-05
% O 0 5.643755230266834e-06
of O 0 3.7430093016155297e-06
52 O 0 7.65100139688002e-06
Ashkenazi O 0 2.930924529209733e-05
Israelis O 0 4.41003248852212e-06
with O 0 8.606080541539995e-07
familial O 1 0.9999881982803345
cancer B-Disease 1 0.9999998807907104
( O 0 3.1750773814565036e-06
P O 0 1.6658710592309944e-05
= O 0 7.509723900511744e-07
0 O 0 4.3282281581014104e-07
. O 0 1.5531702501903055e-07
02 O 0 8.811379302642308e-06
) O 0 1.374837665935047e-07
and O 0 1.213406903843861e-07
was O 0 1.098886173167557e-06
not O 0 1.1465188975989804e-07
detected O 0 2.8322648404355277e-07
in O 0 1.0621156576462454e-07
51 O 0 1.135155343945371e-06
non O 0 8.039394856496074e-07
- O 0 3.707454652612796e-06
European O 0 9.584656481820275e-07
Jews O 0 1.5605153294018237e-06
at O 0 4.16883494835929e-06
increased O 0 8.805146535451058e-06
cancer B-Disease 1 0.9323044419288635
risk O 0 4.215939043206163e-05
. O 0 4.989420631318353e-05

Colorectal B-Disease 1 1.0
neoplasia I-Disease 1 1.0
occurred O 0 0.0002929522015620023
personally O 0 0.00014886970166116953
or O 0 4.083787644049153e-06
in O 0 8.364544896721782e-07
the O 0 8.146395202857093e-07
families O 0 1.2800434490145562e-07
of O 0 4.2463022964511765e-07
13 O 0 8.507294069204363e-07
of O 0 9.515039778307255e-07
20 O 0 1.9160092961101327e-06
Ashkenazi O 0 8.982408871816006e-06
I1307K O 0 1.1826863556052558e-05
carriers O 0 3.325721706914919e-07
, O 0 1.409500072213632e-07
8 O 0 4.974330067852861e-07
of O 0 4.99630971262377e-07
whom O 0 5.274613954497909e-07
also O 0 3.213762340692483e-07
had O 0 6.602862185900449e-07
a O 0 8.634409596197656e-07
personal O 0 3.254354624004918e-06
or O 0 1.7440773945054389e-06
family O 0 2.0299444258853327e-06
history O 0 4.229370460961945e-06
of O 0 1.2696930753008928e-05
noncolonic O 1 0.99992835521698
neoplasia B-Disease 1 0.9999985694885254
. O 0 0.0001408277457812801

CONCLUSIONS O 0 0.00047636122326366603
The O 0 9.781963308341801e-05
I1307K O 0 0.03486700356006622
APC O 1 0.6389350891113281
variant O 0 0.0002432815672364086
may O 0 2.5319470751128392e-06
represent O 0 6.483487027253432e-07
a O 0 9.008022630041523e-07
susceptibility O 0 4.2834058149310295e-06
gene O 0 9.299278644903097e-07
for O 0 2.3649529339309083e-06
colorectal B-Disease 1 1.0
, I-Disease 0 3.838641714537516e-05
or I-Disease 0 6.229818723113567e-07
other I-Disease 0 2.167029578004076e-07
, I-Disease 0 6.437585966523329e-07
cancers I-Disease 0 0.00011597074626479298
in O 0 5.299309577821987e-07
Ashkenazi O 0 0.0004489654384087771
Jews O 0 2.9822601845808094e-06
, O 0 5.099111035633541e-07
and O 0 7.460611186616006e-07
partially O 0 5.950626018602634e-06
explains O 0 1.692169576017477e-06
the O 0 5.081727181277529e-07
higher O 0 1.0524154276936315e-06
incidence O 0 7.524946340708993e-06
of O 0 0.24162077903747559
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.061483873054385e-06
European O 0 1.4230789020075463e-05
Israelis O 0 2.832981954270508e-05
. O 0 3.80783349100966e-05

Systematic O 0 0.00010494270827621222
analysis O 0 9.755141036293935e-06
of O 0 1.4978738363424782e-05
coproporphyrinogen O 1 0.99601811170578
oxidase O 0 0.00042799682705663145
gene O 0 2.7895037419511937e-05
defects O 0 0.012203498743474483
in O 0 7.600371191074373e-06
hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 1.0
and O 0 0.0001235363306477666
mutation O 0 6.694538024021313e-05
update O 0 0.00011201374582014978
. O 0 6.894047692185268e-05

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999997615814209
( O 0 0.058242183178663254
HC B-Disease 1 1.0
) O 0 0.00030744686955586076
is O 0 8.460685421596281e-06
an O 0 1.5481111404369585e-05
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.9960373044013977
autosomal O 1 0.9999977350234985
dominant O 1 0.9999994039535522
inheritance O 1 0.990988552570343
caused O 0 0.0007049330160953104
by O 0 1.0519097486394458e-06
deficient B-Disease 0 4.8625886847730726e-05
activity I-Disease 0 1.4417839793168241e-06
of I-Disease 0 2.5470860691712005e-06
coproporphyrinogen I-Disease 1 0.978400468826294
III I-Disease 1 1.0
oxidase I-Disease 0 6.323733396129683e-05
( O 0 6.780538114981027e-06
CPO O 1 0.6064383387565613
) O 0 2.3589122065459378e-05
. O 0 7.374089182121679e-05

Clinical O 1 0.8903728723526001
manifestations O 1 0.9094564318656921
of O 1 0.7209041714668274
the O 1 0.9735243320465088
disease O 1 0.9999909400939941
are O 0 5.192690082367335e-07
characterized O 0 3.486042032818659e-06
by O 0 5.52239896478568e-07
acute O 1 0.9999892711639404
attacks O 0 0.01913682371377945
of O 1 0.9999998807907104
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 2.444907840981614e-05
precipitated O 0 5.415337727754377e-05
by O 0 6.055955736883334e-07
drugs O 0 1.3985595614940394e-06
, O 0 8.847299568515155e-07
fasting O 0 2.633086978676147e-06
, O 0 1.9037694301005104e-06
cyclical O 0 0.010893886908888817
hormonal O 0 0.0003306349681224674
changes O 0 3.698386080941418e-06
, O 0 8.200356205634307e-06
or O 0 7.65500299166888e-05
infectious B-Disease 1 1.0
diseases I-Disease 1 0.9999979734420776
. O 0 0.00022148163407109678

Skin O 1 1.0
photosensitivity O 1 1.0
may O 0 4.7623841965105385e-05
also O 0 1.118108684750041e-05
be O 0 6.681314062007004e-06
present O 0 1.960129702638369e-05
. O 0 7.822105544619262e-05

The O 0 2.6256988348904997e-05
seven O 0 1.2268150385352783e-05
exons O 0 2.5713463401189074e-05
, O 0 3.33834486809792e-06
the O 0 3.2063214803201845e-06
exon O 0 3.969623867305927e-05
/ O 0 3.809162444667891e-05
intron O 0 7.061435462674126e-05
boundaries O 0 1.407051968271844e-06
and O 0 4.477014670101198e-07
part O 0 8.301826142087521e-07
of O 0 1.0521124522711034e-06
3 O 0 2.1752712200395763e-06
noncoding O 0 7.077549526002258e-06
sequence O 0 7.373608355010219e-07
of O 0 7.1314542537948e-07
the O 0 1.0056002111014095e-06
CPO O 0 0.00014017664943821728
gene O 0 9.057537226908607e-07
were O 0 4.49124200940787e-07
systematically O 0 1.2721892517220112e-06
analyzed O 0 6.157956136121356e-07
by O 0 1.464474763679391e-07
an O 0 4.6510496076734853e-07
exon O 0 1.1648592590063345e-05
- O 0 5.055868314229883e-06
by O 0 7.653560487597133e-07
- O 0 1.1761132554966025e-05
exon O 0 4.616748628905043e-05
denaturing O 0 7.475043094018474e-05
gradient O 0 3.084534910158254e-05
gel O 0 4.065376924700104e-05
electrophoresis O 0 2.113339360221289e-05
( O 0 4.4165144572616555e-06
DGGE O 1 0.5310792922973633
) O 0 1.4788026874157367e-06
strategy O 0 1.765083652571775e-06
followed O 0 3.921544191598514e-07
by O 0 1.0074261780346205e-07
direct O 0 2.1166506769532134e-07
sequencing O 0 7.79448612320266e-07
in O 0 2.1272465744459623e-07
seven O 0 5.607138859886618e-07
unrelated O 0 1.8732821445155423e-06
heterozygous O 0 3.152677436446538e-06
HC B-Disease 1 1.0
patients O 0 2.4847445274644997e-06
from O 0 7.155591106311476e-07
France O 0 8.330715900228824e-06
, O 0 9.662225011197734e-07
Holland O 0 9.838394362304825e-06
, O 0 1.3407197911874391e-06
and O 0 1.3044665365669061e-06
Czech O 0 0.0001331640378339216
Republic O 0 0.00012506102211773396
. O 0 0.00010926345566986129

Seven O 0 9.555721771903336e-05
novel O 0 6.36338081676513e-05
mutations O 0 4.860253739025211e-06
and O 0 1.3194580787967425e-06
two O 0 4.942218083670014e-07
new O 0 1.6097040997919976e-06
polymorphisms O 0 8.156134754244704e-06
were O 0 6.8052459027967416e-06
detected O 0 2.987242623930797e-05
. O 0 4.058458944200538e-05

Among O 0 2.9090986572555266e-05
these O 0 1.3697837175641325e-06
mutations O 0 1.2410823728714604e-06
two O 0 4.3706197061510466e-07
are O 0 2.245764108010917e-07
missense O 0 8.925613656174392e-06
( O 0 1.9695321498147678e-06
G197W O 0 0.00023058518127072603
, O 0 1.5453633750439622e-06
W427R O 0 2.789998507068958e-05
) O 0 5.902280690861517e-07
, O 0 2.4189466785173863e-07
two O 0 9.252265442682983e-08
are O 0 1.052419946745431e-07
nonsense O 0 4.03845842811279e-06
( O 0 6.73944498430501e-07
Q306X O 0 3.417098196223378e-05
, O 0 1.1059512416977668e-06
Q385X O 0 1.1530476513144094e-05
) O 0 6.630443181165901e-07
, O 0 3.809393263054517e-07
two O 0 8.278741603362505e-08
are O 0 5.3527585919255216e-08
small O 0 4.817834451387171e-07
deletions O 0 3.772531044887728e-06
( O 0 1.5923243381621432e-06
662de14bp O 0 3.161199492751621e-05
; O 0 1.1076464261350338e-06
1168del3bp O 0 2.2200660168891773e-05
removing O 0 3.3445683129684767e-06
a O 0 7.888802429079078e-07
glycine O 0 1.6845294794620713e-06
at O 0 1.0047872365248622e-06
position O 0 7.574153642053716e-07
390 O 0 2.595935711724451e-06
) O 0 4.92989443046099e-07
, O 0 2.9754320962638303e-07
and O 0 1.9580188848067337e-07
one O 0 2.0419930990556168e-07
is O 0 1.275740260098246e-07
a O 0 3.781266002533812e-07
splicing O 0 1.9853844150929945e-06
mutation O 0 9.904781563818688e-07
( O 0 1.5385355709440773e-06
IVS1 O 1 0.7254374623298645
- O 0 2.725780723267235e-05
15c O 0 6.349947943817824e-05
- O 0 1.353238712908933e-05
- O 0 1.063044874172192e-05
> O 0 6.309626314759953e-06
g O 0 1.714508471195586e-06
) O 0 4.328533691477787e-07
which O 0 2.0749055806845718e-07
creates O 0 1.1756205822166521e-06
a O 0 8.853140229803103e-07
new O 0 1.5153099184317398e-06
acceptor O 0 7.484894013032317e-06
splice O 0 7.652477506780997e-05
site O 0 5.7683599152369425e-05
. O 0 5.985064126434736e-05

The O 0 0.00010260230919811875
pathological O 0 0.00023475589114241302
significance O 0 1.6352860257029533e-05
of O 0 5.667070581694134e-06
the O 0 2.840443812601734e-06
point O 0 1.1054450624214951e-05
mutations O 0 1.1975059805990895e-06
G197W O 0 1.7443671822547913e-05
, O 0 7.14272573532071e-07
W427R O 0 1.8067956261802465e-05
, O 0 6.334614113256976e-07
and O 0 1.960537616696456e-07
the O 0 2.2037366420590843e-07
in O 0 2.4416718247266544e-07
- O 0 3.6077624372410355e-06
frame O 0 4.27066333941184e-06
deletion O 0 3.265584382461384e-06
390delGly O 0 9.656987458583899e-06
were O 0 3.3209994398930576e-07
assessed O 0 1.082297330867732e-06
by O 0 1.126079496316379e-07
their O 0 1.1139073308186198e-07
respective O 0 3.220419841909461e-07
expression O 0 4.664682364818873e-07
in O 0 2.2593081894228817e-07
a O 0 7.704868494329276e-07
prokaryotic O 0 2.2924753011466237e-06
system O 0 9.616436500436976e-07
using O 0 8.800494697425165e-07
site O 0 7.4816325650317594e-06
- O 0 1.3763671631750185e-05
directed O 0 2.3526914446847513e-05
mutagenesis O 0 0.0004962016246281564
. O 0 8.432540198555216e-05

These O 0 2.6999330657417886e-05
mutations O 0 9.096768735616934e-06
resulted O 0 4.162109235039679e-06
in O 0 8.593598295192351e-07
the O 0 1.4964911088100052e-06
absence O 0 2.232723318229546e-06
or O 0 7.150891292440065e-07
a O 0 1.6773317383922404e-06
dramatic O 0 6.562930138898082e-06
decrease O 0 6.317495717667043e-06
of O 0 1.5332303519244306e-05
CPO O 1 0.9995571970939636
activity O 0 5.9654292272171006e-05
. O 0 5.937856622040272e-05

The O 0 3.490112430881709e-05
two O 0 3.5472933177516097e-06
polymorphisms O 0 9.204419257002883e-06
were O 0 1.587389192536648e-06
localized O 0 6.527961431856966e-06
in O 0 8.79081426319317e-07
noncoding O 0 1.4112990356807131e-05
part O 0 3.568881083992892e-06
of O 0 1.2777337587976945e-06
the O 0 6.800936489526066e-07
gene O 0 3.74381215806352e-07
1 O 0 1.6367382613680093e-06
) O 0 3.646347010999307e-07
a O 0 4.579339076826727e-07
C O 0 4.69918450107798e-06
/ O 0 5.266554126137635e-06
G O 0 6.167721949168481e-06
polymorphism O 0 5.436750711851346e-07
in O 0 3.1836171388022194e-07
the O 0 1.2750898576996406e-06
promotor O 0 0.043843939900398254
region O 0 3.0768919714319054e-06
, O 0 8.843587693263544e-07
142 O 0 3.453501449257601e-06
bp O 0 3.5495436350174714e-06
upstream O 0 2.4448272597510368e-06
from O 0 3.3901130791491596e-07
the O 0 3.2031564956014336e-07
transcriptional O 0 2.1669316083716694e-06
initiation O 0 3.948668108932907e-06
site O 0 2.9871418973925756e-06
( O 0 1.0498872597963782e-06
- O 0 6.249304988159565e-06
142C O 0 1.9289718693471514e-05
/ O 0 7.751242264930625e-06
G O 0 7.4449994826863986e-06
) O 0 3.466299745014112e-07
, O 0 2.063058985868338e-07
and O 0 1.1714399761331151e-07
2 O 0 8.837668588057568e-07
) O 0 3.7217589010651864e-07
a O 0 4.11171868108795e-07
6 O 0 1.5265685533449869e-06
bp O 0 1.6460364804515848e-06
deletion O 0 9.354880603495985e-07
polymorphism O 0 3.7565587263088673e-07
in O 0 1.6418725579114835e-07
the O 0 2.790588951029349e-07
3 O 0 6.45075601823919e-07
noncoding O 0 5.086486453365069e-06
part O 0 9.507674008091271e-07
of O 0 8.810151825855428e-07
the O 0 8.74801173722517e-07
CPO O 0 0.0026898060459643602
gene O 0 8.039977501539397e-07
, O 0 5.481346079250216e-07
574 O 0 6.8691388150909916e-06
bp O 0 4.597700808517402e-06
downstream O 0 1.6903599089346244e-06
of O 0 7.855274475332408e-07
the O 0 4.3631814605760155e-07
last O 0 6.737286071256676e-07
base O 0 1.8931885961137596e-06
of O 0 8.027657258935506e-07
the O 0 9.078119092009729e-07
normal O 0 8.088319987109571e-07
termination O 0 2.1347445908759255e-06
codon O 0 7.606215149280615e-06
( O 0 2.8168105927761644e-06
+ O 0 1.4172564078762662e-05
574 O 0 7.002385973464698e-05
delATTCTT O 0 0.0003409037890378386
) O 0 3.6347693821880966e-05
. O 0 8.570845238864422e-05

Five O 0 9.729838347993791e-05
intragenic O 0 0.2300114631652832
dimorphisms O 0 0.09095436334609985
are O 0 2.166538934034179e-06
now O 0 1.8691313243834884e-06
well O 0 6.732777251272637e-07
characterized O 0 1.305004047935654e-06
and O 0 3.957891294703586e-07
the O 0 9.430015097677824e-07
high O 0 3.1884710551821627e-06
degree O 0 2.3229295038618147e-06
of O 0 2.228577386631514e-06
allelic O 0 5.845431223860942e-05
heterogeneity O 0 4.7006058593979105e-05
in O 0 2.170141215174226e-06
HC B-Disease 1 1.0
is O 0 5.768981282017194e-06
demonstrated O 0 7.881808414822444e-07
with O 0 1.1298595126163491e-07
seven O 0 2.848946678568609e-07
new O 0 1.318470168598651e-07
different O 0 4.283852916842079e-08
mutations O 0 1.0124905003294771e-07
making O 0 1.6458466234325897e-07
a O 0 3.123696217244287e-07
total O 0 3.198254603375972e-07
of O 0 1.0148594355996465e-06
nineteen O 0 1.5844256267882884e-05
CPO O 1 0.9999974966049194
gene B-Disease 0 2.3196720576379448e-05
defects I-Disease 0 0.018651112914085388
reported O 0 2.1392916096374393e-06
so O 0 9.835465561991441e-07
far O 0 2.194336275351816e-06
. O 0 4.696375071944203e-06
. O 0 3.410183489904739e-05

Coincidence O 0 0.00017261005996260792
of O 0 2.2099857233115472e-05
two O 0 3.791538802033756e-06
novel O 0 3.336206282256171e-05
arylsulfatase O 0 0.0002576273982413113
A O 0 2.076317832688801e-05
alleles O 0 2.2905826426722342e-06
and O 0 9.456970246901619e-07
mutation O 0 2.601725327622262e-06
459 O 0 3.9972557715373114e-05
+ O 0 2.7677329853759147e-05
1G O 1 0.9882466197013855
> O 0 1.7377786207362078e-05
A O 0 8.536114364687819e-06
within O 0 4.1905758507709834e-07
a O 0 5.026447524869582e-07
family O 0 6.7107640688846e-07
with O 0 8.478977520098852e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 5.3503463277593255e-06
molecular O 0 6.399929588951636e-06
basis O 0 2.753197577476385e-06
of O 0 5.796699497295776e-06
phenotypic O 0 9.244545071851462e-05
heterogeneity O 0 0.002629090566188097
. O 0 0.00017678760923445225

In O 0 1.708166928438004e-05
a O 0 6.7034993662673514e-06
family O 0 2.780780505418079e-06
with O 0 4.56334362297639e-07
three O 0 7.190801625256427e-07
siblings O 0 2.758872142294422e-06
, O 0 7.039315619294939e-07
one O 0 6.956813649594551e-07
developed O 0 6.709689159833943e-07
classical O 0 5.091703769721789e-06
late O 0 7.909542546258308e-06
infantile O 1 0.9998024106025696
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.003217332763597369
MLD B-Disease 1 1.0
) O 0 5.427775704447413e-06
, O 0 1.4643269423686434e-06
fatal O 0 7.719660970906261e-06
at O 0 1.1494522595967283e-06
age O 0 6.120671400822175e-07
5 O 0 5.826772735417762e-07
years O 0 2.3281093319837964e-07
, O 0 1.6018653070659639e-07
with O 0 1.1324593174322217e-07
deficient O 0 1.6080646673799492e-05
arylsulfatase O 0 0.13975712656974792
A O 0 0.0001389602548442781
( O 0 4.137359155720333e-06
ARSA O 1 0.9996570348739624
) O 0 1.256842779184808e-06
activity O 0 8.582296118220256e-07
and O 0 6.056313850422157e-07
increased O 0 2.3764471279719146e-06
galactosylsulfatide O 0 0.01307610608637333
( O 0 2.049464819720015e-05
GS O 1 0.9999998807907104
) O 0 2.049857721431181e-05
excretion O 0 0.00016671458433847874
. O 0 7.412760896841064e-05

The O 0 2.558741471148096e-05
two O 0 1.7445364619561587e-06
other O 0 1.19267133413814e-06
siblings O 0 7.082855972839752e-06
, O 0 2.0278394003980793e-06
apparently O 0 2.919863391070976e-06
healthy O 0 9.210321536556876e-07
at O 0 7.940672048789565e-07
12 O 0 4.190176525753486e-07
( O 0 2.482735226294608e-07
1 O 0 9.075366733668488e-07
/ O 0 9.100908755499404e-07
2 O 0 7.442021683345956e-07
) O 0 1.5634542194220558e-07
and O 0 8.514373917023477e-08
15 O 0 2.406326586879004e-07
years O 0 1.285956869878646e-07
, O 0 1.0846082432180992e-07
respectively O 0 2.814547599427897e-07
, O 0 1.577418515807949e-07
and O 0 8.345597990455644e-08
their O 0 6.269357299970579e-08
father O 0 6.407219075299508e-07
, O 0 4.001731781499984e-07
apparently O 0 7.908937504907954e-07
healthy O 0 2.4942406184891297e-07
as O 0 1.5950220699778583e-07
well O 0 2.78632910521992e-07
, O 0 5.237071150077099e-07
presented O 0 3.264681481596199e-06
ARSA O 1 0.9999730587005615
and O 0 6.311522156465799e-06
GS O 1 0.9999762773513794
values O 0 2.487935944373021e-06
within O 0 6.528271114802919e-07
the O 0 1.351889864054101e-06
range O 0 7.97566826804541e-06
of O 0 3.0368628358701244e-05
MLD B-Disease 1 1.0
patients O 0 0.0002624872431624681
. O 0 0.00010542755626374856

Mutation O 0 4.0539252950111404e-05
screening O 0 1.0779302101582289e-05
and O 0 1.0243858241665293e-06
sequence O 0 7.053561716929835e-07
analysis O 0 4.971916496288031e-07
disclosed O 0 1.8779900301524322e-06
the O 0 7.468028684343153e-07
involvement O 0 1.9478754893498262e-06
of O 0 7.842130571589223e-07
three O 0 3.027399486654758e-07
different O 0 3.561020491815725e-07
ARSA O 1 0.9995802044868469
mutations O 0 1.11237295641331e-06
being O 0 6.629064728258527e-07
the O 0 5.030466354583041e-07
molecular O 0 1.7281203099628328e-06
basis O 0 1.1384012168491608e-06
of O 0 5.985880761727458e-06
intrafamilial O 0 0.000665363622829318
phenotypic O 0 0.00020394044986460358
heterogeneity O 0 0.00292419595643878
. O 0 0.0001327755453530699

The O 0 0.0001272348454222083
late O 0 0.00010112280142493546
infantile O 1 0.9988793730735779
patient O 0 0.00020689202938228846
inherited O 0 0.001614950830116868
from O 0 2.5666026886028703e-06
his O 0 7.607506177009782e-06
mother O 0 4.375696789793437e-06
the O 0 1.1083332083217101e-06
frequent O 0 1.5628610299245338e-06
0 O 0 2.844871005436289e-06
- O 0 8.849409823596943e-06
type O 0 4.2672922972997185e-06
mutation O 0 1.9452061224001227e-06
459 O 0 9.26774100662442e-06
+ O 0 7.095037744875299e-06
1G O 0 0.00034778667031787336
> O 0 4.304979029257083e-06
A O 0 2.3740822143736295e-06
, O 0 2.496658453310374e-07
and O 0 6.38630623939207e-08
from O 0 1.2053402542733238e-07
his O 0 6.073098006709188e-07
father O 0 1.1512031505844789e-06
a O 0 7.968475301822764e-07
novel O 0 3.31871797243366e-06
, O 0 7.806463031556632e-07
single O 0 1.321774220741645e-06
basepair O 0 6.346486043184996e-05
microdeletion O 0 6.462202145485207e-05
of O 0 3.307504357508151e-06
guanine O 0 8.234792403527535e-06
at O 0 2.5788704078877345e-06
nucleotide O 0 1.1358636129443767e-06
7 O 0 2.3909096853458323e-06
in O 0 5.915850351811969e-07
exon O 0 1.6695721569703892e-05
1 O 0 9.448718628846109e-06
( O 0 7.383075626421487e-06
7delG O 0 0.00019071548013016582
) O 0 2.2089532649260946e-05
. O 0 3.869909778586589e-05

The O 0 6.806747114751488e-05
two O 0 1.3873153875465505e-05
clinically O 0 0.0005005209241062403
unaffected O 0 4.1405386582482606e-05
siblings O 0 7.3077376328001264e-06
carried O 0 3.1831298201723257e-06
the O 0 2.5553877094353084e-06
maternal O 0 5.5952555158000905e-06
mutation O 0 3.0227254228520906e-06
459 O 0 2.6734689527074806e-05
+ O 0 1.1791871656896546e-05
1G O 0 0.11198250949382782
> O 0 7.652753083675634e-06
A O 0 6.2123267525748815e-06
and O 0 3.3928330367416493e-07
, O 0 2.239839318463055e-07
on O 0 2.3445750230166595e-07
their O 0 7.842461968721182e-08
paternal O 0 1.0651115189830307e-06
allele O 0 8.950751180236693e-07
, O 0 4.2284483470211853e-07
a O 0 1.0455438541612239e-06
novel O 0 3.2399550491390983e-06
cytosine O 0 3.3153266940644244e-06
to O 0 4.5095902123648557e-07
thymidine O 0 5.897075880056946e-06
transition O 0 1.5872075209699688e-06
at O 0 2.6893505946645746e-06
nucleotide O 0 3.3963890473387437e-06
2435 O 0 7.325979822780937e-05
in O 0 9.825949973674142e-07
exon O 0 1.261433044419391e-05
8 O 0 1.959897872438887e-06
, O 0 5.752833658334566e-07
resulting O 0 4.941572342431755e-07
in O 0 1.9022870390017488e-07
substitution O 0 1.0985015705955448e-06
of O 0 1.4782469861529535e-06
alanine O 0 1.17608633445343e-05
464 O 0 2.759236485871952e-05
by O 0 3.186732101312373e-06
valine O 0 0.0002860085805878043
( O 0 1.7072159607778303e-05
A464V O 0 0.0006372647476382554
) O 0 4.1915016481652856e-05
. O 0 7.813866250216961e-05

The O 0 0.00011632227688096464
fathers O 0 5.484830035129562e-05
genotype O 0 4.190042818663642e-05
thus O 0 9.515806596027687e-06
was O 0 5.575811883318238e-05
7delG O 0 0.001492351177148521
/ O 1 0.7236893773078918
A464V O 0 0.15581579506397247
. O 0 0.00031070466502569616

Mutation O 0 0.00019114876340609044
A464V O 0 0.0010719747515395284
was O 0 2.495461558282841e-05
not O 0 5.88946022617165e-07
found O 0 4.847209993386059e-07
in O 0 3.6044292528458755e-07
18 O 0 4.430422450241167e-06
unrelated O 0 0.0005440830136649311
MLD B-Disease 1 1.0
patients O 0 2.3249520381796174e-05
and O 0 3.888940682372777e-06
50 O 0 2.2144411559565924e-05
controls O 0 0.00013868306996300817
. O 0 7.306862971745431e-05

A464V O 0 0.003391130128875375
, O 0 3.1463241612073034e-05
although O 0 7.76441902416991e-06
clearly O 0 6.877994110254804e-06
modifying O 0 2.6132012862944975e-05
ARSA O 1 1.0
and O 0 4.5631029934156686e-05
GS O 1 1.0
levels O 0 1.691231591394171e-05
, O 0 2.7612200028670486e-06
apparently O 0 4.727109626401216e-06
bears O 0 8.188149877241813e-06
little O 0 4.171001819486264e-06
significance O 0 6.2398594309343025e-06
for O 0 8.383918839172111e-07
clinical O 0 1.956476626219228e-05
manifestation O 0 0.00041393929859623313
of O 0 0.0036038958933204412
MLD B-Disease 1 1.0
, O 0 9.396723726240452e-06
mimicking O 0 3.4053380659315735e-05
the O 0 9.113006854022387e-06
frequent O 0 3.922135874745436e-05
ARSA O 1 0.9999690055847168
pseudodeficiency O 1 0.6438544988632202
allele O 0 0.00017254224803764373
. O 0 0.00010218870738754049

Our O 0 4.078393249073997e-05
results O 0 4.418725893629016e-06
demonstrate O 0 2.616433448565658e-06
that O 0 2.418506142021215e-07
in O 0 2.155840803652609e-07
certain O 0 2.983461513395014e-07
genetic O 0 1.608249704077025e-06
conditions O 0 4.132154117542086e-06
MLD B-Disease 1 1.0
- O 1 0.9965516328811646
like O 0 4.498295675148256e-05
ARSA O 1 1.0
and O 0 5.402197530202102e-06
GS O 1 1.0
values O 0 1.013450287246087e-06
need O 0 3.614377135363611e-07
not O 0 9.447209947666124e-08
be O 0 7.860912631940664e-08
paralleled O 0 8.943899274527212e-07
by O 0 3.081647435010382e-07
clinical O 1 0.8390029072761536
disease O 1 0.7020348310470581
, O 0 5.91268076277629e-07
a O 0 8.500513786202646e-07
finding O 0 5.833528007315181e-07
with O 0 4.7835430905252e-07
serious O 0 2.3452228560927324e-05
diagnostic O 0 0.0034093568101525307
and O 0 1.5335990610765293e-05
prognostic O 1 0.9999998807907104
implications O 0 0.0035107508301734924
. O 0 7.696782995481044e-05

Moreover O 0 0.0002824581752065569
, O 0 2.809992656693794e-05
further O 0 1.7856507838587277e-05
ARSA O 1 0.9966427087783813
alleles O 0 2.0959876565029845e-05
functionally O 0 1.3097734154143836e-05
similar O 0 8.753386282478459e-07
to O 0 1.071303245225863e-06
A464V O 0 0.00013718682748731226
might O 0 1.1216352504561655e-06
exist O 0 1.4815381632615754e-07
which O 0 1.0786563109377312e-07
, O 0 7.785870792531568e-08
together O 0 5.3425793566930224e-08
with O 0 7.027604453924141e-08
0 O 0 1.5923426417430164e-06
- O 0 8.658646947878879e-06
type O 0 4.487410933506908e-06
mutations O 0 7.995613486855291e-07
, O 0 4.3035981889261166e-07
may O 0 5.497261099662865e-07
cause O 0 3.7298818824638147e-06
pathological O 1 0.9999264478683472
ARSA O 1 1.0
and O 0 0.00017276746802963316
GS O 1 1.0
levels O 0 3.928614205506165e-06
, O 0 3.8939774071877764e-07
but O 0 1.6640201749851258e-07
not O 0 1.5018251531273563e-07
clinical O 0 2.8900076358695515e-06
outbreak O 0 4.492378138820641e-06
of O 0 4.7537100726913195e-06
the O 0 8.275907021015882e-05
disease O 0 0.3749314546585083
. O 0 6.668150035693543e-06
. O 0 3.442663364694454e-05

Human O 1 0.9654011130332947
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 1 0.9998540878295898
to O 0 0.00021272765297908336
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 0.048467185348272324
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.9997239708900452
1 I-Disease 1 0.9575071334838867
. O 0 0.00011973208165727556

Heterozygous O 0 0.001605771598406136
germ O 1 0.9805207252502441
- O 0 0.00038571926415897906
line O 0 3.808429028140381e-05
mutations O 0 3.2686191389075248e-06
in O 0 5.544763439502276e-07
the O 0 1.2580346719914814e-06
DNA O 0 3.7771465031255502e-06
mismatch O 0 0.34069037437438965
repair O 0 0.0006997064920142293
genes O 0 2.120533054039697e-06
lead O 0 3.6007263588544447e-06
to O 0 4.759475814353209e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.02670900896191597

The O 0 0.00026019461802206933
disease O 1 0.6042324304580688
susceptibility O 0 0.00011404296674299985
of O 0 8.426913700532168e-05
individuals O 0 1.7194995507452404e-06
who O 0 8.147054359142203e-06
constitutionally O 0 1.0564222975517623e-05
lack O 0 2.824091779984883e-06
both O 0 8.363372216990683e-07
wild O 0 1.3477985703502782e-05
- O 0 4.2645067878765985e-05
type O 0 9.636122740630526e-06
alleles O 0 3.679339670270565e-06
is O 0 2.8169583856652025e-06
unknown O 0 1.6819252778077498e-05
. O 0 2.537752516218461e-05

We O 0 2.6868721761275083e-05
have O 0 2.7068010695074918e-06
identified O 0 1.6583121578150894e-06
three O 0 4.1412491214032343e-07
offspring O 0 2.006007889576722e-06
in O 0 7.320623467421683e-07
a O 0 7.578743861813564e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.034726325422525406
who O 0 1.1359957170498092e-05
developed O 0 3.0712675652466714e-05
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
at O 0 1.2951971257280093e-05
a O 0 5.722219498238701e-07
very O 0 6.989572653992582e-08
early O 0 1.0971965025419195e-07
age O 0 2.1281799433836568e-07
, O 0 8.31975555115605e-08
and O 0 5.758872489991518e-08
at O 0 3.7793915907968767e-07
least O 0 4.989338719951775e-08
two O 0 2.321382197578714e-08
of O 0 1.227241881451846e-07
them O 0 1.006673144843262e-07
displayed O 0 1.7200915181092569e-06
signs O 0 3.4516774576331954e-06
of O 0 4.973033810529159e-06
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 0.00027387647423893213
1 I-Disease 0 0.00012578627502080053
( O 0 1.1117080248368438e-05
NF1 B-Disease 1 0.9923353791236877
) O 0 1.721275293675717e-05
. O 0 5.3794472478330135e-05

DNA O 0 2.447256883897353e-05
sequence O 0 2.758135678959661e-06
analysis O 0 8.580609573982656e-07
and O 0 5.052524443271977e-07
allele O 0 1.5194456182143767e-06
- O 0 2.1135313090780983e-06
specific O 0 4.2449701709301735e-07
amplification O 0 2.646822849783348e-06
in O 0 3.2395669791185355e-07
two O 0 2.710355602175696e-07
siblings O 0 1.962246869879891e-06
revealed O 0 2.290967358931084e-06
a O 0 2.2824535790277878e-06
homozygous O 0 1.9192431864212267e-05
MLH1 O 0 0.166764035820961
mutation O 0 4.57288115285337e-06
( O 0 2.1869532247364987e-06
C676T O 0 6.458149437094107e-05
- O 0 5.051327752880752e-05
- O 0 0.00010916806786553934
> O 0 8.779042400419712e-05
Arg226Stop O 0 0.11085956543684006
) O 0 2.920406222983729e-05
. O 0 6.500895688077435e-05

Thus O 0 6.667842535534874e-05
, O 0 1.0035165360022802e-05
a O 0 1.1071236258430872e-05
homozygous O 0 4.6381421270780265e-05
germ O 1 0.9991045594215393
- O 1 0.6853257417678833
line O 0 0.0008088712929747999
MLH1 O 1 0.9999958276748657
mutation O 0 1.0196789844485465e-05
and O 0 3.181163265253417e-06
consequent O 1 0.9984215497970581
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 2.079442992908298e-06
in O 0 1.0567421213636408e-06
a O 0 4.73760246677557e-06
mutator O 1 0.9759703874588013
phenotype O 0 7.639554496563505e-06
characterized O 0 1.8133666799258208e-06
by O 0 1.037178890328505e-06
leukemia B-Disease 1 1.0
and O 0 0.00045443460112437606
/ O 1 1.0
or O 1 0.9999706745147705
lymphoma B-Disease 1 1.0
associated O 0 8.461217475996818e-06
with O 0 5.6097987908287905e-06
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 0.4918306767940521
1 I-Disease 0 0.002355236327275634
. O 0 9.973016858566552e-06
. O 0 2.6672549211070873e-05

Missense O 0 0.0009883680613711476
mutations O 0 1.8239801647723652e-05
in O 0 1.8220619040221209e-06
the O 0 2.2371075374394422e-06
most O 0 7.485227229153679e-07
ancient O 0 2.836064368239022e-06
residues O 0 3.2989864848786965e-06
of O 0 2.1114763057994423e-06
the O 0 4.843059741688194e-06
PAX6 O 1 0.9999271631240845
paired O 0 2.672783193702344e-05
domain O 0 6.976951226533856e-06
underlie O 0 2.553123158577364e-05
a O 0 2.0869247236987576e-06
spectrum O 0 1.7883094187709503e-05
of O 0 0.00889902375638485
human O 1 0.9999914169311523
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.8874356746673584

Mutations O 0 9.172425779979676e-05
of O 0 2.111620779032819e-05
the O 0 1.6545018297620118e-05
human O 0 1.3541682164941449e-05
PAX6 O 1 1.0
gene O 0 0.0022639944218099117
underlie O 1 1.0
aniridia B-Disease 1 1.0
( O 1 0.9999750852584839
congenital B-Disease 1 1.0
absence I-Disease 0 4.3737290980061516e-05
of I-Disease 0 0.003980063367635012
the I-Disease 0 0.0001338706206297502
iris I-Disease 1 0.9886924028396606
) O 0 1.2485197657952085e-06
, O 0 7.10271649495553e-07
a O 0 1.3715992963625467e-06
rare O 0 9.255966688215267e-06
dominant O 1 0.9373266100883484
malformation B-Disease 1 0.9999998807907104
of I-Disease 1 0.7910173535346985
the I-Disease 1 0.6400147080421448
eye I-Disease 1 0.9999995231628418
. O 0 0.00010344837210141122

The O 0 6.124241917859763e-05
spectrum O 0 4.539345172815956e-05
of O 0 3.7955935113132e-05
PAX6 O 1 1.0
mutations O 0 1.7303287677350454e-05
in O 0 4.706301751866704e-06
aniridia B-Disease 1 1.0
patients O 0 6.589232725673355e-06
is O 0 6.276560498008621e-07
highly O 0 1.1000920494552702e-06
biased O 0 1.1690510746120708e-06
, O 0 1.8562406012279098e-07
with O 0 9.600631756256917e-08
92 O 0 2.3714935650787083e-06
% O 0 2.615193182009534e-07
of O 0 3.0046251708881755e-07
all O 0 1.3758345573933184e-07
reported O 0 4.2394071897433605e-07
mutations O 0 3.4620180144884216e-07
leading O 0 1.2897560281999176e-06
to O 0 4.134194000471325e-07
premature O 0 1.610173967492301e-06
truncation O 0 3.4045931442960864e-06
of O 0 5.841311008225603e-07
the O 0 3.2132072647073073e-07
protein O 0 3.265342627400969e-07
( O 0 2.4168576828742516e-07
nonsense O 0 1.5773268842167454e-06
, O 0 1.9376061288767232e-07
splicing O 0 5.977792056910403e-07
, O 0 3.254728824231279e-07
insertions O 0 2.0347356439742725e-06
and O 0 3.3525122944411123e-07
deletions O 0 2.029781853707391e-06
) O 0 5.559621172324114e-07
and O 0 2.7991930551252153e-07
just O 0 6.272215955505089e-07
2 O 0 1.209771085086686e-06
% O 0 2.525630691252445e-07
leading O 0 4.4979759650232154e-07
to O 0 1.743776749663084e-07
substitution O 0 6.585084406651731e-07
of O 0 7.117973837011959e-07
one O 0 4.844557111027825e-07
amino O 0 4.68461877289883e-07
acid O 0 5.33179900230607e-07
by O 0 1.795441306740031e-07
another O 0 1.8456790940035717e-06
( O 0 5.027635324950097e-06
missense O 0 9.320599201600999e-05
) O 0 2.7290632715448737e-05
. O 0 5.4656367865391076e-05

The O 0 4.6474749979097396e-05
extraordinary O 0 3.0047367545193993e-05
conservation O 0 2.6958861781167798e-05
of O 0 6.029083124303725e-06
the O 0 5.716514806408668e-06
PAX6 O 1 0.9907984733581543
protein O 0 3.1813849545869743e-06
at O 0 2.136565399268875e-06
the O 0 6.534961016768648e-07
amino O 0 9.289695981351542e-07
acid O 0 1.2731553624689695e-06
level O 0 1.612374376236403e-06
amongst O 0 4.10621942137368e-06
vertebrates O 0 1.6918123947107233e-05
predicts O 0 9.805863555811811e-06
that O 0 9.47400337736326e-07
pathological O 0 3.357917375979014e-05
missense O 0 1.852999957918655e-05
mutations O 0 7.808056921021489e-07
should O 0 1.744062814168501e-07
in O 0 1.2037034480272268e-07
fact O 0 2.0853620696925645e-07
be O 0 9.135163736573304e-08
common O 0 1.7494100745807373e-07
even O 0 1.5205922920813464e-07
though O 0 1.1507187025472376e-07
they O 0 6.535870511470421e-08
are O 0 5.818060699880334e-08
hardly O 0 1.6880916291484027e-06
ever O 0 3.893530902132625e-06
seen O 0 6.4311457208532374e-06
in O 0 6.525938715640223e-06
aniridia B-Disease 1 0.9999995231628418
patients O 0 5.4463078413391486e-05
. O 0 5.787827103631571e-05

This O 0 2.0134166334173642e-05
indicates O 0 7.561216079920996e-06
that O 0 4.20915654331111e-07
there O 0 4.873147645412246e-07
is O 0 4.52075965995391e-07
a O 0 7.343082302213588e-07
heavy O 0 3.0278722988441586e-05
ascertainment O 1 0.8498913049697876
bias O 0 6.288330951065291e-06
in O 0 3.7572826272480597e-07
the O 0 3.118469464880036e-07
selection O 0 6.706381441290432e-07
of O 0 4.914319902127318e-07
patients O 0 2.643811001235008e-07
for O 0 3.3953804745578964e-07
PAX6 O 1 0.9977826476097107
mutation O 0 1.0605007219055551e-06
analysis O 0 2.941064565220586e-07
and O 0 1.7752249448221846e-07
that O 0 2.800311733608396e-07
the O 0 1.40497093070735e-06
missing O 0 1.497152516094502e-05
PAX6 O 1 0.9992974996566772
missense O 0 0.0001994900667341426
mutations O 0 6.044241672498174e-06
frequently O 0 2.723071247601183e-06
may O 0 2.3428165150107816e-06
underlie O 0 4.7423709474969655e-05
phenotypes O 0 1.6148449503816664e-05
distinct O 0 4.621431344276061e-06
from O 0 1.1292630915704649e-05
textbook O 1 0.9941026568412781
aniridia B-Disease 1 1.0
. O 0 0.0003126957162749022

Here O 0 2.3827922632335685e-05
we O 0 2.706904297156143e-06
present O 0 1.4101685792411445e-06
four O 0 1.4318155763248797e-06
novel O 0 1.3160224625607952e-05
PAX6 O 1 0.9863005876541138
missense O 0 5.77400169277098e-05
mutations O 0 2.611375293781748e-06
, O 0 6.665159730800951e-07
two O 0 1.7831027321335569e-07
in O 0 3.17902049573604e-07
association O 0 7.277479880940518e-07
with O 0 8.619025493317167e-07
atypical O 0 0.1934397965669632
phenotypes O 0 0.44289863109588623
ectopia B-Disease 1 1.0
pupillae I-Disease 1 0.999997615814209
( O 0 4.003127287433017e-06
displaced B-Disease 0 2.3878835690993583e-06
pupils I-Disease 0 1.8451474943503854e-06
) O 0 9.304724812864151e-07
and O 0 3.3130763767985627e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9996663331985474
( O 0 2.8780211778212106e-06
searching B-Disease 0 4.74765693070367e-06
gaze I-Disease 0 8.443363185506314e-06
) O 0 4.393462234020262e-07
, O 0 2.5410105308765196e-07
and O 0 1.3643700924603763e-07
two O 0 1.3964121592380252e-07
in O 0 2.9728991535193927e-07
association O 0 6.051931791262177e-07
with O 0 5.739988182540401e-07
more O 0 2.4329883672180586e-06
recognizable O 0 0.2272135317325592
aniridia B-Disease 1 1.0
phenotypes O 0 0.0017370664281770587
. O 0 0.00019785171025432646

Strikingly O 0 0.0002703953650780022
, O 0 1.0703213774831966e-05
all O 0 1.8397531675873324e-06
four O 0 1.1336062470945762e-06
mutations O 0 1.355530571345298e-06
are O 0 2.1744989453509334e-07
located O 0 2.110640934915864e-06
within O 0 5.327315761860518e-07
the O 0 1.7083910961446236e-06
PAX6 O 1 0.999993085861206
paired O 0 1.0830957762664184e-05
domain O 0 2.753131866484182e-06
and O 0 4.987074362361454e-07
affect O 0 4.911653945782746e-07
amino O 0 2.3936877369123977e-07
acids O 0 1.5765373007070593e-07
which O 0 7.157974124538669e-08
are O 0 4.3870979737903326e-08
highly O 0 5.686006261385046e-07
conserved O 0 1.5370661685665254e-06
in O 0 4.355947567091789e-07
all O 0 4.774241233462817e-07
known O 0 2.6194218207820086e-06
paired O 0 1.0100779945787508e-05
domain O 0 1.1801018445112277e-05
proteins O 0 9.030007277033292e-06
. O 0 3.506319262669422e-05

Our O 0 2.643310472194571e-05
results O 0 3.956516593461856e-06
support O 0 1.9533035811036825e-06
the O 0 1.431631289960933e-06
hypothesis O 0 1.759534143275232e-06
that O 0 9.258955202540164e-08
the O 0 2.0578889348144003e-07
under O 0 4.3265774252176925e-07
- O 0 2.170708512494457e-06
representation O 0 2.978674444875651e-07
of O 0 9.845525710261427e-07
missense O 0 2.89805575448554e-05
mutations O 0 7.261215841936064e-07
is O 0 3.2150219908544386e-07
caused O 0 7.027442734397482e-07
by O 0 2.8225630899214593e-07
ascertainment O 1 0.9569411277770996
bias O 0 4.784410066349665e-06
and O 0 2.890550945267023e-07
suggest O 0 2.897403987844882e-07
that O 0 5.733598484880531e-08
a O 0 2.890997734539269e-07
substantial O 0 8.817632988211699e-07
burden O 0 2.8746169391524745e-06
of O 0 6.768598723283503e-06
PAX6 B-Disease 1 1.0
- I-Disease 1 0.999998927116394
related I-Disease 0 0.45688509941101074
disease I-Disease 1 0.7355830073356628
remains O 0 4.46322974312352e-06
to O 0 4.789595777765498e-07
be O 0 1.1593937188081327e-06
uncovered O 0 4.560775778372772e-05
. O 0 6.72498799758614e-06
. O 0 4.602396074915305e-05

The O 0 4.184823774266988e-05
chromosomal O 0 4.283234375179745e-05
order O 0 4.829721092391992e-06
of O 0 6.718897566315718e-06
genes O 0 2.2801973500463646e-06
controlling O 0 1.391205114487093e-05
the O 0 2.7051751203543972e-06
major O 0 0.0015351073816418648
histocompatibility O 1 1.0
complex O 0 0.003352745668962598
, O 0 2.660744939930737e-06
properdin O 0 0.0008507290040142834
factor O 0 2.6544481443124823e-05
B O 0 0.007052299566566944
, O 0 7.087370477165678e-07
and O 0 6.112307460170996e-07
deficiency B-Disease 0 0.02038172446191311
of I-Disease 0 5.985623829474207e-06
the I-Disease 0 4.220168193569407e-06
second I-Disease 0 1.1538164471858181e-05
component I-Disease 0 4.5149870857130736e-05
of I-Disease 0 1.84554355655564e-05
complement I-Disease 0 4.879566768067889e-05
. O 0 5.117594264447689e-05

The O 0 4.426806845003739e-05
relationship O 0 8.343006811628584e-06
of O 0 4.338561666372698e-06
the O 0 1.6259753010672284e-06
genes O 0 9.041864927894494e-07
coding O 0 4.894935955235269e-06
for O 0 1.2158085382907302e-06
HLA O 1 0.805846095085144
to O 0 8.625916620985663e-07
those O 0 2.2745041405869415e-07
coding O 0 1.6183147408810328e-06
for O 0 9.237282938556746e-07
properdin O 0 0.005141518544405699
Factor O 0 3.344966535223648e-05
B O 0 5.977364708087407e-05
allotypes O 0 3.031076084880624e-05
and O 0 4.4431740775507933e-07
for O 0 6.678317845398851e-07
deficiency B-Disease 0 0.01937718316912651
of I-Disease 0 4.1712964957696386e-06
the I-Disease 0 2.3224688447953667e-06
second I-Disease 0 3.739876547115273e-06
component I-Disease 0 1.144785164797213e-05
of I-Disease 0 1.4956264067222946e-06
complement I-Disease 0 2.841579089363222e-06
( O 0 1.8609531480251462e-06
C2 O 1 0.9852433204650879
) O 0 4.932433625981503e-07
was O 0 9.590233958078898e-07
studied O 0 8.231284027715446e-07
in O 0 1.0967634267444737e-07
families O 0 7.731500772933941e-08
of O 0 1.0500875760044437e-06
patients O 0 2.879006842704257e-06
with O 0 1.913814958243165e-05
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.11355660110712051

Patients O 0 0.0001682694855844602
were O 0 5.047943432145985e-06
selected O 0 3.2712136999180075e-06
because O 0 7.824008321222209e-07
they O 0 2.109689773988066e-07
were O 0 3.579259271191404e-07
heterozygous O 0 2.0467241483856924e-06
or O 0 1.0144926818611566e-06
homozygous O 0 1.5712519598309882e-05
for O 0 7.494850433431566e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0004031553689856082

12 O 0 6.975113501539454e-05
families O 0 2.8347556053631706e-06
with O 0 1.4892558510837262e-06
15 O 0 5.028287432651268e-06
matings O 0 3.33589778165333e-05
informative O 0 5.3265779570210725e-05
for O 0 0.0001460940547985956
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 3.041648233192973e-05
found O 0 2.9033059036009945e-05
. O 0 4.00003555114381e-05

Of O 0 9.556105214869604e-05
57 O 0 9.735768981045112e-05
informative O 0 7.234935037558898e-05
meioses O 0 0.0012520195450633764
, O 0 2.8639615266001783e-06
two O 0 4.0904893694460043e-07
crossovers O 0 1.797214281396009e-06
were O 0 2.782728074635088e-07
noted O 0 4.2245707732035953e-07
between O 0 6.073336180634215e-07
the O 0 8.115942182485014e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.4728153701071278e-06
and O 0 5.643425424750603e-07
the O 0 1.7741463125275914e-06
HLA O 1 0.9999984502792358
- O 1 0.9870791435241699
B O 0 0.009865238331258297
gene O 0 5.338331448001554e-07
, O 0 2.1100943570218078e-07
with O 0 1.0733019450981374e-07
a O 0 6.33831234608806e-07
recombinant O 0 2.0054894775967114e-06
fraction O 0 5.013902864448028e-06
of O 0 7.074121640471276e-06
0 O 0 4.274599996278994e-05
. O 0 4.3789543269667774e-05

035 O 1 0.8775179386138916
. O 0 0.004957792814821005

A O 0 0.0002684943610802293
lod O 0 0.0012099421583116055
score O 0 1.6763684470788576e-05
of O 0 5.6089056670316495e-06
13 O 0 4.820518370252103e-06
was O 0 3.4143349694204517e-06
calculated O 0 1.0277540241077077e-06
for O 0 4.54821105222436e-07
linkage O 0 1.4084754184295889e-05
between O 0 4.158114825258963e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 0.00014029591693542898
HLA O 1 1.0
- O 1 0.999943733215332
B O 0 0.046582527458667755
at O 0 1.953178752955864e-06
a O 0 4.2314016468480986e-07
maximum O 0 6.383152140188031e-07
likelihood O 0 4.4537037524605694e-07
value O 0 3.213820320979721e-07
of O 0 5.216350587033958e-07
the O 0 6.968354000491672e-07
recombinant O 0 2.033977125392994e-06
fraction O 0 3.750026735360734e-06
of O 0 7.5639136412064545e-06
0 O 0 3.327684316900559e-05
. O 0 3.42611747328192e-05

04 O 1 0.9826160669326782
. O 0 0.0035796083975583315

18 O 0 6.879042484797537e-05
families O 0 3.007158966283896e-06
with O 0 8.915116040952853e-07
21 O 0 3.7778631849505473e-06
informative O 0 1.034837077895645e-05
matings O 0 6.983588264120044e-06
for O 0 8.04092792350275e-07
both O 0 6.680483579657448e-07
properdin O 0 0.00010496751929167658
Factor O 0 2.9477994758053683e-05
B O 0 0.00013757380656898022
allotype O 0 0.00027002437855117023
and O 0 4.7911721594573464e-06
HLA O 1 0.9999971389770508
- O 1 0.9992676377296448
B O 1 0.7413125038146973
were O 0 7.269805337273283e-06
found O 0 1.0367128197685815e-05
. O 0 2.884831337723881e-05

Of O 0 0.0001634762156754732
72 O 0 7.953675230965018e-05
informative O 0 5.1367751439101994e-05
meioses O 0 0.0008236163412220776
, O 0 2.225586740678409e-06
three O 0 1.0614975280986982e-06
recombinants O 0 4.842001726501621e-05
were O 0 1.1154587582495878e-06
found O 0 2.5948196480385377e-07
, O 0 2.552893079155183e-07
giving O 0 2.767048670193617e-07
a O 0 5.316788929121685e-07
recombinant O 0 2.7991929982817965e-06
fraction O 0 5.0846092563006096e-06
of O 0 9.717979992274195e-06
0 O 0 4.229824844514951e-05
. O 0 4.627556336345151e-05

042 O 1 0.7412626147270203
. O 0 0.004256073851138353

A O 0 0.00017778156325221062
lod O 0 0.0011909089516848326
score O 0 1.0227644452243112e-05
of O 0 6.631963060499402e-06
16 O 0 7.473567620763788e-06
between O 0 1.5233863450703211e-06
HLA O 1 0.9998992681503296
- O 1 0.7343044281005859
B O 0 0.008516858331859112
and O 0 1.1423903742979746e-06
Factor O 0 1.4463450497714803e-05
B O 0 2.5842131435638294e-05
allotypes O 0 3.024628313141875e-05
was O 0 3.1949484764481895e-06
calculated O 0 1.0685829465728602e-06
at O 0 9.280779522669036e-07
a O 0 4.167056033566041e-07
maximum O 0 7.576609846182691e-07
likelihood O 0 7.687987135795993e-07
value O 0 3.0241736226344074e-07
of O 0 3.8355560150193924e-07
the O 0 7.069913294799335e-07
recombinant O 0 2.9282289233378833e-06
fraction O 0 4.874829755863175e-06
of O 0 7.4344134191051126e-06
0 O 0 5.5949389206944034e-05
. O 0 5.4109135817270726e-05

04 O 1 0.927750825881958
. O 0 0.0049535552971065044

A O 0 0.0001609381870366633
crossover O 0 0.00010680084960767999
was O 0 1.5815889128134586e-05
shown O 0 1.2417762036420754e-06
to O 0 4.080503401837632e-07
have O 0 1.1069288063936256e-07
occurred O 0 4.519565663940739e-07
between O 0 1.0487189427976773e-07
genes O 0 7.564828052863959e-08
for O 0 1.5237307593451987e-07
Factor O 0 2.6105387860297924e-06
B O 0 7.579561042803107e-06
and O 0 6.136429533398768e-07
HLA O 1 0.9982286095619202
- O 1 0.9535198211669922
D O 1 0.9994220733642578
, O 0 7.626929345860844e-07
in O 0 2.1570684793914552e-07
which O 0 3.339037562000158e-07
HLA O 0 0.31042808294296265
- O 0 0.08659837394952774
D O 1 0.9966992735862732
segregared O 0 0.0008710207184776664
with O 0 3.6825906590820523e-06
HLA O 1 0.9999958276748657
- O 1 0.7051813006401062
A O 0 0.0595848448574543
and O 0 1.5918785720714368e-05
B O 0 0.0009033228852786124
. O 0 4.021508357254788e-05

These O 0 1.9449427782092243e-05
studies O 0 5.7712813941179775e-06
suggest O 0 1.5860060784689267e-06
that O 0 1.9197426581740729e-07
the O 0 3.013254001871246e-07
genes O 0 1.669091744815887e-07
for O 0 2.7498049348650966e-07
Factor O 0 0.016068680211901665
B O 1 0.999962329864502
and O 0 0.0001739715808071196
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.8046786465220066e-07
located O 0 6.620649060096184e-07
outside O 0 3.401697483695898e-07
those O 0 5.3724992454817766e-08
for O 0 2.1777613312679023e-07
HLA O 1 0.9956821203231812
, O 0 5.834218086420151e-07
that O 0 8.56752961908569e-08
the O 0 1.4707659090618108e-07
order O 0 1.6454652040920337e-07
of O 0 5.411001779975777e-07
genese O 0 0.0003333598142489791
is O 0 9.999893109124969e-07
HLA O 0 0.20121273398399353
- O 0 2.4843679057084955e-05
A O 0 1.4595986613130663e-05
, O 0 4.882525672655902e-07
- O 0 3.772812078750576e-06
B O 0 7.218709015432978e-06
, O 0 5.293218237056863e-07
- O 0 3.42845669365488e-06
D O 0 4.3767875467892736e-05
, O 0 7.961221513141936e-07
Factor O 0 6.440186552936211e-06
B O 0 9.366306767333299e-05
allotype O 1 0.9735667109489441
, O 0 0.0009258654317818582
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 1.3138866279405192e-06
that O 0 2.0221199292791425e-07
the O 0 3.71396964737869e-07
genes O 0 2.7709648975360324e-07
coding O 0 7.219369763333816e-06
for O 0 6.261482485570014e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 4.0287031879415736e-06
Factor O 0 0.00124557560775429
B O 0 6.400968413800001e-05
allotypes O 0 1.486602832301287e-05
are O 0 8.959806052644126e-08
approximately O 0 2.462916484091693e-07
3 O 0 4.986218300473411e-07
- O 0 9.931738986779237e-07
- O 0 1.3575513548857998e-06
5 O 0 1.0568307970970636e-06
centimorgans O 0 5.969342510070419e-06
from O 0 2.5961881533476117e-07
the O 0 4.838171321353002e-07
HLA O 0 0.06758340448141098
- O 0 4.646588786272332e-05
A O 0 4.598815576173365e-05
and O 0 8.288883464047103e-07
HLA O 1 0.999869704246521
- O 0 0.28360000252723694
B O 0 0.03587380424141884
loci O 0 1.9948874978581443e-06
, O 0 2.9756847652606666e-07
and O 0 1.0821162277352414e-07
that O 0 5.7896439642490805e-08
the O 0 1.949442349769015e-07
apparent O 0 1.1832015616164426e-06
lack O 0 8.001173341654066e-07
of O 0 3.0559651804651367e-06
recombinants O 0 0.0012590656988322735
between O 0 6.309779223556689e-07
the O 0 1.195667664433131e-06
Factor O 0 1.3521913388103712e-05
B O 0 9.059430158231407e-05
gene O 0 3.3279918625339633e-06
and O 0 5.159145803190768e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 6.295339517237153e-06
suggests O 0 1.0184904795096372e-06
that O 0 8.586424371515022e-08
these O 0 3.23404130142535e-08
two O 0 5.0660922568113165e-08
genes O 0 2.8602309498637624e-07
lie O 0 1.3725820053878124e-06
in O 0 3.709519944550266e-07
close O 0 1.3732588968196069e-06
proximity O 0 2.0116058294661343e-06
to O 0 1.0596363608783577e-06
one O 0 4.751017968374072e-06
another O 0 1.507052638771711e-05
. O 0 4.1372626583324745e-05

Distribution O 0 4.756565977004357e-05
of O 0 2.220722490164917e-05
emerin O 1 0.9135634303092957
and O 0 9.398274414706975e-06
lamins O 0 0.010054252110421658
in O 0 1.8296906318937545e-06
the O 0 3.030160314665409e-06
heart O 0 9.44954008446075e-05
and O 0 1.0538858532527229e-06
implications O 0 3.949010988435475e-06
for O 0 2.4047328679444036e-06
Emery B-Disease 1 0.998870313167572
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.7536805868148804

Emerin O 1 0.8860594034194946
is O 0 1.392750255035935e-05
a O 0 4.2899059735646006e-06
nuclear O 0 8.251575309259351e-06
membrane O 0 2.0313621007517213e-06
protein O 0 1.0280264177708887e-06
which O 0 3.1040227099765616e-07
is O 0 3.945785636005894e-07
missing O 0 1.2029762501697405e-06
or O 0 5.596475602942519e-07
defective O 0 9.072961802303325e-06
in O 0 2.041577545242035e-06
Emery B-Disease 1 0.820898711681366
- I-Disease 1 0.9999966621398926
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999970197677612
EDMD B-Disease 1 1.0
) O 0 0.00018999203166458756
. O 0 0.00011545655434019864

It O 0 1.2005296412098687e-05
is O 0 2.6613186037138803e-06
one O 0 7.076321253407514e-07
member O 0 6.918835424585268e-07
of O 0 1.1862555311381584e-06
a O 0 1.686982727733266e-06
family O 0 1.9723324840015266e-06
of O 0 6.948698228370631e-06
lamina O 1 0.9999961853027344
- O 0 9.053799294633791e-05
associated O 0 9.419327966497804e-07
proteins O 0 2.2379730069133075e-07
which O 0 2.1456243359807559e-07
includes O 0 7.751462476335291e-07
LAP1 O 1 0.9691758155822754
, O 0 2.1090252175781643e-06
LAP2 O 0 0.033609725534915924
and O 0 3.563595782907214e-06
lamin O 0 0.0002279141772305593
B O 0 0.00033573462860658765
receptor O 0 2.3533759303973056e-05
( O 0 1.1171599908266217e-05
LBR O 1 0.9993577599525452
) O 0 3.542645208653994e-05
. O 0 9.041358134709299e-05

A O 0 0.0001381734327878803
panel O 0 1.9190933016943745e-05
of O 0 5.339703420759179e-06
16 O 0 5.066240646556253e-06
monoclonal O 0 1.3079035852570087e-05
antibodies O 0 2.5024655769811943e-06
( O 0 2.0517995835689362e-06
mAbs O 0 3.9043574361130595e-05
) O 0 1.406247065460775e-06
has O 0 4.649874369988538e-07
been O 0 3.8170628613443114e-07
mapped O 0 1.1189898714292212e-06
to O 0 1.9254082417319296e-07
six O 0 3.3169320090564725e-07
specific O 0 1.5753380466776434e-07
sites O 0 6.497500635305187e-07
throughout O 0 5.990884233142424e-07
the O 0 1.2003611118416302e-06
emerin O 0 2.0325329387560487e-05
molecule O 0 1.7526926967548206e-06
using O 0 6.536369596688019e-07
phage O 0 1.2741812497552019e-05
- O 0 5.174451871425845e-06
displayed O 0 3.095056172242039e-06
peptide O 0 1.978070486075012e-06
libraries O 0 1.1643822972473572e-06
and O 0 3.037961846530379e-07
has O 0 3.579180543056282e-07
been O 0 3.306966789295984e-07
used O 0 2.9637388365699735e-07
to O 0 4.766420715895947e-07
localize O 0 3.430779179325327e-05
emerin O 0 0.025547731667757034
in O 0 1.964107923413394e-06
human O 0 1.8631124021339929e-06
and O 0 6.5820981944852974e-06
rabbit O 1 0.9827240109443665
heart O 1 0.9959967136383057
. O 0 0.00014102905697654933

Several O 0 7.962311065057293e-05
mAbs O 0 0.0001482441439293325
against O 0 1.443627570552053e-05
different O 0 2.1171747448534006e-06
emerin O 0 0.00026624021120369434
epitopes O 0 3.6479439586400986e-05
did O 0 1.843008931246004e-06
not O 0 3.422115355533606e-07
recognize O 0 1.2377727216517087e-06
intercalated O 0 4.518769492278807e-05
discs O 0 0.0003287518920842558
in O 0 1.2172041579106008e-06
the O 0 2.625922206789255e-06
heart O 0 0.004625795409083366
, O 0 5.288541160552995e-07
though O 0 1.9074190049650497e-07
they O 0 1.1212636508162177e-07
recognized O 0 6.956096854082716e-07
cardiomyocyte O 0 2.4629669496789575e-05
nuclei O 0 2.183899596275296e-06
strongly O 0 4.179967163508991e-07
, O 0 3.1467189387512917e-07
both O 0 9.379343168802734e-08
at O 0 1.3065258599453955e-06
the O 0 6.849572855571751e-07
rim O 0 9.935843081620988e-06
and O 0 8.077743700596329e-07
in O 0 1.8169049553762306e-06
intranuclear O 0 0.00854787789285183
spots O 0 3.845265746349469e-05
or O 0 8.121750397549476e-06
channels O 0 3.4386146580800414e-05
. O 0 5.219678860157728e-05

A O 0 0.0008178174612112343
polyclonal O 0 0.0012384208384901285
rabbit O 0 0.0007220202242024243
antiserum O 0 0.0003246731648687273
against O 0 2.936257078545168e-05
emerin O 0 0.16670390963554382
did O 0 3.97766916648834e-06
recognize O 0 1.4302311228675535e-06
both O 0 3.108504529336642e-07
nuclear O 0 2.7900618988496717e-06
membrane O 0 8.429424838141131e-07
and O 0 5.044080353400204e-07
intercalated O 0 2.738827242865227e-05
discs O 0 2.8086478778277524e-05
but O 0 5.82312281949271e-07
, O 0 2.655697812770086e-07
after O 0 2.2177802350142883e-07
affinity O 0 4.704757259332837e-07
purification O 0 3.24178472510539e-06
against O 0 5.944937129243044e-07
a O 0 8.823369626043132e-07
pure O 0 5.643136319122277e-06
- O 0 9.691251761978492e-06
emerin O 0 5.530070484383032e-05
band O 0 4.280832854419714e-06
on O 0 7.392858947241621e-07
a O 0 7.466462079719349e-07
western O 0 1.4566481922884122e-06
blot O 0 3.158054096275009e-05
, O 0 1.1597410320973722e-06
it O 0 5.215554210735718e-07
stained O 0 2.972460242745001e-05
only O 0 1.2234759196871892e-06
the O 0 3.63661274604965e-06
nuclear O 0 2.4527707864763215e-05
membrane O 0 3.875748734571971e-05
. O 0 4.226312375976704e-05

These O 0 6.572707661689492e-06
results O 0 1.092378624889534e-06
would O 0 3.8637665511487285e-07
not O 0 1.0330136035463511e-07
be O 0 9.420183744168753e-08
expected O 0 4.0196474060394394e-07
if O 0 3.9097960780054564e-07
immunostaining O 0 2.4108036086545326e-05
at O 0 4.023746441816911e-06
intercalated O 0 2.48285687121097e-05
discs O 0 1.0178933735005558e-05
were O 0 2.9205716600699816e-07
due O 0 1.433229215308529e-07
to O 0 1.3796712039493286e-07
a O 0 1.997877348003385e-07
product O 0 1.9564994602205843e-07
of O 0 2.667719627424958e-07
the O 0 4.7092822796912515e-07
emerin O 0 2.176257112296298e-05
gene O 0 2.776816643290658e-07
and O 0 1.3752141114764527e-07
, O 0 1.515260805717844e-07
therefore O 0 8.967226250433669e-08
, O 0 1.2532314030977432e-07
cast O 0 2.5816115112320404e-07
some O 0 1.686183708216049e-07
doubt O 0 7.921324822746101e-07
upon O 0 1.5658626750791882e-07
the O 0 1.6970359695278603e-07
hypothesis O 0 1.1314159564790316e-06
that O 0 4.592503444200702e-07
cardiac B-Disease 1 0.9999996423721313
defects I-Disease 1 0.9985923171043396
in O 0 1.9031365809496492e-05
EDMD B-Disease 1 1.0
are O 0 6.537173931064899e-07
caused O 0 1.2238131148478715e-06
by O 0 2.709921318455599e-07
absence O 0 2.393754584772978e-06
of O 0 1.2002034054603428e-05
emerin O 1 0.9473201632499695
from O 0 1.1688988706737291e-05
intercalated O 0 0.0007995771011337638
discs O 0 0.004812224768102169
. O 0 0.00014420856314245611

Although O 0 4.0986873500514776e-05
emerin O 0 0.0012837889371439815
was O 0 2.5605111659388058e-05
abundant O 0 3.287061872470076e-06
in O 0 4.4542048271978274e-07
the O 0 8.482843441015575e-07
membranes O 0 1.5924700846881024e-06
of O 0 3.0290509585029213e-06
cardiomyocyte O 1 0.9468312859535217
nuclei O 0 3.5303107779327547e-06
, O 0 4.054934947816946e-07
it O 0 2.479952456724277e-07
was O 0 1.4297496591098025e-06
absent O 0 9.69645270743058e-07
from O 0 2.0664890598709462e-07
many O 0 3.0698996056344185e-07
non O 0 5.027438874094514e-06
- O 0 0.06473150849342346
myocyte O 1 0.9998382329940796
cells O 0 2.6875659386860207e-06
in O 0 2.082034598061e-06
the O 0 1.0249554179608822e-05
heart O 0 0.007984503172338009
. O 0 7.375299173872918e-05

This O 0 6.8399522206163965e-06
distribution O 0 3.1525812573818257e-06
of O 0 4.3142472350155e-06
emerin O 0 0.0017029648879542947
was O 0 4.929047918267315e-06
similar O 0 2.1040017372797593e-07
to O 0 1.1631754404106687e-07
that O 0 8.51939248036615e-08
of O 0 5.728481937694596e-07
lamin O 0 3.156981983920559e-05
A O 0 1.3129937542544212e-05
, O 0 5.938845220043731e-07
a O 0 6.769384981453186e-07
candidate O 0 9.921543551172363e-07
gene O 0 2.286869147383186e-07
for O 0 2.8987335554120364e-07
an O 0 9.763729167389101e-07
autosomal O 0 7.2595653364260215e-06
form O 0 6.5313743107253686e-06
of O 0 0.2912099063396454
EDMD B-Disease 1 1.0
. O 0 0.0009299341472797096

In O 0 4.091786831850186e-05
contrast O 0 2.2791975425207056e-05
, O 0 1.2078103281965014e-05
lamin O 1 0.8697383999824524
B1 O 1 1.0
was O 0 0.0001540215453132987
absent O 0 1.0747595297289081e-05
from O 0 1.9022703554583131e-06
cardiomyocyte O 0 0.0010418497258797288
nuclei O 0 7.0761457209300715e-06
, O 0 8.254473868873902e-07
showing O 0 1.7216095784533536e-06
that O 0 6.807204613323847e-07
lamin O 0 0.015382974408566952
B1 O 1 0.9999979734420776
is O 0 1.5057590871947468e-06
not O 0 1.8778059995838703e-07
essential O 0 5.917227099416777e-07
for O 0 1.665466413669492e-07
localization O 0 2.9690252176806098e-06
of O 0 3.3518008422106504e-06
emerin O 0 0.0005084886215627193
to O 0 3.339147269798559e-06
the O 0 1.441280710423598e-05
nuclear O 0 0.00016002828488126397
lamina O 0 0.05008342117071152
. O 0 0.00011874697520397604

Lamin O 1 0.9999986886978149
B1 O 1 1.0
is O 0 3.245834159315564e-05
also O 0 4.5434348976414185e-06
almost O 0 1.967307525774231e-06
completely O 0 6.210590981936548e-06
absent O 0 7.675952474528458e-06
from O 0 4.355483724793885e-06
skeletal O 1 0.9998294115066528
muscle O 0 0.47674068808555603
nuclei O 0 0.0016466022934764624
. O 0 0.00012466764019336551

In O 0 7.761304004816338e-05
EDMD B-Disease 1 1.0
, O 0 6.771658718207618e-06
the O 0 1.5665438013456878e-06
additional O 0 7.111968898243504e-07
absence O 0 1.4368041547641042e-06
of O 0 4.516929948295001e-06
lamin O 1 0.9999998807907104
B1 O 1 1.0
from O 0 0.00014756678137928247
heart O 1 0.9999988079071045
and O 0 1.504872489022091e-05
skeletal O 1 1.0
muscle O 1 0.9972681999206543
nuclei O 0 0.00038146061706356704
which O 0 5.51296921003086e-07
already O 0 5.964910769762355e-07
lack O 0 9.186356351165159e-07
emerin O 0 0.00038610558840446174
may O 0 3.440253237840807e-07
offer O 0 2.1276564154959487e-07
an O 0 1.5127210417631431e-07
alternative O 0 4.275265723663324e-07
explanation O 0 4.09633713616131e-07
of O 0 3.6183055840410816e-07
why O 0 6.436923172259412e-07
these O 0 1.6695121018983627e-07
tissues O 0 9.96365315586445e-07
are O 0 1.7537483643081941e-07
particularly O 0 9.393277196068084e-07
affected O 0 1.9266772142145783e-06
. O 0 3.717849949680385e-06
. O 0 2.4978566216304898e-05

Genetic O 0 6.902091990923509e-05
mapping O 0 1.9827692085527815e-05
of O 0 1.6402027540607378e-05
the O 0 1.3546216905524489e-05
copper B-Disease 0 0.18829748034477234
toxicosis I-Disease 1 0.9999910593032837
locus O 0 0.03994884341955185
in O 0 7.69324651628267e-06
Bedlington O 0 0.31173384189605713
terriers O 0 0.00036877149250358343
to O 0 3.223042085664929e-06
dog O 0 1.3540624422603287e-05
chromosome O 0 1.6730166407796787e-06
10 O 0 8.691746415934176e-07
, O 0 2.868677597689384e-07
in O 0 2.804409007239883e-07
a O 0 1.2735074506053934e-06
region O 0 3.238540102756815e-06
syntenic O 0 8.565158350393176e-05
to O 0 2.6503187200432876e-06
human O 0 4.113117029191926e-06
chromosome O 0 2.2800018996349536e-05
region O 0 2.362620216445066e-05
2p13 O 0 0.0013436320004984736
- O 0 0.001233589369803667
p16 O 0 0.0008594846585765481
. O 0 0.00010706128523452207

Abnormal O 1 0.9999842643737793
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9939290285110474
accumulation I-Disease 0 0.06573201715946198
is O 0 2.0730794858536683e-06
recognized O 0 9.275815386899922e-07
as O 0 4.4997094050813757e-07
an O 0 4.72616784463753e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.002284054411575198
man O 1 0.680785596370697
, O 0 4.049975359521341e-06
mouse O 0 0.00013117431080900133
, O 0 6.7439204940455966e-06
rat O 1 0.9850971698760986
and O 0 1.9685332517838106e-05
dog O 0 0.0012600804911926389
. O 0 0.00010654969810275361

The O 0 8.567250188207254e-05
major O 0 0.0001594890491105616
cause O 0 0.00020001862139906734
of O 0 0.424753338098526
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999996423721313
accumulation I-Disease 1 0.7899413704872131
in O 0 3.292853989478317e-06
man O 0 1.0010447113018017e-05
is O 0 1.0208145795331802e-06
a O 0 1.4031846831130679e-06
dysfunctional O 0 3.794345320784487e-05
ATP7B O 1 0.9999997615814209
gene O 0 6.13181236985838e-06
, O 0 3.0208407224563416e-06
causing O 0 6.328583549475297e-05
Wilson B-Disease 1 0.9957767128944397
disease I-Disease 1 0.9735897779464722
( O 0 2.984674574690871e-05
WD B-Disease 1 0.9999992847442627
) O 0 8.263384370366111e-05
. O 0 0.00013673261855728924

Mutations O 0 6.362106068991125e-05
in O 0 5.706514002667973e-06
the O 0 6.946432222321164e-06
ATP7B O 1 0.9999961853027344
genes O 0 2.519453119020909e-06
have O 0 5.719987825614226e-07
also O 0 1.1958431969105732e-06
been O 0 1.2324957197051845e-06
demonstrated O 0 2.6697887278714916e-06
in O 0 1.8195770508100395e-06
mouse O 0 0.00010749809007393196
and O 0 2.5663541237008758e-05
rat O 1 0.9867751598358154
. O 0 0.00025866652140393853

The O 0 0.00015262722445186228
ATP7B O 1 0.9999916553497314
gene O 0 9.337499250250403e-06
has O 0 2.827136768246419e-06
been O 0 7.94424749983591e-07
excluded O 0 1.3578128346125595e-06
in O 0 2.177366695832461e-07
the O 0 4.594956806158734e-07
much O 0 1.909311322378926e-06
rarer O 0 0.0002584190515335649
human O 0 1.1578111298149452e-05
copper B-Disease 1 0.9999994039535522
overload I-Disease 1 1.0
disease O 1 0.999848484992981
non B-Disease 0 3.444081812631339e-05
- I-Disease 0 0.0016602474497631192
Indian I-Disease 0 6.025778020557482e-06
childhood I-Disease 0 0.0001526848936919123
cirrhosis I-Disease 1 0.9999998807907104
, O 0 1.1231039025005884e-05
indicating O 0 2.2108544726506807e-05
genetic O 0 3.013739114976488e-05
heterogeneity O 0 0.0006407269393093884
. O 0 9.912993846228346e-05

By O 0 2.0296471120673232e-05
investigating O 0 4.851333505939692e-05
the O 0 1.0807299076986965e-05
common O 0 2.1835978259332478e-05
autosomal O 0 0.44523748755455017
recessive O 1 0.9980385899543762
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 5.117677210364491e-05
CT B-Disease 1 0.9992918968200684
) O 0 3.016551318069105e-06
in O 0 1.62760738930956e-06
Bedlington O 0 0.006505431607365608
terriers O 0 0.0021378807723522186
, O 0 1.3334362165551283e-06
we O 0 2.417952771338605e-07
have O 0 6.756460635415351e-08
identified O 0 1.725363887317144e-07
a O 0 3.3629291351644497e-07
new O 0 3.51977803347836e-07
locus O 0 1.062024512066273e-05
involved O 0 2.283687990711769e-06
in O 0 5.4443230510514695e-06
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0002840606903191656

We O 0 3.540956458891742e-05
examined O 0 2.353636227780953e-05
whether O 0 2.8261338229640387e-06
the O 0 3.75924309992115e-06
WD B-Disease 1 0.9664733409881592
gene O 0 1.498619621997932e-05
ATP7B O 1 0.9999997615814209
was O 0 5.175698970560916e-05
also O 0 2.2439664917328628e-06
causative O 0 1.2629245247808285e-05
for O 0 1.2763745189658948e-06
CT B-Disease 0 0.00415203208103776
by O 0 6.04663000558503e-07
investigating O 0 2.5622987323004054e-06
the O 0 1.2008625844828202e-06
chromosomal O 0 1.2955812962900382e-05
co O 0 1.6404590496676974e-05
- O 0 2.598105675133411e-05
localization O 0 1.6555593902012333e-05
of O 0 8.69666564540239e-06
ATP7B O 1 0.9999908208847046
and O 0 1.9376000182091957e-06
C04107 O 0 3.121759436908178e-05
, O 0 1.1683389402605826e-06
using O 0 3.7900463212281466e-07
fluorescence O 0 2.1946773358649807e-06
in O 0 1.5855282526899828e-06
situ O 0 3.87983163818717e-05
hybridization O 0 1.3403131561062764e-05
( O 0 5.156854967935942e-06
FISH O 0 4.6668566938024014e-05
) O 0 1.450461149943294e-05
. O 0 3.311399996164255e-05

C04107 O 0 0.0015488524222746491
is O 0 2.487625170033425e-05
an O 0 1.1457223081379198e-05
anonymous O 0 5.2306262659840286e-05
microsatellite O 0 0.0003905218036379665
marker O 0 0.00019933570001740009
closely O 0 1.67995040101232e-05
linked O 0 2.6855195756070316e-05
to O 0 1.3172553735785186e-05
CT B-Disease 1 0.9996933937072754
. O 0 0.00011788367555709556

However O 0 8.21793291834183e-05
, O 0 4.368568625068292e-05
BAC O 1 0.9998852014541626
clones O 0 0.0004763146862387657
containing O 0 6.28194902674295e-05
ATP7B O 1 0.9996204376220703
and O 0 7.273619758052519e-06
C04107 O 0 7.637918315595016e-05
mapped O 0 7.416582320729503e-06
to O 0 1.1914447668459616e-06
the O 0 2.5220881525456207e-06
canine O 0 0.0006397606339305639
chromosome O 0 7.415323125314899e-06
regions O 0 1.4993881904956652e-06
CFA22q11 O 0 0.08640536665916443
and O 0 9.77215904640616e-07
CFA10q26 O 1 0.6893677115440369
, O 0 9.010377084450738e-07
respectively O 0 1.0189276054006768e-06
, O 0 5.413334065451636e-07
demonstrating O 0 2.0344175482023275e-06
that O 0 6.683689548481198e-07
WD B-Disease 0 0.4984908401966095
cannot O 0 1.5830020174689707e-06
be O 0 1.028355882226606e-06
homologous O 0 4.828542387258494e-06
to O 0 8.87104124558391e-06
CT B-Disease 1 0.7157258987426758
. O 0 0.00010085902613354847

The O 0 7.996788190212101e-05
copper O 0 0.00012845732271671295
transport O 0 1.0964326065732166e-05
genes O 0 4.26772385253571e-06
CTR1 O 1 0.9999169111251831
and O 0 3.625988711064565e-06
CTR2 O 1 0.9999990463256836
were O 0 1.4975347539802897e-06
also O 0 7.136978865673882e-07
excluded O 0 1.512761514277372e-06
as O 0 2.9977104532008525e-07
candidate O 0 9.399021223543969e-07
genes O 0 2.3014513317320962e-07
for O 0 3.7124186746950727e-07
CT B-Disease 1 0.8415439128875732
since O 0 6.91332161295577e-07
they O 0 2.293922420903982e-07
both O 0 4.97480016292684e-07
mapped O 0 6.035860224073986e-06
to O 0 2.75150978268357e-06
canine O 0 0.028129292652010918
chromosome O 0 0.00010458406177349389
region O 0 7.275977986864746e-05
CFA11q22 O 1 0.9657631516456604
. O 0 0.00013145353295840323

2 O 0 0.0008400495862588286
- O 0 0.0013150363229215145
22 O 0 0.00046099835890345275
. O 0 0.0002952665963675827

5 O 0 0.002558005042374134
. O 0 0.0009269273141399026

A O 0 9.183980000670999e-05
transcribed O 0 2.0766407033079304e-05
sequence O 0 2.5860767891572323e-06
identified O 0 8.698794999872916e-07
from O 0 5.381790515457396e-07
the O 0 1.2707050700555556e-06
C04107 O 0 4.7528385039186105e-05
- O 0 2.0597673938027583e-05
containing O 0 7.138597538869362e-06
BAC O 1 0.9999927282333374
was O 0 3.887950242642546e-06
found O 0 1.7996670464981435e-07
to O 0 1.0000153594091898e-07
be O 0 8.139346618918353e-08
homologous O 0 1.7242255978544563e-07
to O 0 1.9799416861587815e-07
a O 0 5.53736583697173e-07
gene O 0 7.978992471180391e-07
expressed O 0 2.828744811722572e-07
from O 0 3.5261146535958687e-07
human O 0 8.10708570497809e-07
chromosome O 0 2.8230199404788436e-06
2p13 O 0 2.8358907002257183e-05
- O 0 1.2488956599554513e-05
p16 O 0 1.61895586643368e-05
, O 0 4.4929728915121814e-07
a O 0 5.485927658810397e-07
region O 0 1.2093926216039108e-06
devoid O 0 4.912575604976155e-06
of O 0 1.5989696748874849e-06
any O 0 1.9673693714139517e-06
positional O 0 4.732991510536522e-05
candidate O 0 3.060391827602871e-05
genes O 0 1.981759851332754e-05
. O 0 3.398425178602338e-05

Molecular O 0 0.00011751420242944732
analysis O 0 9.514490557194222e-06
of O 0 4.1640309973445255e-06
the O 0 3.0486530704365578e-06
APC B-Disease 0 0.0007203421555459499
gene O 0 1.2479614497351577e-06
in O 0 6.564568479916488e-07
205 O 0 5.349515049601905e-06
families O 0 2.736196620389819e-07
: O 0 3.7478417880265624e-07
extended O 0 1.6660590063111158e-06
genotype O 0 4.017791070509702e-06
- O 0 6.983381808822742e-06
phenotype O 0 1.9118513137073023e-06
correlations O 0 1.270394932362251e-06
in O 0 5.251004608908261e-07
FAP B-Disease 1 0.9974352717399597
and O 0 4.466992322704755e-07
evidence O 0 4.0171872228711436e-07
for O 0 1.3054493308573e-07
the O 0 3.673719106700446e-07
role O 0 9.49754280554771e-07
of O 0 1.469871676818002e-06
APC B-Disease 0 5.9789941587951034e-05
amino O 0 1.4867356412651134e-06
acid O 0 1.7957049749384169e-06
changes O 0 6.595806780751445e-07
in O 0 1.660233101574704e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 1.0
. O 0 0.0004942778032273054

BACKGROUND O 0 0.0005318777984939516
/ O 0 0.002356324577704072
AIMS O 0 0.00021786677825730294
The O 0 4.876420007349225e-06
development O 0 3.405872803341481e-06
of O 1 0.9877843856811523
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.992351816530572e-06
a O 0 1.7976857407120406e-06
variable O 0 8.790914876044553e-07
range O 0 1.455834421904001e-06
of O 0 2.0133541056566173e-06
extracolonic O 0 0.1249895915389061
manifestations O 0 7.037402974674478e-05
in O 0 8.914206773624755e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9970557689666748
FAP B-Disease 1 1.0
) O 0 2.3962556952028535e-06
is O 0 5.027396809964557e-07
the O 0 2.50237945920162e-07
result O 0 1.6440111494375742e-07
of O 0 5.369015525502618e-07
the O 0 9.594881476004957e-07
dominant O 0 9.969042366719805e-06
inheritance O 0 1.4454791198659223e-05
of O 0 0.03640298917889595
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 5.8816927776206285e-05
APC B-Disease 1 0.8980873227119446
) O 0 8.95901848707581e-06
gene O 0 1.8749531591311097e-05
mutations O 0 2.5188352083205245e-05
. O 0 4.294801692594774e-05

In O 0 1.6585239791311324e-05
this O 0 1.7170086721307598e-06
study O 0 1.0443251312608481e-06
, O 0 3.386003015748429e-07
direct O 0 2.964137308936188e-07
mutation O 0 3.2408371453129803e-07
analysis O 0 1.815150767470186e-07
of O 0 7.334257361435448e-07
the O 0 1.0490765589565854e-06
APC B-Disease 0 0.003649697406217456
gene O 0 2.325984041817719e-06
was O 0 3.5255670809419826e-06
performed O 0 1.181498873847886e-06
to O 0 3.3423381751163106e-07
determine O 0 6.762867883480794e-07
genotype O 0 3.117959749943111e-06
- O 0 5.064352080808021e-06
phenotype O 0 1.952033699126332e-06
correlations O 0 1.1123189551653923e-06
for O 0 3.3102230645454256e-07
nine O 0 1.1426758419474936e-06
extracolonic O 0 0.00019619088561739773
manifestations O 0 4.8931715355138294e-06
and O 0 3.7653106232937716e-07
to O 0 3.0067491252339096e-07
investigate O 0 8.475597610413388e-07
the O 0 3.9916426430863794e-07
incidence O 0 4.34977664554026e-06
of O 0 2.804205223583267e-06
APC B-Disease 0 0.019375132396817207
mutations O 0 1.3505754168363637e-06
in O 0 1.1602697895796155e-06
non O 0 8.647242793813348e-05
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0007184123969636858

METHODS O 0 0.00010071208089357242
The O 0 2.8792517696274444e-05
APC B-Disease 0 0.00031816508271731436
gene O 0 7.061583801259985e-06
was O 0 6.4023593040474225e-06
analysed O 0 3.910070972779067e-06
in O 0 4.6097568429104285e-07
190 O 0 3.5197081160731614e-06
unrelated O 0 4.9114237299363595e-06
FAP B-Disease 1 0.9996620416641235
and O 0 2.3076895558915567e-06
15 O 0 1.391587284160778e-05
non O 0 0.004881730303168297
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.251409104152117e-06
using O 0 9.341953841612849e-07
denaturing O 0 3.586270031519234e-05
gradient O 0 2.243231574539095e-05
gel O 0 2.3074228010955267e-05
electrophoresis O 0 4.928648195345886e-06
, O 0 4.700093541032402e-07
the O 0 2.372087664070932e-07
protein O 0 5.911552989346092e-07
truncation O 0 5.502324711414985e-06
test O 0 8.207141490856884e-07
, O 0 6.419157898562844e-07
and O 0 7.343670631598798e-07
direct O 0 4.786030331160873e-06
sequencing O 0 3.5740882594836876e-05
. O 0 4.2920994019368663e-05

RESULTS O 0 0.00011799028288805857
Chain O 0 3.094062412856147e-05
terminating O 0 1.0829357051989064e-05
signals O 0 2.312196784259868e-06
were O 0 4.955816166329896e-07
only O 0 1.8406431934181455e-07
identified O 0 4.1193487732016365e-07
in O 0 2.5305828899035987e-07
patients O 0 3.650574456059985e-07
belonging O 0 6.85480017637019e-07
to O 0 3.103001517956727e-07
the O 0 3.392090320630814e-06
FAP B-Disease 1 1.0
group O 0 9.297990800405387e-06
( O 0 3.2128107250173343e-06
105 O 0 2.5714371076901443e-05
patients O 0 5.591894478129689e-06
) O 0 6.162747922644485e-06
. O 0 2.8605836632777937e-05

Amino O 0 7.250959606608376e-05
acid O 0 1.8001175703830086e-05
changes O 0 1.4278011803980917e-06
were O 0 8.055880016399897e-07
identified O 0 6.715322342643049e-07
in O 0 1.821429833626098e-07
four O 0 4.5201130660643685e-07
patients O 0 3.5430360867394484e-07
, O 0 2.262958957999217e-07
three O 0 1.627505241685867e-07
of O 0 1.306690251112741e-06
whom O 0 9.497722999185498e-07
belonged O 0 1.7066649888874963e-06
to O 0 3.5138620546604216e-07
the O 0 6.949109092602157e-07
non O 0 6.677708370261826e-06
- O 0 0.0028202489484101534
FAP O 1 1.0
group O 0 5.003485784982331e-05
of O 1 0.9999895095825195
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.5274201035499573
. O 0 6.99669835739769e-05

Genotype O 0 0.0017138280672952533
- O 0 0.00038883433444425464
phenotype O 0 3.670297883218154e-05
correlations O 0 1.4603127965528984e-05
identified O 0 2.4108201159833698e-06
significant O 0 7.336278713410138e-07
differences O 0 5.130133331476827e-07
in O 0 2.6638628014552523e-07
the O 0 6.382032893270662e-07
nature O 0 1.1775180155382259e-06
of O 0 5.560681870520057e-07
certain O 0 5.200787995818246e-07
extracolonic O 1 0.6672736406326294
manifestations O 0 0.0005233748815953732
in O 0 4.1069474718824495e-06
FAP B-Disease 1 1.0
patients O 0 6.486495294666383e-06
belonging O 0 2.4913881588872755e-06
to O 0 1.0658328619683743e-06
three O 0 3.5417697290540673e-06
mutation O 0 1.2090250493201893e-05
subgroups O 0 7.435621228069067e-05
. O 0 5.326471000444144e-05

CONCLUSIONS O 0 0.0002977003459818661
Extended O 0 4.141012323088944e-05
genotype O 0 2.0377228793222457e-05
- O 0 1.8027891201199964e-05
phenotype O 0 2.9501707103918307e-06
correlations O 0 1.0936128091998398e-06
made O 0 4.4014137756676064e-07
in O 0 1.3335947812720406e-07
this O 0 8.192863276690332e-08
study O 0 1.2132818483223673e-07
may O 0 8.461143607974009e-08
have O 0 2.96627433726826e-08
the O 0 1.218072327446862e-07
potential O 0 2.1171028663502511e-07
to O 0 1.0781955239735908e-07
determine O 0 1.1407058053691799e-07
the O 0 2.2009831468494667e-07
most O 0 1.451432609655967e-07
appropriate O 0 2.7503844535203825e-07
surveillance O 0 1.859640292423137e-06
and O 0 6.74332852668158e-07
prophylactic O 0 9.766138100530952e-05
treatment O 0 4.896186965197558e-06
regimens O 0 4.9088480409409385e-06
for O 0 3.7560428722827055e-07
those O 0 1.8931565648472315e-07
patients O 0 2.7998819973618083e-07
with O 0 1.381281293788561e-07
mutations O 0 7.961866685946006e-07
associated O 0 5.138344363331271e-07
with O 0 9.705973980089766e-07
life O 0 1.526790038042236e-05
threatening O 0 0.0001873744186013937
conditions O 0 2.7945201509282924e-05
. O 0 4.186787555227056e-05

This O 0 1.251626144949114e-05
study O 0 6.5003655436157715e-06
also O 0 1.655242158449255e-06
provided O 0 8.628236400909373e-07
evidence O 0 5.734090109399403e-07
for O 0 5.085814223093621e-07
the O 0 1.0380180128777283e-06
pathological O 0 8.106946916086599e-05
nature O 0 1.3026490250922507e-06
of O 0 6.635225417994661e-07
amino O 0 6.234715783648426e-07
acid O 0 2.708288775465917e-07
changes O 0 6.543392316871177e-08
in O 0 1.7635278481975547e-07
APC O 0 2.1886784452362917e-05
associated O 0 2.679208250810916e-07
with O 0 2.2985035741385218e-07
both O 0 5.262028253127937e-07
FAP B-Disease 1 0.9999997615814209
and O 0 1.004941532301018e-05
non O 1 0.9979523420333862
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.035255808383226395
. O 0 7.204308531072456e-06
. O 0 2.353061609028373e-05

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.9999898672103882
cancer B-Disease 1 1.0
risk O 0 0.00024621616466902196
of O 0 1.9950906789745204e-05
the O 0 2.823989234457258e-05
APC O 1 0.8984915018081665
I1307K O 0 0.002472406718879938
polymorphism O 0 0.000126567596453242
. O 0 8.455134957330301e-05

Germ O 1 0.9998533725738525
- O 0 0.000856029917486012
line O 0 4.199227623757906e-05
and O 0 5.37443338544108e-06
somatic O 0 1.9556036932044663e-05
truncating O 0 1.6229749235208146e-05
mutations O 0 1.3102579714541207e-06
of O 0 1.3658702755492413e-06
the O 0 1.4528676501868176e-06
APC B-Disease 0 0.05760456621646881
gene O 0 9.591642537998268e-07
are O 0 1.1492513607436194e-07
thought O 0 9.314092039858224e-07
to O 0 7.435863835780765e-07
initiate O 0 3.5944256524089724e-05
colorectal B-Disease 1 1.0
tumor I-Disease 1 1.0
formation O 0 0.000971142144408077
in O 0 1.7617234334466048e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9459160566329956
sporadic O 1 0.9999998807907104
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 0.01828146167099476
respectively O 0 6.691168528050184e-05
. O 0 9.380991832586005e-05

Recently O 0 0.00013010797556489706
, O 0 9.59289991442347e-06
an O 0 6.739343007211573e-06
isoleucine O 0 0.0039885202422738075
- O 0 0.00019460853945929557
- O 0 6.942776963114738e-05
> O 0 4.5775472244713455e-05
lysine O 0 2.5411673050257377e-05
polymorphism O 0 2.3304160094994586e-06
at O 0 4.275622814020608e-06
codon O 0 1.427328879799461e-05
1307 O 0 4.7303925384767354e-05
( O 0 1.8419301568428637e-06
I1307K O 0 1.4236489732866175e-05
) O 0 6.924908575456357e-07
of O 0 5.895029175917443e-07
the O 0 8.202555932257383e-07
APC B-Disease 0 6.336144724627957e-05
gene O 0 9.65343815551023e-07
has O 0 4.0254440136777703e-07
been O 0 2.610309479678108e-07
identified O 0 1.9769056791574258e-07
in O 0 7.874222518466922e-08
6 O 0 9.965582421500585e-07
% O 0 1.4466567677118292e-07
- O 0 7.264554255925759e-07
7 O 0 1.0398924814580823e-06
% O 0 3.046346535029443e-07
of O 0 5.946564556325029e-07
the O 0 1.3283820408105385e-06
Ashkenazi O 0 2.995555587403942e-05
Jewish O 0 1.451490697945701e-05
population O 0 4.4746334424417e-06
. O 0 1.8147204173146747e-05

To O 0 2.8223443223396316e-05
assess O 0 1.745395638863556e-05
the O 0 4.926322162646102e-06
risk O 0 3.066135832341388e-06
of O 0 1.3495350685843732e-06
this O 0 5.863775527359394e-07
common O 0 2.40692406805465e-06
APC B-Disease 0 0.020360251888632774
allelic O 0 0.03550446033477783
variant O 0 0.07994003593921661
in O 0 1.9762866941164248e-05
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 6.614442554564448e-06
we O 0 6.478771297224739e-07
have O 0 1.531586235614668e-07
analyzed O 0 4.0111157773026207e-07
a O 0 3.039312161945418e-07
large O 0 1.6197382137761451e-06
cohort O 0 8.085797162493691e-06
of O 0 3.117124606433208e-06
unselected O 0 0.002400779165327549
Ashkenazi O 0 4.537769200396724e-05
Jewish O 0 4.816961336473469e-06
subjects O 0 2.0429138203326147e-06
with O 0 6.704661359435704e-07
adenomatous B-Disease 1 0.9999991655349731
polyps I-Disease 1 0.9978330731391907
and O 0 1.4759172017875244e-06
. O 0 1.2838887641919428e-06
or O 0 0.46527180075645447
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 2.9005495889578015e-06
for O 0 7.923123348518857e-07
the O 0 2.741143362072762e-06
APC O 0 0.0012859299313277006
I1307K O 0 0.0006063395412638783
polymorphism O 0 7.546645065303892e-05
. O 0 5.770500501967035e-05

The O 0 0.00019753938249778003
APC O 0 0.001018702401779592
I1307K O 0 0.00047579759848304093
allele O 0 2.50146822509123e-05
was O 0 1.4825680409558117e-05
identified O 0 2.188217422371963e-06
in O 0 3.9905995663502836e-07
48 O 0 1.5432262898684712e-06
( O 0 3.683689726585726e-07
10 O 0 5.294141942613351e-07
. O 0 1.4495597611130506e-07
1 O 0 1.137608933277079e-06
% O 0 6.74343084483553e-07
) O 0 7.269620709848823e-07
of O 0 4.8164374675252475e-06
476 O 0 0.00010302232840331271
patients O 0 3.1301598937716335e-05
. O 0 4.12565132137388e-05

Compared O 0 2.1475072571774945e-05
with O 0 1.0030820476458757e-06
the O 0 9.901286830427125e-07
frequency O 0 8.38831738292356e-07
in O 0 2.718429641390685e-07
two O 0 1.3879946436645696e-07
separate O 0 1.406894796218694e-07
population O 0 9.197351147349764e-08
control O 0 3.433229380789271e-07
groups O 0 1.260047923778984e-07
, O 0 3.203492724423995e-07
the O 0 6.666406306976569e-07
APC O 0 0.005919385701417923
I1307K O 0 0.0001528997818240896
allele O 0 1.0628892823660863e-06
is O 0 1.5918993767627398e-07
associated O 0 7.339077967571939e-08
with O 0 3.447941665513099e-08
an O 0 1.6832177607284393e-07
estimated O 0 7.948218581077526e-07
relative O 0 1.1762361964429147e-06
risk O 0 1.7807078620535322e-06
of O 0 4.241961050865939e-06
1 O 0 7.299746357602999e-05
. O 0 5.272960333968513e-05

5 O 0 0.0006666603730991483
- O 0 0.0009634472662582994
1 O 0 0.0006371390190906823
. O 0 0.00022822404571343213

7 O 0 0.00022409521625377238
for O 0 9.696069173514843e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 1.0
( O 0 3.656777334981598e-05
both O 0 6.133162969490513e-06
P O 0 0.00019253128266427666
= O 0 7.289876066352008e-06
. O 0 3.5217426557210274e-06
01 O 0 0.0002689527173060924
) O 0 2.543790833442472e-05
. O 0 5.567895277636126e-05

Furthermore O 0 0.00011901291873073205
, O 0 1.1075439033447765e-05
compared O 0 4.488044851314044e-06
with O 0 2.228925723102293e-06
noncarriers O 1 0.7300760746002197
, O 0 1.4220518096408341e-05
APC O 1 0.9921532273292542
I1307K O 1 0.772113561630249
carriers O 0 2.7966552806901745e-06
had O 0 9.86694772109331e-07
increased O 0 4.345408513017901e-07
numbers O 0 3.541928208505851e-07
of O 0 2.658946414157981e-06
adenomas B-Disease 1 1.0
and O 0 0.32252734899520874
colorectal B-Disease 1 1.0
cancers I-Disease 1 1.0
per O 0 2.7915816644963343e-06
patient O 0 1.7748639038472902e-06
( O 0 5.048964908382914e-07
P O 0 5.094404514238704e-06
= O 0 5.682493338099448e-07
. O 0 1.309006165683968e-07
03 O 0 9.529782801109832e-06
) O 0 3.9827068576414604e-07
, O 0 2.9980591875755636e-07
as O 0 2.0612712603451655e-07
well O 0 2.0440623416106973e-07
as O 0 3.907768189037597e-07
a O 0 1.1055631148337852e-06
younger O 0 4.13201223636861e-06
age O 0 6.594324986508582e-06
at O 0 3.7416215491248295e-05
diagnosis O 0 0.00017001613741740584
. O 0 6.297483923844993e-05

We O 0 1.9844112102873623e-05
conclude O 0 1.2109750059607904e-05
that O 0 7.950432063807966e-07
the O 0 1.7555314570927294e-06
APC O 0 0.0006218617199920118
I1307K O 0 0.003890130203217268
variant O 0 2.8742260838043876e-05
leads O 0 4.447890205483418e-06
to O 0 8.370329851459246e-07
increased O 0 7.711176294833422e-06
adenoma B-Disease 1 1.0
formation O 0 2.819156725308858e-05
and O 0 7.798144565640541e-07
directly O 0 5.01591216561792e-07
contributes O 0 5.338189339454402e-07
to O 0 1.2865162091202365e-07
3 O 0 7.29757175577106e-07
% O 0 1.7409071517704433e-07
- O 0 5.442446422421199e-07
4 O 0 7.527707452936738e-07
% O 0 1.690458475422929e-07
of O 0 2.8439356469789345e-07
all O 0 4.692014101692621e-07
Ashkenazi O 0 0.00018221346545033157
Jewish O 1 0.8549100160598755
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003005415201187134

The O 0 6.259071233216673e-05
estimated O 0 2.000321910600178e-05
relative O 0 7.422823273373069e-06
risk O 0 4.386605723993853e-06
for O 0 9.97967731564131e-07
carriers O 0 1.1467544709375943e-06
may O 0 4.451232484825596e-07
justify O 0 1.001943360279256e-06
specific O 0 2.0455794924600923e-07
clinical O 0 6.145834845483478e-07
screening O 0 5.045129114478186e-07
for O 0 1.554290633976052e-07
the O 0 3.0549696816706273e-07
360 O 0 3.5285875128465705e-06
, O 0 3.5439148859950365e-07
000 O 0 1.015862608255702e-06
Americans O 0 2.127743528035353e-07
expected O 0 1.402685541052051e-07
to O 0 1.3204055449023144e-07
harbor O 0 3.3642679682088783e-06
this O 0 1.4020326943864347e-07
allele O 0 3.474527829894214e-07
, O 0 1.2867714360709215e-07
and O 0 8.367610604409492e-08
genetic O 0 2.2701246393808105e-07
testing O 0 1.4781666379803937e-07
in O 0 6.650417105902307e-08
the O 0 1.424212001666092e-07
setting O 0 5.481278435581771e-07
of O 0 3.0093337954895105e-07
long O 0 4.746778756725689e-07
- O 0 2.463222244841745e-06
term O 0 8.665857080814021e-07
- O 0 1.3350496601560735e-06
outcome O 0 4.098615420389251e-07
studies O 0 2.64736314647962e-07
may O 0 1.8169207294249645e-07
impact O 0 4.5354335043157334e-07
significantly O 0 5.824766731166164e-07
on O 0 1.602461634320207e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 1 0.8751798272132874
in O 0 1.8681618030313984e-06
this O 0 1.0291585113009205e-06
population O 0 4.0672148315934464e-06
. O 0 1.818876808101777e-05

Localization O 0 0.0003284611739218235
of O 0 4.580708991852589e-05
human O 0 9.212007171299774e-06
BRCA1 O 0 5.194854747969657e-05
and O 0 1.1196890454812092e-06
its O 0 8.502622108608193e-07
loss O 0 8.385363798879553e-06
in O 0 5.31895977928798e-07
high O 0 1.4425402696360834e-05
- O 0 3.817286415142007e-05
grade O 0 0.005004000384360552
, O 0 1.682039737715968e-06
non B-Disease 0 1.7270267562707886e-05
- I-Disease 1 0.9837719798088074
inherited I-Disease 1 0.9999980926513672
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0011596129043027759

Although O 0 1.9326880646985956e-05
the O 0 5.359038368624169e-06
link O 0 5.484329449245706e-06
between O 0 1.0882589549510158e-06
the O 0 9.979952665162273e-06
BRCA1 O 1 0.9997076392173767
tumour B-Disease 1 1.0
- O 1 0.9996243715286255
suppressor O 1 0.9999996423721313
gene O 0 5.687086286343401e-06
and O 0 2.492001385689946e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 8.041127443902951e-07
established O 0 4.149788992435788e-07
, O 0 1.4636788137067924e-07
the O 0 2.0511546949819603e-07
role O 0 4.384161798043351e-07
, O 0 1.9048721355829912e-07
if O 0 6.870429558603064e-08
any O 0 1.0601746680549695e-07
, O 0 1.906875155555099e-07
of O 0 5.076354909760994e-07
BRCA1 O 0 1.0008518074755557e-05
in O 0 4.458259468265169e-07
non B-Disease 0 2.0667763237725012e-05
- I-Disease 1 0.9994370341300964
familial I-Disease 1 0.9999994039535522
cancers I-Disease 1 1.0
is O 0 1.8305459889234044e-05
unclear O 0 1.930370672198478e-05
. O 0 4.004378934041597e-05

BRCA1 O 0 0.05342057719826698
mutations O 0 1.113220878323773e-05
are O 0 7.213357662294584e-07
rare O 0 2.459138158883434e-06
in O 0 1.0494118214410264e-06
sporadic B-Disease 0 0.13350005447864532
cancers I-Disease 1 0.9999998807907104
, O 0 1.881964863059693e-06
but O 0 2.694926877211401e-07
loss O 0 4.675483069149777e-06
of O 0 6.062721240596147e-06
BRCA1 O 0 0.00026905324193648994
resulting O 0 1.25005306017556e-06
from O 0 4.3874328525816964e-07
reduced O 0 1.6691313931005425e-06
expression O 0 7.367380590039829e-07
or O 0 4.0899277564676595e-07
incorrect O 0 1.111973119805043e-06
subcellular O 0 5.816850716655608e-06
localization O 0 3.6809615266975015e-06
is O 0 3.3710273328324547e-07
postulated O 0 1.0299537507307832e-06
to O 0 1.1469585814438688e-07
be O 0 1.0463892152756671e-07
important O 0 2.405615191491961e-07
in O 0 3.416043909965083e-07
non B-Disease 0 5.7231372920796275e-06
- I-Disease 0 0.2403469979763031
familial I-Disease 1 0.9999995231628418
breast I-Disease 1 1.0
and I-Disease 1 0.999996542930603
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.0003052497049793601

Epigenetic O 0 0.006378666032105684
loss O 0 0.12044666707515717
, O 0 1.0078611012431793e-05
however O 0 1.6366726640626439e-06
, O 0 8.917097602534341e-07
has O 0 4.614551016857149e-07
not O 0 7.875004115476258e-08
received O 0 4.6460885982924083e-07
general O 0 5.845724331265956e-07
acceptance O 0 1.4447281273533008e-06
due O 0 7.983688306012482e-07
to O 0 3.410337683362741e-07
controversy O 0 3.1818794923310634e-06
regarding O 0 7.481972374989709e-07
the O 0 6.185430834193539e-07
subcellular O 0 5.8050300140166655e-06
localization O 0 3.861062396026682e-06
of O 0 1.8206289951194776e-06
BRCA1 O 0 7.497310889448272e-06
proteins O 0 1.4934997238924552e-07
, O 0 1.8015302316598536e-07
reports O 0 1.2816693129025225e-07
of O 0 2.2862695914227515e-07
which O 0 7.822607273055837e-08
have O 0 5.075948195099045e-08
ranged O 0 7.279936653503682e-07
from O 0 1.4825826610831427e-07
exclusively O 0 4.039203247430123e-07
nuclear O 0 6.98354256201128e-07
, O 0 1.0921937843022533e-07
to O 0 1.3149117705779645e-07
conditionally O 0 3.4766230783134233e-06
nuclear O 0 1.2463368648241158e-06
, O 0 2.5745970333446166e-07
to O 0 2.6606156211528287e-07
the O 0 1.2081546856279601e-06
ER O 1 0.9999496936798096
/ O 0 0.0013707111356779933
golgi O 0 4.654154690797441e-05
, O 0 1.1672975688270526e-06
to O 0 8.985595059129992e-07
cytoplasmic O 0 9.090004823519848e-06
invaginations O 0 8.935060759540647e-05
into O 0 5.813739335280843e-06
the O 0 7.0456412686326075e-06
nucleus O 0 5.802582745673135e-05
. O 0 3.785844091908075e-05

In O 0 1.664999217609875e-05
an O 0 3.7745683130196994e-06
attempt O 0 5.802002760901814e-06
to O 0 9.25591564282513e-07
resolve O 0 2.1864402697246987e-06
this O 0 4.1325657207380573e-07
issue O 0 1.399875145580154e-06
, O 0 5.992164346935169e-07
we O 0 2.3655837821934256e-07
have O 0 1.3987207125865098e-07
comprehensively O 0 7.022484169283416e-06
characterized O 0 3.065212013098062e-06
19 O 0 1.104708371713059e-05
anti O 0 0.0003307014412712306
- O 0 0.0901530385017395
BRCA1 O 0 0.0003667555865831673
antibodies O 0 2.5627245122450404e-05
. O 0 2.63213696598541e-05

These O 0 2.539292472647503e-05
reagents O 0 9.047481580637395e-05
detect O 0 1.9232009435654618e-05
a O 0 8.259393325715791e-06
220 O 0 1.9530987628968433e-05
- O 0 3.437303166720085e-05
kD O 0 0.07831539213657379
protein O 0 2.7716992008208763e-06
localized O 0 4.59125158158713e-06
in O 0 3.9592273992639093e-07
discrete O 0 2.5326037302875193e-06
nuclear O 0 5.980340120004257e-06
foci O 0 1.23308464026195e-05
in O 0 3.513433171065117e-07
all O 0 3.620262418735365e-07
epithelial O 0 8.220283052651212e-05
cell O 0 4.395516953081824e-06
lines O 0 1.101883299270412e-06
, O 0 4.001586830781889e-07
including O 0 3.6980367212890997e-07
those O 0 3.575936204924801e-07
derived O 0 1.7995382677327143e-06
from O 0 5.1391416491242126e-06
breast B-Disease 1 0.999991774559021
malignancies I-Disease 1 0.9998964071273804
. O 0 0.00011400687071727589

Immunohistochemical O 0 0.016264837235212326
staining O 0 0.0006057531572878361
of O 0 5.9597939980449155e-05
human O 0 2.4848512111930177e-05
breast O 1 0.9657338857650757
specimens O 0 1.0912252037087455e-05
also O 0 1.4618278783018468e-06
revealed O 0 7.672338142583612e-06
BRCA1 O 0 0.00011800896027125418
nuclear O 0 3.198052945663221e-05
foci O 0 0.00014892025501467288
in O 0 4.105467724002665e-06
benign O 1 0.9999986886978149
breast O 1 0.9999998807907104
, O 0 9.085072815651074e-05
invasive B-Disease 1 1.0
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999998807907104
and O 0 9.700869668449741e-06
low B-Disease 0 0.013587682507932186
- I-Disease 1 0.999476969242096
grade I-Disease 1 0.9999959468841553
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0011402805102989078

Conversely O 0 0.0004725511826109141
, O 0 3.7629768485203385e-05
BRCA1 O 0 9.239857172360644e-05
expression O 0 5.011694156564772e-06
was O 0 7.869244655012153e-06
reduced O 0 1.7578032611709205e-06
or O 0 5.04684692259616e-07
undetectable O 0 5.640887593472144e-06
in O 0 1.332894186134581e-07
the O 0 2.3197098641958291e-07
majority O 0 7.283938430191483e-08
of O 0 3.17873258381951e-07
high O 0 1.571749453432858e-05
- O 0 0.007383403833955526
grade O 1 0.9896480441093445
, O 0 1.413237077940721e-05
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 7.676890163565986e-06
suggesting O 0 2.2143447040434694e-06
that O 0 2.9502226084332506e-07
absence O 0 1.317716510129685e-06
of O 0 2.0522634258668404e-06
BRCA1 O 0 9.317283547716215e-05
may O 0 3.462520226094057e-07
contribute O 0 2.7306444394525897e-07
to O 0 2.517363384413329e-07
the O 0 5.228064310358604e-07
pathogenesis O 0 0.00022359471768140793
of O 0 1.3782380392513005e-06
a O 0 8.317533115587139e-07
significant O 0 5.807582965644542e-07
percentage O 0 1.7134035488197696e-06
of O 0 3.6219516914570704e-06
sporadic B-Disease 0 0.16456611454486847
breast I-Disease 1 1.0
cancers I-Disease 1 0.9999878406524658
. O 0 1.7453121472499333e-05
. O 0 3.972767444793135e-05

